Bioworld Statistics Report PDF

BioWorld®
I NDUSTRIAL
B IOTECHNOLGY
S TAT REPORT
IMMEDIATE AND COMPREHENSIVE

INDUSTRY INFORMATION
BioWorld® Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information
Michael Harris, Senior Managing Editor
Amanda Lyle, Senior Editor
Copyright © 2007
AHC Media LLC®
BioWorld Today
3525 Piedmont Road, N.E.
Building Six, Suite 400
Atlanta, GA 30305 U.S.A.
All rights reserved. Printed in the United States of America. Except as permitted under the United States Copyright Act
of 1976, no part of this publication may be reproduced or distributed in any form or by any means, or stored in a database
or retrieval system, without the prior written permission of the publisher.
Product code: SO7429
ISBN-10: 1-933040-67-X
ISBN-13: 978-1-933040-67-7
BioWorld® Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information is published by AHC Media
LLC®, 3525 Piedmont Road, Building Six, Suite 400, Atlanta, GA 30305 U.S.A. Opinions expressed are not necessarily those of the
publication. Mention of products or services does not constitute endorsement. (GST Registration Number R128870672)
Senior Managing Editor: Michael Harris Senior Editor: Amanda Lyle
Marketing Manager: Chris Walker Account Representatives: Steve Roberts, Bob Sobel, Chris Wiley
Vice President/Group Publisher: Donald R. Johnston
Customer Service: (800) 879-8790 or (404) 262-5526
Please visit our web site: www.bioworld.com
Please note:
BioWorld has made every effort to ensure that the information in this report is accurate and up-to-date, but cannot be
responsible for errors, inaccuracies or changes in the data. If the reader identifies any information that is incorrect or has
changed, please notify BioWorld so that it can be corrected for future editions.
Notice:
This report is an information tool, and the user should make business decisions based on an independent investigation,
verification and evaluation of this as well as other information relevant to the user’s business interest. BioWorld has
gathered information for this work from many different sources and quotes information which has been gathered by other
sources. Although BioWorld has taken reasonable steps to ensure the accuracy of this report, due to the tremendous
amount of information, and the third-party control of some information, BioWorld cannot verify the accuracy of all
information that it gathers and reports and thus does not warrant that the information is error-free. AS A RESULT,
BIOWORLD DISCLAIMS ALL WARRANTIES OF MERCHANTABILITY OF FITNESS FOR A PARTICULAR
PURPOSE.
BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information
ABOUT BIOWORLD®
BioWorld Today, the newspaper of record for the biotechnology industry, is read by
biotechnology professionals worldwide for its hard-hitting, objective news reporting. BioWorld Today
is delivered by e-mail and fax every business morning, and is also found exclusively online at
www.bioworld.com. The BioWorld Online website has been internationally recognized as the most
comprehensive resource for strategic biotechnology news and information available today. In
addition to original daily news reporting, BioWorld offers an extensive searchable database with
more than 15 years of biotechnology archives. This site is not only a great source for insightful, up-
to-the-minute news coverage, but a veritable library of information on the developments of the
industry as well. With a quick search, BioWorld subscribers have instant access to a wealth of
biotechnology market intelligence from every biotech hotspot around the globe.
BioWorld does not post press releases, but rather uses information that is researched and written
by the top business and science reporters in the industry. With nearly 20 writers spread throughout
eight countries, BioWorld covers news on public companies and hard-to-find information on private
companies. Our seasoned reporters get the inside scoop on what’s happening within the corporate
walls, on regulatory issues in Washington and elsewhere, and on scientific breakthroughs
worldwide. This news coverage of the biotechnology industry is 100 percent original and available
only at BioWorld.
All of the BioWorld resources are available for easy online searching, including:
BioWorld Today – The daily biotechnology newspaper.
BioWorld International – The weekly monitor of global biotechnology developments.
BioWorld Financial Watch – The weekly report on all market data and business trends in
biotechnology.
BioScan: The Worldwide Biotech Industry Reporting Service – The most comprehensive
directory of biotechnology companies available.
The BioWorld Biotechnology State of the Industry Report – A must-have annual report
reviewing financial trends in the biotechnology industry.
The BioWorld Executive Compensation Report – An annual report revealing executive
compensation data at biotechnology companies in the U.S.
The BioWorld RNA/DNA Therapeutics & Technologies Report 2006 – An in-depth look at
major market opportunities in RNAi, pharmacogenomics and forensics.
The BioWorld Phase III Report – A quarterly compilation of biotechnology products in

late-stage clinical trials.
BioWorld Snapshots – An exclusive online product updated daily with market data, such
as collaborations, mergers, acquisitions, financings, market cap rankings and more.
BioWorld StatReports – Industry-specific reports including contact information and
names, R&D focus, products on the market and in development, agreements and
financial information.
Medical Device Daily – The daily medical technology newspaper. Available every
business morning via fax or online at www.medicaldevicedaily.com.
For more information on BioWorld®, please contact:
Donald R. Johnston, VP/Group Publisher

AHC Media LLC
3525 Piedmont Road
Building Six, Suite 400
Atlanta, GA 30305 USA
Phone: 404-262-5439
Fax: 404-262-5510
E-mail: don.johnston@ahcmedia.com
or customerservice@ahcmedia.com
Website: www.bioworld.com
TABLE OF CONTENTS
How to Use BioWorld StatReports…………………………………………………………………6
List of Companies……………………………………………………………………………………9
Company Profiles…………………………………………………………………………………..13
Subject Index………………………………………………………………………………………397
®
Copyright ©2006 AHC Media 5
BioWorld®
I NDUSTRIAL
B IOTECHNOLOGY
S TAT REPORT
HOW TO USE
BIOWORLD STATREPORTS
®
HOW TO USE BIOWORLD STATREPORTS

BioWorld StatReports are fully searchable through Adobe Acrobat Reader by using its search feature (Ctrl. +
Shift + F).
Companies may also be located using the list of company names at the beginning of the report. This useful
feature provides a quick reference guide to coverage. It is an alphabetical listing of all companies in the
directory and allows the reader to summarily determine if a specific company is represented in the directory.
The Main Entry section is arranged alphabetically by company name.
FIELDS AND THEIR DESCRIPTIONS

Company records include only those fields for which information has been obtained. Where possible, dates
are included to reflect the approximate occurrence of events.
Company Name and Address

Gives the main address, telephone number(s), fax, web site address, and e-mail address, if known. Second
addresses are given for major research facilities, U.S. facilities of non-U.S. companies, and some subsidiaries
and divisions.
Management
Lists management involved in relevant marketing and R&D areas, such as the Chairman of the Board, Chief
Executive Officer (CEO), President, Chief Operating Officer (COO), Chief Financial Officer (CFO), Executive or
Senior Vice Presidents, Vice President or Director of R&D, and Vice President or Director of Marketing. May
also include names of senior scientists/researchers.
Employees
Gives the approximate number employees and, when known, the number of Ph.D.s, M.D.s, and D.V.M.s on
staff.
History
Contains information on founding date, name changes, major acquisitions, previous subsidiaries or
investments and organization memberships.
Facilities
Includes facilities involved in biotechnology. Often provides size (in square feet or square meters).
Stock-Financial History
Contains information on public-private status; initial funding; stock exchange and ticker symbol; public
offerings, including date, price of stock at issuance, number of shares offered and dollar value. For public
companies, information includes financials for most recently completed fiscal year, including revenue, net
income or loss, earnings or loss per share, average shares outstanding and total assets. These figures are
compared with the corresponding figures for the previous year.
Private Placements
Usually these arrangements are made through investment firms to fund clinical research for products in
development. Information may include date, dollar value and use of funds.
Subsidiaries/Divisions
Includes subsidiaries of biotechnology companies and often the location of the subsidiary. The address,
management and research interests are listed if readily available. (A company is usually considered a
subsidiary if 51% or more is owned by the parent company.) Also included are divisions of large companies
that focus on biotechnology.
Subsidiary Of
Lists the parent company and percentage owned when applicable.
®
Investments
Lists investments by biotechnology companies. For nonbiotechnology companies, generally limited to
investments in the biotechnology industry. Joint ventures are also listed here.
Principal Investors
Includes the principal investors in the biotechnology company profiled.
Financial Information
General information, which may include R&D budget, nonprofit offshoots or investment arms of the company.
Business Strategy
Reflects new or changed directions of the company, or the company’s mission.
Agreements
Consists of a brief summary of the research and contents of the agreement and the date agreement
commenced. Agreements are arranged alphabetically by company/organization. May contain agreements
outside of the focus area of the StatReport to ensure completeness.
Research and Development

Briefly describes general research interests and technologies worked on by the company or its subsidiaries.
Research done through agreements with other companies is also included.
Products on the Market

Includes (1) all products of biotechnology companies and (2) biotechnology products of nonbiotechnology
(e.g., chemical and pharmaceutical) companies. May contain products outside of the focus area of the
StatReport to ensure completeness.
Products in Development
Column 1 includes the generic, trade names and uses of the product. The status indicated in column 2 refers
to the standard stages for a U.S. drug or other product in development. Generally, only products in
development related to the industry of the StatReport are included.
Subject Index
Categorizes companies involved in various aspects of biotechnology.
®
®
BioWorld
I NDUSTRIAL
B IOTECHNOLOGY
S TAT REPORT
LIST OF COMPANIES
®
LIST OF COMPANIES
3DM Inc. BioMed Diagnostics Inc.
A/F Protein Inc. Biomeda Corp.
AB Enzymes Oy Biomedical Technologies Inc.
Abbott GmbH & Co. KG BioMerieux INDUSTRY
Abengoa SA BioMerieux SA
Acadian Seaplants Ltd. Biomol GmbH
ADI Group Inc. Bionas GmbH
ADI Systems Inc. Bionov CNP Inc.
Advanced Product Enterprises LLC BIOPAC Systems Inc.
Advanta Seeds UK Ltd. BioPro International Inc.
AEA Technology plc Bioriginal Food & Science Corp.
AGI Dermatics Bioscience Inc.
AgResearch Ltd. BioScreen Testing Services Inc.
AgriSense-BCS Ltd. BioSure Inc.
Agrium Inc. Biosynth International Inc.
Ag-West Bio Inc. Biotal Ltd.
Ajinomoto Co. Inc. Bio-Technical Resources
Akzo Nobel NV Biotechnology Research Institute
Alberta Research Council Inc. Biotecx Laboratories Inc.
Alderon Biosciences Inc. Biotehnos SA
Alltech Inc. Biothane Corp.
Altair Nanotechnologies Inc. BioTime Inc.
Altus Pharmaceuticals Inc. BioVectra dcl
Aluline Ltd. Bioxel Pharma Inc.
AMDL Inc. Biozyme Laboratories Ltd.
American Radiolabeled Chemicals Inc. Boojum Research Ltd.
Analox Instruments Ltd. Boston Life Sciences Inc.
Analox Instruments U.S.A. BRAIN (Biotechnology Research and Information
Applera Corp. Network AG)
Applied Biosystems Inc. Bunge Ltd.
Applikon Biotechnology Inc. CABI
Arch Chemicals Inc. Calzyme Laboratories Inc.
Arch Personal Care Products LP Cambio Ltd.
Archer Daniels Midland Cambrex Corp.
Argonne National Laboratory Canadian Forest Service
Arysta LifeScience Corp. Canadian Seed Coaters
Asahi Kasei Corp. Cantest Ltd.
Associates of Cape Cod Inc. Cardinal Health - Middleton
Astellas Pharma Inc. Cargill Inc.
astre Corp. Ceapro Inc.
Athenix Corp. Celsis International plc
Atrium Biotechnologies Inc. Centre for Innovative Biology and Environmental
Axxora Life Science Inc. Technology
BAC BV (Biotechnology Application Centre) Ceres Inc.
BACHEM AG Chembiotech Ltd.
Bachem California Inc. Chemeq Ltd.
Bangs Laboratories Inc. ChemGenes Corp.
BASF AG Chr. Hansen Inc.
Bayer Corp. Chunghwa Chemical Synthesis & Biotech Co. Ltd.
Bayer CropScience AG Codexis Inc.
Bayou Biolabs Codon Devices
Be-Long Group CombiMatrix Corp.
BioAssay Works LLC Commercial Microbiology Ltd.
Biocatalysts Ltd. Cornell Institute for Biotechnology and Life Science
Bioclear BV Technologies
BioForce Nanosciences Inc. Cosmo Bio Co. Ltd.
BioGenes GmbH CryoLife Inc.
BioGenesis Enterprises Inc. CUBIA (University Centre for Algal Biotechnology)
Biogenie Inc. Cuno Inc.
Bio-Lab Ltd. Cyanotech Corp.
Biolog Inc. Daiichi Pharmaceutical Co. Ltd.
Biologos Inc. Dainippon Sumitomo Pharma Co. Ltd.
®
Dalton Pharma Services International Flavors & Fragrances Inc.

Dextra Laboratories Ltd. Iogen Corp.
Dextran Products Ltd. Isolagen Inc.
Diagnostic Chemicals Ltd. Israel Institute for Biological Research (IIBR)
Digene Corp. Itochu Corp.
Diversa Corp. J. Craig Venter Institute
DNA Technologies Inc. Johnson Matthey Pharma Services
DOE Joint Genome Institute Kanebo Ltd.
Dojindo Laboratories Kaneka Corp.
Don Whitley Scientific Ltd. Kikkoman Corp. (Biochemicals Division)
Dong-A Pharmaceutical Co. Ltd. Kraeber GmbH & Co.
Dow AgroSciences LLC Kuraray Co. Ltd.
Dragon Pharmaceutical Inc. Kyorin Pharmaceutical Co. Ltd.
Droycon BioConcepts Inc. Kyowa Hakko Kogyo Co. Ltd.
DSM Laboratoires Eurobio
DSM Fine Chemicals Lake States
DuPont LANXESS AG
Dyadic International (USA) Inc. Lavipharm SA
Dynavax Europe Lawrence Berkeley National Laboratory
EMD Biosciences Inc./Merck Biosciences LG Chem Ltd.
eMembrane Inc. LG Life Sciences Ltd.
Encelle Inc. LGC (Laboratory of the Government Chemist)
EnSolve Biosystems Inc. LifeCell Corp.
Enviro-Zyme International LLC LifeSensors Inc.
Enzyme Research Laboratories Ltd Link Technologies Ltd.
Epicore Networks (U.S.A.) Inc. Lonza Group Ltd.
Epidauros Biotechnologie AG Maine Biotechnology Services Inc.
Eurogentec SA Mallinckrodt Inc.
EvoGenix Ltd. Marcor Development Corp.
Evolva SA Maruzen Pharmaceuticals Co. Ltd.
F. Hoffmann-La Roche Ltd. Mascoma Corp.
FibroGen Inc. Matreya LLC
First Link (UK) Ltd. Maxxam Analytics Inc.
Fraunhofer Institute for Interfacial Engineering MBI International
and Biotechnology MDS Pharma Services
Galderma SA MedPharm Ltd.
Genencor International Inc. Megabase Research Products
General Electric Global Research Meiji Seika Kaisha Ltd.
Genesearch Pty. Ltd. Mercian Corp.
Geneva Scientific Merck KgaA
Genomatica Inc. Metabolix Inc.
Gentra Systems Inc. Microbe Inotech Laboratories Inc.
Genzyme Corp. Microbia Inc.
GL Biochem (Shanghai) Ltd. Mo Bio Laboratories Inc.
HaloSource Inc. MoBiTec GmbH
Hammen Corp. Molecular Devices Corp.
Harvard Bioscience Inc. Molecular Probes Inc.
Hawaii Biotech Inc. Monsanto Co.
Helmholtz Centre for Infection Research Morishita Jintan Co. Ltd.
Hercules Inc. M-Scan Ltd.
Hidex Oy MSE Technology Applications Inc.
Huntingdon Life Sciences Nanogen Inc.
Hybrizyme Corp. NanoHorizons Inc.
ICPbio NanoLogix Inc.
Idaho National Laboratory Nanophase Technologies Corp.
Idexx Laboratories Inc. National Collection of Yeast Cultures (NCYC)
IGENE Biotechnology Inc. National Institute of Advanced Industrial Science and
Imperial Innovations Ltd. Technology (AIST)
Industrial Biotechnology Corp. National Institutes of Health (NIH)
Industrial Technology Research Institute – National Research Council of Canada
Biomedical Engineering Center Nature Plus Inc.
inGenious Targeting Laboratory Inc. NatureWorks LLC
Institute for Biological Research and Neogen Corp.
Institute for Biological Research and Technology New Brunswick Scientific Co. Inc.
Institute of Food Research New England BioLabs Inc.
®
New Horizons Diagnostics Corp. Response Biomedical Corp.

New Zealand Pharmaceuticals Ltd. Roal Oy
Nigu Bioselect RTI International
Nippon Kayaku Co. Ltd. SafePath Laboratories LLC
Nitto Denko Corp. Sakai Chemical Industry Co. Ltd.
Norac Technologies Inc. Sanyo Chemical Industries Ltd. (Sanyo Kasei)
North Carolina Biotechnology Center Scion - Cellwall Biotechnology Centre
NOVA Chemicals Corp. Sensient Technologies Corp.
NovaSep Process Severn Biotech Ltd.
november AG Showa Denko KK
Noven Pharmaceuticals Inc. SibEnzyme Ltd.
Novozymes A/S Solomon Park Research Laboratories
Novozymes Inc. Spark Holland BV
Omex Environmental Ltd. Spherix Inc.
OmniChem SRI International
OmniGene Bioproducts Inc. Stewart Agricultural Research Services Inc.
Optigenex Inc. Stratagene Corp.
Optronics Strategic Diagnostics Inc.
Organo Corp. Sumitomo Chemical Co. Ltd.
Pacific Biodiesel Inc. SunOpta Inc.
Pacific Northwest National Laboratory Symbio
Pall Corp. Syngenta International AG
Paprican Synthetech Inc.
PBR Laboratories Inc. (PBR) Synthetic Genomics Inc.
PCI Membranes Takeda Pharmaceutical Co. Ltd.
Pentapharm Ltd. Teledyne Isco
PeproTech Inc. The Dow Chemical Co.
Peptides International Inc. The Nitrate Elimination Co. Inc.
Pfeiffer Vacuum Ltd. TNO Quality of Life
Pfizer Inc. Toray Industries Inc.
Pharmbiodyn Consulting Group Toronto Research Chemicals Inc.
Pioneer Hi-Bred International Inc. Union Chemical Laboratories (UCL)
PLANTON GmbH UniQuest Pty. Ltd.
Polium Technologies Inc. University of Nebraska-Lincoln, Center for Biotechnology
Polydex Pharmaceuticals Ltd. UVP Inc.
Polysciences Inc. Valeant Pharmaceuticals International Inc.
POS Pilot Plant Corp. Varied Industries Corp.
PrimeSyn Lab Inc. VECTOR State Research Centre of
Primm S.R.L. Virology/Biotechnology
Procter & Gamble Co. Virinova GbR
Prokaria ehf Vitrolife AB
Prometic BioSciences Inc. Vizon SciTec Inc.
Proteus SA Wako Chemicals U.S.A. Inc.
Qbiogene Waste Stream Technology Inc.
Quip Laboratories Inc. Webs Ltd.
Ramot at Tel Aviv University Ltd. Wedgewood Analytical Inc.
Randox Laboratories Ltd. Westbridge Research Group
Reanal Finechemical Co. Weyerhaeuser Co.
RECO Biotechnology Xethanol Corp.
Recordati SpA Yeda Research and Development Co. Ltd.
Regis Technologies Inc. Yissum Research Development Co.
Renessen LLC YMC Co. Ltd.
Renovo Group plc Zeltia SA
Research Organics Inc. Zeon Corp.
Research Triangle Park Laboratories Inc. Zuckerforschung Tulln GmbH
®
BioWorld®
I NDUSTRIAL
B IOTECHNOLOGY
S TAT REPORT
COMPANY PROFILES
®
3DM Inc.
P.O. Box 425025
Cambridge MA 02142, US
Phone: (877) 430-9595; Fax: (877) 430-9595
Toll-free phone: (877) 430-9595
Web: www.puramatrix.com
E-mail: contact@puramatrix.com
KEY PERSONNEL: Shuguang Zhang, Ph.D.; Chairman
Zen Chu; President
Lisa Spirio, Ph.D.; Director, R&D
EMPLOYEES: 8 employees
HISTORY: Founded in 2001
Began biotech R&D in 1994
FACILITIES: 2,000 sq. ft. headquartes and R&D facilities
Manufacturing is outsourced
STOCK-FINANCIAL HISTORY: Privately held
PRIVATE PLACEMENTS: Raised $1.7M in first round of financing (10/04)
PRINCIPAL INVESTORS: Bain Capital
Monitor Ventures
NMJ Japan
Technology Directors Inc.
BUSINESS STRATEGY: Establish and maintain a position as the leading synthetic cell culture
scaffold for bioproduction, life science R&D and stem cell therapies, through
a worldwide marketing and distribution partnership with Becton Dickinson
BDBiosciences. 3DM is developing a pipeline of medical devices for
orthopedic and cardiac therapies with industry-leading companies.
AGREEMENTS: Name Products Content of Agreement Date
Becton Dickinson BD PuraMatrix worldwide marketing 2004
and distribution
agreement
Becton Dickinson PuraMatrix Synthetic worldwide marketing 2004
Peptide Hydrogel and distribution
agreement
RESEARCH & DEVELOPMENT: Orthopedic and reconstructive surgery medical devices

Cardiac regeneration therapies
Cancer invasion assays
High-content screening
Collagen plug assays
Stem cell expansion and delivery
Bioproduction
Tissue engineering
PRODUCTS ON MARKET: PuraMatrix
PuraMatrixCST
PuraMatrixGMP
BD PuraMatrix
PRODUCTS IN DEVELOPMENT: Name Status
PuraMatrixCST in preclinicals
PuraMatrixRGD in preclinicals
®
A/F Protein Inc.

935 Main Street
Waltham MA 02451, US
Phone: (781) 899-7755; Fax: (781) 899-8482
Web: www.afprotein.com; E-mail: eentis@afprotein.com
KEY PERSONNEL: Elliot Entis; Chairman, President and CEO
Michael Erisman, Ph.D.; Exec. VP, Science and Technology
Ronald M. Slate; COO
Choy L. Hew, Ph.D.; Director and Consultant to A/F Protein
Garth Fletcher, Ph.D.; President, A/F Protein Canada, and VP
Boris Rubinsky, Ph.D.; Director and Consultant to A/F Protein
HISTORY: Founded and began biotech R&D in 1992
Member--Biotechnology Industry Organization
PRIVATE PLACEMENTS: Raised $1.2M in private placement of Reg D stock (1993, 1994)
Raised $4.0M in private placement of Reg D stock (1996)
SUBSIDIARIES/DIVISIONS: A/F Protein Canada
P.O. Box 13422
St. John's, NL A1B 4B7
Canada
Phone: (709) 738-4638
Fax: (709) 738-4644
E-mail: mail@afprotein.com
BUSINESS STRATEGY: Develop the use of antifreeze proteins for the control of cold-induced
damage in medical, food and cosmetic products
Seeking partners to pursue the development of an AFP-based medium for
hypothermic preservation of human platelets and AFP-based strategies for
improved methods of cryosurgery
RESEARCH & DEVELOPMENT: Hypothermic-cryogenic preservation of mammalian cells, tissues and whole
organs
Enhanced cryosurgical ablation of tumours
Food preservation
Preservation of reproductive materials
Enhancement of the protective capacity of skin-care products
PRODUCTS ON MARKET: Antifreeze Protein Type I
Antifreeze Protein Type III
Antifreeze Glycoprotein
AB Enzymes Oy
P.O. Box 26
Rajamaki FIN-05207, Finland
Phone: +358 9 290 22 510; Fax: +358 9 290 22 550
Web: www.abenzymes.com; E-mail: info@abenzymes.com
KEY PERSONNEL: Ralf Lundell; President and CEO
HISTORY: Formed in 1987
Changed name from Alko Ltd./Biotechnology (1995)
Changed name from Primalco Ltd. Biotec (9/97)
Changed name from Rohm Enzyme (10/01)
Acquired GAMMA CHEMIE GmbH (2002)
®

SUBSIDIARIES/DIVISIONS: AB Enzymes GmbH Beijing Representative Office
Room 320B, B Tower, Grand Pacific Building
8A Guanghua Road, Chaoyang District
Beijing 100026 China
Phone: +86 10 65814225; Fax: +86 10 65814227
E-mail: mp_guo@public3.bta.net.cn
Main Office of ABF Ingredients Corp.

Enzyme Division
214 Rockmont Drive
Fort Mill, SC 29708-7934
Phone: (803) 547-7800 or (803) 547-0852
Fax: (803) 547-0891; Cell phone: (704) 400-8099
E-mail: ABEnzymes@comporium.net
AB Enzymes GmbH Guangzhou

Representative Office
Room 2715, Bank of America Plaza
555 Renminzhong Road
Guangzhou City 510145 China
Phone: +86 20 81302718
Fax: +86 20 81302303
E-mail: fjj138@pub.guangzhou.gd.cn
AB Enzimas Brasil Comercial Ltda.

Al. Amazonas, 938 Bloco A, 3. andar
06454 – 070, Barueri, SP Brazil
Phone: +55 11 4688 2555; Fax: +55 11 4688 2259
E-mail: paulo.sandri@abenzimas.com.br
AB Enzymes Singapore Branch

3 International Business Park
# 07-18 Nordic European Centre
Singapore 609927
Phone: +65 6890 6831; Fax: +65 6890 6846
E-mail: trandinh@abenzymes.com.sg
AB Enzymes Poland Sp. Z.o.o.

Ul. POW 35
PL 98-200 Sieradz
Phone: +48 43 8223094
Fax: +48 43 8273808
E-mail: abenzymes@abenzymes.pl
AB Enzymes GmbH
Feldbergstrasse 78
D-64293 Darmstadt
Germany
Phone: +49 (0) 61 51-36 80-100
Fax: +49 (0) 61 51-36 80-120
SUBSIDIARY OF: Abitec Group
PRINCIPAL INVESTORS: Associated British Foods plc
BUSINESS STRATEGY: Develop and market industrial enzymes for feed, textile, and pulp and paper
applications
RESEARCH & DEVELOPMENT: Development of technical enzyme applications

PRODUCTS ON MARKET: Biotouch enzymes for textile biofinishing
Econase enzymes for feed and food
Ecostone enzymes for textile stonewash and finishing
Ecopulp enzymes for pulp bleaching
®
Finase enzymes for feed and food

Veron enzymes for baking
Rohapect, Rohament, Rohavin and Corolase enzymes for fruit/vegetable
processing, cleaning of ultrafiltration membranes and winemaking
Corolase enzymes for protein modification
Abbott GmbH & Co. KG

Max-Planck-Ring 2
Wiesbaden 65205, Germany
Phone: +49 6122-58-0; Fax: +49-6122-58-1244
Web: www.abbott.de
E-mail: info-diagnostik.de@abbott.com
KEY PERSONNEL: Holger Liepmann; Chairman, Supervisory Board and Sr. VP, International
Operations
Jaime Contreras; Managing Director
Siegfried Brune; Managing Director
Geert Walther Nygaard; Managing Director
Rodolfo Viana; Managing Director
EMPLOYEES: 4,000 employees
HISTORY: Formed from the merger of Abbott GmbH, Knoll GmbH and Knoll
Deutschland GmbH (2001)
BUSINESS STRATEGY: Discover, develop, manufacture and market innovative medicines
Establish global network of strategic alliances and partnerships with biotech
companies
Manufacture and market pharma active ingredients
Market proprietary oral drug delivery and process technology of melt
extrusion
Build European generic business
Alza Corp. Oros hydromorphone joint development 2/97
and marketing
agreement for the
U.S.
Cambridge therapeutic antibodies joint research 8/93
Antibody agreement
Technology plc
Center for TET system for licensing research 5/96
Molecular Biology, regulating gene agreement
Heidelberg expression
Eisai Co. Ltd. sibutramine joint development 1/98
and marketing
agreement for Japan
PharmaNetics Inc. thrombin inhibitors R&D collaboration 1996
PharmaNetics Inc. stoke therapy R&D collaboration 1997
Warner-Lambert interleukin-1 converting joint research 5/95
Co. enzyme inhibitors agreement
PRODUCTS ON MARKET: Pharmaceuticals worldwide:

Synthroid® (hypothyroidism)
Isoptin® (coronary heart disease, hypertension, cardiac arrythmia)
Rytmonorm®/Rythmol® (cardiac arrthmia)
Reductil®/ Merida® (obesity)
Vicodin® Vicaprotein (pain)
Bruten® (pain)
Iruxol® (wound healing)
Gopten®/Mavik® (hypertension)
®
Dilaudid® (pain)
Akineton® (parkinson)
Cerebrdysin (cerebral insuffiency)
Pharma active ingredients worldwide:

Ephedrine
Caffeine
Ibuprofen
Theophylline
Abengoa SA
Avenida de la Buhaira 2
Seville 41018, Spain
Phone: +34 954 937 111; Fax: +34 954 937 020
Web: www.abengoa.com; E-mail: abengoa@abengoa.com
KEY PERSONNEL: Felipe Benjumea Llorente; Co-chairman
Javier Benjumea Llorente; Co-chairman
Amando Sanchez Falcon, Financial Director
Juan Carlos Jimenez Lora; Director, Investor Relations
Santiago Seage Medela; Head, Corp. Strategy and Development
Javier Salgado Leirado; President and CEO, Abengoa Bioenergia SA,
Abengoa Bioenergy Corp. and Abengoa Bioenergy R&D
Ignacio Garcia Alvear; CFO, Abengoa Bioenergia SA
Francisco A. Morillo Leon; CTO, Abengoa Bioenergia SA
Gerson Santos-Leon; Director, R&D, Abengoa Bioenergia SA
Joel Stone; COO, Abengoa Bioenergy Corp.
Santiago Ortiz Dominguez; GM, Industrial Waste Management
HISTORY: Acquired Befesa for EUR300M (2000)
Started the first bioethanol facility in Spain (2000)
Acquired High Plains Corp. (now Abengoa Bioenergy Corp.) (2002)
Started the second bioethanol facility in Spain (2002)
Acquired Metso Corp.’s Network Management Solutions Division (now
Telvent Canada and Telvent USA) (2003)
Started construction of the third bioethanol facility in Spain (2003)
Acquired Miner & Miner Consulting Engineers Inc. (2004)
Started construction of the fourth bioethanol facility in Nebraska (2004)
Acquired Almos Systems (2004)
Acquired Energoprojekt Gliwice (EPG) (7/06)
STOCK-FINANCIAL HISTORY: Listed on the Madrid and Barcelona stock exchanges
IPO-1996
Sales EUR2.024b (YE 05) compared to EUR1.746b (YE 04)
Earnings per share EUR0.73/share (YE 05) compared to EUR0.58/share
(YE 04)
SUBSIDIARIES/DIVISIONS: Five business units: Industrial Engineering and Construction, Information
Technology, Environmental Services, Solar and Bioenergy
Six operational fields: Energy, Environment, Transport, Services, Industry

and Telecommunications
Bioenergy subsidiaries:
Ecocarburantes Espanoles SA
Ecoagricola SA
Bioetanol Galicia SA
Biocarburantes de Castilla y Leon SA
ETBE Huelva SA
Abengoa Bioenergia SA
Abengoa Bioenergy Corp.
®
Abengoa Bioenergy France

Abengoa Bioenergy of Hanover
Abengoa Bioenergy R&D Inc.
Greencell SA
BUSINESS STRATEGY: Solar: Design, promote, attain financing for, construct and operate electric
energy generating plants that utilize the sun as the primary energy source
Bioenergy: Produce and develop biofuels for transport--bioethanol and
biodiesel, among others that utilize biomass (cereals, cellulosic biomass and
oleaginous seeds) as the raw material
Environmental Services: Provide environmental services for industry and for
the construction of environmental infrastructures, while conducting
aluminum waste recycling, zinc recycling, industrial waste management and
environmental engineering activities
Information Technology: Provide high value-added solutions in four
industrial sectors: energy, traffic,
transport and the environment)
Industrial Engineering and Construction: Engineer, construct and maintain
electric, mechanical and instrumentation infrastructures for the energy,
industry, transport and services sectors; Promote, construct and operate
industrial and conventional (cogeneration and combined cycle) power plants
and renewable energy (bioethanol, biodiesel, biomass, wind, solar and
geothermal) power plants; Turnkey telecommunication networks and
projects
RESEARCH & DEVELOPMENT: Abengoa Bioenergy R&D Inc.:

Improve actual production process yields and coproduct quality at existing
dry-mills
Increase ethanol capacity and develop new feed co-products
Develop and demonstrate cost competitive technologies for new biomass
facilities
Develop demonstration programs which permit an increase in the field of
ethanol utilization (for example, diesel and hydrogen fuel cells)
Acadian Seaplants Ltd.

30 Brown Avenue
Dartmouth B3B IX8, Canada
Phone: (902) 468-2840; Fax: (902) 468-3474
Web: www.acadianseaplants.com
E-mail: info@acadian.ca
KEY PERSONNEL: Louis Deveau; Chairman
Jean-Paul Deveau; President
Perry Bevin; CFO
Scott Myers; VP, Sales, Plant Science Division
Glen Gabriel; VP, Sales, Animal Science Division
John Sewuster; VP, Sales, Food and Food Ingredients Divisions
Dr. Alan Critchley; VP, Research
Bill Smith; VP, Manufacturing
EMPLOYEES: 310 employees, 8 Ph.D.s
FACILITIES: Head office
Five processing plants
Research facility
Cultivation site
®
BUSINESS STRATEGY: Research and application of technology to develop unique marine plant
applications and strains of cultivated, food-grade seaweed
Manufacture agricultural (feed and fertilizers) and food ingredient products
from seaweed
NRC Institute for plant growth regulators, consulting and 1990
Marine Bioscience seaweed vegetable licensing agreement
RESEARCH & DEVELOPMENT: Seaweed cultivation and processing

Chemical extraction/biostimulants from seaweed
PRODUCTS ON MARKET: Carrageenan-bearing seaweed
Natural plant growth regulators
Hana-nori--edible seaweeds
Ascophyllum nodosum and Chondrus crispus seaweeds--meals, fine-milled
powders, extracts for feed, food and cosmetic and health ingredients
Cultivated edible sea vegetables
ADI Group Inc.

1133 Regent Street, Suite 300
Fredericton E3B 3Z2, Canada
Phone: (506) 452-9000; Fax: (506) 451-7451
Web: www.adi.ca
E-mail: adigroup@adi.ca
KEY PERSONNEL: Hollis B. Cole; President and CEO
A.L. Steeves; VP, Administration and Secretary-Treasurer
Hazen G. Hawker, CFO
Paul D. Morrison; President and COO, ADI Limited
Graham J. Brown, President and COO, ADI Systems Inc.
Brian MacLean, Operations Manager, Geomembrane Technologies Inc.
Since 1981, ADI has conducted R&D into the use of innovative and cost-
effective processes for wastewater treatment as well as removal of arsenic
and other contaminants from drinking water.
FACILITIES: Environmental laboratory
SUBSIDIARIES/DIVISIONS: ADI Systems Inc. (see separate entry)
ADI International Inc.
Geomembrane Technologies Inc.
FINANCIAL INFORMATION: ADI is 100% employee-owned
BUSINESS STRATEGY: Promote and apply its anaerobic and aerobic technologies in the treatment
of high-strength wastewater
Promote and apply water treatment (arsenic, manganese removal)
Continue R&D efforts and develop new treatment processes and systems
Continue to develop innovative monitoring and control systems
RESEARCH & DEVELOPMENT: Wastewater treatment processes

Water treatment processes
Conceptual planning, implementation, supervision, and monitoring of
mineral exploration programs
Evaluation of mining properties and assessment of investment properties
®
PRODUCTS ON MARKET: Patents are held and pending on several of the following systems:
ADI-BVF®
ADI-Hybrid
ADI-SBR
Floating and structurally supported insulated membrane covers
Media G2 arsenic removal
Sulpha Bind H2S removal
ADI Systems Inc.

1133 Regent Street, Suite 300
Fredericton E3B 3Z2, Canada
Phone: (506) 452-7307; Fax: (506) 452-7308
Web: www.adisystems.ca
E-mail: rcl@adi.ca
KEY PERSONNEL: Graham Brown; President
SUBSIDIARIES/DIVISIONS: U.S. office:
182 Main Street, Unit 6
Salem, NH 03079
Phone: (603) 893-2134
Fax: (603) 898-3991
ADI Systems Inc. Laboratory

6 Lewis Street
Oromocto, NB E2V 2X5
Canada
Phone: (506) 357-2470
Contact: Jonathan Dargavel
E-mail: jgd@adi.ca
SUBSIDIARY OF: ADI Group Inc. (see separate entry)
BUSINESS STRATEGY: Supply and install anaerobic and aerobic systems for industrial wastewater
treatment
Seek suitable overseas companies to license ADI wastewater treatment
technology
RESEARCH & DEVELOPMENT: Design anaerobic treatment systems, biogas handling and SBR decanters
PRODUCTS ON MARKET: Proprietary ADI-BVF® low-rate anaerobic system, ADI-Hybrid high-rate
anaerobic system, ADI-SBR (Sequencing Batch Reactor) technology, ADI-
AMR (Anaerobic Modular Reactor), ADI-MBR (Membrane Biological
Reactor), generic and package wastewater treatment systems
Conducts treatability studies, pilot testing, bench-scale studies, operator
training and aftercare services
®
Advanced Product Enterprises LLC

5716-F Industry Lane
Frederick MD 21704, US
Phone: (888) 496-8333; Fax: (888) 496-8333
Web: www.ape-bio.com
E-mail: info@ape-bio.com
KEY PERSONNEL: Joseph N. Garner, Ph.D.; President and CEO
Bhavesh Joshi, Ph.D.; CSO
BUSINESS STRATEGY: Advanced Product Enterprises LLC (or APE) is a Maryland-based
biotechnology company involved in the identification, testing, development,
and production of biomolecular and molecular biology products for industrial
and academic partners. With the provision of services such as antibiotic
assessment, cell based assay development, endotoxin testing, and
pharmaceutical assessment we assist pharmaceutical companies with their
research and development, preclinical testing, and quality control and
assurance needs. The provision of services which include animal model
elucidation, recombinant protein, antibody and virus production APE is
capable of assisting vaccine development companies with all of their
preclinical needs. As services can be bundled or provided individually, we
can assist any individual or company with a project of any size.

Sorbitase in preclinicals
Varimentix in preclinicals
Advanta Seeds UK Ltd.

Off Southgate
Sleaford NG34 7HA, UK
Phone: +44 1529 304511; Fax: +44 1529 303908
Web: www.advantaseeds.co.uk
E-mail: info@advantaseeds.co.uk
KEY PERSONNEL: Dr. Thomas Jolliffe; General Manager
HISTORY: Founded in January 1997 from the merger of Sharpes International Seeds
Ltd. and Zeneca Seeds UK Ltd.
FACILITIES: 2,000 sq. m. headquarters
1,000 sq. m. R&D facility
20,000 sq. m. manufacturing facility
SUBSIDIARY OF: Limagrain Group (France)
PRINCIPAL INVESTORS: Limagrain Group
INVESTMENTS: Plant Breeding--major U.K. crops
BUSINESS STRATEGY: Produce wholesale and multiplication grade seed and conduct plant
breeding
RESEARCH & DEVELOPMENT: Plant breeding

Crop biotechnology
®
PRODUCTS ON MARKET: Crop varieties for U.K. agriculture

Crop varieties in development
AEA Technology plc

Harwell Business Centre
Didcot OX11 ORA, UK
Phone: +44 (0) 870 190 1900; Fax: +44 (0) 870 190 8261
Web: www.aeat.com; E-mail: jan.lindsay@aeat.co.uk
KEY PERSONNEL: Bernard Bulkin; Chairman
Andrew McCree; CEO
David Lindsay; Group Finance Director
Keith Russell; Director, Corporate Resources and Company Secretary
Stuart Hill; Managing Director, Rail
Robert Bell; Managing Director, Environment
Ralph Watts; Managing Director, Nuclear Programs
HISTORY: Evolved from U.K. Atomic Energy Authority, Harwell Laboratory--separated
in 1994
Acquired biotech expertise and facilities of Warren Spring Laboratory (1994)
Acquired the British Rail Research Centre (1996)
Privatized as AEA Technology plc. (1996)
Sold AEA Technology Battery Systems Ltd, AEA HK, QSA, nCode,
Accentus, Engineering, Safety and Risk, Risk Solutions, Safeguard
International, EASA and Lexware International Ltd. to Coller Capital (10/05)
STOCK-FINANCIAL HISTORY: Traded on the London Stock Exchange--AAT
IPO--1996
Turnover £236.7M (YE 05) compared to £251.6M (YE 04)
Net loss <£25.1M> (YE 05) compared to <£2.3M> (YE 04)
Earnings per share 35.7p/share (YE 05) compared to 3.4p/share (YE 04)
SUBSIDIARIES/DIVISIONS: Two core businesses:
Rail
Environment: Future Energy Solutions (FES), Netcen, Waste and Resource
Management, National Chemical Emergency Centre (NCEC), Momenta
Nuclear programmes--One business unit: Waste Management Technology

PRINCIPAL INVESTORS: M&G Investment Management
Invesco Perpetual
Deutsche Asset Management Ltd.
Newton Investment Management Ltd.
BUSINESS STRATEGY: Environmental business--Supply energy and environmental services to the
U.K. government and agencies
®
AGI Dermatics
205 Buffalo Avenue
Freeport NY 11520, US
Phone: (516) 868-9026; Fax: (516) 868-9143
Web: www.agiderm.com
E-mail: businessdevelopment@agiderm.com
KEY PERSONNEL: Daniel B. Yarosh, Ph.D.; Chairman and President
Jonathan D. Klein; VP, Operations
Adrienne O’Connor; Director, Quality Control and Assurance
Georgia W. Binns; Director, Production
Nick Bizios; Director, Process Development
Frederic Carr; Director, Sales and Marketing
HISTORY: Founded in May 1985 to focus on DNA repair technology
Changed name from Applied Genetics Inc. (1998)
FACILITIES: Liposome manufacturing facility
Molecular biology, fermentation and enzyme purification
BUSINESS STRATEGY: Form strategic alliances with cosmetic/dermatology companies for marketing
RESEARCH & DEVELOPMENT: Bicyclic monoterpene diols

DNA repair enzyme delivery
PRODUCTS ON MARKET: Cosmetic ingredients: Photosomes®, Ultrasomes®, Oxysomes®,
Roxisomes™, Thiotaine®, Merospheres®, VitAine®, Evodiox™, Pinoxide™
Pharmaceutical products: Dimericine® (T4N5 Liposome Lotion)

Dimericene for xeroderma pigmentosum completed Phase III
Dimericene for renal transplant in Phase II clinicals
Dimericene for at-risk populations to begin Phase II
AgResearch Ltd.
5th Floor, Tower Block, Ruakura Research Centre, East Street
Hamilton 3123, New Zealand
Phone: +64 7-834-6600; Fax: +64 7-834-6640
Web: www.agresearch.co.nz; E-mail: webmaster@agresearch.co.nz
KEY PERSONNEL: Rick Christie; Chairman
Andrew West, Ph.D.; CEO
Dr. Stephen Goldson; Chief Science Strategist
Jimmy Suttie, Ph.D.; GM, Science and Technology, Applied Biotechnologies
Mark Ward; GM, Sience and Technology, Food and Health
Peter Benfell; GM, Science and Technology, Agriculture and Environment
Ian Boddy, Ph.D.; GM, Commercial Services
Geoff Balme; CFO
Phillip Lindsay, Ph.D.; CIO
Allanah James; Corporate Affairs Manager
EMPLOYEES: 1,000+ employees
HISTORY: Founded in 1992 in a restructuring of the former Ministry of Agriculture and
the Department of Scientific and Industrial Research (DSIR)
Sold AgVax (8/05)
®
FACILITIES: Five campuses

STOCK-FINANCIAL HISTORY: Government-owned company established under the Crown Research
Institutes Act
SUBSIDIARIES/DIVISIONS: BioPacificVentures--50%
EnCoate--50%
Clone International--25%
Grasslanz Technology Ltd.--100%
Farmax--50%
BUSINESS STRATEGY: Three main objectives:
To underpin the New Zealand pastoral sector’s sustainability and profitability
To establish a range of biotechnologies and systems in New Zealand
To export AgResearch biotechnologies and systems where appropriate

Pharming Group recombinant human manufacturing 6/05
NV lactoferrin agreement
RESEARCH & DEVELOPMENT: Agriculture and environment

Applied biotechnologies
Food and health
PRODUCTS ON MARKET: Licensing opportunities:
AGR-0100: Device for Administration of Beneficial Materials to Ruminants
AGR-0101: Delivery Mechanism
AGR-0200: A Thermostable Biomatrix
AGR-0201: Stable Bio-Matrix Composition and Method of Preparation
AGR-0202: A Granulated Composition
AGR-0300: A Method of Processing Data from a Spectrophotometer
AGR-0301: Compound Preparation Method
AGR-0400: Method and Kitset for Sampling and Storage of Biological
Samples
AGR-0401: Improvements in and Relating to a Method of DNA Testing
AGR 0402: Controlled Release Vitamin B12 Compositions and Methods of
Using Them
AGR-0403: Serratia Proteins
AGR-0404: A Novel Drug Dosing Regimen
AGR-0405: Mycobacterial Vaccines
AGR-0406: Hydatids Vaccine
AGR-0407: An Animal Repellent
AGR-0408: Process for Production of Immunoglobulin A in Milk
AGR-0409: Animal Treatment
AGR-0410: Mammary-Specific Transcription Factor BrEts
AGR-0411: Nuclear Transfer with Selected Donor Cells
AGR-0412: Methods and Compositions for Improving the Developmental
Ability and Quality of Pre-Implantation Embryos
AGR-0413: Compositions Isolated from Bovine Tissue and Methods for
Their Use
AGR-0500: Rapid Method for Measuring Complex Carbohydrates in
Mammalian Tissue
AGR-0501: A Homogeniser
AGR-0502: A Sampling Tool
AGR-0503: Apparatus for the Removal of Bone
AGR-0504: Carcass Management
AGR-0505: Neck Breaker Machine
AGR-0506: A Method and Means for the Processing of the Head Portion of
an Animal Carcass
AGR-0507: A Cutting Machine
AGR-0508: A Method and Apparatus for Removing Meat
AGR-0601: Genetically Modified Plants having Modulated Flower
Development
AGR-0602: Flowering Locus T (FT) and Genetically Modified Plants having
Modulated Flower Development
®
AgriSense-BCS Ltd.
Taffs Mead Road, Treforest Industrial Estate
Pontypridd CF37 5SU, UK
Phone: +44 (0)1443 841 155; Fax: +44 (0)1443 841 152
Web: www.agrisense.co.uk
E-mail: mail@agrisense.co.uk
KEY PERSONNEL: Owen Jones, Ph.D.; GM and Director, Business Development
David Judd; Director, Sales and Marketing, Retail
David Loughlin; Director, Sales and Marketing, PCO
David Avery; Business Development Manager
Enzo Casagrande; Director, Technology
Nap Coverdale; Director, Operations
Neil Bryan; Director, Finance
HISTORY: Established in 1984
Formerly Biological Control Systems Ltd., acquired by AgriSense in 1989
Acquired by biosys (1993)
Acquired by Thermo Trilogy (1/97)
Acquired by Mitsui (5/01)
Acquired by Suterra (6/06)
FACILITIES: 20,000 sq. ft. factory with offices, laboratory and production facilities
SUBSIDIARY OF: wholly-owned subsidiary of Suterra LLC
BUSINESS STRATEGY: AgriSense is a major developer and manufacturer of bio-rational insect pest
monitoring and control products for the agricultural, industrial and home and
garden market sectors
RESEARCH & DEVELOPMENT: Insect behavior-modifying chemicals (semiochemicals, attractants and

repellents)
Controlled-release technology for semiochemicals and other volatile
compounds
Insect glue technology
Trap design
PRODUCTS ON MARKET: Trappit™ range of pest trapping systems
Polycore™ range of liquid controlled-release pheromone formulations
Selibate™ range of hand-applied, controlled-release pheromone
formulations
Frustrate™ range of hand-applied, controlled-release pheromone
formulations
Agrium Inc.
13131 Lake Fraser Drive SE
Calgary T2J 7E8, Canada
Phone: (403) 225-7000
Fax: (403) 225-7609
Web: www.agrium.com
E-mail: webmaster@agrium.com
KEY PERSONNEL: Frank W. Proto; Chairman
Michael Wilson; President and CEO
Bruce G. Waterman; Sr. VP, Finance and CFO
Richard L. Gearheard; Sr. VP and President, Retail
Ron Wilkinson; Sr. VP and President, Wholesale
®
Andrew K. Mittag; Sr. VP, Corporate Development and Strategy

Kevin Helash; VP, Marketing and Distribution
Stephen Dyer; VP, Manufacturing
Acquired AgBiologicals division of Esso/Exxon
Acquired Microbials Division of Allelix Crop Technologies
Changed name from Cominco Fertilizers Ltd. AgBiologicals (1995)
Changed name from Agrium Inc. AgBiologicals (1996)
Acquired Nu-Gro fertilizer technology and professional products businesses
from Spectrum Brands Inc. (1/06)
STOCK-FINANCIAL HISTORY: NYSE--AGU / TSX--AGU
Net sales $3.294b (YE 05) compared to $2.838b (YE 04)
Net earnings $283M (YE 05) compared to $266M (YE 04)
Earnings per share $2.14/share (YE 05) compared to $2.03/share (YE 04)
Total assets $2.785b (YE 05) compared to $2.661b (YE 04)
BUSINESS STRATEGY: Develop and commercialize new products and services for agricultural crops
RESEARCH & DEVELOPMENT: Specialty controlled-release fertilizers

Microbial inoculants for nutritional, environmental, pest and disease stresses
PRODUCTS ON MARKET: RhizUp™ legume inoculant
Enfix™ legume inoculant
AtEze™ bacterial inoculant
Controlled-release fertilizers test market
Biological control agents test market
High-sulfur fertilizers test market
Plant growth promoters test market
Insect pheromone mating disruption test market
Ag-West Bio Inc.

101-111 Research Drive
Saskatoon S7N 3R2, Canada
Phone: (306) 975-1939; Fax: (306) 975-1966
Web: www.agwest.sk.ca
E-mail: agwest@agwest.sk.ca
KEY PERSONNEL: Armand Lavoie; Chairman
Dr. Ashley O'Sullivan; CEO and President
Ron Kehrig; VP, BioProducts and BioProcesses
Dr. Lisette Mascarenhas; VP, Health and Nutrition
Muriel Adams; GM
Janice Tranburg; Director, Regulatory Affairs
EMPLOYEES: 10+ employees
HISTORY: Ag-West Botech Inc. was founded in 1989 as nonprofit company in
partnership with the government of Saskatchewan to bring new technologies
to Saskatchewan as well as commercialize technologies developed in the
province
Joined forces with Bio-Products Saskatchewan and Saskatchewan
Nutraceutical Network to create Ag-West Bio Inc. (4/04)
STOCK-FINANCIAL HISTORY: Nonprofit agency
FINANCIAL INFORMATION: Funding provided by Saskatchewan Agriculture and Food
®
BUSINESS STRATEGY: Ag-West Bio Inc., at the forefront of Saskatchewan's bio-economy, works as
a catalyst for industry growth through investments, aiding strategic alliances,
regulatory advice, communications and education. Ag-West's leadership
goes beyond biotech to support agriculture, food, health and bio-based
industries to be a complete resource for bioscience information in
Saskatchewan
RESEARCH & DEVELOPMENT: Promote and facilitate other companies and organizations in research and
development in the sectors of agriculture, environment and natural health
products
Ajinomoto Co. Inc.

15-1 Kyobashi, 1-chome, Chuo-ku
Tokyo 104-8315, Japan
Phone: +81 (3) 5250-8180; Fax: +81 (3) 3297-8720
Web: www.ajinomoto.com
E-mail: info@ajinomoto.co.jp
KEY PERSONNEL: Kunio Egashira; Chairman
Norio Yamaguchi; President and CEO
Takashi Kurematsu; Exec. Officer, Corporate Planning Dept.
Toshio Takahashi ; Exec. Officer, Specialty Chemical Dept.
Takashi Utagawa; Exec. Officer, Fermentation and Biotechnology
Laboratories
Keiichi Yokoyama; Exec. Officer, Marketing Division
Yutaka Kunimoto; Amino Acid Division
Hirozumi Eto; R&D Management Dept.
Yasuhiko Koda; Public Relations Dept.
Kanji Mimoto; Asean Division
Koichi Maeda; China Division
Hiroaki Nomura; Europe and Africa Division
Tomoyasu Toyoda ; Pharmaceutical Dept.
Kiyoshi Miwa; Exec. Officer, Institute of Life Sciences
Tomoaki Hisatsuka; Food Research and Development Laboratories
Keisuke Nagai; Exec. Officer; International Production and Biotechnology
Center
HISTORY: Formed in May 1909
Established in December 1925
Began biotech research in 1955
Acquired Amoy Food Group Companies from Groupe Danone (1/06)
FACILITIES: 102 plants in 16 countries and regions
STOCK-FINANCIAL HISTORY: Listed on Tokyo Stock Exchange
IPO--5/49
Net sales ¥1,073b (YE 05) compared to ¥1,040b (YE 04)
Net income ¥44.817b (YE 05) compared to ¥36.276b (YE 04)
Earnings per share ¥68.8 (YE 05) compared to ¥55.6/share (YE 04)
Total assets ¥903.542b (YE 05) compared to ¥871.780b (YE 04)
SUBSIDIARIES/DIVISIONS: Ajinomoto U.S.A. Inc.
BUSINESS STRATEGY: Maintain a worldwide leadership position as a global food and amino acid
products company
Apex Bioscience hemoglobin to treat collaboration 3/95
Inc. various diseases agreement
Biotech Research MAbs (against human joint venture to
Labs, Fujirebio tumor antigens) for develop and market
cancer treatment and as
antiviral agent
®
Orsan lysine and feed joint venture called

additives Heartland Lysine,
Inc.
Orsan lysine and amino acid joint venture called
feed additives Eurolysine
Sankyo Co. Ltd. development, exclusive global 8/06
manufacturing and licensing agreement
marketing of AJD101
and related compounds
Scotia Holdings Scotia's SC103 for development and 3/97

plc treating diabetes marketing
complications agreement--
Ajinomoto gets
exclusive rights in
Japan and several
other Asian
countries, Scotia
gets up-front fee and
milestones
Senomyx Inc. discovery and R&D, 3/06
development of novel commercialization
flavor ingredients and licensing
Seragen Inc. IL-2 gene patents for worldwide licensing 6/97
fusion toxin agreements (12/94),
restructured to
reduce and defer
Seragen's financial
obligations to
Ajinomoto (including
royalties on product
sales), Seragen's
partner Eli Lilly has
signed separate
licensing agreement
with Ajinomoto and
assumed most of
Seragen's remaining
obligations to
Ajinomoto
Tadamitsu IL-6 joint research 2/97
Kishimoto agreement
PRODUCTS ON MARKET: Food products

Amino acids
Pharmaceuticals
Akzo Nobel NV
Velperweg 76, P.O. Box 9300
Arnhem 6824 BM, Netherlands
Phone: +31 26 366 44 33; Fax: +31 26 3663250
Web: www.akzonobel.com; E-mail: acc@akzonobel.com
KEY PERSONNEL: Hans Wijers; Chairman and CEO
Rob Frohn; CFO
Keith Nichols; Sr. VP, Finance
®
HISTORY: Algemeene Kunstzijde Unie N.V. merged with Koninklijke Zwanenberg

Organon to form Akzo (1969)
Akzo and Nobel Industries merged to form Akzo Nobel (1994)
Acquired Courtaulds (1998)
Intervet subsidiary acquired Hoechst Roussel Vet (1999)
Technical Services department in Rotterdam, the Netherlands, acquired by
Stork NV
Divested its Polymerization Catalysts & Components business in the U.S. to
Basell Polyolefins (4/06)
Acquired remaining shares of its Asian Akzo Nobel Chang Cheng Coatings
joint venture (5/06)
Divested its Ink and Adhesive Resins business to Hexion Specialty
Chemicals (6/06)
STOCK-FINANCIAL HISTORY: NASDAQ--AKZOY / Euronext Amsterdam--AKZ
Revenue EUR13.0M (YE 05) compared to EUR12.833M (YE 04)
Net income EUR 961M (YE 05) compared to EUR945M (YE 04)
(YE 04)
SUBSIDIARIES/DIVISIONS: 13 business units
Subsidiaries in more than 80 countries
Feixiang to form a 50/50 joint strategic alliance 8/06
Chemicals venture
(Zhangjiagang)
Co. Ltd.
PRODUCTS ON MARKET: HUMAN HEALTHCARE: Andriol®, Cerazette®, Desogen® (US),

Esmeron®, Follistim® (US/Japan), Gracial®, Implanon®, Laurina®, Livial®,
Marvelon®, Mercilon®, Norcuron®, NuvaRing®, OncoTice / Tice BCG,
Orgalutran®, Ovestin®, Pregnyl®, Puregon®, Remeron SolTab®,
Remeron®, Riselle®, TOF-watch, Zemuron® (US)
Animal healthcare products

Coatings products
Chemicals products
Alberta Research Council Inc.

NuRx Services, 250 Karl Clark Road
Edmonton T6N 1E4, Canada
Phone: (780) 450-5111; Fax: (780) 450-5333
Web: www.arc.ab.ca/nurx
E-mail: nurx@arc.ab.ca
KEY PERSONNEL: Tom Facklam; VP, Life Sciences
Donna M. Day; Manager, NuRx Services
Member--Society for Industrial Microbiology
Established western Canada's first large-scale biologics manufacturing
facility for development, scale-up and manufacturing
FACILITIES: 1,400 sq. m. pilot plant housing highly instrumented fermenters (oxygen
enrichment and process monitoring) ranging in scale from 20 liters to 5,000
liters
Biotechnology lab that includes a fermentation suite for small-scale research
QC lab has Health Canada establishment license for CGMP analysis
®
STOCK-FINANCIAL HISTORY: Government agency

SUBSIDIARIES/DIVISIONS: NuRx Services
BUSINESS STRATEGY: Provide contract R&D, scale-up and manufacturing services for companies
using bacterial, yeast (including pichia), algal, fungal, insect cell and rDNA
fermentation processes
Biowest Inc. animal vaccine five-year 12/97
manufacturing
agreement
MicroBio Rhizobium manufacturing 1/95
RhizoGen Corp. agreement
Nuvotech collaboration 12/93
Ventures agreement
International
Veterinary memorandum of 3/98
Infectious understanding to
Diseases develop animal
Organization vaccines
RESEARCH & DEVELOPMENT: Contract R&D using bacterial, yeast (including Pichia), algal, fungal and
rDNA processes
Carbohydrate chemistry, process engineering, fermentation optimization and
scale-up manufacturing, including biopharmaceuticals, and enzymes
Alderon Biosciences Inc.

2810 Meridian Parkway, Suite 152
Durham NC 27713, US
Phone: (919) 544-8220; Fax: (919) 544-9808
Web: www.alderonbiosciences.com
E-mail: info@alderonbiosciences.com
KEY PERSONNEL: Robert Henkens, Ph.D.; President and CEO
John O'Daly; VP and COO
Marek Wojciechowski; Director, R&D
HISTORY: Founded in August 2001, building on technology of AndCare (now a division

of Alderon Biosciences)
SUBSIDIARIES/DIVISIONS: Beaufort, N.C. location:
120 Turner Street
Beaufort, NC 28516
Phone: (252) 728-2964
Fax: (252) 728-2109
BUSINESS STRATEGY: Provide alternative, low-cost, simple to use diagnostic systems for medical,
environmental, and laboratory research and testing needs
RESEARCH & DEVELOPMENT: Technologies include unique electrode surfaces modified with colloidal gold
or biomaterials (such as gene probes, enzymes, antibodies, other proteins,
etc.) and proprietary electroanalytical techniques
PRODUCTS ON MARKET: Portable electrochemical instruments
Disposable electrochemical sensors
Test kits
Assay reagents and accessories
Instrument accessories
®
Alltech Inc.
3031 Catnip Hill Pike
Nicholasville KY 40356-9769, US
Phone: (859) 885-9613; Fax: (859) 885-6736
Web: www.alltech.com
E-mail: info@alltech.com
KEY PERSONNEL: Dr. T. P. Lyons; President
W. J. Cheek; VP, Marketing
N. Hohman; VP, Finance
K. A. Jacques, Ph.D.; Director, Nutrition
Dr. Karl Dawson; Director, Worldwide Research
Dr. Ronan Power; Director, Research
HISTORY: Founded in 1980 as a private company
Conducts research and product development at 25 universities
Sells products to more than 85 different countries
Holds annual symposium on biotechnology in feed industry
FACILITIES: 100,000 sq. ft. biotechnology center; 140 acres of property (over $20M
invested in property)
56,000 sq. ft. corporate headquarters (opened in 2004)
Research farm
Opened fermentation block with $2M capital investment (3/88), since
increased capital
North American Bioscience Center in Nicholasville, KY--50 employees
European Bioscience Center in Dublin, Ireland--40 employees
Chinese Bioscience Center Beijing--25 employees
14 production facilities around the world
SUBSIDIARIES/DIVISIONS: Subsidiaries in 35 countries
Animal Nutrition Division, Human Nutrition Division, Agronomic Division,
Alltech Aquaculture
BUSINESS STRATEGY: Improve animal health and performance by adding nutritional value to
animal feed, enhancing the performance of the animal and increasing
animal production
RESEARCH & DEVELOPMENT: Yeast-derived products to maximize animal health through nutrition
PRODUCTS ON MARKET: TOP BRANDS:
ANIMAL NUTRITION: Bio-Mos®, Bioplex® Mineral Range, MTB-100®,
Mycosorb®, Sel-Plex®, Sil-All®, Yea-Sacc®1026
HUMAN NUTRITION: ExlPrime™, Preventox™, All-BGY™, Bio-Mos FG™
AGRONOMIC: Crop-Set™, Turf-Set™, Stubble-Aid™, Grain- Set™, Agro-
Mos™, Compost-Aid™
AQUA: Bio-Mos™ Aqua Grade, Aqua-Mos™, NuPro®, De-Odorase™,
Bioplex®, Sel-Plex®, Mycosorb®, Shrimp-Pak 604™, Allzyme® SSF
Lactoferrin in development
Antisalmonella program in development
New bioherbicide in development
New phytase enzyme in development
Range of immune modulators in development
®
Altair Nanotechnologies Inc.

204 Edison Way
Reno NV 89502, US
Phone: (775) 856-2500; Fax: (775) 856-1619
Web: www.altairnano.com
KEY PERSONNEL: Jon Bengston; Chairman
Alan J. Gotcher, Ph.D.; CEO and President
Edward H. Dickinson; CFO
Douglas K. Ellsworth; Sr. VP, Performance Materials
Roy Graham; Sr. VP, Commercial Development
Ken Lyon; VP, Business Development
Bruce Sabacky, Ph.D.; CTO
Dennis Nagle; VP, Manufacturing
HISTORY: Changed name from Altair International (8/01)
STOCK-FINANCIAL HISTORY: NASDAQ--ALTI (Capital Market)
Revenue $2.807M (YE 05) compared to $1.152M (YE 04)
Net loss <$9.937M> (YE 05) compared to <$7.002M> (YE 04)
Loss per share <$0.17/share> (YE 05) compared to <$0.14/share> (YE 04)
Average shares outstanding 57.767M (YE 05) compared to 48.677M (YE
04)
Total assets $33.464M (YE 05) compared to $15.547M (YE 04)
SUBSIDIARIES/DIVISIONS: Life Sciences division
Performance Materials division
INVESTMENTS: Altairnano Bateman Titania, Inc.--joint venture with Bateman Engineering

BV
Elanco Animal development of animal research, licensing 5/06
Health Division health products using and
(Eli Lilly and Co.) Altairnano's commercialization
nanotechnology-based agreement
products
Spectrum human therapeutic and exclusive worldwide 1/05
Pharmaceuticals diagnostic applications licensing agreement
Inc. to develop, market and
sell RenaZorb™
product line
PRODUCTS ON MARKET: RenaZorb™ products for phosphate control in patients with Chronic Kidney
Disease and hyperphosphatemia associated with End Stage Renal Disease
Renalan products for phosphate control in companion animals suffering from
Chronic Renal Failure
Altium TiNano 40 Series nano-sized TiO2 products
NanoCheck™ for phosphate control in water treatment
TiNano Spheres for drug and chemical delivery
Titanium dioxide and Zirconia based thermal spray grade powders
®
Altus Pharmaceuticals Inc.

125 Sidney Street
Cambridge MA 02139-4807, US
Phone: (617) 299-2900; Fax: (617) 299-2999
Toll-free phone: (888) ALT-CLEC
Web: www.altus.com; E-mail: info@altus.com
KEY PERSONNEL: John Richard; Chairman
Sheldon Berkle; President and CEO
Jonathan Lieber; VP, CFO and Treasurer
Alexey L. Margolin, Ph.D.; Sr. VP, Research and Preclinical Development
and CSO
Burkhard Blank, M.D.; Sr. VP, Medicine, Regulatory Affairs and Project
Management
Renato Fuchs; Sr. VP, Manufacturing and Technical Operations
Don G. Burstyn, Ph.D.; VP, Regulatory Affairs and Quality Assurance
Alan Kimura, M.D., Ph.D.; VP, Clinical Development and Medical Affairs
Robert Gallotto; VP, Commercial Development and Alliance Management
Lauren Sabella; VP, Commercial Development
John M. Sorvillo, Ph.D.; VP, Business Development
HISTORY: Founded in December 1992
FACILITIES: 3,000 sq. ft. fully equipped facility
STOCK-FINANCIAL HISTORY: NASDAQ--ALTU
IPO--7M shares at $15/share, $105M (1/06)
Loss per share <$22.13/share> (YE 05) compared to <$17.33/share> (YE
04)
Average shares outstanding 1.719M (YE 05) compared to 1.704M (YE 04)
PRIVATE PLACEMENTS: Raised $35M in private financing (10/01)
Raised $15M in second closing of Series B financing (12/01)
Raised $51M in Series C financing (5/04)
SUBSIDIARY OF: Vertex Pharmaceuticals Inc. (see separate entry)
PRINCIPAL INVESTORS: BankInvest
China Development Industrial Bank (CDIB)
Clariden Bank
CMEA Ventures
Hotung International Co. Ltd.
Nomura International
Palladin Group
U.S. Venture Partners
Vertex Pharmaceuticals
Warburg Pincus
FINANCIAL INFORMATION: Awarded $500K grant to develop catalysts to neutralize nerve agents using
Cross-Linked Enzyme Crystal technology (1/97)
Received $51M in Series C financing led by Warburg Pincus and including
U.S. Venture Partners, Nomura Phase4 Ventures, BankInvest, CMEA
Ventures and Clariden Bank (5/04)
BUSINESS STRATEGY: Develop a series of products jointly with potential users while retaining broad
rights to distribute to entire market

Dr. Falk Pharma TheraCLEC development and 2/03
GmbH commercialization
agreement
®
GlaxoSmithKline biocatalysts development 7/93

plc agreement
Nagase & Co. biocatalysts joint development 11/93
agreement
Novartis AG cross-linked enzyme two-year R&D 5/96
crystal brand forms of collaboration
subtilisin for use in
detergents
U.S. Department CLEC technology for $100K research 1/96
of Defense high performance grant
catalysts to detoxify
nerve agents
RESEARCH & DEVELOPMENT: Develop highly stable forms of enzymes used in chemical synthesis
PRODUCTS ON MARKET: ChiroCLEC™-BL for performing chiral resolutions and regioselective

reactions in aqueous and organic media
ChiroCLEC™-CR for performing resolutions of chiral chemicals primarily
esters, alcohols, and acids
ChiroCLEC™-EC for resolving alcohols, amines, and acids
ChiroCLEC™-PC for resolving alcohols, acids, and esters under a variety of
reaction conditions
ChiroKit™-EH for performing resolutions of alcohols, acids, and esters by
ester hydrolysis
ChiroKit™-TE for performing resolutions of alcohols and amines by acylation
reactions
PeptiCLEC™-BL for synthesizing peptides and peptidomimetics
PeptiCLEC™-TR for performing peptide coupling of both protected and
unprotected peptides
PeptiKit™ for performing quick identification of best catalyst for peptide
coupling chemistry
SynthaCLEC-PA catalyst for bulk manufacture of semi-synthetic penicillin
antibiotics
TheraCLEC (ALTU-135) in Phase II clinicals, orphan
drug status
ALTU-238 for growth deficiency in Phase II clinicals
ALTU-237 for kidney stones/primary in preclinicals
hyperoxaluria (oral)
ALTU-236 for phenylketonuria (oral) in preclinicals
Aluline Ltd.
Harbour House, 1 Aldborough Street
Blyth NE24 2EU, UK
Phone: +44 (0) 1670 544 322; Fax: +44 (0) 1670 544 340
Web: www.aluline.co.uk
E-mail: enquiry@aluline.co.uk
KEY PERSONNEL: William G. Clark; President
Caroline Clark; Exec. VP
P. Abdo; Purchasing Manager
Ian Richardson; Scientist
FACILITIES: 1,200 sq. ft. headquarters
6,000 sq. ft. manufacturing facility
®
SUBSIDIARIES/DIVISIONS: Aluline LDA--Portugal

Aluline LLC--Dubai
BUSINESS STRATEGY: Supply and manufacture products that do not harm microorganisms in
drainage
RESEARCH & DEVELOPMENT: Chemicals for industrial use

PRODUCTS ON MARKET: Alucleanse stain and odor remover
Aluclean multipurpose detergent
Aluzyme grease trap and drain treatment
Aluclear dish cleaner
Alurinse rinse aid
Alucare cleaner
Aluscale scale build-up remover
Alusoil crystal granules
Alupro biological urinal tablets
Freshloo toilet cleaner
Aquaflush cleaner
Aluclean degreaser
Aluwash
Alubac
Aluline spray polish
Aluclean drain cleaner
Aluglaze
Aluline beerline cleaner
Aluextract
AMDL Inc.
2492 Walnut Avenue, Suite 100
Tustin CA 92780-6953, US
Phone: (714) 505-4460; Fax: (714) 505-4464
Web: www.amdl.com
E-mail: info@amdl.com
KEY PERSONNEL: William M. Thompson III, J.D., M.D.; Chairman
Gary L. Dreher; President and CEO
Akio Ariura; CFO
HISTORY: Founded in June 1987
To acquire Jiangxi Jade Biochemistry Pharmacy Co. Ltd. and Yangbian
Yiqiao Biochemistry Pharmacy Co. Ltd. (as of 5/06)
4,000 sq. ft. R&D and manufacturing facilities
STOCK-FINANCIAL HISTORY: AMEX--ADL
Revenue $67.565K (YE 05) compared to $186.182K (YE 04)
PRIVATE PLACEMENTS: Raised $1.2M from combined Regulation D/Regulation S private offering of
shares and warrants (12/04)
Raised $1.07M from combined Regulation D/Regulation S private offering of
shares and warrants (8/05)
Raised $1.812M from combined Regulation D/Regulation S private offering
of shares and warrants (4/06)
BUSINESS STRATEGY: Supply countries with underserved medical markets with premier diagnostic
products that are accurate, fast and easy to use
®
RESEARCH & DEVELOPMENT: Tumor-marker technology for cancer

PRODUCTS ON MARKET: DR-70 - tumor-marker detection test
PyloriProbe - IVD test for antibodies to H. pylori
More than 300 nonproprietary tests, including CEA for colon cancer, PSA for
prostate cancer and AFP for liver cancer
DR-70 tumor marker for lung cancer filed 510K application
American Radiolabeled Chemicals Inc.

101 ARC Dr.
St. Louis MO 63146, US
Phone: (314) 991-4545; Fax: (314) 991-4692
Web: www.arc-inc.com; E-mail: arcinc@arc-inc.com
KEY PERSONNEL: Surendra Gupta, Ph.D.; Chairman, President, CEO and Purchasing
Manager
Karen Gupta; Exec. VP
Kamal Das, Ph.D.; Sr. Scientist
Chan Vora, Ph.D.; Sr. Scientist
Phil Korb; Scientist
HISTORY: Founded in September 1983
Acquired Radiochemicals Business from Tocris Bioscience (7/05)
2,500 sq. ft. R&D facilities
4,000 sq. ft. manufacturing facilities
20,000 sq. ft. office warehouse building
BUSINESS STRATEGY: Provide high-quality radiolabeled products for biomedical research
RESEARCH & DEVELOPMENT: Radiolabeled drugs

PRODUCTS ON MARKET: Catalog of more than 2,500 different radiolabeled products
Analox Instruments Ltd.

8 Goldhawk Industrial Estate, Brackenbury Road
London W6 0BA, UK
Phone: +44 (0)20-8749-7635; Fax: +44 (0)20-8740-6608
Web: www.analox.com
E-mail: info@analox.com
KEY PERSONNEL: Dr. David Redstone; President
Dr. Stuart Price; Director, R&D
SUBSIDIARIES/DIVISIONS: Analox Instruments U.S.A. (see separate entry)
P.O. Box 208
Lunenburg, MA 01462-0208
Phone: (978) 582-9368; Fax: (978) 582-9588
®
BUSINESS STRATEGY: Develop instrumentation for clinical chemistry, biotechnology, sports science
and industrial applications
RESEARCH & DEVELOPMENT: Biosensors, novel diagnostic techniques

PRODUCTS ON MARKET: Clinical analyzers:
GM9 for the analysis of glucose
LM5 for the analysis of lactate
AM1 for the analysis of alcohol in blood
GL5 for the analysis of glucose, lactate, cholesterol, uric acid and alcohol
GM7 for the analysis of glucose, lactate, urea, uric acid, cholesterol, alcohol,
acetoacetate, 3-hydroxybutyrate, creatinine, pyruvate, ammonia, glutamine,
glycerol and triglycerides.
Industrial/Biotech analyzers:
AM2/AM3 for the analysis of ethanol
AM5 for the analysis of methanol
LM5 for the analysis of lactate
GL6 for the analysis of glucose, lactate, methanol, glycerol and ethanol
GM8 for the analysis of glucose, lactate, methanol, glycerol, urea, ethanol,
sucrose, lactose, pyruvate, ammonia and glutamine
Analox Instruments U.S.A.

P.O. Box 208
Lunenburg MA 01462-0208, US
Phone: (978) 582-9368; Fax: (978) 582-9588
Web: www.analox.com
E-mail: info@analoxusa.com
KEY PERSONNEL: Dr. David Redstone; President
Martin Widdowson; Exec. VP
Dr. Stuart Price; Director, R&D
SUBSIDIARY OF: Analox Instruments Ltd. (see separate entry)
BUSINESS STRATEGY: Develop instrumentation for clinical chemistry, biotechnology, sports science
and industry
RESEARCH & DEVELOPMENT: Biosensors, novel diagnostic techniques

PRODUCTS ON MARKET: Metabolite analyzers
GM9-glucose
LM5-lactate
GM7 microstat (ammonia, ketones, glucose, lactate, cholesterol and
alcohol)
AM1-alcohol
GL5 microstat (glucose, lactate, cholesterol, uric acid and alcohol)
®
Applera Corp.
P. O Box 5435, 301 Merrit 7
Norwalk CT 06856-5435, US
Phone: (203) 840-2000; Fax: (203) 762-6000
Web: www.applera.com
KEY PERSONNEL: Tony L. White; Chairman, President and CEO
Dennis Winger; Sr. VP and CFO
Kathy Ordonez; Sr. VP and President, Celera Genomics Group
Catherine M. Burzik; Sr. VP and President, Applied Biosystems Group
Barbara J. Kerr; VP, Human Resources
William B. Sawch; Sr. VP and General Counsel
Peter Dworkin, VP, Investor Relations and Corporate Communications
EMPLOYEES: 5.024 employees
HISTORY: Member--Biotechnology Industry Organization
Member--Personalized Medicine Coalition
Acquired Applied Biosystems Inc. (2/93)
Acquired Tropix
Acquired amplified fragment-length polymorphisms (AFLP) technology from
Keygene NV in takeover of GenScope Inc. (2/97)
Acquired PerSeptive Biosystems Inc. for $13/share in stock exchange worth
$360M (1/98)
Acquired Molecular Informatics Inc. (11/97)
Formed genomics company with The Institute for Genomic Research (TIGR)
(5/98)
Changed name from PE Corp. to Applera Corp. (11/00)
STOCK-FINANCIAL HISTORY: Applera has two classes of stock: Applera-Applied Biosystems stock and
Applera-Celera Genomics stock. Applera-Applied Biosystems stock is listed
on the New York Stock Exchange under the ticker symbol 'ABI' and is
intended to reflect the relative performance of the Applied Biosystems
Group. Applera-Celera Genomics stock is listed on the New York Stock
Exchange under the ticker symbol 'CRA' and is intended to reflect the
relative performance of the Celera Genomics Group. There is no single
security that represents the performance of Applera Corp. as a whole
SUBSIDIARIES/DIVISIONS: Celera Genomics (see separate entry)
Applied Biosystems Inc. (see separate entry)
BUSINESS STRATEGY: Improve human health and society by understanding and applying the power
of biology to develop breakthrough research technologies, diagnostic
products and drugs
PRODUCTS ON MARKET: DNA and PCR-related systems

Applied Biosystems-MDS SCIEX LC/MS systems
Protein analysis systems
Custom oligosynthesis service
Genetic analysis systems for forensic, animal and plant breeding
Bioinformatics systems for genetic research and genomic drug discovery
Forensics--human identification
Functional genomics systems
Certain infectious disease assays and genetic assays
®
Applied Biosystems Inc.

850 Lincoln Centre Drive
Foster City CA 94404, US
Phone: (650) 638-5800; Fax: (650) 638-5884
Web: www.appliedbiosystems.com
KEY PERSONNEL: Tony L. White; Chairman, President and CEO, Applera Corp.
Catherine M. Burzik; President
Dennis A. Gilbert, Ph.D.; CSO
Paul D. Grossman, Ph.D.; VP, Strategiic Planning and Business
Development
John Duddy; VP, Global Marketing
Laura Lauman; Division President, Proteomics and Small Molecule
Sandeep Nayyar; VP, Finance
Michael G. Schneider; Division President, Service
Mark P. Stevenson; Division President, Molecular and Cell Biology
Leonard Klevan; Division President, Applied Markets
HISTORY: Founded in 1981 in Foster City, Calif.
Sold interest in Celera Diagnostics joint venture to Celera Genomics (1/06)
Acquired the research products division (now called Asuragen Inc.) of
Ambion Inc. (3/06)
Acquired Agencourt Personal Genomics Inc. (7/06)
FACILITIES: US main facilities:
-Foster City, Calif. (headquarters)
-Pleasanton, Calif.
-Bedford, Mass.
-Framingham, Mass.
-Austin, Texas
STOCK-FINANCIAL HISTORY: NYSE--ABI
IPO--Raised $22M (1983)
Revenue $1.8b (YE 05) compared to $1.7b (YE 04)
Net income $236.9M (YE 05) compared to $182.9M (YE 04)
SUBSIDIARIES/DIVISIONS: Applied Biosystems Inc. is one of two businesses of Applera Corp.
SUBSIDIARY OF: Applera Corp. (see separate entry)
PRINCIPAL INVESTORS: Asset Management Co.
BUSINESS STRATEGY: The Applied Biosystems Group serves the life science industry and research
community by developing and marketing instrument-based systems,
consumables, software, and services. Customers use these tools to analyze
nucleic acids (DNA and RNA), small molecules, and proteins to make
scientific discoveries and develop new pharmaceuticals. Applied
Biosystems’ products also serve the needs of some markets outside of life
science research, which we refer to as 'applied markets,' such as the fields
of: human identity testing (forensic and paternity testing); biosecurity, which
refers to products needed in response to the threat of biological terrorism
and other malicious, accidental, and natural biological dangers; and quality
and safety testing, for example in food and the environment. Applied
Biosystems is headquartered in Foster City, Calif., and reported sales of
nearly $1.8 billion during fiscal 2005.

Affymetrix Inc. manufacturing, sales nonexclusive, 12/05
and use of microarrays worldwide licensing
for gene expression agreement
analysis
®
Dionex Corp. (with development of IC- alliance 6/05

MDS Sciex) MS/MS and LC/MS/MS
solutions for emerging
market opportunities
DuPont Qualicon development of next- strategic alliance 8/05
generation DNA
detection tests and
systems for food
testing, targeted food
quality and safety
assessment
Geospiza Inc. integration of genetic platform 2005
analysis products collaboration
agreement,
expanded 8/06
Hitachi High- development and exclusive 1/06
Technologies commercialization of collaboration
Corp. capillary agreement
electrophoresis-based
DNA analysis
technologies
Invitrogen Corp. Deliver advanced strategic alliance 6/05
proteomic solutions for
biomarker discovery
and validation
National Center investigation of toxicity collaboration 3/05
for Toxicological of diabetes drugs
Research of the
FDA
National Institute pharmacogenomic R&D agreement 6/05
of Genomic therapeutics
Medicine (Mexico)
Qiagen NV PCR and PCR-related expanded licensing 12/05
technologies agreement
VisiGen sequencing equity investment 10/05
Biotechnologies technologies
RESEARCH & DEVELOPMENT: Focused on the following markets: basic research, commercial research
(pharmaceutical and biotechnology) and standardized testing, including
forensic human identification, paternity testing and food testing
Development and marketing of instrument-based systems, consumables,
software and services to the life science industry and research community
PRODUCTS ON MARKET: Products for:
DNA Sequencing
Gene Expression
SNP Genotyping
Gene Expression Array
Biochromatography
Cellular Detection Systems
Human Identification/Forensics
BioSecurity (infectious disease identification)
Informatics Software
Mass Spectrometry
Molecular Diagnostics
Molecular Microbiology
Nucleic Acid Sample Preparation
PCR
Peptide Synthesis
Protein Quantitation
Protein Sequencing
Real-Time PCR
Surface Plasmon Resonance
®
Services include:
Custom Services
Support Plans
Service Call Center
Financing Solutions
Applikon Biotechnology Inc.

1180 Chess Drive
Phone: (650) 578-1396; Fax: (650) 578-8836
Web: www.applikon.com
E-mail: info@applikonbio.com
KEY PERSONNEL: John Chory; President
Vickie Sanchez; Purchasing Manager
Arthur Oudshoorn; Director, Biotechnology Division
Christine Corsette; Director, Product Development
FACILITIES: 10,000 sq. ft. facility
SUBSIDIARY OF: Applikon BV Netherlands
BUSINESS STRATEGY: Develop, manufacture and supply bioreactor systems for both research and
production use. Focus on development of innovative technologies and
products compliant with cGMP regulations
Finesse LLC TruBio O/S--Bioreactor licensing agreement 9/06
Control Operating
System
PRODUCTS ON MARKET: Fermentors, cell culture reactors, single use bioreactors, micro-bioreactors,
controllers, PLC integration, fieldbus I/O, sensors, software, biomass
monitor and cell separation
Arch Chemicals Inc.

501 Merritt 7
Norwalk CT 06856-5204, US
Phone: (203) 229-2900; Fax: (203) 229-3652
Web: www.archchemicals.com
KEY PERSONNEL: Michael E. Campbell; Chairman, CEO and President
Paul J. Craney; Exec. VP
Louis S. Massimo; Exec. VP
Hayes Anderson; VP, Human Resources
Sarah A. O’Connor; VP, General Counsel and Secretary
W. Paul Bush; VP and Treasurer
Steven C. Giuliano; Controller
HISTORY: Founded in August 1998 as a wholly-owned subsidiary of Olin Corp.
Became a separate, publicly-held company in February 1999
Acquired remaining 50 percent share of Nordesclor SA joint venture (12/05)
®
FACILITIES: Research sites in Cheshire, Conn.; New Castle, Dela.; South Plainfield, N.J.;
Conley, Ga.; Blackley, U.K.; and Pianoro, Italy
STOCK-FINANCIAL HISTORY: NYSE--ARJ
Sales $1.305b (YE 05) compared to $1.121b (YE 04)
BUSINESS STRATEGY: Provide innovative, chemistry-based solutions to control the growth of

harmful microbes. Concentration is in water, hair and skin care products,
pressure-treated wood, paints and building products, and health and
hygiene applications.
PRODUCTS ON MARKET: Treatment products: HTH water products (HTH®, Poolife®, Baquacil® and
Baqua Spa®)
Personal care and industrial biocides: Omadine®, Omacide®, Triadine®,

Proxel®, Purista®, Vantocil®, Reputex®, Cosmocil® and Densil® biocides
Wood protection and industrial coatings: Wolman®, Dricon®, Tanalith®,

Vacsol® and Resistol®
Performance products: Urethane intermediate products, hydrazine hydrates

and derivatives
Arch Personal Care Products LP

70 Tyler Place
South Plainfield NJ 07080, US
Phone: (908) 561-5200; Fax: (908) 561-9174
Web: www.archpersonalcare.com
E-mail: archpc@archchemicals.com
KEY PERSONNEL: Michael E. Campbell; Chairman, CEO and President, Arch Chemicals
Paul J. Craney; Exec. VP, Arch Chemicals
Louis S. Massimo; Exec. VP, Arch Chemicals
Formerly Brooks Industries Inc.
Acquired by Arch Chemicals Inc. (2000)
SUBSIDIARY OF: Arch Chemicals Inc. (see separate entry)

Ausimont SpA Fomblin sales agreement 1992
Knoll Microcheck protective enzyme sales agreement 1992
system
Polymedica Inc. Pu/Meth entrapment joint venture 1991
technology
Quest ceramides sales agreement 1997
PRODUCTS ON MARKET: Zinc Omadine® anti-dandruff actives

Animal, marine, milk, plant and silk proteins
®
Biotechnological actives: Acqua-Biomin® Calcium Y3, Acqua-Biomin®,

βetavera®, Biocell SOD, Biodynes®, Biomin® Acquacinque Liquid, Biomin®
Marine, Bio-Oil® HBSL, Biophos 35, Bio-Plex NMF, Bio-Plex RNA, Bio-
Pol®, Hydromide™ Blend, Kudzu Zymbiozome® Fermentum, Lotus
Zymbiozome® Fermentum, Musol 20, Peptamide™ 6, Phytohyaluronate,
Pseudocollagen, Pseudofilaggrin, Soy Zymbiozome® Fermentum, Vegepol,
Vitazyme®
Deliver systems: Brookosome® ACE, Brookosome® ACEBC, Brookosome®

EPO, Brookosome® P, Brookosome® Retinol, Brookosome® SOD,
Brookosome® TA, Brookosome® TRF®, Brookosome® V, Brookosome®
Willowbark, Cationic SMEC, ChronoSphere® Bio-Pol® OE, ChronoSphere®
Hyaluronic, ChronoSphere® Sal, Emollient SMEC, Liposome Cocoa Extract
/ Caffeine, SMEC Concentrate #1, SMEC DHA, SMEC Sun, Spiraplex®
technology
Functional ingredients: AquaPhos TD, Brookswax™ D, Brookswax™ P/P,

CT-100, Gel Base, Gel Base 2, Gel Base BSM 5, Gel Base BSM PE, Gel
Base BSM PT, Gel Base BSM VT, Gel Base Product Line, Gel Base SIL,
KeraCoat, Liquiwax™, Liquipure™ EDG NF, Liquiwax™, Quamectant AM-
50, Relaxer Concentrate Product Line, SilSlip™, ViscUp® 160
Rheology modifiers: β-Gel™, ViscUp® EZ
Natural and Plant Actives: Genti-Fol® SA, Honeyquat 50, Marula Oil,
Multifruit® BSC, NAB® Arnica Extract, NAB® Asafetida Extract, NAB®
Clintonia Borealis Extract, NAB® Fennel Seed Extract, NAB® Grape
Extract, NAB® GrassRoots Extract, NAB® Hawthorn Extract, NAB®
Jewelweed Extract, NAB® Mushroom Extract, NAB® Pikea Robusta, NAB®
Queen of the Prairie Extract, NAB® Red Clover Isoflavones, NAB® Rhodiola
Extract, NAB® Siberian Ginseng Extract, NAB® Spotted Geranium Extract,
NAB® Willowbark Extract, NAB® Yucca Glauca Extract, Oligoquat M,
Planell® Oil, ProCircul8, Vital Hair & Scalp Complex
Preservation systems: Biovert® Enzyme and Substrate, Cosmocil® CQ,

Mikrokill™ COS, Mikrokill™ PCC
Archer Daniels Midland

4666 Faries Parkway
Decatur IL 62526, US
Phone: (217) 424-5200; Fax: (217) 424-4004
Web: www.admworld.com; E-mail: info@admworld.com
KEY PERSONNEL: G. Allen Andreas; Chairman
Patricia A. Woertz; CEO and President
David J. Smith; Exec. VP, Secretary and General Counsel
William H. Camp; Exec. VP, Global Processing
John D. Rice; Exec. VP, Global Marketing and Risk Management
Lewis W. Batchelder; Sr. VP, Agricultural Services
Edward A. Harjehausen; Sr. VP, Food and Feed Ingredients
Brian F. Peterson; Sr. VP, Corporate Affairs
Douglas J. Schmalz; Sr. VP and CFO
HISTORY: Formed from the acquisition of Midland Linseed Products Company by
Archer-Daniels Linseed Company (1923)
®
STOCK-FINANCIAL HISTORY: NYSE--ADM

Net earnings $1.044b (YE 05) compared to $494.710M (YE 04)
Average shares outstanding 656.123K (YE 05) compared to 649.810K (YE
04)
Metabolix Inc. eco-friendly, high- commercialization 11/04
performance natural agreement
plastics
RESEARCH & DEVELOPMENT: Fermentation for alcohol production, ethanol

High-fructose corn syrup, enzymes, amino acids
Protein research
PRODUCTS ON MARKET: Feed-grade amino acids, vitamins/colorants
Lysine, threonine, astaxanthan
Food additives: citric acid, lactic acid, xantham gum
Distilled monoglycerides, sodium stearyl lactate, isoflavones
Argonne National Laboratory

9700 South Cass Avenue
Argonne IL 60439, US
Phone: (630) 252-2000; Fax: (630) 252-5230
Web: www.anl.gov; E-mail: partners@anl.gov
KEY PERSONNEL: Robert Rosner; Laboratory Director
Donald Joyce; Deputy Laboratory Director
Adam Cohen; COO
Stuart A. Rice; Scientific Advisor to the Directorate
Phillip Finck; Associate Laboratory Director, Applied Science and
Technology
J. Murray Gibson; Associate Laboratory Director, Scientific User Facilities
Alfred P. Sattelberger; Associate Laboratory Director, Physical Sciences
Rick Stevens; Associate Laboratory Director, Computing and Life Sciences
FACILITIES: 1,500-acre facilities site owned by DOE and operated by the University of
Chicago
STOCK-FINANCIAL HISTORY: Government agency (U.S. Department of Energy)
SUBSIDIARIES/DIVISIONS: Argonne National Laboratory West (Idaho, U.S.)
BUSINESS STRATEGY: Engage in multi-disciplinary research that further increases understanding of
the fundamental mechanisms of life and enables valuable advances in
health protection, environmental restoration, energy production, industrial
processing and other applications
Conduct clinical studies in the areas of bioinformatics, genomics, protein

engineering, biochips, proteomics, bio-based chemicals, structural biology,
and environmental technologies, while maintaining a technology transfer
program that is directed toward enhancing the Laboratory's research and
development programs, meeting federal, national, and international research
needs, and increasing the worldwide competitiveness of U.S. industry
®

Ongoing multi-disciplinary
technology technology transfer
transfer agreements
collaborations for
drug discovery,
contract R&D,
patent licensing,
etc.
RESEARCH & DEVELOPMENT: Bio-chemicals

Nanobiotechnology
Biomimetic membranes
Structural biology
Structural genomics
RNAi technology
Biodefense applications
Environmental biotechnologies
Biochip technology
Batteries and fuel cells
Materials
Nuclear reactor testing
PRODUCTS ON MARKET: Marketable services include technology transfer comprised of:

Cost-shared research and development
Reimbursable R&D (Work-for-Others)
Licensing
Technical assistance
Personnel exchange
Arysta LifeScience Corp.

38/39th Floor, St. Luke's Tower, 8-1, Akashicho, Chuo-Ku
Phone: +81 3-3547-4500; Fax: +81 3-3547-4699
Web: www.arystalifescience.com
E-mail: altin@arysta-ls.com
KEY PERSONNEL: John Hagaman; Chairman
Dr. Christopher Richards; President and CEO
Rudorf Van Houten; CFO
Dipak Amin; Global Head, Strategy
Robert Lence; General Counsel
Makoto Saji; Global Head, Corporate Affairs
Tatsumi Ikeda; Global Head, Acquisitions and Licensing
John Killmer; Global Head, Marketing and Supply Chain
Itaru Hori; Head, Japan
Nobumasa Ishiai; Global Head, Life Science
William Lewis; Head, North America and Australasia
Eric Barbedette; Head, Europe, Africa and Middle East
Yukio Arai; Head, South America
EMPLOYEES: 2,300 employees (including affiliated companies)
HISTORY: Founded in 2000 through a consolidation of the Tomen and Nichimen Agro
and LifeSciences businesses
Acquired Azocyclotin from Bayer CropScience (10/05)
Acquired Prothiofos from Bayer CropScience (11/05)
Acquired Omethoate from Bayer CropScience (1/06)
Acquired major sssets of Micro Flo Co. LLC from BASF Corp. (3/06)
®
SUBSIDIARIES/DIVISIONS: Arysta LifeScience North America (www.arystalifescience-na.com)

Arysta LifeScience Europe, Africa and Middle East (www.arysta-eame.com)
Arysta LifeScience South America (www.arystalifescience-sa.com)
PRINCIPAL INVESTORS: Olympus Capital
BUSINESS STRATEGY: Develop, market and distribute high quality crop protection and lifescience
products to global markets
Bayer amitraz, marketing of licensing 4/05
CropScience fluoxastrobin and co- agreements
marketing of
deltamethrin
PRODUCTS ON MARKET: Select®

Captan
Everest®
Orthene®
Elevate®
Asahi Kasei Corp.

1-2 Yurakucho 1-chome, Chiyoda-ku
Tokyo , Japan
Phone: +81 3-3507-2060; Fax: +81 3-3507-2495
Web: www.asahi-kasei.co.jp
KEY PERSONNEL: Nobuo Yamaguchi; Chairman
Shiro Hiruta; President
Masaki Sakamoto; President, Asahi Kasei Fibers
Taketsugu Fujiwara; President, Asahi Kasei Chemicals
Keiji Kamei; President, Asahi Kasei Life & Living
Yoichi Saji; President, Asahi Kasei Construction Materials
Shingo Hatano; President, Asahi Kasei Homes
Makoto Konosu; President, Asahi Kasei EMD
Kei Ohe; President, Asahi Kasei Pharma
HISTORY: Founded in May 1931
STOCK-FINANCIAL HISTORY: Listed on the Tokyo, Osaka, Nagoya, Fukuoka, Sapporo stock exchanges
Net <loss> income ¥59.67b (YE 06) comapred to ¥56.45b> (YE 05)
Earnings <loss> per share ¥42.46/share (YE 06) compared to ¥40.16/share
(YE 05)
Total assets ¥1,376b (YE 06) compared to ¥1,270b (YE 05)
SUBSIDIARIES/DIVISIONS: Group companies:
Asahi Kasei Fibers
Asahi Kasei Chemicals
Asahi Kasei Life & Living
Asahi Kasei Construction Materials
Asahi Kasei Homes
Asahi Kasei EMD
Asahi Kasei Pharma
BioStar Inc. POC infectious disease, development 8/97
instrumented agreement
City of Hope human gene deletion funding basic
technology research
®
Dainippon, Tokyo rabbit TNF joint development

University agreement
Diffchamb SA fish freshness test distribution 3/90
agreement
G. D. Searle & Co. Angiotensin II licensing 1994
antagonist agreement for
Japan
GenVec Inc. Asahi's gene therapy licensing 4/98
applications of tumor agreement for the
necrosis factor alpha U.S.
gene
Kowa Co. Ltd. tPA as an intravenous joint development 1990
injection for agreement
thrombolysis
Kyowa Hakko tissue plasminogen joint development 1/86
Kogyo activator (tPA) agreement
Memorial Sloan- TNF technology transfer
Kettering agreement
Mie University thrombomodulin R&D agreement
Molecumetics Ltd. oral factor VIIA research and 5/97
inhibitors licensing
agreement
Purely Proteins methods for purifying R&D agreement 12/04
Ltd. proteins using Purely
Proteins' ligand
discovery systems
Queens University atrial natriuretic patent licensing 5/87

(Canada) polypeptide agreement
Samuel Lunenfel cancer cell two-year research 3/96
Research communication agreement
Foundation
RESEARCH & DEVELOPMENT: Directed toward the creation of customer value through high-performance
products based in competitive chemical technology, with emphasis on the
development of new businesses in the growing fields of electronics,
medicine, and energy and ecology, for the future development and growth of
the Asahi Kasei Group
All R&D is guided by the principles of green and sustainable chemistry
Main research fields are: material science and polymer science,

microelectronics, electrochemistry, microbiology, µTAS (micro total
analysis), medical care, biochemistry, residential materials, membrane
science and technology, information technology, analysis and simulation
PRODUCTS ON MARKET: Asahi Kasei Pharma: Elcitonin™, Bredinin™, Flivas™, Toledomin™,
Planova™ virus removal filters, artificial kidneys, Sepacell™, leukocyte
reduction filters, blood and plasma filters, contact lenses
Asahi Kasei Chemicals: Suntec™ polyethylene, Tenac™ polyacetal,

Xyron™ modified polyphenylene ether (mPPE), Leona™ nylon 66,
Duranate™, Ceolus™, APR™ photosensitive resins, AFP™ photosensitive
plates, printing plate making systems, Microza™ ultrafiltration and
microfiltration membranes and systems, Hipore™ fine porous membranes
Asahi Kasei EMD: Sunfort™ photosensitive dry film resist (DFR), Pimel™
photosensitive polyimide, Fine pattern coils, Luminous™ plastic optical fiber
®
Associates of Cape Cod Inc.

Falmouth Technology Park, 124 Bernard E. Saint Jean Drive
East Falmouth MA 02536-4445, US
Phone: (508) 540-3444; Fax: (508) 540-8680
Web: www.acciusa.com; E-mail: info@acciusa.com
KEY PERSONNEL: A.J. Meuse, Ph.D.; President and CEO
Michelle Knuth; Director, Finance
Peter Langlais; VP, Business Development and Global Distribution
Alison Skinner, Ph.D.; Exec. VP
While a senior scientist at Woods Hole Oceanographic Institute, Dr. Stanley
Watson, the founder of ACC, developed LAL (limulus amebocyte lysate) for
enumeration of gram-negative bacteria. Recognizing its use for monitoring
lipopolysaccharides in pharmaceutical products, he formed his own
company and was the first licensed by the FDA for sales of LAL
SUBSIDIARY OF: Seikagaku Corp.
BUSINESS STRATEGY: Develop innovative products from the marine environment for the health
care industry
IBEX IBEX's glycobiology distribution 9/05
Technologies Inc. enzymes agreement
RESEARCH & DEVELOPMENT: LAL methodology and test instrumentation

LAL biochemistry
New products from marine organisms
Endotoxin detection
PRODUCTS ON MARKET: Pyrotell® LAL
LAL-5000 automatic endotoxin detection system
Pyrosol® LAL reconstitution buffer
Endotoxin control standard
LAL reagent water (LRW)
Depyrogenated reaction tubes
Pyroplates, pyroblocks
Pyrochrome® chromogenic LAL test kits
Pyrotell-T® turbidimetirc lysate
Fungitell™
Astellas Pharma Inc.

3-11 Nihonbashi-Honcho 2-chome, Chuo-ku
Phone: +81 3-3244-3000; Fax: +81 3-3244-3272
Web: www.astellas.com
KEY PERSONNEL: Hatsuo Aoki, Ph.D.; Chairman
Toichi Takenaka, Ph.D.; President and CEO
Makoto Nishimura, Ph.D.; Chairman and CEO, Astellas Pharma US, Inc.
Toshinari Tamura, Ph. D.; Exec. VP
Masafumi Nogimori; Exec. VP
Sef Kurstjens, M.D., Ph.D.; Head, R&D, US
®

HISTORY: Created from the merger of Fujisawa Pharmaceutical Co. Ltd. and
Yamanouchi Pharmaceutical Co. Ltd. (4/05)
To sell all rights to Aczone gel to QLT Inc. (as of 7/05)
To sell Zepharma Inc. to Daiichi Sankyo Co. (as of 3/06)
Acquired North Carolina-based research facility of Dynogen
Pharmaceuticals Inc. (3/06)
Astellas Pharma U.S. Inc. to acquire Amevive® (alefacept) from Biogen Idec
Inc. (as of 4/06)
Yamanouchi Pharmaceutical Co. Ltd.:

Founded in 1923
Acquired Shaklee Japan K.K. (1989)
Acquired Shaklee Corp. (USA) (1989)
Fujisawa Pharmaceutical Co. Ltd.:

Founded in 1894
SUBSIDIARIES/DIVISIONS: Astellas US LLC--Ill., U.S.
Astellas Pharma US Inc.--Ill., U.S.
Astellas Pharma Manufacturing Inc.--N.Y., U.S.
Astellas Pharma Technologies Inc.--Okla., U.S.
Astellas Research Institute of America LLC--Ill., U.S.
Astellas Pharma Canada Inc.--Ontario, Canada
Astellas Pharma Europe Ltd.--London, U.K.
Astellas BV--The Netherlands
Astellas Pharma Europe BV--The Netherlands
Astellas Pharma GmbH--Germany
Astellas Ireland Ltd.--Ireland
Astellas Pharma SpA--Italy
Astellas Pharma Korea Inc.
Astellas Pharma Taiwan Inc.
Astellas Pharma China Inc.
Astellas Pharma Hong Kong Ltd.
Astellas Pharma Philippines Inc.
Astellas Pharma (Thailand) Co. Ltd.
P.T. Astellas Pharma Indonesia
Astellas Pharma Chemicals Co. Ltd.
BUSINESS STRATEGY: Develop breakthrough products in the areas of immunology, infectious
disease, dermatology, urology and cardiovascular disease while continuing
to explore unmet needs in other areas
Apoxis SA development and licensing 12/05
marketing of FIK866 agreement
AtheroGenics Inc. AGI-1096 as an oral R&D agreement, 1/04
treatment for the extended 2/06
prevention of organ
transplant rejection
Ferring developing and licensing 1/06
Pharmaceuticals marketing of degarelix agreement
in Japan
FibroGen Inc. FG-2216 in Japan licensing 9/04
agreement
FibroGen Inc. rights to certain licensing 4/06
hypoxia-inducible factor agreement
prolyl hydroxylase
inhibitors for the
treatment of anemia,
including FG-2216 and
FG-4592, in Europe,
CIS, Middle East and
South Africa
Ilypsa Inc. ILY101 in Japan licensing 4/06
agreement
®
MerLion new drug candidates discovery and 10/05

Pharmaceuticals derived from natural development
Pte. Ltd. products chemistry agreement
Metabolex Inc. validation of novel drug multi-year research 3/02
targets identified collaboration,
through Metabolex's expanded 5/05
discovery program, for
diabetes and obesity
Nippon Kayaku Gelpart exclusive licensing 2/05
agreement
Portola development of a series licensing 6/05
Pharmaceuticals of Astelas preclinical agreement
Inc. compounds
Suntory Ltd. Farom (antibiotic) marketing 6/97
agreement
Theravance Inc. Theravance's telavancin development and 11/05
commercialization
agreement,
expanded 7/06
Toyama Chemical marketing. development licensing 3/06
Co. Ltd. of oral formulations of agreement
T-3811 in Japan
XenoPort Inc. development and licensing 12/05
commercialization of agreement
XP13512 in Japan and
other Asian countries
RESEARCH & DEVELOPMENT: Diabetes, infectious diseases, gastrointestinal disorders, disorders of the
central nervous system, urology, inflammatory disorders and immunology
(transplants)
PRODUCTS ON MARKET: Adenoscan®
AmBisome®
Flomax®
Prograf®
Protopic®
VESIcare®
astre Corp.
3801 Mount Vernon Avenue, P.O. Box 25766
Alexandria VA 22313-5766, US
Phone: (703) 548-1343; Fax: (703) 783-1340
Web: www.astrecg.com
E-mail: info@astrecg.com
KEY PERSONNEL: R. A. Ackerman; Chairman and Director, R&D
K. Smith; CEO
BUSINESS STRATEGY: Provide research, development, consulting and production of biotechnology
products/process in environmental and medical domains
PRODUCTS ON MARKET: Process and product design services
®
Athenix Corp.
2202 Ellis Road, Suite B
Durham NC 27703, US
Phone: (919) 281-0900; Fax: (919) 281-0901
Web: www.athenixcorp.com
E-mail: info@athenixcorp.com
KEY PERSONNEL: Jerry Caulder; Chairman
Mike Koziel; President and CEO
Markus Andres; COO
Nadine Carozzi; VP, Product Development
Nicholas Duck; VP, Research and Business Development
Mike Schierbeek; CFO
FACILITIES: 11,000 sq. ft. of laboratory and office space
PRIVATE PLACEMENTS: Raised $8M in financing (9/01)
Raised $12.5M in Series B financing (1/04)
Raised $13M in Series C financing (1/06)
SUBSIDIARIES/DIVISIONS: Agriculture
Industrial
PRINCIPAL INVESTORS: Boston Millennia Partners
Eastman Ventures
Finistere Partners
Hunt Ventures
Intersouth Partners
Polaris Venture Partners
BUSINESS STRATEGY: Develop novel products, technologies and processes for agricultural and
chemical applications
Iowa Corn applying innovative research 2/05
Promotion Board technologies to corn cooperation
RESEARCH & DEVELOPMENT: Athenix is a leading biotechnology company that discovers and develops
novel products, technologies and processes for the agricultural and
chemical businesses. Athenix is focused on enhanced plants, microbes,
enzymes and processes for a variety of industry sectors with emphasis on
two major market opportunities: 1) the discovery of genes and proteins for
novel input traits such as insect resistance, nematode resistance and
herbicide tolerance, and their use to develop transgenic plants for the
agricultural chemical and seed industries, and 2) the discovery of genes and
proteins for use in the chemical and animal feed industries.

Herbicide resistant crops (corn, soybean in greenhouse testing, field
and cotton) testing
Insect resistant crops (corn, soybean, in greenhouse testing
cotton and rice)
Nematode resistant crops (soybean) in laboratory testing, plant
testing
®
Atrium Biotechnologies Inc.

1405 boul. du Parc-Technologique
Quebec G1P 4P5, Canada
Phone: (418) 652-1116; Fax: (418) 652-0151
Web: www.atrium-bio.com
E-mail: atrium@atrium-bio.com
KEY PERSONNEL: Pierre Laurin, Ph.D.; Chairman
Luc Dupont; President and CEO
Richard Bordeleau; President, Health and Nutrition
Charles Boulanger; President, Active Ingredients and Specialty Chemicals
John Dempsey; VP, Finance and CFO
HISTORY: Founded in January 2000
Acquired ADF Chimie S/A (5/02)
Acquired Siricie SA (11/03)
Acquired Pure Encapsulations Inc. (3/04)
Acquired Multichem (1/05)
Acquired HVL Inc. and Douglas Laboratories (12/05)
MultiChem subsidiary acquired Amisol Co. Ltd. (5/06)
Acquired assets of Douglas Laboratories Canada (9/06)
STOCK-FINANCIAL HISTORY: TSX--ATB
IPO--6.250M shares at $12/share, $75M (3/05)
SUBSIDIARIES/DIVISIONS: Atrium Biotech USA--Fairfield, N.J.
Unipex SA--Ruiel-Malmaison, France
Pure Encapsulations Inc.--Sudbury, Mass.
Chimiray--Ruiel-Malmaison, France
Atrium Biotech Europe--Marly le Roi, France
Multichem - Quebec--Boucherville, Canada
SUBSIDIARY OF: Aeterna Zentaris Inc. (see separate entry)
BUSINESS STRATEGY: Acquisition program:
-Acquisition of nutritional supplement products or companies
-Acquisition of companies specializing in the manufacturing of active
ingredients and specialty products
-Acquisition of cosmetic active ingredient lines or companies
Inlicensing program:
-Prospect for new products and new technologies among established or
emerging biotech companies and specialized research centres. Atrium
Biotechnologies can offer its strategic partners rapid access to a network of
leading customers
RESEARCH & DEVELOPMENT: New products and new versions of existing products in response to client
requests
Atrium has a patented molecular separation technology platform
PRODUCTS ON MARKET: More than 1,500 active ingredients and specialty chemicals and 400 health
and nutrition finished products
®
Axxora Life Science Inc.

6181 Cornerstone Court East, Suite 103
San Diego CA 92121, US
Phone: (858) 550-8830; Fax: (858) 550-8825
Web: www.axxora.com
E-mail: axxora-usa@axxora.com
KEY PERSONNEL: Georges Chappuis, Ph.D.; CEO and President
Tamara Sales; CFO
Brian Conkle; President, Axxora LLC
Wilfried Boecher; Managing Director, Axxora Deutschland GmbH and
Axxora Ltd.
Silvia Dettwiler; President, Alexis Corp.
Ravi Kalahasthi; Managing Director, Alexis Laboratories
SUBSIDIARIES/DIVISIONS: Axxora LLC--U.S.
Alexis Corp.--Switzerland
Apotech Corp--Switzerland
Axxora Deutschland GmbH--Germany
Axxora Ltd.--U.K.
Alexis Laboratories--U.S.
Apotech Laboratories--Switzerland
PRINCIPAL INVESTORS: Ampersand Ventures
Ventana Growth Fund
BUSINESS STRATEGY: Develop, produce, market and sell life science research reagents worldwide
RESEARCH & DEVELOPMENT: Life science reagents and fine chemical raw materials
PRODUCTS ON MARKET: Nitric oxide pathway reagents
Neurochemicals
Apoptosis
Signal transduction reagents
Endothelins
Human plasma protein and enzymes
Lipids
Phospholipids
Glycolipids
BAC BV (Biotechnology Application Centre)

Huizerstraatweg 28
Naarden 1411 GP, Netherlands
Phone: +31 35-69-92595; Fax: +31 35-69-49576
Web: www.bac.nl, www.captureselect.com
E-mail: info@bac.nl
KEY PERSONNEL: Dr. Laurens Sierkstra; CEO
Dr. Ingeborg van Gemeren; VP, Business Development
HISTORY: Founded in 1995 as a subsidiary of Unilever
Spun off from Unilever
®
FACILITIES: Production facility comprises a fermentation development laboratory (10L

fermenters), a dedicated quality control laboratory, and a fully contained
processing plant (with medium preparation and continuous sterilization,
fermentation and downstream processing and aseptic packaging)
PRIVATE PLACEMENTS: Raised EUR3.5M in private financing (2/05)
SUBSIDIARY OF: Unilever
BUSINESS STRATEGY: Development and manufacture of ligands for Affinity Separation applications
RESEARCH & DEVELOPMENT: CaptureSelect® products are based on the company's proprietary single
domain antibody fragments and efficiently produced in-house using
Saccharomyces cerevisiae
Expression systems and fermentation production systems
Industrial scale 15,000l for production of novel single-chain Llama antibody
fragments, peptides, fusion proteins
PRODUCTS ON MARKET: Products:
CaptureSelect® products possess a combination of unique properties such
as stability, affinity, and selectivity that provides competitive benefits in
terms of reduced cost of purification, higher quality product, and increased
flexibility in the purification process. BAC offers a wide range of
CaptureSelect® products for different applications:
-Life science research such as sample preparation and small scale
purification
-Biopharma manufacturing including monoclonal antibodies and viruses
-Healthcare applications such as therapeutic apheresis
-Custom tailored purification solutions
Services:
Custom manufacturing and upscaling of production of biotechnological
molecules through microbial fermentations
Plug-in of genes into yeasts, followed by process development and scale up
BACHEM AG
Hauptstrasse 144
Bubendorf CH-4416, Switzerland
Phone: +41 61 935 2323; Fax: +41 61 935 2325
Web: www.bachem.com
E-mail: sales.ch@bachem.com
KEY PERSONNEL: Dr. Peter Grogg; Chairman
Rolf Nyfeler, Ph.D.;CEO
Michael Husler; CFO
Dr. Daniel Erne; CTO
Thomas Fruh, Ph.D; Exec. VP and COO, BACHEM AG
Jose de Chastonay, Ph.D.; President, BACHEM Americas
Philip Ottiger; President and COO, Bachem California Inc.
Dr. Mike Pennington; President and COO, Bachem Bioscience Inc.
Dr. Damir Vidovic; President and COO, Peninsula Laboratories Inc.
Dr. Stanley Moore; COO, Bachem (UK) Ltd.
Dr. Jacques-Alain Cotting; COO, Sochinaz SA
Founded BACHEM Bioscience in Philadelphia, Pa. (1987)
Founded BACHEM Biochemica in Heidelberg, Germany (1988)
Founded BACHEM Biochimie in Voisins-le-Bretonneux, France (1993)
Acquired BACHEM California Inc in Torrance, Calif., and its U.K. subsidiary
in Saffron Walden (1996)
®
Changed name from BACHEM Feinchemikalien AG to BACHEM AG

Acquired Peninsula Laboratories Inc. and Peninsula Laboratories Ltd.
(12/99)
Merger of Peninsula Laboratories Europe Ltd. and Bachem (UK) Ltd. (8/00)
Acquired Sochinaz SA (2001)
FACILITIES: 218,000 sq. ft. facility including GMP production facilities in Bubendorf,
Switzerland, and Torrance, Calif., for large-scale solid phase and solution
phase peptide synthesis
STOCK-FINANCIAL HISTORY: SWX--BANB
Sales CHF153.7M (YE 05) compared to CHF147.8M (YE 04)
Net income CHF39.2M (YE 05) compared to CHF30.7M (YE 04)
Earnings per share CHF2.98/share (YE 05) compared to CHF2.33/share
(YE 04)
SUBSIDIARIES/DIVISIONS: BACHEM California Inc. (see separate entry)
3132 Kashiwa Street
Torrance, CA 90505
Phone: (310) 539-4171; Toll-free phone: (888) 422-2436
Fax: (310) 530-1571; E-mail: sales@us.bachem.com
BACHEM Bioscience Inc.

3700 Horizon Drive
King of Prussia, PA 19406 USA
Fax: (610) 239-0800; E-mail: sales@us.bachem.com
BACHEM Biochemica GmbH

Haberstrasse 6
Heidelberg D-69126 Germany
Phone: +49 06221 33 05 0; Fax: +49 06221/33 05 99
E-mail: verkauf.de@bachem.com
BACHEM Biochimie SARL

136, ave. Joseph Kessel
Voisins-le-Bretonneux F-78960 France
Phone: +33 (0)1 30 12 15 95; Fax: +33 (0)1 30 57 38 82
E-mail: vente@fr.bachem.com
BACHEM (U.K.) Ltd.

69 High Street
Saffron Walden, Essex CB10 1AA UK
Phone: +44 (0)1 799 52 64 65; Fax: +44 (0)1 799 52 63 51
E-mail: sales.uk@bachem.com
BUSINESS STRATEGY: Supply peptides, peptidomimetics, proteins, amino acid derivatives and
related biologicals to the research market
AstraZeneca plc Goserelin extended supply 1/03
agreement
Jerini AG Jerini's Icatibant production and 3/04
supply agreement
mondoBiotech Thymopentin production and 4/05
Holding SA supply agreement
mondoBiotech mondoBiotech's production and 7/04
Holding SA Aviptadil supply agreement
mondoBiotech mondoBiotech's production and 4/05
Holding SA Thymopentin (TP-5) supply agreement
mondoBiotech new peptide projects for development 3/06
Holding SA potential therapeutic agreement
use
®
RESEARCH & DEVELOPMENT: Growth factors, lymphokines

Bioactive peptides, enzyme substrates and inhibitors, cytokines, related
biologicals
GMP production of peptides and related compounds
GMP Contract manufacturing
Peptides and proteins for diagnostics
PRODUCTS ON MARKET: More than 7,000 products including biologically active peptides, proteins,
amino acid derivatives, enzyme substrates and inhibitors, neuropeptides,
cytokines, lymphokines, growth factors, HIV proteins, monoclonal and
polyclonal antibodies
Bachem California Inc.

3132 Kashiwa Street
Torrance CA 90505, US
Phone: (310) 539-4171; Fax: (310) 530-1571
Web: www.bachem.com
E-mail: pottiger@bachem.com
KEY PERSONNEL: Philip Ottiger; President and COO
Acquired by Bachem in 1996
RESEARCH & DEVELOPMENT: Synthetic peptides, reagents, bulk pharmaceuticals, synthetic intermediates
and recombinant growth factors and cytokines
PRODUCTS ON MARKET: Clinical grade peptides (CRF, GRF, somatostatin, LHRH, ANF, calcitonin,
parathyroid hormone, peptide T)
Bioactive peptides
Synthetic intermediates
Recombinant growth factors and cytokines
Large-scale custom synthesis service
Bangs Laboratories Inc.

9025 Technology Drive
Fisher IN 46038-2886, US
Phone: (317) 570-7020; Fax: (317) 570-7034
Web: www.bangslabs.com
E-mail: info@bangslabs.com
KEY PERSONNEL: Michael H. Ott; Chairman and CEO
Chad Owen; President
Kate Edwards; Product Manager
Sharmi Isaiah; Scientist and Lab Coordinator
Mary Meza; Technology Manager
Yun Qiu; Scientist
Kathy Turner; Technical Service Manager
HISTORY: Founded in April 1988
Acquired by Polysciences Inc. (7/03)
®
SUBSIDIARY OF: Polysciences Inc.
PRODUCTS ON MARKET: More than 2,000 varieties of microspheres
BASF AG
Carl Bosch Strasse 38
Ludwigshafen D-67056, Germany
Phone: +49 (0)621 60-0
Fax: +49 (0)621 60-42525
Web: www.basf.de
E-mail: info.service@basf.de
KEY PERSONNEL: Dr. Jurgen Hambrecht; Chairman
Dr. Thorlef Spickschen; Managing Director, Pharmaceuticals
Dr. Friedrich Vogel; Managing Director, Crop Protection
Peter Oakley; Chairman, President and CEO, BASF Corp.
Dr. Stefan Marcinowski; Head, Research
Prof. Dr. Werner Kusters; Head, Main Laboratory
Dr. Robert Kamen; President, BASF Bioresearch Corp.
EMPLOYEES: 94,000 employees worldwide
Acquired Knoll AG (1982)
Acquired Blazer® herbicide business from Rohm and Haas (12/87)
Genzyme Corp. reacquired rights to Protein C (8/88)
Acquired majority interest in BioResearch, an Italian pharmaceutical group
(spring 1990)
International pharmaceutical business combined under BASF Pharma
(1993)
Acquired Boots Pharmaceuticals (3/95)
Acquired Hokuriku Seiyaku (4/96)
Acquired global electronic chemicals business of Merck KGaA (1/05)
To acquire Johnson Polymer from JohnsonDiversey Inc. (as of 5/06)
Acquired Engelhard Corp. (6/06)
FACILITIES: Commercial-scale biotechnology fermentation facility in Ludwigshafen,
Germany, and Worcester, Mass.
Agricultural Research Center in Research Triangle Park, N.C.
Latin American headquarters located in Mexico, and Asian/Australian
regional division headquarters located in Singapore
Nanotechnology research center in Singapore
STOCK-FINANCIAL HISTORY: NYSE and Frankfurt Stock Exchange--BASF
Net income EUR3,007b (YE 05) compared to EUR2.004b (YE 04)
(YE 04)
SUBSIDIARIES/DIVISIONS: Five business segments: Chemicals, Plastics, Performance Products,
Agricultural Products and Nutrition, and Oil and Gas
KNOLL Belgium
Avenue Hamoir 14
B-1180 Bruxelles, Belgium
Phone: +32 2373-1471; Fax: +32 2373-1489
Knoll France S.A.

49, Avenue Georges Pompidou
F-92593, Levallois-Perret, Cedex, France
Phone: +33 1496-45880; Fax: +33 1496-45919
®
Knoll Pharmaceuticals/BASFIN
St. Nicholas Court, 25-27 Castle Gate
Nottingham NG1 7AR, Great Britain
Phone: +44 115-912-4000; Fax: +44 115-912-4816
Ravizza Farmaceutici spa

Via Europa 35
I-20053 Muggio, Italy
Phone: +39 39-24421; Fax: +39 39-791824
Knoll Farmaceutici Spa

Via Europa 35
I-20053 Muggio, Italy
Phone: +39 39-24426; Fax: +39 39-79-5014
Knoll Farmaceutici Spa

Via Lorenteggio 270A
I-20152 Milano, Italy
Phone: +39 24-831-6301; Fax: +39 24-830-1976
Knoll Zagrel
Planinska bb, 10000 Zagreb, Croatia
Phone: +385 1233-3733; Fax: +385 1233-38279
Knoll Pharma
Postbus 22622
NL-1100 DC Amsterdam Z.O., Netherlands
Phone: +31 2056-40101; Fax: +31 2069-14311
EBEWE Arzneimittel GmbH

A-4866 Unterach, Austria
Phone: +43 7665-81230; Fax: +43 7665-812311
Przedstawicielstwo Knoll AG
w Polsce, Aleje Jerozolimskie 154
02-326 Warsaw, Poland
Phone: +48 22-822-462123; Fax: +48 22-822-4624
Knoll Lusitana Lda.

Rua Alfredo da Silva 3 C e D 2
P-1300 Lisboa, Portugal
Phone: +35 1136-15350; Fax: +35 1136-16378
BASF/Knoll AG
ul. Malaja Trubezkaja 8
119881 Moscow, Russia
Phone: +7 95-234-9666; Fax: +7 95-234-9667
Knoll-BioResearch S.A.
Succursale di San Antonino
CH-6592 San Antonino, Switzerland
Phone: +41 9185-19191; Fax: +41 9185-19192
Knoll AG
Postfach 631
CH-4410 Liestal, Switzerland
Phone: +41 6192-50505; Fax: +41 6192-12563
Knoll Prag
Frana Krala 35
81105 Bratislava, Slovak Republic
Phone: +427 398-837; Fax: +427 398-850
®
Laboratoires Knoll S.A.

Avenida Burgos 91
E-28050 Madrid 34, Spain
Phone: +34 91334-3900; Fax: +34 91766-1973
Knoll Alman Ltd.

TR-80040 Tophane-Istanbul, Turkey
Phone: +90 216-492-9400; Fax: +90 216-492-5768
Knoll spol. Sr. o.

Kounicka 70
10000 Prague, Czech Republic
Phone: +420 27822-539; Fax: +420 27822-595
BASF Hungaria Kft./Knoll Divizio

H-1036 Budapest, Galagonya u.5., Hungary
Phone: +36 1-436-0820; Fax: +36 1-436-0830
Knoll Pharma Inc.

100 Allstate Parkway, Suite 600
Markham, ON L3R 6H3, Canada
Phone: (905) 475-7070; Fax: (905) 475-3064
Knoll Pharmaceutical Co.

3000 Continental Drive N.
Mount Olive, NJ 07828-1234 USA
Phone: (973) 428-4000; Fax: (973) 887-8131
BASF Bioresearch Corp.

100 Research Drive
Worcester, MA 01605-4314 USA
Phone: (508) 849-2500
INVESTMENTS: BASF-LYNX Bioscience AG--joint venture with Lynx Therapeutics Inc.
(10/96)
AgBioChem Inc. Gallex distribution
agreement
Ares Sorono human growth hormone manufacturing 8/96
(hGH) agreement
BioBase GmbH Brenda enzyme licensing 6/04
database agreement
Bujard University gene regulation for CNS research 8/92
of Heidelberg disorders agreement
Clontech tetracycline-controlled semi-exclusive 8/96
Laboratories Inc. gene expression system licensing
agreement
Diversa Corp. Diversa to discover and alliance 2/06
optimize new enzymes,
BASF responsible for
product and process
development and
commercialization
IBEX Neutralase production and 10/94
Technologies Inc. supply agreement
Incyte Incyte's LifeSeq research 6/96
Pharmaceuticals genomics database agreement
Inc.
Intercardia Inc. Bextra for CHF development and 12/96
marketing
agreement for
outside the U.S.
and Japan
®
Lynx Therapeutics access to Lynx's cloning technology 10/96

Inc. (now Solexa and sequencing development and
Inc.) technologies services agreement
Mitotix Inc. inhibitors of the cell research 5/96
cycle enzymes cdc 25 agreement
Mitsui Toatsu multiple drug resistance cross-licensing 6/94
Chemicals Inc. suppressors for cancer agreement
chemotherapy
Norak Biosciences Norak's Transfluor collaboration 8/04
Inc. technology to screen
GPCR targets
developed by BASF
Warner-Lambert ICE inhibitors R&D and marketing 3/95
Co. agreement
RESEARCH & DEVELOPMENT: Specialty chemicals, agricultural chemicals, including herbicides for rice and
cereal crops via biotechnology
Vitamin B2 by fermentation
MAb of tumor necrosis factor
PEG-hirudin by recombinant fermentation
Cardiovascular, central nervous system, oncology, and immunology
research
Molecular biology, bioengineering, biophysics, drug design, medicinal
chemistry, combinatorial chemistry, preclinical and clinical development
Thyroid hormone replacement
Drugs for metabolic and immunological diseases
PRODUCTS ON MARKET: INORGANIC CHEMICALS: Adhesives and impregnating resins, alcoholates,
alkali metal amides, alkali metal compounds, ammonium salts, boron
compounds, carbonyl iron powders, catalysts, chlorine compounds,
developmental products, electronic chemicals, food additives,
hydroxyacetophenone, hydroxylamine compounds, nitrogen oxide
derivatives, powder injection molding, sodium carbonate, sodium hydroxide,
potassium hydroxide, sulfur products
PETROCHEMICALS: Alkylen oxide and glycols, cracker products,

plasticizers and plasticizer raw materials, solvents, technical gases
AGRICULTURAL PRODUCTS AND NUTRITION: Herbicides, fungicides,

insecticides, vitamins, pharmaceutical active ingredients and UV absorbers
ANIMAL NUTRITION PRODUCTS

COSMETIC INGREDIENTS/AROMA CHEMICALS
PLASTICS
COATINGS
PERFORMANCE CHEMICALS
FUNCTIONAL POLYMERS
Bayer Corp.
100 Bayer Road
Pittsburgh PA 15205-9741, US
Phone: (412) 777-2000
Web: www.bayerus.com
KEY PERSONNEL: Werner Wenning, Ph.D.; Chairman, Management Board, Bayer AG
Attila Molnar; President and CEO
George J. Lykos; Chief Legal Officer
®

Name changed from Miles Inc. (4/95)
Bayer AG acquired Microbial Developments Ltd. (Malvern, U.K.) (12/95)
Spun off most of chemicals business and about one-third of polymer
business (1/05)
SUBSIDIARIES/DIVISIONS: Business areas:

Bayer HealthCare
Bayer MaterialScience
Bayer CropScience
Service areas:
Bayer Business Services
Bayer Technology Services
Bayer Site Services
SUBSIDIARY OF: Bayer Group AG (see separate entry)
BUSINESS STRATEGY: Improve lives through a broad range of essential products that help
diagnose and treat diseases, protect crops and advance automobile safety
and durability

ALZA Corp. Mycelex antifungal marketing 4/96
agreement
Axys tryptase and chymase five-year, $70M 7/97
Pharmaceutical inhibitors R&D agreement
Inc. (12/94), expanded
to include oral and
inhaled
therapeutics
(10/96), modified--
Bayer returned to
Axys rights to
tryptase inhibitors
for psoriasis and
inflammatory bowel
disease
Celltech Group plc anti-TNF MAbs to treat $47.8M 5/92
septic shock development and
marketing
agreement
Chiron Corp. anti-TNF MAbs to treat licensing 1989
septic shock agreement
Cortex Biochem immunoreagents 1995
Inc.
CV Technologies cardiovascular product research 12/92
Inc. agreement
Dharmacon Inc. siRNAs for drug supply agreement 3/04
discovery research
Genetics Institute DiscoverEase program- partnership 8/97
-provides Bayer access agreement
to GI's library of novel
human secreted
proteins and related
database for identifying
novel human
therapeutics
GlaxoSmithKline cerivastatin reductase co-promotion 1997
plc inhibiting compound agreement for the
U.S.
®
The Immune gene therapy for exclusive licensing 7/96

Response Corp. hemophilia A agreement
Molecular computer software for three-year 4/97
Simulations Inc. use in combinatorial development
chemistry agreement
Myriad Genetics obesity, osteoporosis, research 9/95
Inc. and asthma gene collaboration
discovery
Myriad Genetics Myriad's ProNet protein five-year, $54M 11/97

Inc. interaction database database
subscription--Bayer
gets worldwide
therapeutic rights
for discoveries in
dementia and
depression, Myriad
retains diagnostic
rights and keeps all
rights to
discoveries outside
the fields of
dementia and
depression
Nabi Biopharm- source plasma and five-year contract 2/95
aceuticals certain immune
plasmas
Onyx RAS proteins to treat five-year R&D 5/94
Pharmaceuticals cancer agreement
OSI tumor markers and R&D agreement 12/96
Pharmaceuticals protein products of
Inc. oncogenes, tumor
suppressor genes and
others in cancer
diagnostic tests
Pharmacia & animal health acquisition 1997
Upjohn (now part agreement--Bayer
of Pfizer Inc.) to acquire selected
assets of P&U's
animal health
biologicals
business including
production and
research facilities
Pharmacopeia Pharmacopeia's research 2/96
Inc. combinatorial chemistry collaboration and
and high-throughput library out-licensing
screening technology
for new drug discovery
PharmaNetics Inc. test cards and distribution 1998
analyzers agreement
Serologicals Corp. IVIG five-year supply 12/94
agreement
Takeda Chemical cerivastatin codevelopment 1993
Industries, Ltd. agreement
VI Technologies contract fractionation take-or-pay 1995
processing
agreement to
produce
intermediate
plasma fractions
®
PRODUCTS ON MARKET: 10,000+ products, including:
Animal Health: Advantage®, Baytril®, CheckMite+™ Bee Hive Pest Control

Strip, Clout™ (bromethalin) Rodenticide, Co-Ral® (coumaphos) Fly and Tick
Spray, Co-Ral® Plus Insecticide Cattle Ear Tag, CyLence® (cyfluthrin) Pour-
On Insecticide, CyLence® Ultra Insecticide Cattle Ear Tags, Droncit®,
Drontal®, K9Advantix™, Legend®, Lysoff™ Pour-On Insectide, Marquis®,
QuickBayt™, Spotton® (fenthion) Cattle, Tempo® (cyfluthrin) Insecticide
Biological products: Gaminmune® N, 10%, Kogenate® FS and Kogenate®,

Koate®-DVI, Plasbumin®-5, Albumin (human) 5%, USP, Plasbumin®-20,
Albumin (human) 20%, USP, Plasbumin®-25, Albumin (human) 25%, USP,
Plasmanate®, Plasma Protein Fraction (human) 5%, USP, Prolastin®
Consumer care: Aleve®, Bayer® Aspirin, Vanquish®, Aleve® Cold & Sinus,
Alka-Seltzer Plus®, NaSal™, Alka-Mints®, Alka-Seltzer®, Phillips'®, Phillip's
M-O®, Bactine®, Campho-phenique®, Domeboro®, Flintstones® Vitamins,
Bugs Bunny™ Vitamins, One-A-Day® Vitamins, Fergon®, Midol®,
Mycelex®-7, Mycelex®-3, Femstat® 3
Diagnostics: ADVIA® systems, Technicon H*® Systems, Bayer Immuno 1®

Immunoassay Analyzer, ADVIA CentraLink® Networking Solution,
Rapidlink® Critical Care Information Management System, CLINITEK®
analyzers, Rapidlab® systems, Multistix® reagent strips, TRUGENE® tests
and kits, VERSANT® assays, Bayer ® System 340 (bDNA Analyzer),
OpenGene® DNA Sequencing System, Ascensia® blood glucose
monitoring systems, diabetes self-care software and lancing devices
Bayer MaterialScience: Coating, Adhesive and Sealant Raw Materials,

Inorganic Basic Chemicals, Polycarbonates, Polyurethanes, Thermoplastic
Polyurethanes (TPU)
Bayer CropScience: products for lawn, garden and home care and crop
protection
Bayer CropScience AG
Alfred-Nobel-Str. 50
Monheim am Rhein D-40789, Germany
Phone: +49 (0) 21 73-38-0
Web: www.bayercropscience.com
E-mail: info@bayercropscience.com
KEY PERSONNEL: Prof. Dr. Friedrich Berschauer; Chairman
Dr. Rudiger Scheitza; Portfolio Management and Labor Director
Dr. Dirk Suwelack; Business Planning and Administration
Dr. Wolfgang Welter; Industrial Operations and Investments
HISTORY: Formed from a merger of Bayer Crop Protection and Aventis CropScience in
June 2002
Acquired assets of Associated Farmers Delinting Inc. (2/05)
Acquisition of Icon Genetics AG (1/06)
FACILITIES: R&D centers in Monheim, Frankfurt and Potsdam, Germany; Lyon and
Sophia Antipolis, France; Gent, Belgium; Yuki, Japan; Haelen, the
Netherlands; and Stilwell, Kan., USA
Major sites in Monheim, Germany; Lyon, France; Singapore; Research
Triangle Park, N.C., USA; and Sao Paulo, Brazil
STOCK-FINANCIAL HISTORY: Privately held by Bayer AG
®
SUBSIDIARIES/DIVISIONS: Crop protection business (Insecticides, Herbicides, Fungicides, Seed

Treatment)
BioScience (Green Biotech)
Environmental Science (non-agricultural pest and weed control products)
SUBSIDIARY OF: Bayer Group AG (see separate entry)
Arysta LifeScience amitraz, marketing of licensing 4/05
fluoxastrobin and co- agreements
marketing of deltamethrin
Commonwealth RNAi gene-silencing worldwide 4/04
Scientific and technology for crops licensing
Industrial agreement
Research
Organisation
Cresset use of Cresset's molecular discovery and 1/06

BioMolecular field technology for the licensing
Discovery Ltd. discovery of agreement
agrochemicals
Icon Genetics AG evaluation of expression collaborative 1/05
levels and quality of agreement
selected preclinical
pharmaceutical proteins
Large Scale investigation of the plant- CRADA 4/05
Biology Corp. based expression of
lysosomal acid lipase
Medicago Inc. feasibility of using research 1/05
Medicago technology for agreement
producing human
therapeutic protein
RESEARCH & DEVELOPMENT: Crop protection (herbicides, fungicides, insecticides), seed treatment, seeds,
green biotechnology and non-agricultural pest control
PRODUCTS ON MARKET: Nunhems vegetable seeds (main crops: onions, carrots, melons and leeks),
FiberMax cottonseed (incorporating LibertyLink, Round Up Ready and
Bollgard technologies), InVigor canola (with SeedLink hybridization
technology), hybrid rice seed, pest control and crop protection products
Bayou Biolabs
1500 Edwards Avenue, Suite Q
Harahan LA 70123, US
Phone: (504) 733-3849; Fax: (504) 734-5106
Web: www.bayoubiolabs.com
E-mail: support@bayoubiolabs.com
KEY PERSONNEL: Edward David Hyman; President
Changed name from Sybtrel Biotechnology (1995)
FACILITIES: 1,500 sq. ft. laboratory research facility
BUSINESS STRATEGY: Offer custom plasmid preparation service, including bulk quantities of all
types and sizes
®
RESEARCH & DEVELOPMENT: Custom plasmid preparation

Oligonucleotide synthesis technology
Manufacture of biochemical reagents
PRODUCTS ON MARKET: DNA Ladders for conventional electrophoresis
DNA Ladders for pulsed field gel electrophoresis
Vectors
Lederberg Plasmid Collection
Custom plasmid preparation
Be-Long Group
P.O. Box 139 Gulou Post Office
Nanjing 210008, China
Phone: +86 25 8471 2602; Fax: +86 25 8470 9922
Web: www.be-longgroup.com
E-mail: business@be-long.com.cn
KEY PERSONNEL: Michael Song; President
FACILITIES: Headquarters in Nanjing, China
Branches in Shanghai, Tianjin, Hong Kong, Hebei Langfang and Zhejiang
Wenzhou
Produce plant in Shandong
BUSINESS STRATEGY: Produce and market feed additives, food additives, chemical raw materials,
pharmaceutical raw materials, pearl pigments and traffic marking materials
PRODUCTS ON MARKET: Choline chloride

Zinc bacitracin
Bacitracin methylene dicalicylate
Dicalcium phosphate
Vitamins
Amino-acids
Gelatine
Pearl luster pigments
BioAssay Works LLC

10075 Tyler Place, #18
Ijamsville MD 21754, US
Phone: (301) 874-8888; Fax: (301) 874-8889
Web: www.bioassayworks.com
E-mail: sales@bioassayworks.com
KEY PERSONNEL: Leslie Kirkegaard, Ph.D.; President
Glen Ford; VP, Operations
Stephen Mefferd; VP, Business Development
Leslie Kirkegaard, Ph.D.; Director, R&D
Rachael Keesey; Purchasing Manager
EMPLOYEES: 7 employees, 2 Ph.D.s, 1 M.D.
HISTORY: Founded in May 2005
Began biotech R&D in June 2005
®
BUSINESS STRATEGY: Patents in process for novel gold particle production and new rapid assay,
lateral flow technology. BioAssay Works intends to combine the improved
technologies with assay development experience for contract assay
development.
Biocatalysts Ltd.
Cefn Coed, Parc Nantgarw
Wales CF15 7QQ, UK
Phone: +44 (0)1443 843 712; Fax: +44 (0)1443 846 500
Web: www.biocatalysts.com
E-mail: sales@biocats.com
KEY PERSONNEL: W. Salisbury; Chairman
Stuart West; Managing Director
Martin Duff; Sales Manager
Mike Clay; General Manager
HISTORY: Originally founded in 1983 as part of Grand Metropolitan plc

Acquired by Shell Ventures (9/89)
Regained independence (2/91)
FACILITIES: Laboratory, production and warehouse facilities
BUSINESS STRATEGY: Manufacture and supply industrial enzymes to the food, diagnostic and
pharmaceuticals industries
RESEARCH & DEVELOPMENT: New enzymes for biotransformations, biosensors, diagnostics, chiral
separations and environmental applications
Products include Depol™, Lipomod™, Promod™, Combizyme, food
processing enzymes, tissue culture enzymes including virus-free trypsin,
microbial lipases and xylanase
PRODUCTS ON MARKET: Extensive range of lipases: xylanase, myrosinase, phenylalanine
dehydrogenase, and secondary alcohol dehydrogenase (chiral synthesis
catalysts), galactose dehydrogenase
Bioclear BV
P.O. Box 2262
Groningen 9704 CG, Netherlands
Phone: +31 (0) 50-571 84 55; Fax: +31 (0) 50-571 79 20
Web: www.bioclear.nl
E-mail: bio@bioclear.nl
KEY PERSONNEL: Dr. Sytze Keuning; Managing Director
Dr. Janneke Krooneman; Project Manager
Maurice Henssen; Associate Director and Project Manager
®
RESEARCH & DEVELOPMENT: Environmental biotechnology

Microbial identification
Bioreactor development
Biological treatment processes
Microbiological detection and monitoring
BioForce Nanosciences Inc.

1615 Golden Aspen Drive, Suite 101
Ames IA 50010, US
Phone: (515) 233-8333; Fax: (515) 233-8337
Web: www.bioforcenano.com; E-mail: info@bioforcenano.com
KEY PERSONNEL: Eric Henderson, Ph.D.; Chairman and CEO
Kerry Frey; COO
Curtis Mosher, Ph.D.; VP, R&D
Asrun Kristmundsdottir; Human Resources Manager
Mike Lynch; NanoArrayer Product Manager
Saju Nettikadan, Ph.D.; Director, Applications Development
Collin Dettmann; Production Manager
Merged with BioForce Nanoscience Holdings Inc. (formerly Silver River
Ventures Inc.) (3/06)
STOCK-FINANCIAL HISTORY: OTC BB--BFNH
Net loss <$19.221K> (YE 05) compared to <$15.490K> (YE 04)
Loss per share $0.00/share (YE 05) compared to $0.00/share (YE 04)
Average shares outstanding 4M (YE 05) compared to $4M (YE 04)
PRIVATE PLACEMENTS: Raised $6M in private placement of restricted common shares at
~$1.50/share (3/06)
SUBSIDIARY OF: BioForce Nanosciences Holdings Inc.
PRINCIPAL INVESTORS: Gulfstream Capital Management
Societe Generale Asset Management
Iowa First Capital Fund
FINANCIAL INFORMATION: $4.7M NIH/SBIR; $11M private and institutional investors
BUSINESS STRATEGY: Develop logical business units with synergistic potential. Provide the
NanoArrayer™ System for precise delivery of femtoliter volumes of liquids to
surfaces to enable the production of ultraminiaturized biomedical devices
and other ultraminiaturized sensors and constructs. Ultraminiaturized
biodevices allow biomarker-based disease detection and monitoring with
high sensitivity and accuracy while reducing sample requirements to a few
cells and thereby reducing cost and patient impact.
RESEARCH & DEVELOPMENT: Instrumentation for creating ultraminiaturized diagnostics and devices
Nanotechnology for drug discovery
Nanotechnology for direct pathogen sensing
PRODUCTS ON MARKET: NanoArrayer™ System (NanoArrayer™, Surface Patterning Tools [SPTs™]
and Sindex™ chips)
UV TipCleaner
AFM Solutions (Products and applications for atomic force microscopy)
®
BioGenes GmbH
Kopenicker Strabe 325
Berlin 12555, Germany
Phone: +49 (0)30 65762396; Fax: +49 (0)30 65762397
Web: www.biogenes.de
E-mail: service@biogenes.de
KEY PERSONNEL: Dr. Alexander Knoll; CEO
Dr. Sergej Ovodov; CSO
Dagmar Schwertner; Marketing Director
Dr. Sabine Steinbach; Head, Quality Management
HISTORY: Founded and began biotech R&D in July 1992
STOCK-FINANCIAL HISTORY: Private foundation
PRINCIPAL INVESTORS: Essential Management GmbH
IBB Beteiligungsgesellschaft mbH
BUSINESS STRATEGY: Outsourcing partner for pharmaceutical companies
PRODUCTS ON MARKET: Immunological and biochemical services
BioGenesis Enterprises Inc.

610 West Rawson Avenue
Oak Creek WI 53154, US
Phone: (414) 571-6230; Fax: (414) 571-6231
Web: www.biogenesis.com
E-mail: customerservice@biogenesis.com
KEY PERSONNEL: Paul N. Temple; Chairman
Mohsen C. Amiran, Ph.D.; President, CEO and Technical Director
Charles L. Wilde; COO
Michael Dubey; Operations Manager
EMPLOYEES: 9 employees, 1 Ph.D.
Additional offices in Washington, D.C., and Chicago
SUBSIDIARIES/DIVISIONS: Washington, D.C. office:
7420 Alban Station Blvd., B-208
Springfield, VA 22150
Phone: (703) 913-9700
Fax: (703) 913-9704
BUSINESS STRATEGY: Develop, manufacture and provide products and services for industrial
cleaning, odor control and soil and sediment remediation
PRODUCTS ON MARKET: Soil washing, sediment washing, water treatment, filtration, fire
suppressants, odor control, specialty extractants
®
Biogenie Inc.
350 Franquet Street
Quebec G1P 4P3, Canada
Phone: (418) 653-2074; Fax: (418) 653-2675
Web: www.biogenie-env.com
E-mail: marketing@biogenie-env.com
KEY PERSONNEL: Benoit Cyr; President
Carl Rodzewich; GM, U.S.
Dominic Belanger; GM, Paris
Graham Holtom; GM, U.K.
Richard Corbin; Corporate Director
Bryan O’Gallagher; Project Director
FACILITIES: 28,000 sq. ft. facility including engineering and laboratory space for chemical
analysis, microbiology and process simulation
Operates mobile units for soil biotreatment studies
BUSINESS STRATEGY: Develop biological processes for the treatment of soil, water effluents and air
Seek research contracts, joint ventures and technology transfer
RESEARCH & DEVELOPMENT: Microorganisms, bioreactors, biological and physical/chemical processes for
treatment of contaminated soil, water and air
PRODUCTS ON MARKET: Soil and groundwater decontamination for organic contaminants:
hydrocarbons, solvents, pentachlorophenol, creosote, polyaromatic
hydrocarbons (PAH), nitroaromatics and inorganic contaminants such as
mercury
Waste gas biofilters and air quality services
Bio-Lab Ltd.
P.O. Box 34038
Jerusalem 91340, Israel
Phone: +972 2-584 1110; Fax: +972 2-584 1111
Web: www.bio-lab.co.il; E-mail: bio_lab@netvision.net.il
KEY PERSONNEL: Dr. Leo Samuel; Managing Director
Dr. Michel Ehrenfreund; Managing Director
Dr. Jean Hildesheim; Director, Biotech and R&D
FACILITIES: 7,000 sq. m. facility in Jerusalem
BUSINESS STRATEGY: Produce and distribute high purity solvents and chemicals for research,
routine laboratories and industries
RESEARCH & DEVELOPMENT: HPLC: Up-grading of current specifications, introduction of new products
Molecular biology: Up grading of current specifications, introduction of new
products
DNA synthesis: Up grading of current specifications, introduction of new
products, synthesis of new reagents
Peptide synthesis: Development of formulations, quality up grading of
reagents, blocked amino-acid
®
PRODUCTS ON MARKET: Solvents and chemicals

Solvents and formulations for HPLC
Environmental solvents
Dry solvents
Chiral solvents
Molecular biology solvents, chemicals and formulations
Peptide synthesis solvents and formulations
DNA synthesis solvents
Reagents
Custom synthesis
Biolog Inc.
21124 Cabot Blvd.
Hayward CA 94545, US
Phone: (510) 785-2564; Fax: (510) 782-4639
Web: www.biolog.com; E-mail: info@biolog.com
KEY PERSONNEL: Barry R. Bochner, Ph.D.; President, CEO and CSO
Douglas E. Rife; VP, Operations
Edwin Fineman; VP, Finance and CFO
John D. Groat; VP, Global Sales
R&D facilities opened in July 1984
FACILITIES: Offices, laboratory, R&D and manufacturing facilities
FINANCIAL INFORMATION: Funding from equity, SBIR grants and development contracts
BUSINESS STRATEGY: Continue growing as the recognized authority in cellular phenotype analysis
with particular emphasis in functional genomics and drug discovery,
microbial identification and analysis of microbial ecosystems
Axiohelix and the E. coli genome-- research 11/04
NARA Institute phenotyping and agreement
determining the function
of each gene
RESEARCH & DEVELOPMENT: Broad spectrum kits and phenotype MicroArrays ™ based on a patented
technology for the characterization and identification of microorganisms
(gram-negative, gram-positive, yeast and anaerobe) at the species and
subspecies level, as well as custom kits for specific applications or groups of
microorganisms
Functional genomics, phenotype testing and contamination identification
PRODUCTS ON MARKET: GN2 MicroPlate™--test panel for identification/characterization of 566 gram-
negative bacteria
GP2 MicroPlate™--test panel for identification/characterization of 250 gram-
positive bacteria plus 57 lactic acid bacteria
AN MicroPlate™--test panel for identification/characterization of 300 species
of anaerobic bacteria
YT MicroPlate™--test panel for identification/characterization of 267 yeast
species
FF Microplate™-- test panel for identification/ characterization of filamentons
fungi
MT2 MicroPlate™--test panel for catabolic surveys and bioremediation
studies
ECO MicroPlate™--test panel for microbial community characterization and
analysis
®
BUG™--universal growth medium for growing a broad range of

microorganisms
BUA™--universal growth medium for anaerobes
BUY™ Agar--universal growth medium for yeast
Rainbow® Agar O157--selective chromogenic culture medium for toxigenic
strains of E. coli such as O157:H7
Rainbow® Agar Salmonella--selective chromogenic medium for H2S+
Salmonella species
Rainbow® Agar UTI--non-selective chromogenic medium for enumeration
and identification of urinary tract pathogens
MicroLog™--manual system for reading and interpreting MicroPlate™ tests
MicroStation™--automated microbiology workstation for reading and
interpreting MicroPlate™ tests
OmniLog ID System--rapid automated incubation and identification of
aerobic bacteria
OmniLog PM System--automated instrument and software for kinetic
analysis of 2000 cellular phenotypes
Phenotype MicroArray Panels--MicroPlates for metabolic analysis of
bacterial, fungal and mammalian cells
Biologos Inc.
2235 Cornell Avenue
Montgomery IL 60538-3201, US
Phone: (800) 246-4088; Fax: (630)-801-4766
Web: www.biologos.com; E-mail: info@biologos.com
KEY PERSONNEL: Dennis Raine; President
RESEARCH & DEVELOPMENT: Animal tissue culture

PRODUCTS ON MARKET: Normal animal sera
Tissue culture media
Antibiotic solutions
Enzyme solutions
Growth additives
Miscellaneous biologicals
BioMed Diagnostics Inc.

1388 Antelope Road
White City OR 97503-1619, US
Phone: (541) 830-3000; Fax: (541) 830-3001
Web: www.biomed1.com
E-mail: info@biomed1.com
KEY PERSONNEL: Robert D. Hall; Chairman and Exec. VP
®

BUSINESS STRATEGY: Provide test methodologies that can be performed without sophisticated
equipment or highly skilled personnel
Utilize company's patented and proprietary packaging concepts to extend
shelf life and improve performance of various media
CMS/Fisher InPouch and InTray distribution 7/98
Healthcare systems agreement for the
U.S.
PRODUCTS ON MARKET: InPouch™ and InTray™ systems for detecting protozoa and fungi
Custom contract packaging
Group B strep in field trials
Biomeda Corp.
1191 Chess Drive, Suite F
Phone: (650) 341-8787; Fax: (650) 341-7095
Web: www.biomeda.com; E-mail: customer@biomeda.com
KEY PERSONNEL: Ron Walraven; Chairman
Pete Derrico; CEO
BUSINESS STRATEGY: Develop, manufacture and sell the highest quality immunochemicals
RESEARCH & DEVELOPMENT: Immunology, cell biology, cell culture, molecular biology products
PRODUCTS ON MARKET: Quality Leaders:
-Primary antibodies
-Secondary antibodies
-ELISA
-Detection systems
-Mounting media
-Sera
Biomedical Technologies Inc.

378 Page Street
Stoughton MA 02072, US
Phone: (781) 344-9942; Fax: (781) 341-1451
Web: www.btiinc.com; E-mail: info@btiinc.com
KEY PERSONNEL: Maurice Lamarque; President
PRODUCTS ON MARKET: Cell growth factors

Cell culture products
EIA kits
RIA kits
®
Assay kits and components

MAbs, polyclonals, and proteins
Specialty plastic labware
BioMerieux INDUSTRY
595 Anglum Road
Hazelwood MO 63042-2320, US
Phone: (314) 731-8500; Fax: (314) 731-8678
Web: www.biomerieux-vitek.com
E-mail: tim.malloy@na.biomerieux.com
KEY PERSONNEL: Alain Merieux; Chairman and CEO, bioMerieux sa
Tom O'Brien; Director, U.S. Industry Sales
Karen Mullen; Sr. Market Manager; Pharma
Mike Bullard; National Business Manager, Pharma
Lee Doughton; Corporate Account Manager, Pharma
HISTORY: Began biotech R&D in 1966
Founded in 1977
FACILITIES: Headquarters in St. Louis, Mo.
Manufacturing facilities in St. Louis, Mo., and Rockland, Mass.
STOCK-FINANCIAL HISTORY: Privately held by parent
SUBSIDIARIES/DIVISIONS: BioMerieux Inc.
100 Rodolphe Street
Durham, NC 27717, USA
Phone: (919) 620-2000
SUBSIDIARY OF: BioMerieux SA (see separate entry)
BUSINESS STRATEGY: Develop and manufacture microbiology and immunoassays
Affymetrix Inc. DNA probe arrays using development 9/96
Affymetrix GeneChip agreement for
technology bacteriology testing
Gen-Probe Inc. probe assays for Vidas development 5/97
agreement
MRL The Surveillance global surveillance 5/97
Network (TSN) partnership
OraVax Inc. human diagnostic exclusive 11/96
products incorporating worldwide licensing
CagA for H. pylori agreement
detection
RESEARCH & DEVELOPMENT: Microbiology, immunoassays, pharmacy

PRODUCTS ON MARKET: Vitek
Vidas
mini-Vidas
API
Slidex
Chromogenic media
TheraTrac 2
TSN
®
BioMerieux SA
376 Chemin de l'Orme
Marcy l'Etoile F-69280, France
Phone: +33 04 78 87 20 00; Fax: +33 04 78 87 20 90
Web: www.biomerieux.com
KEY PERSONNEL: Alain Merieux; Chairman
Benoît Adelus; Exec. VP
Christophe Merieux; Sr. VP, R&D and Medical Affairs
Frederic Benoliel; Corp. VP, Asia Pacific
Thierry Bernard; Corp. VP, Europe, Middle East, Africa
Xavier Fargetton; Corp. VP, Global Marketing and Strategic Development
Jocelyne Latour; Corp. VP, Quality Assurance and Regulatory Affairs
Jean-Francois de Lavison; Corp. VP, Public and International Affairs
Marc Mackowiak; Corp. VP, R&D
Pierre Piffeteau; Corp. VP, Industrial Operations and Purchasing
Alexandre Merieux; Corp. VP, Industrial Microbiology
Henri Thomasson; Corp. VP, Finance
Peter Kaspar; Corp. VP and Head, Molecular Biology

Changed name from Institut Merieux (1974)
Acquired API System (1987)
Acquired VITEK Systems (1988)
Acquired the diagnostics unit of Organon Teknika, a division of Akzo Nobel
(2001)
Sold its hemostasis range of products to Trinity Biotech plc (6/06)
FACILITIES: Corporate headquarters facilities in France with 2,100 employees
Operations and facilites in over 130 countries, with more than 110
distributors
Nine research centers worldwide
STOCK-FINANCIAL HISTORY: Listed on the Premier Marche of Euronext, Paris (FR0010096479 – BIM)
Net sales EUR993.6M (YE 05) compared to EUR929.3M (YE 04)
Net income EUR90.1M (YE 05) compared to EUR79.7M (YE 04)
(YE 04)
Total assets EUR906.1M (YE 05) compared EUR838.6M (YE 04)
SUBSIDIARIES/DIVISIONS: Thirty-three subsidiaries in 130 countries
Two business areas:
Clinical diagnostics: Focuses on diagnosing infectious diseases, such as
hepatitis B, HIV, tuberculosis, respiratory infections and increasingly
pathologies, such as cardiovascular diseases and cancers
Industrial diagnostics: Focuses on controlling the microbiological quality of
an industrial or environmental sample
BUSINESS STRATEGY: Become a key player in the in vitro diagnostics field of infectious diseases
and other pathologies, such as cardiovascular diseases or cancers. It has
implemented the following strategy:
-Focusing its development on applications with a high potential
-Launching new products to better satisfy the needs of patients and the
imperatives of public health in general
-Reinforcing its worldwide network to seize growth opportunities
-Continuing with its sustained effort in research and development
-Investing in new technologies via strategic alliances and targeted
purchases that guarantee growth and technological independence
-Pursuing a balanced financial strategy to seize on growth opportunities
®

Affymetrix Inc. detection of nucleic R&D agreement 12/03
acids in bacteriology,
virology and industrial
microbiological control
applications
Apibio molecular biology R&D agreement 12/03
research
Applied biologic test for development 12/04
NeuroSolutions diagnosis of Alzheimer's agreement
Inc. disease
B·R·A·H·M·S AG Procalcitonin as a non-exclusive 3/05
diagnostic marker for licensing
severe bacterial agreement
infections
Cepheid molecular biology R&D agreement 1/04
platforms
DiagnoSwiss development, exclusive 7/05
manufacturing and worldwide licensing
marketing of agreement
electrochemical
microchips
ExonHit new blood diagnostics discovery and 2003
Therapeutics in the area of early development
cancer detection agreement,
extended 10/05
Genome Express Genome Express to licensing 5/05
carry out bacterial agreement
analyses
Gen-Probe Inc. Gen-Probe's ribosomal non-exclusive 10/04
RNA technologies and licensing
bioMerieux's genetic agreements
mutation detection IP
IDI new targets in R&D agreement 4/04
microbiology
applications
Primagen Holding coronavirus CoV-NL63 exclusive licensing 2/06
BV agreement
Proteome Proteome's biomarkers licensing 5/06
Sciences plc for use in stroke agreement
diagnostics
Roche development, non-exclusive 4/05
Diagnostics manufacturing and licensing
marketing of agreement
immunoassays for
congestive heart failure
and acute coronary
syndrome
RESEARCH & DEVELOPMENT: Bacteriology

Immunoassays
Molecular biology
Hemostasis
Instrumentation
Software
Genetics
Pharmacogenomics
Proteomics, biocomputing
Micro-technologies (micro-fluidic, electronic, etc.)
®
PRODUCTS ON MARKET: PHARMACEUTICALS, COSMETICS and BIOTECHNOLOGY:

Identification of micro-organisms
API® strips
mini API®
Vitek®
Vitek®2
apiweb®
Microbiological control for sterile and non sterile products
Bactometer®
BacT/Alert® 3D Pharmaceutical, cosmetics and biotechnology
Culture media - Pharmaceutical, cosmetics and biotech range
Environmental control
Culture media
Culture media - Environmental control range
Air Monitoring
air Ideal®
NucliSens EasyQ® Influenza H5 and N1 - avian flu test (for research)
FOOD:
Culture media
Culture media - Food range
Identification
API® strips
mini API®
Vitek®
FoodExpert-ID®
apiweb®
Pathogen immunodetection
Vidas® Environment
Vidas® Next Day
Vidas® 2nd Generation
Vidas® Safety
Quality indicators
Bactometer®
Sterility testing
BacT/Alert® 3D Food
Tempo® microbial enumeration system
BLOOD BANK and TISSUE BANK:

Culture media
Culture media - environmental control range
Quality control testing of apheresis platelets
BacT/Alert® 3D System
WATER TESTING:
Culture media
Legionella GVPC medium
Identification
API® strips
mini API®
Vitek®
apiweb®
®
Biomol GmbH
Waidmannstrasse 35
Hamburg D-22769, Germany
Phone: +49 40 85 32 600; Fax: +49 40 85 32 6022
Web: www.biomol.de
E-mail: info@biomol.de
KEY PERSONNEL: Dr. Eckhard Renken; Managing Director
Carsten Schulz; Head, Finance
Dr. Thomas Wiesemann; Head, Marketing
Dr. Hans-Jurgen Heilmann; Head, Project Management
Biomol Research signal transduction agency agreement 1989
Laboratories reagents eicosanoids, for Germany,
lipids Austria, and Eastern
Europe
Geneka Immunological and agency agreement 1999
Biotechnology Inc. molecular biology for Germany, Austria
products for and Switzerland
transcription factors and
functional genomics
StressGen Inc. heat shock proteins and agency agreement 1991
antibodies for Germany
Upstate signal transduction sales agreement 1990
Biotechnology Inc. antibodies and agency
agreement for
Germany, Hungary,
Poland, and the
Czech Republic
PRODUCTS ON MARKET: Antibodies

Arrays
Compound libraries
EIA kits/plate assays
Enzymes and proteins
Lectins
Plasmid/vectors
Bionas GmbH
Friedrich-Barnewitz-Strasse 3
Rostock 18119, Germany
Phone: +49 381 5196-241; Fax: +49 381 5196-246
Web: www.bionas.de
E-mail: michael.schulze@bionas.de
KEY PERSONNEL: Dr. Ralf Ehret; CEO
Dr. Michael Schulze; Head, Sales and Marketing
HISTORY: Founded 2001
®
BUSINESS STRATEGY: Bionas specializes in analyzing systems and services for in-vitro profiling of
the metabolic activity of cells to understand cellular function. Bionas® 2500
analyzing system is a bench-top instrument that measures multiple
metabolic parameters simultaneously like acidification, oxygen consumption
and adhesion of living cells.
The label-free and non-invasive live cell-based assay employs sensor chips
that replace the conventional bottom of culture wells. Various cell types
including primary cells have been successfully tested. The readout is carried
out continuously over long periods of time and can be watched online
revealing a deeper insight in cellular function than possible with endpoint-
based assays. Regeneration and recovery effects can also be monitored.
Bionas® 2500 analyzing system closely mimics the in vivo situation and
allows a more precise selection of promising drug candidates for preclinical
development; reduces needless, expensive and time consuming animal
studies; and saves money due to reduction of development time (faster
time-to-market).
PRODUCTS ON MARKET: Bionas 2500 analyzing system
Bionov CNP Inc.

4495, boul. Wilfrid-Hamel
Quebec G1P 2J7, Canada
Phone: (418) 653-4422; Fax: (418) 653-3583
Web: www.qbc.clic.net/~bionov
E-mail: bionov@qbc.clic.net
KEY PERSONNEL: Yvan Pouliot; President
SUBSIDIARIES/DIVISIONS: Nutrimer enr.
BUSINESS STRATEGY: Partnering strategy:
Bionov is looking for:
-Animal food wholesalers interested in the distribution of petfood products
(frozen form in aquarium, seaworld and zoo, and dried form in petshop)
-Companies in the food flavoring industry searching for new raw material for
seafood flavoring
-Food processing plant looking for the development of new products
RESEARCH & DEVELOPMENT: Aquatic and marine resources: Development of new products, nutritional
characteristics, upgrading of new resources or by-products, survey of
natural resource, biomass production (aquaculture)
Environment: Ecological management (pollution control, aesthetic,

biodiversity), control of nuisances (bacteria, algae, weeds), ecological study
and environmental evaluation (contamination), Nordic environment
PRODUCTS ON MARKET: Fish food (from amphipods)
Amphipods
®
BIOPAC Systems Inc.

42 Aero Camino
Goleta CA 93117, US
Phone: (805) 685-0066; Fax: (805) 685-0067
Web: www.biopac.com; E-mail: info@biopac.com
KEY PERSONNEL: Alan Macy; President and CEO
Marc Wester; CFO
William McMullen; VP
3,000 sq. ft. R&D facility
BUSINESS STRATEGY: Provide products for medical research and educational markets
RESEARCH & DEVELOPMENT: High-speed data acquisition platform (MP150)

Computerized student physiology laboratory
PRODUCTS ON MARKET: MP100 System
MP 150 System
Biopac Student Lab
MP30/35
AcqKnowledge waveform analysis software
AcqKnowledge GLP
Biopac Science Lab
MP40
MP200 in development
Telemetry in development
BioPro International Inc.

P.O. Box 156, 265 Conklin Street
Farmingdale NY 11735, US
Phone: (516) 249-0099; Fax: (516) 249-0494
Web: www.biopro.com; E-mail: info@biopro.com
KEY PERSONNEL: Rene Lohser; President and CEO
John Campagnola; Sales and Service Manager
Marc Lohser; Head, Marketing
Therese Furger; Treasurer
Denise Lohser; Head, Administration
BUSINESS STRATEGY: Market and service processing equipment and instruments used for
research, development and production of biochemicals, therapeutic drugs,
enzymes, vaccines, antibodies and other biological products
Aquasant AG sensors custom sensor 1993
(Switzerland) design
Bioengineering fermenter/bioreactors custom equipment 1993
AG (Switzerland) design
®
Bioxplore (UK) multiple fermenters custom fermenter 1996

design
Dairei (Denmark) Ultra-Low Temperature custom design 2005
Freezer
Fedegari (Italy) autoclaves custom designed 2002
autoclaves for labs
Graber vibrating mixer custom design 1993
(Switzerland)
Kuhner AG biological shakers custom shaker 1993
(Switzerland) design
M. Christ Freeze Driers and custom designs for 1999
(Germany) vacuum concentrators drug discovery
Prior (Austria) preparative continuous custom design 1999
annular
chromatography
Riebesam glassware washing custom design 2000
(Germany) machines
RESEARCH & DEVELOPMENT: Bioreactors, fermenters, shakers

PRODUCTS ON MARKET: Marketing and service of processing equipment and instruments from global
sources used for research, development and production of biochemicals,
therapeutic drugs, enzymes, vaccines, antibodies and other biological
products
Processes and designs for chemical engineering and environmental
technology
Bioriginal Food & Science Corp.

102 Melville St.
Saskatoon S7J 0R1, Canada
Phone: (306) 975-1166; Fax: (306) 242-3829
Web: www.bioriginal.com
E-mail: business@bioriginal.com
KEY PERSONNEL: Joe Vidal; President and CEO
Johan Kamphuis; Exec. VP, Global Marketing and Sales
Gene Gerspacher; VP, Finance
Dr. Jim Nugent; Director, Product Development
Manny Sabares; Director, Marketing
PRODUCTS ON MARKET: Condition-Specific Products

Borage Products (oils, softgels, powders)
EPA/DHA Products (oils, softgels, powders)
Flax Products (oils, softgels, powders)
EPO Products (oils, softgels, powders)
®
Bioscience Inc.
1550 Valley Center Parkway, Suite 140
Bethlehem PA 18017, US
Phone: (610) 974-9693; Fax: (610) 691-2170
Web: www.bioscienceinc.com
E-mail: bioscience@bioscienceinc.com
KEY PERSONNEL: Thomas G. Zitrides; CEO
BUSINESS STRATEGY: Provide innovative products and services for environmentally-sound and
efficient treatment of wastewater, wastewater sludge, contaminated soils
and biotreatment for aquaculture and agriculture
PRODUCTS ON MARKET: Microbial products for bioaugmentation

Process improvement and stabilization of wastewater plants
Activated sludge plants
Plumbing systems
Soil reclamation/bioremediation
Aquaculture programs
Analytical instruments and test kits
Heater blocks and colorimeters for monitoring wastewater parameters
Package biotreatment plants, aerators, product feeders and related
instrumentation
Laboratory biodegradation and biotreatability testing
Engineering scale-up for bioremedial projects and in-house technical
services
Environmentally-friendly degreasers and oily water treatment and
management programs
BioScreen Testing Services Inc.

3892 Del Amo Boulevard
Torrance CA 90503, US
Phone: (310) 214-0043; Fax: (310) 370-3642
Web: www.bioscreen.com
E-mail: info@bioscreen.com
KEY PERSONNEL: Bradford L. Rope; President and CEO
Dr. Richard Sullivan; Director, R&D
Dr. Lawrence Rheins; VP, Clinical Services
FACILITIES: Facilities in Phoenix, Ariz., and Shawnee Mission, Kan.
SUBSIDIARIES/DIVISIONS: Pharmaceutical and Biotechnology Services
Medical Device
Cosmetic, Household & Industrial Products
Midwest Clinical Trials (Human Clinical and Claim Substantiations)
®
RESEARCH & DEVELOPMENT: Microbiology, chemistry and toxicology testing

Medical devices
Pharmaceuticals
Water testing
BioSure Inc.
12301 Loma Rica Drive, Suite G
Grass Valley CA 95945-9355, US
Phone: (530) 273-5095; Fax: (530) 273-5097
Web: www.biosure.com; E-mail: richardr@biosure.com
KEY PERSONNEL: J. R. Riese; CEO
HISTORY: Founded and began biotech research in 1986
BUSINESS STRATEGY: Provide unique products and expert technical assistance to research,
industry, clinical laboratories, hospitals and medical/dental facilities
worldwide
The company focuses on biological safety, biological controls and standards
and regulatory conformance in the manufacturing of biomedical devices and
reagents
RESEARCH & DEVELOPMENT: Biological controls and reagents for flow cytometry, immunocytometry and
DNA analysis
PRODUCTS ON MARKET: BioSure® steam sterilization integrators for verification of autoclave cycles
and sterility
BioSure® flow cytometry biological controls, DNA controls, reagents and
buffers
Consulting services, custom products and packaging
Biosynth International Inc.

1665 West Quincy Avenue, Suite 155
Naperville IL 60540, US
Phone: (630) 305-8400; Fax: (630) 305-8420
Web: www.biosynth.com
E-mail: welcome@biosynth.com
KEY PERSONNEL: Urs Spitz, Ph.D.; Chairman and CEO
FACILITIES: Worldwide headquarters:
Biosynth AG
Rietlistr. 4
Postfach 125
9422 Staad, Switzerland
Phone: +41 (0)71 858 20 20
Fax: +41 (0)71 858 20 30
®

BUSINESS STRATEGY: Innovate, develop and produce reagents and biochemicals for the life
science and pharmaceutical industries
RESEARCH & DEVELOPMENT: Manufacture of substances for the detection of enzyme activity indicative of
health conditions in clinical samples
Identification of bacterial infections in clinical, food and environmental
samples or products for hygiene monitoring
Rare biochemicals such as culture media additives, biological detergents,
plant growth hormones, and biochemical reagents used in standard assays
Synthesis of indole derivatives
PRODUCTS ON MARKET: Biochemicals: Biological detergents, plant growth regulators and
biochemical reagents, including diagnostic reagents, cosmetic ingredients,
pharmaceutical ingredients, biochemical substances
Carbohydrates and inositols: Monosaccharides, disaccharides,

oligosaccharides, polysaccharides and inositols
Culture media additives: Carbohydrates, growth inhibitors, C-390, bile acids,

keto acids, L-amino acids and SPS
Dyes, stains, labels and indicators: Colorimetric and fluorometric reagents,

dyes and stains, indicators and labels
Enzyme substrates: Glycosidases, peptidases, esterases, phosphatases,

peroxidases, sulfatases, phospholipases, luciferases and enzyme reagents
Fine chemicals: Alcohols, aldehydes, ketones; amines, amides, guanidines,

ureas; amino acid derivatives; carboxylic and inorganic acids and
derivatives; phenols, quinones, coumarines and other aromatics;
heterocycles and alkaloids; steroids and bile acids
Indole derivatives: Mono-substituted indoles, di-substituted indoles, tri-

substituted indoles, higher substituted indoles, tryptamines, serotonins,
tryptophans, tryptophols, gramines, harmines and harmanes, fluoroindoles,
azaindoles and indolines
Lipids and Phospholipids: Propanol-based lipids, glycol-based lipids,

glycerol-based lipids, other lipids, propanol-based phospholipids, glycol-
based phospholipids, glycerol-based phospholipids, other phospholipids
Life science reagents: Biochemistry tools, cell biology tools, molecular

biology tools, receptor agonists and antagonists and reducing agents
Biotal Ltd.
Collivaud House, Ocean Way
Cardiff CF24 5PD, UK
Phone: +44 (0)29 2047 5550; Fax: +44 (0)29 2047 5598
Web: www.biotal.co.uk
KEY PERSONNEL: Stuart Patterson; Director
SUBSIDIARIES/DIVISIONS: Agricultural business
Equine business
Garden products business
Industrial products business
®
BUSINESS STRATEGY: Develop products based on microbial and enzyme technology
RESEARCH & DEVELOPMENT: Agricultural business: Focus is on the research, development, manufacture
and supply of forage additives using naturally occurring micro-organisms
and enzyme formulations
PRODUCTS ON MARKET: BioCrimp
Biograin
Biostraw
Wholecrop
Wholecrop Legume
Axcool
Solo
Axphast
Supersile
SoloMaize
MaizeCool
Top-Treat
SC yeast range
Equine Gold
Garden cleaners
Compost Maker
Water Clear
Fountain Clear
Refresh and Refresh Plus
Soil Restore
Biotal GD
Biological urinal/toilet cleaner
Bio-Technical Resources
1035 South 7th Street
Manitowoc WI 54220, US
Phone: (920) 684-5518; Fax: (920) 684-5519
Web: www.biotechresources.com
E-mail: info@biotechresources.com
KEY PERSONNEL: Tom Jerrell; President
Reinhardt A. Rosson, Ph.D.; VP and Director, R&D
Michele T. Schmidt; VP, Operations
Julia Maurina-Brunker; Director, Business Development
Dr. Linsheng Song; Sr. Research Scientist
EMPLOYEES: 30 employees, 22 scientists and engineers
FACILITIES: 15,000 sq. ft. facility with extensive analytical equipment, fully equipped
molecular biology laboratory, isotope rooms and fermenters (1 to 250 liters)
SUBSIDIARY OF: Arkion Life Sciences LLC
PRINCIPAL INVESTORS: Arkion Life Sciences LLC
BUSINESS STRATEGY: Develop process technologies based on microbial fermentation and
biocatalysis
Provide laboratory and consulting services--including recombinant and
classical strain improvement, industrial expression systems, fermentation
and downstream process development and scale-up, metabolic engineering
and microbial screening--on a contract basis
®
RESEARCH & DEVELOPMENT: Microbial screening

Strain improvement, classical and recombinant
Fermentation development, recovery and scale-up
Metabolic engineering
Molecular biology
Biocatalysis, enzyme and whole cell
Expression systems
Biotechnology Research Institute

6100 Royalmount Avenue
Montreal H4P 2R2, Canada
Phone: (514) 496-5329; Fax: (514) 496-5007
Web: www.irb-bri.cnrc-nrc.gc.ca
E-mail: bri-info@cnrc-nrc.gc.ca
KEY PERSONNEL: Dr. Michel Desrochers; Director General
Dr. Andrew Storer; Director, Health Sector
Dr. Bernard Massie; Director, Bioprocess Platform
Adrien Pilon; Director, Environmental Sector
Eileen Raymond; Director, Industrial Affairs Sector
EMPLOYEES: 812 employees (277 NRC employees, 304 employees from private
companies, 210 students and guest researchers)
HISTORY: Established by National Research Council of Canada in 1984 to conduct
state-of-the-art research in molecular biology and biochemical engineering
with specific applications to the pharmaceutical and environment and
resource industries
FACILITIES: 315,000 sq. ft. of laboratories, offices, pilot plants and spaces leased to
industry
PRINCIPAL INVESTORS: National Research Council of Canada
BUSINESS STRATEGY: Make a significant contribution to the wealth-generating capability in Canada
and represent a source of expertise for both industry and the scientific
community
Work with companies through collaboration research, contract and licensing
agreements
RESEARCH & DEVELOPMENT: Molecular design strategies for the development of peptidyl and nonpeptidyl
blockers as potential therapeutic agents (cancer, cardiovascular, and
degenerative and inflammatory diseases)
Development of biotechnology products, development of new bioprocesses,
improvement of existing bioprocesses, scale-up of bioprocesses to industrial
levels using microorganisms, animal cells or enzymes as catalysts
Bioremediation of contaminated soils, air, groundwater and sediments
Biological monitoring, biosensors and biopesticides
®
Biotecx Laboratories Inc.

6023 South Loop East
Houston TX 77033, US
Phone: (713) 643-0606; Fax: (713) 643-3143
Web: www.biotecx.com
E-mail: biotecx@aol.com
KEY PERSONNEL: Dr. Mohan Mehra; President
BUSINESS STRATEGY: Develop products for molecular biology and clinical diagnostics
Find partners for OEM distribution and direct selling
RESEARCH & DEVELOPMENT: ELISA products for infectious disease

Hormone assays
PRODUCTS ON MARKET: Ultraspec RNA
RNA Tack
DNA Multriprep
BioPlaz
Ezout
Expresep
Ontrack
Prokay
OptiCoat ELISA kits for TORCH, thyroids, fertility hormones
Biotehnos SA
18, Dumbrava Rosie Street, District 2
Bucharest 020464, Romania
Phone: +40 21 210 20 15; Fax: +40 21 210 97 05
Web: www.bth.ro
E-mail: office@biotehnos.com
KEY PERSONNEL: Prof. Dr. Ioan Manzatu; President and CEO
Liliana Manzatu; Deputy Director General
Iuliana Zaharia; Financial Director
Stefan Badusi; Commercial Director
Alexandru Stoica; Marketing Director
Laura Olariu; Director, R&D
Mariana Ghica; Production Director
Viorica Dinga; QA Director; Quality Control
Ruxandra Elisa Dobos; Head, QC Department
Ludmila Turcanu; Scientific Director
HISTORY: Began biotech R&D in 1983
Founded in 1991
PRINCIPAL INVESTORS: Tehman Ltd.--20%
®
INVESTMENTS: National Institute of Biotechnologies--$30K

Biotehnos and Tehman Association--$5M
BUSINESS STRATEGY: Develop, market and export biopharmaceuticals and biocosmetics
Artur-K pharmaceuticals distribution
agreement
Biotechman pharmaceuticals and Commercialization
GmbH cosmetics of yeast extracts,
marketing,
tehnology transfer,
new products
registration, GMP
rules implementation
CMS GmbH biotechnology joint venture for 1997
R&D, production
and marketing
Falbi pharmaceuticals distribution
agreement
Farmotehnos SA pharmaceuticals and Joint venture for
cosmetics products
registration,
distribution,
promotion of new
technologies and
production
Guangzhou pharmaceuticals and distribution 1997
Economic and cosmetics agreement
Technological
Development
District (China)
Interfarma pharmaceuticals distribution
agreement
Lenniichimmash- pharmaceuticals distribution
Centrofarm agreement
Masung Co. Ltd. pharmaceuticals sales agreement for 1996
(Seoul) the Far East
North pharmaceuticals distribution
Pharmaceutical agreement
Network
Planeta pharmaceuticals distribution
agreement
Protec pharmaceuticals distribution
agreement
Rompharm Co. pharmaceuticals distribution
agreement
Travel Medinsure pharmaceuticals distribution
agreement
PRODUCTS ON MARKET: Biopharmaceuticals: Alflutop®/Alflutop® gel, Armon®, Gelisept®, Alflutop®

vet, Salvapoderm®, Salvaderm®, Rhinogel® vet, Cervisalva® vet
Biocosmetics: Biounda skin care products and body care products,

Solarmon sunbathing products
Plant extracts
Structured water
®
Biothane Corp.
2500 Broadway, Drawer 5
Camden NJ 08104, US
Phone: (856) 541-3500; Fax: (856) 541-3366
Web: www.biothane.com
E-mail: sales@biothane.com
KEY PERSONNEL: Robert I. Sax, Ph.D.; President
Jay Murphy; Exec. VP
Jelte Lanting; Technology Manager
Jill Jordan; Technical Services Manager
SUBSIDIARIES/DIVISIONS: Biothane Systems International
Tanthofdreef 21
P.O. Box 5068
2600 GB Delft, The Netherlands
Phone: +31 15 270 0111
Fax: +31 15 256 0927
E-mail: sales.europe@biothane.com
Biothane Asia Pacific

Ventura Building, 9th floor Suite 903
Jl. R.A. Kartini no 26
Jakarta 12430, Indonesia
Phone: +62 (0)21 750 4707
Fax: +62 (0)21 750 4708
E-mail: sales.asia@biothane.com
Biothane Systems Ltd.

446 Houldsworth Mill Business Centre
Houldsworth Street
Reddish, Stockport SK5 6DA, UK
Phone: +44 (0) 161 975 6052 / 6051
Fax: +44 (0) 161 975 6053
E-mail: sales.europe@biothane.com
SUBSIDIARY OF: Joseph Oat Holding Inc.
PRODUCTS ON MARKET: Biothane high rate anaerobic wastewater treatment process

Biobed high rate anaerobic wastewater treatment process
Biopuric Hydrogen Sulfide biogas scrubber
SEAD- Shear Enhanced Anaerobic Digestion process
®
BioTime Inc.
6121 Hollis Street
Emeryville CA 94608, US
Phone: (510) 350-2940; Fax: (510) 350-2948
Web: www.biotimeinc.com; E-mail: contacts@biotimemail.com
KEY PERSONNEL: Judith Segall; VP, Technology and member of office of president
Hal Sternberg, Ph.D.; VP, R&D and member of office of president
Harold Waitz, Ph.D.; VP, Regulatory and member of office of president
Jeffrey B. Nickel, Ph.D.; VP, Business Development and Marketing
Stephen Seinberg; CFO
HISTORY: Founded in November 1990
FACILITIES: 5,244 sq. ft. of leased space in Emeryville, Calif.
STOCK-FINANCIAL HISTORY: OTC BB--BTIM
Subscription rights offering--283K shares at $20/share (2/97)
3:1 stock split (10/97)
Revenue $903.200K (YE 05) compared to $688.377K (YE 04)
04)
PRIVATE PLACEMENTS: Raised $1.8M in rights offer of stock and warrants (12/05)
BUSINESS STRATEGY: Develop blood plasma volume expanders, blood replacement solutions for
hypothermic surgery, organ preservation solutions and technology for use in
surgery, emergency trauma treatment and other applications
Abbott Hextend plasma- $40M licensing 4/97
Laboratories expanding product agreement--Abbott
paid $1.4M
licensing fee (7/97)
Barrow blood substitute for low- research 1993
Neurological temperature surgery agreement
Institute of St.
Joseph's Hospital
Baylor College of Hextend artificial blood research 12/95
Medicine plasma solution agreement
(Houston, TX)
Bronx Veterans blood replacement research 1993
Affairs Medical solutions agreement
Center
Davies Medical freeze-protecting research 1993
Center--Buncke solutions to preserve full agreement
Clinic thickness skin grafts
McGaw Inc. Hextend production 12/94
agreement
Metropolitan blood replacement research 1993
Hospital solution agreement
Mt. Sinai Medical blood replacement research 1993
Center solution agreement
Summit Hextend and PentaLyte development 12/05
Pharmaceuticals for the Japanese market agreeement
International Corp.
RESEARCH & DEVELOPMENT: Synthetic solutions that can be used as blood plasma volume expanders,
blood replacement solutions during hypothermic surgery, and organ
preservation solutions
®
PRODUCTS ON MARKET: Hextend® blood substitute solution for low-temperature surgical procedures
Pentalyte in Phase II clinicals
Hetacool in discovery
Hetafreeze in discovery
BioVectra dcl
16 McCarville Street
Charlottetown PE--C0A 1H0, Canada
Phone: (902) 566-9116; Fax: (902) 628-2045
Web: www.biovectra.com
E-mail: info@biovectra.com
KEY PERSONNEL: Dr. Rejis Duffy; Chairman
Ron Keefe; President
Dale Zajicek; COO
Gordon Rogers; CFO
Dr. Gary R. Reid; VP, R&D
Dr. Tibor Breining; Director, R&D
Dr. Richard Bethell; Sr. Scientist
Patrick Duffy; Purchasing Manager
EMPLOYEES: 200+ employees, 7 Ph.D.s
SUBSIDIARIES/DIVISIONS: Diagnostic Chemicals Limited
BUSINESS STRATEGY: Custom manufacturing
Provide bioprocessing reagents and services
Bioxel Pharma Inc.

3075 Chemin des Quatre-Bourgeois, Suite 440
Sainte-Foy G1W 4Y5, Canada
Phone: (418) 654-9666; Fax: (418) 654-9655
Web: www.bioxelpharma.com
E-mail: bioxelpharma@bioxelpharma.com
KEY PERSONNEL: Andre P. Boulet, Ph.D.; Chairman
Pascal Delmas; CEO and President
Louis McGuire; VP, Finance and CFO
Paul Metz; Exec. VP, Commercial Operations
Andre Lalonde; VP, Biomass
Louis Estaque, Ph.D.; VP, Production
STOCK-FINANCIAL HISTORY: TSX--BIP
Public offering--13.571M common shares at $0.70/share, $9.5M (3/03)
04)
®
PRIVATE PLACEMENTS: Raised $4.5M in private placement of 6.429M common shares at

$0.70/share (8/03)
Raised $3.3M in private placement of 8.041M units at a $0.41/unit (9/04)
Raised $4.7M in private placement of 13.817M common shares at
$0.34/share (2/06)
Raised $2.7M from 7.980M common shares at $0.34/share, received upon
the exercise of an equivalent number of warrants (4/06)
SUBSIDIARIES/DIVISIONS: U.S. office:
2429 Ginny Way
Lafayette, CO 80026
Phone: (303) 926-9878
Fax: (303) 926-9877
BUSINESS STRATEGY: Manufacture and distribute taxane pharmaceutical ingredients, including
paclitaxel, docetaxel, 9-DHB and 10-DAB
RESEARCH & DEVELOPMENT: Portfolio of new products that include docetaxel, paclitaxel via a semi-
synthetic route of production and innovative taxane-based drugs
PRODUCTS ON MARKET: natural paclitaxel
9-DHB
10-DAB
Biozyme Laboratories Ltd.

Unit 6, Gilchrist Thomas Estate, Blaenavon
Torfaen NP4 9RL, UK
Phone: +44 1495-790678; Fax: +44 1495-791780
Web: www.biozyme.com
E-mail: info@biozyme.co.uk
KEY PERSONNEL: John Chesham; Managing Director
Ken Murray; Sales and Marketing Manager
Jane Howells; Sales and Marketing Coordinator
John O'Shea; Quality Manager
HISTORY: Established in December 1971 at Bourne End, Buckinghamshire, as
manufacturer of enzymes for diagnostic reagents
FACILITIES: Two manufacturing facilities in the U.K.
Sales and marketing office in San diego, Calif.
Worldwide network of distributors
SUBSIDIARIES/DIVISIONS: Biozyme Laboratories International Ltd.
9939 Hibert Street, Suite 101
San Diego, CA 92131-1029
Fax: (858) 549-0138
E-mail: bioinfo@biozyme.com
SUBSIDIARY OF: Theratase plc
BUSINESS STRATEGY: Develop and manufacture high purity enzymes and proteins
RESEARCH & DEVELOPMENT: Enzymes as active pharmaceutical ingredients, for example, high activity
hyaluronidase for applications other than opthalmology
Protein purification specializing in extraction from plant and animal tissues
using chromatography and other methods
Product assay
®
PRODUCTS ON MARKET: Highly purified enzymes and related biochemicals for clinical diagnostics,
immunodiagnostics, biosensors, diagnostic probe and research applications
(includes alkaline phosphatase, peroxidase, glucose oxidase, urease,
catalase, aldehyde dehydrogenase, hexokinase, phospho-enolpyruvate
carboxylase, glycerol-3-phosphate dehydrogenase, ascorbate oxidase,
cholesterol esterase, xanthine oxidase, alpha-glucosidase, elastase,
enterokinase, deoxyribonuclease and ribonuclease)
Boojum Research Ltd.

139 Amelia Street
Toronto M4X 1E6, Canada
Phone: (416) 861-1086; Fax: (416) 861-0634
Web: www.boojumresearch.com; E-mail: margarete.kalin@utoronto.ca
KEY PERSONNEL: Margarete Kalin; President
EMPLOYEES: 2 employees, 4 specialty contractors
FACILITIES: 850 sq. ft. headquarters
BUSINESS STRATEGY: Seek marketing, investment and joint venture opportunities
RESEARCH & DEVELOPMENT: Wetland microbiology and ecosystem recovery

Bioremediation of mining sites
Environmental mining
PRODUCTS ON MARKET: Chara process
Microbiological AMD treatment
Biological polishing
Ecological engineering
ARUM (acid reduction using microbiology) process
Project management for clean-up of mine sites
Boston Life Sciences Inc.

85 Main Street
Hopkinton MA 01748, US
Phone: (508) 497-2360; Fax: (508) 497-9964
Web: www.bostonlifesciences.com
E-mail: ir@bostonlifesciences.com
KEY PERSONNEL: Peter G. Savas; Chairman and CEO
Mark J. Pykett, Ph.D.; President and COO
Kenneth L. Rice Jr.; Exec. VP, Finance and CFO
Mark R. Hurtt, M.D.; CMO
Irene Gonzalez, Ph.D.; Sr. VP, Protein Development
Noel J. Cusack, Ph.D.; Sr. VP, Preclinical Development
Richard Thorn, Ph.D.; Sr. VP, Program Operations
Sharon Correia; Director, Corporate Communications and Investor Relations
HISTORY: Founded in 1992 by the Castle Group and Dr. Marc Lanser
Completed reverse merger with Greenwich Pharmaceuticals Inc. to become
a public company (6/95)
Member--Massachusetts Biotechnology Council
®
FACILITIES: 5,900 sq. ft. office facility in Hopkinton, Mass.

3,300 sq. ft. laboratory facility in Baltimore, Md.
2,500 sq. ft. office facility in Woburn, Mass.
STOCK-FINANCIAL HISTORY: NASDAQ--BLSI
One-for-five reverse stock split (2/05)
Loss per share <$1.03/share> (YE 05) compared to<$1.73/share> (YE 04)
Total assets $10.515M (YE05) compared to $2.545M (YE 04)
PRIVATE PLACEMENTS: Raised $2.2M through issuance of 7% senior bridge notes (6/95) (notes
converted into 157K shares of common stock in 1st quarter 1996)
Raised $1.8M in private placement of 320K shares (11/95)
Raised $24M in private placement of 240K shares of Series A preferred
stock and warrants to purchase 600K shares at $6.70/share (1/96)
Raised $5M in private placement of 500K shares (7/96)
Raised $8M in private placement of convertible preferred stock and warrants
(12/03)
Raised $5M in private placement of 2M shares of common stock at
$2.50/share (3/05)
Raised $12.8M in private placement of 6M shares of common stock at
$2.13/share (8/05)
BUSINESS STRATEGY: Research and clinical development of diagnostic and therapeutic products
for central nervous system (CNS) disorders such as Parkinson’s disease,
essential tremor, ADHD, stroke, traumatic brain injury, spinal cord injury and
ocular indications
Children’s key factors that inhbit exclusive, 5/06
Hospital Boston the inhibitors of axon worldwide licensing
regeneration and sponsored
research
agreements
Children’s key factors that promote exclusive, 12/98
Hospital Boston axon regeneration worldwide licensing
and sponsored
research
agreements,
amended 5/06
Harvard University Altropane molecular exclusive, 3/00
imaging agent for worldwide
ADHD licensing, amended
5/04
Harvard University Altropane molecular exclusive, 12/93
imaging agent for PD worldwide licensing
agreement,
amended 5/04
Harvard University BCLx-gamma gene that licensing 3/98
controls apoptosis agreement
Zeneca small molecule exclusive R&D 6/95
Pharmaceuticals inhibitors of MHC Class agreement
II gene transcription
factors to treat
autoimmune diseases
RESEARCH & DEVELOPMENT: 1) Molecular imaging program focused on molecular imaging agents used
as an aid in diagnosing Parkinson's disease and ADHD with SPECT, PET
and MRI
2) Dopamine transport blocker program as a therapeutic and in potential
disease modification for Parkinson's disease
3) Axon regeneration program focused on treatments for stroke, TBI, SCI
and ocular diseases
®
BRAIN (Biotechnology Research and

Information Network AG)
Darmstadter Strasse 34-36
Zwingenberg 64673, Germany
Phone: +49 (0) 62 51 / 9331-0
Fax: +49 (0) 62 51 / 9331-11
Web: public@brain-biotech.de
E-mail: public@brain-biotech.de
KEY PERSONNEL: Dr. Holger Zinke; Chairman and CEO
Dr. Jurgen Eck; CSO
Dr. U. Dechert; Sr. Scientist
Dr. M. Krohn; Unit Head
Dr. M. Langer; Corporate Development
Dr. P. Lorenz; Unit Head
Dr. G. Meurer; Unit Head
Spun off VISCUM AG (2000)
537 sq. ft. R&D facilities
BUSINESS STRATEGY: Discover and develop novel bioactives, biocatalysts and enzymes
BASF AG new oxidoreductases R&D cooperation 2005
Ciba AG microorganisms for R&D cooperation 2005
production of speciality
chemicals
Degussa AG new ADH for production R&D cooperation 2005
of chiral alkohols
Genencor BRAIN's metagenome R&D agreement 2004
International to develop enzyme
platform
Henkel KGaA new detergent enzymes R&D cooperation 2005
Nutrinova GmbH nutraceuticals development 2004
agreement
Sandoz GmbH enzymes for biotech R&D agreement 2004

prod of ß-lactam
antibiotics
Schering AG design of micro- R&D cooperation 2005
organisms for
production of steroid
drugs
Sudzucker AG functional carbohyrates R&D cooperation 2005
RESEARCH & DEVELOPMENT: Expression systems

Secondary metabolites
Microbial strain optimisation
Bioactive compounds
Industrial enzymes
Technical enzymes and biocatalysts
Cellular based assays
®
Bunge Ltd.
50 Main Street
White Plains NY 10606, US
Phone: (914) 684-2800
KEY PERSONNEL: Alberto Weisser; Chairman and CEO
Andrew J. Burke; Managing Director, New Business, Bunge Ltd.
Archibald Gwathmey; Managing Director, Agribusiness Division, Bunge Ltd.,
and CEO, Bunge Global Markets Inc.
Joao Fernando Kfouri; Managing Director, Food Products Division, Bunge
Ltd.
Flavio Sa Carvalho; Chief Personnel Officer
William M. Wells; CFO
Mario A. Barbosa Neto; CEO, Bunge Fertilizantes SA
Jean Louis Gourbin; CEO, Bunge Europe
Carl L. Hausmann; CEO, Bunge North America Inc.
Raul Padilla; Bunge Argentina SA
Sergio Roberto Waldrich; Bunge Alimentos SA
HISTORY: Founded in 1818 as a grain trading company in Amsterdam, the
Netherlands
In the second half of the 1800s, expanded grain operations in Europe and
entered the South American agricultural commodities market
Entered the South American food products industry (1888)
Started U.S. operations (1923)
Entered the fertilizer industry in Brazil (1938)
FACILITIES: More than 500 facilities in 32 countries:
Agribusiness: 275 grain storage facilities, approximately 50 oilseed
processing plants and approximately 25 international marketing offices
Fertilizer: Four phosphate mines in Brazil, 35 processing plants in Brazil
Food products operations: Approximately 50 refining and bottling facilities
and 20 other facilities
STOCK-FINANCIAL HISTORY: NYSE--BG
IPO--17.6M shares at $16/share (8/01)
Net sales $24.275M (YE 05) compared to $25.168M (YE 04)
Net income $530M (YE 05) compared to $469M (YE 04)
Average shares outstanding 112,132b (YE 05) compared to 106,016b (YE
04)
SUBSIDIARIES/DIVISIONS: Three divisions: Agribusiness, fertilizer and food products, which include
four reporting segments: Agribusiness, fertilizer, edible oil products and
milling products
Subsidiaries:
U.S.A.: AGRI-Bunge LLC, Bunge North America (East) LLC, Bunge North
America Foundation, Sabina Bunge LLC, Bunge North America Inc., Bunge
Milling Inc., The Crete Mills Inc., Lauhoff Finance Corp., Bunge Oils Inc.,
Bunge North America (OPD West) Inc., Bunge Mexico Holdings Inc., Bunge
North America Capital Inc., Bunge Mextrade LLC, Delphos Terminal Co.
Inc., CSY Holdings Inc., CSY Agri-Finance Inc., Universal Financial Services
LP, Batavia Leasing Co., Bunge Chicago Inc., International Produce Inc.,
Bunge NA Holdings Inc., Bunge Global Markets Inc., Bunge Finance North
America Inc., Bunge Management Services Inc., Bunge Funding Inc., Bunge
Asset Funding Corp., Bunge Ltd. Finance Corp., Solae Holdings LLC,
Bunge Canada Investments Inc., DDO Processing LLC
Canada: Bunge of Canada Ltd., Bunge Canada, Bunge Canada Holdings I

ULC, Bunge Canada Holdings II ULC, CF Oils Investments Inc., Leblanc &
Lafrance Inc., Neptune Bulk Terminals (Canada) Ltd.
®
Mexico: Controladora Bunge SA de CV, Agroproductos Bunge SA de CV,

Harinera La Espiga SA de CV, Inmobiliaria A Gil SA, Inmobiliaria Gilsa SA,
Servicios Bunge SA de CV, Molinos Bunge SA de CV, Bunge Comercial SA
de CV
Bermuda: Ceval Holdings Ltd., Brunello Ltd., Greenleaf Ltd., Bunge Finance
Ltd., Serrana Holdings Ltd., Bunge Global Markets Ltd., Fertimport
International Ltd.
Barbados: Bunge Export Sales (Barbados) Corp.
Cayman Islands: Bunge Fertilizantes International Ltd., Santista

International Ltd., Santista Export Ltd., Ceval Export Securitization Ltd.,
Ceval International Ltd., Bunge Trade Ltd.
Argentina: Terminal Bahia Blanca SA, Bunge Argentina SA, Terminal 6 SA,
Terminal 6 Industrial SA
Guide SA, Fertimport SA, Bunge Inversiones SA
Brazil: Fosbrasil SA, Serrana Logistica Ltda., Amoniasul Servicos de

Refrigeracao Industrial Ltda., Bunge Alimentos SA, Bunge Fertilizantes SA,
Fertilizantes Ouro Verde Ltda., Fertilizantes Fosfatados SA, Ultrafertil SA,
Fertifos Administracao e Participacoes SA, Macra Administracao e Servicos
Ltda., Agrisat Solucos Integradas Ltda., IFC Industria de Fertilizantes de
Cubatao SA, Bunge Armazens Gerais Ltda., Ceval Centro Oeste SA,
Terminal de Graneis do Guaruja SA, Terminal Maritimo do Guaruja SA
(TERMAG), IFC - Industria de Fosfatados Catarinense Ltda., Cereol do
Brasil Ltda., MBB Comercio e Servicos Ltda., Serra do Lopo
Empreendimentos e Participacoes SA, Fertimport SA, Moinho Jauense
Industria e Comercio de Alimentos Ltda., Eco Invest Carbon PP Ltda.
Uruguay: Bunge Uruguay SA, Dinelsur Corp. SA, Agritrade SA
Paraguay: Bunge Paraguay SA
Peru: Bunge Peru SAC
Venezuela: Almacen Terminal Santana CA
Dominican Republic: Bunge Caribe SA
Australia: Bunge Global Markets Australia Pty. Ltd.
Southeast Asia: Bunge Agribusiness Singapore Pte. Ltd., PT. Bunge

Agribusiness Indonesia, Bunge Agribusiness (M) Sdn. Bhd., Bunge
(Thailand) Ltd., Bunge Agribusiness Philippines Inc., Grains and Industrial
Products Trading Pte. Ltd.
China: Bunge International Trading (Shanghai) Co. Ltd.

Mauritius: Bunge Mauritius Ltd. Bunge Mauritius Holdings Ltd., International
Produce Ltd.
India: Bunge India Pvt. Ltd.
U.K.: Bunge Corp. Ltd., Bunge UK Ltd.
Spain: Bunge Iberica SA, Estacion de Descarga y Carga SA (Esdecasa),

Ergransa SA, Bunge Iberica Investment SRL, Moyresa Girasol SL, Biodiesel
Bilbao SL
France: Bunge France SAS, Bunge Holdings France SAS, Bunge SAS,
Novaol France SAS, Saipol SAS, Diester Industries International SAS
®
Holland: Koninklijke Bunge BV, Bunge Cooperatief UA, Bunge Europe

Finance BV, Bunge Brasil Holdings BV, Bunge Finance Europe BV, Bunge
Alimentos Holding BV
Switzerland: Bunge SA, Oleina SA, Ecoinvest Carbon SA
Germany: Bunge Deutschland GmbH, Bunge Handelsgesellshaft mbH
Italy: Bunge Italia SpA, Escercizio Raccordi Ferroviari SpA
Turkey: Bunge Gida Ticaret AS
Cyprus: Bunge Cyprus Ltd., Eastern Agro Investment Ltd., Brea

Commodities Ltd.
Hungary: Bunge ZRT, Cereol Befektetesi Kft.
Portugal: Bunge Iberica Portugal SA, Gardone-Consultoria e Servico,

Sociedade Unipessoal Lda.
Luxembourg: Bunge Europe SA
Austria: Bunge Austria GmbH
Latvia: Dan Store LSEZ SIA
Ukraine: Suntrade SE, Fisakiyske Khp, DOEP, CJSC Dolynsky Elevator,

LLC Oleina Distributors, LLC Lan Elevator, Black Sea Industries Ltd.
Romania: SC Unirea SA, Muntenia SA, Interoil SA, Bunge Romania Srl
Poland: ZT Kruszwica SA, EWICO S.p.z.o.o., Polska Trade Services

S.p.z.o.o., ZPT W Warszawie SA, Olvit Pro S.p.z.o.o.
Belgium: Afrique Initiatives
Russia: LLC Bunge CIS, LLC Prichalny Complex, Rostov Grain Terminal
LLC, LLC Elevatorniy Complex, LLC Elevator, LLC Grain CO Dara, OJS
Kholmsky
Bulgaria: Kaliakra AD
INVESTMENTS: The Solae Co.--joint venture with DuPont
Saipol SAS--joint venture with Sofiproteol
Joint venture with Aceitera General Deheza SA for the operation of the
Terminal 6 port facility in Argentina and adjacent crushing facility
AGRI-Bunge LLC--joint venture with AGRI Industries
Fosbrasil SA--joint venture with Astaris Brasil Ltda. and Societe Chimique
Prayon Rupel SA
EWICO S.p.z.o.o.--joint venture in Poland
Harinera La Espiga SA de CV--joint venture with Grupo Neva SA de CV and
Cerrollera SA de CV
Terminal de Graneis do Guaruja SA--joint venture with Ferronorte SA
Diester Industries International SAS--joint venture with Diester Industrie
BUSINESS STRATEGY: Agribusiness division: Purchase, process, store and sell grains and oilseeds
Fertilizer: Involved in every stage of the fertilizer business, from mining raw
materials to the selling fertilizer products
Food products: Two business segments--edible oil products and milling
products. Businesses in these segments produce and sell food products
such as edible oils, shortenings, margarine, mayonnaise and milled products
such as wheat flours and corn products
®

DuPont joint venture for the alliance and 1/03
global production and agreement
distribution of specialty
food ingredients
(starting with soy
proteins and lecithins),
joint development and
commercialization of
soybeans with improved
quality traits, and
development of a
broader offering of
services and products
to farmers
Procter & Gamble production and alliance 11/04
and Peter Cremer marketing of
North America cholesterol-reducing
phytosterol ingredients
for pharmaceuticals and
foods
CABI
Bakeham Lane
Egham TW20 9TY, UK
Phone: +44 (0)1491-829-080; Fax: +44 (0)1491-829-100
Web: www.cabi.org
E-mail: information@cabi.org
KEY PERSONNEL: Dr. Trevor Nicholls; CEO
EMPLOYEES: 350 employees (220 in the U.K.)
HISTORY: CABI was founded in 1920
Formerly the Commonwealth Mycological Institute, International Mycological
Institute (IMI), International Institutes of Entomology (IIE), Parasitology (IIP)
and Biological Control (IIBC)
FACILITIES: 4,200 sq. m. in six buildings in the U.K.
STOCK-FINANCIAL HISTORY: Intergovernmental nonprofit enterprise
FINANCIAL INFORMATION: Nonprofit. Financed through sales of services and consultancies to
governments, foundations and the corporate sector
BUSINESS STRATEGY: CABI is a leading provider of authoritative and unbiased scientific
information in agriculture and the environment. It conducts research into
agricultural and environmental issues, aiming to improve peoples’ lives in
direct and indirect ways. The organization also publish books, journals and
scientific research aiming to further science and its application to real life.

Academia Sinica mycological services, collaborative 2/88
Institute of publications and agreement--
Microbiology, cultures research, training
Systematic courses, exchange
Mycology & of specimens and
Lichenology cultures, and
Laboratory production and sale
(Beijing, China) of books
®
Biosystematics mycological services, collaborative 5/86

Research Centre publications and agreement--
Agriculture cultures identification of
Canada (Ottawa, fungi, research,
Canada) consultancy and
project work in
biosystematics
Fundaçao Tropical mycological services, collaborative 8/90
de Pesquisas e publications, cultures agreement--
Tecnologia and training on exchange of
(FTPT) databases specimens and
(Campinas, Brazil) cultures, training
courses and staff
exchanges
Institute of research and cultures collaborative 12/96
Genetics, agreement
Uzbekistan
N. G. Kholodny mycological specimens collaborative 11/91
Institute of Botany, and cultures, agreement--
Ukrainian publications, exchange of
Academy of geographical data and specimens and
Sciences training cultures, scientific
data, training
courses and staff
exchanges
ODNRI (Overseas consulting and advisory staff support at IMI 1990
Development & services in plant
Natural Resources pathology
Institute)
M. S. research and training, collaborative 11/91
Swaminathan especially in agreement--
Research bioindicators and ecosystem
Foundation India biomonitors research, training
courses in applied
mycology and
exchange of
scientific data
University of Al- research and training collaborative 3/93
Azhar (Egypt) agreement
Universidade research and training collaborative 5/94
Federal do Rio agreement
Grande do Sul
(UFRGS) Brasil
RESEARCH & DEVELOPMENT: Systematic and applied bioscience

PRODUCTS ON MARKET: Identification services
Information services
Contract research
Consultancy
Publications
Fungal and bacterial cultures
Training courses
®
Calzyme Laboratories Inc.

3443 Miguelito Court
San Luis Obispo CA 93401, US
Phone: (805) 541-5754; Fax: (805) 541-8301
Web: www.calzyme.com; E-mail: iqbal@calzyme.com
KEY PERSONNEL: Dr. Muzaffar Iqbal; Chairman, President and CEO
Umer Iqbal; Director, R&D
Usman Iqbal; Purchasing Manager
FACILITIES: Production and research facility on more than 300 acres in Tulelake, Calif.
European sales and research office in Croydon, England
SUBSIDIARIES/DIVISIONS: Calzyme Laboratories Ltd.
102-104 Park Lane
Croydon, Surrey
CRO 1JB, UK
BUSINESS STRATEGY: Custom manufacture enzymes and related biochemicals
PRODUCTS ON MARKET: Enzymes

Proteins
Coenzymes
Substrates
Related biochemicals
Cambio Ltd.
The Irwin Centre, Scotland Road, Dry Drayton
Cambridge CB3 8AR, UK
Phone: +44 (0)1954-210 200
Fax: +44 (0)1954-210 300
Web: www.cambio.co.uk; E-mail: support@cambio.co.uk
KEY PERSONNEL: Peter Dean; Managing Director
Bethy Booth.; Development Manager
Shani Jamieson; Export Manager
Margaret Fox; Office Manager
Paula Cooper; Support
Ian Rushton; Financial Manager
HISTORY: Founded in 1986 as a division of Cambridge Life Sciences
Acquired by management buyout in 1987
IS09002 accreditation (1995)
FACILITIES: Access to R&D laboratories and several production facilities
Biontex entire range of products distribution
agreement
Biotech Support entire range of products distribution 2001
Group agreement
BioVentures entire range of products distribution 1992
agreement
®
Epicentre entire range of products distribution 1990

Technologies agreement
Corp. (now
Epicentre
Biotechnologies
Corp.)
Gene Bridges entire range of products distribution 2004
agreement
Glen Research entire range of products distribution 1989
Corp. agreement
Minerva entire range of products distribution 2002
agreement
MoBio entire range of products distribution 1997
agreement
Open Biosystems entire range of products distribution 2003
agreement
Princeton entire range of products distribution 2003
Separations agreement
University of STAR*FISH distribution 1992
Cambridge chromosome paints agreement
RESEARCH & DEVELOPMENT: Developing novel DNA amplification and processing systems
Contract antibody production
PRODUCTS ON MARKET: Contract RNA and DNA production and technology transfer
Products for DNA, RNA synthesis
More than 3,000 antibodies
Most restriction enzymes
Most modification enzymes
Most polymerases (DNA and RNA)
Wide range of Chromosome Painting kits and DNA probes for various
species
Superior nucleic acid purification kits from MoBio
Mycoplasma detection and elimination
Extract protein by precipitation leaving DNA and RNA unaffected
High quality tools required to unlock the functions of human genes and
proteins and their relationships to disease development
Gene regulation enzymes
Plasmid extraction kits
Cambrex Corp.
One Meadowlands Plaza
East Rutherford NJ 07073, US
Phone: (201) 804-3000; Fax: (201) 804-9852
Web: www.cambrex.com
KEY PERSONNEL: James A. Mack; Chairman, CEO and President
Luke M. Beshar; Exec. VP and CFO
Paulo Russolo; President, Cambrex Profarmaco
Shawn Cavanagh; Sr. VP and GM, Bioproducts
Thomas N. Bird; VP, Business Development
Dan Marshak, Ph.D.; VP and CTO, Biotechnology
Ron D. Carroll, Ph.D.; VP and CTO, Pharmaceutical Technology
Acquired BioWhittaker Inc. (1997)
Acquired Bioproducts Division of FMC (1999)
Acquired LumiTech (2000)
Acquired Cambrex Biosciences (2001)
®
Cambrex France SARL acquired Genolife SA (10/04)

Cambrex Bio Science Walkersville Inc. to acquire Cutanogen Corp. (as of
2/06)
STOCK-FINANCIAL HISTORY: NYSE--CBM
Loss per share $0.49/share (YE 05) compared to $0.77/share (YE 04)
04)
SUBSIDIARIES/DIVISIONS: Cambrex Karlskoga AB
Cambrex Charles City Inc.
Cambrex North Brunswick Inc.
Cambrex Landen NV
Cambrex Cork Ltd.
Cambrex Milan S.r.l.
Cambrex France SARL
Cambrex BioScience Baltimore Inc.
Cambrex BioScience Hopkinton Inc.
Cambrex BioScience Verviers s.p.r.l.
Cambrex BioScience Walkersville Inc.
Cambrex BioScience Wolkingham Ltd.
Cambrex BioScience Nottingham Ltd.
Cambrex BioScience Rockland Inc.
Cambrex BioScience Copenhagen AB
INVESTMENTS: Osiris--$5M
Synthon Chiragenics--$3M
BUSINESS STRATEGY: Maintain a position as a global, diversified life sciences company dedicated
to essential products and services to accelerate drug discovery and
commercialization for our pharmaceutical, biopharmaceutical, biotechnology
and research customers
Ortec International Orcel marketing and 10/04
Inc. distribution
agreement
PRODUCTS ON MARKET: ApoGlow™

BioWhittaker® endotoxin detection products (LAL)
BioWhittaker cell culture media, sera, buffers, reagents and antibiotics
Clonetics® human cells and media
Poietics™ human stem cells and media
GelBond® film
GelStar® nucleic acid gel stain
I.D.NA® agarose
InCert® agarose
IsoGel® IEF plates
Latitude® precast agarose gels
Long Ranger®--DNA sequencing
MetaPhor® agarose--DNA separation
MDE™ gel solutions--mutation detection
NuSieve® agarose--PCR separation
PAGEr™ precast acrylamide gels
ProSieve® protein separation
Reliant® precast agarose gels
SeaPlaque® agarose--DNA separation
SeaKem® agarose--DNA separation
SeaPrep® agarose
SYBR® gel stains--nucleic acid detection
SYPRO® gel stain--protein separation
ViaLight™
Contract development and manufacturing services for small molecule APIs,
biologics and cell therapies
®
Canadian Forest Service

Natural Resources Canada, 580 Booth Street
Ottawa KIA OE4, Canada
Phone: (613) 947-7341; Fax: (613) 947-7397
Web: www.nrcan.gc.ca/cfs-scf
E-mail: info@nrcan.gc.ca/cfs-scf
KEY PERSONNEL: Brian Emmett; Assistant Deputy Minister
Geoff Munro; Director, General Sciences
FACILITIES: Research centers in Victoria, BC; Edmonton, Alberta; Sault Ste. Marie,
Ontario; Sainte-Foy, Quebec; and Fredericton, New Brunswick
SUBSIDIARY OF: Natural Resources Canada
BUSINESS STRATEGY: Mission:

To promote the sustainable development of Canada's forests and
competitiveness of the Canadian forest sector for the well-being of present
and future generations of Canadians
RESEARCH & DEVELOPMENT: Tree biotechnology and advanced genetics

Pest management methods
Environmental safety research
PRODUCTS ON MARKET: Biopesticides
Tissue cultures
Diagnostic kits
Biopesticides in development
Gene isolation in development
Genetic markers in development
Tissue cultures and tissue culture protocols in development
Diagnostic tools in development
Canadian Seed Coaters

P.O. Box 1748
North Battleford , Canada
Phone: (306) 445-1077; Fax: (306) 446-0664
Web: www.seedcoaters.com
E-mail: kelly.ray@canadianseedcoaters.com
KEY PERSONNEL: Kelly Ray; General Manager
Lance Tokle; Assistant Manager
EMPLOYEES: 35 employees (10 full-time/25 seasonal)
FACILITIES: 50,000 sq. ft. building
SUBSIDIARY OF: SeedVentures Inc.
BUSINESS STRATEGY: Provide first-class coating technology and superior service
®
PRODUCTS ON MARKET: Coatings:

Chemseal® (talc based coating for canola)
Chemgard (seed treatment with precise chemical application and
dispersion)
Rhizoseal® and Rhizoseal® Premium (talc based coatings for alfalfa and
other legumes)
Prill-On® (lime/phosphate coat for legumes and turf grasses)
Nutriprill® (lime/phosphate coat for forage and native grasses)

Chemseal Plus in field trials
Cantest Ltd.
Burnaby Life Sciences Centre, 4606 Canada Way
Burnaby V5G 1K5, Canada
Phone: (604) 734-7276; Fax: (604) 731-2386
Web: www.cantest.com; E-mail: cantest@cantest.com
KEY PERSONNEL: Donald B. Rix, M.D.; Chairman
Don Enns; CEO and President
Barbara Morrissey; Director, Forensic Equine Drug Testing Services
Simon Mortimer-Lamb; Director, Finance
Adrien Musuku, Ph.D.; Director, Research
Steve Timuss; Director, Business Development
David Gray, Ph.D.; Director, BioPharma Services
Member of the CANAM Laboratories Group
Acquired JB Laboratories Ltd. (6/04)
Acquired SOILCON Laboratories Ltd. (4/04)
Acquired Elemental Research Inc. (4/06)
Acquired Vizon SciTec Inc. (8/06)
SUBSIDIARIES/DIVISIONS: Offices in British Columbia, Manitoba and Ontario, and affiliates in Canada,
the U.S. and southeast Asia
BUSINESS STRATEGY: Operates as a full service laboratory that provides professional analysis and
consultation for companies, governments and individuals in environmental,
biotechnology, pharmaceutical, food safety and industrial hygiene related
fields
Cantest Ltd. has
partnerships with
Entech, Consolab
and Prime Trials
RESEARCH & DEVELOPMENT: Analytical services

PRODUCTS ON MARKET: BioPharma services:
GLP bioanalysis (including clinical bioanalysis and toxicokinetic bioanalysis)
Drug discovery support
Method development and validation
Pharmacokinetic and bioequivalence studies
Environmental services:
Soil and water contamination
Drinking water analysis
®
Mobile/Field services
Mold speciation and identification
Food safety services:

Nutrition labeling
Food microbiology
Pestices residues and hormones
Nutraceuticals
Industrial hygiene services:

Air quality testing
Bulk insulation identification
Compressed breathing air testing
Medical gas inspection and certification
Mold speciation and identification
Equipment rentals
Forensic equine drug testing services:

Racetrack drug testing
Horseshow drug testing
Pre-purchase screening
Research and development
Cardinal Health - Middleton

8137 Forsythia Street, PO Box 620160
Middleton WI 53562, US
Phone: (608) 824-9920; Fax: (608) 824-9930
Web: www.gala.com
E-mail: galainfo@cardinal.com
KEY PERSONNEL: Paul Weiss, Ph.D.; President and CEO
Boh Branflick; CFO
Mike Jenkins; Director, Commercial Operations
EMPLOYEES: 40+ employees, 16 Ph.D.s
HISTORY: Founded and began biotech R&D in May 1996
Changed name from Gala Biotech
SUBSIDIARY OF: Cardinal Health
PRINCIPAL INVESTORS: Cardinal Health
BUSINESS STRATEGY: To partner with clients with protein expression needs
Cambridge cell line engineering 5/05
Antibody collaboration
Technology
RESEARCH & DEVELOPMENT: Post-genomic protein expression

Novel gene product expression
High-throughtput gene product screening
Manufacture scale-in mammalian cells
Mammalian cell line production and cGMP manufacture
Several development-stage products various stages
®
Cargill Inc.
P.O. Box 9300
Minneapolis MN 55440-9300, US
Phone: (952) 742-7575
Web: www.cargill.com; E-mail: public_relations@cargill.com
KEY PERSONNEL: Warren R. Staley; Chairman and CEO
Gregory R. Page; President and COO
Robert L. Lumpkins; Vice Chairman
Guillaume Bastiaens; Vice Chairman
William Veazey; Sr. VP, CFO
David M. Larson; Exec. VP
Robbin S. Johnson; Sr. VP, Director of Corporate Affairs
David W. Rogers; Sr. VP
Ronald L. Christenson; Corp. VP and CTO
HISTORY: Founded in 1865 as a single grain elevator. Now operates more than 1,000
facilities in 61 countries.
Acquired ingredients operations operations of Degussa AG (2005)
Net earnings $2.103b (YE 05) compared to $1.331b (YE 04)
SUBSIDIARIES/DIVISIONS: Agricultural services: Banks Cargill Agriculture, Cargill AgHorizons Canada,
Cargill AgHorizons United States, Cargill Animal Nutrition, Renessen Feed &
Processing (joint venture)
Food ingredients and applications: Food Ingredients North America (Cargill

Acidulants), Cargill Dressings, Sauces, and Oils North America, Cargill Dry
Corn Ingredients, Cargill Malt Americas, Cargill Specialty Canola Oils,
Cargill Sweeteners North America, Horizon Milling (joint venture with CHS
Cooperatives flour milling), PGLA-1 (joint venture with PURAC)), Food
Ingredients Europe (Cargill Bottled Oil Europe, Cargill Cocoa, Cargill Global
Industrial Starches, Cargill Malt Eurasia, Cargill Refined Oils Europe, Cargill
Starches & Sweeteners Poland, Cargill Starches & Sweeteners Russia,
Cargill Starches & Sweeteners Turkey, Cerestar Sweeteners Europe), Food
Ingredients Latin America (Cargill Cocoa Brazil, Cargill Flour Mercosur,
Cargill Foods Brazil, Cargill Foods Venezuela, Cargill Juice North America,
Cargill Multifruit & Blending, Cargill Starches & Sweeteners Brazil), Food
System Design (Cerestar Food & Pharma Specialties Europe, Cargill Food
& Pharma Specialties North America, Cargill Health & Food Technologies
(HFT), Duckworth Flavors), Meat Solutions(Cargill Beef, Cargill Beef
Australia, Cargill Case Ready, Cargill Food Distribution, Cargill Pork, Taylor
Beef, Cargill Value Added Meats), Retail Food Service Solutions (Cargill
Kitchens, Sunny Fresh Foods, Sun Valley Central America, Sun Valley
Europe, Sun Valley Foods Canada, Sun Valley Thailand)
Industrial: Agricultural Feedstocks (Cargill Dow (joint venture), Cargill

Industrial Oils & Lubricants), Steel, Fertilizer (Cargill Fertilizantes Brazil,
Cargill Phosphate Production, Saskferco (joint venture)), Salt (Cargill Salt,
Cargill Deicing Technology)
Origination and Processing: Cargill Cotton, Cargill Grain & Oilseed Supply
Chain, Cargill Sugar
Risk Management and Financial: Black River Asset Management LLC,

Cargill Ferrous International, Cargill Investor Services, Cargill Petroleum,
Cargill Power & Gas Markets, Cargill Risk Management, Cargill Trade &
Structured Finance, Cargill Value Investment, Cargill Ventures
®
INVESTMENTS: Joint venture with Monsanto Co. to use biotechnology to improve feed for
pigs, cattle, poultry and fish (5/98)
BUSINESS STRATEGY: Provide food, agricultural and risk management products and services
Bayer Crop alliance to produce 1/05
Science high stability
specialty canola
Kansas Polymer soy-based polyols for joint research 8/03
Research Center the urethane industry agreement
(Pittsburg State
University, KS)
Metamorphix exclusive 11/02
agreement with
Caprock Cattle
Feeders and Excel
Corp., both part of
Cargill, to develop
genomic selection
tools for
consistency and
tenderness
Monsanto Co. Vistive low-linolenic participating 10/05
soybeans and marketer processor of
of Vistive oil VISTIVE™
soybeans and
marketer of
VISTIVE oil
Mycogen Corp. NatureGard hybrid seed distribution 9/95
(now Mycogen corn with Bt-based agreement under
Seeds) insect resistance Mycogen™ brand
Zeneca Mogen fungal resistant canola licensing 3/96
and sunflower varieties, agreements
Binary Vector System
for genetic
transformation of crop
plants
RESEARCH & DEVELOPMENT: Fermentation systems and enzyme applications

Biobased urethane polyols
PRODUCTS ON MARKET: Agricultural services: Banks Cargill Agriculture, Cargill AgHorizons Canada,
Cargill AgHorizons United States, Cargill Animal Nutrition, Renessen Feed &
Processing (joint venture)
Food ingredients and applications: Food Ingredients North America (Cargill

Acidulants), Cargill Dressings, Sauces, and Oils North America, Cargill Dry
Corn Ingredients, Cargill Malt Americas, Cargill Specialty Canola Oils,
Cargill Sweeteners North America, Horizon Milling (joint venture with CHS
Cooperatives flour milling), PGLA-1 (joint venture with PURAC)), Food
Ingredients Europe (Cargill Bottled Oil Europe, Cargill Cocoa, Cargill Global
Industrial Starches, Cargill Malt Eurasia, Cargill Refined Oils Europe, Cargill
Starches & Sweeteners Poland, Cargill Starches & Sweeteners Russia,
Cargill Starches & Sweeteners Turkey, Cerestar Sweeteners Europe), Food
Ingredients Latin America (Cargill Cocoa Brazil, Cargill Flour Mercosur,
Cargill Foods Brazil, Cargill Foods Venezuela, Cargill Juice North America,
Cargill Multifruit & Blending, Cargill Starches & Sweeteners Brazil), Food
System Design (Cerestar Food & Pharma Specialties Europe, Cargill Food
& Pharma Specialties North America, Cargill Health & Food Technologies
(HFT), Duckworth Flavors), Meat Solutions(Cargill Beef, Cargill Beef
Australia, Cargill Case Ready, Cargill Food Distribution, Cargill Pork, Taylor
Beef, Cargill Value Added Meats), Retail Food Service Solutions (Cargill
Kitchens, Sunny Fresh Foods, Sun Valley Central America, Sun Valley
Europe, Sun Valley Foods Canada, Sun Valley Thailand)
®
Industrial: Agricultural Feedstocks, NaturedWorks, LLC, Cargill Industrial

Oils & Lubricants (Cargill Industrial Bioproducts), Steel, Fertilizer (Cargill
Fertilizantes Brazil, Cargill Phosphate Production, Saskferco (joint venture),
Salt (Cargill Salt, Cargill Deicing Technology)
Origination and Processing: Cargill Cotton, Cargill Grain & Oilseed Supply
Chain, Cargill Sugar
Risk Management and Financial: Black River Asset Management LLC,

Cargill Ferrous International, Cargill Investor Services, Cargill Petroleum,
Cargill Power & Gas Markets, Cargill Risk Management, Cargill Trade &
Structured Finance, Cargill Value Investment, Cargill Ventures
Ceapro Inc.
Suite# 1008 RTF, University of Alberta, 8308 - 114 Street
Edmonton T6G 2E1, Canada
Phone: (780) 421-4555; Fax: (780) 421-1320
Web: www.ceapro.com
E-mail: info@ceapro.com
KEY PERSONNEL: Edward Taylor; Chairman
Dr. Mark Redmond; President and CEO
Laurie Lanuke; Manager, Customer Service and Logistics
Diana Shaw, Ph.D.; Manager, Business Development
Sarah Lord; Ph.D.; Manager, Clinical Affairs
Shawn McMillan; VP, Finance and CFO
David Fielder; VP, Scientific Affairs
Acquired Minera Animal Health (1996)
Amalgamated Vexco Healthcare (12/96)
STOCK-FINANCIAL HISTORY: TSX Venture Stock Exchange--CZO
IPO--C$10M (1/97)
Net <loss> income <$57K> (YE 05) compared to <$398K> (YE 04)
Earnings <loss> per share <$0.00>/share (YE 05) compared to
<$0.01/share> (YE 04)
PRIVATE PLACEMENTS: Raised $16M in private placement (9/96)
Raised $4M in private placement (1/97)
Raised $2.1M in private placement (10/98)
Raised $204.8K from private placement of 683K units at $0.30/unit (3/05)
Raised $1.3M in financing (12/05)
BUSINESS STRATEGY: Extract natural ingredients from cereal crops and formulate into products for
cosmetics and human or veterinary pharmaceutical industries
Use strategic alliances for distribution and marketing

Alberta Wheat oats strategic alliance-- 2/97
Pool Ceapro has
exclusive 10-year
supply agreement
with AWP, AWP to
make $4M equity
investment with
option to invest
$2M in next year
®
Aventix Veterinary dermal for veterinary 8/04

(Canada) applications
Canderm Pharma Lipsorex exclusive licensing 6/98
Inc. agreement--Ceapro
to get royalties on
sales
Daisen Sangyo dermal for veterinary marketing 9/96
Ltd. (Japan) applications agreement
McCarthy & Sons dermal for veterinary marketing 12/99
(Canada) applications agreement
Nutrinova oat extracts for food letter of intent 12/99
industry regarding
marketing
agreement
Pharmavet (UK) dermal for veterinary 10/05
applications
Veterinary dermal for veterinary marketing 12/99
Marketing applications agreement
Network
(Australia/New
Zealand)
RESEARCH & DEVELOPMENT: Functional foods and nutraceutidals

Dermal and wound care
Diabetes tests and medical foods
Immune system stimulants
Therapeutic shampoos
CeaProve® kit for pets
PRODUCTS ON MARKET: ACTIVE INGREDIENTS: Beta glucan, colloidal oat extract, oat oil
VETERINARY THERAPEUTICS: Oat Shampoo, ear cleanser, dermal
complex
AccuScreen™ - tool for identification of type II diabetes and pre-diabetes
Immune stimulant (veterinary) in preclinicals
Topical non-steroidal anti-inflammatory in preclinicals
Hot spot treatment in Phase I clinicals (veterinary)
Celsis International plc

Suite 15, Lyndon House, Kings Court
Newmarket CB8 7SG, UK
Phone: +44 (0) 1638 600 151; Fax: +44 (0) 1638 600 160
Web: www.celsis.com; E-mail: info@celsis.co.uk
KEY PERSONNEL: Jack Rowell; Chairman
Jay Lecoque; CEO
Christian Madrolle; Finance Director and Company Secretary (U.K.)
Celsis floated on LSE in June 1993
Celsis acquired Lumac in September 1996
Acquired SAI (contract testing laboratory in St. Louis, MO) for £4.4M (10/97)
Acquired In Vitro Technologies Inc. (IVT) (8/06)
STOCK-FINANCIAL HISTORY: London Stock Exchange (LSE)--CEL
IPO--£90M (9/96)
Turnover $30.4M (YE 05) compared to $27.595M (YE 04)
Profit $5.75M (YE 05) compared to $4.83M (YE 04)
Earnings per share 6.83cents/share (YE 05) compared 6.04cents/share (YE
04)
Net assets $33.468M (YE 05) compared to $27.209M (YE 04)
®
PRINCIPAL INVESTORS: Barclays Global Investors

Barclays Personal Investment Management
Cavendish Asset Management
Comdirect
Fidelity Investments
Gartmore Investment Management
Insight Investment Management
M&G Investment Management
SG Asset Management
BUSINESS STRATEGY: Research, develop and manufacture diagnostic kits and instrumentation for
the rapid detection of microorganisms and provide laboratory testing
services
U.K. Adenylate Kinase Assay technology license 1/98
Government's Technology agreement
Defense
Evaluation and
Research Agency
RESEARCH & DEVELOPMENT: Rapid microbiology methods for enumeration, identification and toxicity
measurements
PRODUCTS ON MARKET: Pharmaceutical, personal care and beverage test kits
Advance, Advance coupe and CellScan Innovate luminometers
Centre for Innovative Biology and

Environmental Technology
Chelammotil Building, National Highway 47, Ambattukavu
Aluva-6, Kerala, Kochi 683106, India
Phone: +91 484-2631135; Fax: +91 484-2682557
Web: www.cibet.org; E-mail: info@cibet.org
KEY PERSONNEL: P. Sunil Kumar; CEO
Sabu Abdulhameed, Ph.D.; President
G. Nagendra Prabhu, Ph.D.; Exec. VP and Director, R&D
Jayachandran K., Ph.D.; Exec. VP
Rajeev K. Sukumaran, Ph.D.; Sr. Scientist
Swapna TS, Ph.D.; Sr. Scientist
Began biotech R&D in October 2005
BUSINESS STRATEGY: Transfer scientific know-how in to viable eco-friendly technologies
®
Ceres Inc.
1535 Rancho Conejo Blvd.
Thousand Oaks CA 91320, US
Phone: (805) 376-6500
Web: www.ceres.net
E-mail: info@ceresbiotechnology.com
KEY PERSONNEL: Walter De Logi; Chairman
Dr. Richard Hamilton; CEO
Dr. Patrick McCroskey; CFO
Dr. Richard Flavell; CSO
Dr. Anne-Marie Bouckaert; Sr. VP, Technology Planning, Protection and
Acquisition
Ms. Wilfriede van Assche; Sr. VP, General Counsel and Secretary
Dr. Kenneth Feldmann; VP, Agricultural Genomics/Trait Development
Dr. Peter Mascia; VP, Product Development
Dr. Steven Bobzin; Director, Natural Products Chemistry
Dr. Roger Pennell; Director, Trait Development
Anna Rath; Director, Business Development
Dr. Steven Thomas; Director, Bioproducts
PRINCIPAL INVESTORS: Ambergate Trust
Artal Luxembourg SA
GIMV NV
Hambrecht & Quist Capital
KBC Bank & Insurance Group
Monsanto Co.
Oppenheimer International Growth Fund
Oxford Bioscience Partners
QuestMark Partners LP
Soros Private Equity Partners
BUSINESS STRATEGY: Develop energy crops such as switchgrass, miscanthus and poplar for
cellulosic ethanol
Leverage its technologies into established markets through strategic
partnerships
Agricultural improvement of CRADA 2/06
Research Service switchgrass genetics
(ARS) at the through biotechnology
United States
Department of
Agriculture
Aurora Aurora's fluorescent licensing 10/00
Biosciences Corp. protein technology for agreement
use in agricultural
applications
Genset agricultural genetics alliance 1/98
Monsanto Co. application of genomics discovery and 4/02
technologies to provide development
improvements in certain collaboration
agricultural crops
Oregon State use of genomics to collaboration 9/05
University enhance biomass- agreement
mediated carbon
sequestration
®
The Institute for identification of the collaboration 12/00

Genomic structure of genes and agreement
Research (TIGR) their encoded proteins
in the chromosomes of
the plant species
Arabidopsis thaliana
The Samuel development and long-term 6/06
Roberts Noble commercialization of collaboration
Foundation Inc. new, advanced biomass
crops for fuel ethanol
production
University Of Plant Genetics 4/00
California Partnership
RESEARCH & DEVELOPMENT: Technology platforms:

-Sequencing and cDNAs: Generation and sequencing of full-length cDNA
-Computational biology: EST/cDNA/protein clustering, Ockham gene
prediction, high-throughput functional annotation and expression data
analysis
-Promoters: Computational programs and a transcription profiling database
to identify and analyze novel plant promoters or promoter elements in DNA
sequences for trait development, enhancer-trap system for finding useful
promoters
-Functional genomics: Sequencing of full-length cDNAs; assessment of the
concentrations of mRNAs in extracts from plant tissues; evaluation of plants
with known genes silenced by insertions within them; studies on plants with
new, defined genes inserted into them; screens to find plants with improved
phenotypes; characterization of promoters to determine where and when
they program gene expression and systems to epigenetically change gene
structure and activity; and computational biology analyses of genes
-Metabolites: Metabolic profiling platform to provide plants with optimized
levels and kinds of metabolites for functional foods, pharmaceutical
discovery, feed quality and extractable sources for use in other products
-Genetic confinement: Technology for genetically confining a crop by
eliminating viable seeds and/or pollen
Trait development platform
Switchgrass (Panicum virgatum) genomics program for enhancing biomass

yield, completed analysis of more than 12,000 switchgrass genes and
characterized the genetic variation associated with them (7/06)
Chembiotech Ltd.
Institute of Research and Development
Birmingham Research Park, Vincent Drive, Birmingham
Edgbaston B15 2SQ, UK
Phone: +44 (0)121 414 7029
Web: www.chembiotech.co.uk
E-mail: enquiries@chembiotech.co.uk
KEY PERSONNEL: Prof. John F. Kennedy, Ph.D.; Director
C. J. Knill, Ph.D.; CSO
HISTORY: Founded in 1977 to provide R&D and consultant services and product
development in chemistry, biotechnology, biochemistry and medical devices
FACILITIES: Laboratories and offices in the University of Birmingham Research Park
®
BUSINESS STRATEGY: Deliver world-class contract research and development, and technical and
consultancy services that provide effective and cost-efficient solutions to all
our clients in the areas of, biotechnology, chemistry and biochemistry of
carbohdyrates, proteins and medicine
RESEARCH & DEVELOPMENT: Cellulose and starch

Characterization/modification and design/synthesis of biologically active
derivatives
Enzyme immobilization and glycoprotein characterization
Avoidance methods for river/sea water pollution by carbohydrates
Use of by-products from milk and seaweed industries
Waste water treatment
Downstream processing
Novel developments in starch and paper industries
Wound management compounds
Slow release pharmaceuticals
Chromatography--HPLC, GPC, GC, GC-MS
Starch chemistry and biotechnology
Drug contamination detection
Food components--evaluation analysis
On-site assessments, trouble shooting, surveys and verificaiton
Hylauronan-based products in development
Wound management materials in development
Chemeq Ltd.
3 Brodie Hall Drive, Technology Park
Bentley WA 6102, Australia
Phone: +61 8 9362 0100; Fax: +61 8 9355 0199
Web: www.chemeq.com.au
E-mail: info@chemeq.com.au
KEY PERSONNEL: John Hopkins; Chairman
David Williams; CEO
Brian Mangano; CFO
FACILITIES: Pharmaceutical production facility in Rockingham, Australia
STOCK-FINANCIAL HISTORY: Austalian Stock Exchange--CMQ
IPO--$3.5M (8/99)
Revenue $1.1M (YE 05) compared to $905.177K (YE 04)
Net loss <$60.7M> (YE 05) compared to <$9.9> (YE 04)
Loss per share <63.4cents/share> (YE 05) compared to <11.7cents/share>
(YE 04)
BUSINESS STRATEGY: Focus on its core competencies and pursue further commercialization of its
intellectual property and products through strategic partnerships
PRODUCTS ON MARKET: Chemeq® polymeric antimicrobial (for pigs)

Chemeq® polymeric antimicrobial (for poultry)
®
ChemGenes Corp.
33 Industrial Way
Wilmington MA 01887, US
Phone: (978) 694-4503; Fax: (978) 694-4502
Web: www.chemgenes.com; E-mail: enquiries@chemgenes.com
KEY PERSONNEL: Suresh Srivastava, Ph.D.; President
FACILITIES: Combined R&D and manufacturing facilities
BUSINESS STRATEGY: Form strategic alliances to develop key DNA-based diagnostics for various
diseases and DNA-based antisense therapeutics
RESEARCH & DEVELOPMENT: Antisense DNA-based therapeutics for AIDS
PRODUCTS ON MARKET: DNA and RNA phosphoramidites

Antisense phosphoramidites
Modified base phosphoramidites
Chromophores and ligands
Nucleosides
Reagents for oligosynthesis
Ancillary reagents
Solid supports and prepacked columns for DNA/RNA synthesis
Chr. Hansen Inc.

9015 West Maple Street
Milwaukee WI 53214, US
Phone: (414) 607-5700; Fax: (414) 607-5959
Web: www.chr-hansen.com
E-mail: chr-hansen@info-chr-hansen.com
KEY PERSONNEL: David R. Carpenter; President and CEO
Don Cox; Sr. VP, Sales
Dr. Jeff Kondo; Sr. VP of R&D
STOCK-FINANCIAL HISTORY: Parent company listed on Danish Stock Exchange
SUBSIDIARY OF: Chr. Hansen A/S
BUSINESS STRATEGY: To improve the quality of food and health for people all over the world
Integrated Integrated Genomics' licensing 12/04
Genomics Inc. ERGO database and agreement
genomic discovery
system
RESEARCH & DEVELOPMENT: Ingredients for dairy, food and beverage, meat and prepared foods, and
products for food safety, human health and nutrition and animal health and
nutrition
®
PRODUCTS ON MARKET: Dairy, probiotic, meat and wine cultures

Cheese coagulants
Colors
Flavors
Seasonings
Sweeteners
Natural food safety products
Pharmaceutical coatings and excipients
Silage inoculants
Direct fed microbials
Chunghwa Chemical Synthesis &

Biotech Co. Ltd.
1 Tung-Hsing St., Shu-Lin 238, Hsien
Taipei, Taiwan
Phone: 886-2-8684-3318; Fax: 886-2-8684-3202
Web: www.ccsb.com.tw; E-mail: ccsb@ccsb.com.tw
KEY PERSONNEL: Derek Wang; Chairman
Dr. Steve Chang; President
Founded Pharmaports LLC (1999)
FACILITIES: 8.7 acre manufacturing site
Pilot lab equipped with 100 liter and 250 liter glass reactors, a 75 liter
stainless reactor, 5 liter and 100 liter glass-lined reactor fors scale-up
activities and process validation
Pilot lab equipped with three 20 litre and a 600 litre fermentor for scale-up
study and process validation
SUBSIDIARIES/DIVISIONS: U.S. sales office:
Pharmaports LLC
160 Summit Ave.
Montvale, NJ 07645
Phone: (201) 391-3336
Fax: (201) 391-8811
E-mail: info@pharmaports.com
SUBSIDIARY OF: China Chemical Pharmaceutical Group
BUSINESS STRATEGY: Bulk manufacture of pharmaceuticals Taiwan
RESEARCH & DEVELOPMENT: Products in pipeline: Tacrolimus, Rosuvastatin, Fluvastatin, Lansoprazole,

Perindopril, Terbinafine and Trandolapril
Key technologies: Friedel crafts acetylations, alkylations, chiral resolutions,

hantzsch pyridine synthesis, dehydration, reduction/oxidation,
addition/substitution, ammonolysis, decarboxylation, genetic engineering,
strain improvement, microbial fermentation, cell culture, protein purification,
enzyme immobilization, bio-conversion and impurity analysis
Activities include: Development of innovative and cost-effective

manufacturing processes, custom manufacturing for pharmaceutical
intermediates and bulk pharmaceuticals, collaborating with major
universities and research institutes for technical supports, analysis of
impurity profiles for DMFs, development of innovative and cost-effective
®
manufacturing processes for high value metabolites, recombinant proteins

and enzymes, contract research and custom manufacturing for bio-products
and pharmaceutical intermediates, quality/regulatory testing and release all
raw materials, packaging materials, and final products, provision of
manufacturing operations support across operating units and product lines,
technology transfer and scale-up activities
PRODUCTS ON MARKET: Pharmaceutical bulk products:
ANALGESIC/NSAIDS: Acetaminophen, Bucetin, Oxaprozin
ANTI-ANXIETY AGENTS: Alprazolam, Fluoxetine
ANTIHYPERGLYCEMICS: Glipizide, Glibenclamide, Moclobemide
LAXATIVE: Calcium Polycarbophil
ANTIFUNGAL: Fluconazolel
ANTIHISTAMINE: Dexbrompheniramine Maleate
ANTISEPTIC: Benzalkonium Chloride 50%
CARDIOVASCULAR: Nifedipine
EXPECTORANT: Guaifenesin
ANTILIPEMIC AGENT: Pravastatin Sodium
MUSCULOSKELETAL RELAXANTS: Methocarbamol, Carisoprodol
EXCIPIENT: Sodium Starch Glycolate
IMMUNOSUPPERSSIVE AGENTS: Mycophenolate Mofetil, Rapamycin
Codexis Inc.
200 Penobscot Drive
Redwood City CA 94063, US
Phone: (650) 980-5600; Fax: (650) 298-5449
Web: www.codexis.com; E-mail: tassos.gianakakos@codexis.com
KEY PERSONNEL: Tom Baruch; Chairman
Alan Shaw, Ph.D.; President and CEO
Robert S. Breuil; Sr. VP, Finance and CFO
John Grate, Ph.D.; Sr. VP, R&D and CTO
Tassos Gianakakos; Sr. VP and Head, BU Pharmaceuticals
David Walshaw; VP, Operations
Peter Seufer-Wasserthal, Ph.D.; VP and GM, Codexis Enzymes &
Intermediates
Gregory Rocklin; VP and Head, BU Generics
HISTORY: Started as the chemicals business unit of Maxygen (since 1997)
Founded in February 2002
Private spin-out from Maxygen (2004)
Acquired Julich Fine Chemicals GmbH (2/05)
Acquired assets and IP from Enzis BV (4/06)
PRIVATE PLACEMENTS: Raised $25M in private financing (10/02)
Raised $37M in Series D financing (8/06)
SUBSIDIARIES/DIVISIONS: Julich Chiral Solutions GmbH--independent, wholly-owned subsidiary
SUBSIDIARY OF: Maxygen Inc. (see separate entry)
PRINCIPAL INVESTORS: Bio*One Capital Pte Ltd.
ChevronTexaco Technology Ventures
CMEA Ventures
Maxygen Inc.
Pequot Ventures
BUSINESS STRATEGY: Develop innovative bio-based solutions for pharmaceutical chemical process
development and manufacturing
®

Arch Pharmalabs use of research and 10/05
Ltd. MolecularBreeding manufacturing
technology in agreement
manufacturing
compound
Bristol-Myers pharmaceutical process research 5/05
Squibb Co. research agreement,
extended 1/06
Cargill Dow LLC novel synthesis for development 2002
Cargill Dow's agreement
NatureWorks PLA
(polylactide)
Chevron novel bioprocesses for three-year 10/02
Research and specific petrochemical development
Technology Co. products agreement
Eli Lilly & Co. improved fermentations development 12/02
for Lilly’s natural agreement
product drugs
Gist-brocades NV development of novel three-year research 3/99
(subsidiary of enzymes for the and licensing
DSM NV) manufacture of penicillin agreement
antibiotics
Matrix API for a high-value development and 6/05
Laboratories Ltd. pharmaceutical product commercialization
agreement
Novozymes development and bulk five-year strategic 9/97
production of specific collaboration
industrial enzymes in
fields of laundry
detergents, leather
processing and pulp
and paper
manufacturing, among
others
Pfizer Inc. biochemical extension of 5/98 9/00
manufacturing of agreement
undislcosed
pharmaceutical product
Pfizer Inc. pharmaceutical life R&D agreement 7/04
cycle management
Sandoz process for the development 10/03

production of a key agreement
fermented active
pharmaceutical
compound of Sandoz
Schering-Plough development of a research 3/06
Corp. synthetic process for agreement
Schering-Plough
Shasun pharmaceutical manufacturing and 5/05
Chemicals and intermediate for a supply agreement
Drugs Limited generic drug
Teva improved processes for research 12/04
Pharmaceutical manufacturing of an collaboration
Industries Ltd. undisclosed agreement
pharmaceutical product
using Codexis'
MolecularBreeding™
directed evolution
platform
®
RESEARCH & DEVELOPMENT: Codexis' technology platforms can rapidly generate biocatalysts with desired
commercial properties. The biocatalysts usually fall into two categories:
enzymes and fermentation strains. The technology platforms used to
develop the biocatalysts include MolecularBreeding™ directed evolution and
WGShuffling™ strain development. The technologies can be used to:
-Develop low-cost, efficient catalysts with improved performance for the
synthesis of complex molecules
-Develop improved chemical production organisms in less than the typical
process development time
-Develop proprietary syntheses of high-value chemicals by integrating
chemistry and biology in new ways
-Develop alternative synthesis technologies and intellectual property for use
by pharmaceutical and generic companies in life cycle management, can be
used to create new patents
-Demonstrate the validity of the technology for multiple applications at
relevant commercial scale
PRODUCTS ON MARKET: ThoroughBred™ biocatalysts
ThoroughBred™ cell lines
Active pharmaceutical ingredients
More than 15 products and processes in
the pipeline, with two products in advanced
development
Codon Devices
One Kendall Square, Building 300, Third Floor
Phone: (617) 995-7999; Fax: (617) 995-7970
Web: www.codondevices.com
E-mail: info@codondevices.com
KEY PERSONNEL: Noubar Afeyan; Chairman
John Danner; CEO and President
Brian Baynes; CSO
Craig D. Muir; Sr. VP, Technical Operations
Jennifer Camacho; VP, Intellectual Property and Chief Patent Counsel
Michael J. Fitzpatrick; VP, Sales
PRINCIPAL INVESTORS: Flagship Ventures
Alloy Ventures
Kleiner Perkins
Vinod Khosla
BUSINESS STRATEGY: Provide engineered devices for molecular biology research, improve cell
engineering for the production of high value chemicals and engineer
biotherapeutics
RESEARCH & DEVELOPMENT: Molecular biology: Construction of comprehensive sets of genetic reagents
for basic research and development and in the area of structural/functional
genomics, the construction of codon optimized, expression-ready clones
and designed variants for protein studies
Pharmaceutical: Improved therapeutic protein development, such as
engineering therapeutic proteins to improve properties such as stability,
potency, binding affinity and immunogenicity; natural and engineered
therapeutic production, such as rapidly developing cell lines to explore
biosynthetic pathways for improved performance and cost; rapid response
vaccines, such as rapidly obtaining putative antigen genes, optionally
®
coupled to adjuvants, for pandemic and seasonal vaccine development

Industrial biotech and bioenergy: Focus is on the development of enzymes
with improved properties, including stability, specificity and catalytic
efficiency, as well as engineering cell lines to produce large amounts of
specialty and commodity chemicals from renewable feed stocks
Agriculture: Precision trait engineering, the enhancement of plant genetic
traits by engineering at the kilobase- to megabase-scale - more efficiently
than traditional breeding
PRODUCTS ON MARKET: Constructed clones and custom vectors
Constructed variant libraries
Constructed operons and operon variant libraries
Genomic engineering
CombiMatrix Corp.
6500 Harbour Heights Parkway, Suite 301
Mukilteo WA 98275, US
Phone: (425) 493-2000
Fax: (425) 493-2010
Toll-free phone: (800) 985-CBMX
Web: www.combimatrix.com
E-mail: info@combimatrix.com
KEY PERSONNEL: Amit Kumar, Ph.D.; President and CEO
Brooke Anderson, Ph.D.; COO
John Besser; CFO
Jeffrey Oster, Ph.D.; Sr. VP, Intellectual Property
Scott Burell; VP, Finance
H. Sho Fuji; VP, Engineering and Production
Andy McShea, Ph. D.; VP, Biology and Chemistry
HISTORY: Incorporated in 1999
FACILITIES: Headquarters and R&D facilities in Mukilteo, Wash.
STOCK-FINANCIAL HISTORY: Privately held by parent (NASDAQ--CBMX)
SUBSIDIARIES/DIVISIONS: Acacia Technologies Group
CombiMatrix Molecular Diagnostics Inc.
SUBSIDIARY OF: Acacia Research Corp.
BUSINESS STRATEGY: Leverage strengths in technology, innovation and product development by

establishing partnerships for commercialization. CombiMatrix seeks
partnerships with organizations that have well-developed infrastructure for
manufacturing, sales and distribution. By combining the strengths of our
technologies with the distribution and manufacturing capabilities of partners,
CombiMatrix seeks to successfully develop and introduce industry-leading
products into the life science research, industrial and biothreat markets

Benitec Ltd. Benitec IP related to cross-licensing and 2/05
pools of siRNAs as collaboration
therapeutic agents for agreement
viral diseases,
CombiMatrix sequences
targeting HIV
BioDesign peptide array development 8/05
Institute at Arizona synthesizer agreement
State University
®
Case Western novel diagnostic for R&D agreement 2/04

Reserve Alzheimer's disease
University
Cell Sciences Ltd. CombiMatrix products nonexclusive 12/05
and services in distribution
Singapore agreement
Cyrano Sciences chemical sensors R&D agreement 1/04
InBio CombiMatrix’s distribution 1/05
CustomArray agreement
microarray products in
Australian and New
Zealand
Inter Medical CustomArrays products non-exclusive 5/05
in Japan distribution
agreement
J.K. International CustomArray distribution 7/05
Inc. microarray products in agreement
Japan
Novavax technique for in-process development 11/05
monitoring of vaccine agreement
production
Oklahoma State influenza virus R&D agreement 3/04
University therapeutics
Prisma Biotech CombiMatrix products in distribution and 4/06
Corp. Taiwan, China and manufacturing
other countries agreement
Seattle Biomedical RNAi compounds for R&D agreement 11/03

Research Institute gene regulation
research
St. Jude Influenze A virus R&D agreement 3/04
Children's therapeutics
Research Hospital
STMicroelectro- point-of-care diagnostic co-development 6/05
nics products agreement
Toppan Corp. electrochemical R&D agreement 5/03
detection microarrays
and products
U.S. Army Medical environmental and R&D agreement 10/03
Research Institute medical detection of
of Infectious biothreat agents
Diseases
U.S. Department custom microarrays for R&D agreement 3/04
of Defense biothreats
VWR International CustomArrays and global distribution 9/05
Inc. CatalogArrays agreement
Washington chemical synthesis of R&D agreement 1/04
University non-nucleic acid
molecules
RESEARCH & DEVELOPMENT: RNAi introduction

Systems biology for drug discovery research
PRODUCTS ON MARKET: CombiMatrix CustomArray™ chip
RNAi Express Track program
Nanotechnology/Materials Development Product Service
Biothreat Detection Technology
Ongoing custom array programs various stages of progress
®
Commercial Microbiology Ltd.

Kettock Lodge, Campus 2, Aberdeen Science Park, Bridge of Don
Aberdeen AB22 8GU, UK
Phone: +44 (0) 1224-706-062; Fax: +44 (0) 1224-706-012
Web: www.microbio-centre.co.uk
E-mail: info@commercialmicrobiology.com
KEY PERSONNEL: Dr. Stephen Maxwell; Managing Director
Iain Spark; Consultant
Lisa Graham; Financial Controller
Lucille Harries; Chemist
SUBSIDIARIES/DIVISIONS: Commercial Microbiology Inc.
1764 West Sam Houston Pkwy. N.
Houston, TX 77043
Phone: (713) 974-1211
Fax: (713) 974-3636
Email: infousa@commercialmicrobiology.com
BUSINESS STRATEGY: Offer analytical solutions to problems and processes involving
microbiological growth
RESEARCH & DEVELOPMENT: Bacteria in hostile environments

PCR applications in environmental testing
Optimization of bacterial growth media
PRODUCTS ON MARKET: Food and hygiene testing and services, hygiene test kits, sampling
consumables, equipment for hire, energy/oilfield testing and services,
bacterial growth media / test kits, dipslides, Sidestream®, environmental
testing and services
Cornell Institute for Biotechnology and

Life Science Technologies
Cornell University, 130 Biotechnology Building
Ithaca NY 14853-2703, US
Phone: (607) 255-2300; Fax: (607) 255-6249
Web: www.biotech.cornell.edu; E-mail: nyscat@cornell.edu
KEY PERSONNEL: Kelvin Lee; Director
New York State Office of Science, Technology and Advanced Research
(NYSTAR) designated Center for Advanced Technology ; Cornell Center for
Life Science Enterprise
FACILITIES: Service laboratories-- plant tissue culture and transformation; fermentation;
computing and computational biology; confocal microscopy, imaging, and
fluorimetry; DNA sequencing and genotyping; mouse transgenics;
microarray; proteomics and mass spectrometry; flow cytometry; protein
production and characterization
STOCK-FINANCIAL HISTORY: Partnership of Cornell University, government and industry
®
BUSINESS STRATEGY: The Institute emphasizes technology, people, and research involved in the
life sciences. The Center marries the diversity, discovery, and knowledge
base of Cornell University with the jobs, innovation, and impact of NewYork
State businesses. The result is a diverse portfolio of projects and expertise
that positively impacts human and animal health, agriculture, and the
environment, and leads to economic growth and job creation in New York.
RESEARCH & DEVELOPMENT: Agricultural and environmental biotechnology

Biochemistry and biophysics
Computational biology
Diagnostics and detection technologies
Genomics and proteomics
Health care and biomedical engineering
Nanobiotechnology
Science education and public policy
Cosmo Bio Co. Ltd.

Toyo-Ekimae Bldg., 2-20, Toyo 2-Chome, Koto-ku
Phone: +81 3-5632-9617; Fax: +81 3-5632-9618
Web: www.cosmobio.co.jp
E-mail: export@cosmobio.co.jp
KEY PERSONNEL: Tamostu Nakamura; President
Jihei Suwa; Sr. Exec. Managing Director
Takashi Yokomizo; Managing Director, Research Reagent Development
Department
Yasushi Kuriya; Purchasing Manager
HISTORY: Established in March 1978 as technical development department of
Maruzen Oil Co. Ltd.
Biochemical department established in 1982
Established Maruzen Oil Biochemical Co. Ltd. in 1983
Changed name to Cosmo Bio Co. Ltd. in 1986
SUBSIDIARIES/DIVISIONS: Cosmo Bio USA
PRINCIPAL INVESTORS: Cosmo Oil Co. Ltd.
BUSINESS STRATEGY: Export, import and sell research reagents, instruments and software, and
diagnostics
Biopool AB hemostasis and blood exclusive distribution 1996
group serology agreement
Cappel Lab MAbs, polyclonal exclusive distribution
antibodies agreement
EY Lab lectin exclusive distribution
agreement
Genzyme Corp. lymphokine, cytokine nonexclusive
distribution
agreement
VMRD Inc. biotech products Cosmo to distribute 1989
VMRD's products in
Japan
PRODUCTS ON MARKET: Research Reagents for Gene Engineering: Restriction enzymes,

modification enzymes, nucleic acids, reagents for detecting genes, PCR-
related reagents and equipment
®
Research Reagents for Tissue Culture: Animal serums, media, culture

systems/apparatus and antibiotics
Miscellaneous Research Reagents for Biochemistry: Sugars, lipids, lectins,

hormones, peptides, amino acids, chemical substances, virus, bacteria,
enzymes and enzyme substrates
Apparatus for Biochemical Research: Electrophoresis apparatus, cell-gene

operation equipment, analysis software, isolation-refining equipment, culture
apparatus, measuring instruments, gel photograph devices and related
products, disposable products, biohazard safety appliances and auxiliary
equipment for experiments such as cold insulation
Reagents for Clinical Diagnostics: Reagents for transfusions, blood and

serum, bacteria tests and pathological tests
CryoLife Inc.
1655 Roberts Boulevard NW
Kennesaw GA 30144, US
Phone: (770) 419-3355; Fax: (770) 426-0031
Web: www.cryolife.com
E-mail: info@cryolife.com
KEY PERSONNEL: Steven G. Anderson; Chairman, President and CEO
David M. Fronk; VP, Regulatory Affairs and Quality Assurance
Albert E. Heacox, Ph.D.; Sr. VP, R&D
D. Ashley Lee; Exec. VP, COO and CFO
Gerald B. Seery; Sr. VP, Sales and Marketing
11,000 sq. ft. pilot production facility for bioadhesives
18,000 bioprosthesis lab
STOCK-FINANCIAL HISTORY: NYSE--CRY
IPO--(2/93)
04)
PRIVATE PLACEMENTS: Raised $20M private placement (1/04)
BUSINESS STRATEGY: The company cryopreserves and distributes donated living human tissues
for use in reconstructive cardiac, vascular, and orthopaedic surgeries. The
company’s BioGlue® Surgical Adhesive, is FDA approved as an adjunct to
sutures and staples for use in adult patients in open surgical repair of large
vessels and is CE marked in Europe and approved in Cananda for use in
soft tissue repair and approved in Australia for use in vascular and
pulmonary sealing and repair.

Clearant Inc. Inactivates
microorganisms in
human tissues
®
The Magdi methods to improve the three-year research 6/05

Yacoub Institute at utilization of unfixed collaboration
Imperial College xenografts for human
transplantation
U.S. Department BioFoam for use in deep development
of Defense wound injuries that occur agreement
on the battlefield
RESEARCH & DEVELOPMENT: Bioadhesives, xenograft/allograft implantable heart valves, vascular and
orthopaedic tissues
PRODUCTS ON MARKET: CryoValve® human allograft aortic and pulmonary heart valves
CryoVein® human saphenous veins and superficial femoral veins and
arteries
CryoArtery® aortoiliac artery
CryoGraft Tendon – semitendonosus/gracillis and tibialis tendons,
quadriceps, achilles and patellar tendons
CryoGraft Menisci
Osteoarticular (OA) allografts
BioGlue® Surgical Adhesive
CryoLife-O’Brien porcine heart valves
SG Model #100 bovine ureter for arteriovenous (AV) access
BioFoam in development
BioLastic in development
BioDisc in development
CUBIA (University Centre for Algal

Biotechnology)
University of Liege B22, Sart-Tilman
Liege 4000, Belgium
Phone: +32 4-366-3807; Fax: +32 4-366-2926
Web: No Web site
E-mail: m.brouers@ulg.ac.be
KEY PERSONNEL: M. Brouers; President and CSO
HISTORY: Founded and began biotech R&D in December 1996
FACILITIES: 250 sq. m. offices and laboratory
STOCK-FINANCIAL HISTORY: Nonprofit university research center
RESEARCH & DEVELOPMENT: Edible microalgae

Extraction of byproducts for food, feed, cosmetic, dietetic and parapharmacy
Feasibility studies for construction of industrial microalgae production plant
PRODUCTS ON MARKET: Spirulina algae and byproducts
Colorings
Wound healing
Dietetic complements
Algaplan fertilizer in research phase
®
Cuno Inc.
400 Research Parkway
Meriden CT 06450, US
Phone: (203) 237-5541; Fax: (203) 238-8977
Web: www.cuno.com
KEY PERSONNEL: Mark G. Kachur; CEO and President
Frederick C. Flynn Jr.; Sr. VP, Finance and Administration and CFO
Thomas J. Hamlin; Sr. VP, R&D
Anton McElevey; VP and GM, Europe
Geoff Wilcox; Director, Biopharmaceutical Group
HISTORY: CUNO Inc. founded in 1912
Acquired Polymerics Inc. (6/04)
Acquired WTC Industries Inc. (8/04)
Acquired by 3M (8/05)
Formerly listed on NASDAQ--CUNO

IPO--(9/96)
Net sales $$351.611M (YE 04) compared to $288.231M (YE 03)
03)
Total assets $434.558M (YE 04) compared to $288.008 (YE 03)
SUBSIDIARIES/DIVISIONS: Cuno Ltd.--U.K.
Cuno Pacific Pty. Ltd.--Australia
Cuno Europe SA--France
Cuno SA--France
Cuno Belux--Belgium
Cuno Srl--Italy
Cuno Filtration Asia Pte. Ltd.--Singapore
Cuno Latina Ltda.--Brazil
Cuno Latina Surcusal Argentina
Cuno GmbH--Germany
Cuno KK--Japan
SUBSIDIARY OF: 3M
BUSINESS STRATEGY: Create enhanced methods of purification and unique separation matrices for
use in the biotechnology and bioprocessing industries
RESEARCH & DEVELOPMENT: Filtration/separations for biopharmaceutical process development and

manufacturing
Chromatography column protection
PRODUCTS ON MARKET: Zeta Plus® virus reduction filters
Zeta Plus® disposable prefilter cartridges
Zetapor® nylon membrane filter cartridges
Microfluor II® sterile air filters
SterAssure™ nylon membrane prefilters
Microcheck automated integrity test instrument
Sanitary design cartridge filter housings
PolyPro® XL pleated high area depth filters
PolyNet™ PB polypropylene depth filters
®
Cyanotech Corp.
73-4460 Queen Kaahamanu Hwy., Suite 102
Kailua-Kona HI 96740, US
Phone: (808) 329-4677; Fax: (808) 329-4533
Web: www.cyanotech.com
E-mail: info@cyanotech.com
KEY PERSONNEL: Gerald R. Cysewski; Chairman, President and CEO
William R. Maris; VP, Finance and CFO
Glenn Jenson; VP, Operations
Robert J. Capelli; VP, Sales
HISTORY: Founded in 1983 by Gerald Cysewski (5% equity interest, 6/96)
Originally formed from merger of Altex Technology and White Mountain Inc.
FACILITIES: Algae production facility on 90-acre site in Kailua-Kona, Hawaii
STOCK-FINANCIAL HISTORY: NASDAQ--CYAN (Capital Market)
Follow-on public offering--1.5M shares at $7/share, $11.445M (3/96)
Net loss <$268K> (YE 06) compared to <$486K> (YE 05)
Loss per share <$0.01/share> (YE 06) compared to <$0.02 /share> (YE 05)
05)
PRIVATE PLACEMENTS: Spirulina Research Partners--RDLP for spirulina research--$635K (10/84)
$150K, 600K shares (11/83)
$276K, 920K shares (6/84)
$250K, 625K preferred shares (6/85)
$1.5M (7/86)
$2.35M, 235K shares (1/94)
$1.55M, convertible subordinated debentures and common stock (11/02)
PRINCIPAL INVESTORS: Continental Corp.--$500K, 1.25M preferred shares (1985); 292,430 shares
of common stock at $1/share (1986), $1.97M, 79shares of preferred stock
(2/90)
Cosmo Ventures--$1M, 750K shares (1985, 1986)
BUSINESS STRATEGY: Develop high-value products from microalgae
Establish retail marketing subsidiary
Scripps Research Scripps' Aldolase licensing agreement 4/98
Institute Catalytic Antibody 38C2
in microalgae
University of microalgae that is toxic licensing agreement 7/95
Memphis to mosquito larvae
RESEARCH & DEVELOPMENT: Algal drying technique permitting dormancy

Pigments for cosmetics, fragrances, food coloring
Astaxanthin for aquaculture feeds
PRODUCTS ON MARKET: BioAstin® natural astaxanthin
Phycobiliproteins as fluorescent dyes for labeling MAbs in cell sorters and
assays
Spirulina Pacifica® protein supplement as food supplement
NatuRose® natural astaxanthin product
Genetic engineering of microalgae to produce transgenic protein
®
Daiichi Pharmaceutical Co. Ltd.

14-10, Nihonbashi, 3-chome, Chuo-ku
Phone: +81 3-3272-0611; Fax: +81 3-3272-7348
Web: www.daiichipharm.co.jp
E-mail: andokb5o@daiichipharm.co.jp
KEY PERSONNEL: Kiyoshi Morita; President and CEO
Tsutomu Une, Ph.D.; Sr. Managing Director
Tadao Suzuki, Ph.D.; Sr. Manging Director
Hidetoshi Imaizumi; Managing Director
Ryuzo Takada; Managing Director
Hiroshi Sugiyama; Managing Director
Toru Kuroda; Managing Director
Akira Nagano; Managing Director
HISTORY: Established in January 1918
Founded as Arsemin Shokai in October 1915
Established Daiichi Sankyo Co. Ltd. with Sankyo Co. Ltd., and became its
subsidiary (2005)
FACILITIES: Factories in Osaka, Shizuoka and Akita

Research and development center in Tokyo
STOCK-FINANCIAL HISTORY: Listed on the Tokyo and Osaka stock exchanges
Net sales ¥328.534b (YE 05) compared to ¥322.767b (YE 04)
Earnings per share ¥137.95/share (YE 05) compared to ¥97.25/share (YE
04)
SUBSIDIARIES/DIVISIONS: Daiichi Sankyo Co. Ltd.----Tokyo
Daiichi Sankyo Healthcare Co. Ltd.--Tokyo
Daiichi Pure Chemicals Co. Ltd.--Tokyo
Daiichi Radioisotope Laboratories Ltd.--Tokyo
Daiichi Pharmatech Co. Ltd.--Tokyo
Daiichi Fine Chemical Co. Ltd. (DFK)--Tokyo
Saitama Daiichi Pharmaceutical Co. Ltd.--Saitama
Daiichi Asubio Pharma Co. Ltd. (ASB)--Tokyo
Tokyo Iyaku Shiki Co. Ltd.--Saitama
Nishimura Shiki Co. Ltd.--Osaka
Daiichi Estate Co. Ltd.--Tokyo
Daiichi Butsuryu Co. Ltd.--Tokyo
D.P.C.Medical Co. Ltd.--Tokyo
Kanto Daiichi Service Co. Ltd.--Tokyo
Daiichi Sankyo Inc.--N.J., U.S.
Daiichi Pharmaceuticals UK Ltd.--London
Daiichi Pharmaceutical (Beijing) Co. Ltd.--China
Daiichi Pharmaceutical Asia Ltd.--Hong Kong
Daiichi Pharmaceutical Taiwan Ltd.--Taiwan
Daiichi Pharmaceutical Korea Co. Ltd.--Korea
Daiichi Pharmaceutical (Thailand) Ltd.
Laboratoires Daiichi Sanofi-Aventis--Paris
Daiichi Fine Chemicals Inc.--N.Y., U.S.
Daiichi Fine Chemical Europe GmbH--Germany
Daiichi Asubio Pharmaceuticals Inc.--N.J., U.S.
Daiichi Asubio Holdings Inc.--U.S.
Daiichi Asubio Medical Research Laboratories LLC (Daiamed)--Cambridge,
Mass., U.S.
SUBSIDIARY OF: Daiichi Sankyo Co. Ltd.
®

GE Healthcare research and collaboration 9/05
development of non- agreement
nuclear contrast media
CIMYM development and licensing agreement 7/06
BioSciences Inc. marketing rights for
nimotuzumab in Japan
Ingenuity Systems Ingenuity's Pathways expanded licensing 4/06
Analysis agreement
YM Biosciences development and licensing agreement 7/06
Inc. marketing rights to
TheraCIM
(nimotuzumab) in Japan
PRODUCTS ON MARKET: OTC pharmaceuticals, quasi-pharmaceuticals, pharmaceuticals, cosmetics,

medical equipment, food products, beverages, diagnostic reagents,
radiopharmaceuticals, radioisotope products, fine chemicals, packaging
materials for pharmaceuticals and logistics services
Dainippon Sumitomo Pharma Co. Ltd.

2-6-8 Doshomachi, Chuo-ku
Osaka 541-0045, Japan
Phone: +81 06-6203-5321; Fax: +81 06-6233-2288
Web: www.ds-pharma.co.jp
KEY PERSONNEL: Yasuo Okamoto; Chairman
Kenjiro Miyatake; President
HISTORY: Created from the merger of Dainippon Pharmaceutical Co. Ltd. and
Sumitomo Pharmaceuticals Co. Ltd. (10/05)
Sumitomo Pharmaceuticals:
Founded in February 1984 as a joint venture through merger of respective
pharmaceutical divisions of Sumitomo Chemical Co. Ltd. and Inabata & Co.
Dainippon Pharmaceutical:
Founded in May 1897
STOCK-FINANCIAL HISTORY: Sumitomo Pharmaceuticals:
Dainippon Pharmaceutical:
Earnings per share ¥48.05/share (YE 04) compared to ¥88.02/share (YE 03)
SUBSIDIARIES/DIVISIONS: Pharmaceuticals
Animal science
Food science
Fine chemicals
Laboratory products
BUSINESS STRATEGY: Manufacture, sell/purchase and import/export pharmaceuticals, diagnostics,
medical devices, veterinary products, food additives, industrial chemicals
and other chemical products
®

Chelsea rights to L-Threo DOPS licensing agreement 5/06
Therapeutics (Droxidopa) outside
International Ltd. Asia
Conforma Amrubicin HCl licensing agreement 6/05
Therapeutics (Amrubicin)
Eisai Co. Ltd. development, licensing agreement 4/06
manufacturing and
marketing of Gasmotin
in 10 Asian countries
PRODUCTS ON MARKET: PHARMACEUTICALS UNIT: Amlodin (used in the treatment of hypertension

and angina), Gasmotin (used to improve digestive tract function), Prorenal
(a peripheral circulation stimulant), and Meropen (a carbapenem antiobiotic
preparation)
ANIMAL SCIENCE UNIT: disease prevention and treatment products for

pet, livestock, and marine use
Dalton Pharma Services

349 Wildcat Road
Toronto M3J 2S3, Canada
Phone: (416) 661-2102; Fax: (416) 661-2108
Toll-free phone: (800) 567-5060 (Canada only)
Web: www.dalton.com
E-mail: chemist@dalton.com
KEY PERSONNEL: Peter Pekos; President
Natalie Lazarowych; Director, R&D
Changed name from Dalton Chemical Laboratories Inc. (4/05)
BUSINESS STRATEGY: Maintain a position on the forefront of technology in drug discovery, drug
synthesis and analysis through provision of chemistry expertise to generate
new drugs, optimize the synthesis of potential therapeutic candidates, and
provide chemistry expertise to partners in the biotech and pharma fields
Continue to focus on small molecule chemistry, developing novel routes and

molecules as well as providing focused and directed chemistry for our
partners to enhance their own in-house programs and expertise
As a contract
services company,
majority of
agreements are
confidential
RESEARCH & DEVELOPMENT: All research and development under contract of clients
PRODUCTS ON MARKET: Fine chemicals, custom peptides, custom chemical synthesis
cGMP manufacturing of active pharmaceutical ingredients and sterile filling
of clinical trail drug products
®
Dextra Laboratories Ltd.

Science and Technology Centre, Earley Gate, Whiteknights Road
Reading RG6 6BZ, UK
Phone: +44 (0)118 935 7000; Fax: +44 (0)118 926 7917
Web: www.dextra-labs.co.uk
E-mail: dextra@dextra-labs.co.uk
KEY PERSONNEL: Dr. Andrew Hacking; CEO
Dr. C. J. Lawson; CEO
Dr. Alex Weymouth-Wilson; Head, Chemistry
HISTORY: Founded in October 1989
FACILITIES: 2,500 sq. ft. of laboratories and offices, small pilot chemical equipment and
analytical equipment (HPLC, GC, GC/MS, NMR, DIONEX, DSC, UV, IR)
PRINCIPAL INVESTORS: 3i Group plc--25%
BUSINESS STRATEGY: Exploit emerging technologies related to carbohydrates in medical advances
Cambrex AB, carbohydrate and chiral manufacturing, sales
Karlskoga, intermediates and
Sweden building blocks
and marketing 10/03
agreement
RESEARCH & DEVELOPMENT: Oligosaccharides involved in communication between mammalian cells, cell
adhesion molecules, chiral synthons and intermediates
Drug discovery, carbohydrates, custom synthesis, analytical services,
oligosaccharides, glycoproteins, chiral compounds
PRODUCTS ON MARKET: More than 400 biologically significant oligosaccharides and glycoconjugates
including N-linked, O-linked, fucosylated, sialylated, sulphated sugars,
monosaccharides and lactones derived by synthesis and extraction from
plant and animal tissues
Dextran Products Ltd.

421 Comstock Road
Toronto M1L 2H5, Canada
Phone: (416) 755-2231; Fax: (416) 755-0334
Web: www.polydex.com
E-mail: swardlaw@polydex.com
KEY PERSONNEL: George G. Usher; Chairman
Sharon Wardlaw; President
HISTORY: Founded in 1936 by Thomas Usher, moved from U.K. to present location in
1966
FACILITIES: 30,000 sq. ft. factory
STOCK-FINANCIAL HISTORY: Owned by parent
SUBSIDIARY OF: Polydex Pharmaceuticals Ltd. (see separate entry)
BUSINESS STRATEGY: Develop and sell specialty chemicals
®

Canadian regulation of research agreement 4/94
Bacterial Diseases macrophage
Network antibacterial activity
RESEARCH & DEVELOPMENT: Developing human drugs for AIDS, arteriosclerosis and cystic fibrosis
PRODUCTS ON MARKET: Dextran derivatives
Dextran for lung infections in cystic fibrosis preparing IND application
patients
Ushercell (contraceptive application) in Phase II clinicals
Ushercell (HIV indication) in Phase III clinicals
Diagnostic Chemicals Ltd.

West Royalty Industrial Park
Charlottetown C1E 2A6, Canada
Phone: (902) 566-1396; Fax: (902) 628-6504
Web: www.dclchem.com
E-mail: sales@dclchem.com
KEY PERSONNEL: J. Regis Duffy, Ph.D.; Chairman
Ronald J. Keefe, LL.B, MBA, CA; President and Chief Executive Officer
Rob Binns; Chief Operating Officer
Gordon Rogers, C.A.; VP, Finance and Corporate Systems and CFO
Julien Gaudin, Ph.D.; Director, Diagnostic Manufacturing Operations
Marlene Walker, M.Sc.; Director of Quality Systems
Bob Fredrickson, Ph.D.; Director, Research and New Technology
Development
Lee Lipski; VP, Sales
HISTORY: Founded in 1970 as a manufacturer of fine chemicals, today its major
products are clinical chemistry reagents, fine chemicals and biochemicals
SUBSIDIARIES/DIVISIONS: Biochemical division
Diagnostic division
Diagnostic Chemicals Ltd. (U.S.)
Diagnostic Chemicals Ltd. (Mexico)
BUSINESS STRATEGY: Build on our leadership in clinical chemsitry to develop new and innovative
technology for the in vitro diagnostic industry. Develop new biochemicals,
pharmaceutical intermediates and new immunodiagnostic procedures.
RESEARCH & DEVELOPMENT: New In vitro-diagnostic products and technologies guided by the specific
needs of our OEM partners. New enzymes utilizing immunochemistry and
other proteins as well as enzyme substrates for use in biotechnology.
Chemical process development and production of high purity chemical
intermediates. Individualized contract manufacturing solutions.
PRODUCTS ON MARKET: Clinical chemistry reagents
Calibrators and controls
ImmunoDip®
®
Digene Corp.
1201 Clopper Road
Gaithersburg MD 20878, US
Phone: (301) 944-7000; Fax: (240) 632-7121
Toll-free phone: (800) DIGENE
Web: www.digene.com; E-mail: inforeq@digene.com
KEY PERSONNEL: Attila T. Lorincz; Sr. VP, R&D and CSO
Joseph Slattery; CFO
Belinda O. Patrick; Sr. VP, Manufacturing Operations
Robert McG. Lilley; Sr. VP, Global Sales and Marketing
Donna Marie Seyfried; VP, Business Development
Acquired the molecular diagnostics division of Life Technologies Inc. (12/90)
Name changed from Digene Diagnostics Inc. (1996)
FACILITIES: 110,000 sq. ft. R&D and manufacturing facility
STOCK-FINANCIAL HISTORY: NASDAQ--DIGE
IPO--$35M (5/96)
Public offering--2.25M shares of common stock at $10/share, $22.5M
(10/97)
Public offering--2M shares of common stock at $28/share, $56M (11/05)
Net <loss> income $8.439M (YE 06) compared to <$8.167M> (YE 05)
Earnings <loss> per share $0.39/share (YE 06) compared to <$0.41/share>
(YE 05)
05)
SUBSIDIARIES/DIVISIONS: Digene Europe - London, England
BUSINESS STRATEGY: Develop DNA diagnostic and biomedical supply company through internal
developments, strategic partnerships and acquisitions
Asuragen Inc. Asuragen's cystic worldwide marketing 4/06
fibrosis screening and distribution
products agreement
Cytyc Corp. Digene's DNA probe development 10/96
tests and Cytyc's agreement
specimen collection
and preparation
technology
International five-year exclusive 2/97
Murex agency agreement
Technologies for distribution in
Corp. Europe
International Digene's tests for HIV distribution 9/97
Murex RNA, hepatitis B and agreement for
Technologies cytomegalovirus Europe, the U.K.,
Corp. Africa, the Middle
East and Singapore
(1993), extended
International infectious disease worldwide 4/98
Murex DNA probe diagnostics development and
Technologies distribution
Corp. agreement,
expanded to include
STD products (6/94)
Mitsubishi DNA diagnostic probes distribution 10/98
Petrochemical Co. for disease detection agreement for Japan
®
National Institute herpes simplex virus $750K Phase II 6/98

of Allergy and tests using Hybrid II SBIR contract
Infectious technology
Diseases
NCI diagnostic assays for $600K research 11/92
HPV contract
Toray Industries DNA diagnostic probes distribution 12/00
for disease detection agreement for Japan
RESEARCH & DEVELOPMENT: DNA amplification

Enzymes linked to nucleic acid as diagnostic probes
Diagnostic probes for HPV, infectious disease and cancer
PRODUCTS ON MARKET: DNA probe kits for HBV, CMV, mycobacteria, HIV and HPV
Hybrid Capture System Human Papillomavirus DNA Assay
Hybrid Capture II CT and GC DNA tests for filed three 510(k)s--one for
Chlamydia trachomatis and Neisseria each test individually and one
gonorrhea for collection out of liquid for simultaneous testing
cytology
Diversa Corp.
4955 Directors Place
San Diego CA 92121-1609, US
Phone: (858) 526-5000; Fax: (858) 526-5551
Web: www.diversa.com
E-mail: information@diversa.com
KEY PERSONNEL: James H. Cavanaugh, Ph.D.; Chairman
Edward T. Shonsey; CEO
Anthony E. Altig; Sr. VP, Finance and CFO
William H. Baum; Exec. VP, Bioscience Products
Patrick Simms; Sr. VP, Operations
HISTORY: Founded and began biotech R&D in May 1994
Name changed from Recombinant BioCatalysis Inc. (8/97)
FACILITIES: 75,000 sq. ft. headquarters and R&D facilities
STOCK-FINANCIAL HISTORY: NASDAQ--DVSA
IPO--8.34M shares at $24/share, $200.1M (2/00)
47.1M shares outstanding (6/1/06)
04)
PRIVATE PLACEMENTS: Raised $21M in oversubscribed round of venture capital financing (10/97)
SUBSIDIARIES/DIVISIONS: Innovase LLC
PRINCIPAL INVESTORS: HealthCare Ventures
Syngenta AG
T. Rowe Price
Rho Management
®
BUSINESS STRATEGY: Diversa delivers unparalleled enzyme performance for alternative fuels,
industrial, and health/nutrition processes. Diversa’s patented gene mining
and DirectEvolution technologies have yielded the world’s largest bank of
biodiverse enzymes. These enzymes enable manufacturers to make
products more efficiently and inexpensively while protecting the
environment. Diversa’s goal is to be the leadiing provider of industrial
enzymes and biologically active compounds for use in unique, economically
attractive applications.
The key elements of Diversa’s strategy are to:

Further enhance their technology leadership position
Continue strong focus on alternative fuel markets
Expand their existing DNA libraries through access to novel genetic material
and utilize our proprietary technologies to discover new genes and gene
pathways
Deploy their technologies across diverse markets in order to maximize their
return on investment
Pursue additional strategic alliances with market leaders to access funding
and industry-specific expertise
Independently develop and commercialize products in specific markets to
capture their full economic value
Discover, modify and commercialize protein-based enzyme catalysts for
chemical synthesis and industrial processes
Discover new lead drug compounds from bioactive pathways in
microorganisms and transgenic application of enzymes to plants for insect
and disease control

BASF AG Diversa to discover and alliance 2/06
optimize new enzymes,
BASF responsible for
product and process
development and
commercialization
Cargill Health and enzymes for the cost- discovery and 4/05
Food effective production of a development
Technologies proprietary product agreement
Merck & Co. Inc. therapeutic antibodies development 1/05
using Diversa's MedEv agreement,
platform expanded 6/05
RESEARCH & DEVELOPMENT: Alternative energy

Specialized industrial processes
Health and nutrition
PRODUCTS ON MARKET: Valley Ultra-Thin™ improves ethanol production
Luminase™ enzyme
Phyzyme™ XP enzyme (for pigs and chickens)
Quantum Phytase™ (for pigs and chickens)
Pyrolase™ 160 enzyme
ThermalAce™ DNA Polymerase
Bayovac® SRS (vaccine for farmed salmon, available in Chile)
Sordarins antifungal in preclinicals
Purifine (converts biomass to biofuel) in development
Amylase-T in regulatory review (U.S.)
Enzyme cocktail for cellulosic ethanol in development
production (unnamed)
Phytase-T in development
Various antibodies, anti-SARs, anti-anthrax in development
and anti-plague antibodies
®
DNA Technologies Inc.

201 Perry Parkway, Suite 1
Gaithersburg MD 20877, US
Phone: (301) 956-1065; Fax: (301) 963-2156
Web: www.dnati.com; E-mail: info@dnati.com
KEY PERSONNEL: Dr. Javed Siddiqi; Chairman, President and CEO
FACILITIES: 3,000 sq. ft. R&D facility
BUSINESS STRATEGY: Market kits for DNA research
Market contract research for molecular biology
RESEARCH & DEVELOPMENT: Molecular biology research

PRODUCTS ON MARKET: Cloning and screening kits
Gene expression kits
Premade Western blots
DOE Joint Genome Institute

2800 Mitchell Drive
Walnut Creek CA 94598, US
Phone: (925) 296-5670
Web: www.jgi.doe.gov
E-mail: gilbert21@llnl.gov
KEY PERSONNEL: Dr. Edward M. Rubin; JGI Director
Dr. Steven Chu; Director, Lawrence Berkeley National Laboratory
HISTORY: Founded in 1997, JGI is a collaboration of Lawrence Livermore, Lawrence
Berkeley, and Los Alamos National Laboratories funded by the Department
of Energy's Office of Biological and Environmental Research
FACILITIES: 56,600 sq. ft. Production Genomics Facility (PGF) in Walnut Creek, Calif.
SUBSIDIARIES/DIVISIONS: JGI partner institutions include Oak Ridge National Laboratory (genome
annotation), Pacific Northwest National Laboratory (proteomics) and
Stanford Genome Center (finishing)
SUBSIDIARY OF: U.S. Department of Energy (DOE)
FINANCIAL INFORMATION: Funding for JGI is predominantly from the Office of Biological and
Environmental Research in DOE’s Office of Science, with additional support
from NIH, NSF, USDA and NASA
BUSINESS STRATEGY: Develop and exploit new sequencing and other high-throughput, genome-
scale and computational technologies as a means for discovering and
characterizing the basic principles and relationships underlying the
organization, function and evolution of living systems
Leverage the unique capabilities of the Department of Energy National
Laboratory system to achieve these goals, and to use the resulting
understanding to address key DOE missions related to energy, the
environment and human susceptibilities
®
RESEARCH & DEVELOPMENT: PROGRAMS:

Computational Genomics
Evolutionary Genomics
Production Sequecing
Vertebrate Biology
Microbial Genome Analysis
Microbial Ecology
Technology Development
Community Sequencing Program (CSP): www.jgi.doe.gov/CSP
GENOMES:
Human Chromosomes 5, 16, 19, Poplar, Xenopus tropicalis, Fugu rubripes,
Ciona intestinalis, over 200 microbes and microbial communities.
COMPUTATIONAL/BIOINFORMATIC TOOLS:
Integrated Microbial Genome (IMG) analysis data management system:
http://img.jgi.doe.gov/v1.1/main.cgi
Dojindo Laboratories
2025-5 Tabaru, Mashiki-machi, Kamimashiki-gun
Kumamoto 861-2202, Japan
Phone: +81-96-286-1515
Fax: +81-96-286-1525
Web: www.dojindo.co.jp, www.dojindo.com
E-mail: info@dojindo.co.jp, info@dojindo.com
KEY PERSONNEL: Eiji Noda; President
Mutsuo Yoshida; Marketing Director, Japan
Yasuo Okumura; Marketing Director, USA
Kenichi Mitsuda; Marketing Director, China
SUBSIDIARIES/DIVISIONS: Dojin Glocal Corp.
Dojin East
Dojindo Molecular Technologies Inc.
Dojindo China Republic (Shanghai)
RESEARCH & DEVELOPMENT: Labeling reagents for protein analysis

Cell viability and cytotoxicity assay
Oxidative stress detection
Nitric oxide research
Spin trap compounds
Intracellular fluorescent probes
New water-soluble tetrazolium salts
Reagents for self-assembled monolayers
Detergents for life science research and industry
PRODUCTS ON MARKET: Reagents for life science research, Miscellaneous biochemical reagents,
Organic analytical reagents, Quick test kits, Specialty organic materials,
Reagents for peptide synthesis, Bifunctional cross-linking reagentsm,
Reagents for cell biology, Tetrazolium salts, Calcium chelators
Ionophores
Colloid titration kits
Reagents for research into NO pathway
®
Don Whitley Scientific Ltd.

14 Otley Road
Shipley BD17 7SE, UK
Phone: +44 (0)1274-595-728; Fax: +44 (0)1274-531-197
Web: www.dwscientific.co.uk; E-mail: info@dwscientific.co.uk
KEY PERSONNEL: Don Whitley; Chairman
Paul Walton; Managing Director
Dr. Peter Silley; Research Director
Nyk Kosmirak; Director, Finance
Andrew Pridmore; Head, Microbiology
Sally Shelton; Export Manager
BUSINESS STRATEGY: Develop, manufacture and sell innovative scientific instruments and
associated products for microbiological applications worldwide, ranging from
simple reagents through automated instrumentation for the detection and
enumeration of micro-organisms to specialised workstations
AES Laboratoire dilumat 3 media exclusive distribution 7/95
preparation agreement for the
U.K.
Synoptics Ltd. protocol (image exclusive distribution 2/92
analysis) agreement for the
U.K.
Warnex inc. Genevision pcr for food exclusive 9/04
distributorship in the
U.K.
RESEARCH & DEVELOPMENT: Focus is on the enhancement of existing technologies and the development
of novel microbiological products and services
PRODUCTS ON MARKET: Modular Atmosphere Controlled Systems (MACS)
Whitley Automatic Spiral Plater (WASP)
Rapid Automated Bacterial Impedance Technique (RABIT)
Contract microbiological services (GLP compliant laboratory)
Autoclaves (65 to 150 liters)
Dong-A Pharmaceutical Co. Ltd.

252 Yongdu-Dong, Dongdaemun-Gu
Seoul, Korea
Phone: +82 2 920 8220; Fax: +82 2 925 4026
Web: www.donga.co.kr
E-mail: export@donga.co.kr
KEY PERSONNEL: Kang Shin-Ho; Chairman
Yu Chung-Sik; Vice Chairman
Kim Won-Bea; President
Incorporated in 1949
STOCK-FINANCIAL HISTORY: KSE--000640.KS
Sales W533.625b (YE 05) compared to W541.214b (YE 04)
Net income W25.413b (YE 05) compared to W26.575b (YE 04)
®
Earnings per share W2.886K/share (YE 05) compared to W3.239K/share

(YE 04)
Total assets W576.726b (YE 05) compared to W556.434b (YE 04)
SUBSIDIARIES/DIVISIONS: Dong-A America Corp.
5348 Lindbergh Lane
Bell, CA 90201
Phone: (323) 261-9400
Fax: (323) 261-9500
Toyama Chemical quinolone antibacterial licensing agreement 2/04
Co. Ltd. eye drops TN-3262a
(tosufloxacin tosilate)
PRODUCTS ON MARKET: Biologicals: Eporon, Growtropin II, Leucostim, Stifol and Viteron
Ethical drugs: Alofia, Caltonin, Cholesnone, Closerinn, Diflex, Gabapentin,

Gemcit, Glimel, Melanon, Melocox, Orodipine, Pantoline, Riopedone, Stillen,
Vasotrol, Zydena
OTC: Bacchus, Bacchus Sugar Free, Bacchus-D, Baccus-X, Korean

Ginseng Royal Jelly, Korean Ginseng Ginkgo, Panpyrin® F Liquid,
Panpyrin® F capsule, Champ Cold®, Amcilon® Tablet, Garglin Mint® Mouth
Wash, Garglin Dent® Mouth Wash, Garglin toothpaste, Tempo®, Circulan
capsule, Kyean, Pompolic Liquid
APIs: Cycloserine, epirubicin hydrochloride, formoterol fumarate,

gemcitabine hydrochloride, terizidone, topiramate, voglibose
Cosmetics
DA-3801 for infertility in Phase III clinicals
DA-6034 for ulcerative colitis and Crohn's in Phase II clinicals
disease
VMDA-3601 for ischemic disease in Phase II clinicals
GX-12 for AIDS in Phase I clinicals
DA-9102 for atopic dermatitis in Phase II clinicals
Dow AgroSciences LLC

9330 Zionsville Road
Indianapolis IN 46268, US
Phone: (317) 337-3000; Fax: (317) 337-4096
Web: www.dowagro.com
E-mail: info@dowagro.com
KEY PERSONNEL: Jerome Peribere; President and CEO
Rogelio Lara; VP, Finance
HISTORY: DowElanco joint venture founded (1989)
Acquired majority ownership in Mycogen Seeds (1996)
Acquired by The Dow Chemical Co.; name changed to Dow AgroSciences
(1997)
SUBSIDIARIES/DIVISIONS: Agricultural and Specialty Chemicals

Plant Genetics and Biotechnology
®
SUBSIDIARY OF: The Dow Chemical Co. (see separate entry)

BUSINESS STRATEGY: Provide pest management and biotechnology products to improve the
quality of the earth's food supply and contribute to the health and quality of
life of the world's population

Chlorogen Inc. use of Chlorogen's research 9/05
chloroplast technology agreements
to produce animal
health products in plant
cell cultures
Monsanto Co. new technology options global business 1/06
and more choice in agreement
products for farmers
MTI GmbH exclusive rights to MTI's licensing 4/06
U.S. corn product agreement
development pipeline
Sangamo ZFP TFs and ZFNs for research and 10/05
BioSciences Inc. plant agriculture commercial
licensing
agreement
University of development of plant- research 12/05
Melbourne made production collaboration
systems for an avian
Influenza vaccine
RESEARCH & DEVELOPMENT: Plant-cell-produced vaccines and antibodies for animals

Improvement of crop production and delivery of improved agricultural
outputs for a multitude of food and feed uses
Improvement of plant components
Use of conventional breeding techniques and biotechnology to produce oils
low in saturated fat and trans fat free
PRODUCTS ON MARKET: Herbicides
Insecticides
Fumigants
Fungicides
Agronomic seeds and traits
Healthy oils
Concert Plant-Cell-Produced System approved
Dragon Pharmaceutical Inc.

650 West Georgia Street, Suite 310
Vancouver V6B 4N9, Canada
Phone: (604) 669-8817; Fax: (604) 669-4243
Toll-free phone: (877) 388-DRUG (3784)
Web: www.dragonbiotech.com; E-mail: info@dragonbiotech.com
KEY PERSONNEL: Yanlin Han; CEO
Zhanguo Weng; VP, China
Garry Wong; CFO
Maggie Deng; COO
Acquired Oriental Wave Holding Ltd. (1/05)
To sell part of its formulation business to C&Y Pharmaceutical Investment
Holdings Ltd. (as of 7/06)
®
FACILITIES: 258,300 sq. ft. manufacturing facility (for Pharma Division) in the Datong
Economic and Technology Development Zone in Datong City, Shanxi
Province, China
947,200 sq. ft. Chemical and Biotech Division facilities in Datong City
STOCK-FINANCIAL HISTORY: OTC BB--DRUG / TSX--DDD / BBSE--DRP

Net income $182.6K (YE 05) compared to $6.362M (YE 04)
04)
SUBSIDIARIES/DIVISIONS: Chemical division--bulk pharmaceutical chemical
Biotech division--recombinant drugs (EPO and G-CSF)
Pharma division--prescription and over-the-counter drugs
Suzhou Zhongkai commercialization of licensing agreement 2004
Bio- rhG-CSF worldwide,
Pharmaceuticals excluding China
Co. Ltd.
PRODUCTS ON MARKET: Prescription and over-the-counter generic drugs

Bulk pharmaceutical chemicals
Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF)
Droycon BioConcepts Inc.

315 Dewdney Avenue
Regina S4N 0E7, Canada
Phone: (306) 585-1762; Fax: (306) 585-3000
Web: www.dbi.sk.ca
E-mail: webman@dbi.ca
KEY PERSONNEL: Dr. D. R. Cullimore; President and CEO
Natalie Ostryznuik; Exec. VP
Vincent Ostryzniuk; Operations Manager
BUSINESS STRATEGY: Specialize in applied microbial technology used in environmental diagnostics
and bioremediation
Focus on marketing of products and services
RESEARCH & DEVELOPMENT: Microbial technology as applied to biodetection and bioremediation in soil
and waste water
PRODUCTS ON MARKET: BART™ biodetector systems--portable devices for measuring water filtration
and other properties of soil
BART-READ--computer assisted BART measurement
®
DSM
P.O. Box 6500
Heerlen 6401 JH, Netherlands
Phone: +31 45 578 81 11; Fax: +31 45 571 97 53
Web: www.dsm.com
E-mail: info@dsm.com
KEY PERSONNEL: Peter Elverding; Chairman
Arnold Gratama Van Andel; acting CFO
Paul Fuchs; Corporate Secretary
Rob van Leen; Chief Innovation Officer
Bernard van Schaik; Communications
Aquired Chemie Linz and Deretil (1996)
Aquired Gist-brocades (1998)
Aquired Catalytica Pharmaceuticals (2000)
Aquired Roche's Vitamins and Fine Chemicals Division (10/03)
Acquired NeoResins (2/05)
FACILITIES: More than 250 offices and production sites in more than 40 countries
STOCK-FINANCIAL HISTORY: EURONEXT--DSMN

Net sales EUR8.195b (YE 05) compared to EUR7.832b (YE 04)
Net profit EUR527M (YE 05) compared to EUR293M (YE 04)
(YE 04)
Total assets EUR10.025b (YE 05) compared to EUR9.626b (YE 04)
SUBSIDIARIES/DIVISIONS: Nutrition--DSM Nutritional Products (Human nutrition and health, Animal
nutrition and health), DSM Food Specialties
Pharma--DSM Pharmaceutical Products, DSM Anti-Infectives
Performance Materials--DSM Elastomers, DSM Engineering Plastics, DSM
Resins and DSM Dyneema
Industrial Chemicals--DSM Fibre Intermediates, DSM Melamine, DSM Agro
and DSM Energy
DSM Venturing and Business Development
BUSINESS STRATEGY: Create innovative products and services that help improve the quality of life
in the areas of human and animal nutrition and health, cosmetics,
pharmaceuticals, automotive and transport, coatings, housing and electrics
and electronics
Genomatica Inc. Genomatica's and licensing 4/05
SimPheny agreement
Genomatica Inc. implementation of expanded multi-year 6/06
Genomatica's metabolic collaboration and
modeling and simulation licensing agreement
technologies and
capabilities to help DSM
develop improved
biological processes for
product production
PRODUCTS ON MARKET: Products for the pharmaceutical, food and feed and agrochemical industries
High-quality materials such as UV-coatings for optical fibers, elastomers,
engineering plastics and resins for dry and wet paints and for the production
of pipes, tanks and containers
Production of fiber feedstock, melamine and fertilizers
Production of HPPE fiber for life protection, leisure, marine and medical
applications
®
DSM Fine Chemicals

P.O. Box 43
Sittard 6130 AA, Netherlands
Phone: +31 (46) 4773487; Fax: +31 (46) 4773172
Web: www.dsm.com
E-mail: info@dsm.com
KEY PERSONNEL: Jan Wolters; Business Group Director, DSM Fine Chemicals
Andrea Pollak; Business Unit Director, DSM ACTIS
Frank Teeuwisse; Business Unit, Director DSM Minera
Jan Vriens; Business Unit Director, Special Products
HISTORY: Acquired BMS Regensburg (fine chemicals activities)
Acquired 70% of Chemie Linz (Austria) (1/96)
Acquired Deretil (9/96)
FACILITIES: Plant in Holland to produce aspartame
Multipurpose plants for fine chemical intermediates produced by enzyme
technology
Biotech R&D facility
SUBSIDIARIES/DIVISIONS: Three business units:
DSM ACTIS
DSM Minera
DSM Special Products
SUBSIDIARY OF: DSM (see separate entry)
INVESTMENTS: Holland Sweetener Co.--joint venture with TOSOH Corp. for aspartame
Chemferm--joint venture with Gist-brocades for semi-synthetic
cephalosporines
Bio-Intermediair International Holding BV--7%
To become the partner of choice for innovative life science companies
based upon:
-A superior technology toolbox
-Optimal production facilities
-Service throughout the product life cycle
To ensure our customers benefit from our global leadership and extensive
expertise in:
-The manufacturing of standard and advanced intermediates
-The manufacturing of active ingredients
-Upscaling from kg- to ton-scale
-New process development
-Exclusive synthesis and custom development
RESEARCH & DEVELOPMENT: Aspartame

L- and D-amino acids via enzymatic resolutions, as well as other optically
active compounds
PRODUCTS ON MARKET: REGULAR PRODUCTS: Acetaldehyde oxime, Acetonyl succinic acid
diethylester, 2-Acetylnicotinic Acid, Allantoin, 2-Amino-4,6-
dimethoxypyrimidine, D,L-Aspartic acid, L-Aspartic acid, Benzaldehyde,
Benzoic acid, Benzylalcohol, N-Bromosuccinimide, N-tert.-Butylacrylamide,
N-Butyl levulinate, Carbethoxypyrazolone, N-Chlorosuccinimide, Cinnamic
alcohol, Cinnamic aldehyde, Copper iodide, 1,3-Cyclohexanedione, 1,4-
Cyclohexanedione, Cyclohexanone oxime, Diacetone acrylamide, 1,4-
Diaminobutane, N,N’-Dibenzylethylenediamine diacetate, N,N-
Dibenzylamine, 1,3 Dibromo-5,5-dimethylhydantion, 2,2
Dichlorophenylacetic acid ethylester, Diethyl maleate, Diethyl succinate,
®
Diethylacetal succinate, Diisopropyl succinate, Dimethyl maleate, Dimethyl

succinate, Dimethyl succinylo succinate, Dimethylacetyl succinate, 2,3-
Dimethylpyridine (2,3-Lutidine), Di-n-butyl fumarate, Di-n-butyl maleate,
Dioctylfumarate, Dioctylmaleate, Fumaric acid, Glyoxylic acid 50%, Glyoxylic
acid methylester methylhemiacetal, sec.-Guanidine phosphate, Iodine,
Levulinic acid, Maleic acid, Maleic anhydride, Methyl iodide, Monosodium
fumarate, D,L-Phenylalanine, 3-Phenylpropanol-1, o-Phthalaldehyde,
Potassium benzoate, Potassium iodate, Potassium iodide, Potassium iodide
with Ca-Stearate, Potassium iodide with tixosil, 2,3-Pyridine dicarboxylic
acid, Pyrrolidine, Pyruvic acid ethylester (ethyl pyruvate), Pyruvic acid
methylester (methyl pyruvate), Sodium benzoate, Sodium iodide, Sodium
metaperiodate, Succinic acid, Succinic anhydride, Succinimide, 1,2,4-
Triazole, 1,2,4-Triazole, sodium salt (sodium triazole), Trimethylsulfoxonium
iodide
DEVELOPMENT PRODUCTS: Adipic acid dihydrazide, (R)-2-Chloro-

mandelic acid, Diethoxyethyl acetate, Diethyl succinylo succinate, 2,5-
Dimethoxytetrahydrofuran, Diphenyl acetic acid, Glyoxylic acid ethylester
ethylhemiacetal, Glyoxylic acid methylester, Glyoxylic acid monohydrate, 2-
Hydroxymethylpyrimidine, 1,8-Octanedialtetramethylacetal, 1,8-Octanediol,
N-tert.-Octyl-acrylamide, 4-Oxobutanoic acid methylester, Phthalazine, 2-
Picolinic acid, Pyridine-2-aldehyde
DuPont
Chestnut Run Plaza 728/1307
Wilmington DE 19880, US
Phone: (866) 476-7662 Toll-free phone: (866) 476-7662
Web: www.sorona.dupont.com
KEY PERSONNEL: Charles O. Holliday Jr.; Chairman and CEO
Richard R. Goodmanson; Exec. VP and COO
Jeffrey L. Keefer; Exec. VP and CFO
James C. Borel; Sr. VP, Human Resources
Terry Caloghiris; Group VP, Coatings & Color Technologies
Uma Chowdhry; Sr. VP, CSO and CTO
Thomas M. Connelly; Exec. VP and Chief Innovation Officer
J. Erik Fyrwald; Group VP, Agriculture & Nutrition
Diane H. Gulyas; Group VP, Performance Materials
John C. Hodgson; Sr. VP and Chief Marketing and Sales Officer
W. Donald Johnson; Chairman and Representative Director, DuPont KK
Ellen J. Kullman; Exec. VP, Safety & Protection, Coatings & Color
Technologies, Marketing & Sales and Safety & Sustainability
Stacey J. Mobley; Sr. VP and Chief Administrative Officer and General
Counsel
Craig G. Naylor; Group VP, Electronic & Communication Technologies
Gary M. Pfeiffer; Sr. VP
Mark P. Vergnano; Group VP, Safety & Protection
Mathieu Vrijsen; Sr. VP, Operations & Engineering
FACILITIES: Operates in more than 70 countries
More than 40 R&D and customer service labs in the U.S., and more than 35
labs in 11 other countries
STOCK-FINANCIAL HISTORY: NASDAQ--DD
Net income $2.053b (YE 05) compared to $1.780b (YE 04)
®
SUBSIDIARIES/DIVISIONS: Agriculture and Nutrition

Coatings and Color Technologies
Electronic and Communication Technologies
Performance Materials
Pharmaceuticals
Safety and Protection
Subsidiaries:
Agar Cross SA--Argentina
Antec International Ltd.--U.K.
Building Media Inc.--Delaware
ChemFirst Inc.--Mississippi
Christiana Insurance Ltd.--Bermuda
Destination Realty Inc.--Delaware
DPC (Luxembourg) SARL
DPC S/A Brazil
DPC South America--Brazil
DSRB Ltda. Brazil
DuPont Kansai Automotive Coatings Co.--Delaware
DuPont (Australia) Ltd.
DuPont (Korea) Inc.
DuPont (New Zealand) Ltd.
DuPont (South America) Holdings LLC--Delaware
DuPont (Thailand) Co. Ltd.
DuPont (U.K.) Investments
DuPont (U.K.) Ltd.
DuPont Agricultural Caribe Industries Ltd.--Bermuda
DuPont Agricultural Chemicals Ltd.--China
DuPont Agro Hellas SA--Greece
DuPont Argentina SA--Argentina
DuPont Asia Pacific Ltd.--Delaware
DuPont Beteiligungs GmbH--Austria
DuPont BVco BV--Netherlands
DuPont Capital Management Corp.--Delaware
DuPont Chemical and Energy Operations Inc.--Delaware
DuPont China Holding Co. Ltd.
DuPont China Ltd.--Hong Kong
DuPont China Ltd. (U.S.)--Delaware
DuPont Coatings SAS France
DuPont Company (Singapore) Pte. Ltd.
DuPont Conid SpA Delaware
DuPont Coordination Center NV--Belgium
DuPont CZ sro--Czech Republic
DuPont DACI Beteiligungs GmbH--Austria
DuPont Danmark ApS--Denmark
DuPont de Colombia SA
DuPont de Nemours (Belgium) BVBA
DuPont de Nemours (Deutschland) GmbH--Germany
DuPont de Nemours (Flandre) SA--France
DuPont de Nemours (France) SAS
DuPont de Nemours (Luxembourg) SARL
DuPont de Nemours (Nederland) BV
DuPont de Nemours Development SA--Switzerland
DuPont de Nemours Groupe SARL--France
DuPont de Nemours International SA--Switzerland
DuPont de Nemours International SA--South Africa
DuPont de Nemours Italiana Srl
DuPont Deutschland Holding GmbH & Co. KG--Germany
DuPont Diagnostics Inc.--Delaware
DuPont Display Enhancements Inc.--California
DuPont Displays Inc.--California
DuPont do Brasil SA
DuPont Performance Elastomers LLC--Delaware
DuPont Eastern Europe BV--The Netherlands
DuPont Elastomers Inc.--Delaware
®
DuPont Electronic Materials Inc.--Delaware

DuPont Electronics Microcircuits Industries Ltd.--Bermuda
DuPont Energy Co. LLC--Delaware
DuPont Engineering Products SARL--Luxembourg
DuPont Environmental Remediation Services Inc.--Delaware
DuPont Far East Inc.--Delaware
Dupont Far Eastern Petrochemicals Ltd.--China
DuPont Feedstocks Co.--Delaware
DuPont Flandre Finance--France
DuPont Foreign Sales Corp.--Virgin Islands
DuPont Global Operations Inc.--Delaware
DuPont Herberts Automotive Systems Services BVBA--Belgium
DuPont Holdco Spain I SL--Spain
DuPont Holdco Spain II SL--Spain
DuPont Holographics Inc.--New York
DuPont Iberica SL--Spain
DuPont India Ltd.--Delaware
DuPont International (Luxembourg) SCA
DuPont International Trading Inc.--Delaware
DuPont Kabushiki Kaisha--Japan
DuPont KGA BV--The Netherlands
DuPont Khimprom--Russia
DuPont Medical Products Inc.--New York
DuPont Mexico SA de CV
DuPont North America Inc.--Delaware
DuPont NLco BV--The Netherlands
DuPont Operations (Luxembourg) SARL
DuPont Operations Inc.--Delaware
DuPont Operations Worldwide Inc.--Delaware
DuPont Orient Operations Ltd.--Delaware
DuPont Performance Coatings France SAS
DuPont Performance Coating Nederland BV
DuPont Performance Coatings (Thailand) Ltd.
DuPont Performance Coatings (U.K.) Ltd.
DuPont Performance Coatings Austria GmbH
DuPont Performance Coatings GmbH & Co KG--Germany
DuPont Performance Coatings Iberica SL--Spain
DuPont Performance Coatings Polska Spolka zoo--Poland
DuPont Performance Coatings Pty. Ltd.--Australia
DuPont Performance Coatings Scandinavia AB--Sweden
DuPont Performance Coatings Inc.--Delaware
DuPont Performance Coatings Tintas e Vernizes SA--Portugal
DuPont Pharma Inc.--Delaware
DuPont Poland BV--The Netherlands
DuPont Poland Sp zoo--Poland
DuPont Polimeros Ltda.--Brazil
DuPont Polyester Europe Aps--Denmark
DuPont Polymer Powder SARL--Switzerland
DuPont Powder Coatings (Malaysia) Sdb.
DuPont Powder Coatings Andina SA--Colombia
DuPont Powder Coating Belgium NV
DuPont Powder Coatings France SAS--France
DuPont Powder Coatings Iberica SL--Spain
DuPont Powder Coatings Saudia Co. Ltd.--Saudi Arabia
DuPont Powder Coatings Scandinavia AB--Sweden
DuPont Powder Coatings U.K. Ltd.
DuPont Powder Coatings USA Inc.--Delaware
DuPont Protective Apparel Marketing Co.--Delaware
DuPont Pulverlack Deutschland GmbH & Co. KG--Germany
DuPont Quimica de Venezuela CA
DuPont SA de CV--Mexico
DuPont Scandinavia GmbH--Germany
DuPont Services BV--The Netherlands
DuPont Specialty Grains (dba Optimum Quality Grains LLC)--Delaware
DuPont Taiwan Ltd.
®
DuPont Textile Fibers SA--China

DuPont Textiles & Interiors (South America) Holdings LLC--Delaware
DuPont Textiles & Interiors Holdings Inc.--Delaware
DuPont Trading (Shanghai) Co. Ltd.--China
DuPont Treasury Ltd.--U.K.
DuPont Vespel Parts and Shapes Inc.--Pennsylvania
DuPont Wirex Ltd.--Taiwan
E.I. du Pont Canada Co.
E. I. DuPont India Private Ltd. India
EID Singapore Inc.--Delaware
Electronic Materials DuPont Dongguan Ltd.--China
Entek Corp.--Delaware
Entek Europe Inc.--Delaware
Granirex--California
Griffin Brasil Ltda.
Griffin Colombia SA
Griffin LLC--Delaware
Helmstedter Lack-und Chemische Fabrick GmbH & Co. KG--Germany
Herberts America Inc.--Delaware
Herberts Mexico SA de CV
Herberts Plascon Pty. Ltd.--Delaware
Hickory Holdings Inc.--Delaware
Holding DP SA de CV--Mexico
Huajia Chemical Co.--China
IDAC Belgium – EP Branch BVBA
Initiatives de Mexico SA de CV
International Dioxcide Inc.--Delaware
Liqui-Box Corp.--Ohio
Permatex Italia Srl
Pioneer Hi-Bred International Inc.--Iowa
Pitt-Consol Chemical Co.--New Jersey
PT DuPont Agricultural Products--Indonesia
PT DuPont Powder Coatings--Indonesia
Renner DuPont SA Brazil
Sentinel Transportation LLC--Delaware
Solae Holdings LLC--Delaware
Solae LLC (dba The Solae Co.)--Missouri
Spies-Hecker GmbH--Switzerland
Sporting Goods Properties Inc.--Delaware
Teodur BV--The Netherlands
UNIAX Corp.--California
Verdia Inc.--Delaware
Verniplast SA--Switzerland
INVESTMENTS: Joint venture with Tate & Lyle plc--formed to produce 1,3-propanediol (PDO)
BUSINESS STRATEGY: Offer a wide range of products and services for markets including
agriculture, nutrition, electronics, communications, safety and protection,
home and construction, transportation and apparel
Affinergy Inc. R&D of new line of bioresearch agreement 8/06
based products for
DuPont's BioSurfaces
business
BP development, partnership 6/06
production and
marketing of a next
generation of biofuels
RESEARCH & DEVELOPMENT: Core Research Competencies of DuPont R&D:
Chemical science and catalysis: Chemical synthesis, all fields of chemistry,

catalysis, combinatorial chemistry, discovery chemistry, fine particle
synthesis
®
Leveraged technologies: Analytical science, information science, image

processing, computer science, modeling and simulation, properties
modeling
Biology: Agronomy, Ag environmental chemistry, Ag formulation science,

biochemistry, biochemical engineering, bioinformatics, cell culture,
ecosphere modeling, genetics, genomics, microbiology, molecular biology,
plant science
Material science and engineering: Polymerization fundamentals, polymer

modifications, multi-component polymer systems, interfacial science,
polymer recycling, polymer characterization, polymer process development,
polymer fabrication, fiber science and engineering, fibrous/fibrid systems
engineering, composite structures, coatings, photosensitive coatings and
materials, color science, interfacial science, polymer synthesis, solidification,
image substrate materials
Process science and engineering: Digital imaging systems; environmental

engineering; hazards evaluation and control; materials engineering;
operations optimization; particle technology; process development/scale-up;
process measurement and control; process modeling and simulation;
process synthesis; reaction engineering; thermodynamics, kinetics,
mechanisms; transport phenomena; unit operations; experimental design
and empirical modeling
PRODUCTS ON MARKET: Autograph® non-stick coating for cookware
DuPont™ Air Filters
DuPont™ Biodegradable Stakes™
DuPont™ Bird Netting™
DuPont™ Deer Netting™
Corian® solid surface
DuPont™ Carbon Monoxide Alarms
DuPont™ Car Care Products
DuPont™ FlameResist™ Blanket
DuPont™ Frost Blanket™
DuPont™ Garden Products™
Granite Certified by DuPont
GreenVista™ garden products
Kevlar® ballistic protection
DuPont™ Pool Care System
DuPont™ Self-Charging Smoke Alarms
DuPont™ Spa Care System
DuPont™ Seed Bed Cover™
DuPont™ Seed Germination Blanket™
Kevlar® StormRoom™ residential in-home storm shelter
SentryGlas® safety glass interlayer
Simplicity™ solid surfaces
Solae® soy protein
Stain Protectors
Teflon® surface coatings
Tyvek® envelopes
Tyvek® fibers
Tyvek® HomeWrap®
Tyvek® StuccoWrap®
Tyvek® tape
Tyvek® ThermaWrap™
DuPont™ Vinyl Flooring
DuPont™ Garden Products™ Weed Control Fabric
Water Filtration
Zodiaq® solid surface
®
Dyadic International (USA) Inc.

140 Intracoastal Pointe Drive, Suite 404
Jupiter FL 33477-5094, US
Phone: (561) 743-8333; Fax: (561) 743-8343
Web: www.dyadic-group.com; E-mail: information@dyadic-group.com
KEY PERSONNEL: Mark Emalfarb; Chairman, President and CEO
Wayne Moor; CFO
Dr. Glenn Nedwin; CSO
Kent Sproat; Exec VP, Enzymes
Ray Chandra; Sr. VP, Marketing, Biotech Systems
Alexander (Sasha) Bondar; VP, Corporate Development
Charles W. (Bill) Kling IV; VP, Sales and Marketing, Enzymes
Dan Michalopoulos, Ph.D.; VP, Pulp and Paper
Richard Burlingame, Ph.D.; Exec. Director, R&D
STOCK-FINANCIAL HISTORY: AMEX--DIL
PRIVATE PLACEMENTS: Raised $2.1M in warrants and options exercise (5/06)
SUBSIDIARIES/DIVISIONS: Enzyme Business
Biosciences Business
BUSINESS STRATEGY: Leverage its technology platform to discover novel genes and biological
products for use by its strategic partners, and to further the company’s own
R&D efforts
Seek strategic alliances with leaders in the agricultural, biological, industrial,
chemical and biopharmaceutical industries that have in-house genomic
capabilities. Collaborate with companies whose genomic capabilities are
limited in order to discover and express biological materials for these
strategic partners
Commercialize enzymes for use in targeted markets including the animal
nutrition, detergent, ethanol, pulp and paper, biopharmaceutical, starch and
textile industries
RESEARCH & DEVELOPMENT: Discover, develop and manufacture novel products derived from the DNA of
complex living organisms (including humans)
Development of biological products such as proteins, enzymes, polypeptides
and small molecules for applications in large segments of the agricultural,
industrial, chemical and biopharmaceutical industries
Discovery and expression of eukaryotic genes and manufacturing for
commercial application
Dynavax Europe
Eichsfelder Strasse 11
Dusseldorf 40595, Germany
Phone: +49 (0)211 7 58 45 0; Fax: +49 (0)211 7 58 45 130
Web: www.rheinbiotech.de
E-mail: info@rheinbiotech.de
KEY PERSONNEL: Zbigniew Janowicz, Ph.D.; CEO, Dynavax Europe
Petra Zimmer; CFO
Oliver Bartelsen, Ph.D.; Director, Business Development
®

Acquired by Berna Biotech AG (2002)
Acquired by Dynavax Technologies Corp. (4/06)
Changed name from Rhein Biotech GmbH (4/06)
SUBSIDIARY OF: Dynavax Technologies Corp. (see separate entry)
BUSINESS STRATEGY: Develop proprietary biopharmaceutical products and establish strategic

alliances designed to leverage and add value to the company's core
capabilities in the areas of process, analytical and preclinical development,
quality control, quality assurance, manufacturing and technology transfer
Through marketing and sales of recombinant antigens on the diagnostic
market, leverage the value of the established vaccine production
technologies
EMD Biosciences Inc./Merck Biosciences

10394 Pacific Center Court
Phone: (858) 45005500; Fax: (858) 453-3552
Web: www.emdbiosciences.com
KEY PERSONNEL: Douglas S. Brown; President and CEO
Hans Ahl; GM, European Sales and Marketing
HISTORY: Established in 1952 as a manufacturer of research biochemicals

Sold to Hoechst Corp. in 1977
Sold to Biodor in 1988
Sold to Warburg, Pincus and Alex Brown in 1992
Acquired Oncogene Science Research Products division (8/95)
Changed name from Calbiochem-Novabiochem International (7/96)
Acquired Novagen (12/97)
Acquired by Merek KGaA, Dormstadt, Germany (12/98)
Changed name from CN Biosciences Inc. (2/03)
The company, an affiliate of Merck KGaA, is known as EMD Biosciences in
North America and as Merck Biosciences in all other countries
FACILITIES: Manufacturing facilities in San Diego, Calif.; Cambridge, Mass.; Madison,
Wis.; and Switzerland
SUBSIDIARY OF: Merck KGaA (see separate entry)
Chromagen Inc. Chromagen's Direct multiyear marketing 3/98
Read RNA and DNA and distribution
assays and other agreement--CN
products in life sciences Biosciences'
research market subsidiary
Calbiochem-
Novabiochem
Corp. gains
exclusive access to
certain research
uses of products
and technology that
Chromagen has
developed for other
markets
®
Epitome products based on licensing and 9/05

Biosystems Epitome's EpiTag development
technology agreement
German Resource genome research cooperative 11/04
Center for agreement
Genome
Research
RESEARCH & DEVELOPMENT: Molecular biology kits and reagents

Cellular reagents, including caged compounds, antibodies, intracellular
probes, inhibitors, signal transduction tools, apoptosis tools, proteins, amino
acid derivatives, peptides, buffers, detergents, combinatorial chemistry
linkers and resins
Development of custom products on contractual basis
PRODUCTS ON MARKET: More than 15,000 products on the market, including signal transduction
reagents, molecular biology kits and reagents, apoptosis reagents, cancer
study reagents, combinatorial chemistry, Buffers, Zwittergent® detergents,
Ultrol® grade detergents and buffers, Pronase® protease, Pansorbin® cells,
reagents for peptide synthesis, peptides, inhibitors, enzymes, proteins,
antibodies, immunochemicals, antibodies to signaling proteins, calcium
modulators, neurochemicals and neurotoxins
eMembrane Inc.
4 Richmond Square, Suite 500
Providence RI 02906, US
Phone: (401) 861-9770; Fax: (401) 861-9777
Web: www.emembrane.com
E-mail: info@emembrane.com
KEY PERSONNEL: William Lee, Ph.D.; President and CEO
PRIVATE PLACEMENTS: Raised $370K in three rounds of financing
PRINCIPAL INVESTORS: Slater Technology Fund
--Angels
BUSINESS STRATEGY: Vision:
Be the world leader in research, development and commercialization of
Multifunctional Polymeric Materials and Membranes for chemical and
biological applications
Mission:
To enable chemical and biotech companies to create innovative and cost-
effective solutions to problems of separating and handling chemical and
biological materials by using proprietary technology to functionalize
polymeric materials and membranes used in systems and devices
RESEARCH & DEVELOPMENT: Nano-grafting of combinatorial functionalized polymer brushes
®
EnSolve Biosystems Inc.

3209 Gresham Lake Road, Suite 147
Raleigh NC 27615, US
Phone: (919) 954-6196; Fax: (919) 954-6197
Web: www.ensolve.com
E-mail: info@ensolve.com
KEY PERSONNEL: Dr. Jason Caplan; Chairman, President and CEO
BUSINESS STRATEGY: Develop biospecialty products that eliminate pollutants from air, water and
soil using biotechnology
Bath Iron Works Petroliminator, Oily marketing 8/01
Water Separator agreement for U.S.
Navy projects
Burlington specialty chemicals-- sales and 1/97
Chemical EnSolve's GreaseFeast distribution
biocleanser agreement
PRODUCTS ON MARKET: PetroLiminator® bilge water treatment system

GF 2010™ multi-purpose liquid detergent
EnCell™ bioreactor
EnFlow Air Filter
GreaseFeast® biocleanser
Oxi-Blast™ non-polluting cleaner
EnSorb, granular formulation of EnSolve's oil degrading microbes
Enviro-Zyme International LLC

2885 Bartells Drive
Beloit WI 53511, US
Phone: (800) 882-9904; Fax: (608) 361-9883
Web: www.envirozyme.com
E-mail: info@envirozyme.com
KEY PERSONNEL: Jay Silverstein; Chairman and President
Karen Silverstein; VP
HISTORY: Founded in March 1989
FACILITIES: 20,000 sq. ft. headquarters and manufacturing facility in Beloit, Wis.
BUSINESS STRATEGY: Manufacture products that are all biodegradable, non-toxic, non-corrosive
and non-volatile
PRODUCTS ON MARKET: Degradation of hydrocarbons in wastewater treatment facilities, septic

systems, and grease traps in kitchens and bioremediation of oil, aliphatic,
aromatic chemical pollutants, and composting
BR--Bioremediation of aliphatic and aromatic pollutants
C--degradation of cellulose
COMP--for composting mulch and sludge
DIN--for nitrification and denitrification (liquid)
®
DOC--biological odor control

EZ--sludge reduction and odor control
GT--degradation of grease, oils and fats in kitchen grease traps
L--degradation of animal fats, oils and greases
LGD--liquid for kitchen grease traps
N--to control foaming, bulking or rising sludge caused by filamentors
bacteria
O--wintergreen fragrance and sludge reduction and odor control
P--for phosphorus reduction
Pouch--for lift stations, wet wells and pump stations
R--for septic systems
T--for hydrogen sulfide reduction
XC--degradation of grease oils and fats in kitchen grease
Enzyme Research Laboratories Ltd

15 Sketty Road
Swansea SA2 OEU, UK
Phone: +44 (0)1792 466166; Fax: +44 (0)1792 466366
Web: www.enzymeresearch.co.uk
E-mail: info@enzymeresearch.co.uk
KEY PERSONNEL: Nils von Sicard, Ph.D.; Managing Director
Michael Morris; Exec. VP
Hazel Pannett; Office Manager
EMPLOYEES: 5 employees; 2 Ph.D.s
SUBSIDIARIES/DIVISIONS: Enzyme Research Laboratories Inc.

412 S. Lafayette
South Bend, IN 46601 USA
Phone: (574) 288-2268
Fax: (574) 288-2272
PRINCIPAL INVESTORS: Private LTD Co.
BUSINESS STRATEGY: A drug discovery company
R&D targets new anticoagulant products for the treatment of blood clots,
heart attacks and stroke
RESEARCH & DEVELOPMENT: Anticoagulants from blood sucking animals

PRODUCTS ON MARKET: ERL provides a number of high quality coagulation reagents to scientist
involved in haemostasis and thrombosis research. Products include
coagulation factors, polyclonal and monoclonal antibodies to coagulation
factors, ELISA kits, haematological diagnostic kits and factor deficient
plasmas
TEPI (anticoagulant) in preclinicals
®
Epicore Networks (U.S.A.) Inc.

4 Lina Lane
Eastampton NJ 08060, US
Phone: (609) 267-9118; Fax: (609) 267-9336
Web: www.epicorebionet.com
E-mail: epicore@gbsias.com
KEY PERSONNEL: Hugh C. Hart; Chairman
William P. Long; CEO
Paul Massam; Director, Business Development
Nancy Robinson; Scientist
William Castner; Purchasing Manager
HISTORY: Founded and began biotech R&D in March 1994
STOCK-FINANCIAL HISTORY: Parent company: TSX--EBN
SUBSIDIARIES/DIVISIONS: Epicore Ecuador SA
Attn: Lorena Vanoni
9 de Octubre 2305 y Tungurahua
Primer Piso- Dept. #1
Guayaquil, Ecuador
Phone: 5939 783 5875
Fax: 5934 237 4167
E-mail: lvaepi@telconet.net
SUBSIDIARY OF: Epicore BioNetworks Inc.
BUSINESS STRATEGY: Grow through biological product sales
RESEARCH & DEVELOPMENT: Aquaculture environment treatments

Animal waste digestion
Aquaculture feeds
PRODUCTS ON MARKET: Aquaculture:
Epicin hatchery and pond treatment
Epifeed LHF 1&2&3 liquid feed for hatcheries
Epibal 150, 300 & 500 granular feed for hatcheries
Epifeed MBF maturation feed
Epizym VMC vitamin mineral concentrate
Epizym BGM growth medium for Epicin
Epizym AGP algae growth promoter
Agriculture and Horticulture:

Epizym AW animal waste liquifier and deodorizer
Photozym liquid foliar spray and seed treatment
Epithatch biological thatch digestor
Bioremediation:
Epizym HC microbial ecosystem for hydrocarbon digestion
Nutripak companion product for Epizym HC
Emulsifier companion product for Epizym HC
Waste Water Management:

Epizym 100 microbial ecosystem for municipal and industrial wastewater
treatment
Epizym 200 microbial ecosystem for biodegradation of hydrocarbons in
wastewater
®
Cleaning and Sanitation:

Epizym ST septic and RV tank treatment
Epizym CU carpet and upholstery shampoo
Epizym DT drain and grease trap cleaner
Epizym DG aqueous cleaner and degreaser
Epizym HS hard suface cleaner
Epizym SR scale remover
Epidauros Biotechnologie AG
Am Neuland 1
Bernried 82347, Germany
Phone: +49 (0)8158-9985 - 0; Fax: +49 (0)8158-9985 - 48
Web: www.epidauros.com
E-mail: contact@epidauros.com
KEY PERSONNEL: Falk Nuber; Chairman
Dr. Michael Lutz; CEO
Hubert Wechner; VP, Human Resources, IT, and Finances
Dr. Karl Kleine; VP, Quality Management
Hans Peter Arnold, Ph.D.; Sr. Director, Business Development, Sales and
Marketing
Dr. Katrin Granderath; Director Genotyping Services
Dr. Elke Roschmann; Sr. Manager, Business Development and Marketing
Vera Sturma; Sr. Manager, Business Development and Marketing
Dr. Stephan Reschauer; Director, Patents and Licensing
PRINCIPAL INVESTORS: DEWB
BUSINESS STRATEGY: Make drug development and therapy safer, more focused, and more cost
efficient through pharmacogenetic research and application that investigates
the genetic factors that influence a person's response to a drug
Investigate and characterize variations of genes (polymorphisms) that

encode drug transporter proteins and drug metabolizing enzymes, as well as
investigate genes encoding drug targets to which drugs bind
Offer pharmaceutical and biotechnology companies a comprehensive

package of proprietary pharmacogenetic assays and services which will
significantly improve the results of clinical studies and drug treatment

Focuc Clinical R&D and co-marketing
Drug agreement
Developemnt
GmbH
Parexel R&D and co-marketing
International agreement
Pharmacia Corp. R&D and co-marketing
agreement
Tm Bioscience Epidauros' patents on co-exclusive 3/06
Corp. a biomarker related to commercial licensing
the P450-CYP2D6 agreement
gene
®
PRODUCTS ON MARKET: Genotyping services

Pharmacogenetic contract research
Consulting
Eurogentec SA
LIEGE Science Park, Rue Bois Saint Jean 5
Seraing B-4102, Belgium
Phone: +32 4 372 74 00; Fax: +32 4 372 75 00
Web: www.eurogentec.com
E-mail: info@eurogentec.com
KEY PERSONNEL: Joseph Martial, Ph.D.; Chairman
Jean-Pierre Delwart; CEO
Gottfried Proess; Production Manager
Veronique Distexhe; CFO
Daniel Radoux; Sales and Marketing Manager
Philippe Cronet; Biologics Business Unit Director
HISTORY: Founded in 1985 as a spin-off of the University of Liege
Established Nippon EGT joint venture in Japan (8/03)
PRIVATE PLACEMENTS: EUR5M private placement (2001)
SUBSIDIARIES/DIVISIONS: Subsidiaries:
Eurogentec France s.a.s.u.
Eurogentec Deutschland GmbH
Eurogentec Nederland b.v.
Eurogentec s.a., succursale de Genève
Nippon EGT Co., Ltd.
RB EGT (Singapore)
Eurogentec North America, Inc.
Eurogentec Ltd.
Biotech-related divisions:
Genomics
Proteomics
Biologics
BUSINESS STRATEGY: Design and deliver reliable and innovative services and products for the life
science community
Act as a leading supplier for genomic and proteomic research, in offering the
company's customers integrated solutions, whether they use DNA,
antibodies, peptides or proteins as research tools
Offer research and development services for the biopharmaceutical industry

Alnylam research products and nonexclusive 7/05
Pharmaceuticals services in RNAi under licensing agreement
Alnylam's Kreutzer-
Limmer patent family
®
EvoGenix Ltd.
2/37 Bligh Street
Sydney NSW 2000, Australia
Phone: +61 2 8257 3393
Fax: +61 2 8257 3399
Web: www.evogenix.com
E-mail: m.sleigh@evogenix.com.au
KEY PERSONNEL: Christopher Harris; Chairman
Merilyn Sleigh, Ph.D.; CEO
Steffen Nock, Ph.D.; President, Evogenix Inc. and Exec. Director
Robert Crombie, Ph.D.; COO and VP, Business Development
David Wilson, Ph.D.; VP, Antibody Products
George Kopsidas, Ph.D.; Director, Protein Technologies
HISTORY: Founded and began biotech R&D in August 2001
Acquired Absalus Inc. (4/05)
FACILITIES: Headquarters: Head office in the Sydney CBD
Corporate and R&D facilities in Parkville, Melbourne
EvoGenix Inc.: Leased facilities in Mountain View, Calif.
Manufacturing: access to medium scale fermentation for protein production
STOCK-FINANCIAL HISTORY: Australian Stock Exchange--EGX
IPO--36M shares at A$0.25/share, A$9M (7/05)
PRINCIPAL INVESTORS: Startup Australia Ventures Pty. Ltd.--33%
BioFusion Capital Pty. Ltd.--6%
CRC for Diagnostics--9%
BUSINESS STRATEGY: Utilise technology platform for protein optimisation by molecular evolution to
build improved and novel therapeutic products for partners and internal
pipeline. Through acquisition of US-based Absalus Inc., now Evogenix Inc.,
provide access to integrated humanization and optimisation for developing
novel antibody products. Technology is also available for licensing.
Absalus Inc. combine technology strategic alliance 5/04
BresaGen Ltd. protein production R&D agreement 7/02
protocols
Cooperative protein discovery and licensing 7/01
Research Centre optimization technology agreement
for Diagnostics patents
CSL Ltd. EvoGenix to apply its technology 5/06
technologies to CSL collaboration
antibody products, in
order to generate
superior antibodies
DiNonA Inc. antibody for treatment worldwide licensing 9/05
of leukemia agreement
Domantis Ltd. affinity improve single R&D agreement 8/03
domain antibodies
Genesis R&D select receptor-specific R&D agreement 5/03
Corp. proteins
GlaxoSmithKline application of research and 10/05
plc EvoGenix’s EvoGene collaboration
technology to the agreement
optimisation of GSK
compounds
®
University of anticancer antibody licensing 4/06

Massachusetts agreement
Medical School
Viventia Biotech affinity improve antibody R&D agreement 6/04
Inc. products
RESEARCH & DEVELOPMENT: Antibody optimization projects on behalf of partner companies (4)
commencing April 2003
Internal project for improvement in specificity of a therapeutic growth factor
for large unmet market need
Several antibodies for large markets under development
Continuing strategies for development of technology to improve its efficiency
and scope
Development of Evibody framework for display of peptide libraries for drug
discovery and imaging applications
PRODUCTS ON MARKET: EvoGene™ technology for finetuning of the properties of proteins via a
random mutagenesis and selection approach; antibody
humanization/optimization through acquisition of US-based Absalus Inc.
Evibody technology - novel human protein in research
framework for display of binding peptides
as a tool in drug discovery, diagnostics and
therapeutics
EGX010 - engineered growth factor for in preclinicals
treatment of bone cancer
EGX020 - humanized monoclonal antibody in research
for treatment of infectious diease
EGX030 - humanised monoclonal antibody in research
for treatment of primary liver cancer
EGX040 - humanized monoclonal for in research
treatment of leukaemia
EGX050 - humanized monoclonal for in research
treatment of melanoma/lung cancer
Evolva SA
Hagmattstrasse 6
Allschwil CH-412, Switzerland
Phone: +41 61 485 2000; Fax: +41 61 485 2001
Web: www.evolvabio.com
E-mail: info@evolvabio.com
KEY PERSONNEL: Jean-Philippe Tripet; Chairman
Neil Goldsmith; CEO
Alexandra Santana Sorensen; VP, R&D
Pascal Longchamp; VP, Business Development
Melya Hughes Crameri; VP, Alliances and IP
Michael Naesby; Head, Library Creation
Acquired certain assets of Poalis A/S (9/05)
PRIVATE PLACEMENTS: Raised EUR12M in Series A financing (8/04)
SUBSIDIARIES/DIVISIONS: Evolva A/S
Bulowsveg 25
1870 Fredericksberg C
Denmark
Phone: +45 3536 4429
Fax: +45 3528 3885
®
Evolva India Pvt. Ltd.

IICT, Uppal Rd.
Hyderabad 500 007
India
Phone: +91 93 4673 8534
PRINCIPAL INVESTORS: APIDC-VC
Aravis
Astellas Venture Capital LLC
Danish Growth Fund
Danish Innovation Investment (Dansk Innovationsinvestering)
Novartis Venture Fund
Symbion Capital
BUSINESS STRATEGY: Fundamentally improve the logistics and success rates of small molecule
therapeutic discovery, development and manufacturing through the
application of advanced evolutionary technologies, while sharing in the value
generated by these improvements, and the molecules that result, through
selective partnering, as well as the development of the Company's own
compound pipeline
AnalytiCon generation and research alliance 7/05
Discovery GmbH optimization of nuclear
receptor agonists and
related compounds
RESEARCH & DEVELOPMENT: Compounds for the treatment of cancer and diabetes, as well as anti-
infectives
Watchmaker® technology platform
F. Hoffmann-La Roche Ltd.

Grenzacherstrasse 124
Basel CH-4070, Switzerland
Phone: +41 61-688-1111; Fax: +41 61-691-9391
Web: www.roche.com
E-mail: info@roche.com
KEY PERSONNEL: Dr. Franz B. Humer; Chairman and CEO
Dr. Erich Hunziker; CFO
Prof. Dr. Jonathan K.C. Knowles; Head, Research
William M. Burns; CEO, Pharmaceuticals Division
Dr Severin Schwan; CEO, Diagnostics Division
HISTORY: Founded F. Hoffmann-La Roche & Co. in 1896 (Ltd. Since 1919)
Roche Holdings Inc. incorporated in Delaware in 1987
Scientists at Basel Institute for Immunology (Roche-sponsored) awarded
Nobel Prizes in 1984 and 1987
Founded Roche Holding Ltd. In 1989
Sold Medi-Physics in 1990
Acquired 60% equity in Genentech for $2.1b, with an option to acquire the
remaining interest until June 1999 (9/90)
Sold plant-protection business to Ciba-Geigy Ltd. (9/90)
Acquired worldwide PCR rights (1991)
Roche Biomedical Laboratories merged with National Health Laboratories to
become the Laboratory Corporation of America (1994)
Acquired Syntex Corp. for $5.3b (10/94) and renamed it Roche Bioscience
(see separate entry)
Sold the Syntex animal health products business to American Home
Products Corp. (7/95)
®
Acquired flavors producer Tastemaker (2/97)

Acquired Corange group (Boehringer Mannheim and DePuy) (3/98),
received approval from U.S. FTC to acquire Corange on condition that
Roche not acquire dominant position in the thrombolytics market, Roche
also agreed to sell rights to Retevase to Centocor Inc. (2/98)
Sold DePuy to Johnson & Johnson (7/98)
Changed name from F. Hoffmann-La Roche to Roche Holding Ltd. (8/00)
Roche alliance with Chugai (Japan), majority shareholders--50.1% (10/02)
Acquired Disetronic and Igen (2003)
Acquired GlycoArt Biotechnology AG (7/05)
FACILITIES: Facilities in Switzerland and more than 50 countries worldwide
Expanding research and production facilities
STOCK-FINANCIAL HISTORY: Shares and nonvoting equity securities are listed on the Basel, Zurich and
Geneva stock exchanges
Sales CHF35.511b (YE 05) compared to CHF29.522b (YE 04)
Net income CHF6.730b (YE 05) compared to CHF7.063b (YE 04)
(YE 04)
SUBSIDIARIES/DIVISIONS: American subsidiaries include:
Hoffmann-La Roche Inc.--Nutley, N.J.
American Roche International Inc.--Clifton, N.J.
Genentech Inc.
Roche Holdings Inc.--Dover, Del.
Roche Diagnostic Systems Inc.--Indianapolis, Ind.
Roche Molecular Systems Inc.--Pleasanton, Calif.
Roche Professional Service Centers Inc.--Paramus, N.J.
Roche Bioscience
Divisions: pharmaceuticals, diagnostics
INVESTMENTS: Laboratory Corp. of America
Genentech--about 66%
Foundations:
Roche Research Foundation, Basel (1996)
Roche Organ Transplant Research Foundation--$16.5M (7/98)
BUSINESS STRATEGY: Focus on health care, especially innovative drugs, biotech products, and
molecular diagnostics
Invest in own research and form strong relationships with biotech companies
and universities
Use synergies between diagnostics and drug development to offer
integrated health care solutions

454 Life Sciences development, exclusive five-year 5/05
promotion, sale and worldwide
distribution of 454's agreement
Genome Sequencing
Systems
Actelion Ltd. development and exclusive 7/06

commercialization of worldwide
Actelion's selective collaboration
S1P1 receptor agonist
Affymetrix Inc. Genechip technology research 12/95
for research in agreement--joint
genomics development
agreement through
Roche Molecular
Systems
Alanex Corp. screening libraries 4/97
Ambit Biosciences Ambit's kinase- licensing 8/04
Corp. screening platform agreement
®
Ambrx Inc. next generation proteins development and 12/05

and peptides licensing
agreement
Amira two clinical-stage alliance and option 1/06
Pharmaceuticals compounds from Roche agreement
ArQule Inc. combinatorial chemistry 9/96
BioCryst development and exclusive licensing 11/05
Pharmaceuticals commercialization of agreement
Inc. BioCryst's BCX-4208
BioFocus (service BioFocus to supply three-year 4/06
division of Roche with chemical collaboration
Galapagos NV) compoound libraries
Borean Pharma Trimeric Apo A-I Roche to acquire 5/06
A/S
Caliper ultra high-throughput 10/96
screening (UHTS)
Cardinal Health Tamiflu manufacturing and 7/06
packaging
agreement
Cell Therapeutics Roche's bisplatinum worldwide licensing 12/04
compounds agreement
CombiChem Inc. combinatorial chemistry 12/96
Crucell NV Crucell's PER.C6 licensing 2/05
agreement
deCODE genetics phosphodiesterase 4 development and 11/04
Inc. (PDE4) inhibitors commercialization
agreement
deCODE genetics disease genes based five-year genomics 2/98
Inc. on studies of Iceland's collaboration--
relatively isolated Roche to make
populations equity investment,
provide research
funding and make
milestone
payments,
Entelos Inc. metabolic disease two-year 5/06
research collaboration
Epitomics Inc. Epitomics' rabbit licensing 10/05
monoclonal antibody agreement
technology (RabMab
technology)
Evotec AG two compounds for exclusive 1/06
Alzheimer's disease worldwide licensing
agreement
Evotec AG compounds against a discovery and 6/06
target for CNS diseases development
and other indications agreement
Exonhit identification of bovine research 7/02
Therapeutics SA spongiform agreement
encephalopathy (BSE),
or mad cow disease
Gene Logic Inc. Roche drug candidates drug repositioning 12/05
that did not pass Phase and development
II or III agreement
Genedata AG Genedata Screener multiyear 12/05
technology to estimate expansion of
the biological potency of existing
compounds collaboration
Genentech Inc. Herceptin (trastuzumab) exclusive marketing 7/98
for metastatic breast agreement outside
cancer the U.S.--Roche to
pay up-front fee
plus milestones
®
Genentech Inc. IL-8 and LFA/ICAM research 1994

antagonists collaboration
agreement
Genentech Inc. platelet GPIIb/IIIa research 1994
antagonists collaboration
agreement
Genentech Inc. DNase to treat cystic joint development 1992
fibrosis and chronic and joint marketing
bronchitis agreement
Glycart therapeutic antibodies development and 9/04
Biotechnology AG marketing
agreement
Hitachi High- laboratory automation collaboration 5/04
Technologies solutions in agreement
Corp. immunochemistry
market
Memory PDE4 inhibitors research 2002
Pharmaceuticals agreement,
Corp. extended 7/04,
amended 8/05
Millennium obesity and Type II development and 3/94
Pharmaceuticals diabetes worldwide licensing
Inc. agreement, Roche
has identified lead
obesity gene,
triggering an
undisclosed
milestone to
Millennium (4/98)
MorphoSys AG therapeutic antibodies R&D agreement, 9/00
against Alzheimer's expanded 3/06
disease
Pharmasset Inc. Pharmasset's hepatitis licensing and R&D 10/04
C drug program agreement
Praecis PPI-149 hormone development and 6/98
Pharmaceuticals antagonist marketing
Inc. agreement
Progenics T cell chemokine research contract 12/97
Pharmaceuticals receptor assays for HIV
Inc. drugs
Protein Design Zenapax (daclizumab) development and 9/04
Labs Inc. commercialization
agreement,
expanded 11/05
Sanofi-Aventis shikimic acid by production 3/06
fermentation for agreement
Roche's Tamiflu supply
chain
RESEARCH & DEVELOPMENT: Basic research:

Immunology, molecular biology, cell biology, gene regulation,
neurosciences, molecular oncology, virology and genome research
Pharmaceutical research:
Infectious diseases: antibacterials (Basel)
CNS disorders and chronic degeneration: antidepressants, antiparkinsonian,
drugs for the treatment of Alzheimer's disease; hypnotics, anesthetics
(Basel)
Cardiovascular diseases: antihypertensives, antithrombotics, chronic heart
failure and arteriosclerosis (Basel)
Metabolic diseases: obesity, NIDDM, osteoporosis (Nutley, NJ)
Peripheral nervous system disorders, inflammation/autoimmune diseases
(Palo Alto, CA)
Antifungal drugs (Kamakura, Japan)
Oncology (Penzberg, Bavaria)
®
Nonclinical development (Basel, Nutley, NJ)

Diagnostics:
Clinical chemistry, immunology, hematology, molecular diagnostics (PCR),
diagnostic equipment
PRODUCTS ON MARKET: Pharmaceutical specialties:
Antibacterials (Bactrim, Rocephin, Globocef)
Anticancer drugs (Roferon-A, Furtulon, Xeloda, Vesanoid, Mabthera)
Antidepressants (Aurorix)
Antiepileptic (Rivotril)
Antifungals (Loceryl)
Antimalarials (Fansidar, Lariam, Fansimef)
Antiparkinsonian (Madopar, Tasmar)
Antirheumatic, pain (Tilcotil, Naprosyn/Aneprox, Toradol)
Antivirals (Roferon-A, Hivid, Invirase/Fotovase, Viracept,
Cymevene/Cytovene)
Anxiolytics (Valium Roche, Lexotan, Nobrium, Librium)
Hypnotics and anesthetics (Dormicum/Versed, Rohypnol,
Dalmadorm/Dalmane)
Benzodiazepine antagonist (Anexate, Romazicon)
Cardiovascular (Inhibace, Ticlid, Cardene, Coreg, Dilatrend, Reteplase)
Dermatologicals (Accutane/Roaccutane, Tigason, Neotigason)
Hematological drugs (Neupogen, Recormon)
Immunosuppressant (Cellcept, Zenapax)
Metabolic drugs (Xenical, Rocaltrol, Euglucon, Cedur)
Others (Pulmozyme)
OTC drugs: vitamins, analgesics, antacids
FibroGen Inc.
225 Gateway Boulevard
South San Francisco CA 94080, US
Phone: (650) 866-7200; Fax: (650) 866-7201
Web: www.fibrogen.com; E-mail: info@fibrogen.com
KEY PERSONNEL: Thomas B. Neff; Chairman and CEO
Russell H. Ellison; VP, Clinical Development
William Hodder; VP, Business Development
Wilbert Lee; VP, CFO and Treasurer
David Y. Liu, Ph.D.; VP, Research
Claire J. Lockey; VP, Regulatory Affairs
Tim C. Opler; VP, Strategy
James W. Polarek, Ph.D.; VP, Collagen and Gelatin Development
Leanne C. Price; VP, Intellectual Property
David A. Yeowell, Ph.D.; VP, Product Development
HISTORY: Incorporated in September 1993
Began R&D operations in 1994
FACILITIES: FibroGen Inc.--South San Francisco, Calif. (Headquarters, R&D)
FibroGen Europe Corp.--Helsinki, Finland (R&D)
PRIVATE PLACEMENTS: 5 offerings totalling $94.1M (through 9/00)
Raised $100M from placement of convertible preferred stock (2/05)
FibroGen Europe Ltd.--2 offerings totalling $13.5M
SUBSIDIARIES/DIVISIONS: FibroGen Europe Corp.
Tukholmankatu 8 B (Biomedicum II)
FIN-00290 Helsinki Finland
Phone: +358 9 56 373 220
Fax: +358 9 56 373 224
®
PRINCIPAL INVESTORS: Adage Capital Management

Apothecary Capital
American Express
Astellas Pharma Inc.
Brookside Capital
BankInvest Biomedical Development
Bio Fund Ventures II Oy
Blue Anchor Holdings Corp.
Corriente Biotechnology Partners
Credit Suisse London Nominees
Duquesne Capital Management
Franklin Fairview
Franklin Templeton
Goldman Sachs
Janus Capital
Merlin BioMed Group
Och-Ziff Capital Management
The Parthenon Group
Pictet Bank
Privat Kredit Bank
The Rosewood Corp.
Sedgefield Investments
Sigma Capital Management
SITRA
SMBC Capital
Taisho Pharmaceutical Co. Ltd.
Three Arch Bay Health Science Fund I LP
T. Rowe Price
Wagner & Brown
BUSINESS STRATEGY: Discovery, development and commercialization of novel biomaterials and
therapeutics utilizing expertise in extracelluar matrix biology
Astellas Pharma rights to certain licensing 4/06
Inc. hypoxia-inducible factor agreement
prolyl hydroxylase
inhibitors for the
treatment of anemia,
including FG-2216 and
FG-4592, in Europe,
CIS, Middle East and
South Africa
Astellas Pharma FG-2216 in Japan licensing 9/04
Inc. agreement
Medarex Inc. human monoclonal development 1998
antibodies agreement
PPL Therapeutics recombinant collagen agreement for PPL 6/97
produced in transgenic to produce
animals recombinantcollage
n using transgenic
animals
TEKES recombinant collagen funding for 5/97
development of
recombinant
human collagen
technology for use
in medical and
commercial
applications
Thomas Jefferson collagen biosynthesis license agreement 11/95
University
University of CTGF research and 11/95
Miami development
agreement
®
University of Oulu, recombinant collagen research and 4/94

Finland license agreement
University of CTGF license agreement 6/95
South Florida
University of collagen biosynthesis research and 4/96
Wisconsin license agreement
Zeneca recombinant human process 3/99
LifeScience collagen development/
Molecules (now scale-up
AstraZeneca)
RESEARCH & DEVELOPMENT: Recombinant collagens and gelatin

Anti-fibrotic therapeutics
Wound repair/tissue engineering
FG-3019 (patients with diabetic in Phase Ib clinicals
nephropathy)
FG-3019 (patients with idiopathic completed Phase I
pulmonary fibrosis)
FG-3019 (patients with pancreatic cancer) IND filed
FG-2216 for anemia in Phase II clinicals
FG-4592 for iron processing deficiency in Phase I clinicals
FG-5017 - cosmetic dermal filler to begin pivotal efficacy and
safety trial in 2006
FG-4539 for ischemic disease in preclinicals
FG-5016 completed safety study
FG-5009 completed safety study
First Link (UK) Ltd.

1, Valepits Road, Garretts Green
Birmingham B33 0TD, UK
Phone: +44 121 783 8139; Fax: +44 121 786 2747
E-mail: info.firstlink@virgin.net
KEY PERSONNEL: Mick Terry; Director
Dr. Yvette Goward; Director and Company Secretary
HISTORY: Formed by original management of Advanced Protein Products Ltd. (1995)
BUSINESS STRATEGY: Research, develop, manufacture, and supply in field of biological chemicals,
especially contract manufacturing
RESEARCH & DEVELOPMENT: Large-scale media for mammalian cell culture

Contract process development
Develop culture media for transplantation of natural and artificial organs
PRODUCTS ON MARKET: High-purity bovine serum albumin and porcine serum albumin
Density gradient media for cell separation
Native and recombinant growth factors
Sera and proteins for cell culture and research
®
Fraunhofer Institute for Interfacial

Engineering and Biotechnology
Nobelstrasse 12
Stuttgart 70569, Germany
Phone: +49 (0) 7 11/9 70-40 01; Fax: +49 (0) 7 11/9 70-42 00
Web: www.igb.fraunhofer.de
E-mail: info@igb.fraunhofer.de
KEY PERSONNEL: Prof. Dr. Herwig Brunner; Managing Director
Dr. Steffen Rupp; Head, Department Molecular Biotechnology
Prof. Dr. Walter Troesch; Head, Department Environmental Biotechnology
and Bioprocess Engineering
Prof. Dr. Heike Mertsching; Head, Department Cell and Tissue Engineering
Dr. Christian Oehr; Head, Department Interfacial Technology and Material
Science
Dr. Gunter Tovar; Head, Department Biomimetic Interfaces
Dr. Thomas Schiestel; Head, Department Inorganic Interfaces and
Membranes
SUBSIDIARY OF: Fraunhofer-Gesellschaft
BUSINESS STRATEGY: New technologies for health, the environment and industry
RESEARCH & DEVELOPMENT: Molecular biotechnology for diagnostic, pharma, and fine chemistry:
Research in infectious diseases and drug screening, assay development,
biochip technologies (genomics and proteomics), protein expression,
fermentation and downstream processing.
Tissue Engineering for medical technology, diagnostics, drug development,

and individual therapy:
Three-dimensional organoid human test systems, biocompatibility testing, 3-
D autologous transplants, cell sorting and cell therapy, GMP-compliant
manufacturing of tissue engineering products.
Functional interfaces for technology and medicine:

Molecularly defined and smart surfaces, ultra-thin layers, biomimetic and
biofunctional surfaces, nanobiotechnology, nanoparticles, carbon
nanotubes, membranes.
Sustainable bioprocess engineering for industry, urban infrastructure and

the environment:
Reprocessing and conversion of organic raw and waste materials,
generation of biogas, wastewater purification and urban water management,
production of natural substances (vitamins, neutraceuticals) and energy by
microalgae.
PRODUCTS ON MARKET: Two-stage high performance plant for digestion of organic waste
In-Vitro whole skin model as test system
Cartilage transplant
®
Galderma SA
Tour Europlaza - La Defense 4, 20 avenue Andre Prothin
Levallois-Perret 92927, France
Phone: +33 1 58 86 45 45; Fax: +33 1 58 86 45 00
Web: www.galderma.com
E-mail: contactus@galderma.com
KEY PERSONNEL: Humberto C. Antunes; CEO
HISTORY: Founded in 1981 as a joint venture between Nestle and L’Oreal
FACILITIES: Headquarters in Switzerland
Three R&D centers (in France, the U.S. and Japan)
Three manufacturing sites (in France, Canada and Brazil)
SUBSIDIARIES/DIVISIONS: 32 affiliates
As the global leading company in dermatology, Galderma will contribute to
the treatment of dermatological diseases and conditions by developing and
marketing products to meet the needs of dermatologists and patients
RESEARCH & DEVELOPMENT: Acne, rosacea, psoriasis, seborrheic dermatitis, fungal nail infections,
melasma, non-melanoma skin cancer
PRODUCTS ON MARKET: Arcolan® (ketoconazole), Benzac® (benzoyl peroxide), Calmurid® (urea),
Capex® (fluocinolone acetonide), Cetaphil®, Clindagel® (clindamycin),
Clobex® (clobetasol), Desowen® (desonide), Differin® (adapalene),
Efficort® (hydrocortisone aceponate), Ell Cranell®/Avixis® (alpha-
oestradiol), Eryacne® (erythromycine), Loceryl® lacquer (amorolfine),
Metvix® (methylaminolevulinate), Nutracort® (hydrocortisone), Nutraderm®,
Nutraplus® (urea), Rozex®/Metro® (metronidazole), Silkis® (calcitriol),
Tetralysal® (oral lymecycline), Tri-Luma®
(hydroquinone/tretinoin/fluocinolone/acetonide)
Genencor International Inc.

925 Page Mill Road
Palo Alto CA 94304, US
Phone: (650) 846-7500; Fax: (650) 845-6507
Web: www.genencor.com
KEY PERSONNEL: Robert Mayer; Chairman and CEO
Thomas J. Pekich; President
Michael V. Arbige, Ph.D.; Sr. VP, Technology
Carole Beth Cobb; Sr. VP, Global Supply
HISTORY: Founded in 1990 as a joint venture between Eastman Chemical Co. and
Cultor Ltd.
Member--Enzyme Technology Association
Member--Soap and Detergent Association
Sold dairy and dietary enzyme business to Gist-brocades International BV
(7/97)
Acquired by Danisco A/S (4/05)
®
FACILITIES: European headquarters in Leiden

R&D Facilities in Palo Alto, Calif.; Leiden; Netherlands
Manufacturing facilities in Rochester, N.Y.; Wuxi, China; Arroyito, Argentina;
Hanko and Jamsankoski, Finland; Bruges, Belgium; and Beloit, Wis.
Formerly listed on NASDAQ--GCOR:
03)
SUBSIDIARY OF: Danisco A/S
BUSINESS STRATEGY: Develop, manufacture and market products for healthcare, agriculture,
industrial, and consumer markets using molecular biology and protein
chemistry
Ablynx Ablynx's Nanobody drug discovery 9/04
platform against tumor collaboration
targets specified by
Genencor
BioMarin Genencor to perform contract research 4/06
Pharmaceutical research services for agreement
Inc. BioMarin
CAMR sterilization process for R&D agreement 8/01
medical instruments,
rendered animal
material and human
blood supply
Cargill biocatalysts for wet corn exclusive supply 1/01
milling facilities agreement
Gyros microfluidics technology 5/01
collaboration
Integrated microbial genome licensing 9/01

Genomics sequencing agreement
technologies
Mayo Clinic transgenic mouse for cooperative R&D 1/01
celiac disease agreement
Protein Polymer Genencor biomaterials licensing and 12/00
Technologies and technology and development
personal care product agreement,
applications expanded 3/05
RESEARCH & DEVELOPMENT: Industrial enzymes for use in cleaning, textile, starch, animal feed, food and
biochemical industries
Protein chemistry and genetic engineering
High-expression fungal and bacterial technology
Fine and specialty chemicals based on novel biocatalysts and diols
technology
Biosynthetic peptides
Human Immunology platform
Conversion of biomass to ethanol to reduce the USA's dependence on
foreign oil
PRODUCTS ON MARKET: Through utilization of our i-biotech™ solution, more than 250 biotechnology
products, including:
IndiAge® and Primafast® (textile processing)
Laminex® (brewing enzymes)
Spezyme® (grain processing enzymes)
Multifect® (food enzymes)
Euro® (textile cellulases)
®
Xylanase enzyme for pulp and paper processing

Aromatic amino acids
L-sugars (food and pharmaceutical)
Purafect® (detergent enzymes)
Fermgen™ (acid fungal protease enzyme product)
Glucose oxidase and catalase for industrial and food use
Bioingredients in development
Biomaterials in development
Therapeutics in development
General Electric Global Research

1 Research Circle
Niskayuna NY 12309, US
Phone: (518) 387-7914; Fax: (518) 387-7911
Web: www.crd.ge.com
E-mail: info@ge.com
KEY PERSONNEL: Michael Idelchik; VP and Acting Director, GE Global Research
EMPLOYEES: 2,500 employees, 835+ Ph.D.s
HISTORY: Founded in 1900 as GE and the U.S.'s first industrial research laboratory
FACILITIES: 525-acre Global Research Center Headquarters campus in Niskayuna, N.Y.
STOCK-FINANCIAL HISTORY: NYSE--GE (parent)
SUBSIDIARIES/DIVISIONS: China Technology Center - Shanghai, China
John F. Welch Technology Centre - Bangalore, India
GE Global Research - Europe - Munich, Germany
Technicare--acquired from Johnson & Johnson (7/86)
SUBSIDIARY OF: General Electric Co.
INVESTMENTS: Progene Partners--joint venture with Proteus International and Genelabs
Technologies to design and develop DNA-binding drugs for viral infections
and cancer
BUSINESS STRATEGY: Develop innovative technology that ensures that the customer is always its
first beneficiary and use it to accelerate growth
U.S. Department TCE biodegradation joint research 9/98
of Defense agreement
U.S. Department PCB biodegradation joint research 7/99
of Energy agreement
U.S. TCE biodegradation joint research 9/94
Environmental agreement
Protection Agency
U.S. PCB biodegradation joint research 12/99
Environmental agreement
Protection Agency
U.S. Department TCE biodegradation joint research 9/97
of Energy agreement
RESEARCH & DEVELOPMENT: Core technology areas:
Biosciences: Research in applied biology and biomedicine, with an

emphasis in diagnostic imaging, pharmaceutical discovery technologies and
protein separations
Ceramic and Physical Metallurgy Technologies: Development of advanced

ceramic, composite, electronic, and metallic materials; material life and
®
reliability research; coating composition and process development; joining,

repair and refurbishment studies; and the utilization of novel processes
including high temperature, high pressure and thermal-mechanical, to
achieve the desired material responses for a broad range of products
Computing and Decisioning Sciences: Next generation solutions to take

health care to the next level of personalized medicine and to identify novel
biomedical applications for all GE industries
Electronics and Energy Conversion: Alternative energy and energy systems,

including wind, solar, solar desalination, renewable energy grids; electrical
power distribution and control technologies; mobile electric power systems;
electrical machines; communication systems: controls, diagnostics and
embedded controls and systems; sensor, security and lighting electronics
systems; optoelectronic devices and systems; electrophysics,
electrophysiology, plasma systems, high voltage and vacuum electronics
Energy and Propulsion Technologies: Developing low-emissions combustion

for gas turbines, aircraft engines, and locomotives; fuel Cells, micro turbines,
and other advanced distributed power generation systems; computational
and experimental fluid dynamics for turbo machinery and other components
of aircraft engines and power plants; cooling and sealing technologies for
propulsion, power generation and other industrial and consumer products;
propulsion technology beyond conventional turbine engines and diesels;
technology for remote monitoring and prognostics of high-value assets
towards condition-based maintenance; technologies for hydrogen production
from coal, natural gas and water; coal gasification and integrated
gasification combined cycle; and methods of liquid fuel purification and
conversion
Imaging Technologies: New applications for imaging in both the security and
industrial non-destructive testing spaces, molecular imaging
Material Analysis and Chemical Sciences: Analysis of materials to

understand their chemical composition, surface and bulk structure and
physical properties; development of chemical and biological sensors,
especially the sampling technology and detection chemistry; high-throughput
experimentation to accelerate materials discovery as accomplished via
creation of materials in miniaturized arrays using automation, followed by
rapid testing for desirable properties; application of chemistry and chemical
engineering to environmental issues, such as pollution prevention,
remediation, environmental monitoring and water treatment; and toxicology,
especially as applied to environmental and health issues
Material Systems Technologies: Development of high-performance material

systems to deliver new product breakthroughs and applications for GE
businesses and customers
Micro and Nano Structures Technologies
Polymer and Specialty Chemical Technologies: Development of new and

specialized materials for GE’s Industrial Business, water technologies
(membranes and coatings) and in support of alternate energy activities
(wind turbines, fuel cells and photovoltaics); identification of emerging
technologies (such as nanotechnology, photonics and organic light emitting
diodes)
In addition, GE has an increased focus on six advanced technology

programs:
Molecular imaging and diagnostics
Nanotechnology
Pulse detonation propulsion
Sustainable energy
Energy conversion
®
Genesearch Pty. Ltd.

Gold Coast Technology Park, 14 Technology Drive
Arundel 4214, Australia
Phone: +61 7-5594-0299; Fax: +61 7-5594-0562
Web: www.genesearch.com.au
E-mail: info@genesearch.com.au
KEY PERSONNEL: Dr. John L. Reichelt; CEO
Dr. Robin Craig; Director, R&D
Dr. Bonni Y. Reichelt; Director, R&D
Sarah Reichelt; Scientist
Keith Pyle; Scientist
Joy Pyle; Scientist
Tim Reichelt; Administration
SUBSIDIARIES/DIVISIONS: Ecosearch (waste treatment)
BUSINESS STRATEGY: Conduct in-house R&D to develop products internally, as well as contract
research in microbial genetics and fermentation
RESEARCH & DEVELOPMENT: R&D is focused on:

Enzymes for molecular biology
Microalgal products
Bioplastics
Bioinsecticides
Waste treatment products and processes
Probiotics
Silage inoculants
Microbial genetics and fermentation
The company performs in-house R&D to develop its own products, and
conducts contract research in microbial genetics and fermentation,
including: Industrial and feed chemicals from bacteria (e.g. amino acids),
biodegradable plastics from bacteria grown on sugar, and biopesticides
PRODUCTS ON MARKET: Restriction enzymes
Ecobac powdered bacterial product for waste treatment
Waste treatment processes for food wastes
Si-Lac silage inoculant
®
Geneva Scientific
P.O. Box 408
Fontana WI 53125, US
Phone: (262) 245-1500; Fax: (262) 245-6678
Web: www.geneva-scientific.com
E-mail: john@geneva-scientific.com
KEY PERSONNEL: John Urlakis; President
PRODUCTS ON MARKET: Laboratory equipment

Caseworks
Fume hoods
Autoclaves
Sterilizers
Bio safety cabinets
Glassware washers
Rack washers
Tunnel washers
Refractometers
Environmental rooms
Refrigerators and freezers
Scraping stations
Downdraft tables
Backdraft stations
Hydraulic tables
Vacuum waste management and disposal systems
Automated dump stations
Bulk bag bedding vacuum transfer systems
Automated bedding dispensers
Necropsy tables
Genomatica Inc.
5405 Morehouse Drive, Suite 210
Phone: (858) 824-1771; Fax: (858) 824-1772
Web: www.genomatica.com
E-mail: info@genomatica.com
KEY PERSONNEL: Christophe Schilling, Ph.D.; President and CSO
Thomas Reed; VP, Finance and Corporate Development
FINANCIAL INFORMATION: Received a $750K Phase II Small Business Innovation Research Grant from
the U.S. Department of Energy (9/04)
BUSINESS STRATEGY: As a leader in computational systems biology, use validated technology to
deliver industry-leading solutions for the modeling and simulation of
metabolis. These solutions drive a powerful new paradigm wherein
computer models are used to accelerate biological research and discovery
across the life sciences. To advance to frontiers of biological discovery and
the development of innovative products in medical and industrial
biotechnology while streamlining existing product development and
enhancing the overall business efficiency of our clients
®

DSM Genomatica's licensing agreement 4/05
SimPheny
DSM implementation of expanded multi-year 6/06
Genomatica's metabolic collaboration and
modeling and simulation licensing agreement
technologies and
capabilities to help DSM
develop improved
biological processes for
product production
Kyowa Hakko Genomatica's modeling licensing agreement 1/05
Kogyo Co. Ltd. and simulation platform
Unilever expansion of projects multi-year 8/06
started in 2005--use of collaboration and
Genomatica's metabolic licensing agreement
modeling and simulation
technologies to develop
ingredients to improve
Unilever products
RESEARCH & DEVELOPMENT: Computational systems biology

Medical and industrial biotechnology
PRODUCTS ON MARKET: SimPheny™ modeling platform
Gentra Systems Inc.

13355 10th Avenue N, Suite 120
Minneapolis MN 55441, US
Phone: (763) 543-0678; Fax: (763) 543-0699
Web: www.gentra.com
E-mail: info@gentra.com
KEY PERSONNEL: Ruth M. Shuman, Ph.D.; CEO and President
Dennis Thalhuber; CFO
Robert Kwiatkowski, Ph.D.; VP, R&D
Acquired by Qiagen NV (5/06)
BUSINESS STRATEGY: Develop and market manual and automated nucleic acid purification
products that address the need for high quality nucleic acid, ease of use and
increased throughput for clinical and clinical research laboratories
RESEARCH & DEVELOPMENT: Nucleic acids purification

PRODUCTS ON MARKET: DNA and RNA purification products including:
Puregene® DNA Purification Kit
Generation®
Purescript®
Autopure ls® DNA Purification Instrument
Versagene™ RNA
Versagene™ RNA purification Kit
Clotspin® De-clotting Tubes
Autotech Automated Nucleic Acid Purification Instrument
®
Genzyme Corp.
500 Kendall Street
Phone: (617) 252-7500; Fax: (617) 252-7600
Web: www.genzyme.com; E-mail: info@genzyme.com
KEY PERSONNEL: Henri A. Termeer; Chairman, President and CEO
Mara G. Aspinall; President, Genetics
Mark R. Bamforth; Sr. VP, Corporate Operations and Pharmaceuticals
John Butler; President, Genzyme Renal
Earl M. Collier Jr.; Exec. VP, Cardiovascular and Oncology
Thomas J. DesRosier; Sr. VP, General Counsel and Chief Patent Counsel
Richard H. Douglas, Ph.D.; Sr. VP, Corporate Development
David D. Fleming; Group Sr. VP
Georges Gemayel; Exec. VP, Therapeutics, Transplant and Renal
James A. Geraghty; Sr. VP
Elliott D. Hillback Jr.; Sr. VP, Corporate Affairs
Alison Lawton; Sr. VP, Regulatory Affairs and Corporate Quality Systems
Evan M. Lebson; VP and Treasurer
Roger W. Louis; VP, Healthcare and Regulatory Counsel and Chief
Compliance Officer
Mary McGrane; VP, Government Relations
John M. McPherson, Ph.D.; Sr. VP, Cell and Protein R&D
David Meeker, M.D.; President, Lysosomal Storage Disorder Therapeutics
Ann Merrifield; President, Genzyme Biosurgery
Richard A. Moscicki, M.D.; Sr. VP, Medical, Clinical and Regulatory Affairs
and CMO
Donald E. Pogorzelski; President, Genzyme Diagnostics
Alan E. Smith, Ph.D.; Sr. VP, Research and CSO
Sandford D. Smith; President, International Group
Peter T. Traynor; VP and Corporate Controller
Peter Wirth; Exec. VP, Legal, Corporate Development and Drug Discovery,
Chief Legal Officer and Secretary
Michael S. Wyzga; Exec. VP, Finance, CFO and CAO
HISTORY: Founded in June 1981 by Henry Blair and Sherry Snyder
Began operations by acquiring Whatman Biochemicals Ltd., U.K.
Founded 16 labs (1990)
Formed Neozyme Corp. to fund development of programs (10/90)
Formed Neozyme II to fund the research, development, and clinical testing
of biotherapeutic products for the treatment of cystic fibrosis (4/92)
Subsidiary IG Laboratories Inc. purchased Genetic Design Inc., a privately
held genetic testing company (6/92)
Acquired phospholipid business of Enzymatix Ltd. (6/92)
Acquired Medix Biotech Inc. (6/92)
Acquired Vivigen Inc., in exchange for stock valued at $40M (11/92)
Neozyme I buyback of four programs, $49M (12/92)
Established Genzyme Transgenics (now GTC Biotherapeutics) for
producing human biotherapeutic products in the milk of transgenic animals
(2/93)
Acquired diagnostic business Virotech System-Diagnostika GmbH (4/93)
Acquired diagnostic business Omnia Res srl (5/93)
Neozyme I buyback of two programs, $49M (12/93)
Acquired Swiss pharmaceutical manufacturer, Sygena Ltd. (7/94)
Subsidiary Genzyme Transgenics purchased TSI, a publicly held clinical
testing and production company (10/94)
Created Genzyme Tissue Repair by acquiring BioSurface Technology Inc.
and combining with several of Genzyme Corp.'s tissue repair programs
(12/94)
Acquired all shares of IG Laboratories Inc. (9/95)
®
Formed Aristogen GmbH with Symbiomed (Germany) to offer genetic

diagnostic services in Germany (3/96)
Acquired Genetrix Inc. (4/96)
Acquired Deknatel Snowden Pencer Inc., $250M (7/96)
Neozyme II Corp. buyback, $109M (9/96)
Formed Genzyme Molecular Oncology Division after acquisition of
PharmaGenics Inc. (6/97)
Acquired ABIOMED Inc. for $15M (7/97)
Sold research products business to Techne Corp. for $65.5M (6/98)
Acquired GelTex Pharmaceuticals Inc. (12/00)
Acquired Novazyme Pharmaceuticals (9/01)
Ceased trading of Genzyme Biosurgery and Genzyme Molecular Oncology
stock (7/03)
Acquired Sangstat Medical Corp. (12/03)
Acquired ILEX Oncology Inc. (12/04)
Acquired Verigen AG (2/05)
Acquired Bone Care International (7/05)
Acquired AAV gene therapy assets from Avigen Inc. (12/05)
FACILITIES: 75 locations in 32 countries, including 15 manufacturing facilities and 9
genetic testing laboratories
STOCK-FINANCIAL HISTORY: NASDAQ--GENZ
IPO--2.9M common shares at $10/share (6/86)
Public offering--2.9M common shares at $13.125/share (12/89)
Public offering--4.025M shares of common stock at $35.50/share (3/91)
Authorized shares of Genzyme Corp. common stock redesignated as
General Division Common Stock (GENZ); second class of common stock,
Tissue Repair Division common stock (GENZL), authorized to effect
acquisition of BioSurface Technologies (12/94)
Two-for-one stock split (7/96)
04)
PRIVATE PLACEMENTS: $10M RDLP to fund clinicals and manufacturing of GCR for Gaucher's
disease (closed 9/87)
Formed $36.75M limited partnership to fund development of surgical
products (11/89)
$100M of 6.75% convertible subordinated notes due Oct. 2001 (10/91)
Sold $250M in 5.25% convertible subordinated notes due 2005 (5/98)
SUBSIDIARIES/DIVISIONS: Genzyme General Division
Genzyme Biosurgery Division
Genzyme Molecular Oncology Division
Genzyme de Argentina SA
Genzyme do Brasil Ltda.
Genzyme Chile Ltda.
Genzyme Colombia SA
Genzyme Mexico S. de RL de CV
Genzyme Middle East FZ LLC
Genzyme Turkey Ltd.
Genzyme Israel Ltd.
Genzyme Austria G.m.b.H
Genzyme Flanders BVBA/SPRL--Belgium
Genzyme Belgium NV/SA
Genzyme Europe BV--Czech Republic
Genzyme A/S--Denmark
Genzyme SAS--France
Genzyme Polyclonals SAS--France
Genzyme GmbH--Germany
Genzyme CEE GmbH--Germany
®
Genzyme Virotech GmbH--Germany

Genzyme Hellas LLC--Greece
Genzyme Europe BV Kepviselet--Hungary
Genzyme Ireland Ltd.
Genzyme Italy
Genzyme Polska Sp. z o.o.--Poland
Genzyme Portugal
Genzyme Barcelona
Genzyme Madrid
Genzyme GmbH--Switzerland
Genzyme Sygena--Switzerland
Genzyme Cambridge--U.K.
Genzyme Ltd.--U.K.
Genzyme Oxford--U.K.
Verigen Australia Pty. Ltd.--Australia
Genzyme China
Genzyme Asia Ltd.
Genzyme Tokyo
Genzyme Korea
Genzyme Singapore Pte. Ltd.
Genzyme GmbH Russia
Genzyme Taiwan
INVESTMENTS: Genzyme Clinical Partners LP--reacquired the assets for 1.4M shares of
Genzyme common stock (2/90)
RenaGel LLC--joint venture with GelTex Pharmaceuticals, Inc. to handle
development and commercialization of GelTex's RenaGel non-absorbed
phosphate binder
Abiomed Inc.--14%
50/50 joint venture with Genzyme Transgenics Corp.--$33M (7/97)
Joint venture with BioMarin Pharmaceutical Inc.
Joint venture with Pharming Group NV (7/98)
Acadia Acadia's cell-based collaborative 10/97
Pharmaceuticals screening technology screening
Inc. and Genzyme's library agreement
of more than 1M
compounds
Alcon Labs ophthalmic products supply agreement 12/86
(Nestle) using hyaluronic acid
such as Surgicoat
Angiotech identification, strategic 5/06
Pharmaceuticals development and collaboration
Inc. commercialization of agreement
therapies for cancer
patients undergoing
surgical removal of
tumors
Aronex Atragen development and 3/97
Pharmaceuticals marketing
Inc. agreement (9/93),
amended--
Genzyme has
option to
commercialize
ArQule Inc. drug candidates for development 4/97

identifying cancer, agreement--ArQule
infectious diseases and to provide
autoimmune/inflammato Genzyme with
ry diseases access to Mapping
Array program for
identifying new lead
compounds against
Genzyme's targets
®
Bayer AG Genzyme's small licensing 12/97

molecule library agreement--
Genzyme will
receive up-front
and service fees
and milestones
Behringwerke AG amylase substrate licensing 11/91
agreement
Biogen Idec Inc. Avonex (interferon beta- commercialization 9/98
1a) for MS and exclusive
distribution
agreement for
Japan
Celtrix TGF-B2 for tissue product 6/94
Pharmaceuticals repair, treatment of MS, development,
Inc. and other systemic licensing, and
applications marketing
agreement through
Genzyme Tissue
Repair
Crucell NV production of nonexclusive STAR 12/05
monoclonal antibodies research licensing
agreement
Cubist small molecule drug discovery 3/97
Pharmaceuticals compounds targeting alliance--Cubist will
Inc. bacterial and fungal screen Genzyme's
infections compound library,
once potential
therapeutic
compounds are
discovered, Cubist
and Genzyme will
negotiate
development terms
Cyclacel Group Licensing of two of option agreement 9/05
plc Cyclacel's Cyclin-
Dependent Kinase
inhibitors
Daiichi Pure HDL cholesterol blood distribution 1/96
Chemicals Co. test agreement
Ltd.
De Novo De Novo to apply its drug discovery 1/06
Pharmaceuticals molecular structure collaboration
Ltd. generating technology agreement
to focus on a disease
target that is of interest
to Genzyme
DiagnoCure Inc. 40 genes for potential licensing 11/05
use in detecting lung agreement
cancer
Dyax Corp. Dyax's phage display non-exclusive 1996
patents patent licensing
agreement,
including signing
fees, milestone
payments and
royalties, Dyax gets
access to related
patented
technology owned
by licensee
Dyax Corp. Dyax's human plasma letter of intent for 12/98
Kallikrein inhibitor (EPI- development
KAL-2) agreement
®
Dyax Corp. antibody phage-display license and 6/04

libraries for the research
discovery of human agreement
antibodies
GelTex RenaGel phosphate development and 6/97
Pharmaceuticals binder commercialization
Inc. agreement--
Genzyme to pay
GelTex up to
$27.5M upon FDA
approval of product
Imperial Cancer gene therapies for development 1/96
Research Fund cancer agreement
(ICRF)
Institut Merieux glucocerebrosidase technology license 9/89
(GCR) products to treat and supply
Gaucher's disease agreement
IntroGene BV gene therapy for licensing 10/94
(Netherlands) Gaucher's disease agreement--
Genzyme to make
equity investment
and provide
research,
milestone, and
royalty payments
Johns Hopkins cardiovascular gene devleopment 5/98
University School therapy collaboration
of Medicine
Kaken Seprafilm and marketing 2/97
Pharmaceutical Sepracoat for agreement for
Co. Ltd. prevention of post- Japan
operative adhesions
LeukoSite Inc. drug candidates for screening 6/97
treating autoimmune agreement--
and inflammatory LeukoSite will have
diseases access to more
than 800K
compounds in
Genzyme's library
and will screen
against its
biological targets
related to cell
adhesion and
inflammatory bowel
disease; after
screening is
complete,
companies will
negotiate research
collaboration
covering
development and
commercialization
of compounds
discovered in
screening
Macrozyme Corp. exploration of exclusive 11/05
applications of collaboration
Macrozyme's small
molecule library
Mass General gene therapy development 6/97
Hospital treatments for chronic collaboration
hepatitis B and liver
cancer
®
Medtronic Inc. treatments for joint venture named 6/04

cardiovascular disease MG Biotherapeutics
Molecular MI's BioMerge software licensing 7/97
Informatics Inc. to integrate and analyze agreement
genomics information
National Cancer gene therapy for three-year 10/96
Institute metastatic melanoma collaborative R&D
agreement
Partners research in oncology, non-exclusive basic 9/97
HealthCare orthopedics, tissue and clinical
System repair, genetic research alliance--
metabolic diseases, Genzyme to
cardiovascular disease, provide research
surgical research, tools, probes and
genetics, gene therapy reagents, Genzyme
and neurology to provide $300K
grant to fund
exchange program
RenaMed development and strategic 9/05
Biologics Inc. commercialization of collaboration
RenaMed's Bio-
Replacement
Therapy™
St. Elizabeth's cardiovascular gene development 5/98
Medical Center therapy collaboration
Tm Bioscience undisclosed development and 11/04
Corp. supply agreement
University of gene mutations licensing 10/05
California at Los believed to be agreement
Angeles (UCLA) associated with drug
Jonsson Cancer resistance to Gleevec®
Center
University of gene therapy for research 11/94
Pittsburgh Gaucher's disease collaboration
agreement
Valentis Inc. Valentis' GeneSwitch expanded licesing 9/04
technology, Genzyme's agreement
static mixer intellectual
property
ViaCell Inc. diabetes R&D agreement 3/05
Vical Inc. nonviral vector gene multiyear R&D 10/90
therapies for treating agreement--
cystic fibrosis using includes option for
Vical's cytofectins Genzyme to
exclusively license
Vical's cytofectins
for CF therapy in
exchange for
licensing fee, as
well as research,
milestone, and
royalty payments
(10/93), Genzyme
paid $1M in
exercise of option
for exclusive
license
Wyeth Synvisc Genzyme to buy 11/04
Pharmaceuticals back rights in USA
and five European
countries
RESEARCH & DEVELOPMENT: Chronic kidney disease, cancer treatments, transplantation medicine,
autoimmune disease, orthopaedics, adhesion prevention, cardiovascular
disease, diagnostic products and services
®
PRODUCTS ON MARKET: Lysosomal Storage Disorders

Cerezyme® (imiglucerase for injection) for Type 1 Gaucher disease
Fabrazyme® (agalsidase beta) for Fabry disease
Aldurazyme® (laronidase) for Mucopolysaccharidosis I
Myozyme® (alglucosidase alfa) for Pompe disease
Renal Disease
Renagel® (sevelamer hydrochloride)
Hectorol® (doxercalciferol)
Orthopaedics
Synvisc® (hylan G-F 20)
Carticel® (autologous cultured chondrocytes)
MACI®, (Matrix-induced Autologous Chondrocyte Implantation)
Transplant and Immune Diseases

Thymoglobulin® (anti-thymocyte globulin, rabbit)
Oncology
Campath® (alemtuzumab for injection) for the treatment of B-cell chronic
lymphocytic leukemia
Clolar® (clofarabine for intravenous infusion)
Thyrogen® (thyrotropin alfa for injection)
GL Biochem (Shanghai) Ltd.

351 Guo Shoujing Road
Shanghai 201203, China
Phone: +86 21-54925326; Fax: +86 21-64189186
Web: www.glschina.com; E-mail: glsync@online.sh.cn, glsync@hotmail.com
KEY PERSONNEL: Hongyan Xu, Ph.D.; President
Zhou Min; General Manager
FACILITIES: 17,000 sq. m. manufacturing facility
BUSINESS STRATEGY: Research, develop, manufacture and market diverse biochemicals and fine
chemicals, especially peptide, peptide reagents and related products
PRODUCTS ON MARKET: Coupling reagents

Labeling reagents
Linkers for solid phase synthesis
N-protecting reagents
Unusual amino acids
Amino acids derivatives
Boc-amino acids
Fmoc-amino acids
Z-amino acids
Amino alcohols
N-methyl amino acids
Fmoc-amino acids attached to wang resin
Amino acids attached to 2-chlorotrityl-chloride-resin
Resins
Generic and custom peptides
Specialty chemicals
Custom peptide synthesis
Custom antibody services
Custom organic synthesis
®
HaloSource Inc.
14716 NE 87th Street
Redmond WA 98052, US
Phone: (425) 881-6464; Fax: (425) 882-2476
Web: www.halosource.com
E-mail: info@halosource.com
KEY PERSONNEL: John Kaestle; President and CEO
Jeffrey F. Williams, Ph.D.; Sr. VP and CTO
James Thompson; VP and CFO
Everett J. Nichols, Ph.D.;VP, R&D
Eric B. Robinson; VP, Operations
Merged with HaloSource Corp. (5/02)
Changed name from Vanson Inc.
Changed name from Vanson HaloSource Inc. (2/06)
PRIVATE PLACEMENTS: Raised $5M in financing (3/05)
PRINCIPAL INVESTORS: Mars Inc.
Alexander Hutton Venture Partners LP
Buerk Dale Victor LLC
BUSINESS STRATEGY: Provide reliable, tested and proven solutions in the product categories of
safe water, infection control and healing enhancement
RESEARCH & DEVELOPMENT: Antimicrobial and disease prevention solutions that reliably and effectively
kill germs
PRODUCTS ON MARKET: HaloPure®--Drinking water purification solutions
SeaKlear®--Water treatment solutions for the pool and spa industry
StormKlear® and Klarify®--Waste and storm water treatment solutions
HaloPure FT™--Industrial fluid treatment solutions
HaloShield®--Coating solutions that harness the antimicrobial power of
chlorine
Biomedical--Hemostasis and wound-healing solutions
Hammen Corp.
4200 Fox Farm Road
Missoula MT 59802, US
Phone: (406) 728-5897; Fax: (406) 728-5924
KEY PERSONNEL: Richard F. Hammen, Ph.D.; President
Mary Gordon; Manager, Marketing
FACILITIES: Headquarters, executive offices, and laboratories located in Missoula, Mont.
PRINCIPAL INVESTORS: Montana Science & Technology Alliance (MSTA)
®
BUSINESS STRATEGY: Seek partners to develop technology for removal of toxic metals from water
and to develop drug master files for biotechnology products
PRODUCTS ON MARKET: HiPAC® affinity chromatography columns
Harvard Bioscience Inc.

84 October Hill Road
Holliston MA 01746, US
Phone: (508) 893-8066; Fax: (508) 429-5732
Web: www.harvardbioscience.com
E-mail: info@harvardbioscience.com
KEY PERSONNEL: Chane Graziano; CEO
David Green; President
Susan Luscinski; COO
Bryce Chicoyne; CFO
Mark Norige; COO, Harvard Apparatus
David Strack; President, Genomic Solutions and Union Biometrica
David Parr; Managing Director, Biochrom
HISTORY: Founded in March 1996, when it acquired a portion of the assets of Harvard
Apparatus (founded in 1901)
Changed name from Harvard Apparatus Inc. (12/00)
Asys Hitech GmbH acquired select assets of the microplate reader and
washer product lines from Anthos Labtec Instruments GmbH (6/06)
FACILITIES: 43,750 sq. ft. leased facility in Holliston, Mass. (corporate headquarters)
28,000 sq. ft. leased facility in Cambridge, U.K.
22,600 sq. ft. leased facility in San Francisco, Calif.
18,000 sq. ft. leased facility in Warwickshire, U.K.
15,500 sq. ft. owned facility in Edenbridge, U.K.
9,000 sq. ft. leased facility in March-Hugstetten, Germany
7,500 sq. ft. leased facility in Hamden, Conn.
4,700 sq. ft. leased facility in Eugendorf, Austria
Additional leased facilities for sales and administrative support in Geel,
Belgium; Les Ulix, France; and Montreal, Canada
STOCK-FINANCIAL HISTORY: NASDAQ--HBIO
IPO--7.4M shares, $58.9M (12/00)
Net income <$31.877M> (YE 05) compared to $2.329M (YE 04)
Earnings per share <$1.05/share> (YE 05) compared to $0.08/share (YE
04)
04)
SUBSIDIARIES/DIVISIONS: HBIO Securities Corp.--U.S.
Harvard Apparatus FSC Inc.--U.S. Virgin Islands
Warner Instruments LLC--U.S.
Union Biometrica Inc.--U.S.
Harvard Apparatus Ltd.--U.K.
Harvard Apparatus SARL--France
Biochrom Ltd.--U.K.
Scie-Plas Ltd.--U.K.
Asys Hitech GmbH--Austria
Hugo Sachs Elektronik Harvard Apparatus GmbH--Germany
Union Biometrica GmbH--Germany
Maia Scientific NV--Belgium
Ealing Scientific Ltd. Canada (dba Harvard Apparatus, Canada)
Genomic Solutions Inc.--U.S.
®
Cartesian Technology Inc.--U.S.

Genomic Solutions Ltd.--U.K.
Genomic Solutions Canada Inc.--U.S.
Genomic Solutions Inc.--Canada
Hoefer Inc.--U.S.
KDS Inc.--U.S.
BUSINESS STRATEGY: Have a broad range of specialized products that hold strong positions in
niche markets focused on the bottlenecks in drug discovery research in
order to reduce the risk of being dependent on a single technology, to
reduce head-to-head competition; and to position ourselves to achieve
above-average revenue growth and above-average margins
RESEARCH & DEVELOPMENT: Focus is on the development of products that address bottlenecks within the
drug discovery process, in particular, for application in the areas of ADMET
screening, molecular biology, genomics, proteomics and high-
throughput/high-content screening
PRODUCTS ON MARKET: ADMET screening products, including absorption diffusion chambers, 96
well equilibrium dialysis plate for serum protein binding assays, organ
testing systems, precision infusion pumps, cell injection systems, ventilators,
electroporation products
Molecular biology products, including spectrophotometers;
DNA/RNA/Protein calculators; multi-well plate readers; amino acid analysis
systems; low volume, high-throughput liquid dispensers; gel electrophoresis
systems
Hawaii Biotech Inc.

99-193 Aiea Heights Drive, Suite 200
Aiea HI 96701, US
Phone: (808) 486-5333; Fax: (808) 792-1343
Web: www.hibiotech.com
E-mail: info@hibiotech.com
KEY PERSONNEL: Nicholas Mitsakos; Chairman
David G. Watumull; President and CEO
Samuel F. Lockwood, M.D.; Medical Director
Carolyn Weeks-Levy, Ph.D.; VP, Research, Preclinical Development and
Regulatory Affairs
Richard L. Sherman; Sr. VP, Business Development and General Counsel
Merged vaccine business with Avantogen Ltd.'s vaccine business (5/06)
FACILITIES: 9,000 sq. ft. headquarters and R&D facility
PRIVATE PLACEMENTS: Raised $8.5M in Series A financing
Raised $4M in federal funding (2003)
Raised $8M (2004)
Raised $7.8M in Series C financing (1/06)
INVESTMENTS: PanThera Biopharma Inc.
FINANCIAL INFORMATION: Received $15.5M through three awards from the NIH for West Nile Virus
and dengue vaccine development (12/04)
®

Avantogen Ltd. evaluation of worlwide, 10/05
Avantogen's GPI-0100 nonexclusive
licensing
agreement
Cobra material for clinical trials manufacturing and 3/05
Biomanufacturing of vaccines against supply agreement
plc dengue fever and West
Nile disease
RESEARCH & DEVELOPMENT: rDNA, cell tissue culture, purification (lab-scale), hybridoma/cell fusion
Dengue vaccine
Immunoassays for marine natural products
Taxol immunoassays
Prodrugs
Enteric pathogens
PRODUCTS ON MARKET: Immunoassay kits for Taxol and Taxanes
Marine toxins for palytoxins and derivatives lyngbyatoxin A
Antitoxin moonoclonal antibodies for mAG 73D3, neutralizing anti-palytoxin;
mAGT20G110, neotralizing antitetrodotoxin
Helmholtz Centre for Infection Research

Mascheroder Weg 1
Braunschweig D-38124, Germany
Phone: +49 (0) 531-6181-0; Fax: +49 (0) 531-6181-515
Web: www.helmholtz-hzi.de
E-mail: info@helmholtz-hzi.de
KEY PERSONNEL: Dr. Peter Lange; Chairman, Supervisory Board
Prof. Rudi Balling; Scientific Director
Dr. Georg Frischmann; Administrative Director
HISTORY: Founded by Stiftung Volkswagenwerk in 1965
State-owned research institute since 1976
Changed name from Gesellschaft fur Biotechnologische Forschung mbH
(German Research Centre for Biotechnology) (7/06)
Member--Hermann von Helmholtz-Gemeinschaft Deutscher
Forschungszentren (HGF)
Partner--BioRegioN
STOCK-FINANCIAL HISTORY: Private government agency
PRINCIPAL INVESTORS: German Federal Government (BMBF)--90%
State of Lower Saxony--10%
BUSINESS STRATEGY: Establish collaborative agreements with industrial partners and universities
Contract manufacturing and research for clients from universities and
industry
Non-profit organization (governmental research centre)
Research and development, technology transfer via patents, licensing
National and international cooperation with universities, institutes and
companies
RESEARCH & DEVELOPMENT: Cell and immune biology

Microbiology
Molecular biotechnology
Structural biology
Biochemical engineering
®
Hercules Inc.
Hercules Plaza, 1313 North Market Street
Wilmington DE 19894-0001, US
Phone: (302) 594-5000; Fax: (302) 594-5400
Web: www.herc.com
E-mail: info@herc.com
KEY PERSONNEL: Craig A. Rogerson; President and CEO
Edward V. Carrington; VP, Human Resources
Richard G. Dahlen; Chief Legal Officer
Israel J. Floyd; Corp. Secretary and General Counsel
John E. Panichella; VP and President, Aqualon
Paul C. Raymond III; VP and President, Paper Technologies and Ventures
Group
Allen A. Spizzo; VP and CFO

Sold Aerospace division for $439M to Alliant Techsystems (3/95)
Acquired Quantum Hi-Tech Co. Ltd. (12/03)
Agreed to purchase the guar and guar derivative manufacturing business of
Benchmark Polymer Products LP (subsidiary of Benchmark Performance
Group Inc.) (1/06)
STOCK-FINANCIAL HISTORY: NYSE--HPC
Three-for-one stock split (1/95)
Net income <$29.8M> (YE 05) compared to $28.1M (YE 04)
Earnings per share <$0.27/share> (YE 05) compared to $0.26/share (YE
04)
SUBSIDIARIES/DIVISIONS: Two major operating segments:
Aqualon Group:
Aqualon--Leader in products that modify the physical properties of water-
based systems
Pinova--Leader in pine chemistry since 1920, the world's only pale wood
rosin derivatives producer
Paper Technologies and Ventures Group
BUSINESS STRATEGY: Continuously improve to better serve our customers and extend our
competitive advantage
Maximize cash flow, reduce financial leverage and return to investment
grade credit rating
Grow profitably and increase ROIC
Mitigate and reduce legacy liabilities
Barbara Ann citrus pectin for cancer R&D agreement 12/95
Karmanos Cancer
Institute (Wayne
State University),
University of
Michigan
Uniqema synthetic lubricants extended 7/06
(business of ICI manufacturing
Americas) agreement
RESEARCH & DEVELOPMENT: In-house program in functional foods

Biochemical production of natural food ingredients via fermentation and
enzyme processing, pharmaceutical coatings, excipients, nutraceuticals
®
PRODUCTS ON MARKET: Aqualon--thickeners used in water-based products such as latex paint

FiberVisions--staple fiber used in hygienic products and automotive textiles
Pinova--adhesives, flavor and beverage, construction, fragrance, household
and industrial
Pulp and Paper--solutions for pulp and paper manufacturing needs
Industrial Specialities--thickeners used in water-based products such as
latex paint
Hidex Oy
Mustionkatu 2
Turku 20750, Finland
Phone: +358 2 275 0557; Fax: +358 2 241 0075
Web: www.hidex.com
E-mail: info@hidex.com
KEY PERSONNEL: Haaslahti Jukka; CEO
Ville Haaslahti; Product Specialist
Risto Juvonen; Product Manager
PRINCIPAL INVESTORS: Sitra
PRODUCTS ON MARKET: Plate Chameleon multi technology plate reader, Triathler portable
multitechnology vial reader, Consumables and reagents for our readers,
Radiowater Generator for Positron Emission Tomography (PET) studies.
Micro-Plate Automation / Screening
Systems
Huntingdon Life Sciences

Woolley Road, Alconbury
Huntingdon PE28 4HS, UK
Phone: +44 (0) 1480 892 000; Fax: +44 (0) 1480 890 693
Web: www.huntingdon.com
E-mail: sales@ukorg.huntingdon.com
KEY PERSONNEL: Andrew Baker; Chairman
Brian Cass; Managing Director
Dr. M.J. Butler; Pharmaceutical Services Director
Dr. D.R. Hawkins; Agrochemical and Food Services Director
Dr. P.C. Brooker; Industrial Chemical Services Director
SUBSIDIARY OF: Life Sciences Research
BUSINESS STRATEGY: Provide biological and chemical contract safety evaluation services to
pharmaceutical, biotechnology, agrochemical and industrial chemical
markets
®
Hybrizyme Corp.
2801 Blue Ridge Road, Suite G-70
Raleigh NC 27607, US
Phone: (919) 783-9595; Fax: (443) 494-0005
Web: www.hybrizyme.com
E-mail: hybrizyme@aol.com
KEY PERSONNEL: Randy Allen, Ph.D.; CEO
BUSINESS STRATEGY: Develop proprietary testing methods that incorporate the latest innovations
in molecular and cellular toxicology either as a replacement for existing
protocols or as new tests for compounds that cannot be accurately
measured using current technology
RESEARCH & DEVELOPMENT: Diagnostic tests for environmental toxins and other compounds
PRODUCTS ON MARKET: Wallac Victor2 (with PerkinElmer Life Sciences)
Delfia reagents
AhRC PCR™ assay
Dioxin and Furan assay in development
ICPbio
P. O. Box 1607, 26 Waipareia Avenue
Auckland , New Zealand
Phone: +64 9-838-4205; Fax: +64 9-838-4209
Web: www.icpbio.com
E-mail: dglen@icpbio.com
KEY PERSONNEL: Dr. Earl Stevens; Managing Director
Kelvin Hunter; CFO
Annette Nickless; Financial Controller
Dr Jerome Demmer; Manager, R&D
Ben Perrin; Marketing Manager
Alan Cocks; Sales Manager
Greg Shewfelt; Manager, Business Development
Karen Munro; Production Manager
Praveena Rawls; QA and QC Manager
BUSINESS STRATEGY: Commercialize research to provide innovative technical and commercial
solutions to the animal health and pharmaceutical industries
RESEARCH & DEVELOPMENT: Laboratory and process scale protein purification to levels suitable for
animal trials. Protein purification process development. Analytical protein
chemistry. Development of enzyme immunoassays. Development of embryo
handling products. Bulk formulation of sterile solutions. Sterile lyophilisation.
Clean room facilities.
®
PRODUCTS ON MARKET: Confirm, animal pregnancy test using milk or faeces sample
Emcare, new media for freezing/thawing/culturing animal embryos
(phosphate-free)
Ovagen, an FSH product for superovulation of livestock
Bovine serum albumin for cell culture and laboratory use
Idaho National Laboratory

P.O. Box 1625
Idaho Falls ID 83415, US
Phone: (208) 526-0111
Web: www.inl.gov
KEY PERSONNEL: John J. Grossenbacher; Laboratory Director
Art Clark; Deputy Laboratory Director, Operations
Dr. David Hill; Deputy Laboratory Director, Science and Technology
Juan Alvarez; Deputy Laboratory Director, Management Systems
Dr. James Lake; Associate Laboratory Director, Nuclear Programs
Dr. KP Ananth; Associate Laboratory Director, National and Homeland
Security
Dr. J.W. (Bill) Rogers Jr.; Associate Laboratory Director, Science and
Technology and Chief Research Officer
David L. Kudsin; Associate Laboratory Director, Specific Manufacturing
Capability
David Richardson; Associate Laboratory Director, Nuclear Operations
Fran B. Williams; Director, Environment, Safety, Health and Quality
Dr. Brian Sack; Director, Business Management and CFO
Dwayne Coburn; Director, Facilities and Site Services
John Lindsay; Director, Communications
Dr. Ralph Bennett; Director, Science and Technology Strategic Planning
Dr. Susan B. Arnold; Director, Human Resources and Diversity Programs
Carol Johnson; Director, Infrastructure, Optimization, Integration and
Planning
John J. (Jack) Lance; Director, Technology Partnerships
Mark D. Olsen; General Counsel
Dr. Andrew C. Klein; Director, Education, Training, and Research
Partnerships
Dr. Leonard J. Bond; Director, Center for Advanced Energy Studies
HISTORY: Founded in 1949 as the National Reactor Testing Station
FACILITIES: 890-square-mile area in southeastern Idaho
Materials and Fuels Complex (formerly Argonne National Laboratory-West)
Reactor Technology Complex (formerly Test Reactor Area)
Science and Technology Campus
SUBSIDIARIES/DIVISIONS: Divisions and departments:
Physical Science: Physics, Material Sciences, Chemical Sciences,
Analytical Chemistry & Instrumentation, Advanced Modeling & Simulation,
Prototype Engineering
Life & Earth Science: Biological Sciences, Ecological Sciences,
Geosciences, Modeling & Measurement
Engineering Technology: Environmental Engineering, Process Engineering,
Nuclear Materials Disposal & Engineering, Applied Mechanics & Sustainable
Design, Systems Engineering
Energy & Technology Systems: Fossil Energy, Renewable Energy,
Transportation Technology, Industrial Technology, Robotics & Human
Systems
®
RESEARCH & DEVELOPMENT: Science and Technology: Developing America's hydrogen economy and
alternative fuels and energy systems. Supports the development of
advanced energy storage and transportation systems, critical energy
infrastructure and water resources. Manages the environmental
consequences of energy development and use. Research on compressed
and liquefied natural gas, high powered batteries and ultra capacitors,
integrated fuel processors and fuel cell systems, renewable energy systems,
carbon capture and sequestration, hazardous waste management
treatment, advanced offgas treatment systems, advanced welding systems,
surface and subsurface monitoring systems, sustainable building design,
and autonomous unmanned aerial and ground vehicles.
National and Homeland Security: Global security, homeland security,

national defense, energy security and special programs
Nuclear programs: Nuclear safety analysis, irradiation services, nuclear

operations, management of spent nuclear fuel, biocorrosion of fuels
Idexx Laboratories Inc.

One IDEXX Drive
Westbrook ME 04092, US
Phone: (207) 856-0300; Fax: (207) 856-0346
Web: www.idexx.com
E-mail: businesscommunications@idexx.com
KEY PERSONNEL: Jonathan W. Ayers; Chairman, President and CEO
William C. Wallen, Ph.D.; Sr. VP and CSO
Merilee Raines; VP and CFO
Conan R. Deady; VP, General Counsel and Secretary
Sam Fratoni, Ph.D.; VP and CIO
Robert Hulsy; VP, Laboratory Services
Jennifer Joiner; VP, North American Commercial Operations
Laurel LaBauve; VP, Worldwide Operations
Quentin Tonelli, Ph.D.; VP, Rapid Assay and Production Animal Services
Purchased certain assets of Baxter Diagnostics (2/91)
Purchased diagnostics business of Fermenta Animal Health Co. (10/91)
Purchased assets of VetTest, a manufacturer of biochemical monitoring
tests for animal health care, acquisition completed (1/92)
Acquired Environetics Inc., a manufacturer and marketer of environmental
diagnostics (2/93)
Acquired Amis, a commercial veterinary laboratory in Japan (9/94)
Acquired Cardiopet Inc., which provides veterinary, cardiology, internal
medicine, and other consulting services (5/95)
Acquired VetLab Inc., veterinary laboratory (3/96)
Acquired Grange Laboratories, veterinary laboratory (4/96)
Acquired Veterinary Services Inc., veterinary laboratory (5/96)
Acquired Idetek Inc. (1996)
Acquired Blue Ridge Pharmaceuticals (10/98)
Acquired veterinary laboratory business of Sonora Quest Laboratories (3/99)
Acquired veterinary laboratory business of Tufts University School (12/99)
Acquired Sierra Veterinary Laboratory (3/00)
Acquired Veterinary Pathology Services Pty Ltd. (7/00)
Acquired Genera Technologies Ltd. (9/01)
Acquired Syracuse Bioanalytical Inc. (8/04)
Acquired Bommeli Diagnostics (12/04)
Acquired Vet Med Lab (11/04)
®
FACILITIES: 329,000 sq. ft. of leased office and manufacturing space in Westbrook,
Maine
97,500 sq. ft. of leased industrial space in Memphis, Tenn.
40,000 sq. ft. of leased office and manufacturing space in Eau Claire, Wis.
48,000 sq. ft. of leased warehouse and office space in the Netherlands
STOCK-FINANCIAL HISTORY: NASDAQ--IDXX
IPO--1.6M shares at $15/share (6/91)
Two-for-one common stock split (10/93)
Two-for-one common stock split (6/95)
Public offering--4.6M shares of common stock at $35/share (9/95)
04)
SUBSIDIARIES/DIVISIONS: Three business segments: Companion Animal Group (CAG), Water testing
business and Food Diagnostics Group
BUSINESS STRATEGY: Manufacture, develop and market rapid test kits for food safety, quality
control, environmental testing and veterinary testing
Alteon Inc. pimagedine as oral licensing 6/97
therapeutic for diabetes agreement
and aging in companion
animals
Banfield, The Pet Idexx to provide Idexx five-year 5/05
Hospital® VetLab laboratory agreement
system and rapid assay
products to Banfield
hospitals
Beckman Icon immunoassay worldwide licensing 6/86
Instruments Inc. technology for agreement
veterinary diagnostics
and agricultural
applications
Becton Dickinson BD's hematology development and 10/93
and Co. products and marketing
technology for agreement
veterinary markets
RESEARCH & DEVELOPMENT: Molecular biology, cellular biology, MAbs, immunoassays, membrane filter
delivery systems
Expansion of current EIA test system and micro fabrication technology
Immuno-based optical biosensors
Bacterial Ice Nucleation Diagnostic (BIND) pathogen test kits
Antibody development for antibiotics, toxins, microbial pathogens, pesticides
and environmental contaminants
New immunoassay formats for multi-analyte, one-step testing
PRODUCTS ON MARKET: More than 100 products, including over 50 immunoassays for infectious
diseases in swine, cattle, poultry, horses, cats and dogs
Tests for contaminants on food production surfaces and in milk or grain
Clinical chemistry, hematology, and electrolyte systems and reagents
Tests for environmental monitoring--E. coli, coliforms, and enterococci
ELISA test for B. abortus
LacTek™ residue screening test kits for milk
LacTek™ antibiotic residue test system
Sultamethazine serum/plasma test kit
Phytodetek™ plant growth regulator
Quantix workstation for petroleum/hydrocarbon contamination measurement
in soil and water
®
Quantix labstation test kits for pesticides, petroleum and TNT contaminants
BIND® salmonella one-day pathogen test
SNAP® Heartworm Antigen test
NAVIGATOR® (32% nitazoxanide) Antiprotozoal oral paste treatment for
equine protozoal myeloencephalitis
IGENE Biotechnology Inc.

9110 Red Branch Road
Columbia MD 21045-2024, US
Phone: (410) 997-2599; Fax: (410) 730-0540
Web: www.igene.com
E-mail: igene@igene.com
KEY PERSONNEL: Michael G. Kimelman; Chairman
Stephen F. Hiu, Ph.D.; President, CTO and Director, R&D
Edward J. Weisberger; CFO
Patrick F. Monahan; VP and Director, Manufacturing
Per A. Benjaminsen; Director, Sales and Marketing
HISTORY: Founded in October 1981 by Robert Milch and William Hall
Formerly called Genetic Research Corp. and IGI Biotechnology Inc.
Formed a wholly-owned subsidiary, Igene Chile Comercial Ltda. (2000)
Acquired ProBio Nutraceuticals AS (2001)
Sold ProBio Nutraceuticals AS (2/03)
FACILITIES: Leases approximately 8,500 sq. ft. of space in the Oakland Ridge Industrial
Park located in Columbia, Md.--2,000 sq. ft. of the space is used for
executive and administrative offices; 2,500 sq. ft. for R&D activities; and
4,000 sq. ft. for the company's intermediate-stage or scale-up pilot plant
facility
Leased manufacturing facilities at Fermic SA de CV in Mexico City
Leased warehouse space for product storage in Mexico City
220 sq. ft. of leased office space in Chile
STOCK-FINANCIAL HISTORY: OTC BB
IPO--800K shares at $6/share, $4.8M (7/86)
PRIVATE PLACEMENTS: Private placement 796K share/warrant units (12/83)
Subscription offering of 50K shares (3/85)
Subscription offering of 375K share/note units (2/86)
Private placement 625K shares (9/87)
Private placement 4.596M shares (3/91)
Private placement 1.2M shares (8/95)
SUBSIDIARIES/DIVISIONS: Igene Chile Comercial Ltda.
INVESTMENTS: Formed 50:50 joint venture to produce AstaXin® for the aquaculture industry
with Tate & Lyle plc (3/03)
BUSINESS STRATEGY: Developing, market and manufacture specialty ingredients for human and
animal nutrition
Fermic SA de CV AstaXin renewed 5/00
manufacturing
agreement
®
RESEARCH & DEVELOPMENT: Development of proprietary processes to convert selected agricultural raw
materials or feedstocks into commercially useful and cost effective products
for the food, feed, flavor and agrochemical industries
PRODUCTS ON MARKET: AstaXin® yeast with high level of astaxanthin pigment
Imperial Innovations Ltd.

Electrical and Electronic Engineering Building
Imperial College London, South Kensington
London SW7 2AZ, UK
Phone: +44 020-7581-4949
Fax: +44 020-7589-3553
Web: www.imperialinnovations.co.uk
E-mail: innovations@imperial.ac.uk
KEY PERSONNEL: Martin Knight; Chairman
Susan Searle; CEO
Julian Smith; CFO and COO
Jon Page; Head, New Ventures
Naiem Hussain; Head, Asset and Investment Management
Tony Hickson; Head, Biosciences Team
Brian Graves; Head, Engineering and Technology Team
HISTORY: Name changed from RPMS Technology Ltd. (1998)
Created more than 60 spin-out companies
STOCK-FINANCIAL HISTORY: University-funded research center
PRIVATE PLACEMENTS: Raised US$37.9M in private placement (5/05)
SUBSIDIARY OF: Imperial College London
BUSINESS STRATEGY: Conduct technology transfer from research program of Imperial College
Industrial Biotechnology Corp.

2033 Main Street, Suite 400
Sarasota FL 34237, US
Phone: (941) 925-2500; Fax: (941) 925-2503
Web: www.industrialbiotechnology.com
E-mail: jhensley@industrialbiotechnology.com
KEY PERSONNEL: Andy Badolato; CEO
David L. West; CFO
Mark Truei, Ph.D.; VP, Manufacturing
Gary Howell, Ph.D.; VP, Business Development
Gurinder Shahi, M.D., Ph.D.; Chief Technologist
J. Ron Doran; Director, Sales and Marketing
Tom Hentschell; VP, Operations and Marketing
Jack Hensley; VP, Investor and Public Relations
Dr. Eric I. Tsao; Chief Scientist
HISTORY: Acquired Bio-Repellant Technologies Inc. (BRT) from UTEK Corp. (5/06)
Acquired assets of Bio-Flavorance Technologies and Research Inc. (1/06)
Acquired Advanced Pheromone Technologies Inc. (9/06)
STOCK-FINANCIAL HISTORY: Pink Sheets--IBTY
®
BUSINESS STRATEGY: Commercializes technologies and intellectual property in the field of

biologically produced chemicals
Through licensing, partnerships and direct sales, IBC will bring to market
new and established chemicals for use in flavors and fragrances, fine
chemicals, pharmaceutical, agricultural, environmental and bio-energy
applications
Isis Innovation Cytochrome P-450 expanded licensing 7/06
Ltd. (technology technology and two agreement
transfer company patented technologies
of Oxford
University)
UTEK Corp. UTEK to assist in the strategic alliance 1/06
identification of IP agreement
acquisitions
RESEARCH & DEVELOPMENT: Two platform technologies:

The Oxford Cytochrome P450 Designer Enzyme Technology Platform
The Rice FPP Biosynthesis Technology Platform
PRODUCTS ON MARKET: ALCHEMx Production Platforms™--Processes for the design, development,
scale-up and optimization of specific chemical compounds
Industrial Technology Research Institute –

Biomedical Engineering Center
Room 607, Building 51, Sec. 4, 195 Chunghsing Rd.
Hsin Chu 31040, Taiwan
Phone: +886 3-591-2686; Fax: +886 3-582-0464
Web: www.itri.org.tw; E-mail: lhsieh@itri.org.tw
KEY PERSONNEL: Hsin-I Lin; Chairman
Dr. Johnsee Lee; President
Dr. Jyuo-Min Shyu; Exec. VP
Dr. Hsin-Sen Chu; Exec. VP
Dr. Yeou-Gong Hsu; VP
Dr. Shing-Yuan (Bill) Tsai; VP
HISTORY: Founded in 1973 by the Ministry of Economic Affairs (MOEA) to attend to
the technological needs of Taiwan's industrial development
Spun off United Microelectronices Corp. (UMC) (1979)
Spun off Taiwan Semiconductor Manufacturing Company Ltd. (TSMC)
(1987)
Spun off Taiwan Mask Corp. (TMC) (1988)
Spun off Mirle Automation Corp. (1989)
Spun off Vanguard International Semiconductor Corporation (VIS) (1994)
FACILITIES: Seven laboratories and four centers
SUBSIDIARY OF: Industrial Technology Research Institute
-Engage in applied research and technical services to accelerate the
industrial development of Taiwan
-Develop key, compatible, forward-looking technologies to meet industrial
needs and strengthen industrial competitiveness
-Disseminate research results to the industrial sector in a timely and
appropriate manner, in accordance with the principles of fairness and
openness
®
-Foster the technology development of small and medium-sized businesses,

and cultivating industrial technology human resources for the benefit of the
nation
RESEARCH & DEVELOPMENT: Research projects in the following areas:

Communications and Optoelectronics
Precision Machinery and MEMS
Materials and Chemical Engineering
Sustainable Development
Biotechnology and Medicine
Nanotechnology
inGenious Targeting Laboratory Inc.

LIHTI Building, Suite 106, 25 Health Sciences Drive
Stony Brook NY 11790-3350, US
Phone: (631) 444-6640; Fax: (631) 444-6645
Web: www.genetargeting.com
E-mail: info@genetargeting.com
KEY PERSONNEL: Wel Weng; President and CEO
Paul Sheiffele; Exec. VP
Ellen Chen; Exec. VP
HISTORY: Founded in Febuary 1998
Began biotech R&D in November 2000
FACILITIES: 8,500 sq. ft. headquarters located in Stony Brook, N.Y.
2,000 sq. ft. animal facility located in Stony Brook, N.Y.
3,000 sq. ft. warehouse located in Islip, N.Y.
SUBSIDIARIES/DIVISIONS: mouse-knockout technology
BUSINESS STRATEGY: Improve the R&D conditions and business results for scientists and
companies by offering effective and well defined knockout animals
RESEARCH & DEVELOPMENT: Improve technology for mouse knockout production; search for novel animal
models for drug discovery
Institute for Biological Research and Technology

University of South Carolina
Coker Life Sciences Building, Room 403
Columbia SC 29208, US
Phone: (803) 777-2468; Fax: (803) 777-4002
Web: www.cosm.sc.edu/biotech
E-mail: austin@biol.sc.edu
KEY PERSONNEL: Austin L. Hughes; Director
Travis Glenn; Associate Director
Robert P. Lawther, Director, DNA Synthesis and Licor Sequencing Facility
Loren Knapp; Director, Monoclonal Antibody Facility
Bert Ely; Director, Biotechnology Training Laboratory
Lewis Bowman; Director, Bioinformatics Resources
Laszlo Marton; Director, Plant Genetic Engineering Facility
Michael Dewey; Director, Transgenic Mouse Facility
Thomas Borg; Director, Integrated Microscopic Analysis Facility
®

HISTORY: Founded in 1988 by scientists at the University of South Carolina who had
worked together to acquire the equipment needed to facilitate the use of
biotechnological innovations in their research programs
STOCK-FINANCIAL HISTORY: University research center
BUSINESS STRATEGY: Promote the use of biotechnology and make facilities available to scientists,
industry and other institutions throughout the region
RESEARCH & DEVELOPMENT: Basic research in genetics, molecular biology, biochemistry and
environmental biotechnology
Institute of Food Research

Norwich Research Park, Colney
Norwich NR4 7UA, UK
Phone: +44 1603 255000; Fax: +44 1603 507723
Web: www.ifr.ac.uk; E-mail: ifr.communications@bbsrc.ac.uk
KEY PERSONNEL: Prof. David White; Director
Dr. Roger Fenwick; International Coordinator
Mrs. Catherine Reynolds; Head of Communications
Prof. Sue Southon; Head of Enterprise
HISTORY: Formerly AFRC Institute of Food Research
A company limited by guarantee, grant-aided by the Biotechnology and
Biological Science Research Council
FACILITIES: Laboratory in Norwich
SUBSIDIARIES/DIVISIONS: IFR Enterprises Ltd.
Food and Health Network (FHN)
National Collection of Yeast Cultures (NCYC) (see separate entry)
BUSINESS STRATEGY: Fundamental research applicable to the marketplace
Innovation via patenting, joint ventures, and confidential development
RESEARCH & DEVELOPMENT: Protein and enzyme science for biotransformations of food functional
molecules
Molecular biology
Microbial genetics
Natural preservation
Metabolic engineering
Novel polysaccharides
Personalized nutrition
International Flavors & Fragrances Inc.

521 West 57th Street
New York NY 10019, US
Phone: (212) 765-5500; Fax: (212) 708-7132
Web: www.iff.com
E-mail: iff.information@iff.com
KEY PERSONNEL: Robert M. Amen; Chairman and CEO
Jim Dunsdon; COO
Dennis M. Meany; Sr. VP, General Counsel and Secretary
®
Douglas J. Wetmore; Sr. VP and CFO

Clint D. Brooks, Ph.D.; Sr. VP, R&D
Steven J. Heaslip; Sr. VP, Human Resources
Joe Faranda; VP and Chief Marketing Officer
Nicolas Mirzayantz; Sr. VP, Fine Fragrances and Beauty Care and Regional
Manager, North America
Purchased Auro Tech, a Wisconsin biotechnology company specializing in a
broad range of natural dairy flavors, dairy and meat cultures, natural cheese
and other flavor products (1992)
Acquired Bush, Boake Allen Inc. (2000)
FACILITIES: 62 facilities in 30 countries
30 manufacturing facilities
STOCK-FINANCIAL HISTORY: NYSE--IFF
Repurchase of up to 15M shares of common stock authorized (9/92, 9/96)
04)
BUSINESS STRATEGY: Create and manufacture flavor and fragrance products used by other
manufacturers to impart or improve flavor or fragrance in a wide variety of
consumer products
Johns Hopkins odor binding protein collaborative 1988
Medical School neuroscience
research agreement
Xinanjiang fragrance ingredients joint venture 1993
Perfumery Factory using Chinese raw agreement
materials
RESEARCH & DEVELOPMENT: Enzymology and fermentation to improve ingredients and develop natural
flavor molecules
Large-scale commercial manufacturing
Olfactory biochemistry
Specialty chemicals
Head space analysis techniques for capture and synthesis of
fragrance/flavor molecules from flowers and fruits
Recombinant DNA for production of natural flavoring materials and food
ingredients
Microemulsion preparation for clear beverages
Fragrances with organoleptic properties to provide natural insect and
mosquito repellancy
PRODUCTS ON MARKET: Flavors and fragrances for beverages, dairy products, fabric care, fine
fragrances, home care, ingredients, oral and pharmaceuticals, toiletries,
foods
®
Iogen Corp.
310 Hunt Club Rd. East
Ottawa K1V 1C1, Canada
Phone: (613) 733-9830; Fax: (613) 733-0781
Web: www.iogen.ca
E-mail: info@iogen.ca
KEY PERSONNEL: Patrick Foody, Sr.; Chairman
Brian Foody; President and CEO
Patrick Foody Jr.; COO
Grant Blanchard; CFO
Jeff Passmore; Exec. VP
Ray Barnes; Exec. VP and General Manager, Iogen Bio-Products
Nancy Clark; VP, Human Resources
Ron Paradis; VP, Ethanol and Co-Product Marketing
FACILITIES: Enzyme manufacturing plant--Produces food-grade and industrial-grade
enzymes for use in the pulp and paper, textile and animal feed industries
Cellulose ethanol demonstration facility--Designed to process about 40
tonnes per day of feedstock, and to produce 3 to 4 million litres of ethanol
per year
PRINCIPAL INVESTORS: Goldman Sachs
Royal Dutch/Shell Group
Petro-Canada
Government of Canada
BUSINESS STRATEGY: Specializes in cellulose ethanol
Develop, manufacture and market enzymes used to modify and improve the
processing of natural fibres within the textile, animal feed, and pulp and
paper industries
DSM (formerly exclusive manufacturing supply agreement 1991
Roche Vitamins) and distribution of
Roxazyme G2 animal
feed enzymes
National Research enzymes for the pulp development 1994
Coucil of Canada and paper industry agreement
Petro-Canada develop cellulose partnership 1997
ethanol technology
Royal Dutch/Shell commercialization of development 2002
Group biofuels agreement
Technology partnership 1/99
Partnerships
Canada (TPC)
Volkswagen and assess the economic joint study 1/06
Shell feasibility of producing
cellulose ethanol in
Germany
RESEARCH & DEVELOPMENT: Enzymes for fiber modification in pulp and paper, textile and animal feed
industries
Cellulase and xylanase enzymes
Ethanol from biomass
PRODUCTS ON MARKET: Fiber modifying enzymes able to enhance yield or reduce viscosity
®
Isolagen Inc.
405 Eagleview Boulevard
Exton PA 19341, US
Phone: (484) 713-6000; Fax: (484) 713-6001
Web: www.isolagen.com; E-mail: info@isolagen.com
KEY PERSONNEL: Nicholas J. Teti; Chairman and CEO
Susan Ciallella; President
Declan Daly; CFO and Exec. VP
Steven Trider; Sr. VP, Global Business and Market Development
Dr. Marie Lindner; Sr. VP, Medical and Business Affairs
Acquired a 57% interest in Agera Laboratories Inc. for $2.655M (8/06)
FACILITIES: 86,500 sq. ft. leased facility for manufacturing and product development
STOCK-FINANCIAL HISTORY: AMEX--ILE
IPO--12/02
Public offering--7M shares of common stock at $8.50/share, $61.2M (6/04)
04)
PRIVATE PLACEMENTS: Raised $10.1M from sale of 2.895M shares of Series A Convertible
Preferred Stock at $3.50/share (7/02)
Raised $4.4M from sale of 155.750K shares of Series B Convertible
Preferred Stock at $28/share (5/03)
SUBSIDIARIES/DIVISIONS: UK office:
Isolagen Europe Ltd.
59/61 Park Royal Road
London NW10 7JJ England
Phone: +44 (0) 20 8834 1080
Fax: +44 (0) 20 8834 1165
Email: infouk@isolagen.com
Australia Office
2 Lincoln Street
Lane Cove
NSW 2066
Australia
Tel: 1300 303 906
Fax: 02 9808 4442
Email: info@isolagen.com.au
Web: www.isolagen.com.au
PRINCIPAL INVESTORS: Heartland Advisors
U.S. Bancorp Asset Management
Perceptive Life Sciences
Stark Investments
INVESTMENTS: Agera Laboratories Inc.
BUSINESS STRATEGY: Establish and formalize strategic partnering relationships on a global scale
Accelerate current research efforts in ACS technology
Expand cellular production capacity of laboratory facilities
Expand business development, sales, production and distribution resources
Supplement and leverage existing advisory relationships
Facilitating the company's marketing strategies to supplement and leverage
existing physician and corporate relationships
®
RESEARCH & DEVELOPMENT: Autologous cellular system (ACS) technology, with applications in cosmetic
dermatology, cosmetic surgery, periodontal disease, and reconstructive
dentistry, among other therapies
treatment for dermal defects in Phase III clinicals
treatment of facial wrinkles in Phase III clinicals
autologous fibroblasts for gingival disease in Phase I clinicals
Israel Institute for Biological Research (IIBR)

P.O. Box 19
Ness-Ziona 74100, Israel
Phone: (972) 8-9381656; Fax: (972) 8-9401404
Web: www.iibr.gov.il
E-mail: mambi@iibr.gov.il
KEY PERSONNEL: Avigdor Shafferman, Ph.D.; General Director
Arie Ordentlich, Ph.D.; Head, Biological Sciences
Zvi Teitelbaum, Ph.D.; Head, Medicinal Chemistry
Avraham Lacser, Ph.D.; Head, Environmental Sciences
Baruch Velan, Ph.D.; Coordinator, Biotechnological Projects
Natan Rosenbaum; Head, Personnel
Ariella Raz; Head, Marketing
EMPLOYEES: 350 employees, 150 scientists
FACILITIES: Research facility
Biotechnological and chemical pilot plants
Pharmacological screening facilities including animal housing and
behavioral laboratory
STOCK-FINANCIAL HISTORY: Government applied research institute
SUBSIDIARIES/DIVISIONS: Life Science Research Israel (LSRI)--commercial arm of IIBR to promote
and commercialize IIBR-generated intelligence and applied research
projects (established in 1978)
Three scientific divisions--Biology, Medicinal Chemistry and Environmental

Sciences
BUSINESS STRATEGY: Establish R&D agreements with other companies that could lead to joint
ventures with equity investments
Snow Brand Milk novel treatment for research contract 5/84
Products Co. Ltd. senile dementias of the with rights
Alzheimer's type
RESEARCH & DEVELOPMENT: Biology: Diagnosis of infectious diseases; development of rapid, sensitive
and specific diagnostic methods (and reagents) for pathogen detection and
identification; viral and bacterial pathogenesis mechanisms in order to
design strategies for vaccine and drug development, for the evaluation of
novel modes of therapy and for diagnostic purposes; functional genomics
and proteomics, including microbial genomes, gene selection from various
pathogens; vaccine development and evaluation; engineering of proteins
and enzymes, including molecular design, engineering of novel proteins,
protein and peptide chemistry, chemical modification of engineered proteins,
manipulation of post-translation processing and customized protein
derivatives; generation of human or mammalian cell clones; evaluation of
recombinant producer cells; development of efficient cultivation systems of
mammalian anchorage-dependent cells in surface propagators; fixed-bed
reactors and stirred microcarrier cultures; development of batch, fed batch
®
and perfusion cultures of suspended cells; development of monoclonal

antibodies and antigens from cell culture; development of recombinant
enzymes from animal cells, development of bacterial and viral veterinary
vaccines, subunit vaccines, and human and veterinary recombinant
lymphokines; fuel and environmental biotechnology R&D projects in
petroleum microbiology, biodeterioration, biohydrometallurgy and
bioremediation
Medicinal Chemistry: Therapeutics for Alzheimer's disease; pharmacological

and neuroscience projects include the treatment and therapy of the effects
caused by toxic compounds used in agriculture and industry, prevention,
treatment and therapy of the effects caused by chemical and thermal burns,
ocular studies of chemical and physical injuries to the cornea and retina, and
their prevention and treatment; physiological studies of seizure activity and
prevention of the resulting irreversible brain damage; stress mechanisms
and preventive therapeutic means against aging and stress-induced
neuronal damage; investigation of inflammatory modulators using ex-vivo
and tissue-culture methods; pharmacokinetic studies and investigation of
drug delivery systems, and drug-receptor interactions and physiological
responses mediated by distinct neurotransmitter receptor sub-types; design
and synthesis of biologically active molecules
Environmental Sciences: Air pollution meteorology and risk assessment,

including air pollution measurements on site, occupational air quality
measurements, environmental surveys, meteorological measurements,
granulometric, aerodynamic and image analyses, risk assessment, air
pollution modelling; real time chemical and granulometric analyses--portable
GC, FTIR, MIRAN, Spraytech, Aerosizer, Knollenberg; optics in the
atmosphere; physical protection group; and detectors and biosensors
Itochu Corp.
5-1, Kita-aoyama, 2-chome, Minato-ku
Phone: +81 3-3497-7300; Fax: +81 3-3497-7389
Web: www.itochu.co.jp; E-mail: info@itochu.co.jp
KEY PERSONNEL: Uichiro Niwa; Chairman
Eizo Kobayashi; President and CEO
Akira Yokota; Exec. VP
Kouhei Watanabe; Exec. VP
Toshihito Tamba; CFO
Shigeki Nishiyama; President, Aerospace, Electronics & Multimedia
Masahiro Okafuji; President, Textile Company
Yosuke Minamitani; President, Chemicals, Forest Products & General
Merchandise Company
Shigeharu Tanaka; President, Food Company
Takanobu Furuta; President, Machinery Company
Yoichi Kobayashi; President, Energy, Metals & Minerals Company
Takao Shiomi; President, Finance, Realty, Insurance & Logistics Services
Company
Yoshio Akamatsu; President and CEO, Itochu International Inc.
Yoshihisa Suzuki; President, Itochu Canada Ltd.
Toyoshige Yamada; General Manager, Strategic Business Development
Department
Takeyoshi Ide; General Manager, European Operations
Yuji Fukuda; COO, Chemicals Division
Incorporated in December 1949
Formerly named C. Itoh & Co. Ltd., changed name (10/92)
®
FACILITIES: 18 offices in Japan and 135 offices overseas

STOCK-FINANCIAL HISTORY: Listed on the Tokyo, Osaka, Nagoya, Fukuoka and Sapporo stock
exchanges
05)
SUBSIDIARIES/DIVISIONS: Energy, Metals and Minerals:
Itochu Non-Ferrous Materials Co. Ltd.--Japan
Marubeni-Itochu Steel Inc.--Japan
Itochu Enex Co. Ltd.--Japan
Itochu Petroleum Japan Ltd.
Itochu Energy Marketing Co. Ltd.--Japan
Itochu Oil Exploration Co. Ltd.--Japan
Itochu Minerals & Energy of Australia Pty. Ltd.
Itochu Petroleum Co. (Singapore) Pte. Ltd.
Chemoil Corp.--U.S.
Galaxy Energy Group Ltd.
IPC (USA) Inc.
Chemicals, Forest Products & General Merchandise:

Dailite Co. Ltd.--Japan
Itochu Plastics Inc.--Japan
Itochu Techno-Chemical Inc.--Japan
Chemical Logitec Co. Ltd.--Japan
The Japan Cee-Bee Chemical Co. Ltd.
CI Kasei Co. Ltd.--Japan
Takiron Co. Ltd.--Japan
VCJ Corp.--Japan
Illums Japan Co. Ltd.
Sankyu Pharmaceutical Co. Ltd.--Japan
Itochu Forestry Corp.--Japan
Itochu Kenzai Corp.--Japan
Itochu Pulp & Paper Corp.--Japan
Itochu Ceratech Corp.--Japan
PPG-CI Co. Ltd.--Japan
Itochu Windows Co. Ltd.--Japan
Beaver Tozan Corp.--Japan
Hexa Color (Thailand) Ltd.
Itochu Plastics Pte. Ltd.--Singapore
Tetra Chemicals (Singapore) Pte. Ltd.
Bonset America Corp.--U.S.
Itochu Tekstil Kimya Ltd. Sti.--Turkey
Shanghai Jinchang Engineering Plastics Co. Ltd.--China
Shanghai Baoling Plastics Co. Ltd.--China
Thaitech Rubber Corp. Ltd.--Thailand
CIPA Lumber Co. Ltd.--Canada
Albany Plantation Forest Co. of Australia Pty. Ltd.
Food:
Fuji Oil Co. Ltd.--Japan
Itochu Sugar Co. Ltd.--Japan
Itochu Feed Mills Co. Ltd.--Japan
Japan Foods Co. Ltd.
Shibushi Silo Co. Ltd.--Japan
Cholburi Sugar & Trading Corp. Ltd.--Thailand
Palmaju Edible Oil Sdn. Bhd.--Malaysia
CGB Enterprise Inc.--U.S.
PT Aneka Tuna Indonesia
Winner Food Products Ltd.--Hong Kong
®
BUSINESS STRATEGY: Aim to become a high-profit corporate group earning over ¥100b in
consolidated net income in a steady and sustainable manner by:
Taking on the challenge of expanding earnings
Creating new businesses
Enhancing solid management
Baxter DNA probe licensing agreement 1989
Hemoglobin
Therapeutics Inc.
Bioreactor bioreactor marketing 6/86
Technology agreement
British Technology chemiluminescence licensing agreement 1991
Group
Innogenetics NV cytokinin growth factor, import agreement 1991
hepatitis C virus kit
Repligen Corp. rProtein A import agreement 1986
PRODUCTS ON MARKET: Chemicals, Forest Products & General Merchandise: Logs, lumber, wooden
building materials, wood chips, wood pulp, recycled paper, cotton linter,
paper, paperboard, paper products, natural rubber, tyres, footwear, furniture,
glass, cement, slag, landscape materials, refractory materials and products,
natural gypsum, chemical feedstock, olefin, aromatics, raw materials for
synthetic resins, tar chemicals, raw materials for synthetic fibers, organic
chemicals, methanol, ethanol, solvents, speciality chemicals, inorganic
chemicals, chemical fertilizers, vinyl chloride, polyolefin, synthetic rubbers,
carbon black, thermoplastic and thermosetting resins, resin additives and
glass fibers
Energy, Metals & Minerals: Iron ore, direct reduced iron, coking coal,
thermal coal, ferro alloy and its materials, steel scrap, pig iron, metal
powder, electrodes, activated carbon, steel plates, hot and cold rolled
sheets, galvanised steel, steel for machinery, stainless steel, high tensile
steel, various specialty steel materials, construction materials, welded steel
pipes, seamless steel pipes, steel wires, marine steel structures, bridges,
prefabricated steel for buildings, rails, non-ferrous metals, non-ferrous/light
metal products, rare metals, aluminum, alumina, aluminum rolled products,
aluminum extrusion products, electric wires, optical fiber cables, electronic
materials and products, crude oil, natural gas liquid (NGL), gasoline,
naphtha, kerosene, jet fuel, gas oil, fuel oil, bunker oil, lubricant, asphalt,
liquefied petroleum gas (LPG), liquefied natural gas (LNG), dimethyl ether
(DME) and nuclear fuel
Food: Wheat, barley, wheat flour, rice, starches, soybeans, sunflower oil,
olive oil, palm oil, coconut oil, corn, soybean meal, rapeseed meal, fish
meal, alfalfa pellets, raw sugar, sweeteners, high-fructose corn syrup, dairy
products, nuts, coffee, cocoa, fruit juice, liquor, soft drinks, beef, pork,
chicken, fruits and vegetables, processed foods, frozen foods, canned
foods, pet foods and consulting services for food business
J. Craig Venter Institute

9704 Medical Center Drive
Rockville MD 20850, US
Phone: (240) 268-2605; Fax: (240) 268-4000
Web: www.venterinstitute.org
E-mail: press@venterinstitute.org
KEY PERSONNEL: J. Craig Venter, Ph.D.; President, and Group Leader, Environmental
Genomics
Robert L. Strausberg, Ph.D.; Group Leader, Human Genomic Medicine
Hamilton O. Smith, M.D.; Group Leader, Synthetic Biology and Biological
Energy
®

HISTORY: Formed from the consolidation of The Center for the Advancement of
Genomics (TCAG), the Institute for Biological Energy Alternatives (IBEA)
and the J. Craig Venter Science Foundation Joint Technology Center (JTC)
(9/04)
FACILITIES: Joint Technology Center--60,000 sq. ft.
5 Research Place
Rockville, MD 20850
Phone: (240) 243-1500
Fax: (240) 243-0600
STOCK-FINANCIAL HISTORY: Nonprofit research institute
BUSINESS STRATEGY: The J. Craig Venter Institute is dedicated to the advancement of the science
of genomics, understanding its implications for society, and communicating
those results to the scientific community, public and policymakers.
RESEARCH & DEVELOPMENT: Genomic medicine with an emphasis on cancer genomics and human
genome resequencing and analysis
Environmental genomic analysis with an emphasis on microbial biodiversity,
ecology and evolution
Use of molecular and genomic methods to develop biological sources of
clean energy
Synthetic genome development
Policy research on the ethical, legal and economic issues associated with
genomic science and technology
Johnson Matthey Pharma Services

35 Patton Road
Devins MA 01434, US
Phone: (978) 784-5000; Fax: (978) 784-5000
Web: www.jmpharmaservices.com
E-mail: etetreau@jmusa.com
KEY PERSONNEL: Roger Kilburn; Exec. VP and GM
Lee Piver; Sr. Director, Industry Relations
Mike McKinley; Director, Finance and Materials Management
Harwood Stiles; Director, Quality
Paula J. Lorence; Director, Sales and Marketing
Daniel J. Coughlin, Ph.D.; Director, Medicinal Chemistry
Heather Taft, Ph.D.; Director, Chemical Development
Tony Chong, Ph.D.; Director, Chemical Development and Pilot Plant
Acquired by Johnson Matthey (2001)
Changed name from Pharm-Eco (12/04)
FACILITIES: 50,000 sq. ft. headquarters and R&D facilities
STOCK-FINANCIAL HISTORY: Privately held--Parent company Johnson Matthey is a public company
SUBSIDIARY OF: Johnson Matthey
BUSINESS STRATEGY: Provide API chemistry services to clients throughout the drug development
process, from early stage discovery services to commercial manufacturing.
®
RESEARCH & DEVELOPMENT: Services provided for small molecule drugs; broad range of therapeutic
areas including, but not limited to: oncologics, Alzheimer's disease, AIDS,
infectious diseases, Parkinson's disease, memory enhancement and
schizophrenia
PRODUCTS ON MARKET: Services: medicinal chemistry, chemical development, process research,
process development, process optimization, process scale-up, process
validation, production of intermediates, high potency compounds and
production of APIs, commercial manufacturing, separation technologies,
catalytic services, analytical and regulatory services
Kanebo Ltd.
20-20 Kaigan, 3-chome, Minato-ku
Phone: +81 3-5446-3002; Fax: +81 3-5446-3027
Web: www.kanebo.co.jp
E-mail: webmaster@kanebo.co.jp
KEY PERSONNEL: Akiyoshi Nakajima; Chairman
Tetsuo Komori; President
HISTORY: Established in May 1887 as Tokyo Cotton Trading Co.
Renamed Kanegafuchi Spinning Co. (Kanegafuchi Boseki KK) (1893)
EstablishedKanebo Service Co. (1931)
Established Kanegafuchi Industrial Co. (1938)
Established Kanebo Haris Inc. (1964)
Absorbed Tachibana Confectionery Co. (1964)
Entered pharmaceutical industry by takeover of Yamashiro Pharmaceutical
Co. (1966)
Established Kanebo Cosmetics Sales Co. (1967)
Began biotech research in the 1970s
Established Kanebo Soap Sales Co. (later Kanebo Home Products) (1971)
Established Kanebo Soap Manufacturing Co. (1971)
Absorbed Izumi Confectionery Inc. (1971)
Established Kanebo Synthetic Chemicals Co. (1971)
Established Kanebo-Stevens Co. (1971)
Established Kanebo Engineering Co. (1971)
Established Kanebo Pharmaceuticals Co. (1972)
Absorbed Watanabe Confectionery Co. (1972)
Established the Laboratory for Herbal Medicine (1976)
Established Japan Synthetic Textile Co. with Asahi Kasei (1978)
Established Kanebo Fashion Research Ltd. (1979)
Established Kanebo Cosmetics (Europe) Ltd. (1980)
Opened the Kanebo Museum of Textiles (1986)
Changed name to Kanebo Ltd. (2000)
Established the Kanebo Beauty Care Laboratory (2004)
Sold Synthetic Fiber Division (2005)
Established Kanebo Trinity Horldings Ltd. (2006)
FACILITIES: Plants:
Tsushima (Toiletries)
Second Takatsuki, Takaoka (Pharmaceuticals)
First Takatsuki, Shinmachi, Fukuchiyama (Foods)
STOCK-FINANCIAL HISTORY: Formerly listed on the Tokyo and Osaka stock exchanges; delisted in 2005
SUBSIDIARIES/DIVISIONS: Toiletries, pharmaceuticals and foods divisions
®

Ontogen Corp. compounds to treat skin development 6/96
diseases agreement
Protein Design Smart HUM195 development and 2/92
Labs Inc. (now antibody for acute licensing agreement
PDL BioPharma myelogenous leukemia
Inc.)
PRODUCTS ON MARKET: Toiletries division: Skin care products, body soaps, shampoos, hair
conditioners, hair rinse, hair styling, and bath products
Pharmaceuticals division: Prescription and OTC products
Foods division: chewing gum, confectionaries, powdered drinks and frozen
desserts
KB-195 to treat acute myelogenous in Phase I clinicals
leukemia
Kaneka Corp.
3-2-4, Nakanoshima, Kita-ku
Phone: +81-6-6226-5050; Fax: +81-6-6226-5037
Web: www.kaneka.co.jp; E-mail: info@kaneka.co.jp
KEY PERSONNEL: Masatoshi Takeda; Chairman
Masami Onishi; President
Uichiro Shimomi; Exec. VP
Hideo Yasui; Exec. Officer
Kimikazu Sugawara; Exec. Officer
Yoichi Shima; Exec. Officer
Satomi Takahashi; Exec. Officer
Kiyomi Imou; Exec. Officer
Masatoshi Hatori; Exec. Officer
Toshiji Kanou; Exec. Officer
Toshihiro Suzuki; Exec. Officer
FACILITIES: Plants in Takasago, Osaka, Shiga and Kashima
Research institutes:
Life Science R&D Center
Advanced Polymer Materials R&D Center
Polymer Designing & Processing Product Development Center
Electronics R&D Center
Production Technology R&D Center
Foods R&D Center
High Performance Materials Research Laboratories
Additional locations in the U.S. Belgium, Singapore, Malaysia, Australia and

China
STOCK-FINANCIAL HISTORY: Listed on the Tokyo, Osaka and Nagoya stock exchanges
Total assets ¥453.159b (YE 06) compared to ¥224.143 (YE 05)
SUBSIDIARIES/DIVISIONS: Kaneka Singapore Co. (Pte.) Ltd.--Singapore (sales and manufacture of
pharmaceutical intermediates)
Kaneka Consulting (Shanghai) Co. Ltd.--China (technical consulting for
Kaneka products)
®
Kaneka Technical Service Co. Ltd.--China (technical service of functional

plastics)
Kaneka Eperan (Suzhou) Co. Ltd.--China (manufacture of expandable
plastics and products)
Hifua Fiber Co. Ltd.--China (manufacture of synthetic fibers)
Kaneka (Malaysia) Sdn. Bhd.--Malaysia (sales and manufacture of
functional plastics)
Kaneka Electec Sdn. Bhd.--Malaysia (sales and manufacture of electronic
products)
Kaneka Eperan Sdn. Bhd.--Malaysia (sales and manufacture of expandable
plastics and products)
Kaneka Paste Polymers Sdn. Bhd.--Malaysia (sales and manufacture of
specialty PVC resins)
TGA Pastry Company Pty Ltd.--Australia (sales and manufacture of
foodstuffs products)
Kaneka Texas Corp. (sales and manufacture of functional plastics and
expandable plastics and products)
Kaneka Nutrients LP--U.S. (sales and manufacture of functional foodstuffs)
Kaneka America LLC--U.S. (marketing and technical consulting for Kaneka
products)
Kaneka Pharma America LLC--U.S. (sale of medical devices)
Kaneka Belgium NV (sales and manufacture of functional plastics and
expandable plastics and products)
Kaneka Pharma Europe NV--Belgium (sale of functional foodstuffs and
medical devices)
BUSINESS STRATEGY: Manufacture and sell chemicals, functional plastics, expandable plastics and
products, foodstuffs products, life science products, electronic products and
synthetic fibers
RESEARCH & DEVELOPMENT: Life Science R&D Center: Controlling R&D activities related to fine
chemicals, medical devices and foodstuffs based on the company's bio and
synthesis technologies
Performance Materials R&D Center: R&D for the synthetic resinsmodifiers,

functional (performance) polymers and synthetic fibers based on Kaneka's
macromolecular technology
Electronics R&D Center: Controlling R&D related to information,

communication and clean energy businesses based on high-polymer
material designing, high-polymer fabrication, functional thin-film fabrication
and systematizing technologies
Foods R&D Center: Controlling R&D related to a foodstuff field based on

biotechnologies in cooperation with the Life Science R&D Center
Polymer Designing & Processing Product Development Center:

Development of products related to formed plastics based on the
technologies of high-polymer material designing and forming, mold
designing and plastics fabrication
Production Technology R&D Center: Development of production

technologies ranging from facility-intensive processes to plastisc fabrication
based on reaction analysis, simulation and process designing technologies
in cooperation with each R&D center related to product development
PRODUCTS ON MARKET: Chemicals: Polyvinyl chloride (PVC), caustic soda, hydrochloric acid, flexible
PVC compounds, rigid PVC compounds, paste PVC and chlorinated PVC
Functional Plastics: Modifier resins, heat-resistant ABS resins, self-

extinguishing ABS resins, modified silicone polymer (MS polymer) and Allyl
(Silyl) terminated polyisobuthylenes (Epion®)
®
Expandable Plastics and Products: Extruded polystyrene foam boards,

insulating PVC sash windows, polystyrene foam sheets, polyolefin foam
(beads and moldings) and expandable polystyrene
Foodstuffs: Margarine and shortening, confectionary fats, bakery yeast
Life Science Products: Ubidecarenone (Coenzyme Q10), anti-hypertensive

drug intermediates, intermediates for antibiotics, liposorber system (LDL-
cholesterol adsorption system) and Lixelle® (Adsorption column for dialysis-
related amyloidosis)
Kikkoman Corp. (Biochemicals Division)

2-1-1 , Nishi-Shinbashi, Minato-ku
Phone: +81 3-5521-5490; Fax: +81 3-5521-5498
Web: www.kikkoman.co.jp/bio
E-mail: biochem@mail.kikkoman.co.jp
KEY PERSONNEL: Yuzaburo Mogi; Chairman and CEO, Kikkoman Corp.
Takashi Ushiku; President and COO, Kikkoman Corp.
Shigetaka Ishii; Sr. Corp. Officer, R&D and Biochemicals
STOCK-FINANCIAL HISTORY: Kikkoman Corp. is listed on the Tokyo and Osaka stock exchanges:
SUBSIDIARIES/DIVISIONS: Kikkoman Corp.:
R&D Division
Biochemicals Division
RESEARCH & DEVELOPMENT: Fermentation processes, rDNA, pharmaceuticals, research reagents

(enzymes), luciferase
Protease
PRODUCTS ON MARKET: Nutritional supplements
Pharmaceutical raw materials
Reagents for clinical diagnostics
Checklite 250 Plus luciferase kit to detect microorganisms via
bioluminescence
LuciPac device for hygiene monitoring
ZeptoLite ABC kit for enzyme immunoassay via bioluminescence
InteLite AB kit for enzyme immunoassay via bioluminescence
Cyclic AMP
Ellagic acid dihydrate
Proanthocyanidins
Maltooligosaccharides
Tannase
Protease (acid-stable)
B-glucosidase
Glucoamylase
Sarcosine oxidase
Creatine amidinohydrolase
Uricase
Sucrose phosphorylase
Maltase phosphorylase
B-phosphoglucomutase
®

Diagnostic enzymes in development
High sensitive bioluminescent enzyme in development
immunoassay methods
Kraeber GmbH & Co.

Waldhofstr 14
Ellerbek 25474, Germany
Phone: +49 4101 3053 0; Fax: +49 4101 3053 90
Web: www.kraeber.de
E-mail: kraeber@t-online.de
KEY PERSONNEL: Jens-Uwe Kraeber; President
Birgit Petroschka; Director, R&D
Gabriele Weiss; Head, Pharmaceutical Chemicals division
Acquired Biospa, Wedel (1992)
SUBSIDIARIES/DIVISIONS: Six divisions:
1. Pharmaceutical Chemicals: Active pharmaceutical ingredients, excipients
and intermediates supplied to the pharmaceutical and cosmetic industry as
well as refined materials in bulk for sale to the laboratory chemical sector.
2. Biopharmaceuticals: Active biopharmaceutical ingredients and excipients,
cosmeceuticals and nutraceuticals are supplied to the human and veterinary
pharmaceutical, cosmetic, health food and pet food industries.
3. Animal Blood Fractions: Manufacturer of animal blood fractions presently
reared from 18 spezies for supply to the biotechnology, diagnostic,
pharmaceutical and cosmetic industries.
4. Production: Extraction and separation from other tissues.
5.Distribution Seagarden AS and Maripro AS.
6. Kraeber UK Ltd.
16 The Street
Saxon Street
nr. Newmarket CB8 9RU, UK
Phone: +44 1638-731297
Fax: +44 1638-731291
E-mail: dja@kraeber.com
INVESTMENTS: Kraeber U.K. Ltd.
BUSINESS STRATEGY: Produce animal blood fractions in Europe for biotechnology, pharmacy and
cosmetics
PRODUCTS ON MARKET: Animal blood fractions in various qualities

Pharmaceutical raw materials
Biopharmaceutical raw materials
®
Kuraray Co. Ltd.

Shin-Hankyu Building, 1-12-39, Umeda, Kita-ku
Phone: +81 6-348-2111; Fax: +81 6-6348-2165
Web: www.kuraray.co.jp
E-mail: koho@kuraray.co.jp
KEY PERSONNEL: Hiroto Matsuo; Chairman
Yasuaki Wakui; President
Junsuke Tanaka; Sr. Managing Director
Seiji Wajiki; Managing Director
Osamu Asaba; Managing Director
Nobuo Iwawaki; Managing Director
Yoichi Ninagawa; Managing Director
Fumio Ito; Managing Director
FACILITIES: Headquarters in Tokyo and Osaka, Japan
SUBSIDIARIES/DIVISIONS: Specialty Resins and Films: Poval Resin Co., Poval Film Co., EVAL Co.
Fibers and Textiles: Fibers and Industrial Materials Co., Clarino Co., Kuraray
Fastening Co. Ltd., Kuraray Kuraflex Co. Ltd.
Chemicals: Methacrylate Division, Chemicals Division, Elastomer Division,
Genestar Division
Affiliated companies: Kuraray Trading Co. Ltd., Kuraray America Inc.,
Kuraray Europe GmbH, Kuraray Specialities Europe, Kuraray Plastics Co.
Ltd., Kuraray Medical Inc., Kuraray Chemical Co. Ltd., Kuraray Engineering
Co. Ltd., Kuraray Interior Co. Ltd., Kuraray Family Products Co. Ltd.,
Kuraray Techno Co. Ltd., Techno Soft Co. Ltd.
PRODUCTS ON MARKET: Chemicals and resins, fibers and textiles, high performance material,
medical products
Kyorin Pharmaceutical Co. Ltd.

5, Kanda Surugadai 2-chome, Chiyoda-ku
Phone: +81 03-3293-3411
Fax: +81 03-3293-3470
Web: www.kyorin-pharm.co.jp
KEY PERSONNEL: Hiroshi Uchida; Chairman
Ikuo Ogihara; President and CEO
Yoshizumi Amano; Exec. Director
Keiji Hirai; Exec. Director
Masahiro Yamashita; Exec. Director
Minoru Hogawa; Exec. Director
Shinichi Saito; Exec. Director
Akihiro Tanaka; Exec. Director
Takayoshi Ishizaki; Exec. Director
®

Established in 1940
Acquired ActivX Biosciences Inc. (2/05)
STOCK-FINANCIAL HISTORY: Listed on the Tokyo Stock Exchange
SUBSIDIARIES/DIVISIONS: Kyobundo Co. Ltd.
Bistner Co. Ltd.
Toyo Pharmar Co. Ltd.
Dr. Program Co. Ltd.
ActivX Biosciences Inc.
Kyorin USA. Inc.
Kyorin Europe GmbH
Nisshin Kyorin Pharmaceutical Co. Ltd.
Nippon Rika Co. Ltd.
SUBSIDIARY OF: Kyorin Co. Ltd.
BUSINESS STRATEGY: Manufacture and sell prescription medicines and quasi-drugs, diagnostics
and industrial chemicals
Build alliances that will capitalize on external resources, allowing the
company to further contribute to better the health of people throughout the
world
Invest management resources in specific therapeutic fields for drug
discovery and marketing
MediciNova Inc. development and licensing agreement
MN-001 (except Japan,
China Taiwan and
South Korea)
Novartis AG KRP-203 global development 2/06
and
commercialization
licensing agreement
RESEARCH & DEVELOPMENT: Drug discovery operations are centered on three therapeutic fields:
Infectious diseases, immunological/allergic and metabolic diseases
PRODUCTS ON MARKET: Gatiflo® tablets
Kipres® tablets
Mucodyne®
Ketas® capsules
Baccidal® tablets
Aplace®
Pentasa® tablets
Rocaltrol® capsules
Bestron® for ear and nose
Kyowa Hakko Kogyo Co. Ltd.

1-6-1 Otemachi, Chiyoda-ku
Tokyo 100, Japan
Phone: +81 3-3282-0007; Fax: +81 3-3284-1968
Web: www.kyowa.co.jp/eng; E-mail: info@kyowa.co.jp
KEY PERSONNEL: Dr. Yuzuru Matsuda; President and CEO
Yoshito Imai; Sr. Exec. Managing Officer and President, Pharmaceuticals
Business Unit
Yukinobu Kotani; Sr. Exec. Managing Officer and President, Bio-Chemicals
Business Unit
®
HISTORY: Founded in July 1949

Established Kyowa Hakko Kogyo Co. Ltd. as a secondary company of
Kyowa Sangyo Co. Ltd. (1949)
Bought out Sanyo Kagaku Co. Ltd. (1954)
Established Daikyowa Sekiyu Kagaku Co. Ltd. through joint investment with
Daikyo Sekiyu Co. Ltd. (1961)
Began the pharmaceutical business (1963)
Established Kyowa Yuka Co. Ltd., as a separate company from Daikyowa
Sekiyu Kagaku Co. Ltd. (1966)
Established Kyowa Hakko USA Inc. (1969)
Established Kyowa Hakko Europe GmbH (1973)
Established Kyowa Miles, a merger company with United States Miles Inc.
(1973)
Established Kyowa FD Foods Co. Ltd. to produce freeze-dried foods (1973)
Established Ohland Foods Co. Ltd. to start producing and selling frozen
dough for bread and cake mix (1974)
Established Fermex for the production of feed-grade L-Lysine (1977)
Established Janssen-Kyowa Co. Ltd. (1978)
Established the Bio Business Division (1981)
Established Kyowa Medex Co. Ltd. to develop, produce and sell diagnostic
reagents (1981)
Established Biokyowa Inc. in the U.S. for the production of amino acids
(1984)
Established Kyowa Hakko (Thailand) Ltd. (1985)
Established Agroferm Hungarian-Japanese Fermentation Industry Ltd., a
consolidated company in Hungary (1987)
Established Japan Oxocol Co. Ltd. to strengthen the plasticizers business
(1988)
Acquired all stock of Shinwa Pharmaceutical Co. Ltd. (1989)
Established Nutri-Quest Inc., a company for research and development in
the U.S. (1989)
Established Kyowa Iryo Kaihatsu Co. Ltd. (1989)
Established Kyowa Hakko (HK) Co. Ltd. (1989)
Merger of Kyowa Yuka Co. Ltd. and Japan Oxocol Co. Ltd. (1991)
Established Kyowa Pharmaceutical Inc. in the U.S. (1992)
Established Dinavec Research Inc. (1995)
Established Shanghai Guan Sheng Yuan Kyowa Amino Acid Co. Ltd. (1998)
Established Kyowa America Inc., a holding company in the U.S. (1999)
Established J Plus Co. Ltd., a joint venture for the plasticizers business
(2000)
Established Kyowa Foods (H.K) Co. Ltd. (2000).
Transferred alcoholic beverage business (excluding raw alcohol) to Asahi
Breweries (9/02)
Established Yantai Kyowa Foods Co. Ltd. in China (2002)
Established Japan Ethyl Acetate Co. Ltd., a joint venture with Showa Denko
KK for the production of ethyl acetate (2003)
Established BioWa Inc. in the U.S. to promote Kyowa Hakko’s
biopharmaceutical business (2003)
Spun off Kyowa Hakko Food Specialties Co. Ltd. (2005)
FACILITIES: 27,000 sq. m. pharmaceutical research facilities
STOCK-FINANCIAL HISTORY: Net sales ¥353.440 (YE 06) compared to ¥358.963b (YE 05)
SUBSIDIARIES/DIVISIONS: The company consists of two business units--Pharmaceuticals Business
Unit and Bio-Chemicals Business Unit
Overseas network:
Kyowa America Inc.
767 Third Avenue, 19th Floor
New York, NY 10017 USA
Phone: (212) 319-5353
®
Biokyowa Inc.
5469 Nash Road, P.O.Box 1550
Cape Girardeau, MO 63702-1550 USA
Phone: (573) 335-4849
Kyowa Hakko USA Inc.

767 Third Avenue, 19th Floor
New York,NY 10017 USA
Phone: (212) 319-5353
Web site: www.kyowa-usa.com
Kyowa Hakko USA Inc.

West Coast Office
85 Enterprise, Suite 430
Aliso Viejo,CA 92656 USA
Phone: (949) 425-0707
Select Supplements Inc.

5800 Newton Drive
Carlsbad, CA 92008 USA
Phone: (760) 431-7509
Kyowa Pharmaceutical Inc.

212 Carnegie Center, Suite 101
Princeton, NJ 08540
Phone: (609) 919-1100
Web site: www.kyowa-kpi.com
BioWa Inc.
212 Carnegie Center, Suite 101
Princeton, NJ 08540 USA
Phone: (609) 580-7500
Web site: www.biowa.com
Kyowa Hakko Europe GmbH

Immermannstrasse-3
D-40210, Dusseldorf, Germany
Phone: +49 211-17-728-0
Web site: http://www.kyowa.de
Kyowa Hakko U.K. Ltd.

258 Bath Road, Slough
Berkshire SL1 4DX, UK
Phone: +44 1753-566000
Kyowa Italiana Farmaceutici SRL

Viale Fulvio Testi 280
20126, Milan, Italy
Phone: +39 02-644-704-1
Web site: kyowa@kyowa.it
Kyowa Hakko Industry (S) Pte. Ltd.

260 Orchard Road, #12-04
The Heeren, Singapore 238855
Phone: +65 6733-4948
Kyowa Hakko (Malaysia) Sdn. Bhd.

20, Jalan SS 19/5, 47500 Subang Jaya
Selangor, Darul Ehsan, Malaysia
Phone: +60 3-5634-0669
®

Beijing Representative Office
Room 701, Beijing Fortune Bldg.
5 Dong San Huan Bei-Lu
Chao Yang District, Beijing 100004, China
Phone: +86 10-6590-8515
Web site: http://www.kyowa.bj.cn

Shanghai Representative Office
Room 1712, Rui Jin Bldg.
205 Maoming Nan Lu, Shanghai 200020
China
Phone: +86 21-6466-1222

Guangzhou Representative Office
Room 701, Yi An Plaza No.33
Jianshe 6 Ma Lu, Guangzou 510060, China
Phone: +86 20-8364-4123
Kyowa Hakko (H.K.) Co., Ltd.

Room 2103, Hang Lung Centre,
2-20 Paterson Street,Causeway Bay
Hong Kong, China
Phone: +852 2895-6795
Kyowa Hakko (HK) Co. Ltd.

Guangzhou Representative Office
Room 411, China Hotel Office Tower
Liu Hua Road, Guangzhou 510015
China
Phone: +86 20-8667-5381
Kyowa Pharmaceuticals (HK) Co. Ltd.

Room 2103, Hang Lung Centre
2-20 Paterson Street, Causeway Bay, Hong Kong
China
Phone: 852-2895-6795
Kyowa Hakko Pharmaceuticals (Suzhou) Co. Ltd.

No.115 QingQju Street, Suzhou Industrial Park
Jiangsu 215021, China
Phone: +86 512-6283-1082
Shanghai Kyowa Amino Acid Co. Ltd.

No.158 Xintuan Road
Qingpu Industrial Zone, Shanghai, 201700
China
Phone: +86 21-5970-1998
Wuxi Kyowa Food Co. Ltd.

No.158 Xu Xiang Lane Li Yuan
Wuxi 214072, China
Phone: +86 510-8512-9781
Yantai Kyowa Foods Co. Ltd.

Zhao Wang Zhuang Town,
Laiyang City, Shandong 265225
China
Phone: +86 535-761-5778
®

BioWa Inc. anti IL-5 receptor development and 3/05
antibody commercialization
agreement
BioWa Inc. development and licensing agreement 10/05
Anti-Fibroblast Growth
Factor 8 (FGF8)
monoclonal antibody
worldwide, except Asia
Bunge Australia activated gluten licensing agreement 10/85
Cephalon Inc. Myotrophin (mecasermin development and 7/93
[recombinant DNA marketing
origin]) injection agreement
Cephalon Inc. small neurotrophic licensing agreement 6/92
molecules for treating
head and spinal injuries
and other
neurodegenerative
disorders
COR small molecule three-year 12/95
Therapeutics Inc. pharmaceuticals for development
treating restenosis agreement (12/92),
following angioplasty extended for an
additional two years
Eli Lilly and Co. combinatorial chemistry research 3/97
collaboration--Lilly
to provide
technology transfer
and to receive up-
front fees,
milestone payments
and royalties on first
two products to
reach market
Ethical Holdings morphine product distribution 10/95
plc agreement for
Singapore and
Malaysia
European EO9 anticancer agent R&D agreement
Organization of
Research and
Treatment for
Cancer (EORTC)
Genomatica Inc. Ganomatica's modeling licensing agreement 1/05
and simulation platform
Geron Corp. Geron's assay for licensing agreement 9/96
detection of telomerase
activity in tumors
Geron Corp. small molecule drugs R&D agreement 5/95
Government of genetically engineered joint venture called 1991
Hungary lysine Agroferm
Hungarian-
Japanese
Fermentation
Industry Ltd.,
Kyowa is supplying
the bacterial host
and the
manufacturing
technology
®
LeukoSite Inc. CCRI and CXCR3 collaborative R&D 4/98

and licensing
agreement (4/97),
expanded to include
developing
treatments for
inflammatory and
autoimmune
diseases (11/97),
extended
Murex MAb-based AIDS development, 6/87
Diagnostics Inc. diagnostics manufacturing, and
marketing
agreement through
Kyowa Medex Co.,
Ltd.
Scotia Scotia's Foscan licensing 9/97
Pharmaceuticals photosensitizing drug for agreement--
Ltd. cancer Boehringer
Ingelheim gets
exclusive rights to
develop and market
in North and South
America and
Europe, Kyowa
Hakko gets
exclusive rights in
Japan, Scotia
retains rights in
other territories--
Scotia gets $54M in
up-front and
milestone payments
and will
manufacture
product for both
partners
RESEARCH & DEVELOPMENT: Therapeutics (modified G-CSF), Mab-based cancer diagnostics and
fermentation strain improvement (enzymes, amino acids, and nucleic acids)
Cell fusion technology
Plant cell culture
Aquaculture rDNA salmon growth hormone
Industrial-scale process for cell cultivation, immobilized enzymes
Diagnostics to detect HTLV-I
PRODUCTS ON MARKET: PHARMACEUTICALS: Coniel®, Allelock®, Celtect®, Itrizole®, Durotep
Patch®, Depakene®, Neu-up®, Inovan®, Mitomycin, 5-FU, Leunase®,
diagnostic reagents
BIO-CHEMICALS: amino acids, nucleic acids, malic acid, enzymes,
citicoline, minocycline, ubidecarenone (CoQ10), agrochemicals, animal
health products, feeds, feeds additives, health foods, raw material alcohol
CHEMICALS: solvents, plasticizers and their raw materials, organic acids,
diols
FOOD: seasonings, bakery products and ingredients, freeze-dried foods
®
Laboratoires Eurobio
7 avenue de Scandinavie
Les Ulis 91953, France
Phone: +33 (0) 1 69-07-94-77; Fax: +33 (0) 1 69-07-95-34
Web: www.eurobio.fr
E-mail: adv@eurobio.fr
KEY PERSONNEL: Stephane Reveilleau; President
FACILITIES: 2,000 sq. m. of state-of-the-art clean rooms and GMP biological production
capacity
STOCK-FINANCIAL HISTORY: Privately held--Wholly-owned by the Reveilleau family
SUBSIDIARIES/DIVISIONS: Human Diagnosis division: Immuno-hematology and viral and bacterial
diagnosis
Life Science division: molecular biology and cellular culture
BUSINESS STRATEGY: Develop, produce and market reagents intended for research and the
biomedical diagnosis
Hemagen MRL diagnostic kits distribution 1987
agreement
Institut Merieux HLA typing antisera exclusive worldwide 2/88
(now Sanofi distribution
Pasteur) agreement
MRL distribution 1990
agreement
Roche PCR license 1996
PRODUCTS ON MARKET: Bovine serum

Horse serum
Other sera
Cell culture media
Insect cell culture media
Powdered and liquid salt solutions
Separation media
Antibiotics
Cell culture buffers
Cytogenetics and dissociating reagents
Dyes
RNA extraction kits
RNA/DNA purification
Other reagents for nucleic isolation
Enzymes for reverse transcription
Enzymes for in vitro amplification
dNTP's
Oligonucleotides
Agaroses
Acrylamide
Electrophoresis buffers/dyes
Biochemical products
®
Lake States
515 West Davenport Street
Rhinelander WI 54501, US
Phone: (715) 369-4397; Fax: (715) 369-4034
Web: www.wplakestates.com
E-mail: lgary@wausaupaper.com
KEY PERSONNEL: Linda Fox; Manager
Linda Gary; Marketing
STOCK-FINANCIAL HISTORY: Privately owned by parent
SUBSIDIARY OF: Wausau Paper Corp.
BUSINESS STRATEGY: Develop value-added yeast products for the food, biotech, health food, HBA,
feed, and pet food markets
RESEARCH & DEVELOPMENT: Yeast related research

PRODUCTS ON MARKET: Inactive torula yeast
Autolyzed yeasts
Smoked yeasts
Yeast extracts
LANXESS AG
Building K 10
Leverkusen 51369, Germany
Phone: +49 (0)214 / 30-33333
Web: www.lanxess.com
E-mail: lanxess-info@lanxess.com
KEY PERSONNEL: Dr. Axel Claus Heitmann; Chairman
Matthias Zachert; CFO
Dr. Martin Wienkenhover; Director, Industrial Relations
HISTORY: Byer Ag founded in 1863
Bayer's chemical activities and one-third of polymer activities combined to
form LANXESS Deutschland GmbH (2004)
Divested fine chemicals business, which now operates as Saltigo (4/06)
FACILITIES: 50 locations in 18 countries
STOCK-FINANCIAL HISTORY: Listed on the Frankfurt Stock Exchange
Net loss <EUR63M> (YE 05) compared to <EUR12M> (YE 04)
Loss per share <EUR0.75/share> (YE 05) compared to <EUR0.16/share>
(YE 04)
Total assets EUR4.341b (YE 05) compared to EUR4.577b (YE 04)
SUBSIDIARIES/DIVISIONS: Business units:
Performance Rubber: Butyl Rubber, Polybutadiene Rubber, Technical

Rubber Parts
®
Engineering Plastics: Styrenic Resins, Semi-Crystalline Products

Chemical Intermediates: Basic Chemicals, Inorganic Pigments
Performance Chemicals: Material Production Products, Functional
Chemicals, Leather, Textile Processing Chemicals, Paper, Rubber
Chemicals, Ion Exhcnage Resins
LANXESS Deutschland GmbH--Germany

LANXESS Corp.--Pittsburgh, Pa.
LANXESS Elastomeres SAS--France
LANXESS Inc.--Sarnia, Ontario
LANXESS International SA--Switzerland
LANXESS NV--Belgium
LANXESS Rubber NV--Belgium
RheinChemie--Germany
BUSINESS STRATEGY: Develop, produce and market high-quality chemicals, rubber and plastics
Lavipharm SA
Agias Marinas Str.
Peania NJ 190 02, Greece
Phone: +30 210 6691 000; Fax: +30 210 6645 386
Web: www.lavipharm.gr
E-mail: information@lavipharm.com
KEY PERSONNEL: Dr. Athanase Lavidas; Chairman and CEO
Tania Vranopoulos; COO
Spyridon Fotinos; Exec. VP, Corporate Research and Innovation
Established Laboratoires Lavipharm (1989)
Started Synthelabo-Lavipharm, a joint venture with Synthelabo-France
(1992)
Started Lavicosmetica, a joint venture with L’Oreal CosmetiqueActive (1992)
Lavipharm S.A. listed on the Athens Stock Exchange (1995)
Acquired Separex (2000)
Acquired Phasex (2000)
FACILITIES: 109,000 sq. m. total area (4,600 sq. m. of facilities) in Princeton, N.J.
STOCK-FINANCIAL HISTORY: Athens Stock Exchange--LAVI
Operating profit EUR14.642 (YE 05) compared to EUR18.537M (YE 04)
(YE 04)
Total assets EUR194.701M (YE 05) compared to EUR217.571M (YE 04)
SUBSIDIARIES/DIVISIONS: Lavipharm Hellas SA--Rx and OTC
Castalia Laboratoires Dermatologiques SA--Dermocosmetics
LAS SA--Pharmaceutical wholesaler
Pharma Logistics SA--Logistics service provider
Pharma Plus SA--Integrated services to pharmacies
Lavipharm Pharmaceutical Services Ltd.--joint venture with businessman
Efthyvoulos Paraskevaides
Lavipharm Distribution Ltd.--Subsidiary of Lavipharm Pharmaceutical
Services Ltd.
Lavipharm Cyprus Ltd.--Subsidiary of Lavipharm Pharmaceutical Services
Ltd.
Lavipharm Corp.--Affiliated holding company in the pharmaceutical
technology sector
Lavipharm Laboratories Inc.--R&D center in the U.S.
Phasex SA--Affiliated company specializing in supercritical fluids (SCF)
technology
®
Separex SA--Affiliated French pharmaceutical company pioneering SCF

technology
Hitex SA--Affiliated company that has SCF extraction and contract
manufacturing departments
Laboratoires Lavipharm SA--Affiliated company responsible for international
promotion of dermocosmetic products
BUSINESS STRATEGY: Develop, manufacture, market and distribute pharmaceutical, cosmetic and
consumer health products in Greece and internationally
GlaxoSmithKline Lavipharm's SCF three-year research 4/03
plc technology collaboration and
licenaing agreement
Intervet Pharma Intervet compound for development 5/02
R&D SA (through veterinary agreement
Lavipharm Corp.) pharmaceutical
products
Senetek PLC Lavipharm to launch licensing agreement 3/04
line of Kinetin-based
skin care products
under its Castalia brand
RESEARCH & DEVELOPMENT: Focus is on pioneer technologies of particle design, drug delivery systems,
cosmetic delivery systems, and the development of natural products
Development of pharmaceutical products containing new drugs that might
otherwise have been abandoned because of solubility or other drug delivery
problems
Modification of existing drugs in order to improve their pharmacokinetic-
pharmacodynamic profiles, extend their patent coverage duration and
increase their competitive position, thus extending the drug's life cycle
PRODUCTS ON MARKET: Lavipharm Hellas: Algon (pain reliever), Addditiva (vitamins), Ivaliten (anti-
lice), Laxemel (laxative), Prot Algon-Antipyretic 'enfants,' Breath Right,
RFSU, Lactal
Otccastalia Laboratoires Dermatologiques: Laviderm
Lawrence Berkeley National Laboratory

1 Cyclotron Road
Berkeley CA 94720, US
Phone: (510) 486-6467; Fax: (510) 486-6457
Web: www.lbl.gov; E-mail: ttd@lbl.gov
KEY PERSONNEL: Steven Chu; Laboratory Director
Jeff Fernandez; CFO
EMPLOYEES: 4,000 employees, 1,200 Ph.D.s
SUBSIDIARIES/DIVISIONS: Includes 15 divisions organized within the areas of Computing Sciences,
Energy Sciences, Biosciences, General Sciences, and Resources and
Operations
BUSINESS STRATEGY: Berkeley Lab conducts unclassified research across a wide range of
scientific disciplines with key efforts in fundamental studies of the universe;
quantitative biology; nanoscience; new energy systems and environmental
solutions; and the use of integrated computing as a tool for discovery. It is
organized into 17 scientific divisions and hosts four DOE national user
facilities.
®

undisclosed
RESEARCH & DEVELOPMENT: Materials

Energy efficiency
Energy and environment
Earth science
High energy physics
Accelerator and fusion
Life science
Nanoscience
Physical bioscience
Genomics
Computing science
LG Chem Ltd.
LG Twin Towers, 20, Yeouido-doing, Yeongdeungpo-gu
Seoul 150-721, Korea
Phone: +82 2-3773-0617, 0618; Fax: +82 2-785-0324
Web: www.lgchem.com
E-mail: info@lgchem.com
KEY PERSONNEL: Bahn-Suk Kim; President and CEO
Yu-Sig Kang; CEO and Vice Chairman
Suk-Jeh Cho; Exec. VP and CFO
Kyusok Park; Exec. VP, Industrial Materials
Sangjin Hong; VP, LG Chem, China
Jin-Nyoung; Exec. VP, LG Chem Research Park
Established its central research institute in 1979
Started R&D in genetic engineering field in 1981
Acquired Anjin Pharma Corp., Pharmaceutical Division (1989)
Name changed from Lucky Ltd. (1995)
Demerged from LG Chemical Ltd. into LG Chem Investment, LG Chem and
LG Household & Healthcare (4/01)
STOCK-FINANCIAL HISTORY: Listed on the Korean Stock Exchange
Sales W71.274b (YE 04) compared to W56.725b (YE 03)
Net income W5.364b (YE 04) compared to W3.621b (YE 03)
SUBSIDIARIES/DIVISIONS: Three main businesses: Chemicals and polymers, industrial materials, and
information and electronic materials
Subsidiaries:
LG Petrochemical Ltd.
LG Dow Polycarbonate Ltd.
Tianjin LG Dagu Chemical Co. Ltd.
Ningbo LG Yongxing Chemical Co. Ltd.
Tianjin LG New Building Materials Co. Ltd.
Tianjin LG Window & Doors Co. Ltd.
LG Chemical (Guangzhou) Engineering Plastics Co. Ltd.
LG Chem (Nanjing) Information & Electronica Materials
LG Chemical India Private Ltd.
LG Chemical America Inc.
LG Chemical Hong Kong Ltd.
Compact Power Inc.
LG Chem Industrial Materials
LG VINA Chemcial
LG Chem (China) Investment Co. Ltd.
LG Chem (Tianjin) Engineering Plastics Co. Ltd.
®
Tianjin LG Bohai Chemical Co. Ltd.

LG Chem Poland Sp. zoo
LG Chem Brasil Ltd.
LG Chem Europe GmbH
BUSINESS STRATEGY: Petrochemical and industrial materials business: Consolidate its foothold
and position itself as a major player in main growing markets such as China
and the U.S. by raising its product quality and cost competitiveness through
enhanced R&D and marketing abilities.
Information and electronic materials business: Focus on rapid developments

of new high-tech products and increasing capacities for its main products
such as rechargeable batteries and display materials.
PRODUCTS ON MARKET: Industrial materials: housing and space materials, living materials,
automobile components, interior decoration materials
Chemicals and polymers: PVC and plasticizers, acrylates and e-chemicals,

polyolefin, AVS/PS, engineering plastics, specialty polymers
LG Life Sciences Ltd.

LG Twin Tower, East Tower, 20, Yoido-dong, Youngdungpo-gu
Seoul, Korea
Phone: +82 2-3773-1114; Fax: +82 2-3773-7012
Web: www.lgls.co.kr; E-mail: hycho@lgls.co.kr
KEY PERSONNEL: Heung-Joon Yang; CEO and Chairman
Han-Yong Yang; VP and CFO
Established its central research institute in 1979
Started R&D in genetic engineering field in 1981
Acquired Anjin Pharma Corp., Pharmaceutical Division (1989)
Name changed from Lucky, Ltd. (1995)
Demerged from LG Chemical Ltd. into LG Chem Investment, LG Chem and
LG Household & Healthcare (2001)
Spun off from LGCI and name changed to LG Life Sciences (2002)
Factive quinolone antibiotics approved by US FDA (2003)
FACILITIES: Two manufacturing facilities and R&D Park located in South Korea
Pharmaceutical division has two GMP main factories in Iksan and in
Daejeon
STOCK-FINANCIAL HISTORY: Listed on the Korean Stock Exchange
Sales W213,636 (YE 04) compared to W179,037M (YE 03)
Net income W10,073 (YE 04) compared to W3,225M (YE 03)
SUBSIDIARIES/DIVISIONS: Pharmaceutical Division
Agricultural Division
LG Life Sciences India Pvt. Ltd.
LG Life Sciences Poland Sp. Z.o.o
LG Life Sciences Ltd.
Beijing representative office
INVESTMENTS: Elitra Pharmaceuticals
BUSINESS STRATEGY: Enhancement of Efficiency in R&D:
-Focus all-out efforts on candidate materials for developments that have
passed pre-clinical trials
-More systematic promotion of R&D projects
-Solidify alliances with world-class business enterprises
®
Advance into Markets for Generic Bio Drugs in Industrialized Countries

-Advance into markets in industrialized countries through marketing
alliances
-Establish local corporations in strategically important areas
Firm Up our Position as a Market Leader in the Domestic Market

-Continue development of advanced marketing techniques
-Focus on the development of products meeting our customers’ specific
needs
-Strengthen our licensing activities
Aeterna anti-cancer drug in-licensing 2003
agreement
Anadys hepatitis B treatment out-licensing and 2004
Pharmaceuticals joint development
Inc. agreement
Biogen Idec Inc. psoriasis treatment in-licensing 2004
agreement
BioPartners sustained-release out-licensing and 2001
human growth hormone joint development
agreement
BioPartners genetically-engineered joint development 1997
products and marketing
agreement
DepoMed diabetes treatment in-licensing 2004
agreement
Eximias liver cancer treatment in-licensing 2002
agreement
GlaxoSmithKline new quinolone antibiotic licensing agreement 1997
plc
KYORIN development, licensing agreement 2005
Pharmaceutical manufacturing and
Co. Ltd. sales of KRP-197 in
Korea
Oscient quinolone antibiotics out-licensing 2002
Pharmaceuticals agreement
Sinovac Biotech hepatitis B vaccine in distribution 3/06
Ltd. China agreement
Sinovac Biotech hepatitis A vaccine, letter of intent 5/05
Ltd. hepatitis B vaccine,
combined hep A and
hep B vaccine, avian flu
vaccine
Yamanouchi (now treatments for obesity, R&D collaboration 2001
Astellas Pharma hyperlipidaemia
Inc.)
RESEARCH & DEVELOPMENT: Anti-cancers

Anti-infectives
QOL (Quality of Life)
PRODUCTS ON MARKET: Factive (Quinolone antibiotics)
Intermax gamma (Gamma-IFN)
Intermax alpha (Alpha-IFN)
LG HCD (hepatitis C diagnostic)
LG HBs Ag Elisa (hepatitis B diagnostic)
LG Anti-HBs Elisa (hepatitis B diagnostic)
LG HCD confirm (hepatitis C diagnostic)
Euvax B (hepatitis B vaccine)
Eutropin (hGH)
Leucogen (GM-CSF)
IFN-a
Hyruan (Hyaluronic acid)
HCD
®
HBD
EPO
BGH
Ivermectin
Ceftiofur
NEW CHEMICAL ENTITIES:
LB 80380 for hepatitis B in Phase II clinicals
LB 84451 for HCV, NASH in Phase I clinicals
LB 53280 for obesity in preclinicals
LC15-0133 for Type II diabetes in preclinicals
Thrombin Inh - DVT, AF in preclinicals
HCV inhibitor for hepatitis C completed discovery
LGC (Laboratory of the Government Chemist)

Queens Road
Teddington TW11 0LY, UK
Phone: +44 (0) 20 8943 7000; Fax: +44 (0)20 8943 2767
Web: www.lgc.co.uk
E-mail: info@lgc.co.uk
KEY PERSONNEL: Ian Kent; Chairman
Dr. Nigel Law; CEO
Dr. Paul Debenham; Director, Life Sciences
Dr. Angela Gallop; Director, LGC Forensics
LGC (Holdings) Ltd. is formed (2/93)
LGC (Holdings) Ltd. acquired Laboratory of the Government Chemist (4/96)
Acquired Pipeline Developments Ltd. (1997)
Acquired University Diagnostics Ltd. (1997)
Acquired ICI's Runcorn analytical unit (1998)
Formed GeneSolve, a joint venture with Dundee University (1999)
Acquired the Promochem Group of Companies (2001)
Sold Pipeline Developments Ltd. (2002)
Acquired Forensic Alliance Ltd. (9/05)
Acquired Agowa (1/06)
FACILITIES: Locations in France, Germany, Spain, Sweden, the U.K., Italy and Poland
Distribution office in India
BUSINESS STRATEGY: Vision:
Be an international business, recognised for setting standards in analytical
science and providing best value products, services and solutions
To meet its vision, the company will: increase turnover by 15 percent year
on year with profit at or above 10 percent of sales, and achieve 25% of its
turnover from outside the U.K.

King’s College pharmacogenetic exclusive licensing 11/05
London screening service that agreement
will predict if a patient
with schizophrenia will
respond positively to
clozapine
®
Gentris Corp. Gentris can create, use non-exclusive 6/06

and sale of diagnostic licensing agreement
products and services
which include testing for
the CYP2D6*4
polymorphism in the
U.S.
RESEARCH & DEVELOPMENT: Bioanalytical and genetic diagnostics and detection methodologies
DNA analytical technologies
Reference standards
PRODUCTS ON MARKET: Analytical services/consultancy
Paternity testing
Forensics
Livestock genotyping
GMOs
DNA databasing/analysis
BSE testing
Reference standards
LifeCell Corp.
One Millennium Way
Branchburg NJ 08876-3876, US
Phone: (908) 947-1100; Fax: (908) 947-1089
Web: www.lifecell.com
E-mail: corporatecommunications@lifecell.com
KEY PERSONNEL: Paul G. Thomas; Chairman, President and CEO
Steven T. Sobieski; VP, Finance and Administration and CFO
Lisa N. Colleran; Sr. VP, Commercial Operations
Dr. Bruce Lamb; Sr. VP, Development, Regulatory Affairs and Quality
Young C. McGuinn; VP, Manufacturing Operations
HISTORY: Formed in 1986 by a technology transfer from the University of Texas Health
Science Center in Houston to commercialize patented biopreservation
technology
FACILITIES: 90,000 sq. ft. of leased office, laboratory, production and warehouse space
STOCK-FINANCIAL HISTORY: NASDAQ--LIFC
IPO--800K units, each unit consisting of one share of common stock and
one warrant to purchase 1/2 share of common stock, at $7.75/unit (2/92)
Public offering--4M shares at $4.50/share, $18M (11/97)
04)
PRIVATE PLACEMENTS: $5.3M in an offering of 265K units at $20/unit (11/94)
Raised $15.7M in private placement of 3.7M shares of common stock at
$4.25/share (2003)
®
PRINCIPAL INVESTORS: Medtronic Inc.

Essex Woodlands
Vector Later-Stage Equity Fund
CIBC Wood Gundy
BUSINESS STRATEGY: Develop technology for processing other universally transplantable tissue
grafts and extended preservation of transfusable blood products
LifeCore AlloDerm for periodontal exclusive distribution 6/97
Biomedical Inc. procedures agreement for the
U.S.
Medtronic Inc. porcine-tissue heart licensing agreement 3/94
valves
US Army Institute AlloDerm grafts for use development 1/97
of Surgical in neurological, agreement--LifeCell
Research dermatological and to receive $1.07M
cardiovascular surgery over two years in
product
development
funding and will use
tissue preservation
technology to
develop vascular
grafts for bypass
surgery
US Navy ThromboSol platelet $600K development 8/98
storage solution funding
RESEARCH & DEVELOPMENT: Universal Tissue Grafts, including skin, vascular conduits and heart valves
Products for extending the shelf life of transfusable blood cells including red
blood cells and platelets
PRODUCTS ON MARKET: AlloDerm® - processed tissue products for grafting of third degree burns,
grafting and guided tissue regeneration in periodontal surgery and tissue
repair in plastic reconstructive surgery
Cymetra® - version of AlloDerm in particulate form for the correction of soft
tissue defects
Repliform® - acellular tissue matrix for urologic and gynecologic procedures
Graft Jacket® - accelular tissue matrix for orthopedic applications
AlloCraft™DBM - for bone grafting procedures
LifeSensors Inc.
271 Great Valley Parkway, Suite 100
Malvern PA 19355, US
Phone: (610) 644-8845; Fax: (610) 644-8616
Web: www.lifesensors.com
E-mail: info@lifesensors.com
KEY PERSONNEL: Tauseef R. Butt, Ph.D.; President and CEO
Michael R. Mattern, Ph.D.; VP, Research
John Hall; VP, Business Development
Bob Griess; Director, Finance
Began biotech R&D December 1996
SUBSIDIARY OF: Gene Transcription Technology
®
PRINCIPAL INVESTORS: Ben Franklin Technology Partners

BUSINESS STRATEGY: Discover, develops, manufacture and market important protein expression
technologies based on advances in cellular and molecular biology
Market to academic and government research institutions, and
pharmaceutical and biotechnology companies worldwide in efforts to
improve the quality of human life
Embrex Inc. development of a three-year 1/00
sensor for the poultry agreement
gender sorting market
Rohm & Haas Co. development of insect research 12/96
receptor based collabration
screening technology
RESEARCH & DEVELOPMENT: Protein expression and biosensors utilizing the benefits of SUMO
PRODUCTS ON MARKET: SUMOpro™ Expression System
Split SUMOpro™ Expression System
Fusion controls
Proteases
Expression vectors
Prokaryotic, yeast and insect expression kits
Estrogen detection biosensor development stage
2nd Generation SUMO Expression development stage
Systems
Link Technologies Ltd.

3 Mallard Way, Strathclyde Business Park
Bellshill ML4 3BF, UK
Phone: +44 (0) 1698-849911; Fax: +44 (0) 1698-849922
Web: www.linktech.co.uk
E-mail: enquiries@linktech.co.uk
KEY PERSONNEL: Jim Fisher; Chairman
Dr. Michael Gray; Managing Director
Dr. Douglas Picken; Director, R&D
Dr. John Bremner; Director, Business Development
Began biotech R&D in May 1989
FACILITIES: 7,000 sq. ft. laboratory, office and warehouse facility
RESEARCH & DEVELOPMENT: Nonradioactive labeling of oligonucleotides

Antisense DNA reagents
Base-modified nucleotides
Biomolecule conjugation
PRODUCTS ON MARKET: Range of reagents for DNA synthesis
Supported reagents for large-scale synthesis
®
Lonza Group Ltd.

Muenchensteinerstrasse 38
Phone: +41 61-316-8111; Fax: +41 61-316-9111
Web: www.lonza.com
E-mail: contact@lonza.com
KEY PERSONNEL: Rolf Soiron, Ph.D.; Chairman
Stefan Borgas; CEO
Toralf Haag, Ph.D.; CFO
Lukas Utiger, Ph.D.; Head, Organic Fine & Performance Chemicals
Stephan Kutzer, Ph.D.; Head, Biopharmaceuticals
Rosario Valido; Head, Polymer Intermediates
Acquired biologics contract manufacturing business of UCB (1/06)
FACILITIES: Headquarters in Basel, Switzerland
R&D facilities in Visp, Switzerland; Slough, U.K.; Portsmouth, N.H.; and
Guangzhou, China
Manufacturing facilities in Visp, Switzerland; Kourim, Czech Republic;
Slough, U.K.; Portsmouth, N.H.; and Conshohocken, Pa.
STOCK-FINANCIAL HISTORY: Financial data for the Lonza Group:
Sales CHF2.521b (YE 05) compared to CHF2.182b (YE 04)
Net income CHF188M (YE 05) compared to CHF138M (YE 04)
(YE 04)
Total assets CHF4.331b (YE 05) compared to CHF3.341b (YE 04)
SUBSIDIARIES/DIVISIONS: Exclusive Synthesis & Biopharmaceuticals
Organic Fine & Performance Chemicals
Polymer Intermediates
BUSINESS STRATEGY: Lonza develops products and processes for fine chemicals and active
pharmaceutical ingredients in R&D centres and manufacturing plants in the
U.S., Europe and Asia
Lonza offers custom manufacturing services in the fields of monoclonal
antibodies, therapeutic proteins, biotransformations and fermentation
RESEARCH & DEVELOPMENT: Organic intermediates and APIs

Biotransformation projects
Fermentation processes (microbial and mammalian technologies)
PRODUCTS ON MARKET: Lonza offers a wide range of organic intermediates and active substances
Maine Biotechnology Services Inc.

1037R Forest Avenue
Portland ME 04103, US
Phone: (207) 797-5454; Fax: (207) 797-5595
Web: www.mainebiotechnology.com
E-mail: info@mainebiotechnology.com
KEY PERSONNEL: Joseph P. Chandler, Ph.D.; President
Carrie Cloutier; Sales Director, Custom Services
Michael Sullivans; Production Manager
®

4,200 sq. ft. R&D and manufacturing facilities
BUSINESS STRATEGY: Provide MAb development and production services and immunodiagnostic
reagents to commercial and academic laboratories
Mallinckrodt Inc.
675 McDonnell Boulevard
Hazelwood MO 63042, US
Phone: (314) 654-2000
Web: www.mallinckrodt.com
E-mail: info@mallinckrodt.com
KEY PERSONNEL: Richard J. Meelia; CEO, Tyco Healthcare
Michael J. Collins; President, Pharmaceuticals Division
Douglas A. McKinney; VP, Finance and CFO
Steven Hanley; President, Imaging Division
Scott Drake; President, Respiratory
Lisa Britt; VP, Human Resources
HISTORY: Divested fertilizer business (now IMC Global Inc.)
Bought Mallinckrodt, Inc. from Avon
Bought Coopers Animal Health from ICI/Wellcome
Changed name from IMCERA Group Inc. (3/94)
Name changed from Mallinckrodt Group Inc. (10/96)
Acquired Nellcor Puritan Bennett Inc. for $1.9b (7/97)
Veterinary Division:
Acquired by International Minerals & Chemical Corp. from Johnson &
Johnson (3/87)
Business is a combination of International Minerals & Chemical Corp.'s feed
ingredient division, veterinary products division, Sterwin Poultry Health
Division, Coopers Animal Health and Glaxo AH
Formerly named Pitman-Moore, Inc., changed name (3/94)
Acquired Syntro Corp. (11/95)
Acquired poultry and companion animal business from CBM Laboratories,
Campinas, Sao Paulo, Brazil, (11/95)
Sold animal feeds ingredients business to IMC-Agrico (11/95)
Sold sensor systems business (9/96)
Divested interest in Tastemaker flavors business (1/97)
Agreement reached to sell Mallinckrodt Veterinary to Schering-Plough
Acquired by Tyco International Ltd. (10/00)
SUBSIDIARIES/DIVISIONS: Pharmaceuticals, Respiratory and Imaging
SUBSIDIARY OF: Mallinckrodt is a business unit of Tyco Healthcare
BUSINESS STRATEGY: Create value for shareholders through growth in sales and profitability driven
by innovation and productivity in human healthcare and specialty chemical
businesses

Advanced MRI contrast agent manufacturing and 1990
Magnetics Inc. distribution
agreement in the
U.S. and Canada
®
Advanced WarmTouch worldwide 1992

Warming Systems manufacturing and
Inc. distribution
agreement
Centocor Inc. Myoscint exclusive marketing 9/93
agreement for
Europe, the Middle
East, and Africa
Iradimed Corp. Mridium MRI IV pump in sales agreement 5/06
the U.S., Canada and
Mexico
Medi-Physics radiopharmaceuticals rights for Medi- 1995
Physics proprietary
product line to be
distributed through
Mallinckrodt's 35
radiopharmacies
Metasyn Inc. MS-325 and other MRI worldwide 10/96
vascular agents development and
marketing
agreement (except
Japan)
Molecular MBI's Albunex second distribution 4/96
Biosystems Inc. generation product, agreement
FS069 ultrasound
imaging agents
Netherlands Molybdenum-99 construction of 1992
Energy Research Moly-99 plant
Foundation
OPTIMEDx optical imaging agents exclusive worldwide 1994

licensing rights to
develop optical
imaging agents for
mammography and
nonexclusive
license to develop
agents for use in
other types of
cancer
Palatin Palatin's NeutroSpec marketing
Technologies Inc. agreement,
extended 6/05
Schering AG MRI contrast agent enables both 1993
(Germany) parties to sell select
MRI products under
each others' patents
University Hospital radiopharmaceuticals development, 1991
Dijkzigt and for cancer imaging production, and
Sandoz Pharma marketing
Ltd. agreement
PRODUCTS ON MARKET: Contrast media and delivery systems

Radiopharmaceuticals
Urology imaging systems
Active pharmaceutical ingredients
Addiction treatment products
Restoril®7.5mg and 22.5mg (temazepam capsules USP)
Tofranil®-PM (imipramine pamoate capsules)
Generic pharmaceuticals
®
Marcor Development Corp.

341 Michele Place
Carlstadt NJ 07072-2304, US
Phone: (201) 935-2111; Fax: (201) 935-5223
Web: www.marcordev.com
E-mail: sales@marcordev.com
KEY PERSONNEL: Charles J. Garbarini; President
Sar Dorman; Sales Specialist, Biologicals
Michael J. Malavasic, Ph.D.; Eastern Sales Manager, Biologicals
Patty Powers-Feigel; International Manager
RESEARCH & DEVELOPMENT: Reagents, enzymes

PRODUCTS ON MARKET: Research reagents, enzymes, fermentation nutrients, peptones, yeast
extracts
Maruzen Pharmaceuticals Co. Ltd.

14703-10 Mukaihigashi, Onomichi
Hiroshima 722-0062, Japan
Phone: +81 848-44-2217; Fax: +81 848-44-6851
Web: www.maruzenpcy.co.jp
KEY PERSONNEL: Heishiro Higurashi; Chairman
Akifumi Higurashi; President
Takao Ikeda; Managing Director
SUBSIDIARIES/DIVISIONS: Longev Co. Ltd.
Rooprun Pty. Ltd.
BUSINESS STRATEGY: Manufacture and distribute pharmaceuticals, quasi-drugs, cosmetics,
agricultural industrial products, health food, and food. Manufacture and
distribute veterinary pharmaceuticals, livestock feed and fertilizers for crops.
RESEARCH & DEVELOPMENT: Antityrosinase agents and radical scavengers for cosmetics
Anti-inflammatory agents for cosmetics
Health foods, designer foods
Seasonings, low-calorie sweetener
PRODUCTS ON MARKET: Licorice products for foods: Glycymin®, Glycymin® Cool
Stevia products for foods: Marumilon Pure, alpha-G Sweet H, alpha-G
Sweet PX, MARUMILON RICH A
Licorice products for cosmetics: Dipotassium Glycyrrhizinate, Stearyl
Glycyrrhetinate, Polyol Soluble Licorice Extract P-T (40)
Quillaja saponin preparation
Various plant extracts for cosmetics and toiletries
Health food ingredients
®
Mascoma Corp.
161 First Street, Second Floor East
Phone: (617) 234-0099; Fax: (617) 868-0408
Web: www.mascoma.com
E-mail: info@mascoma.com
KEY PERSONNEL: Vinod Khosla; Chairman
Colin South, Ph.D.; President
Lee R. Lynd, Ph.D.; CSO
Dr. Andrew Richard; CTO
Dr. David Hogsett; VP, R&D
Herve I. Garant, Ph.D.; Director, Bioprocess Engineering/Operations
Siva Subramanian, Ph.D.; Director, Bioprocess Engineering/Design
PRIVATE PLACEMENTS: Secured $4M in Series A financing (7/06)
PRINCIPAL INVESTORS: Khosla Ventures
Flagship Ventures
BUSINESS STRATEGY: Develop unique bio and process technology for cost-effective conversion of
cellulosic biomass (grass, wood, agricultural and forestry wastes)
Two-pronged strategy of technology development and deployment, including
patenting technologies for cellulosic production and forming partnerships to
commercialize new cellulosic ethanol technologies and processes
Dartmouth Mascoma to research exclusive worldwide 8/06
College and produce ethanol license agreement
from cellulosic biomass
based on several
patents from Dartmouth
Integrated analysis of the genome contract 8/06
Genomics Inc. of a microbe important
to breaking down
cellulosic biomass for
conversion into ethanol
RESEARCH & DEVELOPMENT: Cellulosic biomass-to-ethanol development and production, based on work
developed in Prof. Lee R. Lynd’s labs at Dartmouth College
Matreya LLC
168 Tressler Street
Pleasant Gap PA 16823, US
Phone: (814) 359-5060; Fax: (814) 359-5062
Web: www.matreya.com
E-mail: customerservice@matreya.com
KEY PERSONNEL: Gary C. Walker; VP, Manufacturing
Amy Houtz; Office Manager/Purchasing Manager
®

Successor to Matreya Inc., founded in 1988
BUSINESS STRATEGY: Isolate, purify and synthesize bioactive lipids
RESEARCH & DEVELOPMENT: Synthesize sphingolipids

PRODUCTS ON MARKET: 240 lipids and mixtures
Maxxam Analytics Inc.

6740 Campobello Road
Mississauga L5N 2L8, Canada
Phone: (905) 817-5700; Fax: (905) 890-0370
Web: www.maxxam.ca; E-mail: info@maxxamanalytics.com
KEY PERSONNEL: John Martin; Chairman
Patricia Nielsen; CEO
Pierre Beaumier; President
Dean Taylor; CFO
Andrew Masters; VP, Eastern Operations
Bernie Brassard; VP, Western Operations
Name changed from Mann Testing Laboratories Ltd. (1994)
Merged with Chemex Labs Alberta (1996)
Name changed from NOVAMANN (Ontario) Inc. (1997)
Merged with PSC Analytical Services (PSC) (10/04)
FACILITIES: 150,000 sq. ft. laboratory facility
SUBSIDIARY OF: Maxxam Analytics International Corp.
Provide scientific solutions through innovation and expertise
RESEARCH & DEVELOPMENT: Application of PCR and DNA testing to animal genetics, parentage testing
and microbial testing
Agricultural consulting/testing services, residue registration studies
Equine drug testing services and research
PRODUCTS ON MARKET: Services include: drug detection, water quality testing, soil and water
analysis, toxicity evaluation, air monitoring and analysis, ultra trace
contaminant analysis by High Resolution Mass Spectrometry (HRMS),
petroleum testing services, field sampling services, laboratory design and
set-up, food chemistry and nutrition labeling, paternity tests and animal,
plant and food genetics
®
MBI International
3900 Collins Road
Lansing MI 48910, US
Phone: (517) 337-3181; Fax: (517) 337-2122
Web: www.mbi.org
E-mail: info@mbi.org
KEY PERSONNEL: Dr. Mark Stowers; President and CEO
Kellena D. Daigle; VP and CFO
Robert A. DeVries, Ph.D.; Sr. Scientist
Acquired CPC, International Corn Products Co. Technology Portfolio
Package--in-licensing of technologies from several major universities and
corporations
Changed name from Michigan Biotechnology Institute (1995)
SUBSIDIARIES/DIVISIONS: Bio-Business Incubator of Michigan (BBIM)--non-profit subsidiary
Auxein Corp. plant growth technology new company 1994
products formation to
commercialize
products
BioPlastics Inc. biocompostable plastic new company 1995
resins formation
EFX Systems Inc. fluid-bed reactor for new company 1995
environmental cleanup formation
applications
Enzyme Design enzymes for industrial, new company 1996
Inc. consumer and scientific formation
applications
EverCorn Inc. biodegradable plastic joint venture 1993
resins
Lions Adhesives environmentally friendly new company 1996
packaging and wood formation
adhesives
Natura Inc. food ingredients and new company 1994
derivatives formation
Plexis Biosciences expression systems new company 1997
Inc. formation
Synthon Corp. chiral intermediates new company 1993
formation
RESEARCH & DEVELOPMENT: Biomass processing: MBI has licensed the ammonia fiber explosion (AFEX)
process, a leading technology to pretreat biomass; Researching the use of
the AFEX process in ethanol plants to recover sugars from corn fiber waste,
to produce specialty chemicals in addition to ethanol via fermentation, to
produce valued compounds from hemicellulose, in the development of high
protein animal feeds, to facilitate the recovery of other valuable compounds
locked within corn fiber, to expand the use of agricultural biomass as low
cost feedstocks for chemical production and in fiber reinforced composites
Succinic acid production: Isolation of several succinic acid producing

microorganisms and development of a succinic acid producing bacterium,
Actinobacillus succinogenes, and hyperproducing mutants
Polyamide amine polymers: A new class of polymers
®
Biorefinery development: Development of various biochemical and

thermochemical routes to fuels, chemicals and materials and perfecting the
dry mill biorefinery process
Cellulose nanofibers: Production of microcrystalline cellulose nanowhiskers

through the utilization of the low-cost AFEX process with surface, interfacial
and mechanical properties in order to make them suitable as reinforcements
and fillers in polymers
PRODUCTS ON MARKET: Contract Services and Pilot-scale Manufacturing: Production of fragrances,
high cell density Escherichia coli fermentation for protein reagents and
protein biologicals, and the scale up of a specialty chemical produced via
fermentation
Bio-Business Incubator of Michigan: Offers assistance with the regulatory

approval process, interim CEOs, business planning, business plan
development, grant writing, finance and accounting, human resources,
corporate filings, secretarial support, laboratory and technical support, and
access to equipment and offices/laboratory space
MDS Pharma Services

The Triad, 2200 Renaissance Blvd., Suite 400
King of Prussia PA 19406-2755, US
Phone: (610) 239-7900; Fax: (610) 239-7111
Web: www.mdsps.com
E-mail: info@mdsps.com
KEY PERSONNEL: David Spaight; President and CEO
Riaz Bandali; VP and GM, Global Early Clinical Research
Robert Beland; VP, Discovery and Preclinical
Robert Butz, Ph.D.; Interim VP and GM, Global Clinical Development
Scott Neilson; VP and GM, Central Laboratories
John Robson; VP and GM, Global Bioanalytical Services
Peter Abram; Sr. VP, Finance
Cam Hicks; Sr. VP, Human Resources and Organizational Development
Jim McClurg, Ph.D.; Sr. VP and CSO
Robert Castellucci; VP, Quality
HISTORY: MDS Pharma Services was formed in 1999 from the merging of eight legacy
companies: MDS Harris, MDS Panlabs, MDS Glarif, MDS Analytical
Solutions, MDS Clinical Trial Laboratires, MDS Neo-Pharm, MDS Tricon and
Phoenix International Life Sciences
Sold its Fermentation Technologies business to Panlabs Biologics of Taiwan
(12/05)
FACILITIES: Locations in Johannesburg, South Africa; Beijing, China; Yokohama, Japan;
Malaysia; Singapore; Taipei, Taiwan; Pyrmont, Australia; Mississauga,
Blainville and Saint-Laurent, Canada; Mexico; Phoenix, Ariz.; Irvine, Calif.;
Lincoln, Neb.; Neptune and North Brunswick, N.J.; King of Prussia, Penn.;
Bothell, Wash.; New Orleans, La.; Buenos Aries, Argentina; Santiago, Chile;
Lima, Peru; Brussels, Belgium; Czech Republic; France; Germany;
Hungary, Italy; Poland; Romania; Madrid, Spain; Lund, Sweden;
Switzerland; Kiev, Ukraine; and the U.K.
SUBSIDIARY OF: MDS International Inc. (see separate entry)
BUSINESS STRATEGY: To be the premier provider of innovative drug discovery and development
solutions by offering our expertise in the areas of lead optimization, pre-IND
research, pharmaceutical and biopharmaceutical development, early clinical
research (bioequivalence, phases I-IIa), bioanalysis, global clinical
development (phases IIb-IV) and central lab
®
MedPharm Ltd.
Business Centre, Sheep Street, Oxfordshire
Charlbury OX7 3RR, UK
Phone: +44 160 881 9267; Fax: +44 160 881 9268
Web: www.medpharm.co.uk
E-mail: busdev@medpharm.co.uk
KEY PERSONNEL: Dr. Geoffrey Vernon; Chairman
Dr. Andrew Muddle; CEO
Dr. Mark Brown; CSO
Dr. Petra Beck; Director, Pharmaceutical Development
Carole Delauney; Head, Development Manager
EMPLOYEES: 35 employees, 30 scientists
BUSINESS STRATEGY: MedPharm is a specialist pharmaceutical development company of

international reputation, focusing in particular on topical (skin, nail, lung and
other mucous membranes) drug delivery systems. Projects range from
simple feasibility tests, dosage design and optimization through to
preparation of GMP clinical supplies for Phase I/II trials with guaranteed
smooth technology transfer to manufacturing sites. Developments are
performed at MedPharm’s GLP accredited laboratories located in London
and at the GMP facility based closed to London.
MedPharm develops formulations designed to meet the requirements of its
clients while maximizing the chance of clinical success. MedPharm relies on
its high level of scientific expertise to develop pharmaceuticals with all types
of active pharmaceutical ingredients (APIs) including those difficult to
formulate such as small organics with extreme physicochemical properties,
DNA, proteins, peptides and plant-derived active substances.
As of August 2005, MedPharm has been directly involved in the
development of four products currently on the market in the EU and/or U.S.
With more than 60 customers worldwide, MedPharm is recognized
internationally for its unique and highly specialized service in pharmaceutical
contract research and development together with expert project
management, all at an extremely competitive price.
In parallel to its services, MedPharm invests in its own IP in novel drug
delivery technologies which can be licensed to clients.
RESEARCH & DEVELOPMENT: Contract pharmaceutical R&D

Dermal and transdermal patents
Megabase Research Products

2726 N. 48th Street
Lincoln NE 68504, US
Phone: (402) 467-6499; Fax: (402) 467-6495
Web: www.pcrjet.com; E-mail: info@pcrjet.com
KEY PERSONNEL: Michael Nelson; President
Dr. Nisha Padhye; Sr. Scientist
Dr. Osvaldo Lopez; Sr. Scientist
Robyn Hassebrook; Scientist
®
FACILITIES: Microbiology and biochemistry lab
BUSINESS STRATEGY: Seek partners to manufacture and bring patened technologies to market
Biologix Research technology for the licensing agreement
Corp. detection of Thiopurine
Methyl Transferase
(TPMT) from blood
Roche Molecular development of a fast, R&D contract
Diagnostics experimental PCRJet
for evaluation by Roche
Molecular Diagnostics
Toyobo Co. Ltd. development of PCRJet R&D contract and
contract to enter
licensing agreement
University of advanced engineering research ongo
Nebraska (Dr. of PCRJet collaborations ing
Hendrik Viljoen, Thermocyclers
Department of
Chemical
Engineering)
University of rapid diagnostic DNA research ongo
Nebraska Medical tests collaborations ing
Center (Dr. Cathy
Gebhart,
Molecular
Diagnostics
Laboratory)
RESEARCH & DEVELOPMENT: PCRJet®--pressurized gas thermocycler for the high-speed amplification of
DNA
Meiji Seika Kaisha Ltd.

4-16, Kyobashi 2-chome, Chuo-ku
Phone: +81 3-3272-6511; Fax: +81 3-3271-3528
Web: www.meiji.co.jp
KEY PERSONNEL: Ichiro Kitasato; Chairman
Naotada Sato; President
Akio Takahashi; Sr. Exec. VP
Akinobu Otsubo; Exec. VP
Masaki Nagasaki; Exec. VP
Masahiko Matsuo; Sr. VP
Harunobo Tsukanishi; Sr. VP
Masayuki Matsunaga; Sr. VP
Hirobumi Mori; Sr. VP
Hiromichi Kitahara; Sr. VP
Tadao Shibasaki; Sr. VP
Osamu Makabe; Sr. VP
Hideki Takahashi; Sr. VP
Yoshihiko Mizoguchi; Sr. VP
®

Net <loss> income <¥8.240b> (YE 05) compared to ¥348M (YE 04)
Earnings <loss> per share <¥21.53/share> (YE 05) compared to
¥0.79/share (YE 04)
SUBSIDIARIES/DIVISIONS: Meiji Food Materia Co. Ltd.
Donan Shokuhin Co. Ltd.
Zao Shokuhin Kaisha Ltd.
Ronde Corp.
Meiji Sangyo Co. Ltd.
Meiji Chewing Gum Co. Ltd.
Azteca Co. Ltd.
Okayamaken Shokuhin Co. Ltd.
Shikoku Meiji Co. Ltd.
Taiyo Shokuhin Co. Ltd.
Fuji-Amide Chemical Co. Ltd.
Kitasato Pharmaceutical Industry Co. Ltd.
Meiji Sports Plaza Ltd.
Meiji Seika (Singapore) Pte. Ltd.
D.F. Stauffer Biscuit Co. Inc.--York, Pa., U.S.
Laguna Cookie Co. Inc.--Santa Ana, Calif., U.S.
P.T. Meiji Indonesian Pharmaceutical Industries
Thai Meiji Pharmaceutical Co. Ltd.--Bangkok
Tedec-Meiji Farma SA--Madrid, Spain
Mabo Farma SA--Madrid, Spain
Meiji Seika Europe BV--The Netherlands
Mecor Inc.--Golden, Colo., U.S.
Comercio e Industria Uniquimica Ltda.--Sao Paulo, Brazil
Beghin Meiji--France
P.T. Ceres Meiji Indotama--Indonesia
Guangzhou Meiji Confectionery Co. Ltd.--China
Shantou Meiji Pharmaceuticals Co. Ltd.--China
Meiji Lukang Pharmaceutical Co. Ltd.--China
Meiji Seika (Shanghai) Co. Ltd.
PRINCIPAL INVESTORS: Mizuho Bank Ltd.
The Master Trust Bank of Japan Ltd.
The Dai-ichi Mutual Life Insurance Co.
Nippon Life Insurance Co.
Japan Trustee Services Bank Ltd.
Fukoku Mutual Life Insurance Co.
The Bank of Tokyo-Mitsubishi Ltd.
The Tokio Marine and Fire Insurance Co. Ltd.
Asahi Mutual Life Insurance Co.
The Mitsubishi Trust and Banking Corp.
INVESTMENTS: M. D. Research--joint venture with Daicel Chemical and Japan Key
Technology Center
Allergen-Free allergen-free grains R&D agreement 3/92
Technology
Laboratories Inc.
Beghin Say SA fructo-oligosaccharide joint venture to
develop and market
Daicel Chemical, technology for joint R&D venture 3/86
Japan Key producing active called M. D.
Technology peptides via rDNA and Research
Center synthetic processes
MECOR fructo-oligosaccharide joint venture to 11/88
with applications in market in the U.S.,
animal feed, ingredients Canada, and the
and health food Caribbean
NeuroSearch A/S GABA modulators R&D agreement 10/93
®
Nippon Roche KK, cloning of Werner joint venture called 3/93

Eisai Co. Ltd., syndrome gene AGENE
Kissei
Pharmaceuticals
SIBIA SIB-1508Y as first-of- development and 3/97
Neurosciences type treatment for commercialization
Inc. Parkinson's disease agreement--SIBIA
will receive
licensing fee,
milestone payments
and royalties on
future sales, and
will supply product
to Meiji for clinical
use, SIBIA to retain
manufacturing
rights
Tokyo University diagnostics of collaborative 4/90
pancreatic diseases research agreement
PRODUCTS ON MARKET: Anti-infectives: Meiact, Fosmicin, Habekacin, Omegacin, Sword, Ciproxan

Central nervous system drugs: Meilax, Depromel, Ebastel
Agricultural chemicals: Oryzemate, Herbie
Veterinary drugs: Meirich, Meipole, Astop
Animal feed supplements: Colistin, Cellulaze
Healthfood products: Savas, Karadanavi, Lola, Amino Collagen, Prefect
Plus, Protein Diet
Over-the-counter drugs: Isodine, Bayer Aspirin
Food products: Chocolate, chewing gum, snacks, biscuits, candy
Mercian Corp.
1-5-8 Kyobashi Chuo-Ku
Phone: +81 3 3231 3927; Fax: +81 3 3276 0151
Web: www.mercian.co.jp
E-mail: chem@mercian.co.jp
KEY PERSONNEL: Yuji Okabe; President and CEO
Yasuteru Sakamoto; Sr. VP and President, Pharmaceuticals and Chemicals
Company
Yukimichi Tamura; Sr. VP, Finance
Masahide Takai; Sr. VP and President, Liquor Company
Masaaki Oshitani; Sr. VP and President, Processing Liquors Company
Shuji Tsuchimoto; Sr. VP, Sales Dept.
HISTORY: Founded in 1934 as a liquor manufacturer Showa Brewery Co. Ltd.
Merged with Nisshin Brewery Co. Ltd. (1961)
Merged with Ocean Co. Ltd. and changed name to Sanraku Ocean Co. Ltd.
(1962)
Changed name to Sanraku Co. Ltd. (1985)
Acquired Napa, Calif.-based Markham Vineyards (10/87)
Changed name to Mercian Corp. (9/90)
FACILITIES: Five branch offices, eight factories and two research facilities in Japan
One representative office and five production facilities overseas
®

Net income ¥1.409 (YE 05) compared to ¥2.372b (YE 04)
SUBSIDIARIES/DIVISIONS: Liquor Company
Processing Liquors Company
Pharmaceuticals & Chemicals Company
Feedstuffs Company
BUSINESS STRATEGY: Maintain position as a leading producer of alcholic beverages, and
manufactuer of feedstuffs, chemical products and pharmaceuticals
ILEX Oncolgy NM-3 license agreement
RESEARCH & DEVELOPMENT: Screening new anticancer drugs and other chemical compounds produced
using microorganisms
Development of manufacturing processes for chiral compounds utilizing
bioconversion
Analysis of fermentation characteristics and aroma and taste
Breeding of new yeast genes
Study of liquor fermentation mechanisms
Examination of the health benefits of wine
Merck KGaA
Frankfurter Str. 250
Darmstadt D-64293, Germany
Phone: +49 6151-72-0; Fax: +49 6151-72-2000
Web: www.merck.de
E-mail: service@merck.de
KEY PERSONNEL: Dr. Michael Romer; Chairman
Karl-Ludwig Kley; Deputy Chairman
FACILITIES: Production and/or sales operations in 54 countries
STOCK-FINANCIAL HISTORY: Reuters--MRCG / Bloomberg--MRK GY / FSE--ISIN: DE 00065 99905 -
WKN: 659 990
IPO--(1995)
(YE 04)
SUBSIDIARIES/DIVISIONS: Pharmaceuticals Business Sector--divisions include Ethical
Pharmaceuticals, Generics, OTC
Chemicals Business Sector--divisions include Liquid Crystals, Performance
& Life Science
INVESTMENTS: Agribiotics Holdings Inc. in 3/06
Survac ApS in 11/05
Lumitec OLED R&D project of Schott AG in 2/05
OLED materials (Covion Organic Semiconductors GmbH) and polymer
electronics businesses fron Avecia in 4/05
BUSINESS STRATEGY: Focus on business segments in which the company achieves competitive
advantages through excellent quality of products, services and systems by
concentrating on innovations and research in the pharmaceuticals business
and on higher grade products in the chemicals business
®

Biomira Inc. Stimuvax (BLP25) global development 1/06
cancer vaccine and promotion
agreement
ChemGenex preclinical support for three-year alliance 1/06
Pharmaceuticals diabetes, insulin agreement
resistance and
complications
Dyax Corp. Dyax's phage display non-exclusive 8/05
libraries licensing agreement
Eli Lilly and Co. Merck’s Ph. I insomnia licensing agreement 10/04
treatment EMD281014,
a 5-HT2a antagonist
Genaissance development and exclusive worldwide 9/04
Pharmaceuticals commercialization of licensing agreement
Inc. vilazodone
Organon NV EMM 310066, a novel granted worldwide 5/05
combination oral development and
contraceptive marketing rights
Takeda Matuzumab co-development 9/05
Pharmaceutical and co-
Co. Ltd. commercialization
agreement
Tioga Asimadoline, for granted 6/05
Pharmaceuticals treatment of Irritable development rights
Bowel Syndrome
RESEARCH & DEVELOPMENT: See annual report or visit our Web site, www.merck.de
PRODUCTS ON MARKET: PHARMA: Glucophage®, Concor®, Euthyrox®, Jodthyrox®, Praxilene®,
Neurobion®, Cebion®, Erbitux®
angiogenesis inhibitor cilengitide in glioma in Phase II clinicals
humanized monoclonal antibody in Phase II clinicals
Matuzumab (EMD 72000) in EGFR-
expressing tumors
Liposomal cancer vaccine Stimuvax (L- in Phase II/III clinicals
BLP25) in MUC1-expressing tumors: e.g.
non-small cell lung cancer
Metabolix Inc.
21 Erie Street
Cambridge MA 02139-4260, US
Phone: (617) 492-0505; Fax: (617) 492-1996
Web: www.metabolix.com
E-mail: info@metabolix.com
KEY PERSONNEL: Jim Barber; President and CEO
Dr. Oliver Peoples; CSO
Thomas Auchincloss; CFO and VP, Finance and Corporate Development
Johan van Walsem; VP, Manufacturing, Development and Operations
Dr. Robert Whitehouse; Director, Applications Development
Robert Findlen; VP, Sales and Marketing
Dan Gilliland; Director, Business Development
Ben Locke; Director, Government Programs
Acquired Monsanto's Biopol assets (5/01)
Strategic agreement with ADM (11/04)
Presidential Green Chemistry Award (2005)
®

STOCK-FINANCIAL HISTORY: Filed for IPO, NASDAQ--MBLX proposed (7/06)
BUSINESS STRATEGY: Create a compelling, sustainable alternative to petrochemical materials and
establish a technology platform that will enable the widespread adoption of
PHA bioplastics in the marketplace
Archer Daniels commercialization of a strategic alliance 11/04
Midland Co. new generation of high-
performance eco-
friendly natural plastics
Microbe Inotech Laboratories Inc.

7259 Lansdowne Avenue, Suite 200
St. Louis MO 63119-3421, US
Phone: (314) 645-2177; Fax: (314) 645-2544
Web: www.microbeinotech.com; E-mail: info@microbeinotech.com
KEY PERSONNEL: Bruce C. Hemming, Ph.D.; President and CEO
Barry L. Haymore, Ph.D.; Director, Technology
Laurence E. Hallas, Ph.D.; Director, Field Services
John Kent Morgan; Laboratory Manager
Member--Biotech Industry Organization
FACILITIES: Pharmaceutical, environmental and food microbiology laboratories
BUSINESS STRATEGY: Provide microbiological characterization and identification services for
environmental, food and pharmaceutical industries (GC-Fame, Biolog,
Ribotyping, 16SrRNA DNA pair sequence, Custom Microarrays)
RESEARCH & DEVELOPMENT: Rapid microbiological diagnostics, environmental mycobacteria detection

Bio-control technologies, bioremediation assays
PRODUCTS ON MARKET: Rapid Gluten Home Test Kit
CombiMatrix Catalog Microarrays and Custom Arrays
As a full-service microbiology lab, provides testing services for the

environmental, food, biotechnological and industrial communities
Microbia Inc.
320 Bent Street
Phone: (617) 621-7722; Fax: (617) 494-0908
Web: www.microbia.com
E-mail: info@microbia.com
KEY PERSONNEL: Joseph C. Cook Jr.; Chairman
Peter M. Hecht, Ph.D.; CEO
Richard Bailey, Ph.D.; VP and GM, Precision Engineering
Brian M. Cali, Ph.D.; VP, Program Management
Mark G. Currie, Ph.D.; VP, R&D
Michael J. Higgins; Sr. VP, Finance and Strategic Planning and CFO
Jeffrey M. Johnston, M.D.; VP, Clinical Development and CMO
®
G. Todd Nilne, Ph.D.; VP, Biology

James O'Mara; VP, Business Development
John J. Talley, Ph.D.; VP, Drug Discovery
PRIVATE PLACEMENTS: Raised $9.8M in Series A financing (2/99)
Raised $23M in Series B financing (8/00)
Raised $40M in Series D financing (5/04)
Raised $75M in Series E financing (2/06)
PRINCIPAL INVESTORS: Aberdare Ventures
Alton Ltd.
BancBoston Ventures
Bio*One Capital
Essex Investment Management Co.
Fidelity Biosciences Group
Invus LP
Jennison Associates
Linkagene LP
Maverick Capital
Paperboy Ventures
Polaris Venture Partners
Sigma Capital Management
Venrock Associates
BUSINESS STRATEGY: Utilize revenues from yield improvement service business to fund internal
development of novel anti-infectives
DuPont Central biomanufacturing CRADA with 2/06
Research & process for a chemical Microbia's Precision
Development currently manufactured Engineering®
from petrochemical- business unit
based raw materials
Ranbaxy biomanufacturing technology 2/03
Laboratories Ltd. processes using development
Microbia’s Precision agreement
Engineering
Ranbaxy to lower the cost of a research 11/05
Laboratories Ltd. Ranbaxy collaboration
biomanufacturing
process
Teva biomanufacturing development 3/04
Pharmaceutical processes using agreement,
Industries Microbia’s Precision expanded
Engineering technology
RESEARCH & DEVELOPMENT: Precision Engineering platform: Applies molecular genetics and proprietary
profiling methods to rationally design microbes for the efficient production of
commercially valuable metabolites. Applications include the pharmaceutical,
food and feed ingredients, specialty chemical industries and industrial
biotechnology
®
Mo Bio Laboratories Inc.

2746 Loker Ave. West
Carlsbad CA 92010, US
Phone: (760) 929-9911; Fax: (760) 929-0109
Web: www.mobio.com
E-mail: info@mobio.com
KEY PERSONNEL: Mark N. Brolaski; CEO and President
Liz Brolaski; Exec. VP
Ravi Venugopal, Ph.D.; Director, R&D
Melissa Stolow, Ph.D.; Sr. Scientist
David Stolow, Ph.D.; Sr. Scientist
Getachew Sequar, Ph.D.; Scientist
FACILITIES: 11,000 sq. ft. headquarters in Carlsbad, Calif.
SUBSIDIARIES/DIVISIONS: Molecular Biology Manufacturing
Contract Testing Services
BUSINESS STRATEGY: Continue with strength in molecular and microbiology product development
RESEARCH & DEVELOPMENT: Molecular, micro and protein biology kit development; kits for DNA, RNA and
protein isolation
PRODUCTS ON MARKET: DNA and RNA isolation kits used by molecular and microbiologists in fields
of forensics, anti-biowarfare, environmental microbial analysis, basic
research and biopharmaceuticals:
DNA Clean-up and Gel Extraction: PowerClean™ DNA Clean-Up Kit,

UltraClean™ 15 DNA Purification Kit, UltraClean™ GelSpin™ Kit,
UltraClean™ PCR Clean-up™ Kit, UltraClean-htp™ 96 Well PCR Clean-
up™ Kit, UltraClean™ 15 Kit Components, UltraClean™ GelSpin™ Kit
Components, UltraClean™ PCR Clean-up™ Kit Components
Plasmid DNA Isolation: UltraClean™ 6 Minute Mini Plasmid Prep Kit,

UltraClean-htp™ 96 Well Plasmid Prep Kit, UltraClean™ Standard Mini
Plasmid Prep Kit, UltraClean™ Midi Plasmid Prep Kit, UltraClean™ Maxi
Plasmid Prep Kit, UltraClean™ Endotoxin-Free Mini Plasmid Prep Kit,
UltraClean™ Endotoxin-Free Midi Plasmid Prep Kit, UltraClean™
Endotoxin-Free Maxi Plasmid Prep Kit, UltraClean™ Endotoxin Removal Kit,
UltraClean™ Endotoxin-Free Precipitation Kit, UltraClean™ 6 Minute Mini
Prep Kit Components, UltraClean™ Midi Plasmid Prep Kit Components,
UltraClean™ Maxi Plasmid Prep Kit Components, UltraClean™ Endotoxin-
Free Mini Kit Components, UltraClean™ Endotoxin-Free Midi Kit
Components, UltraClean™ Endotoxin-Free Maxi Kit Components,
Endotoxin-Free Reagents and Supplies
Soil DNA Isolation: PowerSoil™ - htp 96 Well Soil DNA Isolation Kit,
PowerClean™ DNA Clean-Up Kit, PowerMax™ Soil DNA Isolation Kit,
PowerSoil™ DNA Isolation Kit, UltraClean™ Soil DNA Kit, UltraClean™
Mega Soil DNA Kit, UltraClean-htp™ 96 Well Soil DNA Kit, UltraClean™
Fecal DNA Kit, PowerMax™ Soil DNA Isolation Kit Components,
PowerSoil™ DNA Isolation Kit Components, UltraClean™ Soil DNA Kit
Components, UltraClean™ Mega Soil DNA Kit Components, UltraClean™
Fecal DNA Kit Components
Microbial DNA Isolation: PowerMicrobial™ Midi DNA Isolation Kit,

PowerMicrobial™ Maxi DNA Isolation Kit, UltraClean™ Microbial DNA Kit,
UltraClean™-htp 96 Well Microbial DNA Kit, UltraClean™ Microbial DNA Kit
®
Components, PowerMicrobial™ Midi DNA Isolation Kit Components,

PowerMicrobial™ Maxi DNA Isolation Kit Components
Blood DNA Isolation: UltraClean™ BloodSpin™ Kit, UltraClean™ Mega
BloodSpin™ Kit, UltraClean™ Blood DNA Kit (Non-Spin), UltraClean-htp™
96 Well BloodSpin™ DNA Kit, UltraClean™ BloodSpin™ Kit Components,
UltraClean™ Mega BloodSpin™ Kit Components, UltraClean™ Blood DNA
Kit (Non-Spin) Components
Tissue DNA Isolation: UltraClean™ Tissue DNA Kit, UltraClean-htp™ 96

Well Tissue DNA Kit, UltraClean™ Tissue DNA Kit Components
Plant DNA Isolation: PowerPlant™ DNA Isolation Kit, UltraClean™ Plant

DNA Kit, UltraClean-htp™ 96 Well Plant DNA Isolation Kit, PowerPlant™
DNA Isolation Kit Components, UltraClean™ Plant DNA Kit Components
Water DNA Isolation: UltraClean™ Water DNA Kit (0.45 um), UltraClean™
Water DNA Kit (0.22 um), UltraClean™ Water DNA Kit (No filters), Water
Filters, UltraClean™ Water DNA Kit Components
Forensic DNA Isolation: UltraClean™ Forensic DNA Kit
RNA Isolation: RNA PowerSoil™ Total RNA Isolation Kit, UltraClean™

Tissue RNA Kit, UltraClean™ Plant RNA Kit, UltraClean™ Microbial RNA
Kit, RNA PowerSoil™ Total RNA Isolation Kit Components, UltraClean™
Tissue RNA Kit Components, UltraClean™ Plant RNA Kit Components,
UltraClean™ Microbial RNA Kit Components
Nuclease Detection: RNase Detection Kit, DNase Detection Kit
Lab Supplies: Electrophoresis Equipment (Mini Horizontal Gel System; Mini

Horizontal Gel Caster; Mini Horizontal Gel Tray; Comb, Polycarbonate;
Comb, Teflon; Dual Comb, Polycarbonate; Dual Comb, Teflon; Power
Supplies), Electrophoresis Reagents (TAE Buffer, 50X (Tris-acetate-EDTA);
TBE Buffer, 10X (Tris-borate-EDTA); UltraClean™ Agarose; UltraClean™
Low Melt Agarose; UltraClean™ Low Melt Sieve Agarose; UltraClean™ MS-
8 Agarose; UltraClean™ Forensic Agarose; DNA Molecular Weight Markers;
Ethidium Bromide Solution; Ethidium Bromide Destaining Tea Bags; Gel
Loading Buffer, Bromophenol Blue; Gel Loading Buffer, Bromophenol
Blue/Xylene Cyanol), Water (PCR Water, Molecular Biology Grade Water,
DEPC Treated Water, Endotoxin-Free Water), Growth Media (TB DRY™
Powder Growth Media; LB Broth Powder Growth Media; LB Agar Powder
Growth Media; LB Broth (Lennox) Powder Growth Media; LB Agar (Lennox)
Powder Growth Media; Soybean-Casein Digest Medium (TSB), USP;
Soybean-Casein Digest Agar Medium (TSA), USP; Yeast Extract; Tryptone;
Agar), Vortexes and Adapters (Vortex-Genie® 2; Labnet VX100 Vortex;
Vortex Adapters for Vortex-Genie® 2; Vortex Adapters for Labnet VX100
Vortex), Lab Accessories (RNase-Free Gloves, UltraClean™ Lab Cleaner),
96 Well Kit Equipment (96 Well Plate, Shaker, Plate Adapter Set, Tube
Adapter Set, UltraVac™ Manifold, Vacuum Pump) and Homogenization
Equipment (Precellys® 24 Homogenizer)
Samples: MO BIO SAMPLES - No Sales Calls & No Interruptions,

UltraClean™ 6 Minute Mini Plasmid Prep Sample Kit, UltraClean™ PCR
Clean-up™ Sample Kit, UltraClean™ GelSpin™ Kit Sample, PowerMax™
Soil DNA Isolation Kit Sample, RNA PowerSoil™ Total RNA Isolation Kit
Sample, UltraClean™ Forensic DNA Sample Kit, UltraClean™ 15 DNA
Purification Kit Sample, UltraClean™ Standard Mini Plasmid Prep Sample
Kit, UltraClean™ Midi Plasmid Prep Sample Kit, UltraClean™ Maxi Plasmid
Prep Sample Kit, UltraClean™ Endotoxin-Free Mini Plasmid Sample Kit,
PowerSoil™ DNA Isolation Kit Sample, UltraClean™ Soil DNA Sample Kit,
UltraClean™ Fecal DNA Sample Kit, UltraClean™ Microbial DNA Sample
Kit, UltraClean™ Microbial RNA Sample Kit, UltraClean™ BloodSpin™
Sample Kit, UltraClean™ Blood DNA Sample Kit (Non-Spin), UltraClean™
Tissue DNA Sample Kit, PowerPlant™ DNA Isolation Sample Kit,
UltraClean™ Tissue RNA Sample Kit, UltraClean™ Plant RNA Sample Kit,
®
TB DRY™ Powder Growth Media Sample, LB Broth Powder Growth Media

Sample, LB Agar Powder Growth Media Sample, LB Agar (Lennox) Powder
Growth Media Sample, LB Broth (Lennox) Powder Growth Media Sample
Yeast Extract Sample, Tryptone Sample, Agar Sample
MoBiTec GmbH
Lotzestrasse 22a
Goettingen 37083, Germany
Phone: +49 551-707-220; Fax: +49 551-707-2222
Web: www.mobitec.com; E-mail: info@mobitec.com
KEY PERSONNEL: Jorg Ronnenberg; Chairman
BUSINESS STRATEGY: Provide an extraordinary wide range of innovative tools for molecular and
cell biology to make daily lab research faster, easier and more efficient
Enzyme technology in research, food technology, pharmaceuticals and
environment
RESEARCH & DEVELOPMENT: Pharmaceutical diagnostics

Environmental purification
Water purification
PRODUCTS ON MARKET: Cloning vectors
Expression systems for E.coli, yeast, B.megaterium, B.subtilis
Two- and One-Hybrid Systems
Phagemid technology
Genomic libraries
Antibodies
Cytokines and growth hormones
Tools for proteomics and genomics
Fluorescence technology
Affinity chromatography
Lab suplies
Molecular Devices Corp.

1311 Orleans Drive
Sunnyvale CA 94089-1136, US
Phone: (408) 747-1700; Fax: (408) 747-3601
Web: www.moleculardevices.com
E-mail: info@moldev.com
KEY PERSONNEL: Joe Keegan; President and CEO
Timothy Harkness; Sr. VP, Finance and CFO
Gillian M.K. Humphries, Ph.D.; VP, Strategic Affairs
Robert Murray; VP, Operations
J. Richard Sportsman, Ph.D.; VP, Assay and Reagent R&D
Robert Wicke; VP, Engineering
Jan Hughes; VP, Marketing
Tom Olenic; VP, Sales
Pat Sharp; VP, Human Resources
®
HISTORY: Founded in 1983 by Dr. Harden McConnell

Reincorporated in Delaware in 1995
Acquired the Laser Capture Microdissection business of Arcturus Bioscience
for $10M (4/06)
FACILITIES: 150,000 sq. ft. facility in Sunnyvale, Calif. (headquarters)
Offices in Union City, Calif.; Great Britain; Korea; China; Japan;
Downingtown, Pa.; Germany; and Brazil
STOCK-FINANCIAL HISTORY: NASDAQ--MDCC
IPO--$11/share (12/95)
04)
BUSINESS STRATEGY: Develop innovative bioanalytical systems for life science research and drug
discovery
RESEARCH & DEVELOPMENT: Microplate readers and spectrophotometers, multi-mode benchtop readers,
electrophysiology instruments, imaging systems, microarray scanning
equipment, amplifiers, software and HTS systems
PRODUCTS ON MARKET: Emax™ Precision Microplate Reader for endpoint analysis
VersaMax, SpectraMax Plus 384, SpectraMax 190, Gemini XPS
FLIPR Tetra Flourometric Imaging Plate Reader
SoftMax Pro® data analysis software
SpectraMax 340PC 384 Microplate Spectrophotometer for UV and visible
analysis of biomolecules
SpectraMax Plus High Throughput Spectrophotometer
SpectraMax® M5 five-mode multi-detection microplate reader system
Threshold® biosensor assay system for rapid sensitive detection of
contaminants in biopharmaceuticals
Threshold® Total DNA assay kit for quantitation of DNA in protein solutions
Threshold® Immuno-Ligand assay kit for immunoassay and other binding
assays in protein solutions
Vmax® Kinetic Microplate Reader using vertical beam photometry
Lmax II Luminomter
IonWorks™ HT Electrophysiology system
PatchXpress Electrophysiology system
OpusXpress Electrophysiology system
GenePix™ 4200AL Microarray Scanner
MetaMorp Imaging Software
MetaFluor Imaging Software
Discovery-1™ Imaging System
Axoporator Amplifier
ImageXpress Imaging System
Analyst HT Multi-Mode System
AquaMax DW4 Dispenser/Washer
QBT™ Fatty Acid Uptake Assay Kit
®
Molecular Probes Inc.

P.O. Box 22010, 29851 Willow Creek Road
Eugene OR 97402-0469, US
Phone: (541) 465-8300; Fax: (541) 335-0504
Toll-free phone: (800) 438-2209 (orders only)
Web: www.probes.invitrogen.com
E-mail: tech@probes.com
KEY PERSONNEL: August Sick; General Manager
Acquired by Invitrogen Corp. (8/03)
SUBSIDIARIES/DIVISIONS: Molecular Probes Europe BV--wholly owned subsidiary located in the
Netherlands
SUBSIDIARY OF: Invitrogen Corp. (see separate entry)
BUSINESS STRATEGY: Be the leading provider of fluorescence-based detection solutions to
advance scientific and biomedical research
PRODUCTS ON MARKET: Over 3,000 fluorescent probes for bioscience research listed in the
'Handbook of Fluorescent Probes and Research Chemicals' including
Calcium Green™, Live/Dead® viability/cytotoxicity kits, SYBR® Green
nucleic acid gel stain, SYPRO® Protein gel stain, FluoSpheres®, Cascade
Blue®, Toto®-1, Yoyo®-1 and Bodipy®
Monsanto Co.
800 North Lindbergh Boulevard
St. Louis MO 63167, US
Phone: (314) 694-1000; Fax: (314) 694-4228
Web: www.monsanto.com
E-mail: info@monsanto.com
KEY PERSONNEL: Hugh Grant; Chairman, President and CEO
Terrell K. Crews; Exec. VP and CFO
Dr. Robert T. Fraley; Exec. VP and CTO
Charles W. Burson; Exec. VP, Secretary and General Counsel
Carl M. Casale; Exec. VP, North America Commercial
Brett D. Begemann; Exec. VP, International Commercial
Robert A. Paley; VP and Treasurer
Mark J. Leidy; Exec. VP, Manufacturing
Gerald A. Steiner; Exec. VP, Commercial Acceptance
Steven C. Mizell; Sr. VP, Human Resources
Cheryl Morley; Sr. VP, Corporate Strategy
Richard B. Clark; VP and Controller
Janet M. Holloway; VP and Chief of Staff
Scarlett Lee Foster; VP, Investor Relations
Agricultural division established (1960)
Acquired the Jacob Hartz Seed Co. (1982)
Acquired 49% of Calgene Inc. (3/96)
Acquired Agracetus (7/96)
Increased ownership of Calgene Inc. to 54.6% through purchase of 6.25M
shares (8/96)
®
Acquired Asgrow agronomics seed business (1997)

Acquired Holden's Foundation Seeds Inc., Corn States Hybrid Service Inc.
and Corn States International Sarl for up to $1b (1/97)
Acquired remaining shares of Calgene for $8/share, $240M (7/97)
Monsanto split into two companies--Monsanto Co. (life sciences, agriculture,
health and food products) and Solutia Inc. (chemicals and fibers) (9/97)
Announced plans to acquire remaining shares of Dekalb Genetics Corp. for
$2.5b and Delta & Pine Land Co. for an undisclosed amount (5/98)
American Home Products Corp. (now Wyeth) and Monsanto Co. announced
plans to merge for $33b in stock and to create new company (6/98)
Announced plans to acquire Cargill's international seed operations in Central
and Latin America, Europe, Asia and Africa for $1.4b (6/98)
Merged with Pharmacia & Upjohn to form Pharmacia Corp. Monsanto is the
acknowledged agricultural subsidiary and will retain its name, while
Pharmacia owns 85% of Monsanto. The business became a separate legal
entity with a stand-alone board of directors and its own publicly traded stock.
(4/00)
Divested by Pharmacia Corp. in lieu of Pharmacia's merger into Pfizer Inc.
(4/03)
Formed American Seeds Inc. (ASI) (2004)
ASI acquired Channel Bio Corp. (including three seed brands: Crows Hybrid
Corn, Midwest Seed Genetics and Wilson Seeds) (2004)
Acquired North American canola seed assets of Advanta Seeds from
Advanta BV (9/04)
Acquired the Stoneville cotton business (including its NexGen brand) (2005)
ASI subsidiary acquired NC+ Hybrids Inc. (2005)
ASI acquired Fontanelle Hybrids, Stewart Seeds, Trelay Seeds and Stone
Seeds (2005)
ASI acquired Specialty Hybrids (2005)
Acquired agricultural genomics assets of Icoria Inc. (3/05)
Acquired Seminis Inc. (3/05)
Acquired Emergent Genetics Inc. (4/05)
Sold Monsanto Enviro-Chem Systems Inc. (8/05)
ASI acquired the seed marketing and sales businesses of Diener Seeds and
and Sieben Hybrids (6/06)
ASI to acquire Kruger Seed Co. Trisler Seed Farms and the seed marketing
and sales business of Campbell Seed (as of 6/06)
To acquire Delta and Pine Land Co. for $1.5b (as of 8/06)
FACILITIES: Manufacturing facilities, laboratories, seed production and other agricultural
facilities, office space, warehouses and other land parcels in North America,
South America, Europe, Asia, Australia and Africa
Seed conditioning plants at Bellary, India; Constantine, Mich.; Eluru, India;
Grinnell, Iowa; Kearney, Neb.; Oxnard, Calif.; Peyehorade, France;
Phitsanoluk, Thailand; Trebes, France; Uberlandia, Brazil; and Villagran,
Mexico
Chemicals manufacturing facilities at Alvin, Texas; Antwerp, Belgium;
Augusta, Ga.; Camacari, Brazil; Luling, La.; Muscatine, Iowa; Sao Jose dos
Campos, Brazil; Soda Springs, Idaho; and Zarate, Argentina
STOCK-FINANCIAL HISTORY: NYSE--MON
SUBSIDIARIES/DIVISIONS: Two business segments:
Seeds and Genomics (global seeds and traits businesses and genetic
technology platforms)
Agricultural Productivity (crop protection products, animal agriculture
businesses and lawn-and-garden herbicide products)
INVESTMENTS: The Liposome Co.
Target Therapeutics
HybriTech Seed Europe-SNC--joint venture with CACBA
Calgene Inc.--100%
®
Joint venture with Cargill to use biotechnology to improve feed for pigs,
cattle, poultry and fish (5/98)
Formed American Seeds Inc. (ASI), a holding company to support regional
seed businesses (11/04)
BUSINESS STRATEGY: Produce leading seed brands and develop biotechnology traits that assist
farmers in controlling insects and weeds
Provide other seed companies with genetic material and biotechnology traits
for their seed brands
Provide lawn-and-garden herbicide products for the residential market
Provide animal agricultural products focused on improving dairy cow
productivity and swine genetics

Genaissance to map single nucleotide research agreement 3/05
Pharmaceuticals polymorphism (SNP)
Inc. and the DNA markers in
Agricultural soybeans
Research Service
(part of USDA)
Agracetus Inc. transgenic cotton purchased all plant 4/96
technology biotech assets from
W.R. Grace & Co
Arcadia development and licensing agreement 9/05
Biosciences Inc. commercialization of
Arcadia's nitrogen use
efficiency technology in
canola
ArQule Inc. agrochemicals development 12/96
agreement
Calgene Inc. fresh produce and plant R&D agreement 10/95
oils
Calgene Inc. oilseed research cross-licensing 5/96
programs agreement--
Calgene will receive
royalty-free license
to current and
future Monsanto
agronomic
technology in
combination with
Calgene's oils
modification genes.
Monsanto will pay
Calgene royalties
and $17M and will
receive portion of
profits of Calgene's
specialty oils
business
Calgene Inc. patented technologies cross-licensing 4/93
agreements--
Monsanto received
licenses to
Calgene's patents
and patents
pending in the
areas of plant
transformation,
certain genetically
engineered plants,
and antisense RNA
technology.
Calgene received
licenses to
®
Monsanto's patents
and patents
pending in the
areas of plant
transformation
technologies,
selectable markers,
and the right to
obtain certain
licenses to
Monsanto's Bt
insect resistance
technology for use
in cotton
Calgene Inc. Russet Burbank development

potatoes genetically agreement
modified to resist potato
viruses X and Y
California Institute instrument design development
of Technology agreement
Columbia patented rDNA nonexclusive
University extraction process licensing agreement
Dekalb Genetics field crops, seeds, R&D collaboration 2/96
Corp. produce and cross-licensing
agreement
Delta and Pine Bollard gene for marketing 11/95
Land Co. selected varieties of agreement
cotton
Divergence Inc. nematode-resistant development and 9/04
soybeans licensing agreement
Dow new technology options global business 1/06
AgroSciences LLC and more choice in agreement
products for farmers
Dyax Corp. Dyax's phage display non-exclusive 5/97
technology licensing
agreement,
including signing
fees, milestone
payments and
royalties, Dyax gets
access to related
patented
technology owned
by licensee
Ecogen Inc. Bt technology for in- development 1/96
plant applications agreement
Finnfeeds feed microingredients joint venture for for 4/98
production and
marketing of feed
microingredients in
plants
GeneTrace Inc. plant and animal $17M technology 4/98
genomics collaboration--
Monsanto gets
exclusive license to
GeneTrace's
technology for plant
and animal
genomics, including
gene-expression
analysis and
genotyping
®
Incyte Incyte's gene 3-year, large-scale, 5/98

Pharmaceuticals expression microarray genome-wide
Inc. technology for agreement--
functional genomics Monsanto gets
applications in plant, access to up to 50K
animal and human DNA microarrays
genomes for use across its
life science
programs, Incyte
will provide data
from custom and
prefabricated DNA
microarrays,
software to manage
and analyze data
and consulting
services
Incyte Incyte's LifeTools broad-based 10/97

Pharmaceuticals software and plant genomics and
Inc. sequences software licensing
agreement (9/96),
expanded to include
LifeSeq®, LifeSeq
FL®, LifeSeq
Atlas™, LifeSeq
GeneAlbum™
cDNA, PathoSeq™
and ZooSeq™
Japan Tobacco high-yield rice joint development 12/95
Inc. agreement
Mendel Monsanto to partnership, 1997
Biotechnology Inc. commercialize expanded and
technologies developed extended through
by Mendel, both 2011 (7/06)
companies will develop
an integrated framework
for predictive control of
plant gene expression
Mexican Ministry genetically engineered R&D agreement 7/93
of Agriculture and potato to resist viral
Water Resources diseases
Millennium Millennium's genomics 5-year, $218M 10/97
Pharmaceuticals technology platform to agreement--
Inc. develop agricultural Monsanto to pay
products $118M in licensing
and technology
transfer fees ($38M
up-front, $16M per
year for five years),
Monsanto could pay
an additional
$20M/year in
milestone payments
based on research
objectives,
Monsanto to form
subsidiary in
Cambridge, MA
with 100 scientists,
Millennium retains
right to use
technologies
developed by the
subsidiary for non-
®
exclusive use
outside of plant and
agricultural areas
Mitsubishi Kasei rDNA and MAbs joint R&D venture in
Corp. Japan
Modular Genetics advancement of three-year 3/05
Inc. Monsanto's protein collaboration
optimization platform
Molecular BioMerge software for three-year licensing 1/97
Informatics Inc. analysis of genomic agreement
data
North Carolina genetically engineered licensing 4/93
State University nematicides agreement--
Monsanto to
develop the
technology in major
agricultural crops in
developed countries
Pioneer Hi-Bred YieldGard insect- licensing agreement 12/95

International Inc. protected Bt corn
Sandia National alignment of Sandia's three-year research 8/06
Laboratories capabilities in collaboration
bioanalytical imaging
and analysis with
Monsanto's research in
the development of
seed-based products,
including corn products
that may be able to
produce more ethanol
per bushel
Sandoz Seeds insect-protected Bt corn nonexclusive 8/95
Ltd. worldwide license to
Monsanto patents
Strategic GeneCheck R&D and
Diagnostics Inc. manufacturing
agreement
Synteni Inc. gene expression in development 6/96
plants and organisms agreement
Targeted Growth development and licensing agreement 9/05
Inc. (TGI) commercialization of a
TGI-developed yield
enhancement gene
The Solae Co. soy proteins development and 10/05
marketing
agreement
RESEARCH & DEVELOPMENT: Insect-protected corn and cotton

Soybeans, canola, cotton, and corn genetically modified to tolerate
Roundup® herbicide
Virus- and insect-protected potatoes
Delayed ripening tomatoes
Cholesterol oxidase gene to protect cotton, corn, and potato plants from
weevils, worms, and beetles
PRODUCTS ON MARKET: Seeds and Genomics:
Roundup Ready traits in soybeans, corn, canola and cotton
Bollgard and Bollgard II traits in cotton
YieldGard Corn Borer and YieldGard Rootworm traits in corn
Agroceres, Asgrow, Dekald, Stoneville and Vistive branded seeds
Holden’s Foundation Seeds
Monsoy foundation seed
American Seeds Inc. branded seed
Seminis, Royal Sluis, Asgrow and Petoseed branded seeds
®
Agricultural Productivity:
Roundup and other glyphosate-based herbicides
Harness, Degree, Lasso, Machete and other acetanilide-based herbicides
Other selective herbicides, such as Maverick, Certainty, Outrider, Leader
and Monitor sulfosulfuron herbicides
Lawn-and-garden herbicides
Posilac bovine somatotropin
Monsanto Choice Genetics genetics lines
Morishita Jintan Co. Ltd.

1-30, Tamatsukuri 1-chome, Chuo-ku
Osaka, Japan
Phone: +81 6-6761-1131; Fax: +81 6-6768-1661
Web: www.jintanworld.com
E-mail: info@jintanworld.com
KEY PERSONNEL: Yukihisa Aibara; President and CEO
HISTORY: Founded in February 1893
SUBSIDIARIES/DIVISIONS: Branches in Shizuoka, Kagawa, Toyama and Shiga Pref.
BUSINESS STRATEGY: Develop and sell health foods, medical supplies, unregulated drugs and
cosmetics based on Chinese medicines and encapsulation technology for
seamless capsules
PRODUCTS ON MARKET: Pharmaceuticals: Bifina Constipation, Solmiran

Health foods and dietary supplements
M-Scan Ltd.
3 Millars Business Centre, Fishponds Close
Wokingham RG41 2TZ, UK
Phone: +44 (0)118 989 6940; Fax: +44 (0)118 989 6941
Web: www.m-scan.com
E-mail: services.ltd@m-scan.com
KEY PERSONNEL: Prof. H. R. Morris; Chairman
Dr. Fiona M. Greer; Director
Dr. Andrew Reason; Director
Dr. C. Harbach; Sr. Scientist
Dr. David Chapman; Business Manager
FACILITIES: Four analytical laboratories--located in: Wokingham, UK; Geneva,
Switzerland; and West Chester, Pa.
Marketing offices in Manchester, U.K.; Freiburg, Bonn and Munich,
Germany; and South Korea
®
SUBSIDIARIES/DIVISIONS: M-Scan SA
12, Chemin des Aulx
1228 Plan-les-Ouates
Geneva, Switzerland
Phone: + 41 (0)22 794 83 74
Fax: + 41 (0)22 794 83 55
E-mail: services.sa@m-scan.com
M-Scan Inc.
Dr. Mark Rogers
606 Brandywine Parkway
West Chester, PA 19380
Phone: (610) 696-8210
Fax: (610) 696-8370
E-mail: services.inc@m-scan.com
RESEARCH & DEVELOPMENT: Use of mass spectrometry for the structure and sequence analysis of
recombinant protein products and analysis of posttranslational modifications
MSE Technology Applications Inc.

P.O. Box 4078, 200 Technology Way
Butte MT 59701, US
Phone: (406) 494-7100; Fax: (406) 494-7230
Web: www.mse-ta.com
E-mail: contact@mse-ta.com
KEY PERSONNEL: Donald R. Peoples; President
Jeff Ruffner; Exec. VP and General Manager
Neal Egan; Head, Business Development
FACILITIES: Butte, Mont.--Corporate office, 53-acre Mike Mansfield Advanced
Technology Center, Montana Information Technology Enterprise Center,
welding and fabrication center
SUBSIDIARY OF: Montana Economic Revitalization and Development Institute
BUSINESS STRATEGY: MSE Technology Applications Inc. is a diversified research and engineering
firm. We are a small business headquartered in Butte, Montana, with offices
in Washington, Idaho, North Carolina, South Carolina, Washington, D.C.,
and West Virginia. MSE scientists and engineers are internationally
recognized as the very best in their fields--developing and deploying some
of the nation’s most sophisticated cutting-edge technology.
Business Areas:
Remediation Services--MSE provides services to private commercial entities

and government agencies for municipal and industrial water treatment,
biotechnologies, biological barriers, biological remediation, enhanced oil
recovery, and counter chemical and biological terrorism.
Site Cleanup and Closure Support--MSE develops, tests, evaluates and

deploys innovative technology to address the environmental issues
surrounding site closures across the United States. We also identify and
develop promising technologies to address the Department of Energy's site
waste problems (such as transuranic mixed waste problems). More than 80
projects, at 26 facilities in 21 states, have been completed or are underway,
resulting in significant operational cost savings.
®
Waste Treatment Technology--The Waste Treatment Technology area

provides a full range of treatment services to customers including plasma
services, facilities and products. We develop and deploy technologies to
resolve Department of Energy and Department of Defense waste problems.
Facility Modernization and Sustainability--MSE supports infrastructure

modernization at troop-based facilities by providing engineering solutions to
plant processes. Specifically, modernizing and increasing the efficiency of
outdated processes at various ammunition and troop installations around the
Army complex. This group’s real strength is providing process modifications
through instrumentation and control system modernization as well as
chemical and materials handling improvements.
Advanced Energy and Aerospace Programs--MSE is conducting cutting

edge research for advanced energy and aerospace technology
development. Projects have the potential for breakthroughs in aerospace
technology and could reduce the cost of commercial and military space
operations. MSE is developing an ultrahigh-pressure test system to provide
ground testing for aerospace technologies that are crucial to development of
the world’s first hypersonic wind tunnel.
Plasma Services--MSE is a world leader in the field of plasma technology for

waste material treatment and is currently deploying two systems for the U.S.
Army in Nevada and West Virginia.
Mine Waste Technology Program--MSE demonstrates innovative

groundwater remediation technologies in Montana, South Dakota, Nevada,
California, Minnesota, Missouri, Utah and Colorado to advance the
development of engineering solutions to national environmental issues
resulting from mining.
Information Technology Services--MSE’s Montana Information Technology

Enterprise Center is a complete data center, provides a strategically isolated
location, redundant power and fire protection, OCx capacity, triple levels of
security and environmental controls. MSE provides contingency planning
and implementation, disaster recovery, online data storage/ warehousing/
vaulting, parallel computing, telecommunications, project management, and
web services and development.
RESEARCH & DEVELOPMENT: Heavy metals in soils and water

Thermal spray technology
Lightweight materials technology
Plasma arc treatment technology
Biological remediation
Counter chemical and biological terrorism
Aerospace technology
Nanogen Inc.
10398 Pacific Center Court
Phone: (858) 410-4600; Fax: (858) 410-4952
Web: www.nanogen.com
E-mail: dludvigson@nanogen.com
KEY PERSONNEL: Howard C. Birndorf; Chairman and CEO
David Ludvigson; President and COO
Robert Saltmarsh; CFO
Graham Lidgard, Ph.D.; Sr. VP, R&D
Walt Mahoney; VP, R&D
Merl F. Hoekstra; VP, Business Development
®

Acquired SynX Pharma Inc. (4/04)
Merged with Epoch Biosciences Inc. (12/04)
To acquire Spectral Diagnostic Inc.’s rapid cardiac immunoassay test
business (as of 12/05)
To acquire the diagnostics division of Amplimedical SpA (as of 4/06)
FACILITIES: 51,000 sq. ft. in San Diego, Calif.

30,000 sq. ft. in Bothell, Wash.
50,000 sq. ft. in Toronto, Canada
2,600 sq. ft. in Helmond, Netherlands
STOCK-FINANCIAL HISTORY: NASDAQ--NGEN
IPO--3.9M shares at $11/share, $42.9M (4/98)
Secondary offering--$80M (11/00)
04)
PRIVATE PLACEMENTS: Raised $26.2M through private placement of Series C preferred stock (3/97)
Raised $20M through private placement of 6.8M shares and 1M warrants
(9/05)
SUBSIDIARIES/DIVISIONS: Molecular Research Products division:
21720 23rd Drive S.E., No. 150
Bothell, WA 98021
Phone: (800) 562-5544
Fax: (425) 482-5550
E-mail: molecularresearch@nanogen.com
Point of Care Diagnostics division:

1 Marmac Drive
Toronto , Ontario
M9W 1E7 Canada
Phone: (877) 246-7593
Fax: (416) 798-3447
E-mail: nanogenpoc@nanogen.com
Nanogen Europe BV:

Steenovenweg 3
5708 HN Helmond
Netherlands
Phone: +31 (0)492-507-160
Fax: +31 (0)492-507-179
PRINCIPAL INVESTORS: Birndorf Biotechnology Development
Enterprise Partners
InterWest Partners
Kleiner, Perkins, Caufield and Byers
New Leaf Venture Partners
INVESTMENTS: Jurilab Ltd.
FINANCIAL INFORMATION: Completed $3.5M round of venture capital financing (2/94)
Completed $9.5M round of venture capital financing (10/95)
Received $2M two-year grant from U.S. Department of Commerce (7/95)
Received $500K grant from Bude Technology Group (4/96)
Received $250K grant from the State of California Defense Conversion
Matching Grant (6/96)
®

Become a leading supplier of molecular diagnostic tests by developing
commercial applications for our proprietary platform technology and by
promoting our technology as the standard for molecular identification and
analysis. Key elements of our strategy include:
-Developing commercial applications
-Developing research and genomics applications
-Establishing strategic collaborations
-Developing advanced technologies and point-of-care applications

Becton Dickinson test systems to worldwide, multi- 5/97
and Co. diagnose infectious year collaborative
diseases (based on agreement
Nanogen's DNA
microchip and Becton
Dickinson's system for
DNA amplification)
Bode Technology forensics one-year 1996
Group development
agreement
deCode Genetics new genomics assay supply and licensing 4/05
using Nanogen agreement
products for single
nucleotide
polymorphism (SNP)
discovery, validation
and screening
Department of integrated two-year, $2M 1995
Commerce microelectronic DNA development grant
diagnostic system
Department of portable genetic $2M development 3/97
Commerce analysis device for grant
forensic investigations,
trauma victim
identification, medical
diagnostics and
environmental
monitoring
Fisher Scientific molecular diagnostics expanded Fisher's 8/06
International Inc. equity investment in
Nanogen (3/06) to
include R&D
collaboration
Jurilab Ltd. development of licensing agreement 7/05
diagnostics based on
genes and markers
discovered by Jurilab
Jurilab Ltd. identification and research 5/06
validatation of collaboration
prognostic markers for
Type II diabetes
Pathway Nanogen to develop nonexclusive, 3/05
Diagnostics diagnostic products that worldwide licensing
detect genetic variations agreement
associated with
responses to
antidepressant and
antipsychotic
therapeutics
®
Prolinx Inc. enhanced sensitivity sponsored research 4/97

detection system for agreement
use with Nanogen's
proprietary
electronically
addressable microchip
array technologies
U.S. Justice portable microchip $710K research 9/97
Department array-based genetic grant
(National Institue detector for rapid
of Justice) genetic testing and
identification at the point
of evidence collection
RESEARCH & DEVELOPMENT: Integrated system for rapid analysis of charged macromolecules using
microelectronics and molecular biology
Nanogen APEX (Automated Programmable Electronic Matrix) to move,
concentrate, bind, wash and separate charged molecules in electronic field
PRODUCTS ON MARKET: NanoChip™ Molecular Biology Workstation
NanoChip™ cartridges
Analyte specific reagents (ASRs)
NanoHorizons Inc.
Technology Center, Suite 208, 200 Innovation Blvd.
State College PA 16803, US
Phone: (814) 861-9909; Fax: (814) 861-9903
Web: www.nanohorizons.com
E-mail: info@nanohorizons.com
KEY PERSONNEL: Stephen Fonash, Ph.D.; Chairman and CTO
Robert F. Burlinson; President and CEO
Joseph D. Cuiffi, Ph.D.; Head, R&D and Production
Daniel J. Hayes, Ph.D.; Head, Operations
Dennis I. Schneider; Head, Marketing
PRINCIPAL INVESTORS: Ben Franklin Technology Partners
Life Sciences Greenhouse of Central Pennsylvania
Pulsar Ventures
Develop and produce state-of-the-art nanotechnology products and
processes for near term biotechnology, pharmaceutical, chemical and
microelectronic applications

Arrow opportunities to apply research 3/04
International Inc. nanotechnology to collaboration
emerging cost and
performance issues in
biomedical technology
pSiMedica opportunities to utilize materials transfer 2/04
NanoHorizon's agreement
nanostructured silicon
films in areas such as
tissue engineering and
diagnostics
®
Solarity NanoHorizons' solar cell exclusive licensing 8/06

technology agreement
RESEARCH & DEVELOPMENT: Technologies: Photovoltaics and organic LEDs, sensors and flexible
electronics
PRODUCTS ON MARKET: Noble Metal Embedded Nanoparticles - Low-cost line of polymer-compatible
anti-odor nanoparticles
QuickMass™ - Mass spectrometry targets for high-speed analysis of small
molecules for pharmaceutical product development and medical research
Humidity Sensors for Respiratory Monitoring - Rapid-response, high-
sensitivity
NanoLogix Inc.
87 Stambaugh Avenue, Suite 2
Sharon PA 16146, US
Phone: (724) 346-1302; Fax: (724) 346-9596
Web: www.nanologix.net
E-mail: ir@nanologix.net
KEY PERSONNEL: Mitchell S. Felder, M.D.; CEO
David McClelland; President
Thomas A Kelly, Ph.D.; Sr. Scientist
Changed name from Infectech Inc. (4/05)
STOCK-FINANCIAL HISTORY: Pink Sheets--NNLX
SUBSIDIARIES/DIVISIONS: MD-Diagnostics.com Inc.
SUBSIDIARY OF: Nutra Pharma Corp.
BUSINESS STRATEGY: NanoLogix is an R&D company which partners with multi-national
corporations for product development
Brigham & Pseudomonas vaccine option agreement 1998
Women's Hospital
BioRemedial bioremediation investment and 1998
Technologies licensing agreement
RESEARCH & DEVELOPMENT: Technologies for the production of bacteria and disease testing kits,
alternative sources of fuel, cancer therapy and remediation of toxic materials
PRODUCTS ON MARKET: M. tuberculosis
M. avium (experimental use)
M. tuberculosis field testing
M. avium field testing
Pseudomonus vaccine clinical stage
Apoptosis (cancer tx) development stage
®
Nanophase Technologies Corp.

1319 Marquette Drive
Romeoville IL 60446, US
Phone: (630) 771-6700; Fax: (630) 771-0825
Web: www.nanophase.com
E-mail: investor-relations@nanophase.com
KEY PERSONNEL: Donald S. Perkins; Chairman
Joseph Cross; CEO and President
Jess Jankowski; CFO
Richard W. Brotzman; VP, R&D
Robert Haines; VP, Operations
Daniel S. Bilicki; VP, Sales and Marketing
Edward G. Ludwig; VP, Business Development
HISTORY: Founded in 1989 as a spinoff of Argonne National Labs
STOCK-FINANCIAL HISTORY: NASDAQ--NANX

IPO--$8/share (11/97)
04)
BUSINESS STRATEGY: Provide nanoengineered solutions for multiple industrial product applications
such as commercial quantity and quality nanoparticles, coated nanoparticles
and nanoparticle dispersions in a variety of media. Sell intermediate
products enabling high-value add customer applications. The company has
major partnerships (including BASF, Rohm & Haas and BYK Chemie)
exploiting broad applications expertise and global distribution channels.
Alfa Aesar nanomaterials for distribution 10/05
(research research and agreement
chemicals unit of development
Johnson Matthey) applications
Competitive CT to identify option, evaluation, 10/05
Technologies nanotechnologies that licensing and
may be synergistic with commercialization
Nanophase’s agreement
technologies
Roche nanoparticles for a supply agreement 3/06
Diagnostics medical diagnostics
application through
2014
PRODUCTS ON MARKET: Metal oxides

Coated metal oxides
Nanoparticle dispersions
Custom synthesis
®
National Collection of Yeast Cultures (NCYC)

Institute of Food Research, Norwich Research Park, Colney
Norwich NR4 7UA, UK
Phone: (+44) 1603-255000; Fax: (+44) 1603-458414
Web: www.ncyc.co.uk; E-mail: ncyc@bbsrc.ac.uk
KEY PERSONNEL: Ian N. Roberts, Ph.D.; Curator
Chris J. Bond; Deputy Curator
Stephen A. James, Ph.D.; Molecular Biologist
Georgina A. Pope, Ph.D.; Molecular Biologist
Robert Davey, Ph.D.; Bioinformaticist
HISTORY: Collection of more than 4,000 yeast cultures used in brewing, winemaking,
biotechnology, and the food industry
SUBSIDIARY OF: IFR Enterprises, Ltd., the technology interaction company of the Institute of
Food Research (see separate entry), a company limited by guarantee,
grant-aided by the Biotechnology and Biological Sciences Research Council
BUSINESS STRATEGY: Supply the academic and industrial community with yeast cultures and yeast
microbiological services
RESEARCH & DEVELOPMENT: Yeast genetics
Identification methods
Yeast biotechnological information databases
PRODUCTS ON MARKET: Catalog of cultures (yeast cultures)
Safe deposit service
Patent deposit service
Online database
Identification service
National Institute of Advanced Industrial

Science and Technology (AIST)
1-1-1 Umezono, Tsukuba
Ibaraki 305-8568, Japan
Phone: +81 29 861 2298; Fax: +81 29 862 6148
Web: www.aist.go.jp; E-mail: maoriya-t@aist.go.jp
KEY PERSONNEL: Dr. Hiroyuki Yoshikawa; President
Kisaburo Kodama; Sr. VP
HISTORY: Formed from the amalgamation of 15 research institutes in April 2001
STOCK-FINANCIAL HISTORY: Publicly funded institution
BUSINESS STRATEGY: Pursue advanced research by exploring broad spectra of research fields and
integrating multidisciplinary subjects to promote innovation in versatile fields
that strengthen the competitiveness of Japanese industries in the world
market and create new industries
Pursue interdisciplinary and cross-disciplinary research that enables
planning long-range governmental policies by exploiting the current and
future needs of society
Pursue basic research that maintains and strengthens competitiveness of
national science and technology by developing and maintaining high
standards of scientific and engineering research under the sole
responsibility of AIST
®
RESEARCH & DEVELOPMENT: Life science and technology: Development of new technologies for drugs
and diagnostic agents based on post-genome research; promotion of
neuroscience, human-technology and biomedical engineering for health
maintenance/improvement; and research for new biofunctions/biomaterials
and development of efficient biomaterial production technology
Information technology: Research and development of ultra-high density

optical storage technology; development of grid middleware; development of
ultrafast optical switching technology using intersubband transition; practical
application of model checking method to embedded software verification;
success in fastest optical fiber quantum crypto transmission; development of
porous silica low permittivity (low-k) insulator film; development of film-
fabrication technologyfor high permittivity (high-k) gate insulatorfilm;
development of miniaturization technology for ultrasonic 3-D tag for
measurement of daily human activities; development of the first 4-terminal
drive type XMOS-FET; development of technology for therapeutic
application of Mental Commitment Robot 'PARO'; development of
CONSORTS multiagent computing architecture; and development of
application system using grid technology
Nanotechnology, materials and manufacturing: Synthesis technology for

single-walled carbon nanotubes; on-demand processing using micro-
plasma; manufacture of active-targeting DDS nanoparticles; development of
analysis method using microreactor; development of highest resolution
magnetic force microscope; development of analytical electron microscope
with the highest sensitivity; development of synthesis technology for large
diamond single crystals; control of interface magnetism of strongly-
correlated electron oxides; discovery of the Hall effect of light; elucidation of
chemical reaction in supercritical water by computational science;
development of room temperature coating technology for ceramic materials;
ceramic sintering technology using centrifugal force; development of
technology for large magnesium alloy components
Environment and energy: Development of new decomposition/detoxification

reaction processes for harmful substances, development of in-plant
separation/concentration processes and environment-friendly alternative
substances; development of distributed energy, including renewable energy,
and energy networks, development of clean coal technology and biomass
fuels and related application technologies; establishment of methods for
estimating resources/energy utilization rates and hazardous substance risk,
development of evaluation methods for global warming countermeasures
and their social acceptability
Geological survey and applied geoscience: Research on volcanoes and

development of methods for survey/evaluation/control of soil contamination
Metrology and measurement technology: Development and supply of

measurement standards, including calibration of measurement instruments,
as well as scientific research in metrology
National Institutes of Health (NIH)

Building 1, 1 Center Drive
Bethesda MD 20892, US
Phone: (301) 496-4000
Web: www.nih.gov
E-mail: info@nih.gov
KEY PERSONNEL: Elias A. Zerhouni, M.D.; Director
Raynard S. Kington, M.D., Ph.D.; Deputy Director
Norka Ruiz Bravo, Ph.D.; Deputy Director, Extramural Research
®
Michael Gottesman, M.D.; Deputy Director, Intramural Research

Colleen Barros; Deputy Director, Management and CFO
FACILITIES: NIH scientists conduct their research in laboratories located on the main
campus in Bethesda, and in several field units across the country and
abroad. The 870,000 sq. ft. Mark O. Hatfield Clinical Research Center
opened in September 2004. The NIH also has facilities in the Rockville, Md.,
area and the NCI Frederick Cancer Research and Development Center
(FCRDC) at Fort Detrick in Frederick, Md. The National Institute of
Environmental Health Sciences' main facility is located in Research Triangle
Park, N.C..
Other laboratory facilities include the NIH Animal Center in Poolesville, Md.;
the National Institute on Aging's Gerontology Research Center in Baltimore,
Md.; the Division of Intramural Research of the National Institute on Drug
Abuse, also in Baltimore; the National Institute of Allergy and Infectious
Diseases' Rocky Mountain Laboratories in Hamilton, Mt., and several
smaller field stations.
FY 2004 Budget: $27.9b
SUBSIDIARIES/DIVISIONS: Office of the Director (OD)--The Office of the Director is the central office at
NIH for its 27 Institutes and Centers. The OD is responsible for setting policy
for NIH and for planning, managing, and coordinating the programs and
activities of all the NIH components. OD's program offices include the Office
of AIDS Research and the Office of Research on Women's Health, among
others.
National Cancer Institute (NCI)--Established in 1937, the NCI leads a

national effort to reduce the burden of cancer morbidity and mortality. Its
goal is to stimulate and support scientific discovery and its application to
achieve a future when all cancers are uncommon and easily treated.
Through basic and clinical biomedical research and training, NCI conducts
and supports programs to understand the causes of cancer; prevent, detect,
diagnose, treat, and control cancer; and disseminate information to the
practitioner, patient, and public.
National Eye Institute (NEI)--Established in 1968, the NEI conducts and

supports research that helps prevent and treat eye diseases and other
disorders of vision. This research leads to sight-saving treatments, reduces
visual impairment and blindness, and improves the quality of life for people
of all ages. NEI-supported research has advanced our knowledge of how
the eye functions in health and disease.
National Heart, Lung, and Blood Institute (NHLBI)--Established in 1948, the
NHLBI provides leadership for a national program in diseases of the heart,
blood vessels, lung, and blood; blood resources; and sleep disorders. Since
October 1997, the NHLBI has also had administrative responsibility for the
NIH.
Woman's Health Initiative--The Institute plans, conducts, fosters, and

supports an integrated and coordinated program of basic research, clinical
investigations and trials, observational studies, and demonstration and
education projects.
National Human Genome Research Institute (NHGRI)--Established in 1989,

the NHGRI supports the NIH component of the Human Genome Project, a
worldwide research effort designed to analyze the structure of human DNA
and determine the location of the estimated 30,000 to 40,000 human genes.
The NHGRI Intramural Research Program develops and implements
technology for understanding, diagnosing, and treating genetic diseases.
®
National Institute on Aging (NIA)--Established in 1974, the NIA leads a

national program of research on the biomedical, social, and behavioral
aspects of the aging process; the prevention of age-related diseases and
disabilities; and the promotion of a better quality of life for all older
Americans.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)--Established in

1970, the NIAAA conducts research focused on improving the treatment and
prevention of alcoholism and alcohol-related problems to reduce the
enormous health, social, and economic consequences of this disease.
National Institute of Allergy and Infectious Diseases (NIAID)--Established in

1948, the NIAID research strives to understand, treat, and ultimately prevent
the myriad infectious, immunologic, and allergic diseases that threaten
millions of human lives.
National Institute of Arthritis and Musculoskeletal and Skin Diseases

(NIAMS)--Established in 1986, the NIAMS supports research into the
causes, treatment, and prevention of arthritis and musculoskeletal and skin
diseases, the training of basic and clinical scientists to carry out this
research, and the dissemination of information on research progress in
these diseases.
National Institute of Biomedical Imaging and Bioengineering (NIBIB)--

Established in 2000, the NIBIB improves health by promoting fundamental
discoveries, design and development, and translation and assessment of
technological capabilities in biomedical imaging and bioengineering, enabled
by relevant areas of information science, physics, chemistry, mathematics,
materials science, and computer sciences.
National Institute on Deafness and Other Communication Disorders

(NIDCD)--Established in 1988, the NIDCD conducts and supports
biomedical research and research training on normal mechanisms as well
as diseases and disorders of hearing, balance, smell, taste, voice, speech,
and language that affect 46 million Americans.
National Institute of Dental and Craniofacial Research (NIDCR)--Established

in 1948, the NIDCR provides leadership for a national research program
designed to understand, treat, and ultimately prevent the infectious and
inherited craniofacial-oral-dental diseases and disorders that compromise
millions of human lives.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)--

Established in 1948, the NIDDK conducts and supports basic and applied
research and provides leadership for a national program in diabetes,
endocrinology, and metabolic diseases; digestive diseases and nutrition;
and kidney, urologic, and hematologic diseases. Several of these diseases
are among the leading causes of disability and death; all seriously affect the
quality of life of those who have them.
National Institute on Drug Abuse (NIDA)--Established in 1973, the NIDA

leads the nation in bringing the power of science to bear on drug abuse and
addiction through support and conduct of research across a broad range of
disciplines and rapid and effective dissemination of results of that research
to improve drug abuse and addiction prevention, treatment, and policy.
National Institute of Environmental Health Sciences (NIEHS)--Established in

1969, the NIEHS reduces the burden of human illness and dysfunction from
environmental causes by, defining how environmental exposures, genetic
susceptibility, and age interact to affect an individual's health.
National Institute of General Medical Sciences (NIGMS)--Established in

1962, the NIGMS supports basic biomedical research that is not targeted to
specific diseases. NIGMS funds studies on genes, proteins, and cells, as
well as on fundamental processes like communication within and between
®
cells, how our bodies use energy, and how we respond to medicines. The
results of this research increase our understanding of life and lay the
foundation for advances in disease diagnosis, treatment, and prevention.
NIGMS also supports research training programs that produce the next
generation of biomedical scientists, and it has special programs to
encourage underrepresented minorities to pursue biomedical research
careers.
National Institute of Mental Health (NIMH)--Established in 1949, the NIMH

provides national leadership dedicated to understanding, treating, and
preventing mental illnesses through basic research on the brain and
behavior, and through clinical, epidemiological, and services research.
National Institute of Neurological Disorders and Stroke (NINDS)--

Established in 1950, the mission of the NINDS is to reduce the burden of
neurological diseases--a burden borne by every age group, every segment
of society, and people all over the world. To accomplish this goal the NINDS
supports and conducts research, both basic and clinical, on the normal and
diseased nervous system, fosters the training of investigators in the basic
and clinical neurosciences, and seeks better understanding, diagnosis,
treatment, and prevention of neurological disorders.
National Institute of Nursing Research (NINR)--Established in 1986, the

NINR supports clinical and basic research to establish a scientific basis for
the care of individuals across the life span--from the management of
patients during illness and recovery to the reduction of risks for disease and
disability; the promotion of healthy lifestyles; the promotion of quality of life
in those with chronic illness; and the care for individuals at the end of life.
This research may also include families within a community context, and it
also focuses on the special needs of at-risk and under-served populations,
with an emphasis on health disparities.
National Library of Medicine (NLM)--Established in 1956, the NLM collects,

organizes, and makes available biomedical science information to
investigators, educators, and practitioners and carries out programs
designed to strengthen medical library services in the United States. Its
electronic data bases, including MEDLINE and MEDLINEplus are used
extensively throughout the world by both health professionals and the public.
Center for Information Technology (CIT formerly DCRT, OIRM, TCB)--

Established in 1964, the CIT incorporates the power of modern computers
into the biomedical programs and administrative procedures of the NIH by
focusing on three primary activities: conducting-computational biosciences
research, developing computer systems, and providing computer facilities.
Center for Scientific Review (CSR)--Established in 1946, the CSR is the

focal point at NIH for the conduct of initial peer review, the foundation of the
NIH grant and award process. The Center carries out peer review of the
majority of research and research training applications submitted to the NIH.
In addition, the Center serves as the central receipt point for all such Public
Health Service (PHS) applications and makes referrals to scientific review
groups for scientific and technical merit review of applications and to funding
components for potential award. To this end, the Center develops and
implements innovative, flexible ways to conduct referral and review for all
aspects of science.
John E. Fogarty International Center (FIC)--Established in 1968, the FIC

promotes and supports scientific research and training internationally to
reduce disparities in global health.
National Center for Complementary and Alternative Medicine (NCCAM)--

Established in 1992, the NCCAM is dedicated to exploring complementary
and alternative medical (CAM) practices in the context of rigorous science;
training CAM researchers and disseminating authoritative information.
®
National Center on Minority Health and Health Disparities (NCMHD)--

Established in 1993, the mission of NCMHD is to promote minority health
and to lead, coordinate, support, and assess the NIH effort to reduce and
ultimately eliminate health disparities. In this effort NCMHD will conduct and
support basic, clinical, social, and behavioral research, promote research
infrastructure and training, foster emerging programs, disseminate
information, and reach out to minority and other health disparity
communities.
National Center for Research Resources (NCRR)--Established in 1962, the

NCRR advances biomedical research and improves human health through
research projects and shared resources that create, develop, and provide a
comprehensive range of human, animal, technological, and other resources.
NCRR's support is concentrated in four areas: biomedical technology,
clinical research, comparative medicine, and research infrastructure.
Warren Grant Magnuson Clinical Center (CC)--Established in 1953, the CC

is the clinical research facility of the National Institutes of Health. As a
national resource, it provides the patient care, services, and environment
needed to initiate and support the highest quality conduct of and training in
clinical research.
SUBSIDIARY OF: NIH is an agency of the U.S. Department of Health and Human Services
BUSINESS STRATEGY: Provide leadership and direction to programs designed to improve the health
of the nation by conducting and supporting research: in the causes,
diagnosis, prevention, and cure of human diseases; in the processes of
human growth and development; in the biological effects of environmental
contaminants; in the understanding of mental, addictive and physical
disorders; in directing programs for the collection, dissemination, and
exchange of information in medicine and health, including the development
and support of medical libraries and the training of medical librarians and
other health information specialists
NIH is the steward of medical and behavioral research for the nation. Its
mission is science in pursuit of fundamental knowledge about the nature and
behavior of living systems and the application of that knowledge to extend
healthy life and reduce the burdens of illness and disability. The goals of the
agency are as follows: 1) foster fundamental creative discoveries, innovative
research strategies, and their applications as a basis to advance
significantly the nation's capacity to protect and improve health; 2) develop,
maintain, and renew scientific human and physical resources that will assure
the nation's capability to prevent disease; 3) expand the knowledge base in
medical and associated sciences in order to enhance the nation's economic
well-being and ensure a continued high return on the public investment in
research; and 4) exemplify and promote the highest level of scientific
integrity, public accountability, and social responsibility in the conduct of
science.

Numerous NIH varied NIH sponsors
programs relating various projects that
to grants, support the
contracts, extramural research
licensing, and community of more
collaborations than 50,000 non-
Federal scientists
located at more than
1,700 universities,
research institutions,
and medical centers
across the United
States and abroad
®
RESEARCH & DEVELOPMENT: NIH is involved in hundreds of research projects, including:

GENOMICS
Human Genome Project
Human Sequence Databases
Human Genetic Variation
Cancer Diagnosis
Genes and Aging
Genes and Environment
Gene Hunting for Schizophrenia and Manic-Depressive Illness
Birth Defects and Inherited and Developmental Disorders
Genes for Diabetes
Genetics of Addiction
Mouse Genome
Mouse Mutants
Genomes of Bacteria, Viruses, and Parasites
ADVANCED TECHNOLOGIES
Structural Genomics
Toxic Chemicals
New Organs and Tissues
Repair and Replacement of Tissues of the Face and Head
Drugs for Neurological Disorders
Drug Addiction
Understanding Alcohol Addiction
Chemical Libraries
Assistive Devices for the Visually Impaired
DISEASE PREVENTION, DIAGNOSIS and TREATMENT

Early Cancer Detection
Alternative Cancer Therapies
Treating Diabetes
Blocking the Effects of Alzheimer's Disease
Preventing and Treating Parkinson's
Autism Centers of Excellence
Treating Mental Illness in Children
Ear Infections in Children
Heart, Lung, and Blood Diseases
Acute Stroke Centers
AIDS Prevention and Treatment
HIV Transmission to Infants
Musculoskeletal Medicine
Overcoming Salivary Gland Problems
Drug Abuse Treatment
Nicotine Addiction
INTERDISCIPLINARY TRAINING AND COLLABORATIVE RESEARCH

Computer Analysis of Biological Data
Virtual Cell Research
Women's Health
Sex and Gender Differences in the Immune System
Alcohol and the Brain
HEALTH DISPARITIES
Cancer Centers for Population Health
Reducing Preterm Births.
Reducing Sudden Infant Death
Geographic and Racial Differences in Stroke
Hepatitis C in Minority Populations
Programs to Train Minority Scientists
Clinical Research Training at Institutions That Serve Minorities
Specialized Neuroscience Research Programs (SNRPs) at Minority
Institutions
Ensuring Access to Information Services
Diabetes in Minority Populations
®
PRODUCTS ON MARKET: NIH research has contributed to numerous therapies, drugs, programs,
innovations and diagnostics that address myriad health issues and
conditions
NIH research has contributed to the
progress of many products and
technologies that advance through the
clinical development stages
National Research Council of Canada

1200 Montreal Road, Bldg. M-58
Ottawa K1A 0R6, Canada
Phone: (613) 993-9101; Fax: (613) 952-9907
Toll-free phone: (877) NRC-CNRC (672-2672)
Web: www.nrc-cnrc.gc.ca
E-mail: info@nrc-cnrc.gc.ca
KEY PERSONNEL: Dr. Pierre Coulombe; President
Dr. Sherif Barakat; VP, Engineering
Don T. Di Salle; VP, Corporate Services
Patricia Mortimer; Acting VP, Technology and Industry Support
Dr. Richard Normandin; VP, Physical Sciences
Dr. Roman Szumski; VP, Life Sciences
Marielle Piche; Acting Secretary General
HISTORY: Created by the Canadian government in 1916, NRC fulfills three main
responsibilities: as a partner with industry in R&D; as a source of basic
scientific and engineering strength for the national interest; and as a
contributor to the development of the national science and technology
infrastructure
SUBSIDIARIES/DIVISIONS: NRC Plant Biotechnology Institute (NRC-PBI), Saskatoon, SK--plant cell
biotechnology
NRC Institute for Biological Sciences (NRC-IBS), Ottawa, ON--cell biology of
neurodegenerative diseases; immunochemistry of vaccines; diagnostics;
immunotherapeutics for human and veterinary applications
NRC Biotechnology Research Institute (NRC-BRI), Montreal, PQ--seeks to
exploit biotechnological processes in collaboration with Canadian industries
NRC Institute for Marine Biosciences (NRC-IMB), Halifax, NS--marine plant
biology and biochemistry
NRC Institute for Biodiagnostics (NRC-IBD), Winnipeg, MB--research in
developing more sophisticated diagnostic techniques
NRC Institute for Nutrisciences and Health (NRC-INH), Charlottetown, PE--
naturally-occurring compounds to benefit human and animal health—impact
of nutraceuticals and bioactives on neurologic, obesity-related disorders;
and infection and immunity
Fourteen other nonbiotech institutes nationwide
Industrial Research Assistance Program Office--supports research in a
number of Canadian industries, including biotechnology
Canada Institute for Scientific and Technical Information (CISTI)
SUBSIDIARY OF: Government of Canada
INVESTMENTS: NRC's Biotechnology Program is a founding member of Genome Canada
and contributes to Canadian innovation in genomics through the NRC
Genome and Health Initiative (GHI), which was launched in 1999
BUSINESS STRATEGY: Enter into agreements with Canadian industries to facilitate creation of
products
®
RESEARCH & DEVELOPMENT: All areas of science and technology, including biotechnology, plant
biotechnology, marine biosciences, molecular sciences, and microstructural
sciences, either as active participants or as consultant/advisors
Research areas include: Bioinformatics, environmental and sustainable
development technologies, fuel cells, genomics, nanotechnology, photonics,
nutraceuticals, proteomics
Nature Plus Inc.

555 Lordship Boulevard
Stratford CT 06115, US
Phone: (203) 380-0316; Fax: (203) 380-0358
Web: www.nature-plus.com
E-mail: info@nature-plus.com
KEY PERSONNEL: Dr. Sheldon R. Murphy; President and CEO
BUSINESS STRATEGY: Expand current products into international sales
RESEARCH & DEVELOPMENT: Ingredients, concentrates

PRODUCTS ON MARKET: TerraZyme® soil stabilizer
EcoCare® odor eliminator products
NaturCare® cleaning and odor control products
SAFE home products
Pool and medical products
NatureWorks LLC
P.O. Box 5830
Minnetonka MN 55440-5830, US
Phone: (989) 633-1746 Toll-free phone: (877) 423-7659
Web: www.natureworksllc.com
KEY PERSONNEL: Dennis McGrew; President and CEO
Lisa Owen; Global Business Leader, Rigid Packaging
HISTORY: Founded in 1997 as Cargill Dow LLC, a 50:50 joint venture between Cargill
and The Dow Chemical Co.
Acquired completed by Cargill (1/05)
FACILITIES: Plant in Blair, Neb.
SUBSIDIARY OF: Cargill
BUSINESS STRATEGY: Produce and sell renewable-resource-based resin derived from the sugar
found in common field corn
PRODUCTS ON MARKET: NatureWorks® PLA--bottles packaging, packaging for consumer goods,

food and serviceware
Ingeo® fibers (www.ingeofibers.com)
®
Neogen Corp.
620 Lesher Place
Lansing MI 48912-1595, US
Phone: (517) 372-9200; Fax: (517) 372-2006
Web: www.neogen.com
E-mail: inform@neogen.com
KEY PERSONNEL: James Herbert; Chairman and CEO
Lon M. Bohannon; President and COO
Richard R. Current; VP and CFO
Edward L. Bradley; VP, Food Safety Sales and Marketing
Kenneth Kodilla; VP, Manufacturing
Joseph M. Madden, Ph.D.; VP, Scientific Affairs
Anthony E. Maltese; VP, Corporate Development
Terri A. Morrical; VP, Animal Safety Sales and Marketing
Mark A. Mozola, Ph.D.; VP, R&D
Paul S. Satoh, Ph.D.; VP, Basic and Exploratory Research
Purchased WTT Inc. (now ELISA Technologies), a developer of
immunoassay diagnostics for the equine and dog racing industries and
research markets (9/92)
Acquired plant diagnostics product lines of Quantix Systems (3/93)
Purchased assets of Enzytec of Kansas City, MO (10/93)
Acquired AMPCOR Diagnostics Inc. of Camden, NJ (8/94)
Acquired International Diagnostic Systems' animal diagnostics product line
(6/95)
Acquired Triple Crown Veterinary Pharmaceuticals (7/97)
Acquired assets of Vetoquinol U.S.A. (ImmunoVet products) (1/98)
Acquired Acumedia (2000)
Acquired Adgen Ltd. (3/03)
Acquired Hacco Inc. and Hess & Clark (11/03)
Acquired distribution business of BiologischeAnalysensysteme GmbH (BAG)
(10/04)
Acquired UCB's dairy antibiotic testing business (12/05)
Acquired Centrus International Inc. (2/06)
FACILITIES: Headquarters in Lansing, Mich.

25,000 sq. ft. food safety diagnostic manufacturing facility near Lansing,
Mich.
30,000 sq. ft facility for veterinary instruement operations in Lansing, Mich.
80,000 sq. ft. Animal Safety Division facility in Lexington, Ky.
STOCK-FINANCIAL HISTORY: NASDAQ--NEOG
IPO--1.2M shares, $7.2M (10/89)
Five-for-four stock split (12/03)
Public offering--800K shares (6/06)
SUBSIDIARIES/DIVISIONS: Food Safety Division
Animal Safety Division
Life Sciences Division
Acumedia
Neogen Europe Ltd.
BUSINESS STRATEGY: Become dominant company in the development and marketing of solutions
for food and animal safety
®

CPI International Colitag water test distribution 6/04
system agreement
RESEARCH & DEVELOPMENT: Food and animal safety--all animals: mycotoxin diagnostics; Food Allergens;
veterinary delivery instrument, microbiological tests and drug detection diay.
PRODUCTS ON MARKET: More than 200 diagnostic test kits, including:
Agri-Screen® aflatoxin B1 diagnostic kit
Agri-Screen® Ticket pesticide detection kit
Agri-Screen® vomitoxin diagnostic kit
Agri-Screen® nitrate diagnostic kit
Agri-Screen® pH diagnostic kit
Agri-Screen® triazine herbicide resistance test in weeds
Agri-Screen® fumonisins diagnostic test
Agri-Screen® ochratoxin diagnostic test
Alert® for histamine
Alert® for sulfites
Ideal® line of veterinary instruments
Bot Tox-B Clostridium botulinum type B vaccine
Alert® disease detection kit
ELISA Technologies® racing kits for detection of drugs of abuse in horses
and dogs
ELISA Technologies® research kits
K-Blue Substrate®
K-Gold™ Substrate
Veratox® vomitoxin diagnostic kit
Veratox® T-2 toxin diagnostic kit
Veratox® aflatoxin quantitative diagnostic kit
Veratox® zearalenone diagnostic kit
Veratox®-AST aflatoxin single diagnostic test kit
Veratox® for fumonisin quantitative diagnostic kit
Ticket™ pesticide detector
Reveal® for E. coli 0157:H7
Reveal® for Salmonella
Reveal® BioPlate for E. coli
Reveal® for listeria
REVIVE media
EqStim®
ImmunoRegulin®
MycAseptic™
MycAseptic E™
New Brunswick Scientific Co. Inc.

44 Talmadge Road
Edison NJ 08817, US
Phone: (732) 287-1200; Fax: (732) 287-4222
Web: www.nbsc.com
E-mail: bioinfo@nbsc.com
KEY PERSONNEL: David Freedman; Chairman and CEO
Jim T. Orcutt; President and COO
Thomas E. Bocchino; VP, Finance and CFO
Dr. Lee Eppstein; VP, Technology
HISTORY: Founded in 1946 by David and Sigmund Freedman
Acquired RS Biotech Laboratory Equipment Ltd. (11/03)
®
STOCK-FINANCIAL HISTORY: NASDAQ--NBSC

Second stock offering (1983)
Net <loss> income $2.494M (YE 05) compared to $1.931M (YE 04)
Earnings <loss> per share <$0.28/share> (YE 05) compared to
<$0.22/share> (YE 04)
SUBSIDIARIES/DIVISIONS: New Brunswick Scientific (U.K.) Ltd. (see separate entry)
New Brunswick Scientific NV

Kerkenbos 1101
6546 BC Nijmegen, The Netherlands
Phone: +31 (0)24 3717 600; Fax: +31 (0)24 3717 640
E-mail: sales@nbsbv.nl; Web site: www.nbsc.com/bv
New Brunswick Scientific GmbH

In der Au 14
D-72622 Nurtingen, Germany
Phone: +49 (0)7022-932490
Fax: +49 (0)7022-32486
E-mail: sales@nbsgmbh.de
Web site: www.nbsgmbh.de
New Brunswick Scientific NV-SA

Stationsstraat 180/4
B-3110 Rotselaar
Belgie/Belgique
Phone: +32 (0) 16 562 831
Fax: +32 (0) 16 572 753
E-mail: sales@nbsnv-sa.be
New Brunswick Scientific SarL

12-14, Rond Point des Champs Elysees
75008 Paris, France
Phone: +33 (0)1 53 53 15 11
Fax: +33 (0)1 53 53 15 57
E-mail: sales@nbssarl.fr
New Brunswick Scientific Sales Office

A903, 904 Yin Hai Building
No. 250, Cao Xi Road
Shanghai, 200235, China
Phone: +86-21-64845955, +86-21-64845966
Fax: +86-21-64845933
E-mail: nbschc@online.sh.cn
BUSINESS STRATEGY: Design, manufacture and market advanced systems for growth, detection
and storage of cultures. Products include the world’s largest line of biological
shakers and a full line of bench-to-production-scale fermentors and
bioreactors used to produce therapeutic drugs, enzymes, biochemicals,
antibiotics, vaccines and more. NBS also manufactures ultra-low
temperature freezers, CO2 incubators, air samplers, automated media
preparation equipment and roller drums.
PRODUCTS ON MARKET: Biological shakers (Innova® and Excella™)

Fermentation systems, bench-to- production-scale (BioFlo®)
Spinners, Mammalian cell culture bioreactors, bench-to-production-scale
(FibraStage Disposable Cell Culture System, Spinner Basket™, CelliGen
Plus®, BioFlo®)
Bioprocessing software (BioCommand®)
Roller drums
Air samplers (STA)
Media sterilization and dispensing equipment (AgarMatic and PourMatic)
®
New England BioLabs Inc.

240 County Road
Ipswich MA 01938-2723, US
Phone: (978) 927-5054; Fax: (978) 921-1350
Toll-free phone: Ordering: (800) 632-5227;
Technical Service: (800) 632-7799
Web: www.neb.com; E-mail: info@neb.com
KEY PERSONNEL: James V. Ellard; CEO
Richard J. Roberts, Ph.D.; CSO
Elisabeth Raleigh, Ph.D.; Director, R&D
FACILITIES: State-of-the-art 140,000 sq. ft. research and production laboratory
SUBSIDIARIES/DIVISIONS: Organic synthesis division
German, Canadian and U.K. subsidiaries
RESEARCH & DEVELOPMENT: Restriction and modification of DNA

Protein analysis and modifications
Parasitic diseases
PRODUCTS ON MARKET: Restriction enzymes for DNA research, oligonucleotides, DNA synthesis kits
Kits for molecular biology
Protein modification/analysis reagents
New Horizons Diagnostics Corp.

9110 Red Branch Road
Columbia MD 21045, US
Phone: (410) 992-9357; Fax: (410) 992-0328
Web: www.nhdiag.com
E-mail: nhdiag@aol.com
KEY PERSONNEL: Lawrence Loomis; President
David Trudil; VP and General Manager
FACILITIES: 14,000 sq. ft. facility in Columbia, Md.
Power3 Medical antibody-based development 3/05
Products Inc. diagnostics for agreement
neurogenerative
diseases
RESEARCH & DEVELOPMENT: Direct Salmonella and E. coli tests

Infectious disease diagnostics for the hospital lab and physician's office
Bioluminescent probes technology for food, environment, biowarfare, water,
and bioluminescence test for urinary infections
Membrane strip technology for direct diagnostic tests, especially for antigen
detection
Develop tests for NASA and U.S. military
Develop tests for detection of food- and water-borne pathogens
®
PRODUCTS ON MARKET: Gonogen II™ (N. gonorrhoeae) diagnostic test reagents using Mab
Bioluminescence test for human, food, environmental, biowarfare
Trust™--Syphilis detection test
Smart II™--diagnostic kit for E. coli and Salmonella
STD tests: GonoGen II and TRUST
Cholera test kits
Environmental testing
Profile-1 bioluminescence test for detection of food, water, environment and
human-borne pathogens
Biowarfare detection kits
New Zealand Pharmaceuticals Ltd.

P. O. Box 1869, 68 Weld Street
Palmerston North 4440, New Zealand
Phone: +64 6-952-3800; Fax: +64 6-952-3801
Web: www.nzp.co.nz
E-mail: market@nzp.co.nz
KEY PERSONNEL: Dr. Richard Garland; Managing Director
Andrew Lewis; General Manager
Barry Old; Marketing and Technical Director
Selwyn Yorke; Market Development Manager
Michael Callagher; Commercial Manager
FACILITIES: Two pilot plants with a total area of 188 sq. m., one of which has explosion
protected operations. Three factory and one more under construtcion.
INVESTMENTS: Just the Berries Ltd.--joint venture between NZP Holdings Ltd. and Just the
Berries Holdings Ltd. (2/03)
BUSINESS STRATEGY: Manufacture plant and animal extracts for biotechnology, pharmaceutical
and health food and cosmetics industries. Chemical synthesis of specialty
carbohydrates and related compounds.
PRODUCTS ON MARKET: Peptones, cholic acid, deoxycholic acid, dehydrocholic acid, taurocholate,
glycocholate taurodeoxycholate, methyl cholate, bile salts, heparin, chiro-
inositol, chondroitin sulphate, ferritin, pinitol, galactasomine, and
acetylmannosamine, mannosamine, sialic acid, actinidin, evening primrose
polyphenolic antioxidants, actinidin, cartilage products.
Carbohydrates in pilot plant
Blackcurrant extracts in pilot plant
Nigu Bioselect
Beuthener Strasse 2
Waldkraiburg D-84478, Germany
Phone: +49 86 38-962-0; Fax: +49 86 38-962-287
Web: www.nigu.de
E-mail: info@nigu.de
KEY PERSONNEL: Dr. Klaus Engel; Chairman, Degussa
Joachim Semel, Ph.D.; Managing Director, Nigu Chemie
®
HISTORY: Chemische Werke LOWI founded in 1947

Spun off NIGU Chemie (1964)
NIGU Chemie acquired by SKW Trostberg AG (from 1987 to 1991)
Became a subsidiary of Degussa AG when SKW Trostberg AG merged with
Degussa-Huls AG
FACILITIES: State-of-the-art, GMP-conform production facilities for ultrapure guanidine
salts and a worldwide unique recycling plant for guanidine-containing
process waste
SUBSIDIARIES/DIVISIONS: Nigu Bioselect is a business area of Nigu Chemie GmbH
SUBSIDIARY OF: Degussa AG
BUSINESS STRATEGY: Develop, produce and distribute fine and biochemicals for the
pharmaceutical, diagnostic and life science industry
PRODUCTS ON MARKET: Ultrapure guanidine hydrochloride

Ultrapure guanidine thiocyanate
Guanidine und derivatives
Recycling of guanidine containing process waste
Nippon Kayaku Co. Ltd.

Tokyo Fujimi Bldg., 11-2, Fujimi 1 chome, Chiyoda-ku
Phone: +81 3-3237-5046; Fax: +81 3-3237-5081
Web: www.nipponkayaku.co.jp
E-mail: kouho@nipponkayaku.co.jp
KEY PERSONNEL: Koichiro Shimada; President
Masao Komaki; Director, Functional Chemicals Group
Akira Mandai; Director, Pharmaceuticals Group
Yoshiyuki Ikeda; General Manager, Safety Systems Division
Yoshiaki Fukushima; Director, Fine Chemicals Group
Hidetoshi Kitazawa; Director, Strategic Corporate Planning Group and
Director, R&D Group
Koichi Chiba; Director, Administration Group
Koichi Takase; President, Polatechno Co. Ltd.
HISTORY: Established in June 1916
Formed Kayaku Asta Medica, joint venture with Asta Medica AG, to develop
the anticancer drugs Cetrorelix and D21266 (6/95)
FACILITIES: Plants located in Tokyo, Takasaki, Kasima, Fukuyama, Asa, and Himeji;
plus four laboratories
Biotech production facility located at Takasaki plant
SUBSIDIARIES/DIVISIONS: Organizaton:
Strategic Corporate Planning Group
Administration Group
Technical Operations Group
Research & Development Group: Research & Development Planning
Division, Intellectual Property Division, Functional Chemicals R&D
Laboratories, Pharmaceuticals Laboratories, Safety Systems Development
Laboratories, Agrochemicals Laboratories
®
Functional Chemicals Group: Functional Materials Division, Electronic

Materials Division, Catalysts Division
Pharmaceuticals Group: Pharmaceuticals Marketing Division, Specialty
Chemicals & Diagnostics Division, Regulatory Affairs Division,
Pharmaceuticals Technical Operations Division, Pharmaceuticals
Development Division, Licensing Division
Fine Chemicals Group: Agrochemicals Division, Color Chemicals Division,
Explosives Division
Group companies:
Functional Chemicals Group: Kouwa Sangyo Co. Ltd., Nippon Kayaku
Tokyo Co. Ltd., Nippon Kayaku Fukuyama Co. Ltd., Tomusu Co. Ltd.,
Naigai Nikka Co. Ltd., Nippon Kayaku (Taiwan) Co. Ltd., Kayaku Chemical
(Wuxi) Co. Ltd., Itabashi Chemical Ind. Co. Ltd., Polatechno Co. Ltd.,
Nippon Kayaku America Inc., Kayafloc Co. Ltd., Wuxi Polatechno Optics Co.
Ltd., Moxtek Inc., Polatechno (Hong Kong) Co. Ltd., Kayaku MicroChem
Corp., Dejima Tech BV, Dejima Optical Films BV, Minoshima Sangyo Co.
Ltd.
Fine Chemicals Group: Kouwa Sangyo Co. Ltd., Nippon KayakuTokyo Co.
Ltd., Nippon Kayaku Fukuyama Co. Ltd., Naigai Nikka Co. Ltd., N.S. Color
Techno Co. Ltd., Shinwa Sangyo Co. Ltd., Sanko Kagaku Kogyo Co. Ltd.,
Dalian Advanced Chemical Co. Ltd., Hokuyou Kayaku Co. Ltd., Zhaoyuan
Advanced Chemical Co. Ltd., Wuxi Advanced Kayaku Chemical Co. Ltd.,
Kayatech Co. Ltd., Techno Green Co. Ltd., P.T. Petrokimia Kayaku, Shikoku
ANFO Inc.
Pharmaceuticals Group: Nac Co. Ltd., Gunnan Sangyo Co. Ltd., Euro
Nippon Kayaku GmbH, Nippon Kayaku (Taiwan) Co. Ltd., Nippon Kayaku
America Inc., JHMS Corp., Nanotherapy Co. Ltd., Kayaku Zentaris Co. Ltd.,
Nippon Kayaku Food Techno Co. Ltd., Nippon Kayaku MedicalCare Co.
Ltd., Nippon Kayaku Medinet Co. Ltd., Naigai Nikka Co. Ltd.
Safety Systems Division: Toyotomi Kogyo Co. Ltd., Indet Safety Systems
AS, LifeSparc Inc., NKNM Ltd.
Other Businesses: Wako Toshi Kaihatsu Co. Ltd., Tocos Co. Ltd., Okiura
Golf Center Co. Ltd., Nikos Co. Ltd., Kayaku Akzo Corp.
BUSINESS STRATEGY: Maintain a strong focus on markets and customers, and rapidly execute
business strategy for targeting niche markets by utilizing a fusion of
technologies within and beyond the company. Based on this basic strategy,
Nippon Kayakyu has identified three growth fields:
information/communications, health care, and safety systems
Astellas Pharma Gelpart exclusive licensing 2/05
Inc. agreement
Axiom small-molecule cancer research 11/97

Biotechnologies drugs agreement--Axiom
Inc./Zaiya Inc. to receive research
funding for three
years, license fees,
milestones and
royalties, Nippon
Kayaku gains Asian
marketing and
manufacturing
rights and options
for other territories
outside North
America
National Cancer MAbs for stomach collaborative
Center (Japan) cancer diagnostics agreement
Pasteur Merieux BCG vaccine for joint development 9/95
Connaught bladder cancer agreement
Canada (now
Sanofi Pasteur)
®
Research anticancer drug-carrier ¥1b 11/90

Development complex for missile commercialization
Corp. of Japan therapy agreement
(JRDC)
Signal small molecule NGF R&D agreement 2/98
Pharmaceuticals mimetics for neuropathy
Inc.
Silenus hemoglobin-specific licensing and 1988
Laboratories MAb for GI cancer supply agreement
diagnosis
SunPharm Corp. diethylnorspermine for exclusive 3/94
cancer development and
marketing rights in
Japan
RESEARCH & DEVELOPMENT: Development of cancer-related products

Fusing technologies from within and beyond the company to accelerate the
development of a broad range of anti-cancer drug products
Development of a drug delivery system in which an anti-cancer drug is
contained inside nano-size polymer
micelles
Development of anti-cancer drugs that are effective against hormone-
dependent cancer
Development of heat immunotherapy, in which heat is used to treat cancer
PRODUCTS ON MARKET: Epoxy resins (EOCN-1020, EPPN-500, NC-3000, BREN)

Hardeners for epoxy resins (Kayahard)
Photo-curing resins (Kayarad, Kayamer, Kayacure)
Polyamide/polyimide resins
Polymer flocculants (Kayafloc) acrylic acids, methacrylic acids and other
catalysts used in manufacturing
Anti-cancer and cancer-related drugs: Calsed, Epirubicin, IA Call, Oncovin,

Exal, Carbomerck, Immucyst, Hycamtin®, MS-Twicelon, Coforin, Fareston,
Odyne, Starasid, Pinorubin, Lastet, Bestatin, Randa, Pepleo, Bleo
Immunosuppressants: Spanidin
Cardiovascular Drugs: Millisrol, Adehl, Millistape, Nitropen Tablets,
Nitroglycerine Tablets
Neurological Drugs: Saligren, Muscalm
Other Drugs: Astric Dry Syrup
Diagnostic Agents: Lana Mammo Card CEA, Lana TP Auto, Lana 1.5AG
Auto Liquid, Lanazyme BFP Plate, Lanazyme ST-439 Plate
Active pharmaceutical ingredients and intermediates
Agrochemicals: Diazinon, Matric, Safrotin, Evisect, Cyclosal, MCPB,

Chloropicrin, Cucumeris, Ratden, Simetryn, Chlorpic-Flow
Color chemicals: Kayalon Polyester, Kayacryl-ED, Kayacelon React,
Kayarus, Kayacion, Kayaaffect, Kayaphor Liquid, Kayaset
Explosives: Dynamite, slurried explosives, ammonium nitrate fuel oil
explosive (ANFO explosive), black powder, electric detonators
Nitto Denko Corp.

2-5-25, Umeda, Kita-ku
Phone: +81 726-22-2981; Fax: +81 726-26-1505
Web: www.nitto.com; E-mail: sales@nitto.com
KEY PERSONNEL: Masamichi Takemoto; CEO and COO
Yukio Nagira; Deputy COO
Yasuo Ninomiya; CTO
®
Tatsunosuke Fujiwara; CFO

Wataru Kitao; CSO
HISTORY: Founded in October 1918 as Nitto Electric Industrial Co. Ltd.
Formed Nitto Denko America Inc. (1969)
Formed Nitto Europe N.V. (1974)
Formed Nitoms Inc. (1975)
Acquired Acquires Hydranautics (1987)
Acquired Permacel (1988)
Acquired Graphic Technology Inc. (1989)
Formed Jinsec Corp. (1990)
Formed Nitto Medical Corp. and Nitto Lifetec Corp. (1996)
Formed Nitto Shinko Corp., Nitto Denko Material (Thailand) Co. Ltd. and
P.T. Nitto Materials Indonesia (1997)
Formed Nitto Denko Packaging System Corp., Nitto Denko Vietnam Co. Ltd.
and Korea Nitto Optical Co. Ltd. (1999)
Formed Nitto Americas Inc., Mie Nitto Denko Corp., Nitto Denko Himawari
Corp., Korea Nitto Denko, Nitto Denko Matex Corp. and Nitto Denko
Technical Corp. (2000)
Formed Nitto Denko Tape Materials (Vietnam) Co. Ltd., Nitto Denko
Philippines Corp. and Nitto Denko (Suzhou) Co. Ltd. (2001)
Formed Nitto Electronics kyusyu Corp. and Aichi Nitto Denko Corp. (2002)
Acquired Elan Transdermal Technologies Inc. (2003)
Formed Kinovate Life Siences Inc. and Nitto Denko Fine Circuit Technology
Co. Ltd. (2004)
Formed Optmate Corp., Nitto Denko (Tianjin) Co. Ltd. and Shanghai Nitto
Optical Co. Ltd. (2005)
FACILITIES: Plants in Tohoku, Kanto, Toyohashi, Kameyama, Shiga and Onomichi
STOCK-FINANCIAL HISTORY: Traded on the Tokyo and Osaka stock exchanges
IPO--1962
05)
SUBSIDIARIES/DIVISIONS: Japan:
Nitto Shinko Co. Ltd.
Nitto Denko CS System Corp.
Nitoms Inc.
Kyoshin Co. Ltd.
Nissho Corp.
Nitto Denko Matex Co. Ltd.
East Asia:
Nitto Denko (China) Investment Co. Ltd.
Nitto Denko (Shanghai Songjiang) Co. Ltd.
Nitto Denko (Shanghai Pu Dong New Area) Co. Ltd.
Nitto Denko (Suzhou) Co. Ltd.
Nitto Denko Xiamen Co. Ltd.
Nitto Denko (HK) Co. Ltd.
Nitto Denko Materials (Shenzhen) Co. Ltd.
Shanghai Nitto Optical Co. Ltd.
Nitto Denko (Taiwan) Corp.
Taiwan Nitto Optical Co. Ltd.
KoreaNitto Denko Co. Ltd.
Korea Nitto Optical Co. Ltd.
South Asia:
Nitto Denko (Singapore) Pte. Ltd.
Nitto Denko Electronics (Malaysia)Sdn. Bhd.
Nitto Denko Materials (Malaysia) Sdn. Bhd.
Nitto Denko Material (Thailand) Co. Ltd.
®
Nitto Denko Vietnam Co. Ltd.

Nitto Denko Tape Materials (Vietnam) Co. Ltd.
Nitto Denko Philippines Corp.
PT Nitto Materials Indonesia
Nitto Denko (Australia) Pty. Ltd.
Europe:
Nitto Europe NV
Nitto U.K. Ltd.
Nitto France Sarl
Nitto Deutschland GmbH
Nitto Scandinavia AB
Nitto Italia SRL
Nitto Polska SP Zoo
U.S.
Nitto Americas Inc.
Nitto Denko America Inc.
Permacel
Permacel Automotive Inc.
Hydranautics
Aveva Drug Delivery Systems Inc.
Nitto Denko Technical Corp.
Eisai Corp. transdermal adhesive joint develop 5/06
preparation of Aricept agreement
PRODUCTS ON MARKET: Industrial products: Double-coated adhesive tapes, surface-protection films,

advanced sealing materials
Electronics products: Polarizing films, retardation films, polarization
conversion films, semiconductor encapsulating resins, thin metal core
boards for MR heads, protection sheet and laminating device applicator for
semiconductor wafer processing
Functional products: Transdermal therapeutic patches, surgical tapes,
tissue-cultured ginseng, high-polymer separation membrane modules,
fluoroplastic porous films, fluoroplastic adhesive tapes
Norac Technologies Inc.

Edmonton Research Park, 9110-23 Avenue
Edmonton T6N 1H9, Canada
Phone: (403) 414-9595; Fax: (403) 450-1016
Web: www.noractech.com
E-mail: norac@noractech.com
KEY PERSONNEL: Dr. D. A. Evans; President
Jaime Calderon; Head, R&D
FACILITIES: Supercritical Fluid Extraction Plant--20,000 sq. ft. facility
SUBSIDIARY OF: Newly Weds Foods Co.
BUSINESS STRATEGY: Develop and manufacture natural botanicals and biological extractives with
companies from the food, beverage, cosmetic, and pharmaceutical
industries, commercial extraction available
RESEARCH & DEVELOPMENT: Supercritical extraction/fractionation of natural materials; separations;

flavors; antioxidants; biologicals; and process development, design, and
commercialization
®
PRODUCTS ON MARKET: Fractionated spice oleoresins SC, broad spectrum essential oils SC, food
colorants SC, natural rosemary antioxidants SC, natural vanilla extracts SC,
fractionated cereal oils, de-fatted cereal germs, brans and flours, low-
fat/low-cholesterol egg powders, nutriceutical oils, botanical gums and beta-
glucans, de-caffeinated tea and coffee, hops resins and oils
Services: Proprietary product manufacturing, toll processing, SFE product

and process development, system design and scale-up, laboratory analytical
services, biomass recoveries, cryogenic grinding, drying (vacuum and
freeze), homogenization, product formulating and packaging, economic
modeling and costings, marketing of SFE products
North Carolina Biotechnology Center

P.O. Box 13547, 15 T.W. Alexander Drive
Research Triangle Park NC 27709-3547, US
Phone: (919) 541-9366; Fax: (919) 990-9544
Web: www.ncbiotech.org
E-mail: info@ncbiotech.org
KEY PERSONNEL: Leslie M. Alexandre, Ph.D.; President and CEO
Ken Tindall, Ph.D.; Sr. VP, Science and Business Development
John Richert; VP, Business and Technology Development
William O. Bullock; Bioscience Industrial Development Director
Cynthia J. Sollod, Ph.D.; Bioscience Industrial Development Specialist
John Richert; VP, Business and Technology Development
Rob Lindberg, Ph.D.; Technology Development Director
Steven Casey; Business Development Director
Steven Burke; Sr. VP, Corporate Affairs
Lori Greenstein; Sr. VP, Corporate Administration and CFO
HISTORY: Established as a non-profit organization in 1984 by State of North Carolina
as the United States' first statewide initiative in biotechnology
FACILITIES: Located in Research Triangle Park, N.C.
47,000 sq. ft., $6M headquarters, including 22,000 sq. ft. program
management center, 2,000 sq. ft. library, and 19,000 sq. ft. conference and
education facility, on 120-acre campus
Regional offices in Asheville, Winston-Salem, Greenville, and Wilmington,
N.C.
The North Carolina Biotechnology Center provides long-term economic and
societal benefits to North Carolina by supporting biotechnology research,
business and education statewide
Goals:
1. Strengthen North Carolina's academic and industrial biotechnology
research capabilities
2. Foster North Carolina's biotechnology industrial development
3. Work with business, government and academia to move biotechnology
from research to commercialization in North Carolina
4. Inform North Carolinians about the science, applications, benefits and
issues of biotechnology
5. Enhance the teaching and workforce-training capabilities of North
Carolina's educational institutions
6. Establish North Carolina as a preeminent international location for the
biotechnology industry
®
RESEARCH & DEVELOPMENT: The center does not conduct laboratory research, but supports and funds
biotechnology R&D at the state's universities, institutions, and biotechnology
companies through grants programs and low-interest loan programs.
NOVA Chemicals Corp.

1000 Seventh Avenue S.W., P.O. Box 2518
Calgary T2P 5C6, Canada
Phone: (403) 750-3600
Web: www.novachem.com
E-mail: public@novachem.com
KEY PERSONNEL: J.E. (Ted) Newell; Chairman
Jeffrey M. Lipton; CEO and President
Larry A. MacDonald; Sr. VP and CFO
Christopher D. Pappas; Sr. VP and President, Styrenics
Dale H. Spiess; Sr. VP and President, Olefins/Polyolefins
John L. Wheeler; Sr. VP and CIO
Albert Terrence Poole; Exec. VP, Corporate Strategy and Development
HISTORY: NOVA Corp. of Alberta was incorporated in 1954

Acquired Polysar Energy & Chemical Corp. (9/88)
Acquired the styrenics business of ARCO Chemical Co. (9/96)
Merged with TransCanada PipeLines Ltd. (7/98)
Acquired the majority of Huntsman Corp.’s U.S. and European styrenics
businesses (12/98)
Changed name to NOVA Chemicals Corp. (1/99)
Acquired the European polystyrene and EPS assets, Chilean EPS
production and molding assets and associated worldwide sales and
marketing operations of The Shell Petroleum Co. Ltd. (1/00)
Sold its interest in the Alberta Ethane Gathering System to Fort Chicago
Energy Partners LP (12/04)
Formed Novidesa SA de CV, a 50:50 joint venture in Mexico Grupo Idesa
(10/05)
Merged its European styrenic polymers business into a 50:50 joint venture
(called NOVA Innovene) with Innovene (the commodity chemicals business
of BP plc) (10/05)
FACILITIES: NOVA Chemicals Research & Technology Center--Calgary, Alberta,
Canada
NOVA Chemicals Technical Center--Calgary, Alberta, Canada
Demonstration plant for Advanced SCLAIRTECH technology--Corunna,
Ontario, Canada
STOCK-FINANCIAL HISTORY: NYSE/TSX--NCX
Net <loss> income <$104M> (YE 05) compared to $252M (YE 04)
Earnings <loss> per share <$1.26/share> (YE 05) compared to $2.91/share
(YE 04)
Average shares outstnading 82.4M (YE 05) compared to 84.8M (YE 04)
PRIVATE PLACEMENTS: Raised $400M in private placement of senior floating rate notes due in 2013
(10/05)
SUBSIDIARIES/DIVISIONS: Two plastics and chemicals businesses: Olefins/polyolefins, which produces
ethylene, polyethylene and a variety of chemical and energy products
(commonly known as co-products), and styrenics, which produces styrene
monomer, polystyrene and expandable polystyrene (EPS)
®
Subsidiaries:
NOVA Chemicals (Canada) Ltd./NOVA Chimie (Canada) Lt´ee--Canada
NOVA Chemicals Inc.--Delaware, U.S.
NOVA Chemicals (International) SA--Switzerland
Novacor Chemicals Investments BV--The Netherlands
NOVA Chemicals Quimica Holdings SL-Spain
NOVA Investments (U.S.) Inc.--Delaware, U.S.
NOVA Petrochemicals Ltd.--Alberta, Canada
BUSINESS STRATEGY: Produce plastics and chemicals that are essential to everyday life, with a
focus on two product chains: ethylene and polyethylene, and styrene and
polystyrene
RESEARCH & DEVELOPMENT: Two internally developed technologies for the production of polyethylene—
Sclairtech technology and Advanced Sclairtech technology. NOVA
Chemicals also conducts R&D on other polyethylene technologies including
gas-phase and high pressure technology
In 2005, the company focused on the development and commercialization of
Performance Products using Advanced Sclairtech technology
NOVA Chemicals has developed three proprietary families of catalyst
technology: A family of single-site catalysts for Advanced Sclairtech and
other polymer technologies including
gas-phase polyethylene; A family of catalysts including Z-N catalysts used
for Sclairtech technology and Advanced Sclairtech technologies; and the
Novacat family of catalysts for use in gas-phase polyethylene
The company owns or has the rights to a portfolio of styrenics technology, in
the fields of polymer production and styrenics polymer applications
PRODUCTS ON MARKET: Arcel®: High-performance, moldable foam resin
Dylark®: Automotive engineering resins
Dylark® FG: High-heat styrenic copolymer
Surpass®: Performance film, rotational molding & thin-wall injection molding
resins
Zylar® EX: Low-temperature, clear acrylic copolymer
Sclair®, Novapol® and high-performance Surpass® resins
Solid polystyrene (SPS)
Expandable polystyrene (EPS)
NovaSep Process
Site Eiffel Boulevard de la Moselle, B.P. 50
Pompey F- 54340, France
Phone: +33 3 83 49 70 00; Fax: +33 3 83 49 70 02
Web: www.novasep.com
E-mail: novasep-process@novasep.com
KEY PERSONNEL: Thierry Faureau; CEO
Jean Blehaut; President
Changed name from Separex (1995)
Changed name from Separex Chromatographie (1996)
Acquired Prochrom S.A. (2000)
Acquired Seripharm (2003)
Acquired Applexion and Orelis (2004)
FACILITIES: 7,280 sq. m. headquarters and industrial plant
SUBSIDIARIES/DIVISIONS: NovaSep Inc.--Boothwyn, Pa.
NovaSep Japan KK--Tokyo, Japan
NovaSep Asia--Shanghai, China
®
SUBSIDIARY OF: Groupe Novasep

PRINCIPAL INVESTORS: Rockwood
BUSINESS STRATEGY: We are a specialist in solving purification and separation needs for the life
science industry, from laboratory to large industrial production.
Our fields of activities include: Process and product development, systems
and APIs.
RESEARCH & DEVELOPMENT: Process modelling and optimisation (chromatography, crystallization,

membranes, adsorption, ion exchange, etc.)
Process development
Process integration (chromatography / adsorption / crystallization /
distillation-evaporation / membranes, etc.)
Custom purification of APIs and intermediates in clinical phase
Custom synthesis (gram to kilogram)
Purification of intermediates and APIs
Production of intermediates and APIs
Cytotoxic expertise
PRODUCTS ON MARKET: High, medium and low pressure Batch preparative chromatography in liquid
and supercritical phase
High, medium and low continuous chromatography
Adsorption and ion exchange
Membranes (micro, nano and ultrafiltration)
Evaporation and crystallization
november AG
Ulrich-Schalk-Str. 3
Erlangen 91056, Germany
Phone: +49 (0) 9131 750 88 0; Fax: +49 (0) 9131 750 88 99
Web: www.november.de
E-mail: info@november.de
KEY PERSONNEL: Dr. Wolf M. Bertling; CEO
Alexander G. Offer; CFO
Astrid Dickert; CFO
Holding since the end of 2003
1,300 sq. m. R&D facility (offices of R&D included)
500 sq. m. administration facility
STOCK-FINANCIAL HISTORY: Traded on the Frankfurt Stock Exchange--NBX
IPO--(4/00)
Traded in segment Prime Standard (since 03/03)
Net loss <EUR2.139M> (YE 04) compared to <EUR2.817M> (YE 03)
Loss per share <EUR0.29/share> (YE 04) compared to <EUR0.41/share>
(YE 03)
SUBSIDIARIES/DIVISIONS: identif GmbH
directif GmbH
responsif GmbH
PEQLAB Biotechnologie GmbH--51%
PRINCIPAL INVESTORS: Dr. Wolf M. Bertling--8.03%
Jupiter Technologie GmbH&Co. KGaA--10.31%
®
BUSINESS STRATEGY: Continue to build on our technological lead in the area of biotechnology and
nanotechnology and in the long term to become market leader in the areas
of our core competencies. Alone or with competent partners and strategic
alliances, we will occupy market niches and develop new markets. The
products of november AG are needed worldwide.
RESEARCH & DEVELOPMENT: Labeling/tracing

Product authentication
DNA diagnostics
Product security and brand protection
PRODUCTS ON MARKET: Molecular fingerprint (DNA codes) and nano-optical seal (cluster codes)=
novel marking systems for brand protection & product security
Biological eartag: bioactive labeling of in development
livestock
System for fully automated, rapid and in development
laboratory-independent nucleic acid testing
Immune therapies for a variety of medical in clinicals
indications
Noven Pharmaceuticals Inc.

11960 S.W. 144th Street
Miami FL 33186, US
Phone: (305) 253-5099; Fax: (305) 251-1887
Web: www.noven.com
KEY PERSONNEL: Robert C. Strauss; Chairman, President and CEO
Diane M. Barrett; VP and CFO
Jeffrey Eisenberg; Sr. VP, Strategic Alliances
Juan Mantelle; VP and CTO
W. Neil Jones; VP, Sales and Marketing
HISTORY: Incorporated in 1987
FACILITIES: 15-acre facility in Miami-Dade County consisting of multiple buildings
totaling 150,000 sq. ft.
STOCK-FINANCIAL HISTORY: NASDAQ--NOVN; Trading halted--12/05
IPO--2.25M shares of common stock (1988)
Secondary public offering--2.749M shares of common stock at $7/share
(4/92)
04)
PRIVATE PLACEMENTS: Raised $800K in private sale of 589K shares of common stock (7/91)
SUBSIDIARIES/DIVISIONS: Novogyne Pharmaceuticals--a women’s health products company jointly
owned by Noven and Novartis Pharmaceuticals Corp.
BUSINESS STRATEGY: Maintain a position as a leader in the development of advanced drug
delivery technologies, while concurrently striving to become the world’s
premier transdermal drug delivery company, through development of a
series of groundbreaking products
®

Aventis S.A. transdermal worldwide 10/99
combination licensing
estrogen/progestogen agreement (except
system Canada, US and
Japan)
Endo Fentanyl transdermal licensing 2/04
delivery system agreement
Novartis AG first-generation co-promotion joint 5/98
transdermal estrogen venture with
delivery system Novogyne
Novartis AG second-generation co-promotion joint 5/99
transdermal estrogen venture with
delivery system Novogyne
P&G transdermal delivery development 4/03
Pharmaceuticals system for HSDD agreement
Inc.
Shire plc Daytrana (transdermal worldwide 6/02
methylphenidate licensing
delivery system) for agreement
ADHD
RESEARCH & DEVELOPMENT: Transdermal and transoral drug delivery systems in development for wide
array of drugs
PRODUCTS ON MARKET: Vivelle-Dot™ (second-generation estradiol transdermal system) for

postmenopausal women. World’s smallest estrogen patch.
DentiPatch™ lidocaine transoral delivery system, on market in U.S.
Vivelle® Menorest® (first-generation estradiol transdermal system)
Menorest® advanced transdermal estrogen patch (Europe and elsewhere)
CombiPatch® (estradiol/norethindrone acetate) combination
estrogen/progestogen patch
Estradot® (estradiol transdermal system) world's smallest transdermal
estrogen patch (Europe & elsewhere)
Estalis®
Novozymes A/S
Krogshoejvej 36
Bagsvaerd 2880, Denmark
Phone: +45 88-249999
Web: www.novozymes.com
KEY PERSONNEL: Steen Riisgaard; President and CEO
Per Falholt; Exec. VP and CSO
Per Mansson; Exec. VP and CFO
Peder Holk Nielsen; Exec. VP, Business Operations
Arne W. Schmidt; Exec. VP, Development, Production and Quality
Anna Lise Mortensen Grandjean; VP, Stakeholder Communications and
Sustainability Development
Mette Vestergaard; VP, People and Organisation
HISTORY: Spun off from Novo Nordisk A/S in November 2000
Acquired Delta Biotechnology Ltd. from Sanofi-Aventis (7/06)
To acquire GroPep Ltd. (as of 8/06)
FACILITIES: Production facilities in Denmark, Sweden, China, North America and South
America
R&D, production and administration facility in Denmark
Research facilities in North America, China and Japan
®
STOCK-FINANCIAL HISTORY: Listed on the Copenhagen Stock Exchange

Sales DKK6.281b (YE 05) compared to DKK5.988b (YE 04)
Net profit DKK861M (YE 05) compared DKK775M (YE 04)
Earnings per share DKK13.11/share (YE 05) compared to DKK11.19/share
(YE 04)
Total assets DKK7.309M (YE 05) compared to DKK7.076b (YE 04)
SUBSIDIARIES/DIVISIONS: Austria: Novozymes Austria GmbH
Australia: Novozymes Australia Pty. Ltd.
Belgium: Novozymes Belgium BV
Brasil: Novozymes Latin America Ltda.
Denmark: Novozymes Bioindustrial China A/S, Novozymes Bioindustrial
Russia A/S, Novozymes Bioindustrial A/S
France: Novozymes France SA, Novozymes Biologicals France SA
The Netherlands: Novozymes Netherlands BV
India: Novozymes South Asia Pvt. Ltd.
Italy: Novozymes Italia Srl.
Japan: Novozymes Japan Ltd., Novozymes Biologicals Japan Ltd.,
Novozymes Property Ltd.
China: Novozymes (China) Biotechnology Co. Ltd., Novozymes (China)
Investment Co. Ltd., Novozymes (Shenyang) Bioprocessing Co. Ltd.,
Suzhou Hongda Enzyme Co. Ltd. (joint venture)
Malaysia: Novozymes Malaysia Sdn. Bhd.
Mexico: Novozymes Mexicana SA de CV, Novozymes Mexico SA de CV
Sweden: Novozymes Biopharma AB
Switzerland: Novozymes Switzerland AG, Novozymes Switzerland Finance
AG, Novozymes Switzerland Holding AG
Singapore: Novozymes Singapore Pte. Ltd.
Spain: Novozymes Spain SA
Great Britain: Novozymes UK Ltd.
South Africa: Enzymes SA (Pty) Ltd.
South Korea: Novozymes Korea Ltd.
Turkey: Novozymes Enzim Dis Ticaret Limited Sirketi
Germany: Novozymes Deutschland GmbH
U.S.: Novozymes North America Inc., Novozymes Biologicals Inc.,
Novozymes Biotech, Inc., Novozymes US Inc.
BUSINESS STRATEGY: Expand the existing enzyme markets through more focused R&D efforts for
new products and applications
Target new geographical markets with enzymatic solutions
Explore new business opportunities based on the company's core
technologies, fermentation and production of proteins
Celliance Corp. Recombinant Human commercialization 7/06
Albumin for use in cell agreement
culture media
formulations
China Resources research into processes three-year 8/06
Alcohol Corp. for producing cellulose- cooperation
based biomass for agreement
biofuel in China
Neugenesis development of a new joint research 10/02
method for the project
production of antibodies
RESEARCH & DEVELOPMENT: Novozymes' core competencies:

1. Genetic and biochemical diversity: Culture collection, strain screening,
genome sequencing, expression cloning
2. Protein design: Protein engineering, gene shuffling, molecular modelling,
molecular dynamics, directed evolution, high-throughput screening, epitope
mapping
3. Protein chemistry: Protein purification, protein sequencing, protein
analysis, protein stability, assay development
®
4. Pathway engineering: Selection of hosts , genetic engineering, metabolic

pathway engineering, homogeneous morphology
5. Strain development and improvement: Promoter selection, manipulation
of operons, yield improvement
6. Large-scale production: Process development, lab fermentation, scale-up,
recovery, formulation
PRODUCTS ON MARKET: Enzymes for industrial use (technical enzymes, comprising detergent
enzymes, those sold to the ethanol industry, and and other technical
enzymes; food enzymes; and feed enzymes)
Microorganisms for industrial use, such as cleaning, wastewater treatment,
aquaculture and biological plant care
Biopolymers and pharmaceutical proteins
More than 700 different products total
Novozymes Inc.
1445 Drew Avenue
Davis CA 95616, US
Phone: (530) 757-8100; Fax: (530) 758-0317
Web: www.novozymesbiotech.com
E-mail: info@novozymes.com
KEY PERSONNEL: Glenn E. Nedwin, Ph.D.; President
Randy M. Berka, Ph.D.; Research Fellow, Core Technologies
Debbie Yaver, Ph.D.; Senior Research Manager
Joel Cherry, Ph.D.; Director, Bioenergy
Alan Sloma, Ph.D.; Director, Molecular Biology
Stephen H. Brown, Ph.D.; Research Manager, Microbial Physiology
Rasmus Thaisen; Finance Manager
Marta L. Hillesheim; Director, People and Organization
Changed name from Novo Nordisk Biotech Inc. (11/00)
Changed name from Novozymes Biotech Inc.
Parent company, Novozymes A/S, traded on Copenhagen stock market
SUBSIDIARY OF: Novozymes A/S
BUSINESS STRATEGY: Focus is on industrial biotechnology R&D and biosolutions: pharma, agri-
biotech and biochemical
Operates as the U.S. research arm of Novozymes A/S
Pursue endeavors and collaborations involving novel enzymes, novel
enzyme applications and novel production technology
RESEARCH & DEVELOPMENT: Cloning, expression, mutagenesis, and characterization of industrial

enzymes
Develop novel high-level expression systems
Functional genomics
Detergents, textiles, starch, food, baking, wine, juice, beer, pulp & paper,
fats, feed and personal care
Low-allergenic protein technology
Anti-microbial compounds
Biopolymers, e.g., hyaluronic acid
®
Omex Environmental Ltd.

Estuary Road, Riverside Industrial Estate
Kings Lynn PE30 2HH, UK
Phone: +44 (0)1553 692380; Fax: +44 (0)1553 770684
Web: www.omex.co.uk
E-mail: environmental@omex.com, deicers@omex.com
KEY PERSONNEL: Alistair Marsh; Head, Sales, U.K.
Gerry Spoors; Head, Sales, Magmex U.K.
Adrian Gebbett; Head, Sales, Europe
Gavin Inglis; Head, Sales, Scotland
Philip Sheppardson; Head, Sales, Anomex U.K.
FACILITIES: Three fully equipped laboratories in the U.K.
SUBSIDIARIES/DIVISIONS: Two divisions:
Wastewater Control
Deicers
SUBSIDIARY OF: Omex Group
BUSINESS STRATEGY: Offer in-depth analysis and treatment of all the potential problems
surrounding modern effluent and septicity treatment systems, from on all
aspects of industrial wastewater treatment, from pre-treatment to sludge
disposal
PRODUCTS ON MARKET: Anti bulking chemicals

Nutrients
pH control
Coagulates
Products for septicity control
Ice control products
OmniChem
Industrial Research Park Fleming
Louvain-la-Neuve B-1348, Belgium
Phone: +32 (10) 48-31-11; Fax: +32 (10) 45-06-93
Web: www.omnichem.be
E-mail: sales@omnichem.be
KEY PERSONNEL: Jean-Claude Bourmanne; Managing Director
HISTORY: Incorporated as Omnium Chimique in 1980
Changed name to OmniChem (1980)
Acquired by Ajinomoto Co. Inc. (1989)
FACILITIES: cGMP chemical facilities
SUBSIDIARY OF: Ajinomoto Co. Inc. (see separate entry)
Under secrecy
agreements
®
RESEARCH & DEVELOPMENT: Industrial expertise in the handling of: Aluminium and hydrides, azide
reagent, boranes, boron trifluoride, butyllithium, carbon disulphide, chlorine,
dimethyl sulfate, epichlorohydrin, ethylene oxide, hydrazine sodium azide,
hydrogen peroxide, lithium diisopropylamide, methyl bromide, nitric acid,
oxalyl chloride, peracids, phosgene, phosphorus oxychloride, phosphorus
pentachloride, sodium amide, sodium cyanide, sulfonitric acid
In-house manufacture or in situ generation of: Azido alkyl acetate, boc-

chloride, diazo ethyl acetate, diphenylphosphorylazide (DPPA), N-vinyl-O-
alkyl carbamate, ruppert reagent: CF3-Si (CH3) 3, trimethylsilylazide (TMS-
N3)
Reaction portfolio: Aldol condensation, Baeyer-Villiger oxidation, Claisen

condensation, Chloromethylation, Diazo coupling, Diels-Alder reaction,
Friedel-Crafts reaction, Hydroxyethylation, Knoevenagel condensation,
Mannich reaction, Methylation, Reimer-Tiemann reaction, Vilsmeier
formylation, Wittig reaction
PRODUCTS ON MARKET: Generic drugs: Synthetic and botanical
Synthetic intermediates: Tetrazoles, nitro compounds, phosgene derivatives
Services: API supply, custom manufacturing, project manufacturing
Under secrecy agreements
OmniGene Bioproducts Inc.

763-D Concord Avenue
Phone: (617) 576-1966; Fax: (617) 547-9256
Web: www.omnigenebioproducts.com
E-mail: info@omnigenebioproducts.com
KEY PERSONNEL: Janice G. Pero, Ph.D.; Chairman and President
Dr. R. Rogers Yocum; Sr. Program Director
Began biotech R&D in October 1995
Formerly a division of OmniGene Inc. and BioTechnica International Inc.;
acquired bioproducts division from OmniGene Inc.
BUSINESS STRATEGY: Contract research and licensing
Expand bioproducts R&D
BASF AG specialty chemicals licensing agreement 1/99
F. Hoffmann-La specialty chemicals licensing agreement 1/88
Roche AG
Genencor industrial enzymes licensing agreement 1/99
International Inc.
RESEARCH & DEVELOPMENT: Genetic engineering of microorganisms to produce specialty products, such
as vitamins, amino acids, enzymes, other proteins and fine chemicals
®
Optigenex Inc.
750 Lexington Avenue, 6th Floor
Phone: (212) 905-0189 Toll-free phone: (866) OPTIGNX
Web: www.ac-11.com
E-mail: info@optigenex.com
KEY PERSONNEL: William Walters; Chairman
Richard Serbin; CEO
Anthony Bonelli; President and COO
Joseph McSherry; CFO
HISTORY: Founded in July 2002 as Idunna Inc.
Changed name to Kronogen Sciences Inc. (11/02)
Changed name to Optigenex Inc. (7/03)
Acquired some assets of CampaMed LLC (11/03)
FACILITIES: 6,125 sq. ft. of leased space in New York, N.Y.
STOCK-FINANCIAL HISTORY: OTC BB--OPGX
Net sales $277.831K (YE 05) compared to $339.065K (YE 04)
Average shares outstanding $10.128M (YE 05) compared to $8.071M (YE
04)
PRIVATE PLACEMENTS: Raised $4M from private placement of 625M shares (9/05)
INVESTMENTS: Formed a joint venture called PMO Products Inc. to develop and market
professional hair care products that contain AC-11 (11/04)
Formed a joint venture company with Prometheon Holding LLC to develop
and market a new line of nutraceutical products containing Optigenex's AC-
11® as its core ingredient (8/05)
BUSINESS STRATEGY: develops and markets proprietary products that are designed to counter
the negative effects of aging by supporting the body's natural ability to repair
and maintain its DNA
RESEARCH & DEVELOPMENT: AC-11™ is a compound derived from the plant Uncaria tomentosa, which is
native to the Amazon rainforest as well as tropical areas in South and
Central America. AC-11™ has demonstrated activity in DNA repair,
autoimmune enhancement, anti-inflammatory and anti-tumor areas.
PRODUCTS ON MARKET: Activar™ AC-11™
Activar™ Age Manager™ (AC-11™, with vitamins and minerals)
Optronics
175 Cremona Drive
Goleta CA 93117, US
Phone: (805) 968-3568; Fax: (805) 968-0933
Web: www.optronics.com
E-mail: oeinfo@optronics.com
KEY PERSONNEL: Doug Merker; General Manager
FACILITIES: 18,000 sq. ft. headquarters, R&D and manufacturing facility
®

SUBSIDIARY OF: Karl Storz Imaging
BUSINESS STRATEGY: Manufacture scientific grade digital cameras and software for research
microscopy
PRODUCTS ON MARKET: Digital microscope cameras: MicroFire color & Monochrome, MacroFire
Color & Momochrom, QuantiFire
Microscope video cameras
PictureFrame
Digital Video Medical Recorders (DVMR)
Cables and accessories
Organo Corp.
2-8, Shinsuna 1-chome, Koto-ku
Tokyo 136, Japan
Phone: +81 3-5635-5100; Fax: +81 3-3699-7030
Web: www.organo.co.jp; E-mail: post-org@organo.co.jp
KEY PERSONNEL: Masahiko Denda; Chairman
Kiyoshi Hashimoto; President, CEO and COO
HISTORY: Founded in 1946 as a pioneer in water and wastewater treatment
Formerly named Japan Organo Co. Ltd.
FACILITIES: Factories in Satte, Tukuba, Nagasaki and Iwaki
Offices in Shanghai and Hongo
Branch offices in Sappro, Sendai, Nagoya, Osaka, Hiroshima, Fukuoka and
Taiwan
STOCK-FINANCIAL HISTORY: Traded on the Tokyo Stock Exchange
Net profit ¥2.090b (YE 05) compared to ¥1.803b (YE 04)
SUBSIDIARIES/DIVISIONS: Hokkaido Organo Shoji Co. Ltd.
Tohoku Organo Shoji Co. Ltd.
Tokyo Organo Shoji Co. Ltd.
Chubu Organo Shoji Co. Ltd.
Kansai Organo Shoji Co. Ltd.
Kyushu Organo Shoji Co. Ltd.
Organo Plant Service Corp.
Organo Acty Co. Ltd.
Organo High Tech Co. Ltd.
Danisco Organo Food Tech Co. Ltd.
Eco-Techno Corp.
Organo (Asia) Sdn. Bhd.
Organo (Asia) Sdn. Bhd. (Penang branch)
Organo (Asia) Sdn. Bhd. (Kulim branch)
Organo (Singapore) Pte. Ltd.
Organo (Thailand) Co. Ltd.
Ortech Chemical Co. Ltd.
Organo (UK) Ltd.
PT.Organo Indonesia
PT.Organo Indonesia (Surabaya office)
Organo (Philippines) Inc.
Organo (Shanghai) Water Treatment Co. Ltd.
Organo (Shanghai) Water Treatment Co. Ltd. (Guangzhou office)
Organo (Suzhou) Water Treatment Co. Ltd.
®
PRINCIPAL INVESTORS: Tosoh Corp.--$16M

Bioremediation R&D agreement
Technology
Biosensor R&D agreement
PRODUCTS ON MARKET: Water treatment equipment: Water softeners, water deionizers, Uultrapure
water systems, condensate filters and demineralizers, multi-functional water
systems, sterile purified water systems, distilled water production
equipment, sea water desalination systems and high-speed filtration
equipment
Municipal water works and sewage water treatment:

Coagulation/sedimentation equipment, high-rate filters, activated carbon
filters, membrane-type water purifiers, advanced water treatment, sewage
treatment facilities, deodorizing systems, pumping facilities, sludge treating
facilities, sewage waste water reclamation
Environment-related equipment: Industrial wastewater treatment equipment,

treatment systems for power station wastewater, recovery and recycling
equipment for industrial wastewater, dual piping water facilities, domestic
wastewater treatment equipment, denitrification and dephosphorization
systems, Closed systems for semiconductor factories, wastewater treatment
equipment for cleaning facility, treatment facility for drainage, agricultural
chemicals removal equipment for golf links
Soil remediation systems: Ground water treatment facilities, off-gas

treatment equipment, soil contamination survey system, soil vapor
purification system, bioremediation system
Separation and refining equipment: Decolorization and refining system for

sugars solution, refining and concentration equipment, chromatographic
separation system
Small-scale standard equipment: Water deionizer series, water softener

series, filter series, ultrapure water production equipment, sub-systems,
small-sized supercritical water oxidation equipment, various types of filters,
homogenizers, distillation stills, various types of water quality analyzers
Water treatment chemicals: Boiler water treatment chemicals, cooling water

treatment chemicals, cleaning and rinsing chemicals, wastewater treatment
chemicals, drinking water treatment chemicals, chemicals feeding
equipment, sanitation chemicals, HACCP-related equipment
Analysis business: Ultra-microanalysis of ultrapure water and evaluation,

analysis of harmful substances in water, soil, and waste materials, general
analysis
Waste disposal facilities and equipment

Food processing materials and food additives
®
Pacific Biodiesel Inc.

40 Hobron Avenue
Kahului HI 96732, US
Phone: (808) 877-3144; Fax: (808) 877-5030
Web: www.biodiesel.com
E-mail: info@biodiesel.com
KEY PERSONNEL: Robert King; President
Kelly Takaya King; VP, Communications and Marketing
William Smith; Production Technology
Amanda Stewart; Production Technology
FACILITIES: Two Hawaii biodiesel processing plants; Oregon plant; Texas plant
SUBSIDIARIES/DIVISIONS: Maui Plant

Central Maui Sanitary Landfill
Pulehu Road
Kahului, Hawaii
Contact Maui Office: (808) 877-3144
Oahu Biofuels Facility

Honolulu, Hawaii
George Aiwohi, Hawaii Operations Manager

BUSINESS STRATEGY: Maintain a position as a leader in the production of biodiesel fuel that is
derived from waste oils and grease as well as virgin crop oil, in order to
minimize the environmental impact of such waste materials and optimize the
conservation of traditonal fuel sources; promote community-based biodiesel
production that utilizes local resources and distributes product locally
RESEARCH & DEVELOPMENT: Conversion of discarded cooking oil and grease trap oil into biofuels;
processing of virgin crop oil into biodiesel; minimizing wastestream; on-
going improvements in process technology and quality control protocol
PRODUCTS ON MARKET: Biodiesel - renewable fuel produced in Hawaii, made from recycled cooking
oil and used in commercial diesel fleets, private vehicles, farm equipment,
generators and marine vessels
Biofuel--vegetable oil burner fuel, made from waste grease trap oil
Biodiesel processing plants (technology, process and construction)
Pacific Northwest National Laboratory

P.O. Box 999
Richland WA 99352, US
Phone: (509) 375-2121
Toll-free phone: (888) 375-PNNL
Web: www.pnl.gov
E-mail: inquiry@pnl.gov
KEY PERSONNEL: Dr. Leonard K. Peters; Director
Dr. David W. Koppenaal; Chief Research Officer (interim)
Dr. Donald M. Boyd; Deputy Laboratory Director for Operations
EMPLOYEES: 4,200 employees, 892 Ph.D.s
®
FACILITIES: 495,623 sq. ft. of active laboratory space

SUBSIDIARIES/DIVISIONS: Environmental Molecular Sciences Laboratory
Marine Sciences Laboratory
BUSINESS STRATEGY: VISION: To be recognized worldwide and valued regionally for leadership in
rapidly translating discoveries into solutions. . . for challenges in energy,
national security and the environment. . .by integrating the chemical,
physical and biological sciences
MISSION: Perform basic and applied research to deliver energy,
environmental and national security for the nation
Micell use of supercritical research and
Technologies fluids for the creation of licensing
medical device surface collaboration,
modifications expanded 8/06
RESEARCH & DEVELOPMENT: More than 100 ongoing R&D projects annually
Pall Corp.
2200 Northern Boulevard
East Hills NY 11548-1248, US
Phone: (516) 484-5400; Fax: (516) 484-5228
Web: www.pall.com; E-mail: info@pall.com
KEY PERSONNEL: Eric Krasnoff; Chairman and CEO
Marc Wilson; President
Lisa McDermott; CFO
Donald Stevens; COO and President, Pall Industrial
Steven Chisholm; Sr. VP and President, Microelectronics Group
Roberto Perez; Sr. VP and President, Pall Life Sciences
Jim Western; Sr. VP and President, Aerospace Group
Acquired Gelman Sciences (2/97)
Acquired Rochem Environmental (1/98)
Acquired the Filtration and Separations Group (2002)
Acquired BioSerpa process chromatography business from Ciphergen
Biosystems Inc. (11/04)
FACILITIES: Offices and plants throughout the world
STOCK-FINANCIAL HISTORY: NYSE—Pll
Net income $140.8M (YE 05) compared to $1.121/share (YE 04)
Total assets $2.265b (YE 05) compared to $2.183 (YE 04)
SUBSIDIARIES/DIVISIONS: Life Sciences business—Medical, Biopharmaceuticals, Laboratory
Industrial business—General Industrial, Aerospace and Microelectronics,
Food & Beverage
BUSINESS STRATEGY: Pursue Growth through aggressive R&D approach that advances company’s
products and creates niche applications across many markets, industries
and geographies
PRODUCTS ON MARKET: Filtration, separation and purification systems for total fluid management in
the industrial and life sciences markets
®
Paprican
570 Boulevard St. Jean
Pointe-Claire H9R 3J9, Canada
Phone: (514) 630-4101; Fax: (514) 630-4134
Toll-free phone: (888) PAPRICAN
Web: www.paprican.ca
E-mail: info@paprican.ca
KEY PERSONNEL: Frank Dottori; Chairman
Joseph Wright; President and CEO
Dave McDonald; VP, Research and Education
Lucie Lapointe; VP, Administration
Richard Berry; Program Manager, Chemical Pulping
Brian O'Connor; Program Manager, Environment
Tom Browne; Program Manager, Mechanical Pulping and Sustainability
Ivan Pikulik; Program Manager, Papermaking
Maurice Douek; Program Manager, Analytical Services and Standards
Christian Thompson; Program Manager, Engineering Development
Jean Hamel; Program Manager, Product Performance
Paul Watson; Program Manager, Fibre Supply and Quality
FACILITIES: Headquarters in Pointe-Claire, PQ, Canada
Laboratories in Quebec and British Columbia
STOCK-FINANCIAL HISTORY: Non-profit agency
SUBSIDIARIES/DIVISIONS: Vancouver:
3800 Wesbrook Mall
Vancouver BC, V6S 2L9
Canada
Phone: (604) 222-3201
Fax: (604) 222-3207
Paprican Prince George:

P.O. Box 21018
Pulp Mill Road
Prince George, BC V2N 7A5
Canada
Phone: (250) 561-3991
Fax: (250) 561-4412
BUSINESS STRATEGY: Paprican, the Pulp and Paper Research Institute of Canada, provides
valuable technology transfer and cost-competitive research addressing both
the short-term and strategic needs of its members
University
collaborations with
McGill University,
the University of
British Columbia
and Ecole
Polytechnique de
Montreal
RESEARCH & DEVELOPMENT: Consortium research:

-Fibre Supply and Quality: Capturing more value from fibre resources and
enhancing performance of market pulps
-Chemical Pulping: Producing superior kraft pulps and the next generation of
bleaching technologies
®
-Mechanical Pulping: Developing the next generation of superior-

performance thermomechanical pulps
-Papermaking: Improving wet-end chemistry, designing and developing
highly-filled printing papers
-Product Performance: Delivering state-of-the-art end use properties from
advances in surfaces, coatings and web structures
-Sustainability and Environment: Minimizing environmental impact, reducing
total emissions,optimizing energy efficiencies in response to climate change
and economic drivers
Multiclient projects: Minimizing linting in mechanical printing grades,

optimization of the use of hardwood pulp, recycling, chemimechanical pulps,
mechanical pulp bleaching, sulphite pulping and packaging
PBR Laboratories Inc. (PBR)

9960 - 67 Ave., N.W.
Edmonton T6E OP5, Canada
Phone: (780) 450-3957; Fax: (780) 450-3960
Web: www.pbr.ca
E-mail: pbr@pbr.ca
KEY PERSONNEL: Dr. Ram D. Mehta; Chairman, President, and CEO
Dr. Ram K. Bishnoi; Director, Lab Operations
FACILITIES: 6,000 sq. ft. laboratory and office space
BUSINESS STRATEGY: Become a leading provider of contract research and bioanalytical services to
environmental, chemical, and human health industries, and to develop
innovative technologies and products
RESEARCH & DEVELOPMENT: Focus is on the development of diagnostic kits and test methods for rapid
detection of environmental toxins and pathogenic bacteria and fungi
PRODUCTS ON MARKET: Genetic and cellular toxicology testing services, environmental toxicology
testing, food and water microbiological analysis, product safety and efficacy
evaluation, and microbial strains for biodegradation
Fast assays for freshwater algal toxins and shellfish toxins
Indoor air quality monitor for mold and bacterial (including endotoxin)
contamination
PCI Membranes
Jays Close, Viables Estate
Basingstoke RG22 4BA, UK
Phone: +44 1256 303800; Fax: +44 1256 303801
Web: www.pcimem.com
E-mail: aquious@itt.com
KEY PERSONNEL: Mike Hughes; General Manager
Alan Merry; Technical Director
Martin Peer; Sr. Scientist
John Hughes; Purchasing Manager
®
FACILITIES: R&D, system building and tubular membrane manufacturing facility
SUBSIDIARIES/DIVISIONS: PCI Membrane Systems Inc.
1615 State Route 131
Milford, OH 45150
Phone: (513) 575-3500
Fax: (513) 575-7393
www.pcims.com
SUBSIDIARY OF: ITT Corporation Inc.
RESEARCH & DEVELOPMENT: Specific application separation studies

PRODUCTS ON MARKET: Membrane separation products and systems
Pentapharm Ltd.
Engelgasse 109
Phone: +41 61 7064848; Fax: +41 61 3199619
Web: www.pentapharm.com
E-mail: pentapharm@pentapharm.com
KEY PERSONNEL: Caspar V. Sturm; CEO
Thomas Grieder; CFO
Dr. Eric J.M. Meier; Head, Quality Management
Markus K. Luthy; Director, Sales and Marketing
Christian Witzig; Head, Production
Dr. Thomas Schreier; Head, R&D
FACILITIES: Headquarters in Basel, Switzerland
Snake venom facilities in Brazil and Bolivia
SUBSIDIARIES/DIVISIONS: Pentapharm do Brasil Ltda.
Pentapharm en Bolivia
RESEARCH & DEVELOPMENT: Extraction of active ingredients from natural sources

Purification and characterization of snake venom enzymes
Synthesis of small peptides and peptide like substances
Biotechnological manufacturing of active ingredients
PRODUCTS ON MARKET: Pefakit®
Defibrase®
Pefachrome®
Pefabloc®
Protac®
Botrocetin®
Prionex®
®
PeproTech Inc.
Princeton Business Park, 5 Crescent Ave., P.O. Box 275
Rocky Hill NJ 08553-0275, US
Phone: (609) 497-0253; Fax: (609) 497-0321
Web: www.peprotech.com; E-mail: info@peprotech.com
KEY PERSONNEL: Irwin Libeskind; VP, Worldwide Marketing
SUBSIDIARIES/DIVISIONS: PeproTech EC Ltd.
PeproTech House
29 Margravine Road
London W6 8LL UK
Phone: (0)20 7610 3055; Fax: (0)20 7610 3430
E-mail: info@peprotech.co.uk; Web site: www.peprotechec.com
CytoLab Ltd.
12 Hamada Street Biet Tamar
Entrance A, 2nd floor
Rehovot, Israel
Phone: +972 (0) 8 946 0948
Fax: +972 (0) 8 946 0861
E-mail: info@cytolab.com
Web site: www.cytolab.com
Peprotech Mexico SA dec V

Montecito 38, Piso 30 Oficina 27
Colonia Napoles CP 03810
Mexico
Phone: +52-55-9000-35-62
Fax: +52-55-9000-35-64
E-mail: pepromex@prodigy.net.mx
PeproTech Brazil FUNPEC

Av. Presidente Vargas 2627
14020-260 Ribeirao Preto
Brazil
Phone: +55 (16) 620 1251
Fax: +55 (16) 621 1991
E-mail: funpecrp@uol.com.br
Web site: www.funpecrp.com.br
BUSINESS STRATEGY: Develop and manufacture cytokines, chemokines, neurotrophic factors,
growth factors, and paired monoclonal and polyclonal antibodies
RESEARCH & DEVELOPMENT: The company has developed high yield, low cost methods for the
commercial production of over 300 recombinant cytokines and related
antibodies
PRODUCTS ON MARKET: Human growth factors and cytokines
Human, murine and rat chemokines
Murine and rat growth factors and cytokines
Human and rat neurotrophins
Additional recombinant proteins
Monoclonal antibodies
Antigen-affinity purified polyclonal antibodies
Biotinylated polyclonal antibodies
ELISA development kits
®
Peptides International Inc.

11621 Electron Drive
Louisville KY 40299, US
Phone: (502) 266-8787; Fax: (502) 267-1329
Web: www.pepnet.com
E-mail: peptides@pepnet.com
KEY PERSONNEL: Jackie B. Spatola; Chair
Dr. Bryce V. Johnson; CEO and President
Krzysztof Darlak, Ph.D.; Director, Research
DeAnna Wiegandt Long, Ph.D.; Director, Sales and Marketing
Miroslawa Darlak; Quality Control Manager
FACILITIES: R&D, manufacturing and distribution facilities
BUSINESS STRATEGY: Focus on proprietary products
Expand upon success in high quality/purity custom synthesis market
Develop strategic joint ventures
University of Cyclic peptide libraries exclusive licensing 2004
Louisville agreement
University of Clear resin solid exclusive licensing 1997
Minnesota supports agreement
RESEARCH & DEVELOPMENT: Novel amino acids

Peptide backbone modifications
Peptide mimetics
Peptide and pseudopeptide libraries
New resins for solid phase synthesis
Solid supports for solid phase synthesis
PRODUCTS ON MARKET: Resins: Clear and Clear-OX™; mini-Peg™ Linkers; TAPI inhibitors,
Urantide™ and other various biologically active peptides, enzyme inhibitors,
substrates and peptide-related products for research purposes,
combinatorial chemistry reagents and supplies
Pfeiffer Vacuum Ltd.

2-4 Cromwell Business Centre, Howard Way, Interchange Park
NewPort MK16 9QS, UK
Phone: +44 1908 500600; Fax: +44 1908 500601
Web: www.pfeiffer-vacuum.co.uk
E-mail: info@pfeiffer-vacuum.de
KEY PERSONNEL: Wolfgang Dondorf; CEO
Manfred Bender; CFO
Peter Knight; GM
Rob Vaughan; Manager, IT and QA
Jackie Williamson; Accounts Administrator
Susan Dixon; Company Secretary
Changed name from Balzers Pfeiffer (1/96)
®
STOCK-FINANCIAL HISTORY: Parent company: NYSE--PV

SUBSIDIARY OF: Pfeiffer Vacuum Technology AG
PRODUCTS ON MARKET: Prisma

Omnistar
Thermostar
Mass spectrometers
Vacuum pumps and gauges
Pfizer Inc.
235 East 42nd Street
New York NY 10017-5755, US
Phone: (212) 573-2323; Fax: (212) 573-7851
Web: www.pfizer.com
E-mail: info@pfizer.com
KEY PERSONNEL: Henry (Hank) A. McKinnell, Ph.D.; Chairman
Jeffrey B. Kindler; CEO
John LaMattina, Ph.D.; President, Pfizer Global Research and Development
Ian Read; President, Worldwide Pharmaceuticals Operations
Joe Feczko, M.D.; CMO
Sylvia Montero; Head, Worldwide Talent Development and Human
Resources
Allen Waxman; General Counsel
Rich Bagger; Head, Worldwide Public Affairs and Policy
Founded in 1849
Signed letter of intent to sell food science group to Cultor Ltd. (11/95)
Acquired Warner-Lambert Co. (6/00)
Acquired Agouron Pharmaceuticals Inc. (2000)
Merged with Pharmacia Corp. (4/03)
Acquired Esperion Therapeutics (2/04)
Acquired Meridica Ltd. (11/04)
Acquired Angiosyn Inc. (4/05)
Acquired Idun Pharmaceuticals Inc. (4/05)
Acquired Bioren Inc. (8/05)
Acquired Vicuron Pharmaceuticals Inc. (9/05)
Acquired worldwide rights to Exubera from Sanofi-Aventis (3/06)
Acquired Rinat Neuroscience Corp. (6/06)
Acquire exclusive worldwide rights to fesoterodine from Schwarz Pharma
AG (6/06)
To sell its Pfizer Consumer Healthcare (PCH) business to Johnson &
Johnson (as of 6/06)
FACILITIES: Corporate headquarters: New York, N.Y.
Research & Development: Groton and New London, Conn.; Sandwich,

England; Ann Arbor and Kalamazoo, Mich.; St. Louis, Mo.; La Jolla, Calif.;
Cambridge, Mass,; and Nagoya and Tokyo, Japan
Veterinary medicine research and development operations in Henrietta and

Richland Township, Mich.; Lincoln, Neb.; Sandwich, England; and
Melbourne, Australia
Consumer Health Care: Morris Plains, N.J.
®
STOCK-FINANCIAL HISTORY: NYSE--PFE / London--PFZ

Also listed on Euronext and Swiss stock exchanges
Average shares outstanding 7.361b (YE 05) compared to 7.531b (YE 04)
SUBSIDIARIES/DIVISIONS: Three business segments: Human Health, Consumer Healthcare and
Animal Health
Other businesses: Manufacture of empty soft-gelatin capsules, contract
manufacturing and bulk pharmaceutical chemicals
Subsidiaries:
412357 Ontario Inc--Canada
A S Ruffel (Mozambique) Limitada
A.S. Ruffel (Private) Ltd.--Zimbabwe
A/O Pfizer--Russia
ACO AB--Sweden
Adenylchemie GmbH--Germany
Agouron Pharmaceuticals Inc.--California
Alginate Industries (Ireland) Ltd.
American Food Industries Inc.--Delaware
Amicore Inc.--Delaware
Andean Services SA--Colombia
Angiosyn Inc.--Delaware
Backsvalan 6 Handelsbolag--Sweden
Balverda SRL--Italy
Bharti Healthcare Ltd.--India
BINESA 2002 SL--Spain
Biocor Animal Health Inc.--Delaware
Bioindustria Farmaceutici SRL--Italy
Bioptics SARL--France
Bioren Inc.--Delaware
Biosearch Manufacturing Srl--Italy
C.P. Pharmaceuticals International CV--Netherlands
Capsugel (Thailand) Co. Ltd.--Thailand
Capsugel AG--Switzerland
Capsugel Belgium BVBA--Belgium
Capsugel France
Capsugel Japan Inc. (KK)
Capsugel Ploermel--France
CARDEL--France
Carlo Erba OTC SpA--Italy
Centrofarma, Sociedad Anonima--Guatemala
Ceuticlab Laboratorios de Produtos Farmaceuticos Lda.--Portugal
Charlie Papa Operations LLC--New Jersey
CHC Direct LLC--Delaware
Compania Farmaceutica Upjohn SA--Guatemala
Consumer Health Products (Minority Interests) Co.--U.K.
Continental Farmaceutica SL--Spain
Continental Pharma Inc.--Delaware
Corporacion Pharmacia de Mexico S de RL de CV--Mexico
CPPI/CV Six (Gibraltar) Ltd.
Davis Medica, Sociedad Limitada, Sociedad Unipersonal--Spain
Diabel GmbH & Co. KG--Germany
Distribuidora Mercantil Centro Americana SA--Delaware
Duchem Laboratories Ltd.--India
Esperion AB--Sweden
Esperion LUV Development Inc.--Delaware
Esperion Therapeutics Inc.--Delaware
Euronett Inc.--Delaware
Eversharp Canada Inc.--Canada
Exchic CA Ltd.--Bermuda
®
Farminova Produtos Farmaceuticos de Inovacao Lda.--Portugal

Farmitalia Carlo Erba Ltd.--U.K.
Farmogene Productos Farmaceuticos Lda.--Portugal
Fyrcia HB--Sweden
G. D. Searle & Co. Ltd.--U.K.
G. D. Searle (Philippines) Inc.
G. D. Searle (Thailand) Ltd.--Thailand
G. D. Searle International Capital LLC--Delaware
G. D. Searle Land Corp.--Philippines
G. D. Searle LLC--Delaware
G. D. Searle South Africa Pty. Ltd.--South Africa
Godecke GmbH--Germany
Godecke OTC Beteiligungs GmbH--Germany
Greenstone Ltd.--Delaware
Heinrich Mack Nachf. GmbH. & Co. KG--Germany
Heumann Beteiligungs GmbH--Germany
Heumann PCS GmbH--Germany
Idun Pharmaceuticals Inc.--Delaware
International Affiliated Corp. LLC--Delaware
Inter-World Insurance Co. Ltd.--Bermuda
Invicta Farma SA--Spain
Island Pharmaceuticals Ltd.--Ireland
J B Tillott Ltd.--U.K.
Jouveinal Holland BV--Netherlands
Kenfarma SA--Spain
Keystone Chemurgic Corp.--Delaware
Kiinteisto Oy Helsingin Tietokuja--Finland
Kommanditbolaget Hus Gron--Sweden
Korea Pharma Holding Co. Ltd.--Hong Kong
Laboratoires Pfizer SA--Morocco
Laboratorios Laprofa, Sociedad Anonima--Guatemala
Laboratorios Parke Davis SL--Spain
Laboratorios Pfizer de Chile
Laboratorios Pfizer Ltda.--Brazil
Laboratórios Pfizer Lda.--Portugal
Laboratorios Visine SL--Spain
Lambert Chemical Co. Ltd.--U.K.
Losbanos Ltd.--Ireland
Lothian Developments V SPRL--Belgium
MED Urological Inc.--Minnesota
Meridica Ltd.--U.K.
Monterey Kelp Corp.--California
MTG Divestitures Handels GmbH--Austria
MTG Divestitures Ltd.--U.K.
MTG Divestitures LLC--Delaware
Nefox Farma SA--Spain
Nostrum Farma SA--Spain
NPF YK--Japan
O.C.T. (Thailand) Ltd.
Omni Laboratories Inc.--Canada
Orsim--France
P&UFSC Inc.--Virgin Islands
PanServ Personalberatungs- und Anzeigenservice GmbH--Germany
Paris Montrouge II BV--Netherlands
Paris Montrouge II SARL--France
Parke Davis & Co. Ltd.--Isle of Jersey
Parke Davis Del Ecuador CA--Ecuador
Parke Davis European Distributors Ltd.--Ireland
Parke Davis International Ltd.--Bahamas
Parke Davis Productos Farmaceuticos Lda.--Portugal
Parke Davis Pty. Ltd.--Australia
Parke, Davis & Co. Ltd.--Pakistan
Parke, Davis & Co. LLC--Michigan
Parke-Davis GmbH--Germany
Parke-Davis Manufacturing Corp.--Delaware
®
Parke-Davis Sales Corp.--Virgin Islands

P-D Co. Inc.--Delaware
Pfidev3 SAS--France
Pfidev4 SAS--France
Pfizer (China) Research and Development Co. Ltd.
Pfizer (Malaysia) Sdn Bhd--Malaysia
Pfizer (Perth) Pty. Ltd.--Australia
Pfizer SAS--France
Pfizer (Thailand) Ltd.
Pfizer AG--Switzerland
Pfizer A/S--Norway
Pfizer AB--Sweden
Pfizer Africa & Middle East for Pharmaceuticals, Animal Health & Chemicals
SAE--Egypt
Pfizer Afrique de L'Ouest--Senegal
Pfizer Algerie Sante et Nutrition Animale spa--Algeria
Pfizer Animal Health BV--Netherlands
Pfizer Animal Health Korea Ltd.--South Korea
Pfizer Animal Health SA--Belgium
Pfizer Antilles Holdings NV--Netherlands Antilles
Pfizer ApS--Denmark
Pfizer Asia Holdings BV--Netherlands
Pfizer Asia Pacific Pte. Ltd.--Singapore
Pfizer Australia Holdings Pty. Ltd.--Australia
Pfizer Australia Pty. Ltd.--Australia
Pfizer Australia Superannuation Pty. Ltd.--Australia
Pfizer BV--Netherlands
Pfizer Beteiligungs GmbH--Germany
Pfizer Canada Inc.--Canada
Pfizer Caribe Ltd.--Guernsey
Pfizer Century Holdings--Ireland
Pfizer CHC GmbH--Germany
Pfizer Chile SA--Chile
Pfizer Cia. Ltda.--Ecuador
Pfizer Consumer Health Care Mexico S de RL de CV--Mexico
Pfizer Consumer Health Products Co.--U.K.
Pfizer Consumer Healthcare--U.K.
Pfizer Consumer Healthcare BV--Netherlands
Pfizer Consumer Healthcare Comm.VA--Belgium
Pfizer Consumer Healthcare GmbH--Germany
Pfizer Consumer Healthcare Ireland
Pfizer Consumer Healthcare S.Com.p.A--Spain
Pfizer Consumer Healthcare Srl--Italy
Pfizer Consumer Inc.--Japan
Pfizer Convention III LLC--Delaware
Pfizer Convention IV LLC--Delaware
Pfizer Co-Promotions Ltd.--Isle of Jersey
Pfizer Cork Ltd.--Ireland
Pfizer Corp.--Panama
Pfizer Corp. Austria Gesellschaft mbH--Austria
Pfizer Corp. Hong Kong Ltd.--Hong Kong
Pfizer Croatia d.o.o.--Croatia
Pfizer Deutschland GmbH
Pfizer Distribution Co.--Ireland
Pfizer Distribution Services--Belgium
Pfizer Domestic Ventures Ltd.--Isle of Jersey
Pfizer Dominicana SA--Dominican Republic
Pfizer Dublin Ltd.--Ireland
Pfizer Egypt SAE--Egypt
Pfizer Enterprises Inc.--Delaware
Pfizer Enterprises SARL--Luxembourg
Pfizer Esbjerg A/S--Denmark
Pfizer ESP Pty. Ltd.--Australia
Pfizer Europe MA EEIG--U.K.
Pfizer European Service Center BVBA--Belgium
®
Pfizer Export AB--Sweden

Pfizer Export Co.--Ireland
Pfizer Finance GmbH & Co. KG--Germany
Pfizer Finance International Ltd.--Ireland
Pfizer Finance Verwaltungs GmbH--Germany
Pfizer Financial Services NV/SA--Belgium
Pfizer Fundings International--Ireland
Pfizer Global Holdings BV--Netherlands
Pfizer Global Supply--Ireland
Pfizer Global Trading--Ireland
Pfizer GmbH--Germany
Pfizer Group Ltd.--U.K.
Pfizer H.C.P. Corp.--New York
Pfizer Health AB--Sweden
Pfizer Health Solutions Inc.--Delaware
Pfizer Healthcare Ireland
Pfizer Hellas AE--Greece
Pfizer HK Service Co. Ltd.--Hong Kong
Pfizer Holding France SCA--France
Pfizer Holding Italy SpA
Pfizer Holding und Verwaltungs GmbH--Germany
Pfizer Holding Ventures--Ireland
Pfizer Holdings BV--Netherlands
Pfizer Holdings Europe--Ireland
Pfizer Holdings International Luxembourg (PHIL) Sarl
Pfizer Holdings Ireland
Pfizer Holdings Mexico S de RL de CV
Pfizer Holdings Netherlands BV
Pfizer Holdings Turkey Ltd.--Isle of Jersey
Pfizer Holland Pharmaceuticals BV--Netherlands
Pfizer Hungary Asset Management LLC
Pfizer Ilaclari Ltd. Sirketi--Turkey
Pfizer International Bank Europe--Ireland
Pfizer International Corp.--Panama
Pfizer International Holdings Ltd.--Ireland
Pfizer International LLC--New York
Pfizer International Luxembourg SA
Pfizer International Portfolio Investments--Ireland
Pfizer Inventory Co.--Delaware
Pfizer Investment Capital--Ireland
Pfizer Investment Co. Ltd.--China
Pfizer Ireland Pharmaceuticals
Pfizer Ireland Ventures
Pfizer Italia Srl--Italy
Pfizer Japan Inc.
Pfizer Jersey Capital Ltd.--Isle of Jersey
Pfizer Jersey Co. Ltd.--Isle of Jersey
Pfizer Jersey Finance Ltd.--Isle of Jersey
Pfizer Laboratories (Pty.) Ltd.--South Africa
Pfizer Laboratories Ltd.--Kenya
Pfizer Laboratories Ltd.--Pakistan
Pfizer Ltda.--Angola
Pfizer Ltd.--Tanzania
Pfizer Ltd.--Thailand
Pfizer Ltd.--Uganda
Pfizer Ltd.--U.K.
Pfizer Ltd. (Taiwan)
Pfizer Luxco Holdings Sarl--Luxembourg
Pfizer Luxco Production SARL--Luxembourg
Pfizer Luxembourg SARL
Pfizer Manufacturing Belgium NV
Pfizer Manufacturing LLC--Delaware
Pfizer Manufacturing Services--Ireland
Pfizer Medical Technology Group (Belgium) NV
Pfizer Medical Technology Group (Netherlands) BV
®
Pfizer Medical Technology Group Ltd.--U.K.

Pfizer Middle East--Egypt
Pfizer Middle East for Pharmaceuticals, Animal Health and Chemicals SAE--
Egypt
Pfizer Namibia (Proprietary) Ltd.
Pfizer New Zealand Ltd.
Pfizer Overseas Pharmaceuticals--Ireland
Pfizer Overseas Inc.--Delaware
Pfizer Oy--Finland
Pfizer Participations SARL--Luxembourg
Pfizer Pension Trustees (Ireland) Ltd.
Pfizer Pension Trustees Ltd.--U.K.
Pfizer PGM SAS--France
Pfizer PGRD SAS--France
Pfizer Pharm Algerie
Pfizer Pharma GmbH--Germany
Pfizer Pharma Trade LLC--Egypt
Pfizer Pharmaceutical (Wuxi) Co. Ltd.--China
Pfizer Pharmaceutical India Pvt. Ltd.
Pfizer Pharmaceutical Trading Ltd. Liability Co. (Pfizer Kft. or Pfizer LLC)--
Hungary
Pfizer Pharmaceuticals BV--Netherlands
Pfizer Pharmaceuticals Israel Ltd.
Pfizer Pharmaceuticals Jersey Ltd.--Isle of Jersey
Pfizer Pharmaceuticals Korea Ltd.--South Korea
Pfizer Pharmaceuticals Ltd.--Cayman Island
Pfizer Pharmaceuticals LLC--Delaware
Pfizer Pharmaceuticals Ltd.--China
Pfizer Pharmaceuticals Tunisie Sarl
Pfizer Pharmaceuticals Inc.--Delaware
Pfizer Pigments Inc.--Delaware
Pfizer Polska Sp. z.o.o.--Poland
Pfizer Precision Holdings SARL--Luxembourg
Pfizer Pvt. Ltd.--Malaysia
Pfizer Pvt. Ltd.--Singapore
Pfizer Production LLC--Delaware
Pfizer Products Inc.--Connecticut
Pfizer Products India Pvt. Ltd.--India
Pfizer Romania SRL
Pfizer SA--Colombia
Pfizer SA--Peru
Pfizer SGPS Lda.--Portugal
Pfizer SRL--Argentina
Pfizer SA (Belgium)
Pfizer Saidal Manufacturing--Algeria
Pfizer Sante Grand Public (SCA)--France
Pfizer Science and Technology Ireland Ltd.
Pfizer Service Company BVBA--Belgium
Pfizer Service Co. Ireland
Pfizer Services 1 (SNC)--France
Pfizer Services 2 (SNC)--France
Pfizer Services LLC--Delaware
Pfizer Servicios de Mexico SA de CV
Pfizer Shared Services--Ireland
Pfizer Shareholdings Intermediate SARL--Luxembourg
Pfizer Singapore Trading Pte. Ltd.
Pfizer Specialties Ltd.--Nigeria
Pfizer SPOL s.r.o.--Czech Republic
Pfizer Sterling Investments Ltd.--Isle of Jersey
Pfizer Suzhou Animal Health Products Co. Ltd.--China
Pfizer Technologies Ltd.--U.K.
Pfizer Trading Polska sp.z.o.o.--Poland
Pfizer Tunisie SA
Pfizer UK Group Ltd.--U.K.
Pfizer Venezuela SA--Venezuela
®
Pfizer Ventures Ltd.--Isle of Jersey

Pfizer Warner Lambert Luxembourg SARL
Pfizer Zona Franca SA--Costa Rica
Pfizer Inc.--Philippines
Pfizer SA--Costa Rica
Pfizer SA (Pfizer Pharmaceutical)--Spain
Pfizer SA de CV--Mexico
Pharmacia & Upjohn AG--Switzerland
Pharmacia & Upjohn Cambridge Ltd.--U.K.
Pharmacia & Upjohn Co. LLC--Delaware
Pharmacia & Upjohn Holding Co.--Delaware
Pharmacia & Upjohn LLC--Delaware
Pharmacia & Upjohn Management Co. Ltd--U.K.
Pharmacia & Upjohn SpA--Italy
Pharmacia & Upjohn Trading Corp.--Michigan
Pharmacia & Upjohn SA de CV--Mexico
Pharmacia (South Africa) (Pty.) Ltd.
Pharmacia Africa Ltd.--U.K.
Pharmacia Animal Health AB--Sweden
Pharmacia Animal Health Ltd.--U.K.
Pharmacia Asia Ltd.--Hong Kong
Pharmacia Australia Pty. Ltd.
Pharmacia BV--Netherlands
Pharmacia Brasil Ltda.
Pharmacia Corp.--Delaware
Pharmacia de Centroamerica SA--Panama
Pharmacia de Centroamerica Sociedad Anonima--Guatemala
Pharmacia de Mexico SA de CV--Mexico
Pharmacia Diagnostics Verwaltungs GmbH--Germany
Pharmacia Enterprises Sarl--Switzerland
Pharmacia Europe EEIG--U.K.
Pharmacia GmbH--Germany
Pharmacia Grupo Pfizer SL--Spain
Pharmacia Hepar Inc.--Delaware
Pharmacia Holding AB--Sweden
Pharmacia Ilac Sanayi ve Ticaret Ltd.--Turkey
Pharmacia Industrifastigheter AB--Sweden
Pharmacia Inter-American LLC--Michigan
Pharmacia International BV--Netherlands
Pharmacia International Inc.--South Dakota
Pharmacia International SARL--Switzerland
Pharmacia International Trading (Shanghai) Ltd.
Pharmacia Ireland Ltd.
Pharmacia Korea Ltd.--South Korea
Pharmacia Laboratories Ltd.--U.K.
Pharmacia Learning Center Corp.--Delaware
Pharmacia Ltd.--U.K.
Pharmacia Ltd. Co.--Michigan
Pharmacia Malaysia Sdn Bhd
Pharmacia Pakistan (Pvt.) Ltd.
Pharmacia-Pfizer EEIG--U.K.
Pharmacia Pharmatrade LLC--Hungary
Pharmacia Polska Sp.z.o.o.--Poland
Pharmacia SpA--Italy
Pharmacia Searle Ltd.--U.K.
Pharmacia Singapore Pte. Ltd.
Pharmacia UK Holding Co.
Pharmacia UK Ltd.
Pharmacia United Inc.--Philippines
Plaistow Ltd.--Ireland
Promotora IPSA SA--Mexico
ProRe SA--Luxembourg
Prosec (Ireland) Ltd.
Prosec Forsakrings AB (Prosec Insurance Co. Ltd.)--Sweden
PT Capsugel Indonesia
®
PT Pfidex Pharma--Indonesia
PT Pfizer Indonesia
PUCN Ltd. Partnership--Nevada
PUCN LLC--Nevada
Quigley Co. Inc.--New York
Reactine SRL--Italy
Renrall LLC--Wyoming
Rivepar--France
Roerig AB--Sweden
Roerig BV--Netherlands
Roerig Produtos Farmaceuticos Lda.--Portugal
Roerig SA--Chile
Roerig Inc.--Philippines
Roerig SA--Venezuela
Searle & Co.--Delaware
Searle Argentina SRL
Searle Belgium BVBA--Belgium
Searle Chemicals Inc.--Delaware
Searle de Mexico SA de CV--Mexico
Searle GmbH--Germany
Searle Holdings BV--Netherlands
Searle Invest BV--Netherlands
Searle Laboratorios Lda.--Portugal
Searle LLC--Nevada
Searle Ltd.--Bermuda
Searle Pharma LLC--Russia
Sefarma Srl--Italy
Sensus Drug Development Corp.--Delaware
Shiley International--California
Shiley LLC--California
Sinergis Farma-Produtos Farmaceuticos Lda.--Portugal
Site Realty Inc.--Delaware
Smith Brothers Cough Drops Canada Ltd.
SmithKline Beecham Animal Health (SWA) (Pty.) Ltd.--Namibia
Solinor LLC--Delaware
Sopaco SRL--Italy
Substantia SAS--France
Sugen Inc.--Delaware
Suzhou Capsugel Ltd.--China
Swordfish Heimtierbedarf Verwaltungsgesellschaft mbH--Germany
Swordfish Holding GmbH--Germany
Tabor Corp.--Delaware
The Kodiak Co. Ltd.--Bermuda
The Upjohn Holding Co. M LLC--Delaware
The Upjohn Manufacturing Co. LLC--Delaware
Thorney Co.--Ireland
Unicliffe Ltd.--U.K.
Upjohn International Holding Co.--Delaware
Upjohn International Inc.--Michigan
Upjohn Laboratorios Lda.--Portugal
Upjohn Pharmaceuticals Ltd.--Delaware
Upjohn Suzhou Pharmaceutical Co. Ltd.--China
Viagra Ltd.--U.K.
Vicuron Pharmaceuticals Inc.--Delaware
Vicuron Pharmaceuticals Italy Srl--Italy
Vinci Farma SA--Spain
Warner Lambert (UK) Ltd.
Warner Lambert Bolivia SA
Warner Lambert Co. (M) Sdn Bhd--Malaysia
Warner Lambert Consumer Healthcare Pty. Ltd.--Australia
Warner Lambert del Uruguay SA
Warner Lambert Ilac Sanayi ve Ticaret Ltd.--Turkey
Warner Lambert Poland Sp.z.o.o
Warner Lambert Pty. Ltd.--Australia
Warner Lambert Zimbabwe (Pvt.) Ltd.
®
Warner-Lambert (East Africa) Ltd.--Kenya

Warner-Lambert (Nigeria) Ltd.
Warner-Lambert (Singapore) Pvt. Ltd.
Warner-Lambert (Tanzania) Ltd.
Warner-Lambert (Thailand) Ltd.
Warner-Lambert (West Indies) Ltd.--Jamaica
Warner-Lambert Co. AG--Switzerland
Warner-Lambert Co. LLC--Delaware
Warner-Lambert de Costa Rica SA
Warner-Lambert de El Salvador SA de CV
Warner-Lambert de Honduras, Sociedad Anonima
Warner-Lambert de Panama, Sociedad Anonima
Warner-Lambert de Puerto Rico Inc.
Warner-Lambert GmbH--Germany
Warner-Lambert Guatemala, Sociedad Anonima
Warner-Lambert Hungary KFT--Hungary
Warner-Lambert International NV--Netherlands Antilles
Warner-Lambert Ireland
Warner-Lambert Kenya Ltd.
Warner-Lambert Manufacturing (Ireland) Ltd.--Cayman Islands
Warner-Lambert Pottery Road Ltd.--Ireland
Warner-Lambert SA (Pty.) Ltd.--South Africa
Warner-Lambert SA--Delaware
Wilcox Sweets (Pty.) Ltd.--South Africa
W-L (Europe)--U.K.
W-L (Portugal)--U.K.
W-L (Spain)--U.K.
WL de Guatemala, Sociedad Anonima
W-L Holding SCA--France
W-L LLC--Delaware
Yusafarm D.O.O.--Serbia and Montenegro
INVESTMENTS: Anaderm Research Corp.--joint venture with OSI Pharmaceuticals Inc.
Gensia Inc.--$5M equity investment
OSI Pharmaceuticals Inc.--587.5K shares, $2.9M
Perlegen Sciences Inc.--$50M (12/05)
BUSINESS STRATEGY: Discover, develop, manufacture and market leading prescription medicines
for humans and animals
250+
collaborations,
including the
following:
Abgenix Inc. Abgenix's XenoMouse development 12/97
to make antibodies agreement--Pfizer
against undisclosed will make equity
antigen targets investment as part
of up-front payment,
Pfizer will pay
milestones,
research costs,
license fees and
provide royalties
from sales of any
products
AccuMed antifungal susceptibility R&D agreement 10/92
International Inc.
ActivX discovery to strategic 3/06
Biosciences Inc. developmental stage collaborative
projects agreement
Advanced APS's microsponge marketing 4/90
Polymer Systems technology agreement
Inc.
®
AEA Technology drug discovery based R&D agreement 3/95

on genomics research
Affymetrix Inc. Affymetrix GeneChip supply agreement 7/97
expression technology
ALZA Corp. Glucotrol XL joint promotion 10/94
agreement
Astex Cytochrome P450 licensing agreement 1/06
Therapeutics
Atrix Laboratories Atrix's delivery feasibility study 3/97
Inc. (QLT USA technology and Pfizer's
Inc.) veterinary drug
Bayer AG nifedipine GITS exclusive marketing 7/88
rights for Bayer
overseas
Bayer Bayer's DGAT-1 exclusive worldwide 6/06

Pharmaceuticals inhibitors licensing agreement
Corp.
BIOSTAR Inc. genetically engineered licensing, research, 12/91
vaccines for animals and supply
agreements through
Pfizer Animal
Health
Calgene Inc. genetically engineered cooperative 2/95
plants research agreement
through Pfizer Food
Science Group
Cambridge phage antibody display nonexclusive 2/96
Antibody and selection licensing agreement
Technology Ltd. technologies
Cantab veterinary vaccines joint development 1995
Pharmaceuticals developed with agreement with
plc Cantab's proprietary Pfizer's Animal
Disc-Virus technology Health Group
ChemTrak Inc. disposable quantitative development 6/98
finger stick whole blood agreement
test for one of Pfizer's
drugs in development
using ChemTrak's
AccuMeter technology
ChondroGene access to two-year research 12/04
Limited ChondroGene's collaboration
database of
osteoarthritis tissue-
specific clinical and
gene expression
information
Chromos development of cell collaborative 12/04
Molecular lines using the ACE agreement
Systems Inc. system for production of
Pfizer recombinant
proteins
Chromos ACE System non-exclusive 5/05
Molecular commercial
Systems Inc. licensing agreement
Chrysalis genomics research for two-year R&D 1/98
International Corp. two major disease agreement
targets
Codexis Inc. pharmaceutical life R&D agreement 7/04
cycle management--use
of Codexis'
MolecularBreeding
technology
®
Coley development, exclusive global 3/05

Pharmaceutical manufacturing and licensing agreement
Group commercialization of
Coley's ProMune (CPG
7909)
Collaborative rennin for making research, licensing, 1/88
Research, The cheese by genetic and worldwide
Dow Chemical Co. manipulation of yeast marketing
agreement--Dow
assigned marketing
rights to Pfizer
Corvas neutrophil inhibitory R&D agreement 2/97
International Inc. factor (NIF) for acute with license option
ischemic stroke (10/95), Pfizer
agreed to pay $1M
plus $29M in
development
funding and
milestones, Pfizer
receives worldwide
license to develop,
manufacture and
market NIFR&D
agreement with
license option,
Pfizer paid $1M
milestone after
starting Phase I
clinical trial (2/98)
Crucell NV Crucell's West Nile virus exclusive licensing 1/04
vaccine for horses agreement
Cubist antibacterial agents R&D collaboration 7/97
Pharmaceuticals (12/95), licensing
Inc. agreement
extended
Deprenyl Animal Anipryl for canine worldwide licensing, 11/97
Health, Inc. Cushing's disease and marketing and
(Draxis Health canine cognitive distribution
Inc.) dysfunction agreement--Draxis
received $15M up-
front payment
(12/97), Draxis to
receive $10M upon
FDA approval of
cognitive
dysfunction
supplementary
claim and up to
$16M contingent
upon regulatory
approval for
Anipryl® in specific
markets
Eyetech Macugen pegaptanib development and 12/02
Pharmaceuticals VEGF-binding aptamer marketing
to treat age-related agreement
macular degeneration
(AMD) and diabetic
macular edema (DME)
G. D. Searle & Co. Searle's celecoxib and copromotion and 2/98
its second-generation development
compound agreement--Searle
will receive $85M
up-front payment
®
Immunicon Corp. reagents for the R&D agreement; 2/03

detection of undisclosed amended 4/04,
antigens on circulating expanded 12/04,
tumor cells (CTCs) extended 3/06
Immusol Inc. target validation 3/98
collaboration
Incyte Corp. Incyte's LifeSeq database 2/98
genomics database, subscription (6/94),
expanded to include extended three
LifeSeq FL database years and
and LifeSeq expandedexpanded
GeneAlbum DNA clone
set
Incyte Corp. development, research and 11/05

manufacture and license agreement
marketing of novel oral
CCR2 antagonists
Inhale Therapeutic pulmonary delivery development 1/95
Systems system for insulin agreement,
completed Phase I
clinicals
Inpharmatica Ltd. identification, subscription 2/01
prioritization and agreement
validation of the
suitability of drug
targets
Isis identification of second- multi-year drug 5/05
Pharmaceuticals generation antisense discovery
drugs for the treatment collaboration--Isis
of ophthalmic disease will receive a $1M
technology access
fee, research
funding, milestone
payments and
royalties
LifeSpan LifeSpan's DrugTarget multiyear 12/05
BioSciences Inc. Database agreement
Medarex Inc. up to 50 antibody development and 9/04
products over 10 years licensing agreement
Metabasis adenosine regulating research 3/98
Therapeutics Inc. agents (ARA) as broad- collaboration (5/96),
(Gensia Sicor Inc.) spectrum analgesic extended through
drugs for treating pain May 1999,
Metabasis gets
additional research
funding plus
milestones and
royalties if Pfizer
selects product for
clinical
development
Microcide antibiotic for animal research 1/99
Pharmaceuticals health applications collaboration
Inc.
Microcide drugs to treat resistant five-year 2/97
Pharmaceuticals bacterial infections collaboration (3/96),
Inc. Microcide received
$1M milestone
payment related to
identification,
validation and
sequencing of
genes
®
Microvascular liposome formulations development 9/87

Systems, MPS for injectable animal agreement
(IGI) vaccines
Millennium fungal diseases research, licensing, 12/97

Pharmaceuticals and product
Inc. development
agreement (3/95),
expanded--
Millennium to add
research personnel
to focus on
application of
transcript profiling
and ultra-high-
throughput
screening
technologies
Mitokor Inc. target and drug R&D agreement 1998
discovery in certain
neurodegenerative
diseases
Moleculon Poroplastic controlled- manufacturing
release disc used in agreement
Paratect antiparasitic
bolus system
Monogram Monogram's HIV Co- nonexclusive 5/06
Biosciences Inc. Receptor Tropism collaboration
Assay to be made agreement
available globally
Myco drug discovery based R&D agreement 3/95
Pharmaceuticals on genomics technology
NAEJA anti-infectives contract research 3/01
Inc.
Neogen Corp. immunoassay development and 8/92
diagnostic kits for the supply agreements
poultry industry
Neurogen Corp. drugs to treat obesity three- to five-year 5/98
and eating disorders joint R&D
agreement--Pfizer
to receive
worldwide exclusive
license to market
any drugs
developed through
the collaboration
and to fund
Neurogen's R&D
program. Neurogen
will retain option to
manufacture the
products for NAFTA
countries.
Neurogen will retain
a profit-sharing
option for NAFTA
countries (11/95).
funded research
portion extended for
one year beginning
in 11/98
®
Neurogen Corp. drugs to treat sleep three-year R&D 12/96

disorders agreement--Pfizer
to fund Neurogen's
R&D program in
exchange for
worldwide
manufacturing and
marketing rights to
any sleep drugs
developed through
the collaboration
(7/94), expanded
for two years
Neurogen Corp. drugs to treat anxiety five-year joint R&D 12/96

and enhance cognition agreement--Pfizer
to fund Neurogen's
R&D program in
exchange for
worldwide
manufacturing and
marketing rights to
anxiolytic or
cognition enhancing
drugs developed
through the
collaboration (2/92),
extended for
additional year
(10/95), expanded
for two years
Neurosearch A/S Neurosearch's non-exclusive 12/97
automated patch clamp licensing agreement
technology
NicOx SA NicOx nitric oxide- R&D and licensing 8/04
donating compounds agreement
NicOx SA NicOx's nitric oxide- licensing agreement 3/06
donating technology
Noxxon Pharma discovery and multi-year global 3/06
AG development of collaboration
Spiegelmer products
Odyssey Thera use of Odyssey Thera's multi-year 9/06
Inc. Protein-fragment collaboration
Complementation agreement
Assay (PCA)
technology to evaluate
selectivity of Pfizer
compounds
OSI compounds to treat three-party 4/96
Pharmaceuticals baldness, wrinkles and collaboration
Inc. pigmentation disorders agreement with
New York
University and
Anaderm Research
Corp.
OSI cancer therapeutics that five-year R&D 3/96
Pharmaceuticals target oncogenes and agreement (7/88),
Inc. tumor suppressor genes extended for five
years (12/90),
extended for
additional five years
®
Oxford Asymmetry drug discovery based R&D agreement 4/97

on genomics research (3/95), extended for
one year, Pfizer will
pay £5.4M over
three years
Oxford OGS' proteomics $50M research 4/98
Glycosciences plc. technology to identify collaboration--Pfizer
disease-specific invested in OGS'
proteins as potential IPO and will fund
diagnostics, clinical research for two
markers and drug years
targets in Alzheimer's
disease
Peptide Peptide's broad development 1/98

Therapeutics spectrum allergy agreement--Pfizer
Group plc. vaccine for veterinary will have exclusive
market option to worldwide
license and will pay
costs of research
and clinical
development for
evaluating the
vaccine
Perlegen identification of genes four-year research 12/05
Sciences Inc. associated with major agreement
diseases
Perlegen discovery of genes research 12/02
Sciences Inc. using Perlegen's DNA collaboration
sample preparation
Phyton Inc. (now collaborative 1996
Phyton Biotech development
Inc.) agreement
Phytopharm plc. obesity drug collaboration and 8/98
licence agreement
Renovis Inc. research, development worldwide 5/05
and commercialization collaboration and
of small molecules that licensing agreement
target VR1
Repligen Corp. growth factor inhibitors research 12/95
collaboration,
Repligen received
milestone payment
(12/97)
Repligen Corp. small molecule research 1/97
compounds that collaboration
stimulate immune
system responses
Rigel development of inhaled research and 1/05
Pharmaceuticals products for allergic licensing agreement
Inc. asthma and other
respiratory diseases
Sangamo Sangamo's zinc finger research agreement 1/05
BioSciences Inc. DNA binding protein
technology for use in
Pfizer's mammalian
cell- based protein
pharmaceutical
production
Schering AG Schering's ADP licensing agreement 2/05
receptor antagonist
program
Schwarz Pharma fesoterodine licensing agreement 6/06
®
The Liposome Co. TLC D-99 licensing 11/90

Inc. agreement--Pfizer
to have worldwide
marketing rights
TheraTech Inc. drug delivery systems R&D agreement 8/94
(8/92), extended for
two years
RESEARCH & DEVELOPMENT: Pharmaceuticals: antibiotics, antifungals, nonsteroidal anti-inflammatory

agents for arthritis and autoimmune disease, cardiovascular agents, CNS
agents, diabetes agents, respiratory diseases
Improved microorganisms for production of fermentation products
Broad range of fermentation-derived products, enzymes (rennet, proteases),
EOR, specialty chemicals, rDNA rennin
Interferons, antibiotics, renin inhibitors
Animal health, including antibiotic and vitamin feed supplements
Antiviral R&D, including AIDS research (Pfizer U.K.)
PRODUCTS ON MARKET: KEY PHARMACEUTICAL PRODUCTS: Aricept® (donepezil hydrochloride
tablets), Celebrex® (celecoxib), Diflucan® (fluconazole), Lipitor®
(atorvastatin calcium) tablets, Neurontin® (gabapentin), Norvasc®
(amlodipine besylate), Viagra® (sildenafil citrate) tablets, Xalatan®
(latanoprost ophthalmic solution), Zithromax® (azithromycin), Zoloft®
(sertraline HCI), Macugen® (pegaptanib sodium injection), Chantix™
(varenicline)
KEY CONSUMER HEALTH CARE PRODUCTS: Benadryl®, Cortizone®,

Desitin®, e.p.t.®, Listerine®, Lubriderm®, Neosporin®, Rolaids®,
Sudafed®, Visine®
KEY ANIMAL HEALTH PRODUCTS: Clavamox®, Synulox®, Equimax®,

Naxcel®/Excenel®, Rimadyl®, Dectomax®, Respisure®/Stellamune®,
Revolution®/Stronghold®
235 projects in development, including 152
new molecular entities and 83 product-line
extensions. More than 400 projects in
discovery research.
Pharmbiodyn Consulting Group

Ferdinand-Porsche-Str. 5/1
Denzlingen D-79211, Germany
Phone: +49 7666-2025; Fax: +49 7666-7255
Web: www.pharmbiodyn.com
E-mail: info@pharmbiodyn.de
KEY PERSONNEL: Dr. G. Friedrich; President
RESEARCH & DEVELOPMENT: Development of products for automation of liquid chromatography

biotechnology, cell and tissue culture
PRODUCTS ON MARKET: Products:
Customer designed fully automated HPLC / LC-MS
Robo-Caesar-Set
®
Consulting services:
Automation in analytical and preparative chromatography
Development and adapting of methods for full automation of procedures in
liquid chromatography
Services: Installation service, services for own products, services for clients
in collaboration with partners, including in vitro and in vivo preclinical and
clinical studies (analytics, drug efficacy, metabolism, pharmacokinetics); free
radicals in vitro and in vivo (preclinical, clinical studies); and cell therapy,
stem cells, their products in different stages of differenciation
Pioneer Hi-Bred International Inc.

7100 NW 62nd Avenue, PO Box 1014
Johnston IA 50131-1014, US
Phone: (515) 248-4800; Fax: (515) 270-3581
Web: www.pioneer.com; E-mail: web.editor@pioneer.com
KEY PERSONNEL: Dean Oestreich; Pioneer President
Diane C. Bridgewater; VP CFO
Dennis Byron; VP, Crop Development
Bill Fleet; VP, North America Sales
Ian Grant; VP, Maize Development
Mike Gumina; VP, Supply Management
Bob Iwig; VP, Strategic Marketing
Daniel Jacobi; VP and General Counsel
Michael Lassner; VP, Trait Discovery
Giuseppe Manara; VP, Global Sales Strategy
Barbara Mazur; VP, Trait Technologies
William Niebur; VP, DuPont Crop Genetics R&D
Franci Phelan; VP, Human Resources
Frank Ross; VP and Business Director, North America Operations
Paul Schickler; VP and Business Director, International Operations
Steve Waite; VP, Information Management and CIO
Thomas G. West; VP, Biotech Affairs and Business Support
Purchased the assets of Allelix Crop Technologies (12/90)
Purchased Plant Cell Research Institute's RFLP program (3/91)
Purchased Native Plants, Inc.'s RFLP program (4/91)
FACILITIES: Research at more than 140 locations in 30 countries worldwide
SUBSIDIARIES/DIVISIONS: Pioneer Argentina SA
Pioneer Hi-Bred Australia Pty. Ltd.
Pioneer Hi-Bred Services GmbH--Austria
Carter's General Stores--Barbados
Pioneer Hi-Bred Northern Europe Sales Division GmbH--Belgium
Midwest Steel & Agro Supplies Co. Ltd.--Belize
Semillas Villacruz SRL--Bolivia
Du Pont do Brasil SA (Divisao Pioneer Sementes)
Pioneer Semena Bulgaria
Pioneer Hi-Bred Ltd.--Canada
Semillas Pioneer Chile Ltda.
Shandong Denghai-Pioneer Seeds Co.--China
DuPont de Colombia SA
Agricola Piscis SA--Costa Rica
Pioneer Sjeme DOO--Croatia
Pioneer Hi-Bred Services GmbH--Czech Republic
Productora de Semillas Dominicanas--Dominican Republic
®
Misr Pioneer Seed Co.--Egypt

Duwest--El Salvador
Pioneer Hi-Bred Seeds (Ethiopia) plc
Pioneer Semences SAS--France
Pioneer Hi-Bred Northern Europe Sales Division GmbH--Germany
Pioneer Hi-Bred Hellas SA--Greece
Duwest--Guatemala
Duwest--Honduras
Pioneer Hi-Bred Magyarorszag Kft.--Hungary
PHI Seeds Ltd.--India
PT DuPont Indonesia
Pioneer Hi-Bred Italia Srl
Pioneer Hi-Bred Japan Co. Ltd.
Farmchem Seedlinks Ltd.--Kenya
Chemicals & Marketing Co. Ltd.--Malawi
PHI Mexico SA de CV--Mexico
Pioneer Hi-Bred Northern Europe Sales Division GmbH--The Netherlands
Genetic Technologies Ltd.--New Zealand
Duwest--Nicargua
Pioneer Pakistan Seed Ltd.--Pakistan
Grupo Melo--Panama
Representaciones Agricolas de Miguel Villanueva EIR Ltda.--Peru
Pioneer Hi-Bred Philippines Inc.
Pioneer Hi-Bred Services GmbH--Poland
Pioneer Hi-Bred Sementes de Portugal SA
Pioneer Hi-Bred Puerto Rico Inc.
Pioneer Hi-Bred Seeds Agro SRL--Romania
Pioneer Semena Holding GmbH--Russia
Pioneer Hi-Bred Services GmbH--Serbia and Montenegro
Pioneer Hi-Bred Slovensko SRO--Slovakia
Pioneer Semena Holding GmbH--Slovenia
Pioneer Hi-Bred RSA (Pty.) Ltd.--South Africa
O.M.C.--South Korea
Pioneer Hi-Bred Spain SL
Pioneer Hi-Bred Switzerland SA
Bytrade Tanzania Ltd.
Pioneer Hi-Bred (Thailand) Co. Ltd.
Sheppard Enterprises Ltd.--Trinidad and Tobago
Pioneer Tohumculuk AS--Turkey
Pioneer Nasinnya Ukraine LLC
Pioneer Hi-Bred Northern Europe Service Division GmbH--U.K.
Agar Cross Uruguaya SA
Semillas Pioneer de Venezuela
Farmchem Services Ltd.--Zambia
Pioneer Hi-Bred Zimbabwe (Pvt.) Ltd.
SUBSIDIARY OF: DuPont
BUSINESS STRATEGY: Produce, market and sell hybrid seed corn in nearly 70 countries worldwide
Market and sell hybrids or improved varieties of sorghum, sunflower,
soybean, alfalfa, canola, wheat, forage and grain additives
Affymetrix Inc. agricultural research feasibility 4/97
collaboration
CuraGen Corp. seed and agricultural $25M research 4/98
products collaboration--
Pioneer made
$7.5M equity
investment and
commitment to fund
research for 5 years
(6/97), expanded
Devgen NV develop superior crop research 5/06
varieties with resistance collaboration
to plant pests
®
DFS Inc. measure levels of joint research 10/05

digestible energy in collaboration
corn grain for animal
feed
Dow Herculex joint development
AgroSciences LLC agreement
E. I. Du Pont genomics and enabling research alliance, 8/97
technologies joint venture and
equity stake
Ecogen Inc. seed corn containing licensing agreement 4/91
Ecogen's Bt genes
Human Genome corn genome collaboration 1/96
Sciences Inc. agreement
InsectiGen InsectiGen's BtBooster licensing agreement 7/05
technology
Kimeragen Inc. agricultural applications licensing agreement 3/97
of Kimeragen's gene
enhancement
technology
Monsanto Co. YieldGard insect- licensing agreement 12/95
protected Bt corn
Mycogen Corp. agricultural seeds for joint development 12/95
(now Mycogen corn, soybean, agreement
Seeds) sunflower, canola,
sorghum, and other
crops with Bt-based
insect resistance
Plant Genetics genetically engineered licensing agreement
Systems NV vegetable seeds
Zeneca Mogen fungal resistance collaborative 2/94
(now technology research and
AstraZeneca) licensing agreement
OGS (Oxford, Proteomics research 9/98
Glyco Sciences) collaboration,
proteomics
technology, for
improving
agricultural seed
products
RESEARCH & DEVELOPMENT: Hybrids of corn, sorghum, sunflower and canola, and varieties of soybean,
alfalfa, wheat and canola
Plant tissue culture, bioengineering of agricultural crops
Gene transfer by DNA-coated tungsten particles (microprojectile
bombardment) and other methods
Specialty hybrids and varieties for end users
PRODUCTS ON MARKET: Hybrid corn, canola, sorghum and sunflower seeds, and seeds of soybeans,
alfalfa and wheat varieties
Silage, hay and high-moisture corn inoculants
Software programs for farm production information
Pioneer Information Network--project to link farmers and agribusiness with
agriculture information
®
PLANTON GmbH
Am Kiel-Kanal 44
Kiel D-24106, Germany
Phone: +49 431 380 15-0; Fax: +49 431 380 15-11
Web: www.planton.de
E-mail: info@planton.de
KEY PERSONNEL: Dr. Michael Kleine; CEO
Prof. Dr. Florian Grundler; Director, R&D
FACILITIES: 440 sq. m. total
BUSINESS STRATEGY: Develop and produce protein-based biopharmaceuticals
Polium Technologies Inc.

2155 Stonington Ave., Suite 119
Hoffman Estates IL 60195, US
Phone: (847) 310-8725; Fax: (847) 310-8725
Web: www.polium.com
E-mail: info@polium.com
KEY PERSONNEL: Michael Gololobov, Ph.D.; President
HISTORY: Founded and began R&D in 2000
BUSINESS STRATEGY: Use its proprietary technology and products to accelerate drug discovery
and pharmaceutical development
RESEARCH & DEVELOPMENT: Patented technology for the immobilization and recovery of enzymes and
small molecule catalysts
PRODUCTS ON MARKET: Finezyme™ systems
Free enzymes
Free ligands
Rexalyst™ systems
Beta amino acids
Chiral intermediates
SoluScav™ systems
Fine chemicals
Custom R&D services
®
Polydex Pharmaceuticals Ltd.

421 Comstock Road
Toronto M1L 2H5, Canada
Phone: (416) 755-2231; Fax: (416) 755-0334
Web: www.polydex.com
E-mail: info@polydex.com
KEY PERSONNEL: George G. Usher; Chairman, President and CEO
Sharon Wardlaw; Exec. VP
Acquired Vet Labs of Lenexa, Kan.
Sold Vet Labs in early 2004
FACILITIES: 28,000 sq. ft. Toronto production facility
STOCK-FINANCIAL HISTORY: NASDAQ--POLXF / Boston Stock Exchange--PXL
Sales $5.265M (YE 06) compared to $6.372M (YE 05)
Earnings <loss> per share <$0.49/share> (YE 06) compared to $0.38/share
(YE 05)
PRIVATE PLACEMENTS: American Heritage Fund--1M shares at $1.75/share (12/94)
SUBSIDIARIES/DIVISIONS: Dextran Products Ltd.--Scarboro, ON (see separate entry)
Corporate office:
Polydex Pharmaceuticals Ltd.
Sandringham House
83 Shirley Street
Nassau, Bahamas
Phone: (242) 322-8571
Fax: (242) 328-6919
PRINCIPAL INVESTORS: American Heritage Fund--$2.25M
Continental Grain Co.--$3.6M
BUSINESS STRATEGY: Conduct research related to dextran
Canadian Dextran research and
Bacterial Disease licensing
Network agreements
RESEARCH & DEVELOPMENT: Cystic fibrosis therapeutics

Contraceptive gel (cellulose sulfate)
PRODUCTS ON MARKET: Iron dextran (veterinary and human)
Dextran sulfate for hybridoma
Veterinary generics
Dextran for cystic fibrosis in clinicals
Ushercell - contraceptive prophylactic in Phase II/III clinicals
®
Polysciences Inc.
400 Valley Road
Warrington PA 18976, US
Phone: (215) 343-6484; Fax: (215) 343-0214
Web: www.polysciences.com
E-mail: info@polysciences.com
KEY PERSONNEL: Michael H. Ott; President
Walter Baker; VP, Operations
Dr. D. Templer; VP, Technology and Business Development
Dr. Mark DeGrandpre; Director, Technology and Business Development
Joe Dudenbostel; Purchasing Manager
FACILITIES: More than 150,000 sq. ft. at four U.S. locations
5,000 sq. ft. facility in Eppelheim, Germany
SUBSIDIARIES/DIVISIONS: Polysciences Europe GmbH
Handelsstr. 3
Eppelheim D-69214, Germany
Phone: +49 6221-765767
Fax: +49 6221-764620
E-mail: info@polysciences.de
PRODUCTS ON MARKET: Diagnostic reagents, electrophoresis and chromatography supplies, electron

and light microscopy supplies, dyes and stains, polymeric biomaterials for
medicine and dentistry, custom packaging and formulations
Sponsored research on confidential basis (FDA facility)
Latex microparticles for antibody coupling and precision size standards
Tetrazolium salts, embedding waxes, and plastic embedding media
Custom reagent synthesis and custom packaging
Magnetic particles and flow cytometry particles
POS Pilot Plant Corp.

118 Veterinary Road
Saskatoon S7N 2R4, Canada
Phone: (306) 978-2800; Fax: (306) 975-3766
Web: www.pos.ca; E-mail: pos@pos.ca
KEY PERSONNEL: Robert E. Morgan, President and CEO
Colin Luciuk; CFO
Paul Fedec; VP, Scientific and Regulatory Affairs
Karen Connell; Director, Finance
HISTORY: Founded in July 1977 as an applied research facility for grains and oilseeds
processing
FACILITIES: 54,000 sq. ft. facility, including five pilot plant processing areas and 11
laboratories
BUSINESS STRATEGY: Provide contract R&D and custom processing services that facilitate the
development of value added processing of agri-products for industries such
as agbiotech, food, nutrachemicals, feed and fine chemicals.
®
PRODUCTS ON MARKET: Services include:

Process/Product development
Laboratory services
Analytical services
Mini-scale product development
Toll processing
Quality assurance
Chromatography
Consulting services
Support services
PrimeSyn Lab Inc.

11 Deer Park Drive, Suite 205
Monmouth Junction NJ 08852, US
Phone: (732) 274-0660; Fax: (732) 274-0907
Toll-free phone: (877) Prime-03
Web: www.primesyn.com
E-mail: info@primesyn.com
KEY PERSONNEL: Surendra Chaturvedi, Ph.D.; CEO
Barry Lynn; Exec. VP
FACILITIES: Headquarters, R&D and manufacturing facilities in Monmouth Junction, N.J.
BUSINESS STRATEGY: Provide products and services for contract research, product development
and assay development within the bio-pharmaceutical industry
Biosearch Quasar, CAL Fluor and licensing agreement 5/05
Technologies Black Hole Quencher
products
Premier Biosoft Array Designer, Beacon marketing and 4/05
International Designer, Primer distribution
Premier, SimVector and agreement
Xpression Primer
software
RESEARCH & DEVELOPMENT: Expertise is in organic synthesis and analysis to method development
PRODUCTS ON MARKET: PrimeSyn Lab Inc. is a recognized leader in the area of custom DNA/RNAi
synthesis and purification within the U.S. PrimeSyn Lab specializes in
ULTRA PURE Oligonucleotides and ASRs for: Cloning, mutagenesis,
fluorescent sequencing, microarrays, diagnostics and therapeutics.
PrimeSyn Lab also provides analytical lab services: protein analysis, mass
spectral analysis, protein purification / characterization, analytical methods
development, small molecule synthesis and analysis.
®
Primm S.R.L.
Via Olgettina 58
Milan 20132, Italy
Phone: +39 02 2104031; Fax: +39 02 2640355
Web: www.primm.it
E-mail: info@primm.it
KEY PERSONNEL: Paolo Sarmientos; CEO
FACILITIES: Laboratories, manufacturing facilities and commercial offices in Italy,
Switzerland and the U.S.
Animal facility located in the area of Treviso, Italy
SUBSIDIARIES/DIVISIONS: Animal Care Unit
Via dell'Artigianato 2
Dosson di Casier, Treviso, Italy
Phone: +39 0422 490200; Fax: +39 0422 490445
Primm GmbH
Hochbordstrasse 9
Dubendorf, Zuerich CH-8600
Phone: +41 1 9423848; Fax: +41 1 9423986
E-mail: info@primm.ch
PrimmBiotech Inc.
Box 425695 Kendall Square
Cambridge, MA 02142, USA
Fax: (617) 325-2703
E-mail: info@primmbiotech.com
Web: www.primmbiotech.com
Naples Facility:
Via P. Castellino 111
80131 Naples, Italy
Phone: +39 081 6132295
Fax: +39 081 19571728
BUSINESS STRATEGY: Provide biotechnology products (DNA, peptides, antibodies), R&D and
contract R&D for an international market
Axxam aim is to set up an technological 6/02
automated high collaboration
throughput sequencing
platform
RESEARCH & DEVELOPMENT: -Design, synthesis and pharmaceutical development of novel bioactive
peptides for various therapeutical applications
-Use of peptides to investigate problems such as the ligand-receptor
interactions or to study the tridimensional structure of specific protein
domains
-Development of recombinant strains and technologies for the industrial
production of biopharmaceuticals. In the last few years, Primm has
developed technologies for the manufacturing of selected recombinant
proteins in heterologous systems
PRODUCTS ON MARKET: Service and product divisions:
DNA and RNA synthesis
Peptide synthesis
®
Peptide nucleic acids

Gene cloning and expression
Analysis of proteins and peptides
Monoclonal and polyclonal antibodies custom service
Animal services
Procter & Gamble Co.

1 Procter and Gamble Plaza
Cincinnati OH 45202, US
Phone: (513) 983-1100; Fax: (513) 562-4500
Web: www.pg.com
E-mail: info@pg.com
KEY PERSONNEL: Alan G. Lafley; Chairman, President and CEO
Clayton C. Daley Jr.; CFO
G. Gilbert Cloyd; CTO
Richard L. Antoine; Global Human Resources Officer
R. Keith Harrison Jr.; Global Product Supply Officer
James J. Johnson; Chief Legal Officer and Secretary
Mariano Martin; Global Customer Business Development Officer
Charlotte R. Otto; Global External Relations Officer
Filippo Passerini; Chief Information Officer and Global Services Officer
James R. Stengel; Global Marketing Officer
HISTORY: Founded in 1837 by William Procter and James Gamble
Acquired the Philippine Manufacturing Company (1935)
Acquired Charmin Paper Mills (1957)
Acquired Nippon Sunhome Company (1973)
Acquired Norwich Eaton Pharmaceuticals (1982)
Acquired Noxell (1989)
Acquired Shulton's Old Spice product line (1990)
Acquired Max Factor and Betrix (1991)
Acquired VP Schickedanz (1994)
Acquired the Iams Company (1999)
Acquired Recovery Engineering Inc. (1999)
Acquired the Clairol business from Bristol-Myers Squibb Co. (2001)
Acquired The Gillette Co. (2005)
FACILITIES: 39 manufacturing facilities in 23 states in the U.S.
107 manufacturing facilities in 42 other countries
STOCK-FINANCIAL HISTORY: NYSE--PG
Net sales $56,741M (YE 05) compared to $51,407M (YE 04)
Net income $7,257M (YE 05) compared to $6,481M (YE 04)
Total assets $61,527M (YE 05) compared to $57,048M (YE 04)
SUBSIDIARIES/DIVISIONS: Modern Products Co.--Saudi Arabia
P&G Interamericas Inc.--Buenos Aires, Argentina
P&G Australia Pty. Ltd.
P&G Austria GmbH
Procter & Gamble--Minsk, Belarus
P&G Belgium BVBA
P&G Trgovacko Drusvo djl--Sarajevo
P&G do Brazil
Procter & Gamble OOD--Sofia, Bulgaria
P&G Inc.--Toronto, Canada
Procter & Gamble Representation Office--Kazakhstan
P&G Guangzhou Ltd.--China
P&G Chile Inc. Agencia--Santiago
®
Procter & Gamble Interamericas--San Jose, Costa Rica

P&G Colombia SA--Bogota
Procter & Gamble doo--Zagreb, Croatia
P&G Rakona AS--Prague, Czech Republic
Procter & Gamble DK A/S--Denmark
Distribuidora Corripio/Division P&G--Santo Domingo, Dominican Republic
P&G Egypt--Cairo
P&G El Salvador--San Salvador
Procter & Gamble--Kalmistu, Estonia
Procter & Gamble Oy--Espoo, Finland
P&G France
Procter & Gamble GmbH--Germany
P&G Hellas--Athens, Greece
P&G Interamericas Inc.--Guatemala City, Guatemala
P&G Hong Kong Ltd.
Procter & Gamble KTT--Budapest, Hungary
P&G India Ltd. GO--Bombay, India
P&G Indonesia--Jakarta
P&G Ireland Ltd.
P&G Israel--Tel-Aviv
P&G Srl--Rome, Italy
Procter & Gamble Far East Inc.--Japan
Procter & Gamble Almaty--Kazakhstan
P&G East Africa Ltd.--Nairobi
P&G Korea Inc.--Seoul
P&G Marketing Latvia Ltd.
P&G Mfg Co. of Lebanon SAL
P&G (M) Sdn Bhd--Malaysia
P&G de Mexico S de RL de CV
Industries Marocaines Modernes--Casablanca, Morocco
Procter & Gamble Nederland BV--Rotterdam, The Netherlands
P&G NPD Inc.--Auckland, New Zealand
P&G Nigeria Ltd.
Procter & Gamble Norway A/S--Oslo
P&G Pakistan Pvt. Ltd.
Procter & Gamble del Peru SA--Lima
P&G Philippines Inc.
P&G Operations Polska SA--Warsaw, Poland
P&G Portugal SA
P&G Commercial Co.--Puerto Rico
P&G Marketing Romania SRL
Procter and Gamble OOO--Russia
P&G (S) Pte. Ltd.--Singapore
Procter & Gamble Spol. Sro--Slovak Republic
Procter & Gamble doo--Slovenia
Procter and Gamble SA (Pty) Ltd.--Johannesburg, South Africa
P&G Espana SA--Madrid, Spain
Procter & Gamble Nordic Inc.--Stockholm, Sweden
Procter & Gamble International Operations SA--Geneva, Switzerland
Procter & Gamble Taiwan Ltd.--Taipei
P&G Manufacturing (Thailand) Ltd.--Bangkok
Procter & Gamble Tuketim Mallari Sanayi AS--Turkey
P&G Ukraine--Kiev
P&G Gulf FZE--Dubai
Procter & Gamble UK--England
The Procter & Gamble Co.--Cincinnati, Ohio
Procter & Gamble Representative Office--Uzbekistan
Procter & Gamble de Venezuela CA--Caracas
Procter & Gamble Vietnam Ltd.
P&G Yemen Ltd.
P&G c/o Nelt--Belgrade, Yugoslavia
®
BUSINESS STRATEGY: Purpose: Provide branded products and services of superior quality and
value that improve the lives of the world's consumers. As a result,
consumers will reward us with leadership sales, profit, and value creation,
allowing our people, our shareholders, and the communities in which we live
and work to prosper
Advanced Microsponge systems licensing and 7/96
Polymer Systems containing dimethicone supply agreement
Inc. for use in baby wipe
products
Advanced Tissue human tissue system to joint development 6/91
Sciences Inc. screen oral drugs agreement
Advanced Tissue in vitro assay to test licensing 9/92
Sciences Inc. products for eye safety agreement--ATS
combining ATS's granted exclusive
Skin2™ with P&G's worldwide rights to
procedure for market
conducting eye irritation
studies
Alimentary Health therapies for worldwide licensing 12/05
Ltd. gastrointestinal agreement
disorders
Alza Corp., Ditropan (oxybutynin Alza acquired 4/98
Hoechst Marion chloride) for treating Canadian marketing
Roussel Inc. urge urinary rights and right to
incontinence use Ditropan®
trademark in
Canada with other
Alza products,
Hoechst will
manufacture and
package product,
Alza will submit
marketing
application for
Ditropan® XL in
Canada
Allelix capillary immunoassays R&D and marketing 4/87

for home market agreement through
Richardson-Vicks
Biopulping lignin degrading fungi collaborative
Consortium research agreement
(University of
Wisconsin and
USDA)
Calgene Inc. rDNA rapeseed for development 1985

specialty oil as food agreement
additive
Curis Inc. treatments for hair research and 9/05
growth using Curis' development
Hedgehog agonist agreement
technology
Cygnus Inc. smoking cessation development and 2/94
products marketing
agreement
Epoch Epoch's periodontal development 10/93
Pharmaceuticals diagnostic test agreement--P&G
Inc. will have first option
to license the test
for exclusive
distribution in the
U.S. and Canada
®
Gene Logic Inc. genetic targets for drug $75M drug 6/97
development in heart development
failure and two ageement
undisclosed diseases
Geron Corp. Geron's human research agreement 7/04
telomerase reverse
transcriptase
technology
Lederle Ziac (bisoprolol and hct) joint marketing 12/92
Laboratories agreement
Locus treatment for diabetes research agreement 7/04
Pharmaceuticals
Inc.
MGI Pharma Inc. Didronel IV infusion MGI bought 1/90
exclusive rights to
IV form for oncology
market (P&G to
retain rights to oral
form)
Oxford Molecular Oxford's RS3 Discovery licensing agreement 5/98
Group plc. and RS3 Discovery
High-Throughput
Screening research
information
management software
in P&G's discovery
research programs
Quidel Corp. Quidel's QuickVue 1- one-year, 1/97
step H. pylori test and renewable
P&G's Helidac therapy copromotion
agreement
Regeneron treatments for muscle drug discovery 7/98
Pharmaceuticals diseases and disorders collaboration
Inc. (12/96), P&G made
equity investment
by purchasing
$10M of Regeneron
stock (3/97),
expanded to include
obesity related to
Type II diabetes
(9/97), P&G made
$5M milestone
payment
Sanofi-Aventis Actonel (risedronate continuation of R&D 10/04
sodium tablets); and
includes option for P&G commercialization
to acquire oral health agreement
care brands from
sanofi-aventis
Synergen Inc. collagenase inhibitor for development 3/86
treatment of periodontal agreement
disease
TheraTech Inc. estradiol and worldwide 3/95
estradiol/progestin development and
distribution
agreement
excluding parts of
Asia
TheraTech Inc. transdermal development 12/97
testosterone and agreement--P&G
combination will fund all
estradiol/testosterone development,
hormone replacement TheraTech gets
patches for women R&D payments and
®
milestones of $35M
as well as royalties,
TheraTech will
manufacture
products and
retains certain
copromotion rights,
P&G gets
worldwide rights
(except Asia)
Trega Biosciences Trega's combinatorial screening 1/95
Inc. chemistry libraries agreement. P&G
identified series of
lead compounds
and has exercised
option to exclusive
worldwide license to
further develop
these compounds,
Trega received
undisclosed
milestone payment
(5/98)
Zila Inc. Zila's diagnostic test for exclusive marketing 2/96
oral cancer rights
RESEARCH & DEVELOPMENT: P&G Health Sciences Institute focuses on gastrointestinal health, pain relief,
respiratory products and safe drinking water
Recent R&D efforts include:

--Dryel®, a way to care for dry-clean-only clothes in the home
--The first recombinant detergent enzymes, developed in collaboration with
Genencor, for use in liquid laundry detergents
--Actonel®, the first osteoporosis therapy to consistently demonstrate a
reduction in the incidence of spinal fractures after one year of treatment
--Physique®, a hair care line using polymers and cleaning/conditioning
systems
--Impress®, a new form of food wrap
--Febreze®, a spray that uses chemistry to capture odor-causing materials
--Iams® Hairball Care™, which uses fiber technology in cats' diets to
prevent hair ball formation
--Crest Whitestrips™, a way to whiten teeth 10 times better than the leading
whitening toothpaste
PRODUCTS ON MARKET: Markets more than 300 branded products in more than 160 countries,
including:
FABRIC AND HOME CARE: Tide, Ariel, Downy, Lenor, Dawn, Fairy, Joy,
Gain, Ace Laundry and Bleach, Swiffer, Dash, Bold, Cascade, Mr. Clean,
Febreze, Bounce, Cheer, Era, Bonux, Dreft, Daz, Flash, Vizir, Salvo, Viakal,
Maestro Limpio, Rindex, Myth, Alomatik
BEAUTY CARE: Pantene, Olay, Head & Shoulders, Clairol’s Herbal

Essences, Nice ‘n Easy, Natural Instincts and Hydrience, Cover Girl, SK-II,
Max Factor, Hugo Boss, Safeguard, Rejoice, Secret, Old Spice, Zest, Vidal
Sassoon, Pert, Ivory, Lacoste, Aussie, Infusium 23, Camay, Noxzema,
Infasil, Joy Parfum, Valentino, Sure, Wash&Go, Wella, Koleston, Wellaflex,
Shockwaves, Rochas, Escada, Gucci, Always, Whisper, Tampax, Naturella,
Evax, Ausonia, Orkid
BABY AND FAMILY CARE: Pampers, Luvs, Kandoo, Dodot, Charmin,

Bounty, Puffs, Tempo
®
HEALTH CARE: Crest, Iams, Eukanuba, Actonel, Vicks, Asacol, Prilosec

OTC, Metamucil, Fixodent, PUR, Scope, Macrobid, Pepto-Bismol, Didronel,
ThermaCare, Blend-a-med
SNACKS AND BEVERAGES: Pringles, Folgers, Millstone
Prokaria ehf
Gylfaflot 5
Reykjavík IS - 112, Iceland
Phone: +354 570 7903; Fax: +354 570 7901
Web: www.prokaria.com
E-mail: info@prokaria.com
KEY PERSONNEL: Prof. Jakob K. Krist; President and CEO
Valborg Guomundsdottir; CFO
Dr. Gudmundur Oli Hreggvidsson; VP, R&D
Dr. Arnbor AEvarsson; Manager, Bioinformatics and Marketing
Dr. Sigríour Hjorleifsdottir; Manager, Operations
HISTORY: Founded in June 1998 as Islenskar hveraorverur
Merged with Islensk natturuefni (Icelandic Natural Substances) (1/00)
PRIVATE PLACEMENTS: Raised US$13.5M (9/00)
BUSINESS STRATEGY: Discover, develop and produce industrial enzymes for food, feed and
chemical applications
Develop, produce and market thermostable molecular enzymes, such as
DNA polymerase, ssDNA ligase and other for genetic research and
diagnostics
Offer DNA analytical services for fish, animals and the environment

bitop AG screening and partnership 5/03
development program agreement
for novel compatible
solutes from
extremophilic
microorganisms
Blue Lagoon Ltd. investigations of the research agreement 6/03
biodiversity
deCODE genetics strategic alliance 12/98
Marine Research fish genetics collaboration 1/04
Institute of Iceland agreement
(MRI)
Nestle Research screening program research agreement 12/03
Center program for the
discovery of natural
components for food
applications
Novartis Animal Prokaria's novel licensing agreement 5/03
Health Inc. biomolecules for
screening purposes
Novozymes A/S Prokaria's industrial licensing agreement 3/03
enzyme specialties
Roquette Frere novel industrial development 3/03
enzymes agreement
®
PRODUCTS ON MARKET: Services:

DNA sequencing
Genotyping
Microbial species analysis: Species composition of unculturables, species
identification of cultivated organisms
Screening assay development
Preparation of HTS extracts for small molecular screening (pharma,
cosmetics)
Discovery and development of extremophilic genes and enzymes
Provision of test samples
Prometic BioSciences Inc.

155 Willowbrook Boulevard, Suite 460
Wayne NJ 07470, US
Phone: (973) 812-9880; Fax: (973) 812-9881
Web: www.prometic.com
E-mail: investor@prometic.com
KEY PERSONNEL: Pierre Laurin; Chairman, President and CEO, Prometic Life Sciences Inc.
Steven J. Burton; CEO, Prometic BioSciences Ltd.
Christopher L. Penney; VP and CSO, Therapeutics

Acquired Affinity Chromatography Ltd. UK
SUBSIDIARY OF: Prometic Life Sciences Inc. (see separate entry)
BUSINESS STRATEGY: Discover and develop proprietary drugs in the fields of cancer and
autoimmune diseases
Actively looking for partners to co-develop and eventually market PBI-1402
and PBI-1393
American Red prion removal/det collaborative R&D 1999
Cross
American Red plasma proteins collaborative R&D 1997
Cross agreement
BioMena SA ProMetic's Enabling licensing agreement 12/04
Technology
Euroflow process columns large scale process 2003
data
GlaxoSmithKline Prometic's purification development 7/04
plc technology agreement
Menarini purification of avidiplas R&D manufacture 2001
agreement
Novo Nordisk proteins collaborative R&D 1995
University of
Cambridge UK
Octapharma AG ProMetic's advanced development 1/05
Mimetic Ligand affinity agreement
technology for
Octapharma protein
product
®
RESEARCH & DEVELOPMENT: Specific affinity ligands for targeting therapeutic proteins
Large scale plasma Avidiplas purification
Therapeutic protein screening from yeast, plasma and transgenic milk
PRODUCTS ON MARKET: Mimetic™ affinity adsorbents
Bioprocess chromatography media
mAB binding adsorbents
PBI-1402 for peripheral arterial disease in Phase Ib/II clinicals
PBI-1393 ready to begin clinicals
Proteus SA
70, allee Graham Bell, Parc Georges Besse
Nimes 30000, France
Phone: +33 (0)4 66 70 64 64; Fax: +33 (0)4 66 70 64 60
Web: www.proteus.fr
E-mail: info@proteus.fr
KEY PERSONNEL: Daniel Dupret; Chairman, President and CEO
Marc Vander Linden; CFO
Gilles Ravot; CSO
Jean-Marie Sonet; VP, Business Development and Marketing
Jean Francois Bloch; VP; Intellectual Property and Licensing
FACILITIES: 2,500 sq. m. R&D facility
PRINCIPAL INVESTORS: Axa Placement Innovation

FCJE
Natexis Ventech
Sofilars
Sofimac
Soridec
Viveris Management
BUSINESS STRATEGY: Contract research
A strategic biotech R&D resource for the industry
Aventis Animal enzymes for animal R&D agreement 1999
Nutrition feed
CEA LETI biochips for biodefense collaborative R&D 2000
(Commissariat a agreement
l’energie
atomique)
Degussa enzymes for specialty R&D agreements 1999
chemistry and alliance 2000
2004
ELF extremophilic micro- screening for novel 1999
organism enzyme from
extremophilic micro-
organism
Girffioth extremophilic micro- screening for novel 2000
University, organism enzyme from
Brisbane, extremophilic micro-
Australia organism
®
Hebrew University extremophilic micro- screening for novel 1999

of Jerusalem organism enzyme from
organism
I.R.D. (Institute of extremophilic micro- screening for novel 1999
R&D) organism enzyme from
organism
Ifremer extremophilic micro- screening for novel 1999
organism enzyme from
organism
Russian Academy extremophilic micro- screening for novel 2005
of Science organism enzyme from
organism
Thales systems for detection R&D agreements 1999
and identification of 2000
biological attack 2002
2003
University of Bern chemistry for high collaborative R&D 2000
throughput funcitonal agreements 2004
screening
University of extremophilic micro- screening for novel 2005
Buenos Aires organism enzyme from
organism
RESEARCH & DEVELOPMENT: Novel proteins, novel industrial enzymes, new industrial chemo-biocatalytoc
routes, biodiversity screening, protein engineering, development of gene
based assay for the industry
Qbiogene
15 Morgan
Irvine CA 92618-2005, Canada
Phone: (440) 337-1200; Fax: (949) 421-2675
Web: www.qbiogene.com
E-mail: info@qbiogene.com
KEY PERSONNEL: Milan Panic; Chairman and CEO, MP Biomedicals
Dr. Garth Cumberlidge; President and CEO
Steve Peronne; CFO
Began sales in 1996
Aquired Appligene-Oncor, Strasbourg, France
Merged with Bio-101, Inc. and changed name from Quantum
Biotechnologies (7/00)
Acquired Alexis Biochemicals, Switzerland
Acquired Bio-101, Carlsbad, California
Acquired by MP Biomedicals
SUBSIDIARY OF: MP Biomedicals
BUSINESS STRATEGY: Develop and market novel and innovative products for gene delivery, gene
therapy applications and molecular biology applications related to the study
of the structure and function of the human genome
®

BTC nucleotides, enzymes, supply agreement 1995
probes
Hoffmann-La native and recombinant development, 3/98
Roche Ltd./Perkin- Taq DNA polymerase manufacturing and
Elmer Corp. and other thermostable marketing
enzymes for use in agreement
polymerase chain
reaction process
INRA CNRS baculovirus expression technology 1996
systems development
agreement
NCI AFP expression vectors distribution license 1996
and CRADA
NRC Canada adenovirus expression exclusive 2/92
system worldwide
agreement
NRC Canada recombinant yeast lytic exclusive 10/91
enzyme worldwide
agreement
NRC Canada site-directed exclusive 10/91
mutagenesis worldwide
agreement
Universite de pGATA cloning system technology 1996
Montreal development
agreement
RESEARCH & DEVELOPMENT: Gene delivery systems

Custom services - Adinoviral
PRODUCTS ON MARKET: FISH kits and buffers
DNA polymerases
Baculovirus expression system and custom services
Peptide coupling reagents
Cloning vectors
Gene delivery systems
DNA panels
Yeast lytic enzyme
Adenovirus and bacterial (Alkaline Phosphatase [PhotA*} fusion)expression
systems
Autofluorescent proteins
Positive selection vector
Custom peptide synthesis
Embyonal tissue mRNAs and cDNAs
Custom services (Adenovirus, antibodies and peptides)
Bio-101 systems
Media
Purification--DNA/RNA
Fast Prep system
Second-generation adenoviral vectors in development
Transfection systems in development
Two-hybrid systems in development
®
Quip Laboratories Inc.

1500 Eastlawn Avenue
Wilmington DE 19802, US
Phone: (302) 791-2600; Fax: (302) 761-2611
Toll-free phone: (800) 424-CHEM (2436)
Web: www.quiplabs.com
E-mail: quip@quiplabs.com
KEY PERSONNEL: Timothy B. Hidell; President
FACILITIES: 30,000 sq. ft. building for administrative offices, R&D, quality control, and
production and shipping facilities
PRODUCTS ON MARKET: ACID CLEANERS:

Acid Detergents: Acidulate, Acidulate 28, Acidulate 30HF, Acidulate 45-C,
Acidulate 45T, Acidulate 50, Acidulate 60, Acidulate 150, Acidulate ATG,
Acid 50-W
Acid Neutralizers: Enviro-Kleen 100, Enviro-Kleen 500, Enviro-Kleen 1500
Acid Neutralizers Caustics: Enviro-Kleen 500N, WWN-1
ALKALINE CLEANERS
Alkaline Detergents: Enviro-Kleen 100, Enviro-Kleen 500, Enviro-Kleen 700,
Enviro-Kleen 900, Enviro-Kleen 900S, Enviro-Kleen 1100, Enviro-Kleen
1200, Enviro-Kleen 1500, Spray Kleen LV, WWN-1
Alkaline Neutrailizers: Acidulate, Acidulate 45C, Acidulate 50
Hard Surface Disinfectants/Cleaners: Anlage 20, Anlage QTB, Iodex AR/18,

MB-2000, MB-10 tablets
Chlorine Dioxide Products: MB-10 tablets, MB DeoTrex-30 sachets
ICS Iodine Solutions: ICS iodine blocks, ICS iodine drain gel powder, ICS
iodine links, Iodex GS25, Iodex hand soap, Iodex AR/18
Ramot at Tel Aviv University Ltd.

P.O. Box 39296, 32 Haim Levanon Street
Tel Aviv 61392, Israel
Phone: +972 3-640-6608; Fax: +972 3-640-6675
Web: www.ramot.org; E-mail: ramot@ramot.org
KEY PERSONNEL: Prof. Hagit Messer-Yaron; Chairman
Yehuda Niv, Ph.D.; CEO
Ze'ev Weinfeld, Ph.D.; Exec. VP, Business Development
Irit Ben Chlouch; Director, Business Development, Life Sciences
Nissim Chen, Ph.D; Director, Business Development, Life Sciences
Amiram Porath; Business Development European Projects Coordinator
Tamar Raz, Ph.D.; Director, Business Development, Life Sciences
Hanan Terkel; VP, Business Development
Ronen Cohen; CFO
Larissa Shniderman; Director, R&D Budget and Control
FACILITIES: R&D facilities on Tel Aviv University campus
®

SUBSIDIARY OF: Tel Aviv University Economic Corp.
BUSINESS STRATEGY: Technology transfer company of Tel Aviv University, dedicated to promoting
research collaboration between the university and industry, through
licensing agreements, joint ventures, start up companies and sponsored
research collaborations
RESEARCH & DEVELOPMENT: The full spectrum of life sciences research

PRODUCTS ON MARKET: Technologies available in agrotech, bioinformatics, biotechnology, computer
science, diagnostics, engineering, medical devices and pharmaceuticals
Randox Laboratories Ltd.

55 Diamond Road, Ardmore
Crumlin BT29 4QY, UK
Phone: +44 (0) 28 9442 2413; Fax: +44 (0) 28 9445 2912
Web: www.randox.com
E-mail: marketing@randox.com
KEY PERSONNEL: Dr. S. Peter Fitzgerald; Managing Director
Wilhelmena Fitzgerald; Director
R. J. Fitzgerald; Facilities Director
C. D. M. Fitzgerald; Sales Director
FACILITIES: 200,000 sq. ft. of production, R&D and office facilities
FINANCIAL INFORMATION: Wholly owned by Fitzgerald family
BUSINESS STRATEGY: Reinvest all profits in company to continue a policy of extensive
development of new products
PRODUCTS ON MARKET: evidence®

evidence investigator™
RX daytona™
Antioxidant tests
Riqas (EQA scheme)
247 software package
Clinical chemistry products
ELISA kits for detection of drug residues in meat, serum and urine
Proteins
Recombinant proteins
Polyclonal antibodies
Reanal Finechemical Co.

Telepes UT 53.
Budapest 1147, Hungary
Phone: +36 (1) 46 77 533; Fax: +36 (1) 384 3102
Web: www.reanal.hu
E-mail: sales@reanal.hu
KEY PERSONNEL: Dr. Istvan Nagy; President
Gyorgy Orosz, Ph.D.; Director, Marketing and Sales
Tamas Nagy; Head, Fine Chemicals, Agrochemicals
®
Zsolt Horvath; Head, Laboratory Reagents, Diagnostics

Andras Lengyel; Director, Production and Engineering
Iren Huszkane Szimuj; Director, Finance
RESEARCH & DEVELOPMENT: Protected amino acids and amino acids derivatives
Peptide reagents
Resins
PRODUCTS ON MARKET: Protected amino acids and amino acids derivatives
Peptide reagents
Resins
Crown ethers
Biological buffers
Cellulose ion exchangers
Agrochemicals
Other fine chemicals
RECO Biotechnology
710 Hospital Street
Richmond VA 23219, US
Phone: (804) 644-2800; Fax: (804) 643-1335
Web: www.recobio.com
E-mail: info@recobio.com
KEY PERSONNEL: Mike Schleinkofer; President and CEO
Shane Kasper; Project Engineer
Charles A. Firth; Sales Manager
Reco Biotechnology is the trade name for Aqua Clean Environmental of
Virginia LLC
165,000 sq. ft. indoor treatment, recycling and waste management facility
SUBSIDIARIES/DIVISIONS: Biotechnology Environmental Division
BUSINESS STRATEGY: Operate as a comprehensive provider for non-hazardous waste
management services
Offer obioremediation, physical and chemical liquids treatment, fuel
recycling, processing and disposal for a variety of industrial and
environmental clean-up residuals
RESEARCH & DEVELOPMENT: Remediation of environmental contaminants using xenobacteria
®
Recordati SpA
Via M. Civitali, 1
Milan 20148, Italy
Phone: +39 2-487871; Fax: +39 2-40073747
Web: www.recordati.com; E-mail: inver@recordati.it
KEY PERSONNEL: Giovanni Recordati; Chairman and CEO
Walter Bevilacqua; VP and Director, Corporate Development
Giorgio Oberrauch; VP and GM, Pharmaceutical Chemicals
Abraham Sartani; VP and Director, Pharmaceutical R&D Division
Fritz Squindo; CFO
Franco TomasniI; VP and Director, Purchasing and Logistics
Acquired Merckle GmbH's branded pharmaceutical business (2/05)
To acquire Jaba Farmaceutica (as of 7/06)
STOCK-FINANCIAL HISTORY: Italian Stock Exchange--(Reuters REC.MI) (Bloomberg REC IM) (ISIN IT
003074447)
IPO--1984
Net income EUR64.5M (YE 05) compared to EUR53.1M (YE 04)
PRIVATE PLACEMENTS: Raised $100M in private placement (10/04)
SUBSIDIARIES/DIVISIONS: Recordati SA--Luxembourg
Innova Pharma SpA--Italy
Bouchara Recordati SAS--France
Recodati Hellas Pharmaceuticals SA--Greece
Recordati Corp.--U.S.
Recordati SA--Switzerland
Recordati Espana SL--Spain
Merckle Recordati GmbH--Germany
Recordati Ireland Ltd.
Recordati Pharmaceuticals Ltd.--U.K.
Allergan Imidazyl, Herbe distribution 1994
agreement
Angelini prulifloxacin non-exclusive 9/04
licensing agreement
ASINEX Ltd. micturition disorders drug discovery 10/04
collaboration
BYK Gulden Peptazol (pantoprazole) non-exclusive 1/02
licensing agreement
Dexcel Ltd. oral formulation of exclusive liensing 10/02
cyclosporin agreement
Digital Gene Digital's gene licensing 4/97
Technologies Inc. expression technology agreement--Digital
and Recordati's calcium received $3M up
channel blocker front and could
(Lercanidipine) against receive milestone
atherosclerosis payments and
royalties
Eurand modified-release development 9/04
International SpA formulation of agreement
lercanidipine (Zanidip)
Grupo Uriach rupatadine licensing agreement 9/04
InfaCare development and exclusive licensing 6/05
Pharmaceutical marketing of Stanate agreement
Corp. (stannsoporfin)
Kissei silodosin licensing agreement 10/04
Pharmaceutical
Co. Ltd.
®
Kowa pitavastatin licensing agreement 10/01

Labopharm once-daily tramadol licensing and 11/05
Europe distribution
agreement for the
UK
Lavipharm transdermal patch multi-territorial 7/05
Laboratories Inc. containing the narcotic license agreement
analgesic fentanyl
LifeCycle Pharma modified-release development 4/04
A/S formulation of agreement
Lercanidipine
Lundbeck escitalopram (Gaudium) marketing and 1/02
licensing agreement
Mylan nitroglycerin exclusive licensing 5/01
Technologies Inc. transdermal patch agreement
Ono alprostadil alpha- licensing-in 1989
Pharmaceuticals ciclodextrin agreement
Pharmacia Corp. treatments for development 8/00
overactive bladder agreement
Syntex-Roche Cymevene, Gynestrel, licensing-in 1961
Naprosyn, Synflex, agreement
Syntaris, Toradol
Tsumurab lercanidipine licensing-out 1996
agreement for
Japan
Warner-Lambert Acequin (quinapri), licensing-in 1988
Co. Acequide (quin+HCTZ) agreement
RESEARCH & DEVELOPMENT: Urogenital and cardiovascular therapeutic areas

PRODUCTS ON MARKET: Fienamina®
Proctolyn®
Lomexin®
Influvit®
Tossoral™
Lacto™
Imidazyl®
Imidazyl® Antistaminico e Eumill™
Antispasmina Colica®
Solvobil®
Alovex®
Antoral®
Dent Oral®
Naprosyn Gel®
Valontan®
Transcop® transdermal patch
Indusil®
Alomed ™
Regis Technologies Inc.

8210 Austin Avenue
Morton Grove IL 60053, US
Phone: (847) 967-6000; Fax: (847) 967-1214
Web: www.registech.com
E-mail: sales@registech.com
KEY PERSONNEL: Louis Glunz IV.; President
Louis Glunz III, Ph.D.; CEO
Sean Bradley, Director, Business Development, Custom Manufacturing
Division
®
FACILITIES: Full service cGMP custom manufacturing facility
BUSINESS STRATEGY: Develop proprietary separations technology for the life sciences industry
Provide contract manufacturing for pharmaceuticals in a GMP facility
Research Corp. chiral stationary phases research agreement 4/93
Technologies
RESEARCH & DEVELOPMENT: Chiral HPLC columns

IAM column for predicting drug permeability
Custom organic synthesis
Analytical method development
Process research
PRODUCTS ON MARKET: Regisil (BSTFA)
Whelk-O
Pinkerton column
Luciferin
Renessen LLC
520 Lake Cook Road, Suite 220
Deerfield IL 60015, US
Phone: (847) 236-5101; Fax: (847) 236-5146
Web: www.renessen.com
E-mail: info@renessen.com
KEY PERSONNEL: Michael Stern, Ph.D.; CEO
Neal Jakel; Ethanol Project Manager
Joint venture between Cargill Inc. and Monsanto Co.
FACILITIES: Building a pilot plant with higher-value ethanol production at Cargill's Iowa
Bioprocesssing Center campus in Eddyville, Iowa (scheduled to open in
1/07)
SUBSIDIARIES/DIVISIONS: Argentina office:

Panamericana
Ramal Pilar. km 49.5
Edificio Bureau
Office 2.2.7 (1629)
Pilar, Buenos Aires, Argentina
Phone: +54 2322.473.821
Fax: +54 2322.473.816
E-mail: argentina@renessen.com
SUBSIDIARY OF: Cargill Inc. and Monsanto Co.
BUSINESS STRATEGY: Develop improved ingredients/inputs for the feed and processing industry
Use biotechnology and breeding to produce corn and soybeans with higher
levels of nutrients (such as oil, protein and amino acids) that are important in
feeding animals and processing grain
®
RESEARCH & DEVELOPMENT: Agricultural biotechnology: Application of plant biotechnology to improve the
energy content, essential amino acids, protein and fiber composition of corn
and oilseeds for animal nutrition. Use biotechnology to improve crop
processing (for example, oil and starch processing, meal, ethanol and
biodiesel production)
Corn processing technology: Pilot plant under construction will test

processing technologies that extract the trait value of the new Mavera high
value corn. The technology is expected to make ethanol manufacturing
more profitable and to provide the opportunity for farmers to grow net
revenue enhancing crops on broad acres.
PRODUCTS ON MARKET: Mavera™ program for growers and animal producers
Renovo Group plc

The Manchester Incubator Building, 48 Grafton Street
Manchester M13 9XX, UK
Phone: +44 (0) 161 606 7222; Fax: +44 (0) 161 606 7333
Web: www.renovo.com
E-mail: info@renovo.com
KEY PERSONNEL: Rodger Pannone; Chairman
Prof. Mark Ferguson; CEO
Dr. Sharon O’Kane, Exec. Director, R&D
Andrew Kay; Exec. Director, Commercial
Robin Cridland; Exec. Director, Finance and Business Development
STOCK-FINANCIAL HISTORY: LSE--RNVO
IPO--87p/share, £50M
PRIVATE PLACEMENTS: Raised £21M (US$33M) in financing (12/02)
Raised £2M (US$3.2M) in over-subscription to its second round of financing
(1/03)
PRINCIPAL INVESTORS: Atlas Venture

BioVeda Capital (Pte.) Ltd.
Care Capital LLC
HealthCap
JPMorgan Partners
Temasek
BUSINESS STRATEGY: Leverage extensive scientific knowledge to develop commercial product

candidates in scar prevention and reduction
Be first-to-market with a pharmaceutical product to prevent and reduce
scarring
Continue to advance and expand the company's clinical and preclinical
pipeline
Extend the significant market potential for the company's lead product
candidates to multiple body sites and fibrotic disorders
Pursue a commercialization strategy working with partners to increase
speed and depth of market penetration
RESEARCH & DEVELOPMENT: Prevention and reduction of scarring throughout the body, including skin,
vascular restenosis, eyes, nerves, adhesions and strictures, tendons and
ligaments, fibrotic disorders
®
Ongoing research focused on:

Investigating the biology of scarring and wound healing
Genomic microarray analysis and the ensuing inhouse databases
Comparison of scar-free embryonic healing with scar-forming adult healing
Hypothesis testing using in vitro and in vivo experimentation
Keloids
Focused proteomics
Focused chemistry
Juvista in Phase II clinicals
Juvidex in Phase II clinicals
Prevascar in Phase II clinicals
Zesteem in Phase II clinicals
Research Organics Inc.

4353 East 49th Street
Cleveland OH 44125, US
Phone: (216) 883-8025; Fax: (216) 883-1576
Web: www.researchorganics.com
E-mail: info@resorg.com
KEY PERSONNEL: Rob Sternfeld; President and CEO
FACILITIES: 40,650 sq. ft. production facilities, laboratories, offices, quality control
division, shipping and receiving, and warehouses
BUSINESS STRATEGY: Develop, manufacture, and supply highly purified biochemicals for molecular
biology, cloning applications, diagnostic chemicals and cell culture
RESEARCH & DEVELOPMENT: Biological buffers

Fluorescent labels, bulk biochemicals, research biochemicals, enzyme test
substrates
Buffers
PRODUCTS ON MARKET: Biological buffers, reagent biochemicals, molecular biology grade products,
enzyme substrates, fluorescent compounds, amino acids and derivatives,
ACS reagents, USP and FCC products, neurochemicals and plant tissue
culture reagents
Research Triangle Park Laboratories Inc.

8109 Ebenezer Church Road
Raleigh NC 27612-7307, US
Phone: (919) 510-0228; Fax: (919) 510-0141
Toll-free phone: (800) 291-4RTP (4787)
Web: www.rtp-labs.com; E-mail: customerservice@rtp-labs.com
KEY PERSONNEL: Alston Sykes; President
Spun off from a division of Corning Inc. in 1997
®

BUSINESS STRATEGY: Support biotech and pharmaceutical industries with R&D analytical services
RESEARCH & DEVELOPMENT: Air toxics testing for hazardous and cancer causing chemicals in products,
pollution sources, landfill gases, ambient and indoor air, and
pesticide/herbicide testing
Chemical emissions testing of building materials, office equipment, printers,
toys, microwavable food and its packaging, paper products, printing inks,
foam insulation products, adhesives and pest control devices
Herbal/botanical nutraceuticals and pharmaceutical industries: Testing for
active compound purity, identification of impurities, stability, cleaning
validations, controlled substances and special projects
Manufacturing industries: Testing of products to support R&D and regulatory
testing activities
Response Biomedical Corp.

100-8900 Glenlyon Parkway
Burnaby V5J 5J8, Canada
Phone: (604) 456-6010; Fax: (604) 456-6066
Web: www.responsebio.com
E-mail: info@responsebio.com
KEY PERSONNEL: Dr. Richard Bastiani; Chairman
Bill Radvak; President and CEO
Brian G. Richards; COO
Robert G. Pilz; VP, Finance and CFO
Joanne Stephenson; VP, Business Development
Paul Harris, Ph.D.; VP, R&D
Reed Simons; VP, Manufacturing
FACILITIES: 12,000 sq. ft. leased space
STOCK-FINANCIAL HISTORY: TSX-V--RBM / OTCBB--RPBIF
Revenue C$3.49M (YE 05) compared to C$2.677M (YE 04)
Net loss <$8.4M> (YE 05) compared to <C$4.939M> (YE 04)
Loss per share <C$0.12/share> (YE 05) compared to <C$0.08/share> (YE
04)
PRIVATE PLACEMENTS: Raised $1.741M in private placement (12/03)

SUBSIDIARIES/DIVISIONS: Response Biomedical Inc.
Response Development Inc.
BUSINESS STRATEGY: Develop and commercialize point-of-care (POC) diagnostic tests for use with
its RAMP System for clinical and environmental applications, providing
reliable information in minutes, anywhere, every time.

3M Co. POC clinical infectious development 11/04
disease test based on agreement
Response Biomedical's
RAMP technology
®
Adapco Inc. RAMP West Nile virus exclusive US 12/03

test distributor
General Dynamics BiodefenseTechnology Military and 2/04
Canada Ltd. Integration Program Homeland Security
Agencies
Internationally
International rapid quantitative test to development 6/04

Biotech Company detect biotech traits in agreement
grain
Roche NT-proBNP nonexlusive 7/05
Diagnostics licensing agreement
Shionogi & Co. rapid quantitative BNP development 10/04
Ltd. test for congestive heart agreement
failure in Japan
Shionogi & Co. commercialization of a marketing and 5/06
Ltd. rapid quantitative RAMP supply agreement
test in Japan for BNP
RESEARCH & DEVELOPMENT: Diagnostic testing systems for point-of-care health, environmental and food
quality testing
MIniRamp™ - quantitative handheld analyzer
PRODUCTS ON MARKET: RAMP® System
RAMP® Troponin I Assay
RAMP® Biodetection System
RAMP® West Nile Virus (WNV) Test
Roal Oy
P.O.B. 57, Tykkimaentie 15
Rajamaki 05200, Finland
Phone: +358 (9) 290-420; Fax: +358 (9) 290 42 111
Web: www.roal.fi
E-mail: roal@roal.fi
KEY PERSONNEL: Heinz-Peter Schwarte; Managing Director
Pentti Honkamaki; Financial Manager
Dr. Jari Vehmaanpera; Research Director
Began biotech R&D in September 1997
SUBSIDIARY OF: ABF Overseas Ltd. (50%), Altia Corp. (50%)
RESEARCH & DEVELOPMENT: Gene technology for fungi and bacteria

PRODUCTS ON MARKET: Industrial enzymes for baking, beverage, feed, textile, and pulp and paper
applications
®
RTI International
P.O. Box 12194, 3040 Cornwallis Road
Research Triangle Park NC 27709-2194, US
Phone: (919) 541-6000 Toll-free phone: (866) RTI-1958
Web: www.rti.org
E-mail: listen@rti.org
KEY PERSONNEL: Victoria Franchetti Haynes, Ph.D.; President
Lon E. Maggart; Sr. VP and Chief of Staff
James J. Gibson; Exec. VP and CFO
J. Scott Merrell; Sr. VP and CLO
HISTORY: Founded in 1958 to conduct R&D as contractor for industry and government
worldwide
RTI offers innovative research and technical solutions to governments and
businesses worldwide in the areas of health and pharmaceuticals, education
and training, surveys and statistics, advanced technology, democratic
governance, economic and social development, energy and the environment
FACILITIES: 180-acre campus
40,000 sq. ft. facilities in other locations
STOCK-FINANCIAL HISTORY: Nonprofit corporation
BUSINESS STRATEGY: Provides R&D services to biotech and pharmaceutical companies in drug
discovery, clinical pharmacology, pharmaceutical R&D, preclinical
pharmacology and safety, drug delivery, natural products,
pharmacoeconomics, statistics, chemical engineering and biomedical
engineering
RESEARCH & DEVELOPMENT: Psychoactive agents, cancer drugs, hormonal agents, natural products
PRODUCTS ON MARKET: Sudaan version 7.5--software for statistical analysis of correlated data
SafePath Laboratories LLC

5909 Sea Lion Place, Suite D
Carlsbad CA 92008, US
Phone: (760) 929-7744; Fax: (760) 431-7759
Web: www.safepath.com
E-mail: info@safepath.com
KEY PERSONNEL: Paul Hansen; Chairman, President and CEO
David Lambillotte; Exec. VP and Director, R&D
Changed name from LMD Agro-Vet, LLC. (1998)
BUSINESS STRATEGY: Continue its record of innovation in the development, manufacturing and
marketing of high performance immunoassays
RESEARCH & DEVELOPMENT: Diagnostics for food animials, water quality and other targeted opportunities
Immunoassay-based diagnostics for food animals, food quality, water
quality, and other targeted opportunities
PRODUCTS ON MARKET: Immunoassays:
Trichinae for swine
Toxoplasma for swine
®
E. coli O157 for meat

Verotoxin for meat
Salmonella
Giardia in water
Cryptosporidium in water
Giardia Iamblia
Camphylobacter
Listeria
Food Allergens: milk, soy, egg, peanut
Sakai Chemical Industry Co. Ltd.

1-1-23, Ebisuno-cho-nishi, Sakai
Phone: +81 72 223 4111; Fax: +81 72 223 8355
Web: www.sakai-chem.co.jp
E-mail: sales-t@sakai-chem.co.jp
KEY PERSONNEL: Kazunobu Abe; President
Established in February 1932
Merged with titanium dioxide business of Tohkem Products Corp. (4/00)
Acquired Kyodo Chemical Co. Ltd. (10/02)
FACILITIES: Branch offices in Tokyo and Osaka
Factories in Semboku, Nagano, Yumoto and Otsurugi
Research center in Osaka
STOCK-FINANCIAL HISTORY: Listed on Osaka Securities Exchange and Tokyo Stock Exchange
IPO--3/50 (Osaka), 10/61 (Tokyo)
SUBSIDIARIES/DIVISIONS: Sakai Division:
5-1, Ebisujima-cho, Sakai
Osaka 590-0985
Phone: +81 72-223-4114
Fax: +81 72-223-6365
Onahama Division:
110, Aza Tajuku, Izumi-machi Shimogawa
Iwaki, Fukushima 971-8183
Phone: +81 246 56 5111
Fax: +81 246 53 5223
BUSINESS STRATEGY: Provide a stable supply of high quality products through the development of
advanced technologies, always striving to create new and useful value
SR Pharma SRP-299 exclusive 11/99
development and
sales agreement in
Japan
Bioglan ES-Gel exclusive 2/00
development and
sales agreement in
Japan
Theratechnologies TH9507 exclusive 5/02
development and
sales agreement in
Japan
®
PRODUCTS ON MARKET: Titanium dioxide

Stabilizers and metallic soaps
Barium and strontium products
Zinc products
Electronic materials
Pharmaceuticals
Catalysts
Fine organic chemicals
Sanyo Chemical Industries Ltd. (Sanyo Kasei)

11-1 Ikkyo Nomoto-cho, Higashiyama-ku
Kyoto 605, Japan
Phone: +81 75-541-4311; Fax: +81 75-551-2557
Web: www.sanyo-chemical.co.jp
E-mail: general-affairs@sanyo-chemical.com
KEY PERSONNEL: Tetsuo Kakehi; Chairman
Masaaki Ienaga; President
Fusayoshi Masuda; Exec. VP
Net sales ¥85,062M (YE 04) compared to ¥82,183M (YE 03)
Net income ¥3,101M (YE 04) compared to ¥3,255M (YE 03)
Earnings per share ¥27.31 (YE 04) compared to ¥27.97 (YE 03)
Total assets ¥112,633M (YE 04) compared to ¥115,013M (YE 03)
RESEARCH & DEVELOPMENT: Immobilized enzyme technology, enzyme immunodiagnostics, specialty

chemicals
Pharmaceuticals
Diagnostic MAbs
Agglutination agent
PRODUCTS ON MARKET: TOILETTRIES AND HEALTHCARE: Superabsorbent Polymers, Surfactants
for Hair Care Products, Surfactants for Detergents, Base Materials for
Cosmetics, Base Materials for Pharmaceuticals, Antibacterial Agents, EIA
Diagnostic Reagents, Potting Resins for Artificial Kidneys, Pressure-
sensitive Adhesives, Hot Melt Adhesives
MACHINES AND AUTOMOBILES: Base Materials for Polyurethane Foam,

Polyurethane Beads for Powder Slush Molding, Lubricating Oil Additives,
Additives for Fuel Oils, Dewaxing Aids, Base Materials for Synthetic
Lubricants, Water-soluble Cutting Fluid, CFC-free Cleaning Agents
PLASTICS: Pigment Dispersants, Permanent Antistatic Agents, Resin

Modifiers, Base Materials for Polyurethane Elastomer, Epoxy Resin Curing
Agents, Epoxy Systems, Emulsifiers for Emulsion Polymerization, Paint
Resins
TEXTILES: Agents for Textile Manufacturing, Scouring Agents, Dyeing

Auxiliaries, Textile Finishing Agents, Modifiers for Polyester Fibers, Flame
Retardants for Polyester Fibers, Polyurethane Resins for Synthetic Leather,
Agents for Fiber Glass
ELECTRONICS AND INFORMATION: Toner Resins, Electrolytes for

Aluminum Electrolytic Capacitors, Electrolytes for Electric Double-layer
Capacitors, Etching Fluids, UV/EB Curing Resins
®
ENVIRONMENTAL PROTECTION AND CONSTRUCTION: Polymer

Flocculants, Polymers for Enhanced Crude Oil Recovery, Synthetic Wood
for Models, Water-swellable Sealants, Adhesives for Elastic Paving
Materials, Permeable Paving Materials, Waterproofing Agents for Concrete,
Polyurethane for Heat-insulating Materials
Scion - Cellwall Biotechnology Centre

Te Papa Tipu Innovation Park, Private Bag 3020, 49 Sala Street
Rotorua, New Zealand
Phone: +64 7 343 5899; Fax: +64 7 348 0952
Web: www.scionresearch.com
E-mail: enquiries@scionresearch.com
KEY PERSONNEL: Dr. Tom Richardson; CEO
Dr. Tim Strabala; Unit Leader, CellWall Biotechnology Centre
Dr. Julia Charity; Sr. Scientist, CellWall Biotechnology
Dr. Phillip Wilcox; Sr. Scientist, CellWall Biotechnology
Dr. Christian Walter; Sr. Scientist, CellWall Biotechnology
Dr. Armin Wagner; Sr. Scientist, CellWall Biotechnology
Dr. Lynette Grace; Sr. Scientist, CellWall Biotechnology
Commenced molecular biology in 1990
BUSINESS STRATEGY: The current focus of the CellWall Biotechnology Centre is to provide
fundamental knowledge on plant cell wall development, genetics, and
biochemistry. The overall purpose is to spawn science discovery and
technological innovation, which will create new products and services for
both forestry and the emerging renewable plant materials markets.
RESEARCH & DEVELOPMENT: Genome mapping

DNA profiling
Marker aided selection
Genetic diversity surveys
Gene transformation in conifers and model plants
Gene isolation
Promoter isolation and analysis
Gene expression
Analysis and manipulation of lignin biosynthesis
In vitro propagation of forest trees
Analysis and manipulation of reproductive development in conifers
Isolation and characterisation of endogenous conifer promoters
Engineering of insect and pathogen resistance in conifers
Engineering of herbicide resistance in conifers
PRODUCTS ON MARKET: DNA testing for forest trees
Transformation protocols for conifer species
Somatic embryogenesis technology for conifer species
Endogenous promoters for gene expression
Propagation systems for forest trees
®

DNA markers for wood properties in development
Transformation protocols for other conifer in commercial evaluation
species
Non-flowering radiata pine in development
Conifers with altered lignin content and/or in development
composition
Efficient methods for mapping ESTS in commercial development
Power of alternative experimental designs in development
for QTL detection
Sensient Technologies Corp.

777 East Wisconsin Avenue
Milwaukee WI 53202-5304, US
Phone: (414) 271-6755; Fax: (414) 347-4795
Web: www.sensient-tech.com
E-mail: corporate.communications@sensient-tech.com
KEY PERSONNEL: Kenneth P. Manning; Chairman, President and CEO
Peter Bradley; President, Color Group
Richard Carney; VP, Administration
Richard F. Hobbs; VP, CFO and Treasurer
Ralph G. Pickles; President, Flavors and Fragrances Group
Stephen J. Rolfs; VP, Controller and Chief Accounting Officer
Ho-Seung Yang, Ph.D.; VP, Marketing and Technology
HISTORY: Founded as Meadow Springs Distillery in 1882
Company's development focused on yeast through the 1950s
In the 1960s, the company diversified into consumer foods through
acquisitions and internal product development, including biotechnology
Acquired 20 companies since 1997
FACILITIES: 74 locations in 30 countries
World headquarters in Milwaukee, Wis.
Flavors and Fragrances Group--Indianapolis, Ind.
Color Group--St. Louis, Mo.
Asia Pacific Group--Singapore
STOCK-FINANCIAL HISTORY: NYSE--SXT
04)
SUBSIDIARIES/DIVISIONS: Flowers and Fragrances Group
Color Group
Asia Pacific Group
BUSINESS STRATEGY: Supply flavors, fragrances and colors used to make foods and beverages,
pharmaceuticals, cosmetics, home and personal care products, printing and
imaging products, computer imaging and industrial colors
PRODUCTS ON MARKET: Dyes, pigments and natural colors

Flavors and flavoring systems
Dehydrated vegetable products
Bioactive antioxidants
Bioactive plant extracts
Formulation systems for food, beverage and dietary supplement products
Pigments and dyes for cosmetics
®
Severn Biotech Ltd.

Unit 2, Park Lane
Kidderminster DY11 6TS, UK
Phone: +44 (0)1562 825286; Fax: +44 (0)1562 825284
Web: www.severnbiotech.com
E-mail: info@severnbiotech.com
KEY PERSONNEL: Andrew Smart; Managing Director/Owner
Kate Fox; Sales Manager
500 sq. ft. R&D facilities
PRODUCTS ON MARKET: DNA, RNA and peptide synthesis

General reagents
Electrophoretic media
Reagent buffers
Service solutions
Nucleotides
Showa Denko KK
13-9, Shiba-Daimon, 1-chome, Minato-ku
Phone: +81 3-5470-3235; Fax: +81 3-3436-2625
Web: www.sdk.co.jp
E-mail: sdk_prir@sdk.co.jp
KEY PERSONNEL: Mitsuo Ohashi; Chairman
Kyohei Takahashi; CEO and President
Hiroshi Nishimoto; Exec. Officer, Petrochemicals
Tetsuo Tamada; Exec. Officer, Inorganics
Norio Masubuchi; Exec. Officer, Chemicals
Koji Kudo; Sr. Corp. Officer and CTO
Ichiro Nomura; Director, Corp. Services, IR and Finance
EMPLOYEES: 11,118 employees (consolidated)
HISTORY: Founded in June 1939 through the merger of Nihon Denki Kogyo KK and
Showa Hiryo KK
STOCK-FINANCIAL HISTORY: Listed on the Tokyo, Osaka and four other domestic stock exchanges
SUBSIDIARIES/DIVISIONS: Showa Highpolymer Co. Ltd.
Showa Denko Plastic Products Co. Ltd.
Heisei Polymer Co. Ltd.
Kokusai Eisei Co. Ltd.
Nippon Polytech Corp.
Showa Titanium Co. Ltd.
Showa Denko Kenso Co. Ltd.
Tohoku Metal Chemical Co. Ltd.
Showa Aluminum Can Corp.
®
Showa Denko Aluminum Trading KK

Showa Denko Packaging Co. Ltd.
Showa Engineering Co. Ltd.
Showa Denko Kenzai KK
Shoko Co. Ltd.
Fuyo Perlite Co. Ltd.
Union Showa KK
PRINCIPAL INVESTORS: Japan Trustee Services Bank Ltd.
The Master Trust Bank of Japan Ltd.
Fukoku Life Insurance Co.
Sompo Japan Insurance Inc.
The Dai-ichi Mutual Life Insurance Co.
Nippon Life Insurance Co.
Mizuho Corporate Bank Ltd.
Meiji Yasuda Life Insurance Co.
Showa Denko Employee Stock Ownership
Trust & Custody Services Bank Ltd.
BUSINESS STRATEGY: Development of new compounds and leading-edge technologies through
biotechnology and organic synthesis technology
RESEARCH & DEVELOPMENT: Technology platforms:

Oranic electronic materials
Batteries
Capacitors
Magnetic/recording media materials
Crystal growth process
Thin film deposition process
Precision fabricating process
Micro-system process
Functional gases
Ultimate conditions process
Heat transfer system
Castion process
Plasticity process
Bonding
Functional metallic materials
Functional molecular design
Controlled reaction design
High-performance catalysts
Specialty polymer design
Fine particles
Biochemistry
Organic chemicals manufacturing process
Surface and interface chemistry
PRODUCTS ON MARKET: Petrochemicals: Ethylene, propylene, C4 fraction, cracked fuel oil,
acetaldehyde, acetic acid, vinyl acetate, ethyl acetate, allyl alcohol, allyl
ester resin
Chemicals: Oxygen, nitrogen, argon, mixed gases, fusing ethylene,

hydrogen, liquefied hydrogen, helium, Nitrogen/JP (laughing gas),
AnesoxynT (inhaled painkiller), FumitoxinT (aluminum phosphide),
AnesoxynT (system for treating excess anesthetic gas), Elaslen™
(Chlorinated polyethylene), Ecoflamer (environmentally-friendly elastomer),
Showflamer (non-plasticizer chlorinated elastomer), Showa Denko
Chloroprene (Chloroprene rubber), Showpalon (Chlorinated rubber),
industrial amino acids for food additives, feed additives, cosmetic
ingredients, amino acids for perm agents, chelating agents, biodegradable
chelating agents, raw materials for photographic chemicals, Acrylonitrile
(AN), High-purity FC-14, High-purity HFC-23, High-purity HFC-32, High-
purity FC-116, High-purity FC-C318, High-purity boron trichloride, High-
purity chlorine, High-purity hydrogen bromide, High-purity sulfur
hexafluoride, High-purity nitrogen trifluoride, High-purity ammonia, High-
purity nitrogen monoxide, High-purity HFC-41, High-purity FC-218, High-
®
purity FC-2316, High-purity tantalum pentaethoxide, High-purity nitrogen

monoxide (for electronic materials), treatment equipment for acid gases
discharged from the dry etching process, treatment equipment for global-
warming PFC emissions discharged from the dry etching process, fluorine
generators, erosion/wear resistance surface treatment, leak detectors,
fluorine/chlorine resistance bellows seal valves, ozone depleting gas
scrubber, Ascorbic acid PM (APM; water-soluble, stable vitamin C
derivative), Ascorbic acid PS (APS; water-soluble, stable vitamin C
derivative), Apprecier (highly permeable, water-soluble vitamin C derivative),
MaxlightT TS/F-TS (silica-coated TiO2), MaxlightT ZS (silica-coated ZnO),
AminofectT (biosurfactant), PhospitanT C (stabilized vitamin C for food
additive), Shodex™ (high-speed liquid chromatographic columns and
instruments), Autoprep™ (pre-treatment for analysis), functional monomers,
intermediates, Nanomax™ (UV interception zinc oxide masterbatch),
Nanoallomer™ (titanium dioxide masterbatch for optical catalyst),
Nanocoat™ (titanium dioxide suitable for optical catalyst coating),
Monogermane GeH4, Xenon difluoride, Triflic acids
(trifluoromethanesulfonic acids) CF3SO3H, Sodium borohydride NaBH4,
CHITOSAR (chitosan -containing fertilizer), IR-photosensitive dyes, organic
borate, DMP Metal Complex (Materials for MOCVD)
Inorganic materials: Alumina products, aluminum hydroxide products

(Higilite™), alumina electrical filler materials, fused materials for refractory,
fluxes, super abrasives, abrasive grains, lapping and polishing materials,
polishing materials, lubrication and mold-release agents, plasma spraying
materials, fine ceramics materials, shaped productions of fine ceramics
materials, materials for photocatalyst applications, materials for heat-
radiation fillers, graphite electrodes, Carbon nanofiber (VGCF™ series),
Negative-electrode material for lithium-ion batteries (SCMG™), Artificial
graphite powder (UF-G), Glassy carbon composite (SG, SR)
SibEnzyme Ltd.
Ak. Timakova Str., 2/12, 117, Academtown
Novosibirsk 630117, Russia
Phone: +7 383-333-4991; Fax: +7 383-333-6853
Web: www.sibenzyme.com; E-mail: info@sibenzyme.com
KEY PERSONNEL: Victoria Sit’ko, Ph.D.; Head, International Operations
EMPLOYEES: 70 employees, 12 Ph.D.s, 45 M.D.s
BUSINESS STRATEGY: Specialize in R&D, manufacture and bulk sale mostly of new enzymes.
Product range includes enzymes of nucleic acids methabolism and related
products for the research in molecular biology and genetic engineering
PRODUCTS ON MARKET: 170 Restriction Enzymes, most of them (including unique) were discovered
and characterized at SibEnzyme Ltd.
Other enzymes for molecular biology application, DNA preparations, DNA
Markers, Nucleotides
®
Solomon Park Research Laboratories

12815 NE 124th Street, Suite I
Kirkland WA 98034, US
Phone: (425) 650-2000; Fax: (425) 650-2008
Web: www.solomonpark.com
E-mail: pclapshaw@solomon.org
KEY PERSONNEL: Patric A. Clapshaw, Ph.D.; Director
Julie Nebeker; Office Manager
Mary Zimmer; Laboratory Manager
Kimberly Anderson; Shipping Manager
HISTORY: Founded in 1984 as a supplier of apolipoprotein
FACILITIES: 2,000 sq. ft. of fully equipped biochemistry, histology and tissue culture
facilities
BUSINESS STRATEGY: Supply phlebotomy services, as well as human blood products for external
quality controls, proficiency testing and calibrators
PRODUCTS ON MARKET: Serum and plasma for custom pools for calibrators, internal controls,
external controls, standards and proficiency testing materials
Lipid reference controls
Spark Holland BV
P. O. Box 388
Emmen 7800 AJ, Netherlands
Phone: +31 591-631700; Fax: +31 591-630035
Web: www.spark.nl; E-mail: sales@sparkholland.com
KEY PERSONNEL: Rob Castien; President
Marcel Jansen; Manager, Sales and Marketing
Rob van der Knaap; Manager, R&D
H. van Oort; Purchasing Manager
J. Crutchfield; General Manager, USA Operations
FACILITIES: 2,250 sq. m. facility
SUBSIDIARIES/DIVISIONS: Spark Holland Inc.--US sales and service office
666 Plainsboro Road, Suite 1336
Plainsboro, NJ 08536, USA
Phone: (609) 799-7250
Fax: (609) 799-8250
E-mail: usa@sparkholland.com
Provide the analytical laboratory with innovative sample introduction,
extraction and separation technology, enabling seamless integration of
automated front end sample preparation into analytical systems such as
HPLC, MS, GC and NMR. By pro-active gathering customer feedback we
seek to understand the analytical problems in the mentioned markets. This
knowledge will direct our R&D efforts. We aim to market our technology
®
under private label as front-end system solutions and through OEM

partnering as customized system components.
Our organization will operate with mutual trust and respect to our customers,
suppliers, employees, shareholders and other parties. Honesty and the right
values will be the basis for our activities. We want to create excellent
shareholder value and achieve sustainable growth by investing in research
and development. We will nurture innovation and continue to look for ways
to improve our products and services.
RESEARCH & DEVELOPMENT: Develop and manufacture automatic sample handling and sample
preparation systems for LC and LC MS
PRODUCTS ON MARKET: Symbiosis system ( automated sample preparation system)
Mistral column oven
Triathlon Endurance autosampler
Midas autosampler
Reliance autosampler
Basic Marathon autosampler
Spherix Inc.
12051 Indian Creek Court
Beltsville MD 20705, US
Phone: (301) 419-3900; Fax: (301) 210-4908
Web: www.spherix.com
E-mail: info@spherix.com
KEY PERSONNEL: Dr. Gilbert V. Levin; Chairman and Exec. Officer for Science
Richard C. Levin; CEO and President
Roger A. Downs; VP, Operations
Steven M. Wade; VP, Information Technology
Jeffrey T. Lowe; VP, Corporate Communications
Katherine M. Brailer; Corporate Secretary
Sold Environmental & Laboratory Service Division to ManTech
Environmental Corp. (3/96)
FACILITIES: 95,000 sq. ft. office facility
12,700 sq. ft. regional office located in Cumberland, Md.
STOCK-FINANCIAL HISTORY: NASDAQ--SPEX
Revenue $23.046M (YE 05) compared $22.348M (YE 04)
SUBSIDIARIES/DIVISIONS: InfoSpherix Inc. (wholly-owned subsidiary)
BioSpherix Division
BUSINESS STRATEGY: Create value and increase the wealth of our shareholders through
innovations that benefit our clients and the human condition
Albert Einstein certain medicinal uses licensing agreement 11/05
College of of Naturlose
Medicine
GleneaglesCRC Naturlose for the GleneaglesCRC to 5/06
treatment for Type II conduct Phase IIII
diabetes trials
MD Foods D-tagatose licensing agreement 1/97
Ingredients amba
(Denmark)
®
Tetra PhoStrip wastewater patent rights in 4/91

Technologies Inc. treatment technology exchange for
payments and
continuing royalties
on sales
RESEARCH & DEVELOPMENT: Nonfattening sugars, antidiabetes agent, information systems, and database
management in health and education
PRODUCTS ON MARKET: Call center for reservations
Telephone hotlines and information management for clinical trials applicants
(for major pharmaceutical companies)
PhoStrip® system for phosphorus removal from wastewater
Tagatose nonfattening sweetner
Naturlose for Type II diabetes to begin Phase III
SRI International
333 Ravenswood Avenue
Menlo Park CA 94025-3493, US
Phone: (650) 859-2000; Fax: (650) 859-2889
Web: www.sri.com/biosciences
E-mail: biosciences@sri.com
KEY PERSONNEL: Samuel H. Armacost; Chairman
Curtis R. Carlson; CEO and President
Thomas J. Furst; Senior Vice President and CFO
Dennis Beatrice; VP, Policy Division
Lawrence H. Dubois; VP, Physical Sciences
William Mark; VP, Information and Computing Sciences
Walter Moos; VP, Biosciences Division
John W. Prausa; VP, Engineering and Systems Division
Leonard Polizzotto; VP, Business Development and Marketing
Alice R. Resnick; VP, Corporate and Marketing Communications
Norman Winarsky; VP, Ventures and Strategic Programs
HISTORY: Founded as Stanford Research Institute in 1946
Spun out Artificial Muscle Inc. and Bridge Pharmaceuticals (2004)
To acquire Quality Clinical Labs (as of 4/06)
Member--American Association for Cancer Research
Member--American Association of Pharmaceutical Scientists
Member--American Chemical Society
Member--Drug Information Association
FACILITIES: Headquarters on 63-acre campus with more than 1.4M sq. ft. in Menlo Park,
Calif.
Offices located in the U.S., Europe and Asia
STOCK-FINANCIAL HISTORY: Private, nonprofit contract research organization
SUBSIDIARIES/DIVISIONS: Sarnoff Corp.--Princeton, N.J.
Five divisions: Engineering and Systems, Policy, Information and Computing

Sciences, Biosciences and Physical Sciences
BUSINESS STRATEGY: Grow by building and leveraging our assets--client relationships, our
intellectual property and staff--in important markets
®

Biosource oncology, infectious joint R&D 1/96
Technologies disease, and agreement
inflammation treatments
Dura SRI's jet milling process licensing agreement 7/97
Pharmaceuticals for protein and peptide
formulations of dry
powder drugs for use
with Dura's Spiros™
pulmonary drug delivery
technology
MDS Panlabs, combinatorial chemistry technology access 3/98
Tripos Inc., libraries for designing agreement--Tripos
Genelabs small molecule will design
Technologies Inc. compounds that bind compounds via
double-stranded DNA molecular modeling,
MDS Panlabs will
synthesize
compounds, SRI
(working
independently) will
use solid-phase
combinatorial
synthesis to make
molecules to
Genelabs
specifications
Taiho endocrine approach for research agreement 10/96
Pharmaceutical chemotherapy in
Co. Ltd. estrogen-dependent
breast cancer
RESEARCH & DEVELOPMENT: Pharmaceutical Discovery and Screening: custom drug design, synthesis
and efficacy screens for drug development of: antibacterials; antivirals;
anticancer agents; lipid-lowering agents; neurobiological therapeutics;
women's health therapeutics; steroids (anti-inflammation, hormone analogs,
vitamin analogs, neuroprotection); and other synthetic drugs (anticancer,
anti-inflammation, anti-angiogenesis, nootropics, cardiovascular, CNS,
neuroprotection), combinatorial chemistry; radiolabeled synthesis; process
development; scale-up
Biopharmaceutical Development: pharmacology, mammalian toxicology;
molecular and genetic toxicology; microbiology, pharmacokinetic and
metabolism studies; in vitro comparative metabolism; immunology and
immunotoxicology; cGMP manufacturing; formulation design;
preformulation; stability monitoring; analytical chemistry
Drug Delivery: transdermal; topical; controlled release; standard
formulations (oral, injectable, topical); alternative drug delivery (aerosols,
nasal, controlled release, microencapsulation, taste masking, bioerodable
polymers, protein peptide delivery)
Edatrexate (with Memorial Sloan Kettering) in Phase I clinicals
Tirapazamine (with Sanofi) in Phase III clinicals
SR 4980 in preclinicals
SR 4554 (with CRCT) in preclinicals
SR 16234 (TAS-108) (with Taiho) in preclinicals
*pipeline as of 10/05
®
Stewart Agricultural Research Services Inc.

P.O. Box 509
Macon MO 63552, US
Phone: (660) 762-4240; Fax: (660) 762-4295
Web: www.stewartag.com
E-mail: stewart1@marktwain.net
KEY PERSONNEL: Ellsworth R. Stewart; President and Treasurer
David R. Johnson, Ph.D.; VP
Patricia A. Stewart; Secretary
EMPLOYEES: 25 employees, 6 Ph.D.s, 6 M.D.s.
HISTORY: Independent company which has been providing services to the life science
and chemical industries since 1975
FACILITIES: 832 acre research farm in north central Missouri
Offices in Arlington, Va. and Columbia, Mo.
Facilities and headquarters in Macon, Mo.
BUSINESS STRATEGY: Provide a broad spectrum of services to its clients that enable them to
identify, register, develop, and commercialize successful products
PRODUCTS ON MARKET: Services include: screening, efficacy testing, study monitoring, regulatory
project coordination, efficacy project coordination, market assessment,
marketing agreements, new product technology, product development, QA
monitoring, registration, reregistration, organizational development,
technology management, licensing agreements, data package development,
strategic planning, training, seminars, diagnostics
Stratagene Corp.
11011 N. Torrey Pines Road
La Jolla CA 92037, US
Phone: (858) 373-6300; Fax: (858) 535-0034
Web: www.stratagene.com; E-mail: info@stratagene.com
KEY PERSONNEL: Joseph A. Sorge, M.D.; Chairman and CEO
Steve R. Martin; VP and CFO
Ronni L. Sherman; Exec. VP and General Counsel
John R. Pouk; Sr. VP, Global Sales and International Operations
Nelson F. Thune; Sr. VP, Operations and GM, Hycor Biomedical Inc.
Name changed from Stratagene Cloning Systems (1990)
Merged with Hycor Biomedical Inc. (6/04)
FACILITIES: Headquarters and R&D facilities in La Jolla, Calif.
Manufacturing facility in Austin, Texas, includes Reagent and Instrument
Manufacturing/Production Planning facilities
Additional offices in Amsterdam, the Netherlands and Tokyo, Japan
STOCK-FINANCIAL HISTORY: NASDAQ--STGN
04)
®
SUBSIDIARIES/DIVISIONS: Hycor Biomedical Inc.--Garden Grove, Calif. (see separate entry)

Affymetrix Inc. Stratagene to provide nonexclusive 2/05
software for GeneChip alliance
data analysis and
develop ArrayAssist Life
software
Jingmei Biotech all products exclusive

Co. Ltd. distribution
agreement for
China
Layton BioScience Layton's hNT human marketing and 8/94
Inc. neuronal cell kits, cDNA distribution
libraries derived from agreement for the
LNT neuron cells U.S., Canada,
Europe, and the Far
East
Rosetta creation of an development and 8/06
Inpharmatics LLC automated solution for licensing agreement
the isolation of nucleic
acids from clinical
samples
Strand Life suite of next-generation development 12/05
Sciences bioinformatics software partnership
RESEARCH & DEVELOPMENT: Research reagents

Transgenic technology for modeling and assaying human diseases
Enzymes
Human genome mapping technology
Genetic diseases
PRODUCTS ON MARKET: More than 1,000 molecular biotechnology products for the research market,
including antibodies, bioinformatics software, Quantos™ Cell Proliferation
Assay Kit, cloning vectors, DNA extraction and microextraction kits,
fluorescent proteins, benchtop coolers, microcentrifuges, Parafilm®
dispensers, PCR labware, radioactivity shields, real-time instruments,
temperature cyclers, tips and tubes, library construction products, library
packaging extracts and host strains, markers and restriction enzymes, mass
spectrometry, microarray reagents, modifying enzymes, mutagenesis,
cloning kits, PCR instruments, PCR reagents, premade libraries, protein
expression systems, QPCR & QRT-PCR reagents, real-time instruments,
reference RNA, Absolutely RNA® nanoprep, miniprep and micorprep kits,
RT-PCR reagents, RNA, DNA, two-hybrid products and viral gene delivery
systems
Strategic Diagnostics Inc.

111 Pencader Drive
Newark DE 19702, US
Phone: (302) 456-6789; Fax: (302) 456-6770
Web: www.sdix.com
E-mail: sales@sdix.com
KEY PERSONNEL: Grover Wrenn; Chairman
Matthew H. Knight; President and CEO
Tony Simonetta; CFO
James W. Stave, Ph.D.; VP, R&D
Jim Byron; National Sales Manager
David Schlecker; Director, Human Resources
®

Acquired Ohmicron (6/96)
Acquired TSD BioServices Inc. (6/96)
Acquired EnSys Environmental Products Inc. (12/96)
Acquired HTI Bio-Products Inc. (1998)
Acquired AZUR Environmental (2001)
FACILITIES: 28,655 sq. ft. headquarters in Newark, Del.
25,600 sq. ft. R&D and technical facility in Newark, Del.
STOCK-FINANCIAL HISTORY: NASDAQ--SDIX
Net income $584K (YE 05) compared to $1.379M (YE 04)
04)
SUBSIDIARIES/DIVISIONS: Strategic BioSolutions (www.strategicbiosolutions.com)
SDI Europe
BUSINESS STRATEGY: Strategic Diagnostics is a custom antibody production and services
company and a leader in using immunoassay and bio-response technology
to assure safety and quality in food, water and other environmental matrices.
US Biosystems SDI's environmental exclusive distribution 4/05
(USB) test kits when sold agreement
through an analytical,
laboratory channel
RESEARCH & DEVELOPMENT: Rapid quantitative lateral flow assays

Genetic modified crop test kits
PRODUCTS ON MARKET: GeneChek®
RaPID Assay®
EnviroGard®
DTECH®
RapidChek®
TraitChek®
SeedChek®
Sumitomo Chemical Co. Ltd.

27-1 Shinkawa, 2-chome, Chuo-ku
Phone: +81 3-5543-5500; Fax: +81 3-5543-5901
Web: www.sumitomo-chem.co.jp
E-mail: info@sumitomo-chem.co.jp
KEY PERSONNEL: Hiromasa Yonekura; President
Masami Nakamoto; Exec. VP
Satoshi Kawachi; Exec. VP
Shigehiro Oba; Sr. Managing Exec. Officer, Agricultural Chemicals Sector
Ichiro Miyawaki; Sr. Managing Exec. Officer, Petrochemicals and Plastics
Sector
Hideaki Watababe; Sr. Managing Exec. Officer, Basic Chemicals Sector
Masashi Araki; Managing Exec. Officer, Fine Chemicals Sector
Naoya Kanda; Sr. Managing Exec. Officer
Osamu Ishitobi; Sr. Managing Exec. Officer
HISTORY: Founded in Sepember 1913
®
FACILITIES: Headquarters in Osaka and Tokyo, Japan

Laboratories and research facilities in Takarazuka, Ehime, Chiba, Osaka,
Takatsuki, and Tsukuba
Manufacturing facilities in Ehime, Oita, Osaka, Chiba, Aomori and Singapore
04)
SUBSIDIARIES/DIVISIONS: 104 subsidiaries and affiliates, including:
Sumitomo Pharmaceuticals Co. Ltd. (see separate entry)
Koei Chemical Co. Ltd.
Taoka Chemical Co. Ltd.
The Polyolefin Company (Singapore) Pte. Ltd.
Sumitomo Chemical America Inc.
Valent U.S.A. Corp.
Nihon Medi-Physics Co. Ltd.
Sumika Fine Chemicals Co. Ltd.
BUSINESS STRATEGY: Create new and useful technologies and products in order to improve living
standards and alleviate the problems of society
PRODUCTS ON MARKET: Basic chemicals

Petrochemicals and plastics
Fine chemicals
IT-related chemicals
Agricultural chemicals
Pharmaceuticals
SunOpta Inc.
2838 Bovaird Drive West
Brampton L7A 0H2, Canada
Phone: (905) 455-2528; Fax: (905) 455-2529
Web: www.sunopta.com
E-mail: susan.wiekenkamp@sunopta.com
KEY PERSONNEL: Jeremy N. Kendall; Chairman and CEO
Steven R. Bromley; President and COO
John H. Dietrich; VP and CFO
Benjamin Chhiba; VP and General Counsel
Roger Eacock; VP, Supply Chain
Debra A. Boyle; Corp. VP, Public Relations
Allan G. Routh; President, SunOpta Grains and Foods Group
Arthur J. McEvily; President, SunOpta Ingredients Group
Sergio A. Varela; President, SunOpta Fruit Group
Joseph J. Stern; President, Organic Ingredients and Exec. VP, SunOpta
Fruit Group
Stephen B. Easterbrook; President, SunOpta Canadian Food Distribution
Group
David J. Kruse; President and COO, Opta Minerals Inc.
Murray Burke; VP and GM, SunOpta BioProcess Group
HISTORY: Founded in 1973 as Stake Technology
Acquired Barnes Environmental International (1995)
Created the SunOpta Food Group (1999)
SunOpta Food Group acquired Sunrich Inc. (8/99)
Opta Minerals acquired eorge F. Pettinos (Canada) Ltd. (PECAL) (3/00)
SunOpta Food Group acquired Northern Food and Dairy Inc. (9/00)
®
Opta Minerals acquired Temisca Inc. (11/00)

SunOpta Food Group acquired First Light Foods Inc. (3/01)
Opta Minerals acquired Virginia Materials and Supplies Inc. (10/01)
Opta Minerals acquired a 51% interest in International Materials & Supplies
Inc. (10/01)
SunOpta Food Group acquired Wild West Organic Harvest Co-operative
Association (11/02)
SunOpta Food Group acquired Simply Organic Co. Ltd. (12/02)
SunOpta Food Group acquired Opta Food Ingredients Inc. (12/02)
SunOpta Food Group acquired Kettle Valley Dried Fruit Ltd. (5/03)
SunOpta Food Group acquired Pro Organics Marketing Inc. (10/03)
Changed name to SunOpta Inc. (10/03)
SunOpta Food Group acquired SIGCO Sun Products Inc. (11/03)
Opta Minerals acquired the remaining 49% of International Materials (11/03)
SunOpta Food Group acquired Sonne Labs Inc. (12/03)
SunOpta Food Group acquired Distribue-Vie Fruits & Legumes Biologiques
Inc. (3/04)
SunOpta Food Group acquired Supreme Foods Ltd. (5/04)
SunOpta Food Group acquired the assets of Snapdragon Natural Foods Inc.
(5/04)
SunOpta Food Group acquired Kofman-Barenholtz Foods Ltd. (9/04)
SunOpta Food Group acquired 51% of the outstanding shares of Organic
Ingredients Inc. (9/04)
SunOpta Food Group acquired remaining 49.9% of Organic Ingredients
(4/05)
Opta Minerals acquired Distribution A&L (4/04)
SunOpta Food Group acquired Earthwise Processors LLC (6/05)
SunOpta Food Group acquired Cleugh’s Frozen Foods Inc. (6/05)
SunOpta Food Group acquired Pacific Fruit Processors Inc. (7/05)
Opta Minerals acquired certain assets of the abrasives production division of
Hillcrest Industries Inc. (10/05)
SunOpta Food Group acquiredLes Importations Cacheres Hahamovitch Inc.
(12/05)
Opta Minerals acquired Magnesium Technologies Corp. (2/06)
STOCK-FINANCIAL HISTORY: NASDAQ--STKL / TSX--SOY

Net earnings $13.558M (YE 05) compared to $11.016M (YE 04)
SUBSIDIARIES/DIVISIONS: SunOpta Food Group: Natural, organic and specialty foods markets.
Comprised of four operating groups:
SunOpta Grains and Foods Group: Bringing identity preserved, non-GMO
and organic soybeans, sunflower and corn products to market utilizing
vertically integrated business models, and markets value-added soymilk
concentrates, powders and ingredients, aseptic and ESL soy and rice
beverages and grain snacks
SunOpta Ingredients Group: Technical processing and contract
manufacturing of value-added food ingredients such as oat fibers, stabilized
brans, germs and natural preservatives
SunOpta Fruit Group: Global sourcing and processing of organic and natural
fruits, fruit ingredients and packaged products for industrial, food service and
private label retail customers
SunOpta Canadian Food Distribution Group: Distributor of organic, natural,
kosher and specialty foods
Opta Minerals Inc. (TSX--OPM, 70.6% owned): Processing and recycling

silica free abrasives and a wide range of industrial minerals
SunOpta BioProcess Group: Processing of biomass for the production of

cellulosic ethanol and other bio-products
®

Rapidly grow revenues, profits and shareholder value through an effective
balance of internal growth and acquisition, with a focus on integrated
business models in the natural, organic and specialty food markets
Mikro-Technik sales, marketing and exclusive licensing 6/06
GmbH & Co. KG distribution of Mikro- arrangement with
Technik's wheat and
bamboo fibers and
powdered cellulose
products in North
America
Royal Nedalco Nedalco's pentose licensing agreement 6/06
fermenting yeast for the
production of cellulosic
ethanol in North
America
Symbio
38 Bookham Industrial Park, Church Road
Great Bookham KT23 3EU, UK
Phone: +44 (0) 1372 456101; Fax: +44 (0) 1372 456099
Web: www.symbio.co.uk
E-mail: info@symbio.co.uk
KEY PERSONNEL: Martin Ward; President
David Ward, B.Sc.; Sr. Scientist
Polly Gearing; Head, Administration
Judy Moffat; Head, Accounts and Credit Control
Commenced sales in 1991
Began international distribution in 1995
BUSINESS STRATEGY: Develop and market biotech solutions for industry and the environment,
specifically: waste water and industrial effluent; sports turf and horticulture;
forestry and arboriculture; industrial and commercial cleaning; lake and river
restoration and management; and soil decontamination
RESEARCH & DEVELOPMENT: Biological plant growth enhancement

Wastewater and industrial effluent treatment
Sports turf fungal control in field trials
®
Syngenta International AG
P.O. Box
Phone: +41 61 323 11 11
Web: www.syngenta.com
KEY PERSONNEL: Martin Taylor; Chairman
Michael Pragnell; CEO
John Atkin; COO, Crop Protection
Bruce Bissell; Head, Global Operations and Human Resources
David Jones; Head, Business Development
David Lawrence; Head, R&D
Michael Mack; COO, Seeds
Christoph Mader; Head, Legal and Taxes
Domenico Scala; CFO
HISTORY: Formed in November 2000 from the merger of Novartis and AstraZeneca’s
agribusinesses
Acquired all outstanding shares of Dia-Engei (2/04)
To acquire Emergent Genetics Vegetable A/S (as of 6/06)
To acquire Conrad Fafard, Inc. (as of 7/06)
FACILITIES: Four major research sites--Located in Switzerland, the U.K. and the U.S.
Two molecular marker laboratories--Located in Stanton Minn., and
Toulouse, France
STOCK-FINANCIAL HISTORY: Swiss stock exchange--SYNN / NYSE--SYT
Sales $8.104b (YE 05) compared to $7.269b (YE 04)
SUBSIDIARIES/DIVISIONS: Syngenta Agro SA--Argentina

Syngenta Crop Protection Pty. Ltd.--Sydney, Australia
Syngenta Seeds Pty Ltd.--Australia
Syngenta Crop Protection NV--Brussels, Belgium
Syngenta Seeds NV--Brussels, Belgium
Syngenta Protecao de Cultivos Ltda.--Sao Paulo, Brazil
Syngenta Crop Protection Canada Inc.--Guelph, Ontario
Syngenta Seeds Canada Inc.--Arva, Ontario
Syngenta Agribusiness SA--Santiago, Chile
Syngenta (China) Investment Co. Ltd.--Shanghai, China
Syngenta Crop Protection Ltd.--Hong Kong
Syngenta Seeds (Beijing) Co. Ltd.--Beijing, China
Syngenta SA--Bogota, Columbia
Syngenta Czech s.r.o.--Czech Republic
Syngenta Seeds A/S--Skaelskor, Denmark
Syngenta Crop Protection A/S--Copenhagen, Denmark
Syngenta Agro SAE--Giza, Egypt
Syngenta Agro SAS--France
Syngenta Seeds SAS--France
Syngenta Agro GmbH--Germany
Syngenta Seeds GmbH--Germany
Syngenta Hellas AEBE--Athens, Greece
Syngenta LAN SA--Guatemala
Syngenta Kft--Budapest, Hungary
Syngenta India Ltd.--Mumbai, India
Syngenta Crop Protection SpA--Milan, Italy
Syngenta Japan KK--Tokyo, Japan
Syngenta Seeds KK--Japan
Syngenta Crop Protection Sdn. Bhd.--Malaysia
Syngenta Maroc SA--Casablanca, Morocco
®
Syngenta Seeds BV--The Netherlands

Syngenta Crop Protection BV--The Netherlands
Syngenta Pakistan Ltd.--Pakistan
Syngenta Crop Protection Lda.--Lisbon, Portugal
O.O.O. Syngenta--Moscow, Russia
Syngenta Asia Pacific Pte. Ltd.--Singapore
Syngenta South Africa (Pty.) Ltd.--Johannesburg, South Africa
Syngenta Korea Ltd.--Seoul, South Korea
Syngenta Agro SA--Madrid, Spain
Syngenta Seeds SA--Barcelona, Spain
Syngenta Seeds AB--Sweden
Syngenta Crop Protection AG--Basel, Switzerland
Syngenta Seeds--Basel, Switzerland
Syngenta Crop Protection Schweizerhalle AG--Pratteln, Switzerland
Syngenta Crop Protection Munchwilen AG--Switzerland
Syngenta Agro AG--Dielsdorf, Switzerland
Syngenta Crop Protection Monthey SA--Monthey, Switzerland
Syngenta Crop Protection Ltd.--Bangkok, Thailand
Syngenta Seeds Ltd.--Bangkok, Thailand
Syngenta Tarim Sanayi ve Ticaret AS--Turkey
Syngenta Crop Protection UK Ltd.--U.K.
Syngenta Seeds Ltd.--U.K.
TOV Syngenta--Kiev, Ukraine
Syngenta Crop Protection Inc.--Greensboro, N.C.
Syngenta Seeds Inc.--Golden Valley, Minn.
Syngenta Corp.--Wilmington, Dela.
Syngenta Vietnam Ltd.
COMPO development and strategic alliance 9/05
marketing of a
comprehensive range of
plant protection and
pest control products
Delta and Pine biotechnology products development and 8/04
Land Co. for cotton commercialization
agreement
Diversa establishment of shared research and 12/02

biotechnology research product
platform and discovery development
of products collaboration
Sumitomo SYN 523 herbicide development and 2/05
Chemical marketing
agreement
Tanimura & Antle joint venture, Dulcinea partnership 3/04
Farms LLC, to market
Dulcinea brand produce
items
RESEARCH & DEVELOPMENT: Chemical innovation to discover new active ingredients: Plans to launch one
active ingredient per year
Product innovation using existing active ingredients
New products through plant breeding (vegetables and flowers): Input traits--
Full suite of stacked traits in corn, glyphosate tolerance and resistance to
leaf and soil insects, Output traits--Corn for animal feed and ethanol
production
PRODUCTS ON MARKET: Actara®, Amistar®, Callisto®, Cruiser®, Dual Gold®, Gramoxone®,
Karate®, Ridomil Gold®, Score®, Topik®, Touchdown®, Garst®, Golden
Harvest®, NK®, Rogers®, S&G®
®

Active ingredients:
Mandipropamid in late development
Insecticide in late development
Fungicides in early development
Herbicide 1 in early development
Herbicide 2 in early development
Corn traits:
Corn Root Worm (CRW) in elite breeding, planned
launch in 2007
GT / CRW in elite breeding, planned
launch in 2007
CRW / ECB in elite breeding, planned
launch in 2008
GT / CRW / ECB in elite breeding, planned
launch in 2008
Corn amylase (biofuels) in late development
Corn phytase in early development
Synthetech Inc.
1290 Industrial Way
Albany OR 97322, US
Phone: (541) 967-6575; Fax: (541) 967-9424
Web: www.synthetech.com
E-mail: customer@synthetech.com
KEY PERSONNEL: Daniel T. Fagan; Chairman
Dr. Gregory Hahn; President and COO
Gary Weber; CFO and VP, Finance and Administration
Dr. Mike Standen; Director, Technology
Brett Reynolds; Director, Sales and Marketing
HISTORY: Founded in 1981 by Paul Ahrens
Acquired fine chemicals manufacturing facilities in Albany, Ore. (1987)
Acquired technology assets and customer lists of Colorado Biotechnology
Associates Inc. (1/06)
FACILITIES: 25,000 sq. ft. manufacturing plant, research labs, warehouse and
administrative offices
20,000 sq. ft. pilot manufacturing plant
STOCK-FINANCIAL HISTORY: NASDAQ--NZYM
IPO--3M shares at $1/share, $3M (1984)
PRIVATE PLACEMENTS: $1M private placement of stock and warrants (8/91)
$1M exercise of above warrants (3/96)
BUSINESS STRATEGY: Develop and market amino acid derivatives
Develop and scale-up bio-organic processes for chiral fine chemicals and
pharmaceutical intermediates, especially specialty amino acids and
derivatives
Biomeasure Inc. specialty amino acids supply and 5/89
technology
agreement
Miwon Korea aspartame licensing agreement 12/89
®
RESEARCH & DEVELOPMENT: Focus is on nonnatural amino acids, amino acid derivatives, and small
peptides for pharmaceutical applications (peptides, peptidomimetics, small
molecules, etc.)
PRODUCTS ON MARKET: Peptide building blocks--more than 400 products on market in 22 countries
Wide range of amino acid derivatives, amino alcohols, and specialty amino
acids--capacity from kilos to tons
Synthetic Genomics Inc.

9601 Blackwell Road, Ste. 200
Rockville MD 20850, US
Phone: (240) 238-0800; Fax: (240) 238-0888
Web: www.syntheticgenomics.com
E-mail: info@syntheticgenomics.com
KEY PERSONNEL: J. Craig Venter, Ph.D.; Chairman, CEO and Co-CSO
Aristides Patrinos, Ph.D.; President
Hamilton O. Smith, M.D.; Exec. VP and Co-CSO
David Kiernan, M.D.; Exec. VP and General Counsel
BUSINESS STRATEGY: Develop and commercialize recently discovered and potentially world-
changing genomic synthesis technologies
RESEARCH & DEVELOPMENT: Initial focus is on ethanol and hydrogen production
Takeda Pharmaceutical Co. Ltd.

1-1, Doshomachi 4-chome, Chuo-ku
Phone: +81 6-6204-2111; Fax: +81 6-6204-2880
Web: www.takeda.co.jp
KEY PERSONNEL: Kunio Takeda; Chairman
Yasuchika Hasegawa; President
Hiroshi Akimoto, Ph.D.; Managing Director
Makoto Yamaoka; Sr. Managing Director and GM, Pharmaceutical
Marketing Division
Kiyoshi Kitazawa, Ph.D.; Managing Director and GM, Strategic Product
Planning
Hiroshi Shinha; GM, Legal
Toyoji Yoshida; GM, Corp. Communications
Hiroshi Takahara; GM, Finance and Accounting
Hiroaki Ogata; GM, Business Development and Global Licensing
EMPLOYEES: 14,510 employees; 7,345 in parent company
Incorporated in January 1925
FACILITIES: ¥53M Tsukuba Research Laboratories, a biotechnology research center in
Tsukuba Science City
Branches in Sapporo, Tohoku, Kitakanto-Koshinetsu, Tokyo, Yokohama,
Chiba-Saitama, Nagoya, Kyoto, Osaka, Kobe, Shikoku, Chugoku, Fukuoka
Plants in Osaka, Shonan, Hikari, Takasago, Kashima, Shimizu and
Tokuyama
®
Research laboratories in Osaka and Tsukuba

Farm and herbal garden in Fukuchiyama and Kyoto
STOCK-FINANCIAL HISTORY: Listed on the Tokyo, Osaka, Nagoya, Fukuoka and Sapporo stock
exchanges
04)
SUBSIDIARIES/DIVISIONS: Takeda America Holdings Inc.--New York, N.Y.
Takeda Research Investment Inc.--Palo Alto, Calif.
Takeda San Diego Inc.--San Diego, Calif.
Takeda Pharmaceuticals North America Inc.--Lincolnshire, Ill.
Takeda Global Research and Development Center Inc.--Lincolnshire, Ill.
TAP Pharmaceutical Products Inc.--Lake Forest, Ill.
Takeda Global Research & Development Centre (Europe) Ltd.--London
Laboratoires Takeda--France
Takeda UK Ltd.
Takeda Italia Farmaceutici SpA--Rome, Italy
Takeda Pharma GmbH--Germany
Takeda Pharma Ges. mbH--Vienna, Austria
Takeda Pharma AG--Lachen, Switzerland
Takeda Ireland Ltd.--Wicklow, Ireland
Takeda Pharma Ireland Ltd.--Dublin, Ireland
Tianjin Takeda Pharmaceuticals Co. Ltd.--China
Takeda Chemical Industries (Taiwan) Ltd.--Taipei, Taiwan
Boie-Takeda Chemicals Inc.--The Phillipines
Takeda (Thailand) Ltd.--Bangkok, Thailand
P.T. Takeda Indonesia--Indonesia
INVESTMENTS: Wyeth-Lederle (Japan) Ltd.--30%
TAP Pharmaceutical Products Inc.--50% (joint venture with Abbott
Laboratories)
Laboratoires Takeda--100%
Takeda Italia Farmaceutici SpA--76.92% (with Finfarma SpA)
Tianjin Takeda Pharmaceuticals Co. Ltd.--75% (with Tainjin Lisheng
Pharmaceutical Factory)

3M topical treatment for exclusive co- 2/05
Pharmaceuticals cervical high-risk HPV development and
infection and cervical joint marketing
dysplasia agreement
Abbott drug for prostate cancer joint venture called 8/77
Laboratories and ulcer TAP Holdings to
market drug
developed by
Takeda
Affymax Inc. Affymax's Hematide in development and 2/06
Japan commercialization
agreement
Affymax Inc. Affymax's Hematide in development and 6/06
the U.S. commercialization
agreement
Ajinomoto risedronate for codevelopment 1992
osteoporosis agreement for
Japan and South
Korea
Alizyme plc development, licensing agreement 1/04
manufacturing and
marketing of ATL-962 in
Japan
®
Arius Research Arius' FunctionFIRST three-year, multi- 4/06

Inc. Platform to discover product
treatments for human collaboration
disease
BioNumerik Tavocept (dimesna) marketing 10/04
Pharmaceuticals agreement (USA
Inc. and Canada)
Galaxy Biotech monoclonal antibody development, 7/06
manufacturing and
sales agreement
Human Genome gene sequence collaboration 6/95
Sciences Inc. database agreement
Lexicon Genetics Takeda can select and partnership 7/04
purchase targets for
anti-hypertension
medicine discovered in
Lexicon's Genome5000
program
McNeil Consumer McNeil's OTC products marketing 1997
Products Co. agreement for
(Johnson & Japan
Johnson)
Merck KGaA Matuzumab co-development 9/05
and co-
commercialization
agreement
Pharmacia & smoking cessation joint marketing 1996
Upjohn (now part agreement--Takeda
of Pfizer) to sell P&U smoking
cessation products
in Japan
PPD Inc. development and licensing agreement 7/05
marketing rights to
PPd's DPP4 inhibitors
Santhera Idebenone (SNT-MC17) development and 8/05
Pharmaceuticals commercialization
AG agreement
For all recent
agreements,
please visit:
takeda.co.jp/englis
h/press/press.htm
RESEARCH & DEVELOPMENT: Lifestyle-related diseases

Cancer and urological diseases, gynecological disorders
Central nervous system disorders and bone and joint disorders
Life-cycle management of drugs for digestive system disorders
PRODUCTS ON MARKET: Diabetes: ACTOS®, BASEN®
Cardiovascular: BLOPRESS®, CALSLOT®, ADECUT®
Gastrointestinal: PREVACID®
Urology and Gynecology: LUPRON DEPOT®
Osteoporosis: OSTEN®, BENET®
Infection: PANSPORIN®, FIRSTCIN®, BESTCALL®, TAKESULIN®,
LILACILLIN®, AMASULIN®, PANSPORIN T®
Interferon and Interleukin: CANFERON A®, CELEUK®
Central Nervous System: NICHOLIN®, HIRTONIN®, EURODIN®
Inflammation: DASEN®
Vitamin: ALINAMIN F®, VITANEURIN®, HICEE®, PANVITAN®
Allergy: BRONICA®, SOLFA®
Vaccine: Adsorbed Diphtheria-purified Pertussis-tetanus Combined Vaccine,
Dried Live Attenuated Measles Vaccine, Dried Live Attenuated Mumps
Vaccine, Dried Live Attenuated Rubella Vaccine, Japanese Encephalitis
Vaccine
®
Cold Remedies: Benza® Block IP

Preparations for Rhinitis: Benza® AL, Benza® AL Spray
Gastrointestinal Drugs: That's®, That's® 21, That's® Block
Vitamin Products: Alinamin® A25, New Alinamin® A, Alinamin® EX,
Hicee®-L, Hicee® 1000, Hicee® white2, Hicee® B Mate2, Hicee® E-class,
Vitamin C ‘TAKEDA,’ Vitamin E ‘TAKEDA,’ Panvitan HI
Vitamin-containing Tonics (Quasi-drugs): Alinamin® V, Alinamin® V&V,
Alinamin® 7, Hicee® CEtime
Vitamin-containing Tonics: Alinamin® e
Athlete's Foot Treatments: Scorba® LX, Scorba®
Laxatives: TAKEDA KANPO BENPIYAKU, Clear®
Teledyne Isco
4700 Superior Street
Lincoln NE 68504, US
Phone: (402) 464-0231; Fax: (402) 465-3022
Web: www.isco.com
E-mail: iscoinfo@teledyne.com
KEY PERSONNEL: David Kennedy, Ph.D.; General Manager
EMPLOYEES: 467 employees worldwide
HISTORY: Founded by Robert W. Allington in 1958
Signed agreement to acquire Suprex Corp. of Pittsburgh, PA (8/96)
Signed agreement to acquire Geomation Inc. of Golden, CO (9/97)
Acquired STIP Siepmann und Teutscher GmbH (1/98)
Merged with subsidiary of Teledyne Technologies Inc. (2004)
Changed name from Isco Inc. (2004)
Acquired MGD Technologies Inc. (12/05)
Teledyne MGD Inc. subsidiary merged into Teledyne Isco (5/06)
FACILITIES: Sales offices in Belgium, Germany, China and Lincoln, Neb.
200,000 sq. ft. plant
Formerly listed on NASDAQ--ISKO:

IPO--$7.43/share (1985)
SUBSIDIARY OF: Teledyne Technologies Inc.
INVESTMENTS: Geomation, Inc.
Advanced Flow Technology Co. (AFTCO)--joint venture with AMJ
Equipment Corp.
BUSINESS STRATEGY: Growth by internal product development in closely related lines
supplemented by product acquisition
PRODUCTS ON MARKET: Instrumentation--LC and HPLC products, optical detectors, fraction

collectors, pumps, electrophoresis apparatus, supercritical fluid extraction
systems, and syringe pumps
Environmental products--wastewater samplers, parameter monitoring
products, and process monitoring products
®
The Dow Chemical Co.

2030 Willard H. Dow Center
Midland MI 48674, US
Phone: (989) 636-1000; Fax: (989) 636-1830
Web: www.dow.com
KEY PERSONNEL: Andrew N. Liveris; President, CEO and Chairman
Geoffery E. Merszei; Exec. VP and CFO
William F. Banholzer; Corp. VP and CTO
Bill Weideman; VP and Controller
Frank H. Brod; Corp. VP
Heinz Haller; Corp. VP, Strategic Development and New Ventures
Michael R. Gambrell; Exec. VP, Basic Plastics and Chemicals Portfolio
Charles J. Kalil; Corp. VP, General Counsel and Corp. Secretary
David E. Kepler; Sr. VP, Shared Services and Environment, Health and
Safety and CIO
Romeo Kreinberg; Exec. VP, Performance Plastics and Chemicals Portfolio
Julie Fasone Holder; Corp.VP, Human Resources, Diversity and Inclusion
and Public Affairs
Luciano Respini; Corp. VP, Geography
Fernando Ruiz; Corp. VP and Treasurer
Gary R. Veurink; Corp. VP, Manufacturing and Engineering
Acquired United AgriSeeds Inc. (crop biotechnology) for $45M (1987)
Formed joint venture (Dow Elanco & Co.) with Eli Lilly and Co. by combining
their plant-sciences businesses and Dow's industrial pest-control business
(10/89)
Completed $38/share cash tender offer for 58.5M shares of Marion
Laboratories, and acquired 67% of outstanding shares, which finalized
merger to create new company, Marion Merrell Dow (12/89)
Sold the assets from the Biotech Project of CD Medical Inc. to UniSyn
Technologies, a wholly owned subsidiary of Synbiotics Corp. (6/90)
Finalized agreement for Hoechst AG to acquire all outstanding shares of
Marion Merrell Dow (2Q95)
Member--Biotechnology Research and Development Corp (BRDC)
Member--Midwest Plant Biotechnology/Consortium
FACILITIES: 165 manufacturing sites in 37 countries
STOCK-FINANCIAL HISTORY: NYSE--DOW
SUBSIDIARIES/DIVISIONS: Divisions:
Perfornace Plastics
Performance Chemicals
Plastics
Chemicals
Agricultural Science
Hydrocarbon & Engergy
INVESTMENTS: Collaborative Research, Inc.--$5M, 5% equity
Dow Corning Corp.--joint venture with Corning Inc.
Millipore Corp.--9.5% (1984)
Haeger & Kaessner GmbH--acquired (1986)
United AgriSeeds, Inc.--acquired for $45M (12/87)
Montedison SpA--less than 5%
®
Lamaur, Inc.--acquired (1987)

FilmTec Corp. (membrane manufacturer for water purification and
separation processes), acquired capital stock for $75M (1987)
Essex Chemical Corp.--acquired for $366.1M, $36/share (9/88)
Neoprobe Corp.--minority equity
Sumitomo Chemical Co.--joint venture to manufacture polycarbonates in
Japan (12/89)
BOC Group plc--joint venture to develop and market membrane-based air-
separation systems (12/89)
BUSINESS STRATEGY: Provide innovative chemical, plastic and agricultural products and services
to many essential consumer markets
Access Access' bioresponsive collaboration 8/97
Pharmaceuticals polymer systems and agreement--Access
Inc. Dow's chelation gets rights to
technology to develop chelation
MRI contrast agents, technology. Dow
radiopharmaceutical has equity position,
diagnostics and manufacturing
therapeutics rights and future
royalties
Caliper Dow's polymer R&D collaboration 3/97
Technologies technology to the
Corp. development and
manufacturing of
disposable LabChips
Cytogen Corp. radiopharmaceutical to exclusive U.S. 5/93
alleviate the bone pain marketing rights to
associated with Cytogen
metastatic cancer
Diversa Corp. enzymatic method that partnership 8/97
modifies a chemical
process used by Dow
Ecogen Inc. microbial biopesticide collaborative 11/89
development
agreement (through
joint venture, Dow
Elanco & Co.)
Kereos Inc. patent portfolios for licensing agreement 9/04
development and
imaging agents for
diagnosis of cancer and
cardiovascular disease
Neoprobe Corp. Dow's licensed MAbs R&D, supply, and 3/89,
and radiolabeling licensing agreement 8/92
technology
OSI more than 140,000 of exclusive worldwide 3/97
Pharmaceuticals Dow's compounds for licensing
Inc. screening and potential agreement--Dow
development of small received 350K
molecule drugs shares of OSI
common stock
Sumitomo polycarbonates joint venture to 12/89
Chemical Co. Ltd. manufacture in
Japan
RESEARCH & DEVELOPMENT: Agricultural products, industrial catalysts, cancer therapy and detection
rDNA techniques, human health care
®
PRODUCTS ON MARKET: PLASTICS: automotive products, electronics, engineering plastics, epoxy

products, polyolefin products, polystyrene, polyurethane, polyurethane
systems, synthetic rubber
CHEMICALS: calcium chloride, caustic soda, emulsion polymers, biocides,

coolants, heat transfer fluids, polypropylene glycols and copolymers,
surfactants, UCAR aircraft deicing fluids, UCAR emulsion systems, acrylate
monomers, oxygenated solvents, alkyl alkanolamines, ethanolamines,
ethyleneamines, isopropanolamines, glycol ethers and acetates, propylene
oxide and propylene glycols, specialty polymers, water soluble polymers
AGRICULTURE: fungicides, herbicides, insecticides, soil fumigants, films,

seeds, fumigants
The Nitrate Elimination Co. Inc.

334 Hecla Street
Lake Linden MI 49945, US
Phone: (906) 296-1115; Fax: (906) 296-8003
Toll-free phone: (888) NITRATE (648-7283)
Web: www.nitrate.com
E-mail: ellenr@nitrate.com
KEY PERSONNEL: Dr. Wilbur H. 'Bill' Campbell, Ph.D.; President
Ellen R. Campbell; VP and COO
Troy P. Kinnunen-Skidmore; Sr. Lab Technician for Enzyme Production
Michael J. Brodeur-Campbell; Lab Technician and Marketing Assistant
Thomas A. Rodeheffer; Instrument Technician
FACILITIES: 2,500 sq. ft. R&D facilities and biochemistry lab
BUSINESS STRATEGY: As an environmental biotechnology company, develop and commercialize
enzyme-based products for water testing and water treatment, with R&D
funding derived from competitive grant awards and collaborative
agreements
Provide contract protein expression and purification services for nonmedical
enzymes, and environmental and industrial enzyme discovery research
EPA enzymatic nitrate Phase I & II SBIR 9/95,
elimination technology contract 9/97.
NIH Phase I/II expression of nitrate Phase I/II SBIR 8/98-
reductase in Pichia grants 12/03
NIH SBIR nitrate biosensor R&D Phase I SBIR grant (9/99
-
9/00)
NIST biosensors two-year CRADA 7/96
Biotechnology agreement (8/94),
Division extended three
years
Sigma, Assay stabilized nitrate supply agreements 2/95
Designs, Oxford reductase
Biomedical
Research
U.S. Army Corps enzymes involved in contract R&D 2/98,
of Engineers degradation of 12/00
Research Lab nitroaromatic explosives
®
USDA nitrate test kit for Phase II SBIR grant 7/96

consumers
USDA Phase I/II rapid nitrate test kits for SBIR awards 3/02-
grants agricultural samples 9/05
USDA SBIR enzyme-based reagent Phase I/II awards 3/02-
packages for automated 9/05
equipment
YSI, Inc. enzymes contract production 6/99
for YSI proprietary
products
RESEARCH & DEVELOPMENT: Enzyme-based biosensors

Expression of complex enzymes
Immobilized enzyme systems for water treatment and other processes
'Battery powered' enzyme processes
Most recent R&D:

Enhancement of Nitrate Reductase production, which resulted in the
production of a new form of commercial Nitrate Reductase, called New NECi
NaR
Ag-Nitrate test kits to assist Ag consultants and farmers to easy evaluate the
nitrate content of feed, soil and water
Discrete analyzer reagent kits (D-ARK)
The Nitrate Reductase-linked Nitrate Biosensor: Nitrate Biosensor
Enzymatic Nitrate Elimination Technology: EzNET®
PRODUCTS ON MARKET: Nitrate reductase, NADH forms, native and recombinant
Nitrate kit for biomedical (NO) research
Nitrate test kit for consumers
Nitrate test kits for education, research, ag diagnostics, environmental
diagnostics, water quality
Reagent packs for water analysis equipment
Nitrate biosensor prototype
Enzymatic process for removal of nitrate prototype
from water
Additional enzymes for analytical in development
applications
TNO Quality of Life

Utrechtseweg 48, P.O.Box 360
Zeist 3700 AJ, Netherlands
Phone: +31 (0)30 694 41 44; Fax: +31 (0)30 695 72 24
Web: www.tno.nl/voeding; E-mail: infofood@voeding.tno.nl
KEY PERSONNEL: Dr. C.L Ekkers; Director
Dr. N.J. Snoeij; Director, Marketing and Sales
EMPLOYEES: 750 employees, 80% scientific personnel
HISTORY: Founded in 1940 at Utrecht
FACILITIES: Facilities in Zeist, Leiden and Groningen, Netherlands
SUBSIDIARY OF: TNO, the Netherlands Organization for Applied Scientific Research
BUSINESS STRATEGY: As a contract organization in the field of life sciences, TNO seeks to provide
a link of knowledge between fundamental research and its applications to
foods, drugs and (agro)chemicals in relation to health, safety and quality as
well as product and process innovation
®

Dyadic Dyadic's fungal high- profit-sharing and 8/03
International Inc. throughput screening royalty rights
system agreement,
restructured 12/05
University of carbohydrate collaborative
Groningen bioengineering in the agreement
TNO-RUG Centre for
Carbohydrate
Bioengineering
University of plant biotechnology in collaborative
Leiden the TNO-RUL Centre agreement
for Biotechnology
University of microbiology in the collaborative
Utrecht TNO-UU Centre for agreement
Veterinary Health
University of protein technology in collaborative
Wageningen the TNO-LUW Centre agreement
for Protein Technology
RESEARCH & DEVELOPMENT: Food and feed research

Nutrition
Toxicology
TQM
Biochemistry
Biopharmaceutical R&D
TNO's 23 core technologies:

Analytical and Molecular Pharmacology
Animal Food Technology
Applied Plant Sciences
Carbohydrate Technology
Damage Assessment and Consultancy
Environmental Toxicology
Explanatory Toxicology
Food and Food Supplement Analysis
Food Science and Technology
General Toxicology
Microbial Physiology and Gene Technology
Microbiology and Quality Management
Nutritional Epidemiology
Nutritional Physiology
Packaging Research
Protein and Meat Technology
Residue Analysis
Sensor Technology
Target Organ Toxicology
Toxicological Risk Assessment
PRODUCTS ON MARKET: Contract research
®
Toray Industries Inc.

Nihonbashi Mitsui Tower
1-1, Nihonbashi-Muromachi 2-chome, Chuo-ku
Phone: +81 3-3245-5111; Fax: +81 3-3245-5555
Web: www.toray.com; E-mail: webmaster@toray.com
KEY PERSONNEL: Sadayuki Sakakibara; President, CEO and COO
Kazuo Tomiita; Exec. VP
Kiyoshi Fukuchi; GM, Personnel and Industrial Relations Division
Osamu Nakatani; GM, Manufacturing Division
Kazuhiro Maruyama; GM, General Administration Division
Norihiko Saitou; Chief Investor Relations Officer
Hiroaki Kobayashi; GM, Technology Center
Munehiro Se; GM, Purchasing and Logistics Division
STOCK-FINANCIAL HISTORY: Common stock listed on Tokyo, Osaka, Nagoya, Fukuoka, Sapporo, London
and Luxemburg stock exchanges
SUBSIDIARIES/DIVISIONS: 237 subsidiaries and affiliates, including:
DuPont-Toray Co. Ltd.
Opelontex Co. Ltd.
Ogaki Fuso Spinning Co. Ltd.
Toray Textiles Inc.
Inami Textiles Inc.
Matsumoto Textiles Co. Ltd.
Toray Coatex Co. Ltd.
Towa Orimono Co. Ltd.
Toray Monofilament Co. Ltd.
Toyo Tire Cord Co. Ltd.
Toyo Flocking Co. Ltd.
Maruichi Fiber Co. Ltd.
Sowa Textile Co. Ltd.
Toyo Plastic Seiko Co. Ltd.
Toray PEF Products Inc.
Toray Advanced Film Co. Ltd.
Dow Corning Toray Silicone Co. Ltd.
Toray Fine Chemicals Co. Ltd.
Soda Aromatic Co. Ltd.
Toray ACE Co. Ltd.
Toray Engineering Co. Ltd.
Toray Precision Co. Ltd.
Toray Medical Co. Ltd.
Toray Research Center Inc.
Toyo Jitsugyo Co. Ltd.
Toray Plastics (America) Inc.
Toray Resin Co.
Toray Carbon Fibers America Inc.
Toray Composites (America) Inc.
Toray Textiles Europe Ltd.
Alcantara SpA
Toray Textiles Central Europe s.r.o.
Toray Plastics Europe SA
Société des Fibres de Carbone SA
P.T. Acryl Textile Mills
P.T. Century Textile Industry Tbk
®
P.T. Easterntex
P.T. Indonesia Synthetic Textile Mills
P.T. Indonesia Toray Synthetics
Luckytex (Thailand) Public Co. Ltd.
Thai Toray Textile Mills Public Co. Ltd.
Thai Toray Synthetics Co. Ltd.
Penfabric Sdn. Berhad
Penfibre Sdn. Berhad
Toray Plastics (Malaysia) Sdn. Berhad
Toray Fibers (Nantong) Co. Ltd.
Toray Sakai Weaving & Dyeing (Nantong) Co. Ltd.
Taltex (Zhuhai) Ltd.
Toray Plastics (Shenzhen) Ltd.
Toray Film Products (Zhongshan) Ltd.
Toray Sanko Precision (Zhongshan) Ltd.
INVESTMENTS: Fujirebio
Toray-Fuji Bionics--joint venture of Toray and Fujirebio

Acologix Inc. development and collaboration and 6/05
commercialization of licensing
Toray's TRK-820 in agreement
North America and co-
development in Europe
Acologix Inc. Acologix's AC-200 development and 6/06
program in Japan licensing
agreement
Biotech Australia animal vaccines R&D agreement 1994
Pty. Ltd.
Daiichi Seiyaku Feron natural beta-IFN development and
for hepatitis B and C, marketing
brain tumors, malignant agreement
melanoma
Daiichi Seiyaku, gamma-IFN development and
Genentech Inc. marketing
agreement for
Japan, clinical
studies shared
with Daiichi
Digene Corp. DNA diagnostic probes distribution 12/90
for disease detection agreement for
Japan
DNA Chip high-performance DNA joint development 12/05
Research Inc. microarrays agreement
Japan Tobacco TRK-820 development and 3/05
Inc. and Torii marketing
Co. Ltd.
Maruho Co. Ltd. development and 3/05
marketing
agreement
Takeda compound for urinary development and 4/05
Pharmaceutical incontinence marketing
Co. Ltd. agreement
Uniqlo Co. Ltd. development of strategic 6/06
breakthrough material partnership
for new product
creation, creation of
product development
system
®
PRODUCTS ON MARKET: Fibers and Textiles: Nylon, Tetoron (polyester), Toraylon (acrylic), Ecsaine,
sillook
Water Treatment Membranes and Systems: Romenbra, High recovery

seawater desalination system, Torayfil, Torayvino (household water purifier)
Plastics: Amilan (nylon), Toyolac (ABS), Toraycon (PBT), Torelina (PPS),

Toraypef (polyolefin foam)
Fine Chemicals: Torayblan (synthetic gypsam), aromatic fine chemicals,

high-functional catalysts, specialty chemicals, Intercat (Interferon for cats
and dogs)
Carbon Fibers and Composite Materials: Torayca, Torayca Prepreg,

Torayca composites
Pharmaceuticals and Medical Products: Feron (natural interferon

preparation), Dorner (oral prostacyclin (PGI2) derivative) and Filtryzer
artificial kidneys for dialysis
Toronto Research Chemicals Inc.

2 Brisbane Road
North York M3J 2J8, Canada
Phone: (416) 665-9696; Fax: (416) 665-4439
Web: www.trc-canada.com
E-mail: info@trc-canada.com
KEY PERSONNEL: Dr. David S. Dime; President
Charles E. Dime; Exec. VP
FACILITIES: 42,000 sq. ft. of state-of-the-art laboratory space
BUSINESS STRATEGY: Develop, manufacture and supply fine chemicals for biomedical research
Seek pharmaceutical partnerships for joint development of novel
therapeutics and contract research opportunities
RESEARCH & DEVELOPMENT: Novel therapeutics as anticancer, anti-AIDS and cardiac active compounds
Contract R&D
Custom synthesis and process development
PRODUCTS ON MARKET: Biomedical research chemicals including enzyme inhibitors,
oligosaccharides, nitric oxide synthase reagents, phosphoramidites,
carbohydrates, detergents, fluorescent probes and crosslinkers
Tyrosine kinase inhibitors, signal transduction, protein/ion channel reagents
®
Union Chemical Laboratories (UCL)

321, Sec. 2, Kuang Fu Road, Kuang Fu Compound, Taiwan
Hsinchu 30042, China
Phone: (+86) 886-35-732-616; Fax: (+86) 886-35-732-359
Web: www.ucl.itri.org.tw/eng/
E-mail: 620257@itri.org.tw
KEY PERSONNEL: Dr. Wu-Hsun Cheng; General Director
EMPLOYEES: 500+ employees, 230+ Ph.D.s/masters degrees
HISTORY: Officially organized in 1946 as Union Industrial Research Laboratories
(UIRL)
Merged with the Industrial Technology Research Institute (ITRI) (1973)
UIRL changed name to Union Chemical Laboratories (UCL) (1983)
STOCK-FINANCIAL HISTORY: Nonprofit government-sponsored agency
SUBSIDIARY OF: Industrial Technology Research Institute (ITRI)
BUSINESS STRATEGY: Develop technologies in packaging and electronic materials, specialty
polymers and resins, metallocene-based catalysts/polymers, nano-
polymers, nanochemistry, nanobiochemistry, functional and high-tech fibers
and combinatorial chemistry
Commonwealth Development of cooperative R&D 6/02
Scientific and advanced project
Industrial polymerization catalyst
Research technology
Organization
(CSIRO)
RESEARCH & DEVELOPMENT: Precision polymers

Hi-tech polymers
Functional and high-tech fibers
Nanobio-chemistry
Nanochemistry
Combinatorial chemistry
Specialty chemicals
Advanced chemical engineering
Optoelectronic/electronic chemicals
PRODUCTS ON MARKET: Services include:
R&D in new product/process/application
Collaboration in new product/process/application
Process modification/optimization
Chemical analysis/product testing
Technical assistance/consultation/training
UniQuest Pty. Ltd.

Level 2, Cumbrae-Stewart Building, Research Road
The University of Queensland
Brisbane Q1D 4072, Australia
Phone: +61 7 3365-4037; Fax: +61 7 3365-4433
Web: www.uniquest.com.au
E-mail: enquiries@uniquest.com.au
KEY PERSONNEL: Norbury Rogers; Chairman
David Henderson; Managing Director
Richard Symons; CFO
David Henderson; Managing Director
®
Gary Heyden; GM, Consulting and Research

Harleigh Luscombe; GM, International Projects
Dean Moss; Manager, Technology Commercialization
Andrew Davis; Manager, Technology Commercialization
Julia Renaud; Manager, Corp. Development
Incorporated in July 1984
SUBSIDIARY OF: The University of Queensland
BUSINESS STRATEGY: Tech transfer company for The University of Queensland
RESEARCH & DEVELOPMENT: Commercialization of innovations via licenses, patents and establishing
start-ups
Assembling multi-disciplinary consulting teams for international development
projects
Providing government, industry, and the wider community with a wide range
of consulting, testing, expert opinion and advisory services as well as
research and development projects
University of Nebraska-Lincoln,
Center for Biotechnology
P.O. Box 880665, N300 Beadle Center
Lincoln NE 68588-0665, US
Phone: (402) 472-2635; Fax: (402) 472-3139
Web: www.biotech.unl.edu; E-mail: mfromm@unlnotes.unl.edu
KEY PERSONNEL: Dr. Michael Fromm; Director
Rik Barrera; Manager, Business Office
Dr. Yuannan Xia; Manager, Genomics and Flow Cytometry
Dr. Tom Clemente; Manager, Plant Transformation
Dr. Ron Cerny; Manager, Mass Spectrometry and Proteomic Analysis
Dr. Y. (Joe) Zhou; Manager, Microscopy
Dr. Jean-Jack M. Riethoven; Manager, Bioinformatics
Dr. Hideaki Moriyama; Manager, Structual Biology
EMPLOYEES: 5 employees, 165 faculty associates
Affiliated with the University of Nebraska at Lincoln
FACILITIES: Protein sequencing and proteomics, bioinformatics, genomics and DNA
sequencing, flow cytometry analysis, plant transformation, mass
spectrometry, and microscopy research facilities
BUSINESS STRATEGY: Foster research and development in high priority areas of biotechnology
RESEARCH & DEVELOPMENT: All aspects of molecular life sciences research, leading to improvements in
agriculture, health care and the environment
®
UVP Inc.
2066 W. 11th Street
Upland CA 91786, US
Phone: (909) 946-3197; Fax: (909) 946-3597
Web: www.uvp.com
E-mail: info@uvp.com
KEY PERSONNEL: Paul Warren; Chairman
Leighton Smith; President
Alex Waluszko; Exec. VP
SUBSIDIARIES/DIVISIONS: Ultra-Violet Products Ltd.
BioImaging Systems Group
Laboratory Products Group
Ultra-Violet Products Group
PRODUCTS ON MARKET: BioImaging Systems, CCD-based, for fluorescent, chemiluminescent,

chemifluorescent and visible light imaging of gels, blots, membranes, plates,
slides, microarrays, film and live specimens
analysis software in development
imaging systems in development
Valeant Pharmaceuticals International Inc.

Valeant Plaza, 3300 Hyland Avenue
Costa Mesa CA 92626, US
Phone: (714) 545-0100; Fax: (714) 556-0131
Web: www.valeant.com
E-mail: info@valeant.com
KEY PERSONNEL: Timothy C. Tyson; President and CEO
Bary G. Bailey; CFO and Exec. VP
Eileen C. Pruette; Exec. VP and General Counsel
Martin N. Mercer; Exec. VP, Latin America Operations
Wesley P. Wheeler; President, Global Marketing and Business Development
Charles J. Bramlage; President, Europe
David W. Kwo; Exec. VP, Asia, Africa and Australia
John I. Cooper; Exec. VP, Global Manufacturing and Supply
Geoffrey M. Glass; Sr. VP and CIO
HISTORY: Founded in 1960 by Milan Panic
Eastern European venture company ICN Galenika (75% owned by ICN,
25% owned by Galenika) formed in May 1991 (based in Belgrade, former
Yugoslavia)
Former subsidiaries SPI Pharmaceuticals Inc., Viratek Inc., ICN Biomedicals
Inc., and ICN Pharmaceuticals Inc. combined into new corporation named
ICN Pharmaceuticals Inc. (11/94)
Signed letter of intent to acquire 75% of Tuobin Chemicals and
Pharmaceuticals General Corp. (China) (7/95)
Acquired 40% of SeaLite Sciences Inc. (11/95)
®
Acquired Gly Derm Inc., skin care company (2/96)

Won bid to purchase 49% of Alkaloida Chemical Co. Ltd. (6/96)
Acquired Dosimetry Service from Siemens Medical System Inc. (6/96)
Acquired Leksredstva, Russian pharmaceutical company (7/96)
Signed letter of intent to manufacture and distribute pharmaceutical products
in Bosnia (8/96)
Acquired Vuab, manufacturing and research facility in the Czech Republic
(6/98)
Changed name from ICN Pharmaceuticals (11/03)
Sold raw materials and manufacturing operations in Czech Republic to
Chemoprojekt, a.s. (8/04)
Acquired Xcel Pharmaceuticals (2/05)
To purchase Infergen® from InterMune Inc. (as of 11/05)
FACILITIES: Headquarters in Costa Mesa, Calif., and Moscow, Russia
Research Products facilities in Aurora, Ohio; Irvine, Calif.; Costa Mesa,
Calif.; Sydney, Australia; Tokyo, Japan; Eschwege, Germany; Opera, Italy;
Orsay, France; Brussels, Belgium; High Wycombe, UK; and Thame, U.K.
Pharmaceuticals facilities in Bryan, OH; Costa Mesa, CA; Bueno Aires,
Argentina; Montreal, Canada; Wuxi, China; Mexico City, Mexico;
Chelyabinsk, Russia; Moscow, Russia; Kursk, Russia; St. Petersburg,
Russia; Tomsk, Russia; Yoshkar-Ola, Russia; Rseczow, Poland; Belgrade,
Yugoslavia; Zoetermeer, Holland; and High Wycombe, U.K.
Diagnostics facility in Orangeburg, N.Y.
STOCK-FINANCIAL HISTORY: NYSE--VRX
Public offering--2.1M shares at $17.50/share (7/86)
Public offering--$20M Swiss franc exchangeable certificates, 5.5% (2/87)
Public offering--$37M subordinated double convertible bonds, 3.25% (3/87)
Public offering--3M shares, $21M (6/96)
Public offering--7.2M shares of common stock at $24/share (2/05)
04)
SUBSIDIARIES/DIVISIONS: ICN Canada Ltd.--Canada
ICN Pharmaceutica SA--Mexico
Laboratorios Grossman SA--Mexico
ICN Pharmaceuticals Holland BV--Netherlands
ICN Biomedicals Inc.--Delaware
ICN Yugoslavia--Yugoslavia
ICN Biomedicals GmbH--Germany
ICN Pharmaceuticals Australasia Pty. Ltd.--Australia
ICN Pharmacueticals Japan KK--Japan
ICN Iberica--Spain
Labsystems Benelux BV--Netherlands
Labsystems Benelux NV--Belgium
ICN Biomedicals Ltd.--U.K.
ICN France SARL--France
ICN Biomedicals SRL--Italy
ICN Biomedicals NV/SA--Belgium
ICN Oktybr--Russia
ICN Polypharm--Russia
ICN Leksredstva--Russia
Wuxi ICN Pharmaceuticals--China
ICN Tomsk--Russia
ICN Yoshkar-Ola--Russia
INVESTMENTS: SeaLite Sciences Inc.
Biomedpreparat (Russia)--joint venture with Allen & Associates International
Ltd.
Alkaloida Chemical Co. Ltd. (Hungary)--won competitve bid to acquire up to
59% of the company
®
BUSINESS STRATEGY: Transform from an entrepreneurially focused corporation into an improved,

research-based and integrated specialty pharmaceutical company, focused
on marketing and distributing pharmaceuticals in the areas of infectious
disease, neurology and dermatology
Alliance Valeant's Mestinon and co-promotion 11/04
Pharmaceuticals Alliance's Symmetrel agreement
Biocode SA radioimmunoassay kits production 12/02
agreement
Fujisawa U.S.A. compounds related to licensing agreement 11/01
Inc. (now part of hGH
Astellas Pharma
Inc.)
Metabasis pradefovir (formerly development 10/01
Therapeutics Inc. called remofovir) agreement
Schering-Plough ICN's oral ribavirin for licensing agreement 7/98
Corp. hepatitis C for Europe--ICN
retains rights to all
other forms of
ribavarin and
indications
Schering-Plough Virazole in combination licensing agreement 7/99

Corp. with Schering's Intron A
SeaLite Sciences AquaLite TSH test for distribution 11/98
Inc. thyroid disorders agreement
Senetek plc Zeatin exclusive worldwide 5/04
licensing agreement
VWR Scientific biomedical research marketing and 5/99
Products Corp. products distribution
agreement for U.S.,
Canada and Puerto
Rico
RESEARCH & DEVELOPMENT: Drugs for the treatment of hepatitis C and hepatitis B and in the areas of
neurology and infectious disease
PRODUCTS ON MARKET: More than 575 branded products, including:
8-MOP™ (8 methoxypsoralen) 10 mg capsule for treatment of cutaneous T
cell lymphoma by extracorporeal photochemotherapy
Virazole™ (ribavirin) for treatment of viral diseases including hepatitis,
herpes, and childhood diseases such as chickenpox, approved in 43
countries
Virazole™ for respiratory syncytial virus (RSV), on market in the U.S.,
Canada, the U.K., Spain, Australia, Hungary, New Zealand, and 13 other
countries
Immunodiagnostic reagents and instruments
Neonatal thyroxine and thyroid-stimulating hormone diagnostic kits
Test for galactosemia in newborns
Dermatologicals and myasthenia product lines in U.S.
Multiple product lines abroad including antivirals, antibiotics,
dermatologicals, cardiovasculars, analgesics, antirheumatics, central
nervous systems compounds and vision care lines
Tasmar® (tolcapone) (EU)--acquired from Roche (9/04)
®
Varied Industries Corp.

905 South Carolina Avenue
Mason City IA 50401, US
Phone: (641) 423-1460; Fax: (515) 423-0832
Web: www.vi-cor.com, www.milktothemax.com
E-mail: vi-cor@vi-cor.com
KEY PERSONNEL: Mark Holt; President
Michael Lunning; Controller/Purchasing
John Oppy; Technical Services Specialist
Jodi Ames; Director, Marketing
Pioneer in the organic foods industry
SUBSIDIARIES/DIVISIONS: Fermented Products
SUBSIDIARY OF: Vi-COR
BUSINESS STRATEGY: Develop products for the production of naturally grown foodstuffs
RESEARCH & DEVELOPMENT: Biotechnical applications

Production of naturally grown foodstuffs
Fermented products
Plant extracts
Enzymes and microbial products
PRODUCTS ON MARKET: Lactic acid fermentation products
Desert plant extracts
Enzymes and microbial products
VECTOR State Research Centre of

Virology/Biotechnology
SRC VB Vector, Novosibirsk Region
Koltsovo 630559, Russia
Phone: +7 3832-36-60-10; Fax: +7 3832-36-74-09
Web: www.vector.nsc.ru; E-mail: lev@vector.nsc.ru
KEY PERSONNEL: Prof. Lev. S. Sandakhchiev; Director General
Jury I. Klimov; Exec. VP
Prof. Sergey V. Netesov; Scientific Director
Raisa A. Martynyuk; Director, R&D
EMPLOYEES: 1,056 employees, 143 Ph.D.s, 14 M.D.s, 1 D.V.M.
Level 3 and 4 biosafety laboratory
Full cycle biotech production facility
SUBSIDIARIES/DIVISIONS: Subsidiaries:
Vector-Pharm--production and sales company
Vector-Best--joint stock company
Vector-BiAlgam--production and sales company
®
Divisions:
Research Institute of Molecular Biology
Research Institute of Cell Cultures
Research Institute of Bioengineering
Research Institute of Aerobiology
Research and Design Institute of Biologically Active Substances
Institute of Collection of Cultures of Microorganisms
WHO Collaborating Center for Orthopoxvirus Diagnosis and Repository for
Variola Virus Strains and DNA
BUSINESS STRATEGY: Acknowledge structure function of virus genomes
Create highly sensitive diagnostic kits for viruses, prophylactics, and antiviral
and anticancer treatments
RESEARCH & DEVELOPMENT: Diagnostics kits

Antivirals
Vaccines
PRODUCTS ON MARKET: Diagnostic kit for HIV
Diagnostic kits for hepatitis A, B and C
Recolin--recombinant interferon
Profezyme
Reaferon ridostin
Hepatitis A vaccine
Measles vaccine
Nutrient media, sera
Enzymes
Biochemical reagents for laboratory studies
Alpha-interferon analogues in preclinicals
Subalin in preclinicals
Erythropoietin in preclinicals
TNF-beta analogue in preclinicals
Alnorin in Phase II clinicals
Virinova GbR
Luisenstrasse. 23 a
Burscheid 51399, Germany
Phone: +49 (0) 2174 671 9990; Fax: +49 (0) 2174 894501
Web: www.virinova.de; E-mail: contact@virinova.de
KEY PERSONNEL: Prof. H.J. Duerr; Managing Director
BUSINESS STRATEGY: Provide diagnostic technology enables the detection and quantification of
viruses without the use of PCR or antibodies
RESEARCH & DEVELOPMENT: Virus diagnostics for AIDS/HIV, hepatitis C (HCV), hepatitis B (HBV), herpes
simplex (HSV-1 and HSV-2), parvo B19, paramyxo virus, adeno virus, rhino
viruses, cytomegalo virus (CMV), parapox virus, foot and mouth disease
virus, several plant viruses
PRODUCTS ON MARKET: Novel virus diagnostic technology for process control and diagnostic
monitoring of viral infections
®
Vitrolife AB
Faktorvagen 13
Kungsbacka SE-434 37, Sweden
Phone: +46 31-721 80 00; Fax: +46 31-721 80 90
Web: www.vitrolife.com
E-mail: info@vitrolife.com
KEY PERSONNEL: Patrik Tigerschiold; Chairman
Dr. Magnus Nilsson; CEO
Christer de Flon; Director, Global Sales and Marketing and VP
Anna Ahlberg; CFO
Stefan Blomsterberg; Director, Logistics
Hans Lehmann; Director, Development
Goran Mellbin; Director, Quality Assurance and Quality Control
Neil Murphy; Director, Production
Emma Sjoqvist; Deputy Production Director
Tony Winslof; Director, Marketing
Nils Sellbom; President, Vitrolife Inc.
Vitrolife AB founded in 1997 as the group holding company
STOCK-FINANCIAL HISTORY: Listed on the Stockholm Stock Exchange since 2001
SUBSIDIARIES/DIVISIONS: Vitrolife Sweden AB
Faktorvagen 13
SE-434 37 Kungsbacka
Sweden
Vitrolife Inc.
3601 South Inca Street
Englewood, CO 80110
Swemed Lab International AB

Billdalsvagen 2
SE-427 36 Billdal
Sweden
BUSINESS STRATEGY: Provide innovative enabling technologies and products
Develop and market complex but convenient ready-to-use/ready-to-choose
solutions
Target and work with opinion leaders in marketing/sales and R&D
Position Company to benefit from regulatory environment
Control in-house manufacturing
RESEARCH & DEVELOPMENT: Cell Therapy:

Media to enable the use of stem cells for therapeutic purposes
Transplantation:
Solutions and systems to maintain tissue in optimal condition outside the
body for the required time while waiting for transplantation. New product
CE-marked January 2006: Steen Solution™
Fertility:
Nutrient solutions (media) and advanced one-time instruments such as
needles and pipettes, for the treatment of human infertility
PRODUCTS ON MARKET: EmbryoGlue®
Culture media
Media for micro-manipulation
Media for sperm preparation
Freeze-Kit1™ (for embryos)
Thaw-Kit1™ (for embryos)
®
VitroHES
Perfadex®
Steen Solution™
ClearVision™ ETC
Needles
Pipettes
Vizon SciTec Inc.

BC Research Complex, 3650 Wesbrook Mall
Vancouver V6S 2L2, Canada
Phone: (604) 224-4331; Fax: (604) 224-0540
Web: www.vizonscitec.com
E-mail: info@vizonscitec.com
KEY PERSONNEL: Brian Nixon; President and CEO
Purchased the assets of the British Columbia Research Corp. from
bankruptcy (1993)
Acquired Silvagen Inc.
Acquired Lockhart Risk Management
Formerly operated as BC Research Inc.
Acquired by Cantest Ltd. (8/06)
FACILITIES: 185,000 sq. ft.research complex on 10 acres
PRIVATE PLACEMENTS: Initial investment in new corporation (6/93)
BUSINESS STRATEGY: Contract R&D and joint ventures, product development
Commercialize environmental and biotech technologies
Silvagen Inc. tissue culture spruce exclusive 4/91
licensing/partnership
agreement
Various clean fuel engine licensing
companies system agreements
Various process chemistry licensing
companies agreements
RESEARCH & DEVELOPMENT: Forest and agriculture biotechnology, environmental toxicity and chemical
analysis, biological and chemical treatment, ocean engineering, clean fuels,
automotive structures, ergonomics systems
PRODUCTS ON MARKET: Chemical services: Analytical chemistry, methods development, chemical
GLP services, environmental processes, thermochemical processes,
electrochemical processes, chemical product development, chemical
product evaluation, material and surface science investigation, chemical
engineering
Biotechnology services: Custom genetic analysis, (DNA fingerprinting,

sequencing, cloning, PCR analysis and primer design), seed orchard
monitoring, plant bioassays for phytotoxicity assessment, in vitro efficacy
testing of antimicrobial compounds, bacterial diversity assessments, applied
plant pathology research
Toxicology: Aquatic toxicology, evaluation and monitoring of chemicals,

contaminants, industrial effluents, and environmental effects
®
Technology assessment and development: Bench-scale proof-of-concept,

pilot plant development and scale up, market assessment, intellectual
property management, literature searches and patent assessments
Mining: Acid mine drainage, acid rock drainage and metal leaching services
(geochemical characterisation, mineralogical analysis, static testing, kinetic
testing); mineral processing and hydrometallurgy testing services (project
design and management, mineral processing, hydrometallurgy, pilot
studies); water and waste water treatment services (laboratory testing and
characterisation, pilot scale testing)
Energy and environment: Evaluation of technologies designed to improve air

quality, reduce greenhouse gas and other emissions and improve energy
efficiency; provision of energy market insight to assist customers with
technology purchases or other business decisions; assistance with energy
management initiatives; third party review of environmental and energy
usage implications of business investments; assistance with energy utilities'
integrated resource planning activities; verification and monitoring of
greenhouse gas offsets, both from the purchaser's and vendor's
perspectives
Environment, Health and Safety: Safety management, occupational hygiene,

risk assessment and management, indoor air quality, industrial training
Wako Chemicals U.S.A. Inc.

1600 Bellwood Road
Richmond VA 23237-1326, US
Phone: (804) 271-7677; Fax: (804) 271-7791
Web: www.wakousa.com
E-mail: information@wakousa.com
KEY PERSONNEL: Hiroshi Shima; President
Acquired the LAL business of Haemachem Inc. (2/02)
SUBSIDIARY OF: Wako Pure Chemical Industries Ltd.
Assure customers' and vendors' success through:
-Integrating our international cultural attributes
-Supplying unique and innovative quality products
-Committing to safety, employee effectiveness, the highest level of integrity
and a strong sense of public responsibility
PRODUCTS ON MARKET: Hemoglobin - Hemoglobin B, UIBC - L-Type UIBC, Ketones,

Hydroxybutyrate - Autokit 3-HB, Fatty Acids, Free - NEFA C, Total Ketone -
Autokit Total Ketone Bodies, Albumin - Albumin HR2, Direct Bilirubin - Direct
Bilirubin Vanadate, Bile Acids, Total - Total Bile Acids Kit, Total Bilirubin -
Total Bilirubin Vanadate, Total Protein - Total Protein 2HA, (CH50)
Complement, Total Activity - Autokit CH50, Apolipoprotein A1 - Autokit Apo
A1, Apolipoprotein A2 - Autokit Apo A2, Apolipoprotein B - Autokit Apo B,
Apolipoprotein C2 - Autokit Apo C2, Apolipoprotein C3 - Autokit Apo C3,
Apolipoprotein E - Autokit Apo E, Cholesterol Ester Transfer Protein - CETP
Test, HDL-Cholesterol - HDL-Cholesterol E, Triglycerides - L-Type TG H,
Creatinine, Lp(a) - Autokit Lp(a), Urine Total Protein - Autokit Micro TP
®
Waste Stream Technology Inc.

302 Grote Street
Buffalo NY 14207-2442, US
Phone: (716) 876-5290; Fax: (716) 876-2412
Web: www.sevenson.com/analytical, www.wastestream.com
E-mail: mbarnhart@sevenson.com
KEY PERSONNEL: Joseph V. Giacomazza; Project Manager
Dr. James Hyzy; Director of R&D/Operations Manager
Dr. Brian Schepart; Laboratory Director
Daniel Vollmer; QA/QC Officer
Maria Bradley; Radiochemistry Manager
Amy J. Toth; R&D Manager
Sidney Tyrrell; Assistant Laboratory Director
STOCK-FINANCIAL HISTORY: Parent company financials:
NASDAQ--SEVN
PRIVATE PLACEMENTS: $1M in start-up financing (1986-1987)
SUBSIDIARY OF: Sevenson Environmental Services Inc.
PRODUCTS ON MARKET: Analysis for organics by gas chromatography (GC) and GC/mass
spectrometry (GC/MS), analysis for metals by inductively coupled argon
plasma (ICAP) and flame/graphite furnace atomic absorption (FAA/GFAA),
and wet chemistry
Webs Ltd.
Ashbourne House, Waterperry Court, Middleton Road
Banbury OX16 4QG, UK
Phone: +44 (1295) 277272; Fax: +44 (1295) 264070
Web: www.websint.com
E-mail: info@websint.com
KEY PERSONNEL: Francis Saunders; Chairman and Managing Director
Stephen Pickin; Technical Director
BUSINESS STRATEGY: Provide toxicity monitor sales, laboratory analysis (water testing) and
effluent treatment consulting
RESEARCH & DEVELOPMENT: Toxicity monitors

PRODUCTS ON MARKET: Amtox nitrification inhibition monitor
®
Wedgewood Analytical Inc.

4123 E. La Palma Avenue, Suite 200
Anaheim CA 92807, US
Phone: (714) 577-5600; Fax: (714) 577-5688
Web: www.wedgewoodanalytical.com
E-mail: info@wedgewoodanalytical.com
KEY PERSONNEL: Dr. Wolfgang Babel; President and CEO
Dr. Ian Tribick; VP, Operations
Began biotech R&D in June 1979
Merged Innovative Sensors and Wedgewood Technology (2004)
Purchased Stip (2005)
Purchased Entech (2005)
FACILITIES: 31,000 sq. ft. manufacturing facility
STOCK-FINANCIAL HISTORY: Privately held by Endress +Hauser AG
BUSINESS STRATEGY: Balance growth through new product development as a liquid analytical
'specialist.' Offer the most complete line of liquid analytical instrumentation,
including optical (UV, absorbance, color, cell grwoth), pH, conductivity,
chlorine, dissolved oxygen, TSS, turbidity, TOC, BOD, COD, liquid interface
monitoring
RESEARCH & DEVELOPMENT: Multi-ion and optical sensors and transmitters

PRODUCTS ON MARKET: Optical: absorbance, ultraviolet, color, suspended solids, turbidity, NIR
Electrochemical: pH / ORP, conductivity, dissolved oxygen, chlorine, ISE
Westbridge Research Group

1150 Joshua Way
Vista CA 92083, US
Phone: (760) 599-8855; Fax: (760) 599-6965
Web: www.westbridge.com
E-mail: wrg@westbrige.com
KEY PERSONNEL: Tina Koenemann; President
Dr. Lawrence W. Parker; Director, R&D
Javier Lopez; Production Manager
Nancy Tami; Manager, Quality Control
STOCK-FINANCIAL HISTORY: Publicly held, trading restricted
$4.5M initial capital from limited partnership (4/82)
Net <loss. Income $11.967K (YE 04) compared to <$6.711K> (YE 03)
Earnings <loss> per share $0.01/share (YE 04) compared to <$0.03/share>
(YE 03)
PRIVATE PLACEMENTS: $1.9M RDLP and $1M equity (4/85)
$2.7M Reg D offering (1/88)
$892K (9/91)
$700K notes (9/91)
®
SUBSIDIARIES/DIVISIONS: Westbridge Agricultural Products

BUSINESS STRATEGY: Develop and manufacture environmentally safe products for agriculture, turf,
lawn and garden, odor control and bioremediation products for agriculture,
industrial and municipal wastes
PRODUCTS ON MARKET: Soil Triggrr® plant growth regulator

Foliar Triggrr® plant growth regulator
Sunburst® fertilizers
ST-12™ odor control
BNB 931™ bioremediation nutrient blend
BNB Micro™
BNB Micro+™
Suppress® odor control
Biolink® organic farm inputs
Weyerhaeuser Co.
33663 Weyerhaeuser Way South
Federal Way WA 98003, US
Phone: (253) 924-2345; Fax: (253) 924-2685
Web: www.weyerhaeuser.com
E-mail: info@weyerhaeuser.com
KEY PERSONNEL: Steven R. Rogel; Chairman, President and CEO
Richard E. Hanson; Exec. VP and COO
Susan M. Mersereau; Sr. VP, Information Technology and CIO
Richard J. Taggart; Exec. VP and CFO
George H. Weyerhaeuser Jr.; Sr. VP, Technology
Divested aquaculture and hydroponics business divisions (1988)
Divested Personal Care Products and GNA Insurance (1993)
STOCK-FINANCIAL HISTORY: NYSE--WY
Three-for-two stock split (6/88)
Board authorized issue of 400M shares of common stock (6/88), 202M
shares outstanding
Net income $733M (YE 05) compared to $1.283b (YE 04)
SUBSIDIARIES/DIVISIONS: Five major business segments:
Timberlands--Grows and harvests trees in renewable cycles
Wood Products--Manufactures and distributes building materials for homes
and other structures
Pulp and Paper--Produces a variety of papers, and the pulp to produce
papers, absorbent products for specialty uses such as photographic film
Containerboard Packaging and Recycling--Produces paper, boxes and bags
to move products from factory to store to consumer. Collects and recycles
wastepaper, boxes and newsprint to make new products
Real Estate--Builds single- and multi-family homes and develops land

Biopulping lignin degrading fungi collaborative
Consortium research agreement
(University of
Wisconsin and
USDA)
Chiron Corp. cellulose and other research agreement
projects
®
Plant Genetics embryogenesis and R&D agreement

Inc. artificial seed
Plant Genetics Gel-Coat technology for development and
Inc. specific woody plants licensing agreement
and ornamentals
RESEARCH & DEVELOPMENT: Tree cell and tissue culture

Economic mass propagation of high-value forest trees
Genetic transformation
Selection of high-value genotypes and varieties of forest trees
Forest establishment and management technologies
New biological products, wood-based products
Wood processing technologies
Environmental research: wildlife, hydrology, fisheries, waste management
Pulp, paper, and packaging technologies
PRODUCTS ON MARKET: Forestry products
Genetically improved seeds, including loblolly and ponderosa pines and
Douglas fir
Nursery and garden supply products, chemicals
Xethanol Corp.
1185 Avenue of the Americas, 20th Floor
Phone: (646) 723-4000; Fax: (646) 723-4001
Web: www.xethanol.com; E-mail: inquiries@xethanol.com
KEY PERSONNEL: Christopher d’Arnaud-Taylor; Chairman, President and CEO
Larry Bellone; CFO
Franz A. Skryanz; VP, Secretary and Treasurer
Robin Buller; VP, Operations
Jim Stewart; VP, Plant Operations and GM, Xethanol BioFuels
David Kreitzer; VP, Business Development
Mark Austin; Chief Technology Strategist
HISTORY: Founded in January 2000 as Freereal-Timequote.com Inc.
Acquired Permeate Refining Inc. (8/03)
Merged with Zen Acquisition Corp. (2/05)
Acquired Advanced Biomass Gasification Technologies Inc. from UTEK
Corp. (6/06)
FACILITIES: Two 25,000 sq. ft. ethanol production facilities in Iowa
STOCK-FINANCIAL HISTORY: AMEX--XNL
Formerly listed on the OTC BB--XTHN (through 6/06)
Net sales $4.343M (YE 05) compared to $465K (YE 04)
04)
PRIVATE PLACEMENTS: Raised $34M in equity capital (4/06)
SUBSIDIARIES/DIVISIONS: Xethanol BioFuels LLC--Blairstown, Iowa
PRINCIPAL INVESTORS: Fusion Capital Fund II LLC
®
BUSINESS STRATEGY: Increase production capacity at Iowa facilities through physical expansion
using cutting-edge engineering design and integrating processing
technologies
Employ a regional approach to new ethanol production by focusing on port
sites and coastal urban areas on the Atlantic and Gulf coasts
Employ a sector strategy to expansion by focusing on the forests products
industry
Aventine Xethanol products distribution
agreement
Forest Products engineering of CRADA
Laboratory genetically modified
yeasts to decrease
fermentation time of
feedstocks in the
production of ethanol
and/or xylitol
National Clean Fractionation research agreement
Renewable technology
Energy Laboratory
Queens University development of a research agreement
process to reduce the
time required to ferment
feedstock in the
production of ethanol
Virginia investigation of the research alliance
Polytechnic effect of newly
Institute developed enzymes on
feedstocks
RESEARCH & DEVELOPMENT: Production of ethanol and related products using locally available biomass
rather than corn as the primary raw material
Yeda Research and Development Co. Ltd.

Weizmann Institute of Science, P.O. Box 95
Rehovot 76100, Israel
Phone: +972 8-947-0617; Fax: +972 8-947-0739
Web: www.yedarnd.com; E-mail: info.yeda@weizmann.ac.il
KEY PERSONNEL: Prof. Haim Garty; Chairman
Amir Naiberg.; CEO
Einat Zisman, Ph.D.; CBO
Ziv Hermon, Ph.D.; Sr. Licensing Officer
Noa Shelach, Ph.D.; Sr. Licensing Officer
Gil Granot-Mayer, Adv; General Counsel
Cohen Yaacov; CFO
Ruth Granoth, Ph.D.; Chief Intellectual Property Officer
FACILITIES: Offices located at the Weizmann Institute of Science
STOCK-FINANCIAL HISTORY: Technology transfer entity
BUSINESS STRATEGY: Serve as a patent and licensing organization that acts as an intermediary
with industry and investors interested in licensing technologies from the
Weizmann Institute in return for commitment to develop the technologies
into products & payment of financial considerations to the Institute.
®
RESEARCH & DEVELOPMENT: Biochemistry, genetics, immunology, virology, cancer, , neurobiology,

industrial and specialty chemicals, nanotechnologies membranes, plant
genetics, bioinformatics and proteomics, diagnostics
PRODUCTS ON MARKET: Copaxone® synthetic copolymer for treatment of multiple sclerosis (licensed
to Teva Pharmaceuticals)
Rebif® (recombinant interferon beta) for multiple sclerosis and several viral
diseases (licensed to InterPharm Laboratories Ltd.
Dunaliella (beta carotene) health food product with potential anticancer
properties (licensed to Nikken Sohosha)
GeneCards® bionformatics database
Improved crop varieties and hybrid cultivars of cucumbers and melons
(licensed to Isreali seed companies)
Yissum Research Development Co.

P.O. Box 39135
Jerusalem 91390, Israel
Phone: +972 2-658-6688; Fax: +972 2-658-6689
Web: www.yissum.co.il; E-mail: tamir@yissum.co.il
KEY PERSONNEL: Dr. Giora Yaron; Chairman
Nava Swersky Sofer; CEO
Tamir Huberman; Director, IT
Zvika Weiss; CFO
Renee Ben-Israel; VP, Intellectual Property
Gustavo Fuchs; Technology Officer
Ken Shaked; VP, Portfolio Companies
Ziv Shomroni; VP, Nature Science and Agriculture
Elena Canetti; VP, Marketing, Scientific Services
Yehuda Yarmut; Exec. VP
Tami Kfir; VP, Marketing, Healthcare
HISTORY: Founded in 1964 to commercialize R&D developed at the Hebrew University
of Jerusalem
FACILITIES: Multipurpose chemical pilot plant
Environmental R&D laboratories
Pharmacokinetic and biopharmaceutic research laboratory
SUBSIDIARY OF: Hebrew University of Jerusalem
BUSINESS STRATEGY: Establish R&D, licensing, and joint venture agreements with numerous
companies worldwide in all areas
BioLineRx Ltd. BL-3020 licensing agreement 7/06
RESEARCH & DEVELOPMENT: Applied research in biotechnology, agriculture, chemistry, medical sciences
and pharmaceuticals using organisms and products of organisms in
biological processes, genetic engineering, food sciences, physical sciences
and environmental sciences
PRODUCTS ON MARKET: Diagnostic kits for screening of urinary tract infections and detection of
antibiotics in milk
Cherry tomatoes--cocktail hybrids
New Drugs:
Doxil--an approved and clinically used anticancer drug
Exelon--a new treatment for Alzheimer's disease
®
YMC Co. Ltd.

YMC Karasuma Gojo Building, 284 Daigo-cho
Karasuma Nishiiru, Gojo-dori, Shimogyo-ku
Kyoto 600-8106, Japan
Phone: +81 75-342-4510; Fax: +81 75-342-4511
Web: www.ymc.co.jp; E-mail: sales@ymc.co.jp
KEY PERSONNEL: Ryuji Yamamura; CEO
Masaru Wakeshima; Exec. VP
Takamaru Komatsu; Exec. Director
Naohiro Kuriyama; Director, R&D
EMPLOYEES: 112 employees, 2 Ph.D.s, 27 M.D.s
Established YMC Europe GmbH in 1993
FACILITIES: R&D labs, technology development center and S&S (separation and
synthesis) center and production facilities (YSP-2, YSP-3, YSP-4)
SUBSIDIARIES/DIVISIONS: YMC Europe GmbH
Seika Corp. of America
Kyoto Chromato Co. Ltd.
Synthesis and separation division
Chromatography division
Sales and marketing division
BUSINESS STRATEGY: Meet a greater diversity of markets by offering a wide variety of products
RESEARCH & DEVELOPMENT: Chromatography and purification technology

Fine chemicals synthesis
PRODUCTS ON MARKET: Packed columns and packing materials for HPLC
Preparative HPLC instruments
Synthensis and separation technology
Various peptides in development
Glucose and oligosaccharide separation in development
Separation and purification system in development
Various packing materials for in development
chromatography
Zeltia SA
Jose Abascal St. 2
Madrid 28003, Spain
Phone: +34 91 444 4500; Fax: +34 91 593 2954
Web: www.zeltia.com
E-mail: zeltia@zeltia.com
KEY PERSONNEL: Jose Maria Fernandez Sousa-Faro; Chairman and CEO
Maria Luisa Francia; CFO
Teresa Garcia Buey; Director, Corporate Communications
Isabel Lozano; Managing Director, PharmaMar
Rosario Cospedal; Managing Director, Genomica
Gonzalo Duran; Managing Director, Zelnova
Jose Benito Mallo; XylaZel
®
STOCK-FINANCIAL HISTORY: Mercado Continuo--ZEL

Net sales EUR471K (YE 05) compared to EUR669K (YE 04)
Operating loss <EUR8.397M> (YE 05) compared to <EUR8.701M> (YE 04)
PRIVATE PLACEMENTS: Raised EUR65M through private placement of 10.75M shares at
EUR6.05/share (6/05)
SUBSIDIARIES/DIVISIONS: Zeltia Group:
PharmaMar SA
Genomica SAU
Neuropharma SA
Xylazel SA
Promax SA
Zelnova SA
Branch offices in France, Germany, Britain and Italy
BUSINESS STRATEGY: Operate as a biopharmaceutical leader in oncology-advancing cancer care
through the discovery and development of innovative marine-derived
medicines
PRODUCTS ON MARKET: Various products through the Zeltia Group
Zeon Corp.
Shin Marunouchi Center Building, 1-6-2 Marunouchi, Chiyoda-ku
Phone: +81 3-3216-1772; Fax: +81 3-3216-0501
Web: www.zeon.co.jp
E-mail: saitoh@lab.zeon.co.jp
KEY PERSONNEL: Katsuhiko Nakano; Chairman
Naozumi Furukawa; President and CEO
Masahiro Yamazaki; Exec. Managing Director
Tadao Natsuume; GM, R&D Center
HISTORY: Established in April 1950 by three Japanese companies in the Furukawa
Group--Furukawa Electric
Co. Ltd., Yokohama Rubber Co. Ltd. and Nippon Light Metal Co. Ltd.
Formed Syntro Zeon LC, a joint venture between Nippon Zeon of America
Inc. and Syntro Venture Corp., to commercialize poultry vaccines resulting
from existing development program of parent companies (2/93)
Changed name from Nippon Zeon Co. Ltd. (7/00)
FACILITIES: Headquarter facilities in Tokyo
Plants in Kawasaki, Tokuyama, Mizushima and Takaoka
Offices in Nagoya and Osaka
STOCK-FINANCIAL HISTORY: Tokyo Stock Exchange--ZEON
Listed on Osaka Stock Exchange
SUBSIDIARIES/DIVISIONS: Rubber Division
Latex Division
Chemicals Division
Specialty Plastics Division
Specialty Chemicals Division
Specialty Materials Division
53 subsidiaries
®
BUSINESS STRATEGY: Continually focus on creating new businesses, taking full advantage of
steady revenue generated by existing businesses
Delaware fowlpox vectored cooperative R&D 1994
University vaccine for infectious agreement
laryngotracheitis
vaccine
Syntro Corp., recombinant viral development 9/90

Hoechst-Roussel vaccines for poultry agreement--Nippon
Agri-Vet Corp. Zeon to fund Syntro
development,
testing, and ultimate
registration of
poultry vaccines--
Syntro to get U.S.
manufacturing
rights, Syntro Zeon
to receive domestic
marketing rights
USDA/ARS fowlpox vectored cooperative R&D 1992
vaccines for coccidiosis agreement
USDA/ARS fowlpox vectored cooperative R&D 1990
vaccines for Marek's agreement
disease and other
poultry diseases
RESEARCH & DEVELOPMENT: C5 chemicals technology: Organic synthesis technology and monomer
extraction technology
Polymer technology: Elastomer technology and cyclo-olefinpolymer
technology
Precision modeling technology: Film molding and ultra-fine molding
technology
Bio-technology: Recombinant DNA technology
PRODUCTS ON MARKET: Synthetic rubbers
Imaging and electronics materials
Specialty plastics
Environmental materials
Synthetic latices
Toner
RIM
Medical products: Cardiovascular, nutritional and gastrointestinal products
(from ZEON Medical Inc.)
Chemicals: Quintone 100 series (aliphatic hydrocarbon resin), Quintone
1000 series (alicyclic hydrocarbon resin), Quinhard series (acid anhydride
type epoxy resin hardening agent), Quinflow series (polycarboxilic acid
sodium or ammonium salt, water type dispersant), Quintac series (styrene
isoprene block polymer)
Specialty chemicals: Aroma chemicals include cis-3-Hexenol (leaf alcohol)
and leaf esters, Claigeon® (methyl dihydrojasmonate), Cepionate® (methyl
epi-dihydrojasmonate), Jasmoneige® (methyl jasmonate), Zeppin® (methyl
epi-jasmonate), delta-lactones, Triflaige®, alkyl cyclopentanones,
hydrocarbons, alcohols, 5-membered ketones, hero compounds,
heterocyclic compounds, Zorora®H fluoride compound, Zeorola®-H,
Zeonsolve® HP (cyclopentane)
®
Zuckerforschung Tulln GmbH

Reitherstrasse 21-23
Tulln A-3430, Austria
Phone: +43 2272-602-11402; Fax: +43 2272-602-11420
Web: www.zuckerforschung.at
E-mail: info@zuckerforschung.at
KEY PERSONNEL: Mag. Gerhard Robl; Commercial Manager
Dr. Dietmar Grüll; Technical Manager
Dr. Herbert Wesner; Technical Manager
Changed name from Raiffeisen-Bioforschung GmbH (1994)
FACILITIES: 2,000 sq. m. of laboratory space
Pilot plant with fermentors, chamber filter press, separators, spray-dryer,
autoclaves, chemical pilot plant and extruder
PRINCIPAL INVESTORS: Agrana Zucker GesmbH
Agrana Starke GesmbH
Bioethanol GmbH
BUSINESS STRATEGY: Provide R&D for Austrian sugar, starch & Bioethanol industry
Render essential services to agriculture and industry by developing products
and technology that promote the use of renewable resources in the
manufacturing industry
RESEARCH & DEVELOPMENT: Sugar technology, modified starches for food and non-food, feedstuff,
cereals, baby food, modified proteins, wastewater treatment and improved
crops
Biotechnology
Bioethanol
PRODUCTS ON MARKET: Culture collection (catalog available)
®
®
BioWorld
I NDUSTRIAL
B IOTECHNOLOGY
S TAT REPORT
SUBJECT INDEX
®
SUBJECT INDEX
Droycon BioConcepts Inc.
EnSolve Biosystems Inc.
Biopreservation Enviro-Zyme International LLC
A/F Protein Inc. Epidauros Biotechnologie AG
Agrium Inc. Fraunhofer Institute for Interfacial Engineering
Argonne National Laboratory and Biotechnology
Biologos Inc. General Electric Global Research
Bioscience Inc. Genomatica Inc.
BioTime Inc. HaloSource Inc.
Chembiotech Ltd. Harvard Bioscience Inc.
Chr. Hansen Inc. Helmholtz Centre for Infection Research
CryoLife Inc. Imperial Innovations Ltd.
Don Whitley Scientific Ltd. Institute for Biological Research and
Encelle Inc. Technology
Epidauros Biotechnologie AG
Geneva Scientific
Lawrence Berkeley National Laboratory
Gentra Systems Inc.
LGC (Laboratory of the Government Chemist)
Harvard Bioscience Inc.
MBI International
ICPbio
Mo Bio Laboratories Inc.
Lake States
LifeCell Corp.
NanoLogix Inc.
Maine Biotechnology Services Inc.
Nature Plus Inc.
New Brunswick Scientific Co. Inc.
New Horizons Diagnostics Corp.
Snamprogetti Services SpA
TNO Quality of Life
Vizon SciTec Inc.
Novozymes A/S
Zeltia SA
Novozymes Inc.
Bioremediation Organo Corp.
Agrium Inc. Pacific Biodiesel Inc.
Ag-West Bio Inc. Pacific Northwest National Laboratory
Alberta Research Council Inc. Pall Corp.
Altus Pharmaceuticals Inc. PBR Laboratories Inc. (PBR)
Aluline Ltd. Ramot at Tel Aviv University Ltd.
ARC Geobac Group Inc. RECO Biotechnology
Argonne National Laboratory Research Triangle Park Laboratories Inc.
astre Corp. RTI International
Bayer Corp. Spark Holland BV
Bioclear BV Stewart Agricultural Research Services Inc.
BioGenesis Enterprises Inc. Symbio
Biogenie Inc. The Nitrate Elimination Co. Inc.
Biolog Inc. UniQuest Pty. Ltd.
Biopraxis Inc. University of Nebraska-Lincoln, Center for
BioPro International Inc. Biotechnology
Bioscience Inc. Varied Industries Corp.
Bio-Technical Resources VECTOR State Research Centre of
Biotechnology Research Institute Virology/Biotechnology
Biotehnos SA Vizon SciTec Inc.
Boojum Research Ltd. Waste Stream Technology Inc.
CABI Westbridge Research Group
Chembiotech Ltd.
Commercial Microbiology Ltd. Biosensors
Cornell Institute for Biotechnology and Life
Science Technologies AEA Technology plc
AgResearch Ltd.
Ajinomoto Co. Inc.
Biotechnology)
Diversa Corp.
Altus Pharmaceuticals Inc.
®
AMDL Inc. Cardinal Health - Middleton

Analox Instruments Ltd. Ceapro Inc.
Analox Instruments U.S.A. Celsis International plc
Applied Biosystems Inc. Chemeq Ltd.
astre Corp. CUBIA (University Centre for Algal
Biocatalysts Ltd. Biotechnology)
BioForce Nanosciences Inc. Cyanotech Corp.
BioGenes GmbH Daiichi Pharmaceutical Co. Ltd.
Bionas GmbH Diversa Corp.
BIOPAC Systems Inc. Dong-A Pharmaceutical Co. Ltd.
Biopraxis Inc. DSM
BioPro International Inc. Epidauros Biotechnologie AG
Bio-Technical Resources F. Hoffmann-La Roche Ltd.
Biotechnology Research Institute FibroGen Inc.
Cornell Institute for Biotechnology and Life Galderma SA
Science Technologies Geneva Scientific
Epidauros Biotechnologie AG HaloSource Inc.
Eurogentec SA Harvard Bioscience Inc.
Helmholtz Centre for Infection Research IGENE Biotechnology Inc.
Idexx Laboratories Inc. inGenious Targeting Laboratory Inc.
Israel Institute for Biological Research (IIBR) Isolagen Inc.
LGC (Laboratory of the Government Chemist) Kanebo Ltd.
LifeSensors Inc. Kraeber GmbH & Co.
MBI International Lavipharm SA
Megabase Research Products LGC (Laboratory of the Government Chemist)
Microbe Inotech Laboratories Inc. Maruzen Pharmaceuticals Co. Ltd.
MoBiTec GmbH MedPharm Ltd.
Molecular Devices Corp. Merck KGaA
Molecular Probes Inc. Morishita Jintan Co. Ltd.
NanoHorizons Inc. Nanophase Technologies Corp.
National Research Council of Canada New Brunswick Scientific Co. Inc.
North Carolina Biotechnology Center New Zealand Pharmaceuticals Ltd.
november AG Norac Technologies Inc.
Organo Corp. North Carolina Biotechnology Center
Pall Corp. Novozymes A/S
PBR Laboratories Inc. (PBR) Optigenex Inc.
Pharmbiodyn Consulting Group Pentapharm Ltd.
Ramot at Tel Aviv University Ltd. Pharmbiodyn Consulting Group
The Nitrate Elimination Co. Inc. PLANTON GmbH
TNO Quality of Life Polysciences Inc.
Union Chemical Laboratories (UCL) POS Pilot Plant Corp.
University of Nebraska-Lincoln, Center for Prokaria ehf
Biotechnology Proteus SA
Vizon SciTec Inc. Ramot at Tel Aviv University Ltd.
Webs Ltd. Renovo Group plc
Yissum Research Development Co. Sensient Technologies Corp.
Wako Chemicals U.S.A. Inc.
Cosmetics Yissum Research Development Co.
3DM Inc.
A/F Protein Inc.
Energy/Biomass
Acadian Seaplants Ltd. Abengoa SA
AGI Dermatics Advanta Seeds UK Ltd.
Altair Nanotechnologies Inc. Agrium Inc.
Arch Personal Care Products LP Ag-West Bio Inc.
Arysta LifeScience Corp. Alberta Research Council Inc.
Atrium Biotechnologies Inc. ARC Geobac Group Inc.
BioMerieux INDUSTRY Archer Daniels Midland
Bionas GmbH Argonne National Laboratory
Bioriginal Food & Science Corp. Athenix Corp.
BioScreen Testing Services Inc. BASF AG
Bio-Technical Resources Bioclear BV
Biotehnos SA Bionov CNP Inc.
BRAIN (Biotechnology Research and Bio-Technical Resources
Information Network AG) Biotehnos SA
®
Bioxel Pharma Inc. Biosynth International Inc.

Canadian Forest Service Biotechnology Research Institute
Canadian Seed Coaters Boojum Research Ltd.
Celsis International plc CABI
Ceres Inc. Cantest Ltd.
Chembiotech Ltd. Celsis International plc
Cornell Institute for Biotechnology and Life Centre for Innovative Biology and
Science Technologies Environmental Technology
CUBIA (University Centre for Algal Chembiotech Ltd.
Biotechnology) Commercial Microbiology Ltd.
Diversa Corp. Cornell Institute for Biotechnology and Life
DOE Joint Genome Institute Science Technologies
EnSolve Biosystems Inc. Dojindo Laboratories
Epicore Networks (U.S.A.) Inc. Don Whitley Scientific Ltd.
Fraunhofer Institute for Interfacial Engineering General Electric Global Research
and Biotechnology Hammen Corp.
Genencor International Inc. Helmholtz Centre for Infection Research
General Electric Global Research Hidex Oy
Idaho National Laboratory Huntingdon Life Sciences
Iogen Corp. Hybrizyme Corp.
Itochu Corp. Idexx Laboratories Inc.
J. Craig Venter Institute Imperial Innovations Ltd.
Lake States Institute for Biological Research and
Mascoma Corp. Technology
MBI International Itochu Corp.
National Research Council of Canada J. Craig Venter Institute
North Carolina Biotechnology Center Lawrence Berkeley National Laboratory
Novozymes A/S LGC (Laboratory of the Government Chemist)
Pacific Biodiesel Inc. Maxxam Analytics Inc.
Pennzoil Co. MBI International
Pfizer Inc. Merck KGaA
Recordati SpA Microbe Inotech Laboratories Inc.
Renessen LLC Mo Bio Laboratories Inc.
RTI International Molecular Devices Corp.
Scion - Cellwall Biotechnology Centre M-Scan Ltd.
Snamprogetti Services SpA MSE Technology Applications Inc.
SunOpta Inc. Nanogen Inc.
Synthetic Genomics Inc. National Institutes of Health (NIH)
University of Nebraska-Lincoln, Center for National Research Council of Canada
Biotechnology NatureWorks LLC
Xethanol Corp. Neogen Corp.
Environmental Analysis Omex Environmental Ltd.
Optronics
Agrium Inc. Organo Corp.
Ag-West Bio Inc. Pacific Northwest National Laboratory
Alderon Biosciences Inc. PBR Laboratories Inc. (PBR)
ANU Enterprise Pty. Ltd. Pfeiffer Vacuum Ltd.
Applera Corp. Randox Laboratories Ltd.
ARC Geobac Group Inc. Research Triangle Park Laboratories Inc.
Argonne National Laboratory Response Biomedical Corp.
Associates of Cape Cod Inc. RTI International
astre Corp. SafePath Laboratories LLC
BASF AG Spark Holland BV
Bayer Corp. Spherix Inc.
BioAssay Works LLC SRI International
Biocatalysts Ltd. Stewart Agricultural Research Services Inc.
Bioclear BV Strategic Diagnostics Inc.
BioGenes GmbH Symbio
Biolog Inc. Teledyne Isco
BioMed Diagnostics Inc. The Nitrate Elimination Co. Inc.
BioMerieux INDUSTRY TNO Quality of Life
BioMerieux SA University of Nebraska-Lincoln, Center for
Bionov CNP Inc. Biotechnology
Bioscience Inc. UVP Inc.
®
Varied Industries Corp. New Zealand Pharmaceuticals Ltd.

Virinova GbR Nigu Bioselect
Vizon SciTec Inc. North Carolina Biotechnology Center
Wako Chemicals U.S.A. Inc. OmniChem
Waste Stream Technology Inc. OmniGene Bioproducts Inc.
Webs Ltd. Optronics
Wedgewood Analytical Inc. PCI Membranes
Weyerhaeuser Co. PeproTech Inc.
Peptides International Inc.
Fine Chemicals Polium Technologies Inc.
Abbott GmbH & Co. KG Polysciences Inc.
Agrium Inc. POS Pilot Plant Corp.
Alberta Research Council Inc. Primm S.R.L.
Altus Pharmaceuticals Inc. Prokaria ehf
American Radiolabeled Chemicals Inc. Proteus SA
Athenix Corp. Reanal Finechemical Co.
Axxora Life Science Inc. Regis Technologies Inc.
BACHEM AG Research Organics Inc.
BASF AG Sakai Chemical Industry Co. Ltd.
Be-Long Group Sensient Technologies Corp.
Biologos Inc. Severn Biotech Ltd.
Biomol GmbH Snamprogetti Services SpA
Biosynth International Inc. Stewart Agricultural Research Services Inc.
Bio-Technical Resources Sumitomo Chemical Co. Ltd.
Biotecx Laboratories Inc. Toronto Research Chemicals Inc.
Bioxel Pharma Inc. Union Chemical Laboratories (UCL)
Cambrex Corp. University of Nebraska-Lincoln, Center for
Ceapro Inc. Biotechnology
Cuno Inc. Wako Chemicals U.S.A. Inc.
Daiichi Pharmaceutical Co. Ltd. Xinchem Corp.
Dainippon Sumitomo Pharma Co. Ltd. Yissum Research Development Co.
Dalton Pharma Services YMC Co. Ltd.
Dextra Laboratories Ltd. Zeltia SA
Diagnostic Chemicals Ltd. Zeon Corp.
Diversa Corp.
Dojindo Laboratories Industrial/Laboratory
DSM Fine Chemicals Enzymes
DuPont AB Enzymes Oy
EMD Biosciences Inc./Merck Biosciences Agrium Inc.
First Link (UK) Ltd. Alberta Research Council Inc.
Genencor International Inc. Altus Pharmaceuticals Inc.
Genomatica Inc. ANU Enterprise Pty. Ltd.
Genzyme Corp. Arch Chemicals Inc.
GL Biochem (Shanghai) Ltd. Argonne National Laboratory
Industrial Biotechnology Corp. Astellas Pharma Inc.
Institute of Food Research astre Corp.
Israel Institute for Biological Research (IIBR) Athenix Corp.
Itochu Corp. Bayou Biolabs
Johnson Matthey Pharma Services Biocatalysts Ltd.
Kaneka Corp. Biologos Inc.
Kirin Brewery Co. Ltd. Biomeda Corp.
Kraeber GmbH & Co. BioMerieux SA
Laboratoires Eurobio Biomol GmbH
Lake States Bioscience Inc.
LG Chem Ltd. Biotal Ltd.
LG Life Sciences Ltd. Biotehnos SA
Link Technologies Ltd. Biozyme Laboratories Ltd.
Lonza Group Ltd. Cambio Ltd.
MBI International Canadian Seed Coaters
Mercian Corp. Cardinal Health - Middleton
Merck KGaA Cargill Inc.
Microbia Inc. Centre for Innovative Biology and
Molecular Probes Inc. Environmental Technology
Nanophase Technologies Corp. Chembiotech Ltd.
®
Chunghwa Chemical Synthesis & Biotech Co. Showa Denko KK

Ltd. SibEnzyme Ltd.
Codon Devices Spark Holland BV
Cornell Institute for Biotechnology and Life Stratagene Corp.
Science Technologies Symbio
Cosmo Bio Co. Ltd. Synthetech Inc.
Diagnostic Chemicals Ltd. The Dow Chemical Co.
Digene Corp. The Nitrate Elimination Co. Inc.
Diversa Corp. Toray Industries Inc.
Dynavax Europe Union Chemical Laboratories (UCL)
EMD Biosciences Inc./Merck Biosciences University of Nebraska-Lincoln, Center for
eMembrane Inc. Biotechnology
EnSolve Biosystems Inc. Valeant Pharmaceuticals International Inc.
Enviro-Zyme International LLC Varied Industries Corp.
Enzyme Research Laboratories Ltd Wako Chemicals U.S.A. Inc.
EvoGenix Ltd. Waste Stream Technology Inc.
First Link (UK) Ltd. Yeda Research and Development Co. Ltd.
Fraunhofer Institute for Interfacial Engineering Zeltia SA
and Biotechnology
Genencor International Inc. Mining Biotechnology
Agrium Inc.
Hawaii Biotech Inc.
astre Corp.
Hercules Inc.
Be-Long Group
IGENE Biotechnology Inc.
Bioclear BV
Industrial Biotechnology Corp.
Chembiotech Ltd.
International Flavors & Fragrances Inc.
Iogen Corp.
Diversa Corp.
Itochu Corp.
Hammen Corp.
Kikkoman Corp. (Biochemicals Division)
Kirin Brewery Co. Ltd.
Nature Plus Inc.
KRKA d.d.
Kyorin Pharmaceutical Co. Ltd.
PrimeSyn Lab Inc.
UniQuest Pty. Ltd.
Lake States
UVP Inc.
Marcor Development Corp.
Vizon SciTec Inc.
MBI International
MDS Pharma Services
Meiji Seika Kaisha Ltd. Oil Recovery
Merck KGaA Biotehnos SA
Microbe Inotech Laboratories Inc. Biothane Corp.
Microbia Inc. Chembiotech Ltd.
National Institutes of Health (NIH) Commercial Microbiology Ltd.
National Research Council of Canada Diversa Corp.
New Brunswick Scientific Co. Inc. Epicore Networks (U.S.A.) Inc.
New England BioLabs Inc. Geneva Scientific
Nitto Denko Corp. HaloSource Inc.
North Carolina Biotechnology Center MSE Technology Applications Inc.
Novozymes A/S National Research Council of Canada
Novozymes Inc. North Carolina Biotechnology Center
Optronics Novozymes A/S
Pall Corp. Novozymes Inc.
Paprican Pacific Biodiesel Inc.
PBR Laboratories Inc. (PBR) RECO Biotechnology
PCI Membranes Snamprogetti Services SpA
Pfizer Inc. Vizon SciTec Inc.
PLANTON GmbH Yissum Research Development Co.
Polium Technologies Inc.
Prokaria ehf Specialty Chemicals
Proteus SA
Qbiogene Acadian Seaplants Ltd.
Recordati SpA Agrium Inc.
Roal Oy Ajinomoto Co. Inc.
Sanyo Chemical Industries Ltd. (Sanyo Kasei) Akzo Nobel NV
Sensient Technologies Corp. Altus Pharmaceuticals Inc.
®
Aluline Ltd. LANXESS AG

American Radiolabeled Chemicals Inc. LG Chem Ltd.
Applied Biosystems Inc. LG Life Sciences Ltd.
Arch Chemicals Inc. Mallinckrodt Inc.
Arch Personal Care Products LP Marcor Development Corp.
Archer Daniels Midland Matreya LLC
Argonne National Laboratory MBI International
Asahi Kasei Corp. Merck KGaA
Astellas Pharma Inc. Microbia Inc.
Athenix Corp. Molecular Probes Inc.
Atrium Biotechnologies Inc. Monsanto Co.
Axxora Life Science Inc. Nanophase Technologies Corp.
BAC BV (Biotechnology Application Centre) Nature Plus Inc.
BACHEM AG New Zealand Pharmaceuticals Ltd.
Bachem California Inc. Nigu Bioselect
Bangs Laboratories Inc. North Carolina Biotechnology Center
BASF AG Noven Pharmaceuticals Inc.
Be-Long Group OmniChem
Biocatalysts Ltd. OmniGene Bioproducts Inc.
BioGenesis Enterprises Inc. Pacific Northwest National Laboratory
Bio-Lab Ltd. PCI Membranes
Biologos Inc. Pennzoil Co.
Biomedical Technologies Inc. Pentapharm Ltd.
Biomol GmbH Peptides International Inc.
Biopraxis Inc. Pfizer Inc.
Bioscience Inc. Polium Technologies Inc.
Bio-Technical Resources Polydex Pharmaceuticals Ltd.
Biotecx Laboratories Inc. Polysciences Inc.
BioVectra dcl Procter & Gamble Co.
Boston Life Sciences Inc. Prometic BioSciences Inc.
Calzyme Laboratories Inc. Proteus SA
Cambrex Corp. Quip Laboratories Inc.
Ceapro Inc. Recordati SpA
Chembiotech Ltd. Regis Technologies Inc.
ChemGenes Corp. Research Organics Inc.
Commercial Microbiology Ltd. Sanyo Chemical Industries Ltd. (Sanyo Kasei)
Cosmo Bio Co. Ltd. Sensient Technologies Corp.
Cyanotech Corp. Showa Denko KK
Dalton Pharma Services Solomon Park Research Laboratories
Dextra Laboratories Ltd. SRI International
Dextran Products Ltd. Stewart Agricultural Research Services Inc.
Diagnostic Chemicals Ltd. Sumitomo Chemical Co. Ltd.
Diversa Corp. Symbio
DNA Technologies Inc. Synthetech Inc.
Dojindo Laboratories Takeda Pharmaceutical Co. Ltd.
Dow AgroSciences LLC The Dow Chemical Co.
Dragon Pharmaceutical Inc. Toray Industries Inc.
DSM Fine Chemicals Toronto Research Chemicals Inc.
EMD Biosciences Inc./Merck Biosciences Union Chemical Laboratories (UCL)
EnSolve Biosystems Inc. University of Nebraska-Lincoln, Center for
Evolva SA Biotechnology
F. Hoffmann-La Roche Ltd. Valeant Pharmaceuticals International Inc.
First Link (UK) Ltd. Vitrolife AB
Genencor International Inc. Wako Chemicals U.S.A. Inc.
General Electric Global Research Wedgewood Analytical Inc.
HaloSource Inc. Xinchem Corp.
Helmholtz Centre for Infection Research Yeda Research and Development Co. Ltd.
IGENE Biotechnology Inc. Zeltia SA
International Flavors & Fragrances Inc. Zeon Corp.
Itochu Corp. Waste Treatment
Johnson Matthey Pharma Services
Kaneka Corp. Abengoa SA
Kraeber GmbH & Co. ADI Group Inc.
Kyowa Hakko Kogyo Co. Ltd. ADI Systems Inc.
®
AgResearch Ltd. RTI International

Ag-West Bio Inc. Spherix Inc.
Alltech Inc. Stewart Agricultural Research Services Inc.
Aluline Ltd. Strategic Diagnostics Inc.
ANU Enterprise Pty. Ltd. The Nitrate Elimination Co. Inc.
Applikon Biotechnology Inc. UniQuest Pty. Ltd.
ARC Geobac Group Inc. UVP Inc.
Arch Chemicals Inc. Varied Industries Corp.
astre Corp. Vizon SciTec Inc.
Be-Long Group Waste Stream Technology Inc.
Biocatalysts Ltd. Webs Ltd.
Bioclear BV Wedgewood Analytical Inc.
BioGenesis Enterprises Inc. Weyerhaeuser Co.
Biogenie Inc. Xethanol Corp.
Biolog Inc. Yissum Research Development Co.
Biopraxis Inc. Zeon Corp.
BioPro International Inc. Zuckerforschung Tulln GmbH
Bioscience Inc.
BioSure Inc.
Bio-Technical Resources
Biotechnology Research Institute
Biotehnos SA
Biothane Corp.
Centre for Innovative Biology and
Environmental Technology
Chembiotech Ltd.
Cornell Institute for Biotechnology and Life
Science Technologies
Biotechnology)
Dojindo Laboratories
eMembrane Inc.
Enviro-Zyme International LLC
Fraunhofer Institute for Interfacial Engineering
and Biotechnology
General Electric Global Research
HaloSource Inc.
Hammen Corp.
Helmholtz Centre for Infection Research
Idaho National Laboratory
Imperial Innovations Ltd.
Itochu Corp.
KRKA d.d.
MBI International
Nature Plus Inc.
Nigu Bioselect
Novozymes A/S
Novozymes Inc.
Organo Corp.
Pacific Northwest National Laboratory
Pall Corp.
Paprican
PCI Membranes
Proteus SA
RECO Biotechnology
®

Bioworld Statistics Report PDF

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Bioworld Statistics Report PDF

Uploaded by

Copyright:

Available Formats

BioWorld®

IMMEDIATE AND COMPREHENSIVE

Product code: SO7429

Senior Managing Editor: Michael Harris Senior Editor: Amanda Lyle

Vice President/Group Publisher: Donald R. Johnston

Customer Service: (800) 879-8790 or (404) 262-5526

Please visit our web site: www.bioworld.com

 The BioWorld Phase III Report – A quarterly compilation of biotechnology products in

For more information on BioWorld®, please contact:

Donald R. Johnston, VP/Group Publisher

HOW TO USE BIOWORLD STATREPORTS

FIELDS AND THEIR DESCRIPTIONS

Company Name and Address

Research and Development

Products on the Market

Dalton Pharma Services International Flavors & Fragrances Inc.

New Horizons Diagnostics Corp. Response Biomedical Corp.

RESEARCH & DEVELOPMENT: Orthopedic and reconstructive surgery medical devices

A/F Protein Inc.

STOCK-FINANCIAL HISTORY: Privately held

Main Office of ABF Ingredients Corp.

AB Enzymes GmbH Guangzhou

AB Enzimas Brasil Comercial Ltda.

AB Enzymes Singapore Branch

AB Enzymes Poland Sp. Z.o.o.

RESEARCH & DEVELOPMENT: Development of technical enzyme applications

Finase enzymes for feed and food

Abbott GmbH & Co. KG

PRODUCTS ON MARKET: Pharmaceuticals worldwide:

Pharma active ingredients worldwide:

Six operational fields: Energy, Environment, Transport, Services, Industry

Abengoa Bioenergy France

RESEARCH & DEVELOPMENT: Abengoa Bioenergy R&D Inc.:

Acadian Seaplants Ltd.

RESEARCH & DEVELOPMENT: Seaweed cultivation and processing

ADI Group Inc.

RESEARCH & DEVELOPMENT: Wastewater treatment processes

ADI Systems Inc.

ADI Systems Inc. Laboratory

Advanced Product Enterprises LLC

PRODUCTS IN DEVELOPMENT: Name Status

Advanta Seeds UK Ltd.

RESEARCH & DEVELOPMENT: Plant breeding

PRODUCTS ON MARKET: Crop varieties for U.K. agriculture

AEA Technology plc

Nuclear programmes--One business unit: Waste Management Technology

RESEARCH & DEVELOPMENT: Bicyclic monoterpene diols

Pharmaceutical products: Dimericine® (T4N5 Liposome Lotion)

PRODUCTS IN DEVELOPMENT: Name Status

FACILITIES: Five campuses

AGREEMENTS: Name Products Content of Agreement Date

RESEARCH & DEVELOPMENT: Agriculture and environment

RESEARCH & DEVELOPMENT: Insect behavior-modifying chemicals (semiochemicals, attractants and

Andrew K. Mittag; Sr. VP, Corporate Development and Strategy

RESEARCH & DEVELOPMENT: Specialty controlled-release fertilizers

Ag-West Bio Inc.

Ajinomoto Co. Inc.

Orsan lysine and feed joint venture called

Scotia Holdings Scotia's SC103 for development and 3/97

PRODUCTS ON MARKET: Food products

HISTORY: Algemeene Kunstzijde Unie N.V. merged with Koninklijke Zwanenberg

PRODUCTS ON MARKET: HUMAN HEALTHCARE: Andriol®, Cerazette®, Desogen® (US),

Animal healthcare products

The BioWorld Phase III Report – A quarterly compilation of biotechnology products in